[{"id": 242001, "ingredient1": "Darifenacin", "ingredient2": "Phenelzine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/271653/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Mirabegron, Acetohydroxamic acid, Phenyl salicylate, Magnesium hydroxide, Ammonium chloride, Dimethyl sulfoxide", "alternatives_b": "Desvenlafaxine, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Vilazodone, Esketamine", "updated_at": 1767369485}, {"id": 242002, "ingredient1": "Darifenacin", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/271655/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Phenyl salicylate, Ammonium chloride, Dimethyl sulfoxide", "alternatives_b": "Acalabrutinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More", "updated_at": 1767369485}, {"id": 242003, "ingredient1": "Darifenacin", "ingredient2": "Botulinum toxin type B", "severity": "Moderate", "effect": "Use of anticholinergic drugs after administration of botulinum toxin may potentiate systemic anticholinergic effects such as dry mouth, blurred vision, and urinary disorders.  Botulinum toxin inhibits the release of acetylcholine from peripheral cholinergic nerve endings, thus additive or synergistic anticholinergic effects may occur when these agents are used together.", "source": "DDInter", "management_text": "Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) are used after administration of botulinum toxin.", "mechanism_text": "Synergism", "recommendation": "Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/271656/", "reference_text": "[1] \"Product Information. Myobloc (rimabotulinumtoxinB).\" Elan Pharmaceuticals[2] \"Product Information. Dysport (abobotulinumtoxinA).\" Tercica Inc[3] \"Product Information. Botox (onabotulinumtoxinA).\" Allergan Inc[4] \"Product Information. Xeomin (incobotulinumtoxinA).\" Merz Pharmaceuticals  (2022):[5] \"Product Information. Jeuveau (prabotulinumtoxinA).\" Evolus, Inc.  (2022):[6] \"Product Information. Daxxify (daxibotulinumtoxinA).\" Revance Therapeutics, Inc.  (2022):", "alternatives_a": "Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Avanafil, Papaverine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242004, "ingredient1": "Dasatinib", "ingredient2": "Darolutamide", "severity": "Moderate", "effect": "Long-term androgen deprivation therapy can prolong the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.  Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.", "mechanism_text": "Synergism", "recommendation": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/271659/", "reference_text": "[1] \"Product Information. Lupron (leuprolide).\" TAP Pharmaceuticals Inc  (2002):[2] \"Product Information. Zoladex (goserelin).\" Astra-Zeneca Pharmaceuticals  (2001):[3] \"Product Information. Trelstar (triptorelin).\" Pharmacia and Upjohn  (2001):[4] \"Product Information. Eligard (leuprolide).\" Sanofi Winthrop Pharmaceuticals  (2002):[5] \"Product Information. Plenaxis (abarelix).\" Praecis Pharmaceuticals Inc  (2003):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] \"Product Information. Vantas (histrelin).\" Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc)  (2010):[8] \"Product Information. Firmagon (degarelix).\" Ferring Pharmaceuticals Inc  (2013):", "alternatives_a": "Anastrozole, Exemestane, Fulvestrant", "alternatives_b": "Acalabrutinib, Dacomitinib, Avapritinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, Axitinib, More", "updated_at": 1767369485}, {"id": 242005, "ingredient1": "Doxepin", "ingredient2": "Darolutamide", "severity": "Moderate", "effect": "Long-term androgen deprivation therapy can prolong the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.  Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.", "mechanism_text": "Synergism", "recommendation": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/271660/", "reference_text": "[1] \"Product Information. Lupron (leuprolide).\" TAP Pharmaceuticals Inc  (2002):[2] \"Product Information. Zoladex (goserelin).\" Astra-Zeneca Pharmaceuticals  (2001):[3] \"Product Information. Trelstar (triptorelin).\" Pharmacia and Upjohn  (2001):[4] \"Product Information. Eligard (leuprolide).\" Sanofi Winthrop Pharmaceuticals  (2002):[5] \"Product Information. Plenaxis (abarelix).\" Praecis Pharmaceuticals Inc  (2003):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] \"Product Information. Vantas (histrelin).\" Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc)  (2010):[8] \"Product Information. Firmagon (degarelix).\" Ferring Pharmaceuticals Inc  (2013):", "alternatives_a": "Anastrozole, Aminoglutethimide, Exemestane, Fulvestrant", "alternatives_b": "Citalopram, Maprotiline, Vortioxetine, Milnacipran, Levomilnacipran, Duloxetine, Isocarboxazid, Amoxapine, Esketamine, Phenelzine, Desipramine, More", "updated_at": 1767369485}, {"id": 242006, "ingredient1": "Epirubicin", "ingredient2": "Darolutamide", "severity": "Moderate", "effect": "Long-term androgen deprivation therapy can prolong the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.  Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.", "mechanism_text": "Synergism", "recommendation": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/271662/", "reference_text": "[1] \"Product Information. Lupron (leuprolide).\" TAP Pharmaceuticals Inc  (2002):[2] \"Product Information. Zoladex (goserelin).\" Astra-Zeneca Pharmaceuticals  (2001):[3] \"Product Information. Trelstar (triptorelin).\" Pharmacia and Upjohn  (2001):[4] \"Product Information. Eligard (leuprolide).\" Sanofi Winthrop Pharmaceuticals  (2002):[5] \"Product Information. Plenaxis (abarelix).\" Praecis Pharmaceuticals Inc  (2003):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] \"Product Information. Vantas (histrelin).\" Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc)  (2010):[8] \"Product Information. Firmagon (degarelix).\" Ferring Pharmaceuticals Inc  (2013):", "alternatives_a": "Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "alternatives_b": "Valrubicin, Plicamycin, Ixabepilone, Bleomycin, Mitomycin, Dactinomycin", "updated_at": 1767369485}, {"id": 242007, "ingredient1": "Eribulin", "ingredient2": "Darolutamide", "severity": "Moderate", "effect": "Long-term androgen deprivation therapy can prolong the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.  Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.", "mechanism_text": "Synergism", "recommendation": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/271663/", "reference_text": "[1] \"Product Information. Lupron (leuprolide).\" TAP Pharmaceuticals Inc  (2002):[2] \"Product Information. Zoladex (goserelin).\" Astra-Zeneca Pharmaceuticals  (2001):[3] \"Product Information. Trelstar (triptorelin).\" Pharmacia and Upjohn  (2001):[4] \"Product Information. Eligard (leuprolide).\" Sanofi Winthrop Pharmaceuticals  (2002):[5] \"Product Information. Plenaxis (abarelix).\" Praecis Pharmaceuticals Inc  (2003):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] \"Product Information. Vantas (histrelin).\" Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc)  (2010):[8] \"Product Information. Firmagon (degarelix).\" Ferring Pharmaceuticals Inc  (2013):", "alternatives_a": "Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "alternatives_b": "Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Enasidenib, More", "updated_at": 1767369485}, {"id": 242008, "ingredient1": "Fesoterodine", "ingredient2": "Darolutamide", "severity": "Moderate", "effect": "Long-term androgen deprivation therapy can prolong the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.  Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.", "mechanism_text": "Synergism", "recommendation": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/271664/", "reference_text": "[1] \"Product Information. Lupron (leuprolide).\" TAP Pharmaceuticals Inc  (2002):[2] \"Product Information. Zoladex (goserelin).\" Astra-Zeneca Pharmaceuticals  (2001):[3] \"Product Information. Trelstar (triptorelin).\" Pharmacia and Upjohn  (2001):[4] \"Product Information. Eligard (leuprolide).\" Sanofi Winthrop Pharmaceuticals  (2002):[5] \"Product Information. Plenaxis (abarelix).\" Praecis Pharmaceuticals Inc  (2003):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] \"Product Information. Vantas (histrelin).\" Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc)  (2010):[8] \"Product Information. Firmagon (degarelix).\" Ferring Pharmaceuticals Inc  (2013):", "alternatives_a": "Tamoxifen, Anastrozole, Letrozole, Toremifene, Fulvestrant, Abarelix, Flutamide, Relugolix, Degarelix, Nilutamide, Abiraterone, Exemestane", "alternatives_b": "Darifenacin, Tadalafil, Ammonium chloride, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, More", "updated_at": 1767369485}, {"id": 242009, "ingredient1": "Fidaxomicin", "ingredient2": "Darolutamide", "severity": "Moderate", "effect": "Coadministration with fidaxomicin may increase the plasma concentrations of some orally administered drugs that are substrates of the P-glycoprotein (P-gp) transporter.  In vitro, fidaxomicin and its main metabolite are substrates and inhibitors of P-gp, an efflux transporter expressed in the gastrointestinal tract.", "source": "DDInter", "management_text": "Caution is advised when fidaxomicin is used in combination with P-gp substrates that may be sensitive to intestinal P-gp inhibition.", "mechanism_text": "Absorption", "recommendation": "Caution is advised when fidaxomicin is used in combination with P-gp substrates that may be sensitive to intestinal P-gp inhibition.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/271666/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Dificid (fidaxomicin).\" Optimer Pharmaceuticals  (2011):[4] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):", "alternatives_a": "Anastrozole, Letrozole, Toremifene, Fulvestrant, Abarelix, Flutamide, Bicalutamide, Degarelix, Nilutamide, Aminoglutethimide, Abiraterone, Exemestane", "alternatives_b": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Paromomycin, Neomycin", "updated_at": 1767369485}, {"id": 242010, "ingredient1": "Flecainide", "ingredient2": "Darolutamide", "severity": "Moderate", "effect": "Long-term androgen deprivation therapy can prolong the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.  Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.", "mechanism_text": "Synergism", "recommendation": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/271667/", "reference_text": "[1] \"Product Information. Lupron (leuprolide).\" TAP Pharmaceuticals Inc  (2002):[2] \"Product Information. Zoladex (goserelin).\" Astra-Zeneca Pharmaceuticals  (2001):[3] \"Product Information. Trelstar (triptorelin).\" Pharmacia and Upjohn  (2001):[4] \"Product Information. Eligard (leuprolide).\" Sanofi Winthrop Pharmaceuticals  (2002):[5] \"Product Information. Plenaxis (abarelix).\" Praecis Pharmaceuticals Inc  (2003):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] \"Product Information. Vantas (histrelin).\" Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc)  (2010):[8] \"Product Information. Firmagon (degarelix).\" Ferring Pharmaceuticals Inc  (2013):", "alternatives_a": "Anastrozole, Aminoglutethimide, Exemestane, Fulvestrant", "alternatives_b": "Quinidine, Lidocaine, Tocainide, Procainamide, Disopyramide, Mexiletine, Dofetilide, Bretylium, Moricizine, Ibutilide", "updated_at": 1767369485}, {"id": 242011, "ingredient1": "Fluoxetine", "ingredient2": "Darolutamide", "severity": "Moderate", "effect": "Long-term androgen deprivation therapy can prolong the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.  Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.", "mechanism_text": "Synergism", "recommendation": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/271668/", "reference_text": "[1] \"Product Information. Lupron (leuprolide).\" TAP Pharmaceuticals Inc  (2002):[2] \"Product Information. Zoladex (goserelin).\" Astra-Zeneca Pharmaceuticals  (2001):[3] \"Product Information. Trelstar (triptorelin).\" Pharmacia and Upjohn  (2001):[4] \"Product Information. Eligard (leuprolide).\" Sanofi Winthrop Pharmaceuticals  (2002):[5] \"Product Information. Plenaxis (abarelix).\" Praecis Pharmaceuticals Inc  (2003):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] \"Product Information. Vantas (histrelin).\" Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc)  (2010):[8] \"Product Information. Firmagon (degarelix).\" Ferring Pharmaceuticals Inc  (2013):", "alternatives_a": "Aminoglutethimide, Fulvestrant", "alternatives_b": "Citalopram, Maprotiline, Vortioxetine, Milnacipran, Levomilnacipran, Duloxetine, Isocarboxazid, Amoxapine, Esketamine, Phenelzine, Desipramine, More", "updated_at": 1767369485}, {"id": 242012, "ingredient1": "Fluphenazine", "ingredient2": "Darolutamide", "severity": "Moderate", "effect": "Long-term androgen deprivation therapy can prolong the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.  Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.", "mechanism_text": "Synergism", "recommendation": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/271669/", "reference_text": "[1] \"Product Information. Lupron (leuprolide).\" TAP Pharmaceuticals Inc  (2002):[2] \"Product Information. Zoladex (goserelin).\" Astra-Zeneca Pharmaceuticals  (2001):[3] \"Product Information. Trelstar (triptorelin).\" Pharmacia and Upjohn  (2001):[4] \"Product Information. Eligard (leuprolide).\" Sanofi Winthrop Pharmaceuticals  (2002):[5] \"Product Information. Plenaxis (abarelix).\" Praecis Pharmaceuticals Inc  (2003):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] \"Product Information. Vantas (histrelin).\" Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc)  (2010):[8] \"Product Information. Firmagon (degarelix).\" Ferring Pharmaceuticals Inc  (2013):", "alternatives_a": "Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "alternatives_b": "Haloperidol, Thiothixene, Amisulpride, Promazine, Thioridazine, Lumateperone, Pimozide, Cariprazine, Mesoridazine, Pimavanserin, Clozapine, More", "updated_at": 1767369485}, {"id": 242013, "ingredient1": "Foscarnet", "ingredient2": "Darolutamide", "severity": "Moderate", "effect": "Long-term androgen deprivation therapy can prolong the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.  Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.", "mechanism_text": "Synergism", "recommendation": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/271670/", "reference_text": "[1] \"Product Information. Lupron (leuprolide).\" TAP Pharmaceuticals Inc  (2002):[2] \"Product Information. Zoladex (goserelin).\" Astra-Zeneca Pharmaceuticals  (2001):[3] \"Product Information. Trelstar (triptorelin).\" Pharmacia and Upjohn  (2001):[4] \"Product Information. Eligard (leuprolide).\" Sanofi Winthrop Pharmaceuticals  (2002):[5] \"Product Information. Plenaxis (abarelix).\" Praecis Pharmaceuticals Inc  (2003):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] \"Product Information. Vantas (histrelin).\" Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc)  (2010):[8] \"Product Information. Firmagon (degarelix).\" Ferring Pharmaceuticals Inc  (2013):", "alternatives_a": "Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "alternatives_b": "Lamivudine, Tenofovir alafenamide, Maraviroc, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Dolutegravir, Oseltamivir, Acyclovir, Stavudine, More", "updated_at": 1767369485}, {"id": 242014, "ingredient1": "Fostemsavir", "ingredient2": "Darolutamide", "severity": "Moderate", "effect": "Long-term androgen deprivation therapy can prolong the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.  Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.", "mechanism_text": "Synergism", "recommendation": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/271671/", "reference_text": "[1] \"Product Information. Lupron (leuprolide).\" TAP Pharmaceuticals Inc  (2002):[2] \"Product Information. Zoladex (goserelin).\" Astra-Zeneca Pharmaceuticals  (2001):[3] \"Product Information. Trelstar (triptorelin).\" Pharmacia and Upjohn  (2001):[4] \"Product Information. Eligard (leuprolide).\" Sanofi Winthrop Pharmaceuticals  (2002):[5] \"Product Information. Plenaxis (abarelix).\" Praecis Pharmaceuticals Inc  (2003):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] \"Product Information. Vantas (histrelin).\" Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc)  (2010):[8] \"Product Information. Firmagon (degarelix).\" Ferring Pharmaceuticals Inc  (2013):", "alternatives_a": "Anastrozole, Fulvestrant, Exemestane, Letrozole", "alternatives_b": "Lamivudine, Tenofovir alafenamide, Maraviroc, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Dolutegravir, Oseltamivir, Acyclovir, Stavudine, More", "updated_at": 1767369485}, {"id": 242015, "ingredient1": "Granisetron", "ingredient2": "Darolutamide", "severity": "Moderate", "effect": "Long-term androgen deprivation therapy can prolong the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.  Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.", "mechanism_text": "Synergism", "recommendation": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/271673/", "reference_text": "[1] \"Product Information. Lupron (leuprolide).\" TAP Pharmaceuticals Inc  (2002):[2] \"Product Information. Zoladex (goserelin).\" Astra-Zeneca Pharmaceuticals  (2001):[3] \"Product Information. Trelstar (triptorelin).\" Pharmacia and Upjohn  (2001):[4] \"Product Information. Eligard (leuprolide).\" Sanofi Winthrop Pharmaceuticals  (2002):[5] \"Product Information. Plenaxis (abarelix).\" Praecis Pharmaceuticals Inc  (2003):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] \"Product Information. Vantas (histrelin).\" Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc)  (2010):[8] \"Product Information. Firmagon (degarelix).\" Ferring Pharmaceuticals Inc  (2013):", "alternatives_a": "Anastrozole, Aminoglutethimide, Exemestane, Fulvestrant", "alternatives_b": "Nabilone, Scopolamine, Rolapitant, Dolasetron, Dronabinol", "updated_at": 1767369485}, {"id": 242016, "ingredient1": "Halothane", "ingredient2": "Darolutamide", "severity": "Moderate", "effect": "Long-term androgen deprivation therapy can prolong the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.  Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.", "mechanism_text": "Synergism", "recommendation": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/271674/", "reference_text": "[1] \"Product Information. Lupron (leuprolide).\" TAP Pharmaceuticals Inc  (2002):[2] \"Product Information. Zoladex (goserelin).\" Astra-Zeneca Pharmaceuticals  (2001):[3] \"Product Information. Trelstar (triptorelin).\" Pharmacia and Upjohn  (2001):[4] \"Product Information. Eligard (leuprolide).\" Sanofi Winthrop Pharmaceuticals  (2002):[5] \"Product Information. Plenaxis (abarelix).\" Praecis Pharmaceuticals Inc  (2003):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] \"Product Information. Vantas (histrelin).\" Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc)  (2010):[8] \"Product Information. Firmagon (degarelix).\" Ferring Pharmaceuticals Inc  (2013):", "alternatives_a": "Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "alternatives_b": "Thiopental, Alfentanil, Remifentanil, Isoflurane, Sodium oxybate, Methohexital, Fentanyl, Desflurane, Nitrous oxide, Sufentanil, Propofol, More", "updated_at": 1767369485}, {"id": 242017, "ingredient1": "Hydroxychloroquine", "ingredient2": "Darolutamide", "severity": "Moderate", "effect": "Long-term androgen deprivation therapy can prolong the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.  Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.", "mechanism_text": "Synergism", "recommendation": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/271675/", "reference_text": "[1] \"Product Information. Lupron (leuprolide).\" TAP Pharmaceuticals Inc  (2002):[2] \"Product Information. Zoladex (goserelin).\" Astra-Zeneca Pharmaceuticals  (2001):[3] \"Product Information. Trelstar (triptorelin).\" Pharmacia and Upjohn  (2001):[4] \"Product Information. Eligard (leuprolide).\" Sanofi Winthrop Pharmaceuticals  (2002):[5] \"Product Information. Plenaxis (abarelix).\" Praecis Pharmaceuticals Inc  (2003):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] \"Product Information. Vantas (histrelin).\" Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc)  (2010):[8] \"Product Information. Firmagon (degarelix).\" Ferring Pharmaceuticals Inc  (2013):", "alternatives_a": "Anastrozole, Aminoglutethimide, Exemestane, Fulvestrant", "alternatives_b": "Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Halofantrine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 242018, "ingredient1": "Idarubicin", "ingredient2": "Darolutamide", "severity": "Moderate", "effect": "Long-term androgen deprivation therapy can prolong the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.  Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.", "mechanism_text": "Synergism", "recommendation": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/271676/", "reference_text": "[1] \"Product Information. Lupron (leuprolide).\" TAP Pharmaceuticals Inc  (2002):[2] \"Product Information. Zoladex (goserelin).\" Astra-Zeneca Pharmaceuticals  (2001):[3] \"Product Information. Trelstar (triptorelin).\" Pharmacia and Upjohn  (2001):[4] \"Product Information. Eligard (leuprolide).\" Sanofi Winthrop Pharmaceuticals  (2002):[5] \"Product Information. Plenaxis (abarelix).\" Praecis Pharmaceuticals Inc  (2003):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] \"Product Information. Vantas (histrelin).\" Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc)  (2010):[8] \"Product Information. Firmagon (degarelix).\" Ferring Pharmaceuticals Inc  (2013):", "alternatives_a": "Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "alternatives_b": "Valrubicin, Plicamycin, Ixabepilone, Bleomycin, Mitomycin, Dactinomycin", "updated_at": 1767369485}, {"id": 242019, "ingredient1": "Imipramine", "ingredient2": "Darolutamide", "severity": "Moderate", "effect": "Long-term androgen deprivation therapy can prolong the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.  Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.", "mechanism_text": "Synergism", "recommendation": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/271677/", "reference_text": "[1] \"Product Information. Lupron (leuprolide).\" TAP Pharmaceuticals Inc  (2002):[2] \"Product Information. Zoladex (goserelin).\" Astra-Zeneca Pharmaceuticals  (2001):[3] \"Product Information. Trelstar (triptorelin).\" Pharmacia and Upjohn  (2001):[4] \"Product Information. Eligard (leuprolide).\" Sanofi Winthrop Pharmaceuticals  (2002):[5] \"Product Information. Plenaxis (abarelix).\" Praecis Pharmaceuticals Inc  (2003):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] \"Product Information. Vantas (histrelin).\" Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc)  (2010):[8] \"Product Information. Firmagon (degarelix).\" Ferring Pharmaceuticals Inc  (2013):", "alternatives_a": "Anastrozole, Aminoglutethimide, Exemestane, Fulvestrant", "alternatives_b": "Citalopram, Maprotiline, Vortioxetine, Milnacipran, Levomilnacipran, Duloxetine, Isocarboxazid, Amoxapine, Esketamine, Phenelzine, Desipramine, More", "updated_at": 1767369485}, {"id": 242020, "ingredient1": "Darolutamide", "ingredient2": "Lefamulin", "severity": "Minor", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or P-glycoprotein (P-gp) may increase the plasma concentrations of darolutamide, which is a substrate of both the isoenzyme and the efflux transporter.", "source": "DDInter", "management_text": "Caution is advised when darolutamide is used with CYP450 3A4 or P-gp inhibitors.  Patients should be monitored more frequently for adverse effects such as fatigue, hypertension, neutropenia and abnormal liver function tests, and the darolutamide dosage adjusted as necessary in accordance with the product labeling.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when darolutamide is used with CYP450 3A4 or P-gp inhibitors.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/271678/", "reference_text": "[1] \"Product Information. Nubeqa (darolutamide).\" Bayer HealthCare Pharmaceuticals Inc.  (2019):", "alternatives_a": "Anastrozole, Fulvestrant", "alternatives_b": "Tinidazole, Linezolid, Bacitracin, Polymyxin B, Daptomycin, Vancomycin, Metronidazole, Telavancin, Methenamine, Spectinomycin, Nitrofurantoin, More", "updated_at": 1767369485}, {"id": 242021, "ingredient1": "Darolutamide", "ingredient2": "Lenvatinib", "severity": "Moderate", "effect": "Long-term androgen deprivation therapy can prolong the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.  Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.", "mechanism_text": "Synergism", "recommendation": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/271680/", "reference_text": "[1] \"Product Information. Lupron (leuprolide).\" TAP Pharmaceuticals Inc  (2002):[2] \"Product Information. Zoladex (goserelin).\" Astra-Zeneca Pharmaceuticals  (2001):[3] \"Product Information. Trelstar (triptorelin).\" Pharmacia and Upjohn  (2001):[4] \"Product Information. Eligard (leuprolide).\" Sanofi Winthrop Pharmaceuticals  (2002):[5] \"Product Information. Plenaxis (abarelix).\" Praecis Pharmaceuticals Inc  (2003):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] \"Product Information. Vantas (histrelin).\" Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc)  (2010):[8] \"Product Information. Firmagon (degarelix).\" Ferring Pharmaceuticals Inc  (2013):", "alternatives_a": "Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "alternatives_b": "Acalabrutinib, Dacomitinib, Avapritinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, Axitinib, More", "updated_at": 1767369485}, {"id": 242022, "ingredient1": "Darolutamide", "ingredient2": "Levofloxacin", "severity": "Moderate", "effect": "Long-term androgen deprivation therapy can prolong the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.  Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.", "mechanism_text": "Synergism", "recommendation": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/271681/", "reference_text": "[1] \"Product Information. Lupron (leuprolide).\" TAP Pharmaceuticals Inc  (2002):[2] \"Product Information. Zoladex (goserelin).\" Astra-Zeneca Pharmaceuticals  (2001):[3] \"Product Information. Trelstar (triptorelin).\" Pharmacia and Upjohn  (2001):[4] \"Product Information. Eligard (leuprolide).\" Sanofi Winthrop Pharmaceuticals  (2002):[5] \"Product Information. Plenaxis (abarelix).\" Praecis Pharmaceuticals Inc  (2003):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] \"Product Information. Vantas (histrelin).\" Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc)  (2010):[8] \"Product Information. Firmagon (degarelix).\" Ferring Pharmaceuticals Inc  (2013):", "alternatives_a": "Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "alternatives_b": "Enoxacin, Gatifloxacin, Nalidixic acid, Gemifloxacin, Lomefloxacin, Grepafloxacin, Moxifloxacin, Cinoxacin, Trovafloxacin, Sparfloxacin, Tinidazole, More", "updated_at": 1767369485}, {"id": 242023, "ingredient1": "Darolutamide", "ingredient2": "Lisdexamfetamine", "severity": "Moderate", "effect": "Long-term androgen deprivation therapy can prolong the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.  Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.", "mechanism_text": "Synergism", "recommendation": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/271683/", "reference_text": "[1] \"Product Information. Lupron (leuprolide).\" TAP Pharmaceuticals Inc  (2002):[2] \"Product Information. Zoladex (goserelin).\" Astra-Zeneca Pharmaceuticals  (2001):[3] \"Product Information. Trelstar (triptorelin).\" Pharmacia and Upjohn  (2001):[4] \"Product Information. Eligard (leuprolide).\" Sanofi Winthrop Pharmaceuticals  (2002):[5] \"Product Information. Plenaxis (abarelix).\" Praecis Pharmaceuticals Inc  (2003):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] \"Product Information. Vantas (histrelin).\" Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc)  (2010):[8] \"Product Information. Firmagon (degarelix).\" Ferring Pharmaceuticals Inc  (2013):", "alternatives_a": "Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "alternatives_b": "Amphetamine, Pemoline, Metamfetamine, Solriamfetol, Caffeine, Methylphenidate, Dexmethylphenidate, Dextroamphetamine, Citicoline", "updated_at": 1767369485}, {"id": 242024, "ingredient1": "Darolutamide", "ingredient2": "Lithium carbonate", "severity": "Moderate", "effect": "Long-term androgen deprivation therapy can prolong the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.  Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.", "mechanism_text": "Synergism", "recommendation": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/271684/", "reference_text": "[1] \"Product Information. Lupron (leuprolide).\" TAP Pharmaceuticals Inc  (2002):[2] \"Product Information. Zoladex (goserelin).\" Astra-Zeneca Pharmaceuticals  (2001):[3] \"Product Information. Trelstar (triptorelin).\" Pharmacia and Upjohn  (2001):[4] \"Product Information. Eligard (leuprolide).\" Sanofi Winthrop Pharmaceuticals  (2002):[5] \"Product Information. Plenaxis (abarelix).\" Praecis Pharmaceuticals Inc  (2003):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] \"Product Information. Vantas (histrelin).\" Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc)  (2010):[8] \"Product Information. Firmagon (degarelix).\" Ferring Pharmaceuticals Inc  (2013):", "alternatives_a": "Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242025, "ingredient1": "Darolutamide", "ingredient2": "Mefloquine", "severity": "Moderate", "effect": "Long-term androgen deprivation therapy can prolong the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.  Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.", "mechanism_text": "Synergism", "recommendation": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/271686/", "reference_text": "[1] \"Product Information. Lupron (leuprolide).\" TAP Pharmaceuticals Inc  (2002):[2] \"Product Information. Zoladex (goserelin).\" Astra-Zeneca Pharmaceuticals  (2001):[3] \"Product Information. Trelstar (triptorelin).\" Pharmacia and Upjohn  (2001):[4] \"Product Information. Eligard (leuprolide).\" Sanofi Winthrop Pharmaceuticals  (2002):[5] \"Product Information. Plenaxis (abarelix).\" Praecis Pharmaceuticals Inc  (2003):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] \"Product Information. Vantas (histrelin).\" Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc)  (2010):[8] \"Product Information. Firmagon (degarelix).\" Ferring Pharmaceuticals Inc  (2013):", "alternatives_a": "Anastrozole, Fulvestrant, Exemestane, Letrozole", "alternatives_b": "Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Halofantrine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 242026, "ingredient1": "Darolutamide", "ingredient2": "Methotrimeprazine", "severity": "Moderate", "effect": "Long-term androgen deprivation therapy can prolong the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.  Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.", "mechanism_text": "Synergism", "recommendation": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/271687/", "reference_text": "[1] \"Product Information. Lupron (leuprolide).\" TAP Pharmaceuticals Inc  (2002):[2] \"Product Information. Zoladex (goserelin).\" Astra-Zeneca Pharmaceuticals  (2001):[3] \"Product Information. Trelstar (triptorelin).\" Pharmacia and Upjohn  (2001):[4] \"Product Information. Eligard (leuprolide).\" Sanofi Winthrop Pharmaceuticals  (2002):[5] \"Product Information. Plenaxis (abarelix).\" Praecis Pharmaceuticals Inc  (2003):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] \"Product Information. Vantas (histrelin).\" Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc)  (2010):[8] \"Product Information. Firmagon (degarelix).\" Ferring Pharmaceuticals Inc  (2013):", "alternatives_a": "Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "alternatives_b": "Haloperidol, Thiothixene, Amisulpride, Promazine, Thioridazine, Lumateperone, Pimozide, Cariprazine, Mesoridazine, Pimavanserin, Clozapine, More", "updated_at": 1767369485}, {"id": 242027, "ingredient1": "Darolutamide", "ingredient2": "Midostaurin", "severity": "Moderate", "effect": "Long-term androgen deprivation therapy can prolong the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.  Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.", "mechanism_text": "Synergism", "recommendation": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/271689/", "reference_text": "[1] \"Product Information. Lupron (leuprolide).\" TAP Pharmaceuticals Inc  (2002):[2] \"Product Information. Zoladex (goserelin).\" Astra-Zeneca Pharmaceuticals  (2001):[3] \"Product Information. Trelstar (triptorelin).\" Pharmacia and Upjohn  (2001):[4] \"Product Information. Eligard (leuprolide).\" Sanofi Winthrop Pharmaceuticals  (2002):[5] \"Product Information. Plenaxis (abarelix).\" Praecis Pharmaceuticals Inc  (2003):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] \"Product Information. Vantas (histrelin).\" Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc)  (2010):[8] \"Product Information. Firmagon (degarelix).\" Ferring Pharmaceuticals Inc  (2013):", "alternatives_a": "Anastrozole, Fulvestrant, Exemestane, Letrozole", "alternatives_b": "Acalabrutinib, Dacomitinib, Avapritinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, Axitinib, More", "updated_at": 1767369485}, {"id": 242028, "ingredient1": "Darolutamide", "ingredient2": "Mirtazapine", "severity": "Moderate", "effect": "Long-term androgen deprivation therapy can prolong the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.  Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.", "mechanism_text": "Synergism", "recommendation": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/271690/", "reference_text": "[1] \"Product Information. Lupron (leuprolide).\" TAP Pharmaceuticals Inc  (2002):[2] \"Product Information. Zoladex (goserelin).\" Astra-Zeneca Pharmaceuticals  (2001):[3] \"Product Information. Trelstar (triptorelin).\" Pharmacia and Upjohn  (2001):[4] \"Product Information. Eligard (leuprolide).\" Sanofi Winthrop Pharmaceuticals  (2002):[5] \"Product Information. Plenaxis (abarelix).\" Praecis Pharmaceuticals Inc  (2003):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] \"Product Information. Vantas (histrelin).\" Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc)  (2010):[8] \"Product Information. Firmagon (degarelix).\" Ferring Pharmaceuticals Inc  (2013):", "alternatives_a": "Fulvestrant", "alternatives_b": "Citalopram, Maprotiline, Vortioxetine, Milnacipran, Levomilnacipran, Duloxetine, Isocarboxazid, Amoxapine, Esketamine, Phenelzine, Desipramine, More", "updated_at": 1767369485}, {"id": 242029, "ingredient1": "Darolutamide", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Long-term androgen deprivation therapy can prolong the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.  Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.", "mechanism_text": "Synergism", "recommendation": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/271691/", "reference_text": "[1] \"Product Information. Lupron (leuprolide).\" TAP Pharmaceuticals Inc  (2002):[2] \"Product Information. Zoladex (goserelin).\" Astra-Zeneca Pharmaceuticals  (2001):[3] \"Product Information. Trelstar (triptorelin).\" Pharmacia and Upjohn  (2001):[4] \"Product Information. Eligard (leuprolide).\" Sanofi Winthrop Pharmaceuticals  (2002):[5] \"Product Information. Plenaxis (abarelix).\" Praecis Pharmaceuticals Inc  (2003):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] \"Product Information. Vantas (histrelin).\" Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc)  (2010):[8] \"Product Information. Firmagon (degarelix).\" Ferring Pharmaceuticals Inc  (2013):", "alternatives_a": "Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "alternatives_b": "Tinidazole, Tetracycline, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Amikacin, Gatifloxacin, Rifamycin, Kanamycin, More", "updated_at": 1767369485}, {"id": 242030, "ingredient1": "Darolutamide", "ingredient2": "Ofloxacin", "severity": "Moderate", "effect": "Long-term androgen deprivation therapy can prolong the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.  Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.", "mechanism_text": "Synergism", "recommendation": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/271692/", "reference_text": "[1] \"Product Information. Lupron (leuprolide).\" TAP Pharmaceuticals Inc  (2002):[2] \"Product Information. Zoladex (goserelin).\" Astra-Zeneca Pharmaceuticals  (2001):[3] \"Product Information. Trelstar (triptorelin).\" Pharmacia and Upjohn  (2001):[4] \"Product Information. Eligard (leuprolide).\" Sanofi Winthrop Pharmaceuticals  (2002):[5] \"Product Information. Plenaxis (abarelix).\" Praecis Pharmaceuticals Inc  (2003):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] \"Product Information. Vantas (histrelin).\" Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc)  (2010):[8] \"Product Information. Firmagon (degarelix).\" Ferring Pharmaceuticals Inc  (2013):", "alternatives_a": "Anastrozole, Aminoglutethimide", "alternatives_b": "Enoxacin, Gatifloxacin, Nalidixic acid, Gemifloxacin, Lomefloxacin, Grepafloxacin, Moxifloxacin, Cinoxacin, Trovafloxacin, Sparfloxacin, Tinidazole, More", "updated_at": 1767369485}, {"id": 242031, "ingredient1": "Darolutamide", "ingredient2": "Oxaliplatin", "severity": "Moderate", "effect": "Long-term androgen deprivation therapy can prolong the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.  Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.", "mechanism_text": "Synergism", "recommendation": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/271694/", "reference_text": "[1] \"Product Information. Lupron (leuprolide).\" TAP Pharmaceuticals Inc  (2002):[2] \"Product Information. Zoladex (goserelin).\" Astra-Zeneca Pharmaceuticals  (2001):[3] \"Product Information. Trelstar (triptorelin).\" Pharmacia and Upjohn  (2001):[4] \"Product Information. Eligard (leuprolide).\" Sanofi Winthrop Pharmaceuticals  (2002):[5] \"Product Information. Plenaxis (abarelix).\" Praecis Pharmaceuticals Inc  (2003):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] \"Product Information. Vantas (histrelin).\" Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc)  (2010):[8] \"Product Information. Firmagon (degarelix).\" Ferring Pharmaceuticals Inc  (2013):", "alternatives_a": "Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "alternatives_b": "Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Enasidenib, More", "updated_at": 1767369485}, {"id": 242032, "ingredient1": "Darolutamide", "ingredient2": "Palbociclib", "severity": "Minor", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or P-glycoprotein (P-gp) may increase the plasma concentrations of darolutamide, which is a substrate of both the isoenzyme and the efflux transporter.", "source": "DDInter", "management_text": "Caution is advised when darolutamide is used with CYP450 3A4 or P-gp inhibitors.  Patients should be monitored more frequently for adverse effects such as fatigue, hypertension, neutropenia and abnormal liver function tests, and the darolutamide dosage adjusted as necessary in accordance with the product labeling.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when darolutamide is used with CYP450 3A4 or P-gp inhibitors.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/271695/", "reference_text": "[1] \"Product Information. Nubeqa (darolutamide).\" Bayer HealthCare Pharmaceuticals Inc.  (2019):", "alternatives_a": "Tamoxifen, Anastrozole, Letrozole, Fulvestrant, Abarelix, Flutamide, Relugolix, Bicalutamide, Degarelix, Nilutamide, Abiraterone, Exemestane", "alternatives_b": "Acalabrutinib, Dacomitinib, Avapritinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, Axitinib, More", "updated_at": 1767369485}, {"id": 242033, "ingredient1": "Darolutamide", "ingredient2": "Paliperidone", "severity": "Moderate", "effect": "Long-term androgen deprivation therapy can prolong the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.  Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.", "mechanism_text": "Synergism", "recommendation": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/271696/", "reference_text": "[1] \"Product Information. Lupron (leuprolide).\" TAP Pharmaceuticals Inc  (2002):[2] \"Product Information. Zoladex (goserelin).\" Astra-Zeneca Pharmaceuticals  (2001):[3] \"Product Information. Trelstar (triptorelin).\" Pharmacia and Upjohn  (2001):[4] \"Product Information. Eligard (leuprolide).\" Sanofi Winthrop Pharmaceuticals  (2002):[5] \"Product Information. Plenaxis (abarelix).\" Praecis Pharmaceuticals Inc  (2003):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] \"Product Information. Vantas (histrelin).\" Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc)  (2010):[8] \"Product Information. Firmagon (degarelix).\" Ferring Pharmaceuticals Inc  (2013):", "alternatives_a": "Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "alternatives_b": "Haloperidol, Thiothixene, Amisulpride, Promazine, Thioridazine, Lumateperone, Pimozide, Cariprazine, Mesoridazine, Pimavanserin, Clozapine, More", "updated_at": 1767369485}, {"id": 242034, "ingredient1": "Darolutamide", "ingredient2": "Pentamidine", "severity": "Moderate", "effect": "Long-term androgen deprivation therapy can prolong the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.  Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.", "mechanism_text": "Synergism", "recommendation": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/271697/", "reference_text": "[1] \"Product Information. Lupron (leuprolide).\" TAP Pharmaceuticals Inc  (2002):[2] \"Product Information. Zoladex (goserelin).\" Astra-Zeneca Pharmaceuticals  (2001):[3] \"Product Information. Trelstar (triptorelin).\" Pharmacia and Upjohn  (2001):[4] \"Product Information. Eligard (leuprolide).\" Sanofi Winthrop Pharmaceuticals  (2002):[5] \"Product Information. Plenaxis (abarelix).\" Praecis Pharmaceuticals Inc  (2003):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] \"Product Information. Vantas (histrelin).\" Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc)  (2010):[8] \"Product Information. Firmagon (degarelix).\" Ferring Pharmaceuticals Inc  (2013):", "alternatives_a": "Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "alternatives_b": "Miltefosine, Nifurtimox, Benznidazole", "updated_at": 1767369485}, {"id": 242035, "ingredient1": "Darolutamide", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/271700/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Anastrozole, Aminoglutethimide, Fulvestrant", "alternatives_b": "Acalabrutinib, Dacomitinib, Avapritinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, Axitinib, More", "updated_at": 1767369485}, {"id": 242036, "ingredient1": "Darolutamide", "ingredient2": "Primaquine", "severity": "Moderate", "effect": "Long-term androgen deprivation therapy can prolong the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.  Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.", "mechanism_text": "Synergism", "recommendation": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/271701/", "reference_text": "[1] \"Product Information. Lupron (leuprolide).\" TAP Pharmaceuticals Inc  (2002):[2] \"Product Information. Zoladex (goserelin).\" Astra-Zeneca Pharmaceuticals  (2001):[3] \"Product Information. Trelstar (triptorelin).\" Pharmacia and Upjohn  (2001):[4] \"Product Information. Eligard (leuprolide).\" Sanofi Winthrop Pharmaceuticals  (2002):[5] \"Product Information. Plenaxis (abarelix).\" Praecis Pharmaceuticals Inc  (2003):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] \"Product Information. Vantas (histrelin).\" Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc)  (2010):[8] \"Product Information. Firmagon (degarelix).\" Ferring Pharmaceuticals Inc  (2013):", "alternatives_a": "Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "alternatives_b": "Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Halofantrine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 242037, "ingredient1": "Dextropropoxyphene", "ingredient2": "Darolutamide", "severity": "Moderate", "effect": "Long-term androgen deprivation therapy can prolong the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.  Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.", "mechanism_text": "Synergism", "recommendation": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/271702/", "reference_text": "[1] \"Product Information. Lupron (leuprolide).\" TAP Pharmaceuticals Inc  (2002):[2] \"Product Information. Zoladex (goserelin).\" Astra-Zeneca Pharmaceuticals  (2001):[3] \"Product Information. Trelstar (triptorelin).\" Pharmacia and Upjohn  (2001):[4] \"Product Information. Eligard (leuprolide).\" Sanofi Winthrop Pharmaceuticals  (2002):[5] \"Product Information. Plenaxis (abarelix).\" Praecis Pharmaceuticals Inc  (2003):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] \"Product Information. Vantas (histrelin).\" Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc)  (2010):[8] \"Product Information. Firmagon (degarelix).\" Ferring Pharmaceuticals Inc  (2013):", "alternatives_a": "Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "alternatives_b": "Naltrexone, Oxymorphone, Oxycodone, Methadone, Pentazocine, Oliceridine, Morphine, Butorphanol, Fentanyl, Ibuprofen, Codeine, More", "updated_at": 1767369485}, {"id": 242038, "ingredient1": "Darolutamide", "ingredient2": "Quinine", "severity": "Moderate", "effect": "Long-term androgen deprivation therapy can prolong the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.  Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.", "mechanism_text": "Synergism", "recommendation": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/271703/", "reference_text": "[1] \"Product Information. Lupron (leuprolide).\" TAP Pharmaceuticals Inc  (2002):[2] \"Product Information. Zoladex (goserelin).\" Astra-Zeneca Pharmaceuticals  (2001):[3] \"Product Information. Trelstar (triptorelin).\" Pharmacia and Upjohn  (2001):[4] \"Product Information. Eligard (leuprolide).\" Sanofi Winthrop Pharmaceuticals  (2002):[5] \"Product Information. Plenaxis (abarelix).\" Praecis Pharmaceuticals Inc  (2003):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] \"Product Information. Vantas (histrelin).\" Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc)  (2010):[8] \"Product Information. Firmagon (degarelix).\" Ferring Pharmaceuticals Inc  (2013):", "alternatives_a": "Anastrozole, Fulvestrant, Exemestane, Letrozole", "alternatives_b": "Risdiplam, Collagenase clostridium histolyticum, Onasemnogene abeparvovec, Hyaluronic acid, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Halofantrine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 242039, "ingredient1": "Darolutamide", "ingredient2": "Rilpivirine", "severity": "Moderate", "effect": "Long-term androgen deprivation therapy can prolong the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.  Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.", "mechanism_text": "Synergism", "recommendation": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/271704/", "reference_text": "[1] \"Product Information. Lupron (leuprolide).\" TAP Pharmaceuticals Inc  (2002):[2] \"Product Information. Zoladex (goserelin).\" Astra-Zeneca Pharmaceuticals  (2001):[3] \"Product Information. Trelstar (triptorelin).\" Pharmacia and Upjohn  (2001):[4] \"Product Information. Eligard (leuprolide).\" Sanofi Winthrop Pharmaceuticals  (2002):[5] \"Product Information. Plenaxis (abarelix).\" Praecis Pharmaceuticals Inc  (2003):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] \"Product Information. Vantas (histrelin).\" Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc)  (2010):[8] \"Product Information. Firmagon (degarelix).\" Ferring Pharmaceuticals Inc  (2013):", "alternatives_a": "Anastrozole, Fulvestrant, Exemestane, Letrozole", "alternatives_b": "Lamivudine, Tenofovir alafenamide, Maraviroc, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Dolutegravir, Oseltamivir, Acyclovir, Stavudine, More", "updated_at": 1767369485}, {"id": 242040, "ingredient1": "Darolutamide", "ingredient2": "Romidepsin", "severity": "Moderate", "effect": "Long-term androgen deprivation therapy can prolong the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.  Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.", "mechanism_text": "Synergism", "recommendation": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/271705/", "reference_text": "[1] \"Product Information. Lupron (leuprolide).\" TAP Pharmaceuticals Inc  (2002):[2] \"Product Information. Zoladex (goserelin).\" Astra-Zeneca Pharmaceuticals  (2001):[3] \"Product Information. Trelstar (triptorelin).\" Pharmacia and Upjohn  (2001):[4] \"Product Information. Eligard (leuprolide).\" Sanofi Winthrop Pharmaceuticals  (2002):[5] \"Product Information. Plenaxis (abarelix).\" Praecis Pharmaceuticals Inc  (2003):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] \"Product Information. Vantas (histrelin).\" Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc)  (2010):[8] \"Product Information. Firmagon (degarelix).\" Ferring Pharmaceuticals Inc  (2013):", "alternatives_a": "Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "alternatives_b": "Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Enasidenib, More", "updated_at": 1767369485}, {"id": 242041, "ingredient1": "Darolutamide", "ingredient2": "Solifenacin", "severity": "Moderate", "effect": "Long-term androgen deprivation therapy can prolong the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.  Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.", "mechanism_text": "Synergism", "recommendation": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/271706/", "reference_text": "[1] \"Product Information. Lupron (leuprolide).\" TAP Pharmaceuticals Inc  (2002):[2] \"Product Information. Zoladex (goserelin).\" Astra-Zeneca Pharmaceuticals  (2001):[3] \"Product Information. Trelstar (triptorelin).\" Pharmacia and Upjohn  (2001):[4] \"Product Information. Eligard (leuprolide).\" Sanofi Winthrop Pharmaceuticals  (2002):[5] \"Product Information. Plenaxis (abarelix).\" Praecis Pharmaceuticals Inc  (2003):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] \"Product Information. Vantas (histrelin).\" Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc)  (2010):[8] \"Product Information. Firmagon (degarelix).\" Ferring Pharmaceuticals Inc  (2013):", "alternatives_a": "Anastrozole, Fulvestrant, Exemestane, Letrozole", "alternatives_b": "Darifenacin, Tadalafil, Ammonium chloride, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, More", "updated_at": 1767369485}, {"id": 242042, "ingredient1": "Darolutamide", "ingredient2": "Trazodone", "severity": "Moderate", "effect": "Long-term androgen deprivation therapy can prolong the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.  Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.", "mechanism_text": "Synergism", "recommendation": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/271708/", "reference_text": "[1] \"Product Information. Lupron (leuprolide).\" TAP Pharmaceuticals Inc  (2002):[2] \"Product Information. Zoladex (goserelin).\" Astra-Zeneca Pharmaceuticals  (2001):[3] \"Product Information. Trelstar (triptorelin).\" Pharmacia and Upjohn  (2001):[4] \"Product Information. Eligard (leuprolide).\" Sanofi Winthrop Pharmaceuticals  (2002):[5] \"Product Information. Plenaxis (abarelix).\" Praecis Pharmaceuticals Inc  (2003):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] \"Product Information. Vantas (histrelin).\" Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc)  (2010):[8] \"Product Information. Firmagon (degarelix).\" Ferring Pharmaceuticals Inc  (2013):", "alternatives_a": "Anastrozole, Fulvestrant, Aminoglutethimide, Letrozole", "alternatives_b": "Citalopram, Maprotiline, Vortioxetine, Milnacipran, Levomilnacipran, Duloxetine, Isocarboxazid, Amoxapine, Esketamine, Phenelzine, Desipramine, More", "updated_at": 1767369485}, {"id": 242043, "ingredient1": "Darolutamide", "ingredient2": "Alimemazine", "severity": "Moderate", "effect": "Long-term androgen deprivation therapy can prolong the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.  Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.", "mechanism_text": "Synergism", "recommendation": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/271709/", "reference_text": "[1] \"Product Information. Lupron (leuprolide).\" TAP Pharmaceuticals Inc  (2002):[2] \"Product Information. Zoladex (goserelin).\" Astra-Zeneca Pharmaceuticals  (2001):[3] \"Product Information. Trelstar (triptorelin).\" Pharmacia and Upjohn  (2001):[4] \"Product Information. Eligard (leuprolide).\" Sanofi Winthrop Pharmaceuticals  (2002):[5] \"Product Information. Plenaxis (abarelix).\" Praecis Pharmaceuticals Inc  (2003):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] \"Product Information. Vantas (histrelin).\" Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc)  (2010):[8] \"Product Information. Firmagon (degarelix).\" Ferring Pharmaceuticals Inc  (2013):", "alternatives_a": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, More", "alternatives_b": "Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "updated_at": 1767369485}, {"id": 242044, "ingredient1": "Darolutamide", "ingredient2": "Vardenafil", "severity": "Moderate", "effect": "Long-term androgen deprivation therapy can prolong the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.  Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.", "mechanism_text": "Synergism", "recommendation": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/271710/", "reference_text": "[1] \"Product Information. Lupron (leuprolide).\" TAP Pharmaceuticals Inc  (2002):[2] \"Product Information. Zoladex (goserelin).\" Astra-Zeneca Pharmaceuticals  (2001):[3] \"Product Information. Trelstar (triptorelin).\" Pharmacia and Upjohn  (2001):[4] \"Product Information. Eligard (leuprolide).\" Sanofi Winthrop Pharmaceuticals  (2002):[5] \"Product Information. Plenaxis (abarelix).\" Praecis Pharmaceuticals Inc  (2003):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] \"Product Information. Vantas (histrelin).\" Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc)  (2010):[8] \"Product Information. Firmagon (degarelix).\" Ferring Pharmaceuticals Inc  (2013):", "alternatives_a": "Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "alternatives_b": "Darifenacin, Tadalafil, Ammonium chloride, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, More", "updated_at": 1767369485}, {"id": 242045, "ingredient1": "Darolutamide", "ingredient2": "Vasopressin", "severity": "Moderate", "effect": "Long-term androgen deprivation therapy can prolong the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.  Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.", "mechanism_text": "Synergism", "recommendation": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/271711/", "reference_text": "[1] \"Product Information. Lupron (leuprolide).\" TAP Pharmaceuticals Inc  (2002):[2] \"Product Information. Zoladex (goserelin).\" Astra-Zeneca Pharmaceuticals  (2001):[3] \"Product Information. Trelstar (triptorelin).\" Pharmacia and Upjohn  (2001):[4] \"Product Information. Eligard (leuprolide).\" Sanofi Winthrop Pharmaceuticals  (2002):[5] \"Product Information. Plenaxis (abarelix).\" Praecis Pharmaceuticals Inc  (2003):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] \"Product Information. Vantas (histrelin).\" Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc)  (2010):[8] \"Product Information. Firmagon (degarelix).\" Ferring Pharmaceuticals Inc  (2013):", "alternatives_a": "Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242046, "ingredient1": "Darolutamide", "ingredient2": "Venlafaxine", "severity": "Moderate", "effect": "Long-term androgen deprivation therapy can prolong the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.  Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.", "mechanism_text": "Synergism", "recommendation": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/271712/", "reference_text": "[1] \"Product Information. Lupron (leuprolide).\" TAP Pharmaceuticals Inc  (2002):[2] \"Product Information. Zoladex (goserelin).\" Astra-Zeneca Pharmaceuticals  (2001):[3] \"Product Information. Trelstar (triptorelin).\" Pharmacia and Upjohn  (2001):[4] \"Product Information. Eligard (leuprolide).\" Sanofi Winthrop Pharmaceuticals  (2002):[5] \"Product Information. Plenaxis (abarelix).\" Praecis Pharmaceuticals Inc  (2003):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] \"Product Information. Vantas (histrelin).\" Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc)  (2010):[8] \"Product Information. Firmagon (degarelix).\" Ferring Pharmaceuticals Inc  (2013):", "alternatives_a": "Aminoglutethimide", "alternatives_b": "Citalopram, Maprotiline, Vortioxetine, Milnacipran, Levomilnacipran, Duloxetine, Isocarboxazid, Amoxapine, Esketamine, Phenelzine, Desipramine, More", "updated_at": 1767369485}, {"id": 242047, "ingredient1": "Drospirenone", "ingredient2": "Darunavir", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of drospirenone, which is partially metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution and close clinical monitoring are recommended when drospirenone is prescribed with CYP450 3A4 inhibitors, particularly in patients requiring long-term concomitant use and those with other risk factors for hyperkalemia (e.g., renal insufficiency; coadministration with medications that can increase potassium such as aldosterone antagonists, angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, nonsteroidal anti-inflammatory drugs (NSAIDs), potassium-sparing diuretics, potassium supplements, and heparin).  Consider checking serum potassium levels during the first treatment cycle and periodically thereafter as indicated.", "mechanism_text": "Metabolism", "recommendation": "Caution and close clinical monitoring are recommended when drospirenone is prescribed with CYP450 3A4 inhibitors, particularly in patients requiring long-term concomitant use and those with other risk factors for hyperkalemia (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/271718/", "reference_text": "[1] \"Product Information. Victrelis (boceprevir).\" Schering-Plough Corporation  (2011):[2] \"Product Information. Slynd (drospirenone).\" Exeltis USA, Inc.  (2022):[3] \"Product Information. Angeliq (drospirenone-estradiol).\" Bayer Pharmaceutical Inc  (2017):[4] \"Product Information. Slinda (drospirenone).\" Besins Healthcare Australia Pty Ltd  (2021):[5] \"Product Information. Angeliq 1/2 (drospirenone-estradiol).\" Bayer Australia Limited  (2021):[6] \"Product Information. Slynd (drospirenone).\" Duchesnay Inc  (2021):[7] \"Product Information. Evotaz (atazanavir-cobicistat).\" Bristol-Myers Squibb  (2022):[8] \"Product Information. Evotaz (atazanavir-cobicistat).\" Bristol-Myers Squibb Australia Pty Ltd  (2023):[9] \"Product Information. Evotaz (atazanavir-cobicistat).\" Bristol-Myers Squibb Pharmaceuticals Ltd  (2021):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More", "alternatives_b": "Dienogest, Estetrol, Ethinylestradiol, Etynodiol, Dienogest, Etynodiol", "updated_at": 1767369485}, {"id": 242048, "ingredient1": "Dextropropoxyphene", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/271761/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Oxymorphone, Tapentadol, Butorphanol, Hydromorphone, Dezocine, Opium, Pentazocine, Acetylsalicylic acid, Naloxone, Nalbuphine", "alternatives_b": "Imatinib, Dabrafenib, Acalabrutinib, Pexidartinib, Tepotinib, Avapritinib, Larotrectinib, Bosutinib, Selumetinib, Cobimetinib, Capmatinib, More", "updated_at": 1767369485}, {"id": 242049, "ingredient1": "Dextropropoxyphene", "ingredient2": "Tolevamer", "severity": "Moderate", "effect": "Coadministration with medications that can cause constipation such as opioids may increase the risk of intestinal injuries associated with the use of sodium polystyrene sulfonate.", "source": "DDInter", "management_text": "Because opioids commonly cause constipation, caution is advised when used during treatment with sodium polystyrene sulfonate.  The prescribing information recommends avoiding the use of sodium polystyrene sulfonate in patients who are at risk for developing constipation or impaction, including those with a history of impaction, chronic constipation, inflammatory bowel disease, ischemic colitis, vascular intestinal atherosclerosis, previous bowel resection, or bowel obstruction, as well as those who have not had a bowel movement post-surgery.  If clinically significant constipation develops, treatment with sodium polystyrene sulfonate should be discontinued until normal bowel motion is resumed.  Concomitant administration of sorbitol is not recommended.", "mechanism_text": "Synergism", "recommendation": "Because opioids commonly cause constipation, caution is advised when used during treatment with sodium polystyrene sulfonate.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/271762/", "reference_text": "[1] Foresti V \"Intestinal obstruction due to kayexalate in a patient concurrently treated with aluminum hydroxide and morphine sulfate.\" Clin Nephrol 41 (1994):  252[2] \"Product Information. Kayexalate (sodium polystyrene sulfonate).\" Sanofi Winthrop Pharmaceuticals  (2001):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):", "alternatives_a": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "alternatives_b": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Deferoxamine, Levoleucovorin, Arginine, Methionine, More", "updated_at": 1767369485}, {"id": 242050, "ingredient1": "Dasatinib", "ingredient2": "Bacillus calmette-guerin substrain tice live antigen", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/271768/", "reference_text": "[1] \"Product Information. Meruvax II (rubella virus vaccine).\" Merck & Co., Inc  (2022):[2] \"Product Information. Attenuvax (measles virus vaccine).\" Merck & Co., Inc  (2022):[3] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD \"Harrison's Principles of Internal Medicine.\" New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] \"Product Information. DENGVAXIA (dengue vaccine).\" sanofi pasteur  (2022):", "alternatives_a": "Entrectinib, Pralsetinib, Dabrafenib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Larotrectinib, Vemurafenib, Lapatinib, Selumetinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242051, "ingredient1": "Drospirenone", "ingredient2": "Dasatinib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of drospirenone, which is partially metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution and close clinical monitoring are recommended when drospirenone is prescribed with CYP450 3A4 inhibitors, particularly in patients requiring long-term concomitant use and those with other risk factors for hyperkalemia (e.g., renal insufficiency; coadministration with medications that can increase potassium such as aldosterone antagonists, angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, nonsteroidal anti-inflammatory drugs (NSAIDs), potassium-sparing diuretics, potassium supplements, and heparin).  Consider checking serum potassium levels during the first treatment cycle and periodically thereafter as indicated.", "mechanism_text": "Metabolism", "recommendation": "Caution and close clinical monitoring are recommended when drospirenone is prescribed with CYP450 3A4 inhibitors, particularly in patients requiring long-term concomitant use and those with other risk factors for hyperkalemia (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/271775/", "reference_text": "[1] \"Product Information. Victrelis (boceprevir).\" Schering-Plough Corporation  (2011):[2] \"Product Information. Slynd (drospirenone).\" Exeltis USA, Inc.  (2022):[3] \"Product Information. Angeliq (drospirenone-estradiol).\" Bayer Pharmaceutical Inc  (2017):[4] \"Product Information. Slinda (drospirenone).\" Besins Healthcare Australia Pty Ltd  (2021):[5] \"Product Information. Angeliq 1/2 (drospirenone-estradiol).\" Bayer Australia Limited  (2021):[6] \"Product Information. Slynd (drospirenone).\" Duchesnay Inc  (2021):[7] \"Product Information. Evotaz (atazanavir-cobicistat).\" Bristol-Myers Squibb  (2022):[8] \"Product Information. Evotaz (atazanavir-cobicistat).\" Bristol-Myers Squibb Australia Pty Ltd  (2023):[9] \"Product Information. Evotaz (atazanavir-cobicistat).\" Bristol-Myers Squibb Pharmaceuticals Ltd  (2021):", "alternatives_a": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Zanubrutinib, More", "alternatives_b": "Ulipristal, Megestrol acetate, Etynodiol, Desogestrel, Dienogest, Estetrol, Megestrol acetate, Dienogest, Etynodiol, Desogestrel", "updated_at": 1767369485}, {"id": 242052, "ingredient1": "Heparin (flush)", "ingredient2": "Dasatinib", "severity": "Moderate", "effect": "Concomitant use of heparin flush and drugs that interfere with platelet function or coagulation or drugs that commonly cause thrombocytopenia may potentiate the risk of bleeding complications.  Although uncommon, inadvertent anticoagulation resulting in hemorrhagic events may occur with heparin flushes, particularly during repeated or excessive use or administration of higher concentration flush solutions.", "source": "DDInter", "management_text": "Caution and monitoring (e.g., platelet counts, hematocrits, tests for occult blood in stools) are advised when heparin flushes are given to patients receiving systemic anticoagulants, platelet inhibitors, antithrombotic agents, thrombolytics, or drugs with known risks of thrombocytopenia or bleeding.  An unexplained fall in hematocrit, fall in blood pressure, or any other unexplained symptom should lead to serious consideration of a hemorrhagic event.", "mechanism_text": "Synergism", "recommendation": "Caution and monitoring (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/271784/", "reference_text": "[1] Passannante A, Macik BG \"The heparin flush syndrome: a cause of iatrogenic hemorrhage.\" Am J Med Sci 296 (1988):  71-3[2] \"Product Information. Heparin Sodium in Sodium Chloride (heparin flush).\" Baxter Healthcare Corporation  (2022):[3] \"Product Information. Canusal (heparin flush).\" Wockhardt UK Ltd  (2018):[4] \"Product Information. Heparinised Saline (Pfizer) (heparinised saline).\" Pfizer Australia Pty Ltd  (2022):", "alternatives_a": "Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Larotrectinib, Bosutinib, More", "alternatives_b": "Protein C, Acenocoumarol, Selexipag, Ascorbic acid, Vitamin A, Potassium Iodide, Acetylcysteine, Nandrolone", "updated_at": 1767369485}, {"id": 242053, "ingredient1": "Dasatinib", "ingredient2": "Varicella Zoster Vaccine (Recombinant)", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual's risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, the U.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/271843/", "reference_text": "[1] \"Product Information. Fluzone (influenza virus vaccine, inactivated).\" Connaught Laboratories Inc[2] \"Product Information. Omnihib (haemophilus b conjugate vaccine (obsolete)).\" SmithKline Beecham[3] \"Product Information. Havrix (hepatitis A adult vaccine).\" SmithKline Beecham[4] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[5] \"Product Information. Imovax Rabies (rabies vaccine, human diploid cell).\" sanofi pasteur  (2022):[6] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc.  (2003):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline  (2022):[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations.  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf\"   (2019):[11] CDC Centers for Disease Control and Prevention \"Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html\"   (2022):", "alternatives_a": "Entrectinib, Pralsetinib, Dabrafenib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Larotrectinib, Vemurafenib, Lapatinib, Selumetinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242054, "ingredient1": "Doxorubicin", "ingredient2": "Delavirdine", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of daunorubicin and idarubicin, both of which are substrates of the efflux transporter also known as ABCB1 or MDR1.", "source": "DDInter", "management_text": "Caution is advised if daunorubicin or idarubicin is prescribed in combination with a P-gp inhibitor.  Patients should be closely monitored for increased adverse effects including cardiotoxicity and myelosuppression.", "mechanism_text": "Absorption", "recommendation": "Caution is advised if daunorubicin or idarubicin is prescribed in combination with a P-gp inhibitor.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/271845/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] \"Product Information. Cerubidine (daunorubicin).\" Wyeth-Ayerst Laboratories  (2001):[3] \"Product Information. Idamycin (idarubicin).\" Pharmacia and Upjohn  (2001):[4] \"Product Information. Daunoxome (daunorubicin liposomal).\" Nexstar Pharmaceuticals Inc  (2001):", "alternatives_a": "Paritaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Dolutegravir, Cobicistat, Brincidofovir, Remdesivir, More", "alternatives_b": "Valrubicin, Plicamycin, Bleomycin, Mitomycin, Dactinomycin, Epirubicin", "updated_at": 1767369485}, {"id": 242055, "ingredient1": "Doxorubicin", "ingredient2": "Mechlorethamine", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.  Dosing adjustments may be necessary.  The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/271847/", "reference_text": "[1] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb  (2001):[2] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb  (2001):[3] \"Product Information. Fluorouracil (fluorouracil).\" Roche Laboratories  (2022):[4] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn  (2001):[5] \"Product Information. Ellence (epirubicin).\" Pharmacia and Upjohn  (2001):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] Agencia Espala de Medicamentos y Productos Sanitarios Healthcare \"Centro de informaci online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):", "alternatives_a": "Valrubicin, Plicamycin, Ixabepilone, Dactinomycin, Epirubicin", "alternatives_b": "Uracil mustard", "updated_at": 1767369485}, {"id": 242056, "ingredient1": "Doxorubicin", "ingredient2": "Pentostatin", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.  Dosing adjustments may be necessary.  The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/271848/", "reference_text": "[1] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb  (2001):[2] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb  (2001):[3] \"Product Information. Fluorouracil (fluorouracil).\" Roche Laboratories  (2022):[4] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn  (2001):[5] \"Product Information. Ellence (epirubicin).\" Pharmacia and Upjohn  (2001):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] Agencia Espala de Medicamentos y Productos Sanitarios Healthcare \"Centro de informaci online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):", "alternatives_a": "Valrubicin, Plicamycin, Ixabepilone, Dactinomycin, Epirubicin", "alternatives_b": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Selinexor, Aflibercept, Estramustine, Vorinostat, More", "updated_at": 1767369485}, {"id": 242057, "ingredient1": "Doxorubicin", "ingredient2": "Telaprevir", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of daunorubicin and idarubicin, both of which are substrates of the efflux transporter also known as ABCB1 or MDR1.", "source": "DDInter", "management_text": "Caution is advised if daunorubicin or idarubicin is prescribed in combination with a P-gp inhibitor.  Patients should be closely monitored for increased adverse effects including cardiotoxicity and myelosuppression.", "mechanism_text": "Absorption", "recommendation": "Caution is advised if daunorubicin or idarubicin is prescribed in combination with a P-gp inhibitor.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/271850/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] \"Product Information. Cerubidine (daunorubicin).\" Wyeth-Ayerst Laboratories  (2001):[3] \"Product Information. Idamycin (idarubicin).\" Pharmacia and Upjohn  (2001):[4] \"Product Information. Daunoxome (daunorubicin liposomal).\" Nexstar Pharmaceuticals Inc  (2001):", "alternatives_a": "Valrubicin, Plicamycin, Bleomycin, Mitomycin, Dactinomycin, Epirubicin", "alternatives_b": "Paritaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Dolutegravir, Cobicistat, Brincidofovir, Remdesivir, More", "updated_at": 1767369485}, {"id": 242058, "ingredient1": "Ginkgo biloba", "ingredient2": "Oxaprozin", "severity": "Moderate", "effect": "Ginkgo may potentiate the risk of bleeding associated with anticoagulants, platelet inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), and thrombolytic agents.  Ginkgolide B, a component of ginkgo, inhibits platelet-activating factor by displacing it from its receptor-binding site, resulting in reduced platelet aggregation.", "source": "DDInter", "management_text": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.  In general, consumption of ginkgo should be avoided during use of coagulation-modifying agents and at least two weeks prior to surgery.  In patients who have used this herb extensively prior to receiving anticoagulation, antiplatelet, NSAID or thrombolytic therapy, the potential for an interaction should be considered.  Close clinical and laboratory observation for hematologic complications is recommended.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/271981/", "reference_text": "[1] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[2] Rosenblatt M, Mindel J \"Spontaneous hyphema associated with ingestion of Ginkgo biloba extract.\" N Engl J Med 336 (1997):  1108[3] Rowin J, Lewis SL \"Spontaneous bilateral subdural hematomas associated with chronic Gingko biloba ingestion.\" Neurology 46 (1996):  1775-6[4] Chung KF, McCusker M, Page CP, Dent G, Guinot P, Barnes PJ \"Effect of ginkgolide mixture (BN 52063) in antagonising skin and platelet responses to platelet acitivating factor in man.\" Lancet 1 (1987):  248-51[5] Fugh-Berman A \"Herb-drug interactions.\" Lancet 355 (2000):  134-8[6] Heck AM, DeWitt BA, Lukes AL \"Potential interactions between alternative therapies and warfarin.\" Am J Health Syst Pharm 57 (2000):  1221-7; quiz 1228-30[7] Vaes LP, Chyka PA \"Interactions of warfarin with garlic, ginger, or ginseng: nature of evidence.\" Ann Pharmacother 34 (2000):  1478-82[8] Fessenden JM, Wittenborn W, Clarke L \"Gingko biloba: A case report of herbal medicine and bleeding postoperatively from a laparoscopic cholecystectomy.\" Am Surg 67 (2001):  33-5[9] Benjamin J, Muir T, Briggs K, Pentland B \"A case of cerebral haemorrhage - can Ginkgo biloba be implicated?.\" Postgrad Med J 77 (2001):  112-3[10] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001):  2163-75[11] Evans V \"Herbs and the brain: friend or foe? The effects of ginkgo and garlic on warfarin use.\" J Neurosci Nurs 32 (2000):  229-32[12] Cupp MJ \"Herbal remedies: adverse effects and drug interactions.\" Am Fam Physician 59 (1999):  1239-45[13] Matthews MK Jr \"Association of Ginko biloba with intracerebral hemorrhage.\" Neurology 50 (1998):  1933-4[14] Engelsen J, Nielsen JD, Winther K \"Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in stable, long-term warfarin treated outpatients. A randomised, double blind, placebo-crossover trial.\" Thromb Haemost 87 (2002):  1075-6[15] Fong KC, Kinnear PE \"Retrobulbar haemorrhage associated with chronic Gingko biloba ingestion.\" Postgrad Med J 79 (2003):  531-2[16] Sierpina VS, Wollschlaeger B, Blumenthal M \"Ginkgo biloba.\" Am Fam Physician 68 (2003):  923-6[17] Jiang X, Williams KM, Liauw WS, et al. \"Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.\" Br J Clin Pharmacol 59 (2005):  425-32[18] Jayasekera N, Moghal A, Kashif F, Karalliedde L \"Herbal medicines and postoperative haemorrhage.\" Anaesthesia 60 (2005):  725-6[19] Wolf HR \"Does Ginkgo biloba special extract EGb 761 provide additional effects on coagulation and bleeding when added to acetylsalicylic acid 500 mg daily?\" Drugs R D 7 (2006):  163-72", "alternatives_a": "Rivastigmine, Galantamine, Aducanumab, Memantine, Tacrine", "alternatives_b": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "updated_at": 1767369485}, {"id": 242059, "ingredient1": "Heparin (flush)", "ingredient2": "Oxaprozin", "severity": "Moderate", "effect": "Concomitant use of heparin flush and drugs that interfere with platelet function or coagulation or drugs that commonly cause thrombocytopenia may potentiate the risk of bleeding complications.  Although uncommon, inadvertent anticoagulation resulting in hemorrhagic events may occur with heparin flushes, particularly during repeated or excessive use or administration of higher concentration flush solutions.", "source": "DDInter", "management_text": "Caution and monitoring (e.g., platelet counts, hematocrits, tests for occult blood in stools) are advised when heparin flushes are given to patients receiving systemic anticoagulants, platelet inhibitors, antithrombotic agents, thrombolytics, or drugs with known risks of thrombocytopenia or bleeding.  An unexplained fall in hematocrit, fall in blood pressure, or any other unexplained symptom should lead to serious consideration of a hemorrhagic event.", "mechanism_text": "Synergism", "recommendation": "Caution and monitoring (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/271982/", "reference_text": "[1] Passannante A, Macik BG \"The heparin flush syndrome: a cause of iatrogenic hemorrhage.\" Am J Med Sci 296 (1988):  71-3[2] \"Product Information. Heparin Sodium in Sodium Chloride (heparin flush).\" Baxter Healthcare Corporation  (2022):[3] \"Product Information. Canusal (heparin flush).\" Wockhardt UK Ltd  (2018):[4] \"Product Information. Heparinised Saline (Pfizer) (heparinised saline).\" Pfizer Australia Pty Ltd  (2022):", "alternatives_a": "Protein C, Acenocoumarol, Selexipag, Pentosan polysulfate, Vitamin A, Ascorbic acid, Nandrolone, Acetylcysteine", "alternatives_b": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "updated_at": 1767369485}, {"id": 242060, "ingredient1": "Acrivastine", "ingredient2": "Lemborexant", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/271998/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 242061, "ingredient1": "Fenfluramine", "ingredient2": "Lemborexant", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272003/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Dexfenfluramine, Naltrexone, Ephedrine, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol, Lacosamide", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 242062, "ingredient1": "Lemborexant", "ingredient2": "Lanreotide", "severity": "Major", "effect": "Coadministration with weak inhibitors of CYP450 3A4 may increase the plasma concentrations of lemborexant, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The lemborexant dose should be limited to 5 mg no more than once per night when coadministered with weak CYP450 3A4 inhibitors.", "mechanism_text": "Metabolism", "recommendation": "The lemborexant dose should be limited to 5 mg no more than once per night when coadministered with weak CYP450 3A4 inhibitors.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272009/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Dayvigo (lemborexant).\" Eisai Inc  (2020):", "alternatives_a": "Ganirelix, Cetrorelix, Nafarelin, Gonadorelin", "alternatives_b": "Suvorexant, Triazolam, Flurazepam, Methohexital, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, More", "updated_at": 1767369485}, {"id": 242063, "ingredient1": "Levodopa", "ingredient2": "Lemborexant", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272011/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "Amantadine, Cabergoline", "updated_at": 1767369485}, {"id": 242064, "ingredient1": "Melatonin", "ingredient2": "Lemborexant", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272014/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Melatonin, Nitrazepam, Zopiclone", "alternatives_b": "Nitrazepam, Zopiclone, Lemborexant", "updated_at": 1767369485}, {"id": 242065, "ingredient1": "Acrivastine", "ingredient2": "Oxycodone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272024/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Azelastine, Ketotifen, Terfenadine, Astemizole", "alternatives_b": "Naltrexone, Acetaminophen, Dextropropoxyphene, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 242066, "ingredient1": "Entrectinib", "ingredient2": "Oxycodone", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of oxycodone, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution may be advisable when oxycodone is prescribed with weak CYP450 3A4 inhibitors.  The risk of overdose may be increased following the initiation of a CYP450 3A4 inhibitor in patients already receiving oxycodone.  Patients should be closely monitored for signs and symptoms of sedation, respiratory depression, and hypotension.  Following discontinuation of the CYP450 3A4 inhibitor, patients should be monitored for reduced efficacy of oxycodone or development of withdrawal symptoms due to reduced plasma oxycodone levels.", "mechanism_text": "Metabolism", "recommendation": "Caution may be advisable when oxycodone is prescribed with weak CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272029/", "reference_text": "[1] \"Product Information. OxyContin (oxycodone).\" Purdue Frederick Company  (2001):[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More", "alternatives_b": "Codeine, Morphine, Oxymorphone, Tapentadol, Meperidine, Butorphanol, Acetaminophen, Hydromorphone, Dezocine, Opium, Ibuprofen, More", "updated_at": 1767369485}, {"id": 242067, "ingredient1": "Oxycodone", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272038/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Safinamide, Amantadine", "alternatives_b": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 242068, "ingredient1": "Oxycodone", "ingredient2": "Melatonin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272041/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Naltrexone, Acetaminophen, Dextropropoxyphene, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242069, "ingredient1": "Pralsetinib", "ingredient2": "Oxycodone", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272049/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Oxymorphone, Tapentadol, Butorphanol, Hydromorphone, Dezocine, Opium, Pentazocine, Acetylsalicylic acid, Naloxone, Nalbuphine", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More", "updated_at": 1767369485}, {"id": 242070, "ingredient1": "Tolevamer", "ingredient2": "Oxycodone", "severity": "Moderate", "effect": "Coadministration with medications that can cause constipation such as opioids may increase the risk of intestinal injuries associated with the use of sodium polystyrene sulfonate.", "source": "DDInter", "management_text": "Because opioids commonly cause constipation, caution is advised when used during treatment with sodium polystyrene sulfonate.  The prescribing information recommends avoiding the use of sodium polystyrene sulfonate in patients who are at risk for developing constipation or impaction, including those with a history of impaction, chronic constipation, inflammatory bowel disease, ischemic colitis, vascular intestinal atherosclerosis, previous bowel resection, or bowel obstruction, as well as those who have not had a bowel movement post-surgery.  If clinically significant constipation develops, treatment with sodium polystyrene sulfonate should be discontinued until normal bowel motion is resumed.  Concomitant administration of sorbitol is not recommended.", "mechanism_text": "Synergism", "recommendation": "Because opioids commonly cause constipation, caution is advised when used during treatment with sodium polystyrene sulfonate.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272050/", "reference_text": "[1] Foresti V \"Intestinal obstruction due to kayexalate in a patient concurrently treated with aluminum hydroxide and morphine sulfate.\" Clin Nephrol 41 (1994):  252[2] \"Product Information. Kayexalate (sodium polystyrene sulfonate).\" Sanofi Winthrop Pharmaceuticals  (2001):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):", "alternatives_a": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "alternatives_b": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Deferoxamine, Levoleucovorin, Arginine, Methionine, More", "updated_at": 1767369485}, {"id": 242071, "ingredient1": "Heparin (flush)", "ingredient2": "Deferasirox", "severity": "Moderate", "effect": "Concomitant use of heparin flush and drugs that interfere with platelet function or coagulation or drugs that commonly cause thrombocytopenia may potentiate the risk of bleeding complications.  Although uncommon, inadvertent anticoagulation resulting in hemorrhagic events may occur with heparin flushes, particularly during repeated or excessive use or administration of higher concentration flush solutions.", "source": "DDInter", "management_text": "Caution and monitoring (e.g., platelet counts, hematocrits, tests for occult blood in stools) are advised when heparin flushes are given to patients receiving systemic anticoagulants, platelet inhibitors, antithrombotic agents, thrombolytics, or drugs with known risks of thrombocytopenia or bleeding.  An unexplained fall in hematocrit, fall in blood pressure, or any other unexplained symptom should lead to serious consideration of a hemorrhagic event.", "mechanism_text": "Synergism", "recommendation": "Caution and monitoring (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272060/", "reference_text": "[1] Passannante A, Macik BG \"The heparin flush syndrome: a cause of iatrogenic hemorrhage.\" Am J Med Sci 296 (1988):  71-3[2] \"Product Information. Heparin Sodium in Sodium Chloride (heparin flush).\" Baxter Healthcare Corporation  (2022):[3] \"Product Information. Canusal (heparin flush).\" Wockhardt UK Ltd  (2018):[4] \"Product Information. Heparinised Saline (Pfizer) (heparinised saline).\" Pfizer Australia Pty Ltd  (2022):", "alternatives_a": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Cobicistat, Deferoxamine, Levoleucovorin, More", "alternatives_b": "Protein C, Acenocoumarol, Pentosan polysulfate, Ascorbic acid, Vitamin A, Potassium Iodide, Acetylcysteine, Nandrolone", "updated_at": 1767369485}, {"id": 242072, "ingredient1": "Deferasirox", "ingredient2": "Moxetumomab Pasudotox", "severity": "Major", "effect": "Theoretical concerns exist regarding the potential for increased risk of renal impairment during coadministration of deferasirox with other nephrotoxic agents.", "source": "DDInter", "management_text": "Caution is advised if deferasirox is used in combination with other potentially nephrotoxic agents (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents).  Serum creatinine and/or creatinine clearance should be closely monitored (e.g., prior to initiation of deferasirox therapy, then weekly during the first month after initiation or modification of therapy and monthly thereafter), especially in the elderly and patients with preexisting renal impairment, comorbid conditions, dehydration, or severe infections.  Dosage reduction, interruption, or discontinuation should be considered in the presence of creatinine elevations.  A progressive increase in serum creatinine beyond the age-appropriate upper limit of normal may warrant an interruption of therapy.  Once the creatinine has returned to within the normal range, therapy may be reinitiated at a lower dose followed by a gradual dose escalation according to the product labeling, provided the clinical benefit is expected to outweigh potential risks.  In clinical studies, the daily dosage of deferasirox was reduced by 10 mg/kg for increases of serum creatinine on two consecutive measures (i.e., >33% in patients older than 15 years of age, or >33% and greater than the age-appropriate upper limit of normal in patients younger than 15 years of age).  Care should be taken to maintain adequate hydration in patients who develop diarrhea or vomiting.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if deferasirox is used in combination with other potentially nephrotoxic agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272075/", "reference_text": "[1] \"Product Information. Exjade (deferasirox).\" Novartis Pharmaceuticals  (2005):[2] Rafat C, Fakhouri F, Ribeil JA, Delarue R, Le Quintrec M \"Fanconi Syndrome Due to Deferasirox.\" Am J Kidney Dis  (2009):", "alternatives_a": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Cobicistat, Deferoxamine, Levoleucovorin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242073, "ingredient1": "Deferasirox", "ingredient2": "Perampanel", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations and pharmacologic effects of perampanel, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "According to the manufacturer, concomitant use of perampanel with strong CYP450 3A4 inducers should be avoided.", "mechanism_text": "Metabolism", "recommendation": "According to the manufacturer, concomitant use of perampanel with strong CYP450 3A4 inducers should be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272077/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):", "alternatives_a": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Cobicistat, Deferoxamine, Levoleucovorin, Arginine, More", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Lacosamide, Levetiracetam, Oxcarbazepine, Ethotoin, Rufinamide, More", "updated_at": 1767369485}, {"id": 242074, "ingredient1": "Deferiprone", "ingredient2": "Melphalan flufenamide", "severity": "Major", "effect": "Coadministration of deferiprone and other drugs that can cause neutropenia or agranulocytosis may increase the risk and/or severity of hematologic toxicity.", "source": "DDInter", "management_text": "Concomitant use of deferiprone with other drugs known to be associated with neutropenia or agranulocytosis should generally be avoided.  Otherwise, close monitoring of absolute neutrophil count (ANC) is recommended if coadministration is required.  The ANC should be measured prior to initiating deferiprone and weekly during therapy.  The manufacturer recommends that treatment be interrupted if neutropenia (ANC between 0.5 and 1.5 x 10^9/L) or infection develops.  Patients should be advised to immediately discontinue deferiprone as well as all other medications with a potential to cause neutropenia and seek medical attention if they experience symptoms indicative of infection such as fever, sore throat, and flu-like symptoms.  A complete blood cell (CBC) count, including a white blood cell (WBC) count corrected for the presence of nucleated red blood cells, an absolute neutrophil count (ANC), and a platelet count should be obtained daily until recovery.  For patients who develop agranulocytosis (ANC less than 0.5 x 10^9/L), hospitalization should be considered, and deferiprone should not be resumed following recovery unless potential benefits outweigh the risks.  Likewise, patients who develop neutropenia with deferiprone should not be rechallenged unless potential benefits outweigh the risks.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of deferiprone with other drugs known to be associated with neutropenia or agranulocytosis should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272100/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Ferriprox (deferiprone).\" ApoPharma USA Inc  (2011):", "alternatives_a": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Cobicistat, Deferoxamine, Levoleucovorin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242075, "ingredient1": "Deferiprone", "ingredient2": "Promazine", "severity": "Major", "effect": "Coadministration of deferiprone and other drugs that can cause neutropenia or agranulocytosis may increase the risk and/or severity of hematologic toxicity.", "source": "DDInter", "management_text": "Concomitant use of deferiprone with other drugs known to be associated with neutropenia or agranulocytosis should generally be avoided.  Otherwise, close monitoring of absolute neutrophil count (ANC) is recommended if coadministration is required.  The ANC should be measured prior to initiating deferiprone and weekly during therapy.  The manufacturer recommends that treatment be interrupted if neutropenia (ANC between 0.5 and 1.5 x 10^9/L) or infection develops.  Patients should be advised to immediately discontinue deferiprone as well as all other medications with a potential to cause neutropenia and seek medical attention if they experience symptoms indicative of infection such as fever, sore throat, and flu-like symptoms.  A complete blood cell (CBC) count, including a white blood cell (WBC) count corrected for the presence of nucleated red blood cells, an absolute neutrophil count (ANC), and a platelet count should be obtained daily until recovery.  For patients who develop agranulocytosis (ANC less than 0.5 x 10^9/L), hospitalization should be considered, and deferiprone should not be resumed following recovery unless potential benefits outweigh the risks.  Likewise, patients who develop neutropenia with deferiprone should not be rechallenged unless potential benefits outweigh the risks.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of deferiprone with other drugs known to be associated with neutropenia or agranulocytosis should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272106/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Ferriprox (deferiprone).\" ApoPharma USA Inc  (2011):", "alternatives_a": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Cobicistat, Deferoxamine, Levoleucovorin, Arginine, More", "alternatives_b": "Fluphenazine, Haloperidol, Thiothixene, Risperidone, Amisulpride, Quetiapine, Prochlorperazine, Thioridazine, Lumateperone, Pimozide, Trifluoperazine, More", "updated_at": 1767369485}, {"id": 242076, "ingredient1": "Heparin (flush)", "ingredient2": "Defibrotide", "severity": "Moderate", "effect": "Concomitant use of heparin flush and drugs that interfere with platelet function or coagulation or drugs that commonly cause thrombocytopenia may potentiate the risk of bleeding complications.  Although uncommon, inadvertent anticoagulation resulting in hemorrhagic events may occur with heparin flushes, particularly during repeated or excessive use or administration of higher concentration flush solutions.", "source": "DDInter", "management_text": "Caution and monitoring (e.g., platelet counts, hematocrits, tests for occult blood in stools) are advised when heparin flushes are given to patients receiving systemic anticoagulants, platelet inhibitors, antithrombotic agents, thrombolytics, or drugs with known risks of thrombocytopenia or bleeding.  An unexplained fall in hematocrit, fall in blood pressure, or any other unexplained symptom should lead to serious consideration of a hemorrhagic event.", "mechanism_text": "Synergism", "recommendation": "Caution and monitoring (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272112/", "reference_text": "[1] Passannante A, Macik BG \"The heparin flush syndrome: a cause of iatrogenic hemorrhage.\" Am J Med Sci 296 (1988):  71-3[2] \"Product Information. Heparin Sodium in Sodium Chloride (heparin flush).\" Baxter Healthcare Corporation  (2022):[3] \"Product Information. Canusal (heparin flush).\" Wockhardt UK Ltd  (2018):[4] \"Product Information. Heparinised Saline (Pfizer) (heparinised saline).\" Pfizer Australia Pty Ltd  (2022):", "alternatives_a": "Acenocoumarol, Selexipag", "alternatives_b": "Defibrotide, Protein C, Acenocoumarol, Selexipag, Ascorbic acid, Cyclosporine, Sirolimus, Potassium Iodide, Vitamin A, Acetylcysteine, Nandrolone", "updated_at": 1767369485}, {"id": 242077, "ingredient1": "Pralsetinib", "ingredient2": "Perflutren", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272121/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242078, "ingredient1": "Deflazacort", "ingredient2": "Axicabtagene ciloleucel", "severity": "Major", "effect": "Prophylactic use of systemic corticosteroids prior to CD19- or BCMA-directed genetically modified autologous T cell immunotherapy may interfere with the therapeutic effects of such drugs as axicabtagene ciloleucel, brexucabtagene autoleucel, idecabtagene vicleucel, ciltacabtagene autoleucel and lisocabtagene maraleucel.  The mechanism for this interaction has not been delineated.  Administration of systemic corticosteroids in an effort to manage the toxicities associated with these drugs does not affect the expansion and persistence of CAR T cells.", "source": "DDInter", "management_text": "The prophylactic use of systemic corticosteroids prior to CD19- or BCMA-directed genetically modified autologous T cell immunotherapy with drugs such as axicabtagene ciloleucel, brexucabtagene autoleucel, idecabtagene vicleucel, ciltacabtagene autoleucel and lisocabtagene maraleucel is not recommended.  However, systemic corticosteroids may be used for the management of adverse effects associated with these drugs, such as cytokine release syndrome and neurological-related toxicities, without affecting the expansion and persistence of CAR T cells.", "mechanism_text": "Others", "recommendation": "The prophylactic use of systemic corticosteroids prior to CD19- or BCMA-directed genetically modified autologous T cell immunotherapy with drugs such as axicabtagene ciloleucel, brexucabtagene autoleucel, idecabtagene vicleucel, ciltacabtagene autoleucel and lisocabtagene maraleucel is not recommended.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272125/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Yescarta (axicabtagene ciloleucel).\" Kite Pharma, Inc.  (2017):[3] \"Product Information. Tecartus (brexucabtagene autoleucel).\" Kite Pharma, Inc.  (2020):[4] \"Product Information. Breyanzi (lisocabtagene maraleucel).\" Bristol-Myers Squibb  (2021):[5] \"Product Information. Abecma (idecabtagene vicleucel).\" Celgene Corporation  (2021):", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Porfimer sodium, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242079, "ingredient1": "Deflazacort", "ingredient2": "Bacillus calmette-guerin substrain tice live antigen", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272126/", "reference_text": "[1] \"Product Information. Meruvax II (rubella virus vaccine).\" Merck & Co., Inc  (2022):[2] \"Product Information. Attenuvax (measles virus vaccine).\" Merck & Co., Inc  (2022):[3] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD \"Harrison's Principles of Internal Medicine.\" New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] \"Product Information. DENGVAXIA (dengue vaccine).\" sanofi pasteur  (2022):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242080, "ingredient1": "Doxacurium", "ingredient2": "Deflazacort", "severity": "Moderate", "effect": "Corticosteroids may inhibit or enhance the action of nondepolarizing skeletal muscle relaxants.", "source": "DDInter", "management_text": "Patients should be closely monitored for altered neuromuscular blockade and signs of myopathy.  Dose adjustments of the muscle relaxant may be required.  The benefit-to-risk ratio should be considered and the duration of administration of the neuromuscular blocking agent should be limited as much as clinically feasible.", "mechanism_text": "Synergism", "recommendation": "Patients should be closely monitored for altered neuromuscular blockade and signs of myopathy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272131/", "reference_text": "[1] Parr SM, Galletly DC, Robinson BJ \"Betamethasone-induced resistance to vercuronium: a potential problem in neurosurgery.\" Anaesth Intensive Care 19 (1991):  103-5[2] Laflin MJ \"Interaction of pancuronium and corticosteroids.\" Anesthesiology 47 (1977):  471-2[3] Meyers EF \"Partial recovery from pancuronium neuromuscular blockade following hydrocortosone administration.\" Anesthesiology 46 (1977):  148-50[4] \"Product Information. Zemuron (rocuronium).\" Organon  (2001):[5] \"Product Information. Norcuron (vecuronium).\" Organon  (2001):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Agencia Espala de Medicamentos y Productos Sanitarios Healthcare \"Centro de informaci online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):[8] \"Product Information. Betamethasone Acet-Betamethasone Na Phos (betamethasone).\" Exela Pharma  (2022):", "alternatives_a": "Botulinum toxin type A", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242081, "ingredient1": "Deflazacort", "ingredient2": "Metocurine", "severity": "Moderate", "effect": "Corticosteroids may inhibit or enhance the action of nondepolarizing skeletal muscle relaxants.", "source": "DDInter", "management_text": "Patients should be closely monitored for altered neuromuscular blockade and signs of myopathy.  Dose adjustments of the muscle relaxant may be required.  The benefit-to-risk ratio should be considered and the duration of administration of the neuromuscular blocking agent should be limited as much as clinically feasible.", "mechanism_text": "Synergism", "recommendation": "Patients should be closely monitored for altered neuromuscular blockade and signs of myopathy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272151/", "reference_text": "[1] Parr SM, Galletly DC, Robinson BJ \"Betamethasone-induced resistance to vercuronium: a potential problem in neurosurgery.\" Anaesth Intensive Care 19 (1991):  103-5[2] Laflin MJ \"Interaction of pancuronium and corticosteroids.\" Anesthesiology 47 (1977):  471-2[3] Meyers EF \"Partial recovery from pancuronium neuromuscular blockade following hydrocortosone administration.\" Anesthesiology 46 (1977):  148-50[4] \"Product Information. Zemuron (rocuronium).\" Organon  (2001):[5] \"Product Information. Norcuron (vecuronium).\" Organon  (2001):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Agencia Espala de Medicamentos y Productos Sanitarios Healthcare \"Centro de informaci online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):[8] \"Product Information. Betamethasone Acet-Betamethasone Na Phos (betamethasone).\" Exela Pharma  (2022):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242082, "ingredient1": "Deflazacort", "ingredient2": "Mivacurium", "severity": "Moderate", "effect": "Corticosteroids may inhibit or enhance the action of nondepolarizing skeletal muscle relaxants.", "source": "DDInter", "management_text": "Patients should be closely monitored for altered neuromuscular blockade and signs of myopathy.  Dose adjustments of the muscle relaxant may be required.  The benefit-to-risk ratio should be considered and the duration of administration of the neuromuscular blocking agent should be limited as much as clinically feasible.", "mechanism_text": "Synergism", "recommendation": "Patients should be closely monitored for altered neuromuscular blockade and signs of myopathy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272154/", "reference_text": "[1] Parr SM, Galletly DC, Robinson BJ \"Betamethasone-induced resistance to vercuronium: a potential problem in neurosurgery.\" Anaesth Intensive Care 19 (1991):  103-5[2] Laflin MJ \"Interaction of pancuronium and corticosteroids.\" Anesthesiology 47 (1977):  471-2[3] Meyers EF \"Partial recovery from pancuronium neuromuscular blockade following hydrocortosone administration.\" Anesthesiology 46 (1977):  148-50[4] \"Product Information. Zemuron (rocuronium).\" Organon  (2001):[5] \"Product Information. Norcuron (vecuronium).\" Organon  (2001):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Agencia Espala de Medicamentos y Productos Sanitarios Healthcare \"Centro de informaci online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):[8] \"Product Information. Betamethasone Acet-Betamethasone Na Phos (betamethasone).\" Exela Pharma  (2022):", "alternatives_a": "Botulinum toxin type A", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242083, "ingredient1": "Deflazacort", "ingredient2": "Osilodrostat", "severity": "Moderate", "effect": "Coadministration with osilodrostat may increase the plasma concentrations of drugs that are metabolized by CYP450 1A2, 2C19, 2D6, and/or 3A4.  Osilodrostat has been shown to be a moderate inhibitor of CYP450 1A2, a mild to borderline moderate inhibitor of CYP450 2C19, and a weak inhibitor of CYP450 2D6 and 3A4.", "source": "DDInter", "management_text": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever osilodrostat is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272159/", "reference_text": "[1] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Inc  (2020):[2] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Australia Pty Ltd  (2022):[3] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases UK Ltd  (2021):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242084, "ingredient1": "Deflazacort", "ingredient2": "Pancuronium", "severity": "Moderate", "effect": "Corticosteroids may inhibit or enhance the action of nondepolarizing skeletal muscle relaxants.", "source": "DDInter", "management_text": "Patients should be closely monitored for altered neuromuscular blockade and signs of myopathy.  Dose adjustments of the muscle relaxant may be required.  The benefit-to-risk ratio should be considered and the duration of administration of the neuromuscular blocking agent should be limited as much as clinically feasible.", "mechanism_text": "Synergism", "recommendation": "Patients should be closely monitored for altered neuromuscular blockade and signs of myopathy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272160/", "reference_text": "[1] Parr SM, Galletly DC, Robinson BJ \"Betamethasone-induced resistance to vercuronium: a potential problem in neurosurgery.\" Anaesth Intensive Care 19 (1991):  103-5[2] Laflin MJ \"Interaction of pancuronium and corticosteroids.\" Anesthesiology 47 (1977):  471-2[3] Meyers EF \"Partial recovery from pancuronium neuromuscular blockade following hydrocortosone administration.\" Anesthesiology 46 (1977):  148-50[4] \"Product Information. Zemuron (rocuronium).\" Organon  (2001):[5] \"Product Information. Norcuron (vecuronium).\" Organon  (2001):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Agencia Espala de Medicamentos y Productos Sanitarios Healthcare \"Centro de informaci online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):[8] \"Product Information. Betamethasone Acet-Betamethasone Na Phos (betamethasone).\" Exela Pharma  (2022):", "alternatives_a": "Botulinum toxin type A", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242085, "ingredient1": "Deflazacort", "ingredient2": "Pipecuronium", "severity": "Moderate", "effect": "Corticosteroids may inhibit or enhance the action of nondepolarizing skeletal muscle relaxants.", "source": "DDInter", "management_text": "Patients should be closely monitored for altered neuromuscular blockade and signs of myopathy.  Dose adjustments of the muscle relaxant may be required.  The benefit-to-risk ratio should be considered and the duration of administration of the neuromuscular blocking agent should be limited as much as clinically feasible.", "mechanism_text": "Synergism", "recommendation": "Patients should be closely monitored for altered neuromuscular blockade and signs of myopathy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272161/", "reference_text": "[1] Parr SM, Galletly DC, Robinson BJ \"Betamethasone-induced resistance to vercuronium: a potential problem in neurosurgery.\" Anaesth Intensive Care 19 (1991):  103-5[2] Laflin MJ \"Interaction of pancuronium and corticosteroids.\" Anesthesiology 47 (1977):  471-2[3] Meyers EF \"Partial recovery from pancuronium neuromuscular blockade following hydrocortosone administration.\" Anesthesiology 46 (1977):  148-50[4] \"Product Information. Zemuron (rocuronium).\" Organon  (2001):[5] \"Product Information. Norcuron (vecuronium).\" Organon  (2001):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Agencia Espala de Medicamentos y Productos Sanitarios Healthcare \"Centro de informaci online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):[8] \"Product Information. Betamethasone Acet-Betamethasone Na Phos (betamethasone).\" Exela Pharma  (2022):", "alternatives_a": "Botulinum toxin type A", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242086, "ingredient1": "Deflazacort", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272171/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Entrectinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Lapatinib, Selumetinib, Vandetanib, Cobimetinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242087, "ingredient1": "Deflazacort", "ingredient2": "Rapacuronium", "severity": "Moderate", "effect": "Corticosteroids may inhibit or enhance the action of nondepolarizing skeletal muscle relaxants.", "source": "DDInter", "management_text": "Patients should be closely monitored for altered neuromuscular blockade and signs of myopathy.  Dose adjustments of the muscle relaxant may be required.  The benefit-to-risk ratio should be considered and the duration of administration of the neuromuscular blocking agent should be limited as much as clinically feasible.", "mechanism_text": "Synergism", "recommendation": "Patients should be closely monitored for altered neuromuscular blockade and signs of myopathy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272174/", "reference_text": "[1] Parr SM, Galletly DC, Robinson BJ \"Betamethasone-induced resistance to vercuronium: a potential problem in neurosurgery.\" Anaesth Intensive Care 19 (1991):  103-5[2] Laflin MJ \"Interaction of pancuronium and corticosteroids.\" Anesthesiology 47 (1977):  471-2[3] Meyers EF \"Partial recovery from pancuronium neuromuscular blockade following hydrocortosone administration.\" Anesthesiology 46 (1977):  148-50[4] \"Product Information. Zemuron (rocuronium).\" Organon  (2001):[5] \"Product Information. Norcuron (vecuronium).\" Organon  (2001):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Agencia Espala de Medicamentos y Productos Sanitarios Healthcare \"Centro de informaci online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):[8] \"Product Information. Betamethasone Acet-Betamethasone Na Phos (betamethasone).\" Exela Pharma  (2022):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242088, "ingredient1": "Deflazacort", "ingredient2": "Tubocurarine", "severity": "Moderate", "effect": "Corticosteroids may inhibit or enhance the action of nondepolarizing skeletal muscle relaxants.", "source": "DDInter", "management_text": "Patients should be closely monitored for altered neuromuscular blockade and signs of myopathy.  Dose adjustments of the muscle relaxant may be required.  The benefit-to-risk ratio should be considered and the duration of administration of the neuromuscular blocking agent should be limited as much as clinically feasible.", "mechanism_text": "Synergism", "recommendation": "Patients should be closely monitored for altered neuromuscular blockade and signs of myopathy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272200/", "reference_text": "[1] Parr SM, Galletly DC, Robinson BJ \"Betamethasone-induced resistance to vercuronium: a potential problem in neurosurgery.\" Anaesth Intensive Care 19 (1991):  103-5[2] Laflin MJ \"Interaction of pancuronium and corticosteroids.\" Anesthesiology 47 (1977):  471-2[3] Meyers EF \"Partial recovery from pancuronium neuromuscular blockade following hydrocortosone administration.\" Anesthesiology 46 (1977):  148-50[4] \"Product Information. Zemuron (rocuronium).\" Organon  (2001):[5] \"Product Information. Norcuron (vecuronium).\" Organon  (2001):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Agencia Espala de Medicamentos y Productos Sanitarios Healthcare \"Centro de informaci online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):[8] \"Product Information. Betamethasone Acet-Betamethasone Na Phos (betamethasone).\" Exela Pharma  (2022):", "alternatives_a": "Botulinum toxin type A", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242089, "ingredient1": "Deflazacort", "ingredient2": "Vecuronium", "severity": "Moderate", "effect": "Corticosteroids may inhibit or enhance the action of nondepolarizing skeletal muscle relaxants.", "source": "DDInter", "management_text": "Patients should be closely monitored for altered neuromuscular blockade and signs of myopathy.  Dose adjustments of the muscle relaxant may be required.  The benefit-to-risk ratio should be considered and the duration of administration of the neuromuscular blocking agent should be limited as much as clinically feasible.", "mechanism_text": "Synergism", "recommendation": "Patients should be closely monitored for altered neuromuscular blockade and signs of myopathy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272203/", "reference_text": "[1] Parr SM, Galletly DC, Robinson BJ \"Betamethasone-induced resistance to vercuronium: a potential problem in neurosurgery.\" Anaesth Intensive Care 19 (1991):  103-5[2] Laflin MJ \"Interaction of pancuronium and corticosteroids.\" Anesthesiology 47 (1977):  471-2[3] Meyers EF \"Partial recovery from pancuronium neuromuscular blockade following hydrocortosone administration.\" Anesthesiology 46 (1977):  148-50[4] \"Product Information. Zemuron (rocuronium).\" Organon  (2001):[5] \"Product Information. Norcuron (vecuronium).\" Organon  (2001):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Agencia Espala de Medicamentos y Productos Sanitarios Healthcare \"Centro de informaci online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):[8] \"Product Information. Betamethasone Acet-Betamethasone Na Phos (betamethasone).\" Exela Pharma  (2022):", "alternatives_a": "Botulinum toxin type A", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242090, "ingredient1": "Deflazacort", "ingredient2": "Varicella Zoster Vaccine (Recombinant)", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual's risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, the U.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272206/", "reference_text": "[1] \"Product Information. Fluzone (influenza virus vaccine, inactivated).\" Connaught Laboratories Inc[2] \"Product Information. Omnihib (haemophilus b conjugate vaccine (obsolete)).\" SmithKline Beecham[3] \"Product Information. Havrix (hepatitis A adult vaccine).\" SmithKline Beecham[4] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[5] \"Product Information. Imovax Rabies (rabies vaccine, human diploid cell).\" sanofi pasteur  (2022):[6] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc.  (2003):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline  (2022):[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations.  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf\"   (2019):[11] CDC Centers for Disease Control and Prevention \"Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html\"   (2022):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242091, "ingredient1": "Degarelix", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272214/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Anastrozole, Aminoglutethimide, Fulvestrant", "alternatives_b": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "updated_at": 1767369485}, {"id": 242092, "ingredient1": "Torasemide", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272228/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Entrectinib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, Lapatinib, More", "alternatives_b": "Furosemide, Bumetanide, Etacrynic acid, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, Clindamycin, More", "updated_at": 1767369485}, {"id": 242093, "ingredient1": "Oxitriptan", "ingredient2": "Meperidine", "severity": "Major", "effect": "Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John's wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.", "source": "DDInter", "management_text": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.  Patients should be closely monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.  For example, some experts suggest a 5-week washout period following use of fluoxetine and 3 weeks following the use of vortioxetine before administering another serotonergic agent.  Individual product labeling for washout periods should be consulted for current recommendations.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.", "mechanism_text": "Synergism", "recommendation": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272254/", "reference_text": "[1] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[2] Achamallah NS \"Visual hallucinations after combining fluoxetine and dextromethorphan .\" Am J Psychiatry 149 (1992):  1406[3] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993):  84-8[4] Metz A \"Interaction between fluoxetine and buspirone.\" Can J Psychiatry 35 (1990):  722-3[5] Goldberg RJ, Huk M \"Serotonin syndrome from trazodone and buspirone.\" Psychosomatics 33 (1992):  235-6[6] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation  (2002):[7] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[8] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990):  213-7[9] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics.\" J Clin Psychopharmacol 10 (1990):  48-50[10] \"Product Information. Zoloft (sertraline).\" Roerig Division  (2001):[11] \"Product Information. Prozac (fluoxetine).\" Dista Products Company  (2001):[12] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[13] Insel TR, Roy BF, Cohen RM, Murphy DL \"Possible development of the serotonin syndrome in man.\" Am J Psychiatry 139 (1982):  954-5[14] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories  (2001):[15] Gilman AG, eds., Nies AS, Rall TW, Taylor P \"Goodman and Gilman's the Pharmacological Basis of Therapeutics.\" New York, NY: Pergamon Press Inc.  (1990):[16] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline  (2001):[17] \"Product Information. Flexeril (cyclobenzaprine).\" Merck & Co., Inc  (2001):[18] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[19] \"Product Information. Imitrex (sumatriptan).\" Glaxo Wellcome  (2001):[20] Ruiz F \"Fluoxetine and the serotonin syndrome.\" Ann Emerg Med 24 (1994):  983-5[21] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc  (2001):[22] Reeves RR, Bullen JA \"Serotonin syndrome produced by paroxetine and low-dose trazodone.\" Psychosomatics 36 (1995):  159-60[23] Harvey AT, Preskorn SH \"Interactions of serotonin reuptake inhibitors with tricyclic antidepressants.\" Arch Gen Psychiatry 52 (1995):  783-4[24] Baetz M, Malcolm D \"Serotonin syndrome from fluvoxamine and buspirone.\" Can J Psychiatry 40 (1995):  428-9[25] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995):  440-2[26] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995):  481-2[27] George TP, Godleski LS \"Possible serotonin syndrome with trazodone addition to fluoxetine.\" Biol Psychiatry 39 (1996):  384-5[28] Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM \"The serotonin syndrome associated wtih paroxetine, an over-the-counter cold remedy, and vascular disease.\" Am J Emerg Med 12 (1994):  642-4[29] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[30] John L, Perreault MM, Tao T, Blew PG \"Serotonin syndrome associated with nefazodone and paroxetine.\" Ann Emerg Med 29 (1997):  287-9[31] \"Product Information. Zomig (zolmitriptan).\" Astra-Zeneca Pharmaceuticals  (2001):[32] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[33] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[34] Bhatara VS, Magnus RD, Paul KL, Preskorn SH \"Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms.\" Ann Pharmacother 32 (1998):  432-6[35] \"Product Information. Maxalt (rizatriptan).\" Merck & Co., Inc  (2001):[36] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals  (2001):[37] Gardner DM, Lynd LD \"Sumatriptan contraindications and the serotonin syndrome.\" Ann Pharmacother 32 (1998):  33-8[38] Mathew NT, Tietjen GE, Lucker C \"Serotonin syndrome complicating migraine pharmacotherapy.\" Cephalalgia 16 (1996):  323-7[39] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[40] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[41] Weiner AL \"Meperidine as a potential cause of serotonin syndrome in the emergency department.\" Acad Emerg Med 6 (1999):  156-8[42] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[43] Gordon JB \"SSRI's and St. John's Wort: possible toxicity?\" Am Fam Physician 57 (1998):  950,953[44] Lantz MS, Buchalter E, Giambanco V \"St. John's wort and antidepressant drug interactions in the elderly.\" J Geriatr Psychiatr Neurol 12 (1999):  7-10[45] Fugh-Berman A \"Herb-drug interactions.\" Lancet 355 (2000):  134-8[46] \"Product Information. Zyvox (linezolid).\" Pharmacia and Upjohn  (2001):[47] Perry NK \"Venlafaxine-induced serotonin syndrome with relapse following amitriptyline.\" Postgrad Med J 76 (2000):  254-6[48] Manos GH \"Possible serotonin syndrome associated with buspirone added to fluoxetine.\" Ann Pharmacother 34 (2000):  871-4[49] Nijhawan PK, Katz G, Winter S \"Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission.\" Crit Care Med 24 (1996):  1086-9[50] Laird LK \"Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder.\" Psychopharmacol Bull 32 (1996):  569-78[51] Margolese HC, Chouinard G \"Serotonin syndrome from addition of low-dose trazodone to nefazodone.\" Am J Psychiatry 157 (2000):  1022[52] Mackay FJ, Dunn NR, Mann RD \"Antidepressants and the serotonin syndrome in general practice.\" Br J Gen Pract 49 (1999):  871-4[53] Smith DL, Wenegrat BG \"A case report of serotonin syndrome associated with combined nefazodone and fluoxetine.\" J Clin Psychiatry 61 (2000):  146[54] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[55] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001):  2163-75[56] Duggal HS, Fetchko J \"Serotonin syndrome and atypical antipsychotics.\" Am J Psychiatry 159 (2002):  672-3[57] Wigen CL, Goetz MB \"Serotonin syndrome and linezolid.\" Clin Infect Dis 34 (2002):  1651-2[58] Hammerness P, Parada H, Abrams A \"Linezolid: MAOI Activity and Potential Drug Interactions.\" Psychosomatics 43 (2002):  248-9[59] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[60] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[61] Turkel SB, Nadala JG, Wincor MZ \"Possible serotonin syndrome in association with 5-HT3 antagonist agents.\" Psychosomatics 42 (2001):  258-60[62] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[63] Lavery S, Ravi H, McDaniel WW, Pushkin YR \"Linezolid and serotonin syndrome.\" Psychosomatics 42 (2001):  432-4[64] Lane R, Baldwin D \"Selective serotonin reuptake inhibitor--induced serotonin syndrome: review.\" J Clin Psychopharmacol 17 (1997):  208-21[65] Bernard L, Stern R, Lew D, Hoffmeyer P \"Serotonin syndrome after concomitant treatment with linezolid and citalopram.\" Clin Infect Dis 36 (2003):  1197[66] Dannawi M \"Possible serotonin syndrome after combination of buspirone and St John's Wort.\" J Psychopharmacol 16 (2002):  401[67] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[68] Hachem RY, Hicks K, Huen A, Raad I \"Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients.\" Clin Infect Dis 37 (2003):  E8-E11[69] Gillman PK \"Linezolid and serotonin toxicity.\" Clin Infect Dis 37 (2003):  1274-5[70] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[71] Giese SY, Neborsky R \"Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl.\" Plast Reconstr Surg 107 (2001):  293-4[72] Jones SL, Athan E, O'Brien D \"Serotonin syndrome due to co-administration of linezolid and venlafaxine.\" J Antimicrob Chemother 54 (2004):  289-90[73] Tahir N \"Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram.\" J Am Med Dir Assoc 5 (2004):  111-3[74] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company  (2004):[75] Thomas CR, Rosenberg M, Blythe V, Meyer WJ 3rd \"Serotonin syndrome and linezolid.\" J Am Acad Child Adolesc Psychiatry 43 (2004):  790[76] Boyer EW, Shannon M \"The serotonin syndrome.\" N Engl J Med 352 (2005):  1112-20[77] Bergeron L, Boule M, Perreault S \"Serotonin toxicity associated with concomitant use of linezolid.\" Ann Pharmacother 39 (2005):  956-61[78] Morales N, Vermette H \"Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine.\" Psychosomatics 46 (2005):  274-5[79] Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M, Grau S \"Linezolid-associated serotonin syndrome: what we can learn from cases reported so far.\" J Antimicrob Chemother 56 (2005):  1176-8[80] DeBellis RJ, Schaefer OP, Liquori M, Volturo GA \"Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient.\" J Intensive Care Med 20 (2005):  351-3[81] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[82] Taylor JJ, Wilson JW, Estes LL \"Linezolid and serotonergic drug interactions: a retrospective survey.\" Clin Infect Dis 43 (2006):  180-7[83] Strouse TB, Kerrihard TN, Forscher CA, Zakowski P \"Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine.\" J Clin Psychopharmacol 26 (2006):  681-683[84] Keegan MT, Brown DR, Rabinstein AA \"Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs.\" Anesth Analg 103 (2006):  1466-8[85] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S \"Rare case of serotonin syndrome with therapeutic doses of paroxetine.\" Am J Ther 13 (2006):  550-552[86] Steinberg M, Morin AK \"Mild serotonin syndrome associated with concurrent linezolid and fluoxetine.\" Am J Health Syst Pharm 64 (2007):  59-62[87] Packer S, Berman SA \"Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid.\" Am J Psychiatry 164 (2007):  346-7[88] Shapiro RE, Tepper SJ \"The serotonin syndrome, triptans, and the potential for drug-drug interactions.\" Headache 47 (2007):  266-9[89] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[90] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories  (2008):[91] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[92] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals  (2009):[93] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals  (2009):[94] Lee J, Franz L, Goforth HW \"Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine.\" Psychosomatics 50 (2009):  638-9[95] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC  (2011):[96] Mugele J, Nanagas KA, Tormoehlen LM \"Serotonin Syndrome Associated With MDPV Use: A Case Report.\" Ann Emerg Med  (2012):[97] \"Product Information. Oleptro (trazodone).\" Labopharm Inc  (2012):[98] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals  (2013):[99] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America  (2013):", "alternatives_a": "Naltrexone, Acetaminophen, Opium, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "alternatives_b": "Viloxazine", "updated_at": 1767369485}, {"id": 242094, "ingredient1": "Acrivastine", "ingredient2": "Meperidine", "severity": "Moderate", "effect": "The central nervous system and respiratory depressant effects of meperidine may be potentiated by concomitant use of other agents with CNS depressant effects.", "source": "DDInter", "management_text": "Caution and dosage adjustments are advisable when meperidine is used in combination with other narcotic analgesics, general anesthetics, phenothiazines, sedative-hypnotics, tranquilizers, tricyclic antidepressants, or other CNS depressants such as alcohol.  A lower dosage of meperidine should be considered initially, then titrated carefully according to pain level and clinical response.  Meperidine dosage reductions of 25% to 50% have been recommended for patients receiving phenothiazines and other tranquilizers.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position, and to notify their physician if they experience dizziness, lightheadedness, orthostasis, syncope, tachycardia, or excessive CNS effects that interfere with their normal activities.  Patients should also avoid driving or operating hazardous machinery until they know how these medications affect them.", "mechanism_text": "Synergism", "recommendation": "Caution and dosage adjustments are advisable when meperidine is used in combination with other narcotic analgesics, general anesthetics, phenothiazines, sedative-hypnotics, tranquilizers, tricyclic antidepressants, or other CNS depressants such as alcohol.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272256/", "reference_text": "[1] Lambertsen CJ, Wendel H, Longenhagen JB \"The separate and combined respiratory effects of chlorpromazine and meperidine in normal men controlled at 46 mm Hg alveolar pCO2.\" J Pharmacol Exp Ther 131 (1961):  381-93[2] Hoffman JC, Smith TC \"The respiratory effects of meperidine and propiomazine in man.\" Anesthesiology 32 (1970):  325-31[3] Stambaugh JE, Wainer IW \"Drug interaction: meperidine and chlorpromazine, a toxic combination.\" J Clin Pharmacol 21 (1981):  140-6[4] \"Product Information. Demerol (meperidine).\" Sanofi Winthrop Pharmaceuticals  (2002):[5] \"Product Information. Meperidine Hydrochloride (meperidine).\" Astra-Zeneca Pharmaceuticals  (2022):", "alternatives_a": "Azelastine, Ketotifen, Terfenadine, Astemizole", "alternatives_b": "Naltrexone, Acetaminophen, Dextropropoxyphene, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 242095, "ingredient1": "Eletriptan", "ingredient2": "Meperidine", "severity": "Major", "effect": "Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John's wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.", "source": "DDInter", "management_text": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.  Patients should be closely monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.  For example, some experts suggest a 5-week washout period following use of fluoxetine and 3 weeks following the use of vortioxetine before administering another serotonergic agent.  Individual product labeling for washout periods should be consulted for current recommendations.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.", "mechanism_text": "Synergism", "recommendation": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272260/", "reference_text": "[1] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[2] Achamallah NS \"Visual hallucinations after combining fluoxetine and dextromethorphan .\" Am J Psychiatry 149 (1992):  1406[3] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993):  84-8[4] Metz A \"Interaction between fluoxetine and buspirone.\" Can J Psychiatry 35 (1990):  722-3[5] Goldberg RJ, Huk M \"Serotonin syndrome from trazodone and buspirone.\" Psychosomatics 33 (1992):  235-6[6] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation  (2002):[7] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[8] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990):  213-7[9] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics.\" J Clin Psychopharmacol 10 (1990):  48-50[10] \"Product Information. Zoloft (sertraline).\" Roerig Division  (2001):[11] \"Product Information. Prozac (fluoxetine).\" Dista Products Company  (2001):[12] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[13] Insel TR, Roy BF, Cohen RM, Murphy DL \"Possible development of the serotonin syndrome in man.\" Am J Psychiatry 139 (1982):  954-5[14] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories  (2001):[15] Gilman AG, eds., Nies AS, Rall TW, Taylor P \"Goodman and Gilman's the Pharmacological Basis of Therapeutics.\" New York, NY: Pergamon Press Inc.  (1990):[16] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline  (2001):[17] \"Product Information. Flexeril (cyclobenzaprine).\" Merck & Co., Inc  (2001):[18] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[19] \"Product Information. Imitrex (sumatriptan).\" Glaxo Wellcome  (2001):[20] Ruiz F \"Fluoxetine and the serotonin syndrome.\" Ann Emerg Med 24 (1994):  983-5[21] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc  (2001):[22] Reeves RR, Bullen JA \"Serotonin syndrome produced by paroxetine and low-dose trazodone.\" Psychosomatics 36 (1995):  159-60[23] Harvey AT, Preskorn SH \"Interactions of serotonin reuptake inhibitors with tricyclic antidepressants.\" Arch Gen Psychiatry 52 (1995):  783-4[24] Baetz M, Malcolm D \"Serotonin syndrome from fluvoxamine and buspirone.\" Can J Psychiatry 40 (1995):  428-9[25] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995):  440-2[26] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995):  481-2[27] George TP, Godleski LS \"Possible serotonin syndrome with trazodone addition to fluoxetine.\" Biol Psychiatry 39 (1996):  384-5[28] Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM \"The serotonin syndrome associated wtih paroxetine, an over-the-counter cold remedy, and vascular disease.\" Am J Emerg Med 12 (1994):  642-4[29] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[30] John L, Perreault MM, Tao T, Blew PG \"Serotonin syndrome associated with nefazodone and paroxetine.\" Ann Emerg Med 29 (1997):  287-9[31] \"Product Information. Zomig (zolmitriptan).\" Astra-Zeneca Pharmaceuticals  (2001):[32] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[33] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[34] Bhatara VS, Magnus RD, Paul KL, Preskorn SH \"Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms.\" Ann Pharmacother 32 (1998):  432-6[35] \"Product Information. Maxalt (rizatriptan).\" Merck & Co., Inc  (2001):[36] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals  (2001):[37] Gardner DM, Lynd LD \"Sumatriptan contraindications and the serotonin syndrome.\" Ann Pharmacother 32 (1998):  33-8[38] Mathew NT, Tietjen GE, Lucker C \"Serotonin syndrome complicating migraine pharmacotherapy.\" Cephalalgia 16 (1996):  323-7[39] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[40] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[41] Weiner AL \"Meperidine as a potential cause of serotonin syndrome in the emergency department.\" Acad Emerg Med 6 (1999):  156-8[42] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[43] Gordon JB \"SSRI's and St. John's Wort: possible toxicity?\" Am Fam Physician 57 (1998):  950,953[44] Lantz MS, Buchalter E, Giambanco V \"St. John's wort and antidepressant drug interactions in the elderly.\" J Geriatr Psychiatr Neurol 12 (1999):  7-10[45] Fugh-Berman A \"Herb-drug interactions.\" Lancet 355 (2000):  134-8[46] \"Product Information. Zyvox (linezolid).\" Pharmacia and Upjohn  (2001):[47] Perry NK \"Venlafaxine-induced serotonin syndrome with relapse following amitriptyline.\" Postgrad Med J 76 (2000):  254-6[48] Manos GH \"Possible serotonin syndrome associated with buspirone added to fluoxetine.\" Ann Pharmacother 34 (2000):  871-4[49] Nijhawan PK, Katz G, Winter S \"Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission.\" Crit Care Med 24 (1996):  1086-9[50] Laird LK \"Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder.\" Psychopharmacol Bull 32 (1996):  569-78[51] Margolese HC, Chouinard G \"Serotonin syndrome from addition of low-dose trazodone to nefazodone.\" Am J Psychiatry 157 (2000):  1022[52] Mackay FJ, Dunn NR, Mann RD \"Antidepressants and the serotonin syndrome in general practice.\" Br J Gen Pract 49 (1999):  871-4[53] Smith DL, Wenegrat BG \"A case report of serotonin syndrome associated with combined nefazodone and fluoxetine.\" J Clin Psychiatry 61 (2000):  146[54] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[55] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001):  2163-75[56] Duggal HS, Fetchko J \"Serotonin syndrome and atypical antipsychotics.\" Am J Psychiatry 159 (2002):  672-3[57] Wigen CL, Goetz MB \"Serotonin syndrome and linezolid.\" Clin Infect Dis 34 (2002):  1651-2[58] Hammerness P, Parada H, Abrams A \"Linezolid: MAOI Activity and Potential Drug Interactions.\" Psychosomatics 43 (2002):  248-9[59] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[60] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[61] Turkel SB, Nadala JG, Wincor MZ \"Possible serotonin syndrome in association with 5-HT3 antagonist agents.\" Psychosomatics 42 (2001):  258-60[62] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[63] Lavery S, Ravi H, McDaniel WW, Pushkin YR \"Linezolid and serotonin syndrome.\" Psychosomatics 42 (2001):  432-4[64] Lane R, Baldwin D \"Selective serotonin reuptake inhibitor--induced serotonin syndrome: review.\" J Clin Psychopharmacol 17 (1997):  208-21[65] Bernard L, Stern R, Lew D, Hoffmeyer P \"Serotonin syndrome after concomitant treatment with linezolid and citalopram.\" Clin Infect Dis 36 (2003):  1197[66] Dannawi M \"Possible serotonin syndrome after combination of buspirone and St John's Wort.\" J Psychopharmacol 16 (2002):  401[67] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[68] Hachem RY, Hicks K, Huen A, Raad I \"Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients.\" Clin Infect Dis 37 (2003):  E8-E11[69] Gillman PK \"Linezolid and serotonin toxicity.\" Clin Infect Dis 37 (2003):  1274-5[70] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[71] Giese SY, Neborsky R \"Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl.\" Plast Reconstr Surg 107 (2001):  293-4[72] Jones SL, Athan E, O'Brien D \"Serotonin syndrome due to co-administration of linezolid and venlafaxine.\" J Antimicrob Chemother 54 (2004):  289-90[73] Tahir N \"Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram.\" J Am Med Dir Assoc 5 (2004):  111-3[74] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company  (2004):[75] Thomas CR, Rosenberg M, Blythe V, Meyer WJ 3rd \"Serotonin syndrome and linezolid.\" J Am Acad Child Adolesc Psychiatry 43 (2004):  790[76] Boyer EW, Shannon M \"The serotonin syndrome.\" N Engl J Med 352 (2005):  1112-20[77] Bergeron L, Boule M, Perreault S \"Serotonin toxicity associated with concomitant use of linezolid.\" Ann Pharmacother 39 (2005):  956-61[78] Morales N, Vermette H \"Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine.\" Psychosomatics 46 (2005):  274-5[79] Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M, Grau S \"Linezolid-associated serotonin syndrome: what we can learn from cases reported so far.\" J Antimicrob Chemother 56 (2005):  1176-8[80] DeBellis RJ, Schaefer OP, Liquori M, Volturo GA \"Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient.\" J Intensive Care Med 20 (2005):  351-3[81] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[82] Taylor JJ, Wilson JW, Estes LL \"Linezolid and serotonergic drug interactions: a retrospective survey.\" Clin Infect Dis 43 (2006):  180-7[83] Strouse TB, Kerrihard TN, Forscher CA, Zakowski P \"Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine.\" J Clin Psychopharmacol 26 (2006):  681-683[84] Keegan MT, Brown DR, Rabinstein AA \"Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs.\" Anesth Analg 103 (2006):  1466-8[85] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S \"Rare case of serotonin syndrome with therapeutic doses of paroxetine.\" Am J Ther 13 (2006):  550-552[86] Steinberg M, Morin AK \"Mild serotonin syndrome associated with concurrent linezolid and fluoxetine.\" Am J Health Syst Pharm 64 (2007):  59-62[87] Packer S, Berman SA \"Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid.\" Am J Psychiatry 164 (2007):  346-7[88] Shapiro RE, Tepper SJ \"The serotonin syndrome, triptans, and the potential for drug-drug interactions.\" Headache 47 (2007):  266-9[89] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[90] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories  (2008):[91] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[92] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals  (2009):[93] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals  (2009):[94] Lee J, Franz L, Goforth HW \"Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine.\" Psychosomatics 50 (2009):  638-9[95] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC  (2011):[96] Mugele J, Nanagas KA, Tormoehlen LM \"Serotonin Syndrome Associated With MDPV Use: A Case Report.\" Ann Emerg Med  (2012):[97] \"Product Information. Oleptro (trazodone).\" Labopharm Inc  (2012):[98] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals  (2013):[99] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America  (2013):", "alternatives_a": "Rimegepant, Eptinezumab, Ubrogepant, Galcanezumab, Atogepant, Methysergide, Erenumab, Fremanezumab", "alternatives_b": "Opium, Dextropropoxyphene, Naloxone, Naltrexone", "updated_at": 1767369485}, {"id": 242096, "ingredient1": "Ergotamine", "ingredient2": "Meperidine", "severity": "Major", "effect": "Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John's wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.", "source": "DDInter", "management_text": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.  Patients should be closely monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.  For example, some experts suggest a 5-week washout period following use of fluoxetine and 3 weeks following the use of vortioxetine before administering another serotonergic agent.  Individual product labeling for washout periods should be consulted for current recommendations.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.", "mechanism_text": "Synergism", "recommendation": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272262/", "reference_text": "[1] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[2] Achamallah NS \"Visual hallucinations after combining fluoxetine and dextromethorphan .\" Am J Psychiatry 149 (1992):  1406[3] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993):  84-8[4] Metz A \"Interaction between fluoxetine and buspirone.\" Can J Psychiatry 35 (1990):  722-3[5] Goldberg RJ, Huk M \"Serotonin syndrome from trazodone and buspirone.\" Psychosomatics 33 (1992):  235-6[6] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation  (2002):[7] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[8] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990):  213-7[9] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics.\" J Clin Psychopharmacol 10 (1990):  48-50[10] \"Product Information. Zoloft (sertraline).\" Roerig Division  (2001):[11] \"Product Information. Prozac (fluoxetine).\" Dista Products Company  (2001):[12] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[13] Insel TR, Roy BF, Cohen RM, Murphy DL \"Possible development of the serotonin syndrome in man.\" Am J Psychiatry 139 (1982):  954-5[14] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories  (2001):[15] Gilman AG, eds., Nies AS, Rall TW, Taylor P \"Goodman and Gilman's the Pharmacological Basis of Therapeutics.\" New York, NY: Pergamon Press Inc.  (1990):[16] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline  (2001):[17] \"Product Information. Flexeril (cyclobenzaprine).\" Merck & Co., Inc  (2001):[18] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[19] \"Product Information. Imitrex (sumatriptan).\" Glaxo Wellcome  (2001):[20] Ruiz F \"Fluoxetine and the serotonin syndrome.\" Ann Emerg Med 24 (1994):  983-5[21] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc  (2001):[22] Reeves RR, Bullen JA \"Serotonin syndrome produced by paroxetine and low-dose trazodone.\" Psychosomatics 36 (1995):  159-60[23] Harvey AT, Preskorn SH \"Interactions of serotonin reuptake inhibitors with tricyclic antidepressants.\" Arch Gen Psychiatry 52 (1995):  783-4[24] Baetz M, Malcolm D \"Serotonin syndrome from fluvoxamine and buspirone.\" Can J Psychiatry 40 (1995):  428-9[25] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995):  440-2[26] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995):  481-2[27] George TP, Godleski LS \"Possible serotonin syndrome with trazodone addition to fluoxetine.\" Biol Psychiatry 39 (1996):  384-5[28] Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM \"The serotonin syndrome associated wtih paroxetine, an over-the-counter cold remedy, and vascular disease.\" Am J Emerg Med 12 (1994):  642-4[29] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[30] John L, Perreault MM, Tao T, Blew PG \"Serotonin syndrome associated with nefazodone and paroxetine.\" Ann Emerg Med 29 (1997):  287-9[31] \"Product Information. Zomig (zolmitriptan).\" Astra-Zeneca Pharmaceuticals  (2001):[32] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[33] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[34] Bhatara VS, Magnus RD, Paul KL, Preskorn SH \"Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms.\" Ann Pharmacother 32 (1998):  432-6[35] \"Product Information. Maxalt (rizatriptan).\" Merck & Co., Inc  (2001):[36] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals  (2001):[37] Gardner DM, Lynd LD \"Sumatriptan contraindications and the serotonin syndrome.\" Ann Pharmacother 32 (1998):  33-8[38] Mathew NT, Tietjen GE, Lucker C \"Serotonin syndrome complicating migraine pharmacotherapy.\" Cephalalgia 16 (1996):  323-7[39] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[40] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[41] Weiner AL \"Meperidine as a potential cause of serotonin syndrome in the emergency department.\" Acad Emerg Med 6 (1999):  156-8[42] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[43] Gordon JB \"SSRI's and St. John's Wort: possible toxicity?\" Am Fam Physician 57 (1998):  950,953[44] Lantz MS, Buchalter E, Giambanco V \"St. John's wort and antidepressant drug interactions in the elderly.\" J Geriatr Psychiatr Neurol 12 (1999):  7-10[45] Fugh-Berman A \"Herb-drug interactions.\" Lancet 355 (2000):  134-8[46] \"Product Information. Zyvox (linezolid).\" Pharmacia and Upjohn  (2001):[47] Perry NK \"Venlafaxine-induced serotonin syndrome with relapse following amitriptyline.\" Postgrad Med J 76 (2000):  254-6[48] Manos GH \"Possible serotonin syndrome associated with buspirone added to fluoxetine.\" Ann Pharmacother 34 (2000):  871-4[49] Nijhawan PK, Katz G, Winter S \"Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission.\" Crit Care Med 24 (1996):  1086-9[50] Laird LK \"Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder.\" Psychopharmacol Bull 32 (1996):  569-78[51] Margolese HC, Chouinard G \"Serotonin syndrome from addition of low-dose trazodone to nefazodone.\" Am J Psychiatry 157 (2000):  1022[52] Mackay FJ, Dunn NR, Mann RD \"Antidepressants and the serotonin syndrome in general practice.\" Br J Gen Pract 49 (1999):  871-4[53] Smith DL, Wenegrat BG \"A case report of serotonin syndrome associated with combined nefazodone and fluoxetine.\" J Clin Psychiatry 61 (2000):  146[54] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[55] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001):  2163-75[56] Duggal HS, Fetchko J \"Serotonin syndrome and atypical antipsychotics.\" Am J Psychiatry 159 (2002):  672-3[57] Wigen CL, Goetz MB \"Serotonin syndrome and linezolid.\" Clin Infect Dis 34 (2002):  1651-2[58] Hammerness P, Parada H, Abrams A \"Linezolid: MAOI Activity and Potential Drug Interactions.\" Psychosomatics 43 (2002):  248-9[59] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[60] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[61] Turkel SB, Nadala JG, Wincor MZ \"Possible serotonin syndrome in association with 5-HT3 antagonist agents.\" Psychosomatics 42 (2001):  258-60[62] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[63] Lavery S, Ravi H, McDaniel WW, Pushkin YR \"Linezolid and serotonin syndrome.\" Psychosomatics 42 (2001):  432-4[64] Lane R, Baldwin D \"Selective serotonin reuptake inhibitor--induced serotonin syndrome: review.\" J Clin Psychopharmacol 17 (1997):  208-21[65] Bernard L, Stern R, Lew D, Hoffmeyer P \"Serotonin syndrome after concomitant treatment with linezolid and citalopram.\" Clin Infect Dis 36 (2003):  1197[66] Dannawi M \"Possible serotonin syndrome after combination of buspirone and St John's Wort.\" J Psychopharmacol 16 (2002):  401[67] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[68] Hachem RY, Hicks K, Huen A, Raad I \"Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients.\" Clin Infect Dis 37 (2003):  E8-E11[69] Gillman PK \"Linezolid and serotonin toxicity.\" Clin Infect Dis 37 (2003):  1274-5[70] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[71] Giese SY, Neborsky R \"Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl.\" Plast Reconstr Surg 107 (2001):  293-4[72] Jones SL, Athan E, O'Brien D \"Serotonin syndrome due to co-administration of linezolid and venlafaxine.\" J Antimicrob Chemother 54 (2004):  289-90[73] Tahir N \"Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram.\" J Am Med Dir Assoc 5 (2004):  111-3[74] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company  (2004):[75] Thomas CR, Rosenberg M, Blythe V, Meyer WJ 3rd \"Serotonin syndrome and linezolid.\" J Am Acad Child Adolesc Psychiatry 43 (2004):  790[76] Boyer EW, Shannon M \"The serotonin syndrome.\" N Engl J Med 352 (2005):  1112-20[77] Bergeron L, Boule M, Perreault S \"Serotonin toxicity associated with concomitant use of linezolid.\" Ann Pharmacother 39 (2005):  956-61[78] Morales N, Vermette H \"Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine.\" Psychosomatics 46 (2005):  274-5[79] Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M, Grau S \"Linezolid-associated serotonin syndrome: what we can learn from cases reported so far.\" J Antimicrob Chemother 56 (2005):  1176-8[80] DeBellis RJ, Schaefer OP, Liquori M, Volturo GA \"Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient.\" J Intensive Care Med 20 (2005):  351-3[81] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[82] Taylor JJ, Wilson JW, Estes LL \"Linezolid and serotonergic drug interactions: a retrospective survey.\" Clin Infect Dis 43 (2006):  180-7[83] Strouse TB, Kerrihard TN, Forscher CA, Zakowski P \"Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine.\" J Clin Psychopharmacol 26 (2006):  681-683[84] Keegan MT, Brown DR, Rabinstein AA \"Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs.\" Anesth Analg 103 (2006):  1466-8[85] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S \"Rare case of serotonin syndrome with therapeutic doses of paroxetine.\" Am J Ther 13 (2006):  550-552[86] Steinberg M, Morin AK \"Mild serotonin syndrome associated with concurrent linezolid and fluoxetine.\" Am J Health Syst Pharm 64 (2007):  59-62[87] Packer S, Berman SA \"Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid.\" Am J Psychiatry 164 (2007):  346-7[88] Shapiro RE, Tepper SJ \"The serotonin syndrome, triptans, and the potential for drug-drug interactions.\" Headache 47 (2007):  266-9[89] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[90] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories  (2008):[91] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[92] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals  (2009):[93] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals  (2009):[94] Lee J, Franz L, Goforth HW \"Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine.\" Psychosomatics 50 (2009):  638-9[95] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC  (2011):[96] Mugele J, Nanagas KA, Tormoehlen LM \"Serotonin Syndrome Associated With MDPV Use: A Case Report.\" Ann Emerg Med  (2012):[97] \"Product Information. Oleptro (trazodone).\" Labopharm Inc  (2012):[98] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals  (2013):[99] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America  (2013):", "alternatives_a": "Rimegepant, Eptinezumab, Ubrogepant, Galcanezumab, Atogepant, Methysergide, Erenumab, Fremanezumab", "alternatives_b": "Naltrexone, Oxymorphone, Oxycodone, Methadone, Buprenorphine, Oliceridine, Morphine, Butorphanol, Ibuprofen, Codeine, Nalbuphine, More", "updated_at": 1767369485}, {"id": 242097, "ingredient1": "Frovatriptan", "ingredient2": "Meperidine", "severity": "Major", "effect": "Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John's wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.", "source": "DDInter", "management_text": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.  Patients should be closely monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.  For example, some experts suggest a 5-week washout period following use of fluoxetine and 3 weeks following the use of vortioxetine before administering another serotonergic agent.  Individual product labeling for washout periods should be consulted for current recommendations.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.", "mechanism_text": "Synergism", "recommendation": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272264/", "reference_text": "[1] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[2] Achamallah NS \"Visual hallucinations after combining fluoxetine and dextromethorphan .\" Am J Psychiatry 149 (1992):  1406[3] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993):  84-8[4] Metz A \"Interaction between fluoxetine and buspirone.\" Can J Psychiatry 35 (1990):  722-3[5] Goldberg RJ, Huk M \"Serotonin syndrome from trazodone and buspirone.\" Psychosomatics 33 (1992):  235-6[6] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation  (2002):[7] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[8] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990):  213-7[9] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics.\" J Clin Psychopharmacol 10 (1990):  48-50[10] \"Product Information. Zoloft (sertraline).\" Roerig Division  (2001):[11] \"Product Information. Prozac (fluoxetine).\" Dista Products Company  (2001):[12] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[13] Insel TR, Roy BF, Cohen RM, Murphy DL \"Possible development of the serotonin syndrome in man.\" Am J Psychiatry 139 (1982):  954-5[14] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories  (2001):[15] Gilman AG, eds., Nies AS, Rall TW, Taylor P \"Goodman and Gilman's the Pharmacological Basis of Therapeutics.\" New York, NY: Pergamon Press Inc.  (1990):[16] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline  (2001):[17] \"Product Information. Flexeril (cyclobenzaprine).\" Merck & Co., Inc  (2001):[18] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[19] \"Product Information. Imitrex (sumatriptan).\" Glaxo Wellcome  (2001):[20] Ruiz F \"Fluoxetine and the serotonin syndrome.\" Ann Emerg Med 24 (1994):  983-5[21] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc  (2001):[22] Reeves RR, Bullen JA \"Serotonin syndrome produced by paroxetine and low-dose trazodone.\" Psychosomatics 36 (1995):  159-60[23] Harvey AT, Preskorn SH \"Interactions of serotonin reuptake inhibitors with tricyclic antidepressants.\" Arch Gen Psychiatry 52 (1995):  783-4[24] Baetz M, Malcolm D \"Serotonin syndrome from fluvoxamine and buspirone.\" Can J Psychiatry 40 (1995):  428-9[25] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995):  440-2[26] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995):  481-2[27] George TP, Godleski LS \"Possible serotonin syndrome with trazodone addition to fluoxetine.\" Biol Psychiatry 39 (1996):  384-5[28] Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM \"The serotonin syndrome associated wtih paroxetine, an over-the-counter cold remedy, and vascular disease.\" Am J Emerg Med 12 (1994):  642-4[29] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[30] John L, Perreault MM, Tao T, Blew PG \"Serotonin syndrome associated with nefazodone and paroxetine.\" Ann Emerg Med 29 (1997):  287-9[31] \"Product Information. Zomig (zolmitriptan).\" Astra-Zeneca Pharmaceuticals  (2001):[32] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[33] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[34] Bhatara VS, Magnus RD, Paul KL, Preskorn SH \"Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms.\" Ann Pharmacother 32 (1998):  432-6[35] \"Product Information. Maxalt (rizatriptan).\" Merck & Co., Inc  (2001):[36] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals  (2001):[37] Gardner DM, Lynd LD \"Sumatriptan contraindications and the serotonin syndrome.\" Ann Pharmacother 32 (1998):  33-8[38] Mathew NT, Tietjen GE, Lucker C \"Serotonin syndrome complicating migraine pharmacotherapy.\" Cephalalgia 16 (1996):  323-7[39] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[40] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[41] Weiner AL \"Meperidine as a potential cause of serotonin syndrome in the emergency department.\" Acad Emerg Med 6 (1999):  156-8[42] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[43] Gordon JB \"SSRI's and St. John's Wort: possible toxicity?\" Am Fam Physician 57 (1998):  950,953[44] Lantz MS, Buchalter E, Giambanco V \"St. John's wort and antidepressant drug interactions in the elderly.\" J Geriatr Psychiatr Neurol 12 (1999):  7-10[45] Fugh-Berman A \"Herb-drug interactions.\" Lancet 355 (2000):  134-8[46] \"Product Information. Zyvox (linezolid).\" Pharmacia and Upjohn  (2001):[47] Perry NK \"Venlafaxine-induced serotonin syndrome with relapse following amitriptyline.\" Postgrad Med J 76 (2000):  254-6[48] Manos GH \"Possible serotonin syndrome associated with buspirone added to fluoxetine.\" Ann Pharmacother 34 (2000):  871-4[49] Nijhawan PK, Katz G, Winter S \"Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission.\" Crit Care Med 24 (1996):  1086-9[50] Laird LK \"Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder.\" Psychopharmacol Bull 32 (1996):  569-78[51] Margolese HC, Chouinard G \"Serotonin syndrome from addition of low-dose trazodone to nefazodone.\" Am J Psychiatry 157 (2000):  1022[52] Mackay FJ, Dunn NR, Mann RD \"Antidepressants and the serotonin syndrome in general practice.\" Br J Gen Pract 49 (1999):  871-4[53] Smith DL, Wenegrat BG \"A case report of serotonin syndrome associated with combined nefazodone and fluoxetine.\" J Clin Psychiatry 61 (2000):  146[54] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[55] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001):  2163-75[56] Duggal HS, Fetchko J \"Serotonin syndrome and atypical antipsychotics.\" Am J Psychiatry 159 (2002):  672-3[57] Wigen CL, Goetz MB \"Serotonin syndrome and linezolid.\" Clin Infect Dis 34 (2002):  1651-2[58] Hammerness P, Parada H, Abrams A \"Linezolid: MAOI Activity and Potential Drug Interactions.\" Psychosomatics 43 (2002):  248-9[59] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[60] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[61] Turkel SB, Nadala JG, Wincor MZ \"Possible serotonin syndrome in association with 5-HT3 antagonist agents.\" Psychosomatics 42 (2001):  258-60[62] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[63] Lavery S, Ravi H, McDaniel WW, Pushkin YR \"Linezolid and serotonin syndrome.\" Psychosomatics 42 (2001):  432-4[64] Lane R, Baldwin D \"Selective serotonin reuptake inhibitor--induced serotonin syndrome: review.\" J Clin Psychopharmacol 17 (1997):  208-21[65] Bernard L, Stern R, Lew D, Hoffmeyer P \"Serotonin syndrome after concomitant treatment with linezolid and citalopram.\" Clin Infect Dis 36 (2003):  1197[66] Dannawi M \"Possible serotonin syndrome after combination of buspirone and St John's Wort.\" J Psychopharmacol 16 (2002):  401[67] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[68] Hachem RY, Hicks K, Huen A, Raad I \"Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients.\" Clin Infect Dis 37 (2003):  E8-E11[69] Gillman PK \"Linezolid and serotonin toxicity.\" Clin Infect Dis 37 (2003):  1274-5[70] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[71] Giese SY, Neborsky R \"Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl.\" Plast Reconstr Surg 107 (2001):  293-4[72] Jones SL, Athan E, O'Brien D \"Serotonin syndrome due to co-administration of linezolid and venlafaxine.\" J Antimicrob Chemother 54 (2004):  289-90[73] Tahir N \"Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram.\" J Am Med Dir Assoc 5 (2004):  111-3[74] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company  (2004):[75] Thomas CR, Rosenberg M, Blythe V, Meyer WJ 3rd \"Serotonin syndrome and linezolid.\" J Am Acad Child Adolesc Psychiatry 43 (2004):  790[76] Boyer EW, Shannon M \"The serotonin syndrome.\" N Engl J Med 352 (2005):  1112-20[77] Bergeron L, Boule M, Perreault S \"Serotonin toxicity associated with concomitant use of linezolid.\" Ann Pharmacother 39 (2005):  956-61[78] Morales N, Vermette H \"Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine.\" Psychosomatics 46 (2005):  274-5[79] Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M, Grau S \"Linezolid-associated serotonin syndrome: what we can learn from cases reported so far.\" J Antimicrob Chemother 56 (2005):  1176-8[80] DeBellis RJ, Schaefer OP, Liquori M, Volturo GA \"Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient.\" J Intensive Care Med 20 (2005):  351-3[81] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[82] Taylor JJ, Wilson JW, Estes LL \"Linezolid and serotonergic drug interactions: a retrospective survey.\" Clin Infect Dis 43 (2006):  180-7[83] Strouse TB, Kerrihard TN, Forscher CA, Zakowski P \"Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine.\" J Clin Psychopharmacol 26 (2006):  681-683[84] Keegan MT, Brown DR, Rabinstein AA \"Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs.\" Anesth Analg 103 (2006):  1466-8[85] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S \"Rare case of serotonin syndrome with therapeutic doses of paroxetine.\" Am J Ther 13 (2006):  550-552[86] Steinberg M, Morin AK \"Mild serotonin syndrome associated with concurrent linezolid and fluoxetine.\" Am J Health Syst Pharm 64 (2007):  59-62[87] Packer S, Berman SA \"Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid.\" Am J Psychiatry 164 (2007):  346-7[88] Shapiro RE, Tepper SJ \"The serotonin syndrome, triptans, and the potential for drug-drug interactions.\" Headache 47 (2007):  266-9[89] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[90] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories  (2008):[91] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[92] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals  (2009):[93] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals  (2009):[94] Lee J, Franz L, Goforth HW \"Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine.\" Psychosomatics 50 (2009):  638-9[95] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC  (2011):[96] Mugele J, Nanagas KA, Tormoehlen LM \"Serotonin Syndrome Associated With MDPV Use: A Case Report.\" Ann Emerg Med  (2012):[97] \"Product Information. Oleptro (trazodone).\" Labopharm Inc  (2012):[98] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals  (2013):[99] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America  (2013):", "alternatives_a": "Rimegepant, Eptinezumab, Ubrogepant, Galcanezumab, Atogepant, Methysergide, Erenumab, Fremanezumab", "alternatives_b": "Naltrexone, Acetaminophen, Opium, Dextropropoxyphene, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 242098, "ingredient1": "Meperidine", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "The central nervous system and respiratory depressant effects of meperidine may be potentiated by concomitant use of other agents with CNS depressant effects.", "source": "DDInter", "management_text": "Caution and dosage adjustments are advisable when meperidine is used in combination with other narcotic analgesics, general anesthetics, phenothiazines, sedative-hypnotics, tranquilizers, tricyclic antidepressants, or other CNS depressants such as alcohol.  A lower dosage of meperidine should be considered initially, then titrated carefully according to pain level and clinical response.  Meperidine dosage reductions of 25% to 50% have been recommended for patients receiving phenothiazines and other tranquilizers.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position, and to notify their physician if they experience dizziness, lightheadedness, orthostasis, syncope, tachycardia, or excessive CNS effects that interfere with their normal activities.  Patients should also avoid driving or operating hazardous machinery until they know how these medications affect them.", "mechanism_text": "Synergism", "recommendation": "Caution and dosage adjustments are advisable when meperidine is used in combination with other narcotic analgesics, general anesthetics, phenothiazines, sedative-hypnotics, tranquilizers, tricyclic antidepressants, or other CNS depressants such as alcohol.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272271/", "reference_text": "[1] Lambertsen CJ, Wendel H, Longenhagen JB \"The separate and combined respiratory effects of chlorpromazine and meperidine in normal men controlled at 46 mm Hg alveolar pCO2.\" J Pharmacol Exp Ther 131 (1961):  381-93[2] Hoffman JC, Smith TC \"The respiratory effects of meperidine and propiomazine in man.\" Anesthesiology 32 (1970):  325-31[3] Stambaugh JE, Wainer IW \"Drug interaction: meperidine and chlorpromazine, a toxic combination.\" J Clin Pharmacol 21 (1981):  140-6[4] \"Product Information. Demerol (meperidine).\" Sanofi Winthrop Pharmaceuticals  (2002):[5] \"Product Information. Meperidine Hydrochloride (meperidine).\" Astra-Zeneca Pharmaceuticals  (2022):", "alternatives_a": "Amantadine, Cabergoline", "alternatives_b": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 242099, "ingredient1": "Meperidine", "ingredient2": "Melatonin", "severity": "Moderate", "effect": "The central nervous system and respiratory depressant effects of meperidine may be potentiated by concomitant use of other agents with CNS depressant effects.", "source": "DDInter", "management_text": "Caution and dosage adjustments are advisable when meperidine is used in combination with other narcotic analgesics, general anesthetics, phenothiazines, sedative-hypnotics, tranquilizers, tricyclic antidepressants, or other CNS depressants such as alcohol.  A lower dosage of meperidine should be considered initially, then titrated carefully according to pain level and clinical response.  Meperidine dosage reductions of 25% to 50% have been recommended for patients receiving phenothiazines and other tranquilizers.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position, and to notify their physician if they experience dizziness, lightheadedness, orthostasis, syncope, tachycardia, or excessive CNS effects that interfere with their normal activities.  Patients should also avoid driving or operating hazardous machinery until they know how these medications affect them.", "mechanism_text": "Synergism", "recommendation": "Caution and dosage adjustments are advisable when meperidine is used in combination with other narcotic analgesics, general anesthetics, phenothiazines, sedative-hypnotics, tranquilizers, tricyclic antidepressants, or other CNS depressants such as alcohol.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272273/", "reference_text": "[1] Lambertsen CJ, Wendel H, Longenhagen JB \"The separate and combined respiratory effects of chlorpromazine and meperidine in normal men controlled at 46 mm Hg alveolar pCO2.\" J Pharmacol Exp Ther 131 (1961):  381-93[2] Hoffman JC, Smith TC \"The respiratory effects of meperidine and propiomazine in man.\" Anesthesiology 32 (1970):  325-31[3] Stambaugh JE, Wainer IW \"Drug interaction: meperidine and chlorpromazine, a toxic combination.\" J Clin Pharmacol 21 (1981):  140-6[4] \"Product Information. Demerol (meperidine).\" Sanofi Winthrop Pharmaceuticals  (2002):[5] \"Product Information. Meperidine Hydrochloride (meperidine).\" Astra-Zeneca Pharmaceuticals  (2022):", "alternatives_a": "Nitrazepam", "alternatives_b": "Naltrexone, Acetaminophen, Dextropropoxyphene, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 242100, "ingredient1": "Pralsetinib", "ingredient2": "Meperidine", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272278/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Oxymorphone, Tapentadol, Butorphanol, Hydromorphone, Dezocine, Opium, Pentazocine, Acetylsalicylic acid, Naloxone, Nalbuphine", "alternatives_b": "Entrectinib, Imatinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, More", "updated_at": 1767369485}, {"id": 242101, "ingredient1": "Rizatriptan", "ingredient2": "Meperidine", "severity": "Major", "effect": "Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John's wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.", "source": "DDInter", "management_text": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.  Patients should be closely monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.  For example, some experts suggest a 5-week washout period following use of fluoxetine and 3 weeks following the use of vortioxetine before administering another serotonergic agent.  Individual product labeling for washout periods should be consulted for current recommendations.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.", "mechanism_text": "Synergism", "recommendation": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272279/", "reference_text": "[1] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[2] Achamallah NS \"Visual hallucinations after combining fluoxetine and dextromethorphan .\" Am J Psychiatry 149 (1992):  1406[3] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993):  84-8[4] Metz A \"Interaction between fluoxetine and buspirone.\" Can J Psychiatry 35 (1990):  722-3[5] Goldberg RJ, Huk M \"Serotonin syndrome from trazodone and buspirone.\" Psychosomatics 33 (1992):  235-6[6] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation  (2002):[7] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[8] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990):  213-7[9] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics.\" J Clin Psychopharmacol 10 (1990):  48-50[10] \"Product Information. Zoloft (sertraline).\" Roerig Division  (2001):[11] \"Product Information. Prozac (fluoxetine).\" Dista Products Company  (2001):[12] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[13] Insel TR, Roy BF, Cohen RM, Murphy DL \"Possible development of the serotonin syndrome in man.\" Am J Psychiatry 139 (1982):  954-5[14] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories  (2001):[15] Gilman AG, eds., Nies AS, Rall TW, Taylor P \"Goodman and Gilman's the Pharmacological Basis of Therapeutics.\" New York, NY: Pergamon Press Inc.  (1990):[16] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline  (2001):[17] \"Product Information. Flexeril (cyclobenzaprine).\" Merck & Co., Inc  (2001):[18] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[19] \"Product Information. Imitrex (sumatriptan).\" Glaxo Wellcome  (2001):[20] Ruiz F \"Fluoxetine and the serotonin syndrome.\" Ann Emerg Med 24 (1994):  983-5[21] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc  (2001):[22] Reeves RR, Bullen JA \"Serotonin syndrome produced by paroxetine and low-dose trazodone.\" Psychosomatics 36 (1995):  159-60[23] Harvey AT, Preskorn SH \"Interactions of serotonin reuptake inhibitors with tricyclic antidepressants.\" Arch Gen Psychiatry 52 (1995):  783-4[24] Baetz M, Malcolm D \"Serotonin syndrome from fluvoxamine and buspirone.\" Can J Psychiatry 40 (1995):  428-9[25] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995):  440-2[26] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995):  481-2[27] George TP, Godleski LS \"Possible serotonin syndrome with trazodone addition to fluoxetine.\" Biol Psychiatry 39 (1996):  384-5[28] Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM \"The serotonin syndrome associated wtih paroxetine, an over-the-counter cold remedy, and vascular disease.\" Am J Emerg Med 12 (1994):  642-4[29] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[30] John L, Perreault MM, Tao T, Blew PG \"Serotonin syndrome associated with nefazodone and paroxetine.\" Ann Emerg Med 29 (1997):  287-9[31] \"Product Information. Zomig (zolmitriptan).\" Astra-Zeneca Pharmaceuticals  (2001):[32] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[33] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[34] Bhatara VS, Magnus RD, Paul KL, Preskorn SH \"Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms.\" Ann Pharmacother 32 (1998):  432-6[35] \"Product Information. Maxalt (rizatriptan).\" Merck & Co., Inc  (2001):[36] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals  (2001):[37] Gardner DM, Lynd LD \"Sumatriptan contraindications and the serotonin syndrome.\" Ann Pharmacother 32 (1998):  33-8[38] Mathew NT, Tietjen GE, Lucker C \"Serotonin syndrome complicating migraine pharmacotherapy.\" Cephalalgia 16 (1996):  323-7[39] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[40] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[41] Weiner AL \"Meperidine as a potential cause of serotonin syndrome in the emergency department.\" Acad Emerg Med 6 (1999):  156-8[42] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[43] Gordon JB \"SSRI's and St. John's Wort: possible toxicity?\" Am Fam Physician 57 (1998):  950,953[44] Lantz MS, Buchalter E, Giambanco V \"St. John's wort and antidepressant drug interactions in the elderly.\" J Geriatr Psychiatr Neurol 12 (1999):  7-10[45] Fugh-Berman A \"Herb-drug interactions.\" Lancet 355 (2000):  134-8[46] \"Product Information. Zyvox (linezolid).\" Pharmacia and Upjohn  (2001):[47] Perry NK \"Venlafaxine-induced serotonin syndrome with relapse following amitriptyline.\" Postgrad Med J 76 (2000):  254-6[48] Manos GH \"Possible serotonin syndrome associated with buspirone added to fluoxetine.\" Ann Pharmacother 34 (2000):  871-4[49] Nijhawan PK, Katz G, Winter S \"Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission.\" Crit Care Med 24 (1996):  1086-9[50] Laird LK \"Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder.\" Psychopharmacol Bull 32 (1996):  569-78[51] Margolese HC, Chouinard G \"Serotonin syndrome from addition of low-dose trazodone to nefazodone.\" Am J Psychiatry 157 (2000):  1022[52] Mackay FJ, Dunn NR, Mann RD \"Antidepressants and the serotonin syndrome in general practice.\" Br J Gen Pract 49 (1999):  871-4[53] Smith DL, Wenegrat BG \"A case report of serotonin syndrome associated with combined nefazodone and fluoxetine.\" J Clin Psychiatry 61 (2000):  146[54] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[55] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001):  2163-75[56] Duggal HS, Fetchko J \"Serotonin syndrome and atypical antipsychotics.\" Am J Psychiatry 159 (2002):  672-3[57] Wigen CL, Goetz MB \"Serotonin syndrome and linezolid.\" Clin Infect Dis 34 (2002):  1651-2[58] Hammerness P, Parada H, Abrams A \"Linezolid: MAOI Activity and Potential Drug Interactions.\" Psychosomatics 43 (2002):  248-9[59] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[60] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[61] Turkel SB, Nadala JG, Wincor MZ \"Possible serotonin syndrome in association with 5-HT3 antagonist agents.\" Psychosomatics 42 (2001):  258-60[62] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[63] Lavery S, Ravi H, McDaniel WW, Pushkin YR \"Linezolid and serotonin syndrome.\" Psychosomatics 42 (2001):  432-4[64] Lane R, Baldwin D \"Selective serotonin reuptake inhibitor--induced serotonin syndrome: review.\" J Clin Psychopharmacol 17 (1997):  208-21[65] Bernard L, Stern R, Lew D, Hoffmeyer P \"Serotonin syndrome after concomitant treatment with linezolid and citalopram.\" Clin Infect Dis 36 (2003):  1197[66] Dannawi M \"Possible serotonin syndrome after combination of buspirone and St John's Wort.\" J Psychopharmacol 16 (2002):  401[67] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[68] Hachem RY, Hicks K, Huen A, Raad I \"Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients.\" Clin Infect Dis 37 (2003):  E8-E11[69] Gillman PK \"Linezolid and serotonin toxicity.\" Clin Infect Dis 37 (2003):  1274-5[70] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[71] Giese SY, Neborsky R \"Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl.\" Plast Reconstr Surg 107 (2001):  293-4[72] Jones SL, Athan E, O'Brien D \"Serotonin syndrome due to co-administration of linezolid and venlafaxine.\" J Antimicrob Chemother 54 (2004):  289-90[73] Tahir N \"Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram.\" J Am Med Dir Assoc 5 (2004):  111-3[74] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company  (2004):[75] Thomas CR, Rosenberg M, Blythe V, Meyer WJ 3rd \"Serotonin syndrome and linezolid.\" J Am Acad Child Adolesc Psychiatry 43 (2004):  790[76] Boyer EW, Shannon M \"The serotonin syndrome.\" N Engl J Med 352 (2005):  1112-20[77] Bergeron L, Boule M, Perreault S \"Serotonin toxicity associated with concomitant use of linezolid.\" Ann Pharmacother 39 (2005):  956-61[78] Morales N, Vermette H \"Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine.\" Psychosomatics 46 (2005):  274-5[79] Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M, Grau S \"Linezolid-associated serotonin syndrome: what we can learn from cases reported so far.\" J Antimicrob Chemother 56 (2005):  1176-8[80] DeBellis RJ, Schaefer OP, Liquori M, Volturo GA \"Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient.\" J Intensive Care Med 20 (2005):  351-3[81] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[82] Taylor JJ, Wilson JW, Estes LL \"Linezolid and serotonergic drug interactions: a retrospective survey.\" Clin Infect Dis 43 (2006):  180-7[83] Strouse TB, Kerrihard TN, Forscher CA, Zakowski P \"Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine.\" J Clin Psychopharmacol 26 (2006):  681-683[84] Keegan MT, Brown DR, Rabinstein AA \"Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs.\" Anesth Analg 103 (2006):  1466-8[85] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S \"Rare case of serotonin syndrome with therapeutic doses of paroxetine.\" Am J Ther 13 (2006):  550-552[86] Steinberg M, Morin AK \"Mild serotonin syndrome associated with concurrent linezolid and fluoxetine.\" Am J Health Syst Pharm 64 (2007):  59-62[87] Packer S, Berman SA \"Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid.\" Am J Psychiatry 164 (2007):  346-7[88] Shapiro RE, Tepper SJ \"The serotonin syndrome, triptans, and the potential for drug-drug interactions.\" Headache 47 (2007):  266-9[89] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[90] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories  (2008):[91] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[92] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals  (2009):[93] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals  (2009):[94] Lee J, Franz L, Goforth HW \"Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine.\" Psychosomatics 50 (2009):  638-9[95] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC  (2011):[96] Mugele J, Nanagas KA, Tormoehlen LM \"Serotonin Syndrome Associated With MDPV Use: A Case Report.\" Ann Emerg Med  (2012):[97] \"Product Information. Oleptro (trazodone).\" Labopharm Inc  (2012):[98] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals  (2013):[99] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America  (2013):", "alternatives_a": "Opium, Dextropropoxyphene, Naloxone, Naltrexone", "alternatives_b": "Rimegepant, Eptinezumab, Ubrogepant, Galcanezumab, Atogepant, Methysergide, Erenumab, Fremanezumab", "updated_at": 1767369485}, {"id": 242102, "ingredient1": "Tolevamer", "ingredient2": "Meperidine", "severity": "Moderate", "effect": "Coadministration with medications that can cause constipation such as opioids may increase the risk of intestinal injuries associated with the use of sodium polystyrene sulfonate.", "source": "DDInter", "management_text": "Because opioids commonly cause constipation, caution is advised when used during treatment with sodium polystyrene sulfonate.  The prescribing information recommends avoiding the use of sodium polystyrene sulfonate in patients who are at risk for developing constipation or impaction, including those with a history of impaction, chronic constipation, inflammatory bowel disease, ischemic colitis, vascular intestinal atherosclerosis, previous bowel resection, or bowel obstruction, as well as those who have not had a bowel movement post-surgery.  If clinically significant constipation develops, treatment with sodium polystyrene sulfonate should be discontinued until normal bowel motion is resumed.  Concomitant administration of sorbitol is not recommended.", "mechanism_text": "Synergism", "recommendation": "Because opioids commonly cause constipation, caution is advised when used during treatment with sodium polystyrene sulfonate.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272280/", "reference_text": "[1] Foresti V \"Intestinal obstruction due to kayexalate in a patient concurrently treated with aluminum hydroxide and morphine sulfate.\" Clin Nephrol 41 (1994):  252[2] \"Product Information. Kayexalate (sodium polystyrene sulfonate).\" Sanofi Winthrop Pharmaceuticals  (2001):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):", "alternatives_a": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "alternatives_b": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Cobicistat, Deferoxamine, Levoleucovorin, Arginine, More", "updated_at": 1767369485}, {"id": 242103, "ingredient1": "Acrivastine", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272284/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Levocetirizine, Chlorcyclizine, Cetirizine, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "updated_at": 1767369485}, {"id": 242104, "ingredient1": "Esketamine", "ingredient2": "Metyrosine", "severity": "Major", "effect": "Concomitant use of esketamine with central nervous system (CNS) depressants may increase sedation and impairment of attention, judgment, thinking, reaction speed, and psychomotor skills.", "source": "DDInter", "management_text": "Caution is advised and patients should be closely monitored during concomitant use of esketamine with CNS depressants or other drugs that can cause sedation or dizziness.  Due to the risk of delayed or prolonged sedation and other adverse effects, patients should be monitored for at least 2 hours after esketamine administration, followed by an assessment to determine when the patient is considered clinically stable and ready to leave the healthcare setting.  Patients should be instructed not to engage in potentially hazardous activities that require complete mental alertness and motor coordination, such as driving a motor vehicle or operating machinery, until the next day after a restful sleep.", "mechanism_text": "Synergism", "recommendation": "Caution is advised and patients should be closely monitored during concomitant use of esketamine with CNS depressants or other drugs that can cause sedation or dizziness.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272288/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Spravato (esketamine).\" Janssen Pharmaceuticals  (2019):", "alternatives_a": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion, Halothane, Sodium oxybate, Isoflurane, More", "alternatives_b": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "updated_at": 1767369485}, {"id": 242105, "ingredient1": "Fenfluramine", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272289/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Dexfenfluramine, Naltrexone, Ephedrine, Bupropion, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol, Lacosamide", "alternatives_b": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "updated_at": 1767369485}, {"id": 242106, "ingredient1": "Metyrosine", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272293/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Apomorphine, Amantadine, Cabergoline", "alternatives_b": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "updated_at": 1767369485}, {"id": 242107, "ingredient1": "Metyrosine", "ingredient2": "Melatonin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272294/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "updated_at": 1767369485}, {"id": 242108, "ingredient1": "Selegiline", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272298/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Bosentan, Riociguat, Ambrisentan, Macitentan", "alternatives_b": "Apomorphine, Amantadine, Cabergoline", "updated_at": 1767369485}, {"id": 242109, "ingredient1": "Denosumab", "ingredient2": "Melphalan flufenamide", "severity": "Moderate", "effect": "Concomitant use of immunosuppressive or myelosuppressive agents with denosumab may increase the risk of serious infections.", "source": "DDInter", "management_text": "Caution is advised if denosumab must be used in combination with immuno- or myelosuppressive agents.  Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.  The need for continued denosumab therapy should be assessed when serious infections occur during treatment.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if denosumab must be used in combination with immuno- or myelosuppressive agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272445/", "reference_text": "[1] \"Product Information. Prolia (denosumab).\" Amgen USA  (2010):", "alternatives_a": "Tiludronic acid, Alendronic acid, Vosoritide, Etidronic acid, Ibandronate, Cholecalciferol, Burosumab, Risedronic acid, Romosozumab, Zoledronic acid, Pamidronic acid", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242110, "ingredient1": "Denosumab", "ingredient2": "Promazine", "severity": "Moderate", "effect": "Concomitant use of immunosuppressive or myelosuppressive agents with denosumab may increase the risk of serious infections.", "source": "DDInter", "management_text": "Caution is advised if denosumab must be used in combination with immuno- or myelosuppressive agents.  Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.  The need for continued denosumab therapy should be assessed when serious infections occur during treatment.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if denosumab must be used in combination with immuno- or myelosuppressive agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272449/", "reference_text": "[1] \"Product Information. Prolia (denosumab).\" Amgen USA  (2010):", "alternatives_a": "Tiludronic acid, Alendronic acid, Vosoritide, Etidronic acid, Ibandronate, Cholecalciferol, Burosumab, Risedronic acid, Romosozumab, Zoledronic acid, Pamidronic acid", "alternatives_b": "Fluphenazine, Haloperidol, Thiothixene, Risperidone, Amisulpride, Quetiapine, Prochlorperazine, Thioridazine, Lumateperone, Pimozide, Trifluoperazine, More", "updated_at": 1767369485}, {"id": 242111, "ingredient1": "Heparin (flush)", "ingredient2": "Deoxycholic acid", "severity": "Moderate", "effect": "Concomitant use of heparin flush and drugs that interfere with platelet function or coagulation or drugs that commonly cause thrombocytopenia may potentiate the risk of bleeding complications.  Although uncommon, inadvertent anticoagulation resulting in hemorrhagic events may occur with heparin flushes, particularly during repeated or excessive use or administration of higher concentration flush solutions.", "source": "DDInter", "management_text": "Caution and monitoring (e.g., platelet counts, hematocrits, tests for occult blood in stools) are advised when heparin flushes are given to patients receiving systemic anticoagulants, platelet inhibitors, antithrombotic agents, thrombolytics, or drugs with known risks of thrombocytopenia or bleeding.  An unexplained fall in hematocrit, fall in blood pressure, or any other unexplained symptom should lead to serious consideration of a hemorrhagic event.", "mechanism_text": "Synergism", "recommendation": "Caution and monitoring (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272451/", "reference_text": "[1] Passannante A, Macik BG \"The heparin flush syndrome: a cause of iatrogenic hemorrhage.\" Am J Med Sci 296 (1988):  71-3[2] \"Product Information. Heparin Sodium in Sodium Chloride (heparin flush).\" Baxter Healthcare Corporation  (2022):[3] \"Product Information. Canusal (heparin flush).\" Wockhardt UK Ltd  (2018):[4] \"Product Information. Heparinised Saline (Pfizer) (heparinised saline).\" Pfizer Australia Pty Ltd  (2022):", "alternatives_a": "Tacrolimus, Minoxidil, Calcium gluconate, Glycopyrronium, Magnesium sulfate, Pimecrolimus, Aminobenzoic acid, Finasteride, Ivermectin, Caffeine, Cromoglicic acid, More", "alternatives_b": "Defibrotide, Protein C, Acenocoumarol, Selexipag, Drotrecogin alfa, Pentosan polysulfate, Ascorbic acid, Cyclosporine, Sirolimus, Potassium Iodide, Vitamin A, More", "updated_at": 1767369485}, {"id": 242112, "ingredient1": "Carteolol", "ingredient2": "Morphine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272454/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Methazolamide, Neostigmine, Physostigmine, Acetylcholine, Diclofenamide, Brinzolamide, Brimonidine, Levobunolol", "alternatives_b": "Diphenoxylate, Opium, Eluxadoline, Difenoxin, Loperamide, Naltrexone, Oxymorphone, Oxycodone, Methadone, Pentazocine, Buprenorphine, More", "updated_at": 1767369485}, {"id": 242113, "ingredient1": "Etidocaine", "ingredient2": "Morphine", "severity": "Moderate", "effect": "Concomitant epidural administration of local anesthetics may affect the release of morphine sulfate from the liposomal formulation.  The mechanism of interaction is unknown.", "source": "DDInter", "management_text": "To minimize the potential for interaction between liposomal morphine and lidocaine-epinephrine test dose (1.5%-1:200,000, 3 mL), flush the epidural catheter with 1 mL of preservative-free 0.9% normal saline and wait at least 15 minutes after the test dose before administering the morphine.  Following administration of an analgesic dose of bupivacaine (0.25%, 20 mL), flush the epidural catheter with 1 mL of preservative-free 0.9% normal saline and wait at least 30 minutes before administering the morphine.  Liposomal morphine should not be mixed with any other medications.  Once it has been administered, no other medication should be administered into the epidural space for at least 48 hours.", "mechanism_text": "Absorption", "recommendation": "To minimize the potential for interaction between liposomal morphine and lidocaine-epinephrine test dose (1.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272455/", "reference_text": "[1] \"Product Information. DepoDur (morphine liposomal).\" Endo Laboratories LLC  (2004):", "alternatives_a": "Procaine, Chloroprocaine, Tetracaine", "alternatives_b": "Diphenoxylate, Opium, Eluxadoline, Difenoxin, Loperamide, Naltrexone, Oxymorphone, Oxycodone, Methadone, Pentazocine, Buprenorphine, More", "updated_at": 1767369485}, {"id": 242114, "ingredient1": "Morphine", "ingredient2": "Levobupivacaine", "severity": "Moderate", "effect": "Concomitant epidural administration of local anesthetics may affect the release of morphine sulfate from the liposomal formulation.  The mechanism of interaction is unknown.", "source": "DDInter", "management_text": "To minimize the potential for interaction between liposomal morphine and lidocaine-epinephrine test dose (1.5%-1:200,000, 3 mL), flush the epidural catheter with 1 mL of preservative-free 0.9% normal saline and wait at least 15 minutes after the test dose before administering the morphine.  Following administration of an analgesic dose of bupivacaine (0.25%, 20 mL), flush the epidural catheter with 1 mL of preservative-free 0.9% normal saline and wait at least 30 minutes before administering the morphine.  Liposomal morphine should not be mixed with any other medications.  Once it has been administered, no other medication should be administered into the epidural space for at least 48 hours.", "mechanism_text": "Absorption", "recommendation": "To minimize the potential for interaction between liposomal morphine and lidocaine-epinephrine test dose (1.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272456/", "reference_text": "[1] \"Product Information. DepoDur (morphine liposomal).\" Endo Laboratories LLC  (2004):", "alternatives_a": "Procaine, Chloroprocaine, Tetracaine", "alternatives_b": "Diphenoxylate, Opium, Eluxadoline, Difenoxin, Loperamide, Naltrexone, Oxymorphone, Oxycodone, Methadone, Pentazocine, Buprenorphine, More", "updated_at": 1767369485}, {"id": 242115, "ingredient1": "Penbutolol", "ingredient2": "Morphine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272457/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Diphenoxylate, Opium, Eluxadoline, Difenoxin, Loperamide, Codeine, Naltrexone, Oxymorphone, Naloxone, Oxycodone, Tapentadol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242116, "ingredient1": "Ropivacaine", "ingredient2": "Morphine", "severity": "Moderate", "effect": "Concomitant epidural administration of local anesthetics may affect the release of morphine sulfate from the liposomal formulation.  The mechanism of interaction is unknown.", "source": "DDInter", "management_text": "To minimize the potential for interaction between liposomal morphine and lidocaine-epinephrine test dose (1.5%-1:200,000, 3 mL), flush the epidural catheter with 1 mL of preservative-free 0.9% normal saline and wait at least 15 minutes after the test dose before administering the morphine.  Following administration of an analgesic dose of bupivacaine (0.25%, 20 mL), flush the epidural catheter with 1 mL of preservative-free 0.9% normal saline and wait at least 30 minutes before administering the morphine.  Liposomal morphine should not be mixed with any other medications.  Once it has been administered, no other medication should be administered into the epidural space for at least 48 hours.", "mechanism_text": "Absorption", "recommendation": "To minimize the potential for interaction between liposomal morphine and lidocaine-epinephrine test dose (1.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272458/", "reference_text": "[1] \"Product Information. DepoDur (morphine liposomal).\" Endo Laboratories LLC  (2004):", "alternatives_a": "Diphenoxylate, Opium, Eluxadoline, Difenoxin, Loperamide, Naltrexone, Oxymorphone, Methadone, Pentazocine, Buprenorphine, Oliceridine, More", "alternatives_b": "Procaine, Chloroprocaine, Tetracaine", "updated_at": 1767369485}, {"id": 242117, "ingredient1": "Dexmethylphenidate", "ingredient2": "Desflurane", "severity": "Moderate", "effect": "The administration of volatile general anesthetics during therapy with methylphenidate or its derivatives may increase the risk of hypertension and/or arrhythmias during surgery.  The proposed mechanism is anesthetic-induced myocardial sensitization to the stimulation caused by methylphenidate.", "source": "DDInter", "management_text": "When surgery is planned, it is recommended that methylphenidate or its derivatives should not be taken on the day of surgery.", "mechanism_text": "Synergism", "recommendation": "When surgery is planned, it is recommended that methylphenidate or its derivatives should not be taken on the day of surgery.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272460/", "reference_text": "[1] \"Product Information. Ritalin (methylphenidate).\" Novartis Pharmaceuticals  (2001):[2] \"Product Information. Metadate CD (methylphenidate).\" Celltech Pharmaceuticals Inc  (2022):[3] \"Product Information. Focalin (dexmethylphenidate).\" Mikart Inc  (2001):[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ritalin LA (methylphenidate).\" Quality Care Products/Lake Erie Medical  (2013):[7] \"Product Information. Azstarys (dexmethylphenidate-serdexmethylphenidate).\" Corium, Inc.  (2021):", "alternatives_a": "Thiopental, Alfentanil, Remifentanil, Sodium oxybate, Methohexital, Fentanyl, Nitrous oxide, Sufentanil, Propofol, Etomidate", "alternatives_b": "Amphetamine, Pemoline, Atomoxetine, Metamfetamine, Lisdexamfetamine, Solriamfetol, Caffeine, Dextroamphetamine, Armodafinil, Citicoline, Modafinil", "updated_at": 1767369485}, {"id": 242118, "ingredient1": "Esketamine", "ingredient2": "Desflurane", "severity": "Major", "effect": "Concomitant use of esketamine with central nervous system (CNS) depressants may increase sedation and impairment of attention, judgment, thinking, reaction speed, and psychomotor skills.", "source": "DDInter", "management_text": "Caution is advised and patients should be closely monitored during concomitant use of esketamine with CNS depressants or other drugs that can cause sedation or dizziness.  Due to the risk of delayed or prolonged sedation and other adverse effects, patients should be monitored for at least 2 hours after esketamine administration, followed by an assessment to determine when the patient is considered clinically stable and ready to leave the healthcare setting.  Patients should be instructed not to engage in potentially hazardous activities that require complete mental alertness and motor coordination, such as driving a motor vehicle or operating machinery, until the next day after a restful sleep.", "mechanism_text": "Synergism", "recommendation": "Caution is advised and patients should be closely monitored during concomitant use of esketamine with CNS depressants or other drugs that can cause sedation or dizziness.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272461/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Spravato (esketamine).\" Janssen Pharmaceuticals  (2019):", "alternatives_a": "Esketamine", "alternatives_b": "Citalopram, Sertraline, Maprotiline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Viloxazine, More", "updated_at": 1767369485}, {"id": 242119, "ingredient1": "Esketamine", "ingredient2": "Desipramine", "severity": "Major", "effect": "Concomitant use of esketamine with central nervous system (CNS) depressants may increase sedation and impairment of attention, judgment, thinking, reaction speed, and psychomotor skills.", "source": "DDInter", "management_text": "Caution is advised and patients should be closely monitored during concomitant use of esketamine with CNS depressants or other drugs that can cause sedation or dizziness.  Due to the risk of delayed or prolonged sedation and other adverse effects, patients should be monitored for at least 2 hours after esketamine administration, followed by an assessment to determine when the patient is considered clinically stable and ready to leave the healthcare setting.  Patients should be instructed not to engage in potentially hazardous activities that require complete mental alertness and motor coordination, such as driving a motor vehicle or operating machinery, until the next day after a restful sleep.", "mechanism_text": "Synergism", "recommendation": "Caution is advised and patients should be closely monitored during concomitant use of esketamine with CNS depressants or other drugs that can cause sedation or dizziness.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272471/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Spravato (esketamine).\" Janssen Pharmaceuticals  (2019):", "alternatives_a": "Citalopram, Sertraline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Viloxazine, Esketamine, Fluvoxamine, More", "alternatives_b": "Desipramine, Desflurane, Enflurane, Etomidate, Nitrous oxide", "updated_at": 1767369485}, {"id": 242120, "ingredient1": "Desipramine", "ingredient2": "Melatonin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272481/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Vilazodone, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Bupropion, Esketamine", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 242121, "ingredient1": "Desipramine", "ingredient2": "Botulinum toxin type A", "severity": "Moderate", "effect": "Use of anticholinergic drugs after administration of botulinum toxin may potentiate systemic anticholinergic effects such as dry mouth, blurred vision, and urinary disorders.  Botulinum toxin inhibits the release of acetylcholine from peripheral cholinergic nerve endings, thus additive or synergistic anticholinergic effects may occur when these agents are used together.", "source": "DDInter", "management_text": "Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) are used after administration of botulinum toxin.", "mechanism_text": "Synergism", "recommendation": "Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272486/", "reference_text": "[1] \"Product Information. Myobloc (rimabotulinumtoxinB).\" Elan Pharmaceuticals[2] \"Product Information. Dysport (abobotulinumtoxinA).\" Tercica Inc[3] \"Product Information. Botox (onabotulinumtoxinA).\" Allergan Inc[4] \"Product Information. Xeomin (incobotulinumtoxinA).\" Merz Pharmaceuticals  (2022):[5] \"Product Information. Jeuveau (prabotulinumtoxinA).\" Evolus, Inc.  (2022):[6] \"Product Information. Daxxify (daxibotulinumtoxinA).\" Revance Therapeutics, Inc.  (2022):", "alternatives_a": "Citalopram, Sertraline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Isocarboxazid, Viloxazine, Esketamine, More", "alternatives_b": "Atracurium, Doxacurium, Succinylcholine, Rocuronium, Vecuronium, Tubocurarine, Mivacurium, Pancuronium, Pipecuronium, Cisatracurium", "updated_at": 1767369485}, {"id": 242122, "ingredient1": "Desipramine", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272489/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Phenelzine, Duloxetine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Bupropion, More", "alternatives_b": "Dabrafenib, Acalabrutinib, Pexidartinib, Tepotinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More", "updated_at": 1767369485}, {"id": 242123, "ingredient1": "Desipramine", "ingredient2": "Botulinum toxin type B", "severity": "Moderate", "effect": "Use of anticholinergic drugs after administration of botulinum toxin may potentiate systemic anticholinergic effects such as dry mouth, blurred vision, and urinary disorders.  Botulinum toxin inhibits the release of acetylcholine from peripheral cholinergic nerve endings, thus additive or synergistic anticholinergic effects may occur when these agents are used together.", "source": "DDInter", "management_text": "Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) are used after administration of botulinum toxin.", "mechanism_text": "Synergism", "recommendation": "Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272492/", "reference_text": "[1] \"Product Information. Myobloc (rimabotulinumtoxinB).\" Elan Pharmaceuticals[2] \"Product Information. Dysport (abobotulinumtoxinA).\" Tercica Inc[3] \"Product Information. Botox (onabotulinumtoxinA).\" Allergan Inc[4] \"Product Information. Xeomin (incobotulinumtoxinA).\" Merz Pharmaceuticals  (2022):[5] \"Product Information. Jeuveau (prabotulinumtoxinA).\" Evolus, Inc.  (2022):[6] \"Product Information. Daxxify (daxibotulinumtoxinA).\" Revance Therapeutics, Inc.  (2022):", "alternatives_a": "Citalopram, Sertraline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Isocarboxazid, Viloxazine, Esketamine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242124, "ingredient1": "Heparin (flush)", "ingredient2": "Desirudin", "severity": "Moderate", "effect": "Concomitant use of heparin flush and drugs that interfere with platelet function or coagulation or drugs that commonly cause thrombocytopenia may potentiate the risk of bleeding complications.  Although uncommon, inadvertent anticoagulation resulting in hemorrhagic events may occur with heparin flushes, particularly during repeated or excessive use or administration of higher concentration flush solutions.", "source": "DDInter", "management_text": "Caution and monitoring (e.g., platelet counts, hematocrits, tests for occult blood in stools) are advised when heparin flushes are given to patients receiving systemic anticoagulants, platelet inhibitors, antithrombotic agents, thrombolytics, or drugs with known risks of thrombocytopenia or bleeding.  An unexplained fall in hematocrit, fall in blood pressure, or any other unexplained symptom should lead to serious consideration of a hemorrhagic event.", "mechanism_text": "Synergism", "recommendation": "Caution and monitoring (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272498/", "reference_text": "[1] Passannante A, Macik BG \"The heparin flush syndrome: a cause of iatrogenic hemorrhage.\" Am J Med Sci 296 (1988):  71-3[2] \"Product Information. Heparin Sodium in Sodium Chloride (heparin flush).\" Baxter Healthcare Corporation  (2022):[3] \"Product Information. Canusal (heparin flush).\" Wockhardt UK Ltd  (2018):[4] \"Product Information. Heparinised Saline (Pfizer) (heparinised saline).\" Pfizer Australia Pty Ltd  (2022):", "alternatives_a": "Acenocoumarol, Selexipag", "alternatives_b": "Acenocoumarol, Selexipag, Desirudin, Pentosan polysulfate, Ascorbic acid, Cyclosporine, Sirolimus, Potassium Iodide, Vitamin A, Acetylcysteine, Nandrolone", "updated_at": 1767369485}, {"id": 242125, "ingredient1": "Desvenlafaxine", "ingredient2": "Acrivastine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272521/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Chlorcyclizine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "updated_at": 1767369485}, {"id": 242126, "ingredient1": "Desvenlafaxine", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272531/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "alternatives_b": "Apomorphine, Amantadine, Cabergoline", "updated_at": 1767369485}, {"id": 242127, "ingredient1": "Desvenlafaxine", "ingredient2": "Melatonin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272534/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Vilazodone, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Bupropion, Esketamine", "alternatives_b": "Nitrazepam", "updated_at": 1767369485}, {"id": 242128, "ingredient1": "Acrivastine", "ingredient2": "Trazodone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272540/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Azelastine, Ketotifen, Dexchlorpheniramine, Pheniramine", "alternatives_b": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "updated_at": 1767369485}, {"id": 242129, "ingredient1": "Chlorcyclizine", "ingredient2": "Trazodone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272543/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Azelastine, Ketotifen, Dexchlorpheniramine, Pheniramine", "alternatives_b": "Duloxetine, Vilazodone, Sertraline, Paroxetine, Desvenlafaxine, Fluoxetine, St. John's Wort, Nefazodone, Oxitriptan, Viloxazine, Milnacipran, More", "updated_at": 1767369485}, {"id": 242130, "ingredient1": "Dimenhydrinate", "ingredient2": "Trazodone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272545/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Azelastine, Ketotifen, Dexchlorpheniramine, Pheniramine", "alternatives_b": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "updated_at": 1767369485}, {"id": 242131, "ingredient1": "Trazodone", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272554/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Amantadine", "alternatives_b": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "updated_at": 1767369485}, {"id": 242132, "ingredient1": "Trazodone", "ingredient2": "Melatonin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272557/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ethchlorvynol, Thiopental", "alternatives_b": "Vilazodone, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Bupropion, Esketamine", "updated_at": 1767369485}, {"id": 242133, "ingredient1": "Trazodone", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272564/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Acalabrutinib, Pexidartinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, Zanubrutinib, More", "alternatives_b": "Phenelzine, Duloxetine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Bupropion, More", "updated_at": 1767369485}, {"id": 242134, "ingredient1": "Isocarboxazid", "ingredient2": "Tolterodine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272573/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "St. John's Wort, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Vilazodone, Esketamine", "alternatives_b": "Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Mirabegron, Acetohydroxamic acid, Phenyl salicylate, Magnesium hydroxide, Ammonium chloride, Dimethyl sulfoxide", "updated_at": 1767369485}, {"id": 242135, "ingredient1": "Botulinum toxin type A", "ingredient2": "Tolterodine", "severity": "Moderate", "effect": "Use of anticholinergic drugs after administration of botulinum toxin may potentiate systemic anticholinergic effects such as dry mouth, blurred vision, and urinary disorders.  Botulinum toxin inhibits the release of acetylcholine from peripheral cholinergic nerve endings, thus additive or synergistic anticholinergic effects may occur when these agents are used together.", "source": "DDInter", "management_text": "Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) are used after administration of botulinum toxin.", "mechanism_text": "Synergism", "recommendation": "Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272579/", "reference_text": "[1] \"Product Information. Myobloc (rimabotulinumtoxinB).\" Elan Pharmaceuticals[2] \"Product Information. Dysport (abobotulinumtoxinA).\" Tercica Inc[3] \"Product Information. Botox (onabotulinumtoxinA).\" Allergan Inc[4] \"Product Information. Xeomin (incobotulinumtoxinA).\" Merz Pharmaceuticals  (2022):[5] \"Product Information. Jeuveau (prabotulinumtoxinA).\" Evolus, Inc.  (2022):[6] \"Product Information. Daxxify (daxibotulinumtoxinA).\" Revance Therapeutics, Inc.  (2022):", "alternatives_a": "Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Avanafil, Papaverine, More", "alternatives_b": "Atracurium, Doxacurium, Succinylcholine, Rocuronium, Vecuronium, Tubocurarine, Mivacurium, Pancuronium, Pipecuronium, Cisatracurium", "updated_at": 1767369485}, {"id": 242136, "ingredient1": "Tolterodine", "ingredient2": "Palbociclib", "severity": "Moderate", "effect": "Coadministration with drugs that are inhibitors of CYP450 3A4 may increase the plasma concentrations of tolterodine, which is partially metabolized by the isoenzyme.  The possibility of prolonged and/or increased pharmacologic effects of tolterodine should be considered.  Although tolterodine is primarily metabolized by CYP450 2D6, there is some evidence that CYP450 3A4 may play a minor role, thus any alteration in its activity levels could conceivably affect the metabolism of tolterodine.", "source": "DDInter", "management_text": "The manufacturer recommends a maximum tolterodine dosage of 1 mg twice daily in patients receiving concomitant CYP450 3A4 inhibitors.  Close clinical and laboratory monitoring is advised whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy.  Patients should be advised to notify their physician if they experience an irregular heartbeat, severe blurry vision, difficulty urinating, dry mouth, headache, drowsiness, dizziness, or GI upset.", "mechanism_text": "Metabolism", "recommendation": "The manufacturer recommends a maximum tolterodine dosage of 1 mg twice daily in patients receiving concomitant CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272580/", "reference_text": "[1] \"Product Information. Detrol (tolterodine).\" Pharmacia and Upjohn  (2001):[2] Brynne N, Forslund C, Hallen B, Gustafsson LL, Bertilsson L \"Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity.\" Br J Clin Pharmacol 48 (1999):  564-72", "alternatives_a": "Acalabrutinib, Pexidartinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More", "alternatives_b": "Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Avanafil, Papaverine, More", "updated_at": 1767369485}, {"id": 242137, "ingredient1": "Tolterodine", "ingredient2": "Phenelzine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272581/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "St. John's Wort, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Vilazodone, Esketamine", "alternatives_b": "Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Mirabegron, Acetohydroxamic acid, Phenyl salicylate, Magnesium hydroxide, Ammonium chloride, Dimethyl sulfoxide", "updated_at": 1767369485}, {"id": 242138, "ingredient1": "Tolterodine", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272583/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Acalabrutinib, Pexidartinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More", "alternatives_b": "Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Phenyl salicylate, Ammonium chloride, Dimethyl sulfoxide", "updated_at": 1767369485}, {"id": 242139, "ingredient1": "Botulinum toxin type B", "ingredient2": "Tolterodine", "severity": "Moderate", "effect": "Use of anticholinergic drugs after administration of botulinum toxin may potentiate systemic anticholinergic effects such as dry mouth, blurred vision, and urinary disorders.  Botulinum toxin inhibits the release of acetylcholine from peripheral cholinergic nerve endings, thus additive or synergistic anticholinergic effects may occur when these agents are used together.", "source": "DDInter", "management_text": "Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) are used after administration of botulinum toxin.", "mechanism_text": "Synergism", "recommendation": "Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272584/", "reference_text": "[1] \"Product Information. Myobloc (rimabotulinumtoxinB).\" Elan Pharmaceuticals[2] \"Product Information. Dysport (abobotulinumtoxinA).\" Tercica Inc[3] \"Product Information. Botox (onabotulinumtoxinA).\" Allergan Inc[4] \"Product Information. Xeomin (incobotulinumtoxinA).\" Merz Pharmaceuticals  (2022):[5] \"Product Information. Jeuveau (prabotulinumtoxinA).\" Evolus, Inc.  (2022):[6] \"Product Information. Daxxify (daxibotulinumtoxinA).\" Revance Therapeutics, Inc.  (2022):", "alternatives_a": "Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Avanafil, Papaverine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242140, "ingredient1": "Dextroamphetamine", "ingredient2": "Ketamine", "severity": "Moderate", "effect": "Ketamine can cause hemodynamic instability such as arrhythmias and transient increases or decreases in blood pressure, heart rate, and cardiac index.  Coadministration of ketamine with direct or indirect acting sympathomimetics or vasopressin may enhance the sympathomimetic effects of ketamine leading to additive increases in blood pressure and heart rate.", "source": "DDInter", "management_text": "Close monitoring of vital signs, including blood pressure and heart rate is recommended whenever ketamine is used concomitantly with direct or indirect acting sympathomimetics or vasopressin.  Dosage adjustments should be considered according to the patient's clinical situation.  Some authorities suggest avoiding the use of ketamine in patients receiving drugs with a hypertensive effect such as ergometrine.", "mechanism_text": "Synergism", "recommendation": "Close monitoring of vital signs, including blood pressure and heart rate is recommended whenever ketamine is used concomitantly with direct or indirect acting sympathomimetics or vasopressin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272840/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Ketalar (ketamine).\" JHP Pharmaceuticals  (2009):", "alternatives_a": "Pemoline, Citicoline, Caffeine", "alternatives_b": "Halothane, Thiopental, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate", "updated_at": 1767369485}, {"id": 242141, "ingredient1": "Dextroamphetamine", "ingredient2": "Ritonavir", "severity": "Moderate", "effect": "Coadministration with ritonavir may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme.  The mechanism is decreased clearance due to competitive inhibition of CYP450 2D6 activity by ritonavir.", "source": "DDInter", "management_text": "Caution is advised if ritonavir must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ritonavir is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if ritonavir must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272844/", "reference_text": "[1] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical  (2001):", "alternatives_a": "Pemoline, Lisdexamfetamine, Solriamfetol, Caffeine, Dexmethylphenidate, Citicoline", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More", "updated_at": 1767369485}, {"id": 242142, "ingredient1": "Dexlansoprazole", "ingredient2": "Pemigatinib", "severity": "Moderate", "effect": "Coadministration of pemigatinib with proton pump inhibitors may result in a reduction in the plasma concentrations of pemigatinib.  The mechanism for this interaction has not been delineated.", "source": "DDInter", "management_text": "Until more information is available, caution is recommended when pemigatinib is used concomitantly with proton pump inhibitors.  Patients should be monitored for potentially reduced efficacy.", "mechanism_text": "Others", "recommendation": "Until more information is available, caution is recommended when pemigatinib is used concomitantly with proton pump inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272852/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Tinidazole, Levofloxacin, Tetracycline, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Nizatidine, Ranitidine, Amoxicillin", "alternatives_b": "Entrectinib, Pralsetinib, Dabrafenib, Asciminib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Vemurafenib, Selumetinib, More", "updated_at": 1767369485}, {"id": 242143, "ingredient1": "Dexmedetomidine", "ingredient2": "Acrivastine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272858/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Fexofenadine, Phenindamine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 242144, "ingredient1": "Dexmedetomidine", "ingredient2": "Chlorcyclizine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272860/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Fexofenadine, Phenindamine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Temazepam, Butabarbital, Chloral hydrate, Nitrazepam, Paraldehyde, Amobarbital, Meprobamate, Butalbital, Eszopiclone, Estazolam, Methylphenobarbital, More", "updated_at": 1767369485}, {"id": 242145, "ingredient1": "Fenfluramine", "ingredient2": "Dexmedetomidine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272863/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "Dexfenfluramine, Naltrexone, Ephedrine, Bupropion, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol, Lacosamide, Methylphenobarbital", "updated_at": 1767369485}, {"id": 242146, "ingredient1": "Dexmedetomidine", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272866/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "Amantadine, Cabergoline", "updated_at": 1767369485}, {"id": 242147, "ingredient1": "Dexmedetomidine", "ingredient2": "Melatonin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272867/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Melatonin, Nitrazepam, Zopiclone", "alternatives_b": "Nitrazepam, Butalbital, Dexmedetomidine, Ethchlorvynol, Methylphenobarbital, Zopiclone, Dichloralphenazone", "updated_at": 1767369485}, {"id": 242148, "ingredient1": "Dexmedetomidine", "ingredient2": "Methdilazine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272868/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Chloral hydrate, Nitrazepam, Quazepam, Paraldehyde, Propiomazine, Estazolam, Ethchlorvynol, Zolpidem, Zopiclone, Zaleplon, Dichloralphenazone", "alternatives_b": "Ketotifen, Fexofenadine, Phenindamine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "updated_at": 1767369485}, {"id": 242149, "ingredient1": "Dexmedetomidine", "ingredient2": "Metoclopramide", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272869/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ethchlorvynol, Thiopental", "alternatives_b": "Cisapride", "updated_at": 1767369485}, {"id": 242150, "ingredient1": "Dexmedetomidine", "ingredient2": "Phenytoin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272871/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Thiopental", "alternatives_b": "Lacosamide, Methylphenobarbital", "updated_at": 1767369485}, {"id": 242151, "ingredient1": "Dexmedetomidine", "ingredient2": "Pimozide", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272872/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ethchlorvynol, Zopiclone, Nitrazepam", "alternatives_b": "Amisulpride, Pimavanserin", "updated_at": 1767369485}, {"id": 242152, "ingredient1": "Dexmedetomidine", "ingredient2": "Selegiline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272875/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam", "alternatives_b": "Amantadine, Cabergoline", "updated_at": 1767369485}, {"id": 242153, "ingredient1": "Dexmedetomidine", "ingredient2": "Alimemazine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272877/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Fexofenadine, Phenindamine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Nitrazepam, Chloral hydrate, Paraldehyde, Propiomazine, Ethchlorvynol, Zopiclone", "updated_at": 1767369485}, {"id": 242154, "ingredient1": "Dexmethylphenidate", "ingredient2": "Bendroflumethiazide", "severity": "Moderate", "effect": "Methylphenidate and other derivative amphetamines may decrease the therapeutic effects of antihypertensive drugs.", "source": "DDInter", "management_text": "Caution and monitoring of blood pressure is recommended if methylphenidate, dexmethylphenidate or serdexmethylphenidate are administered with antihypertensives agents such as:  potassium-sparing and thiazide diuretics, calcium channel blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers or centrally acting alpha-2 receptor agonists.  The dosage of the antihypertensive drug should be adjusted as needed.", "mechanism_text": "Antagonism", "recommendation": "Caution and monitoring of blood pressure is recommended if methylphenidate, dexmethylphenidate or serdexmethylphenidate are administered with antihypertensives agents such as:  potassium-sparing and thiazide diuretics, calcium channel blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers or centrally acting alpha-2 receptor agonists.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272878/", "reference_text": "[1] \"Product Information. Ritalin (methylphenidate).\" Novartis Pharmaceuticals  (2001):[2] \"Product Information. Metadate CD (methylphenidate).\" Celltech Pharmaceuticals Inc  (2022):[3] \"Product Information. Focalin (dexmethylphenidate).\" Mikart Inc  (2001):[4] \"Product Information. Metadate ER (methylphenidate).\" Celltech Pharmaceuticals Inc  (2002):[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Ritalin LA (methylphenidate).\" Quality Care Products/Lake Erie Medical  (2013):[8] \"Product Information. Azstarys (dexmethylphenidate-serdexmethylphenidate).\" Corium, Inc.  (2021):", "alternatives_a": "Furosemide, Bumetanide, Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More", "alternatives_b": "Amphetamine, Pemoline, Atomoxetine, Metamfetamine, Lisdexamfetamine, Solriamfetol, Caffeine, Dextroamphetamine, Armodafinil, Citicoline, Modafinil", "updated_at": 1767369485}, {"id": 242155, "ingredient1": "Dexmethylphenidate", "ingredient2": "Benzthiazide", "severity": "Moderate", "effect": "Methylphenidate and other derivative amphetamines may decrease the therapeutic effects of antihypertensive drugs.", "source": "DDInter", "management_text": "Caution and monitoring of blood pressure is recommended if methylphenidate, dexmethylphenidate or serdexmethylphenidate are administered with antihypertensives agents such as:  potassium-sparing and thiazide diuretics, calcium channel blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers or centrally acting alpha-2 receptor agonists.  The dosage of the antihypertensive drug should be adjusted as needed.", "mechanism_text": "Antagonism", "recommendation": "Caution and monitoring of blood pressure is recommended if methylphenidate, dexmethylphenidate or serdexmethylphenidate are administered with antihypertensives agents such as:  potassium-sparing and thiazide diuretics, calcium channel blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers or centrally acting alpha-2 receptor agonists.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272879/", "reference_text": "[1] \"Product Information. Ritalin (methylphenidate).\" Novartis Pharmaceuticals  (2001):[2] \"Product Information. Metadate CD (methylphenidate).\" Celltech Pharmaceuticals Inc  (2022):[3] \"Product Information. Focalin (dexmethylphenidate).\" Mikart Inc  (2001):[4] \"Product Information. Metadate ER (methylphenidate).\" Celltech Pharmaceuticals Inc  (2002):[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Ritalin LA (methylphenidate).\" Quality Care Products/Lake Erie Medical  (2013):[8] \"Product Information. Azstarys (dexmethylphenidate-serdexmethylphenidate).\" Corium, Inc.  (2021):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, More", "alternatives_b": "Amphetamine, Pemoline, Atomoxetine, Metamfetamine, Lisdexamfetamine, Solriamfetol, Caffeine, Dextroamphetamine, Armodafinil, Citicoline, Modafinil", "updated_at": 1767369485}, {"id": 242156, "ingredient1": "Dexmethylphenidate", "ingredient2": "Bepridil", "severity": "Moderate", "effect": "Methylphenidate and other derivative amphetamines may decrease the therapeutic effects of antihypertensive drugs.", "source": "DDInter", "management_text": "Caution and monitoring of blood pressure is recommended if methylphenidate, dexmethylphenidate or serdexmethylphenidate are administered with antihypertensives agents such as:  potassium-sparing and thiazide diuretics, calcium channel blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers or centrally acting alpha-2 receptor agonists.  The dosage of the antihypertensive drug should be adjusted as needed.", "mechanism_text": "Antagonism", "recommendation": "Caution and monitoring of blood pressure is recommended if methylphenidate, dexmethylphenidate or serdexmethylphenidate are administered with antihypertensives agents such as:  potassium-sparing and thiazide diuretics, calcium channel blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers or centrally acting alpha-2 receptor agonists.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272880/", "reference_text": "[1] \"Product Information. Ritalin (methylphenidate).\" Novartis Pharmaceuticals  (2001):[2] \"Product Information. Metadate CD (methylphenidate).\" Celltech Pharmaceuticals Inc  (2022):[3] \"Product Information. Focalin (dexmethylphenidate).\" Mikart Inc  (2001):[4] \"Product Information. Metadate ER (methylphenidate).\" Celltech Pharmaceuticals Inc  (2002):[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Ritalin LA (methylphenidate).\" Quality Care Products/Lake Erie Medical  (2013):[8] \"Product Information. Azstarys (dexmethylphenidate-serdexmethylphenidate).\" Corium, Inc.  (2021):", "alternatives_a": "Amphetamine, Pemoline, Atomoxetine, Metamfetamine, Solriamfetol, Caffeine, Dextroamphetamine, Citicoline", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242157, "ingredient1": "Dexmethylphenidate", "ingredient2": "Carteolol", "severity": "Moderate", "effect": "Methylphenidate and other derivative amphetamines may decrease the therapeutic effects of antihypertensive drugs.", "source": "DDInter", "management_text": "Caution and monitoring of blood pressure is recommended if methylphenidate, dexmethylphenidate or serdexmethylphenidate are administered with antihypertensives agents such as:  potassium-sparing and thiazide diuretics, calcium channel blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers or centrally acting alpha-2 receptor agonists.  The dosage of the antihypertensive drug should be adjusted as needed.", "mechanism_text": "Antagonism", "recommendation": "Caution and monitoring of blood pressure is recommended if methylphenidate, dexmethylphenidate or serdexmethylphenidate are administered with antihypertensives agents such as:  potassium-sparing and thiazide diuretics, calcium channel blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers or centrally acting alpha-2 receptor agonists.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272882/", "reference_text": "[1] \"Product Information. Ritalin (methylphenidate).\" Novartis Pharmaceuticals  (2001):[2] \"Product Information. Metadate CD (methylphenidate).\" Celltech Pharmaceuticals Inc  (2022):[3] \"Product Information. Focalin (dexmethylphenidate).\" Mikart Inc  (2001):[4] \"Product Information. Metadate ER (methylphenidate).\" Celltech Pharmaceuticals Inc  (2002):[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Ritalin LA (methylphenidate).\" Quality Care Products/Lake Erie Medical  (2013):[8] \"Product Information. Azstarys (dexmethylphenidate-serdexmethylphenidate).\" Corium, Inc.  (2021):", "alternatives_a": "Latanoprost, Apraclonidine, Methazolamide, Neostigmine, Pilocarpine, Physostigmine, Acetylcholine, Diclofenamide, Bimatoprost, Travoprost, Acetazolamide, More", "alternatives_b": "Amphetamine, Pemoline, Atomoxetine, Metamfetamine, Lisdexamfetamine, Solriamfetol, Caffeine, Dextroamphetamine, Armodafinil, Citicoline, Modafinil", "updated_at": 1767369485}, {"id": 242158, "ingredient1": "Diazoxide", "ingredient2": "Dexmethylphenidate", "severity": "Moderate", "effect": "Methylphenidate and other derivative amphetamines may decrease the therapeutic effects of antihypertensive drugs.", "source": "DDInter", "management_text": "Caution and monitoring of blood pressure is recommended if methylphenidate, dexmethylphenidate or serdexmethylphenidate are administered with antihypertensives agents such as:  potassium-sparing and thiazide diuretics, calcium channel blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers or centrally acting alpha-2 receptor agonists.  The dosage of the antihypertensive drug should be adjusted as needed.", "mechanism_text": "Antagonism", "recommendation": "Caution and monitoring of blood pressure is recommended if methylphenidate, dexmethylphenidate or serdexmethylphenidate are administered with antihypertensives agents such as:  potassium-sparing and thiazide diuretics, calcium channel blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers or centrally acting alpha-2 receptor agonists.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272883/", "reference_text": "[1] \"Product Information. Ritalin (methylphenidate).\" Novartis Pharmaceuticals  (2001):[2] \"Product Information. Metadate CD (methylphenidate).\" Celltech Pharmaceuticals Inc  (2022):[3] \"Product Information. Focalin (dexmethylphenidate).\" Mikart Inc  (2001):[4] \"Product Information. Metadate ER (methylphenidate).\" Celltech Pharmaceuticals Inc  (2002):[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Ritalin LA (methylphenidate).\" Quality Care Products/Lake Erie Medical  (2013):[8] \"Product Information. Azstarys (dexmethylphenidate-serdexmethylphenidate).\" Corium, Inc.  (2021):", "alternatives_a": "Amphetamine, Pemoline, Atomoxetine, Metamfetamine, Lisdexamfetamine, Solriamfetol, Caffeine, Dextroamphetamine, Armodafinil, Citicoline, Modafinil", "alternatives_b": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, More", "updated_at": 1767369485}, {"id": 242159, "ingredient1": "Eplerenone", "ingredient2": "Dexmethylphenidate", "severity": "Moderate", "effect": "Methylphenidate and other derivative amphetamines may decrease the therapeutic effects of antihypertensive drugs.", "source": "DDInter", "management_text": "Caution and monitoring of blood pressure is recommended if methylphenidate, dexmethylphenidate or serdexmethylphenidate are administered with antihypertensives agents such as:  potassium-sparing and thiazide diuretics, calcium channel blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers or centrally acting alpha-2 receptor agonists.  The dosage of the antihypertensive drug should be adjusted as needed.", "mechanism_text": "Antagonism", "recommendation": "Caution and monitoring of blood pressure is recommended if methylphenidate, dexmethylphenidate or serdexmethylphenidate are administered with antihypertensives agents such as:  potassium-sparing and thiazide diuretics, calcium channel blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers or centrally acting alpha-2 receptor agonists.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272885/", "reference_text": "[1] \"Product Information. Ritalin (methylphenidate).\" Novartis Pharmaceuticals  (2001):[2] \"Product Information. Metadate CD (methylphenidate).\" Celltech Pharmaceuticals Inc  (2022):[3] \"Product Information. Focalin (dexmethylphenidate).\" Mikart Inc  (2001):[4] \"Product Information. Metadate ER (methylphenidate).\" Celltech Pharmaceuticals Inc  (2002):[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Ritalin LA (methylphenidate).\" Quality Care Products/Lake Erie Medical  (2013):[8] \"Product Information. Azstarys (dexmethylphenidate-serdexmethylphenidate).\" Corium, Inc.  (2021):", "alternatives_a": "Amphetamine, Pemoline, Atomoxetine, Metamfetamine, Lisdexamfetamine, Solriamfetol, Caffeine, Dextroamphetamine, Citicoline", "alternatives_b": "Finerenone", "updated_at": 1767369485}, {"id": 242160, "ingredient1": "Eprosartan", "ingredient2": "Dexmethylphenidate", "severity": "Moderate", "effect": "Methylphenidate and other derivative amphetamines may decrease the therapeutic effects of antihypertensive drugs.", "source": "DDInter", "management_text": "Caution and monitoring of blood pressure is recommended if methylphenidate, dexmethylphenidate or serdexmethylphenidate are administered with antihypertensives agents such as:  potassium-sparing and thiazide diuretics, calcium channel blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers or centrally acting alpha-2 receptor agonists.  The dosage of the antihypertensive drug should be adjusted as needed.", "mechanism_text": "Antagonism", "recommendation": "Caution and monitoring of blood pressure is recommended if methylphenidate, dexmethylphenidate or serdexmethylphenidate are administered with antihypertensives agents such as:  potassium-sparing and thiazide diuretics, calcium channel blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers or centrally acting alpha-2 receptor agonists.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272886/", "reference_text": "[1] \"Product Information. Ritalin (methylphenidate).\" Novartis Pharmaceuticals  (2001):[2] \"Product Information. Metadate CD (methylphenidate).\" Celltech Pharmaceuticals Inc  (2022):[3] \"Product Information. Focalin (dexmethylphenidate).\" Mikart Inc  (2001):[4] \"Product Information. Metadate ER (methylphenidate).\" Celltech Pharmaceuticals Inc  (2002):[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Ritalin LA (methylphenidate).\" Quality Care Products/Lake Erie Medical  (2013):[8] \"Product Information. Azstarys (dexmethylphenidate-serdexmethylphenidate).\" Corium, Inc.  (2021):", "alternatives_a": "Amphetamine, Pemoline, Atomoxetine, Metamfetamine, Lisdexamfetamine, Solriamfetol, Caffeine, Dextroamphetamine, Armodafinil, Citicoline, Modafinil", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 242161, "ingredient1": "Felodipine", "ingredient2": "Dexmethylphenidate", "severity": "Moderate", "effect": "Methylphenidate and other derivative amphetamines may decrease the therapeutic effects of antihypertensive drugs.", "source": "DDInter", "management_text": "Caution and monitoring of blood pressure is recommended if methylphenidate, dexmethylphenidate or serdexmethylphenidate are administered with antihypertensives agents such as:  potassium-sparing and thiazide diuretics, calcium channel blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers or centrally acting alpha-2 receptor agonists.  The dosage of the antihypertensive drug should be adjusted as needed.", "mechanism_text": "Antagonism", "recommendation": "Caution and monitoring of blood pressure is recommended if methylphenidate, dexmethylphenidate or serdexmethylphenidate are administered with antihypertensives agents such as:  potassium-sparing and thiazide diuretics, calcium channel blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers or centrally acting alpha-2 receptor agonists.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272888/", "reference_text": "[1] \"Product Information. Ritalin (methylphenidate).\" Novartis Pharmaceuticals  (2001):[2] \"Product Information. Metadate CD (methylphenidate).\" Celltech Pharmaceuticals Inc  (2022):[3] \"Product Information. Focalin (dexmethylphenidate).\" Mikart Inc  (2001):[4] \"Product Information. Metadate ER (methylphenidate).\" Celltech Pharmaceuticals Inc  (2002):[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Ritalin LA (methylphenidate).\" Quality Care Products/Lake Erie Medical  (2013):[8] \"Product Information. Azstarys (dexmethylphenidate-serdexmethylphenidate).\" Corium, Inc.  (2021):", "alternatives_a": "Amphetamine, Pemoline, Atomoxetine, Metamfetamine, Lisdexamfetamine, Solriamfetol, Caffeine, Dextroamphetamine, Citicoline", "alternatives_b": "Acetylsalicylic acid, Ivabradine, Celecoxib", "updated_at": 1767369485}, {"id": 242162, "ingredient1": "Fosinopril", "ingredient2": "Dexmethylphenidate", "severity": "Moderate", "effect": "Methylphenidate and other derivative amphetamines may decrease the therapeutic effects of antihypertensive drugs.", "source": "DDInter", "management_text": "Caution and monitoring of blood pressure is recommended if methylphenidate, dexmethylphenidate or serdexmethylphenidate are administered with antihypertensives agents such as:  potassium-sparing and thiazide diuretics, calcium channel blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers or centrally acting alpha-2 receptor agonists.  The dosage of the antihypertensive drug should be adjusted as needed.", "mechanism_text": "Antagonism", "recommendation": "Caution and monitoring of blood pressure is recommended if methylphenidate, dexmethylphenidate or serdexmethylphenidate are administered with antihypertensives agents such as:  potassium-sparing and thiazide diuretics, calcium channel blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers or centrally acting alpha-2 receptor agonists.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272889/", "reference_text": "[1] \"Product Information. Ritalin (methylphenidate).\" Novartis Pharmaceuticals  (2001):[2] \"Product Information. Metadate CD (methylphenidate).\" Celltech Pharmaceuticals Inc  (2022):[3] \"Product Information. Focalin (dexmethylphenidate).\" Mikart Inc  (2001):[4] \"Product Information. Metadate ER (methylphenidate).\" Celltech Pharmaceuticals Inc  (2002):[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Ritalin LA (methylphenidate).\" Quality Care Products/Lake Erie Medical  (2013):[8] \"Product Information. Azstarys (dexmethylphenidate-serdexmethylphenidate).\" Corium, Inc.  (2021):", "alternatives_a": "Amphetamine, Pemoline, Atomoxetine, Metamfetamine, Lisdexamfetamine, Solriamfetol, Caffeine, Dextroamphetamine, Armodafinil, Citicoline, Modafinil", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242163, "ingredient1": "Indapamide", "ingredient2": "Dexmethylphenidate", "severity": "Moderate", "effect": "Methylphenidate and other derivative amphetamines may decrease the therapeutic effects of antihypertensive drugs.", "source": "DDInter", "management_text": "Caution and monitoring of blood pressure is recommended if methylphenidate, dexmethylphenidate or serdexmethylphenidate are administered with antihypertensives agents such as:  potassium-sparing and thiazide diuretics, calcium channel blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers or centrally acting alpha-2 receptor agonists.  The dosage of the antihypertensive drug should be adjusted as needed.", "mechanism_text": "Antagonism", "recommendation": "Caution and monitoring of blood pressure is recommended if methylphenidate, dexmethylphenidate or serdexmethylphenidate are administered with antihypertensives agents such as:  potassium-sparing and thiazide diuretics, calcium channel blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers or centrally acting alpha-2 receptor agonists.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272891/", "reference_text": "[1] \"Product Information. Ritalin (methylphenidate).\" Novartis Pharmaceuticals  (2001):[2] \"Product Information. Metadate CD (methylphenidate).\" Celltech Pharmaceuticals Inc  (2022):[3] \"Product Information. Focalin (dexmethylphenidate).\" Mikart Inc  (2001):[4] \"Product Information. Metadate ER (methylphenidate).\" Celltech Pharmaceuticals Inc  (2002):[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Ritalin LA (methylphenidate).\" Quality Care Products/Lake Erie Medical  (2013):[8] \"Product Information. Azstarys (dexmethylphenidate-serdexmethylphenidate).\" Corium, Inc.  (2021):", "alternatives_a": "Amphetamine, Pemoline, Atomoxetine, Metamfetamine, Lisdexamfetamine, Solriamfetol, Caffeine, Dextroamphetamine, Armodafinil, Citicoline, Modafinil", "alternatives_b": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, More", "updated_at": 1767369485}, {"id": 242164, "ingredient1": "Isoflurane", "ingredient2": "Dexmethylphenidate", "severity": "Moderate", "effect": "The administration of volatile general anesthetics during therapy with methylphenidate or its derivatives may increase the risk of hypertension and/or arrhythmias during surgery.  The proposed mechanism is anesthetic-induced myocardial sensitization to the stimulation caused by methylphenidate.", "source": "DDInter", "management_text": "When surgery is planned, it is recommended that methylphenidate or its derivatives should not be taken on the day of surgery.", "mechanism_text": "Synergism", "recommendation": "When surgery is planned, it is recommended that methylphenidate or its derivatives should not be taken on the day of surgery.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272893/", "reference_text": "[1] \"Product Information. Ritalin (methylphenidate).\" Novartis Pharmaceuticals  (2001):[2] \"Product Information. Metadate CD (methylphenidate).\" Celltech Pharmaceuticals Inc  (2022):[3] \"Product Information. Focalin (dexmethylphenidate).\" Mikart Inc  (2001):[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ritalin LA (methylphenidate).\" Quality Care Products/Lake Erie Medical  (2013):[7] \"Product Information. Azstarys (dexmethylphenidate-serdexmethylphenidate).\" Corium, Inc.  (2021):", "alternatives_a": "Amphetamine, Pemoline, Atomoxetine, Metamfetamine, Lisdexamfetamine, Solriamfetol, Caffeine, Dextroamphetamine, Armodafinil, Citicoline, Modafinil", "alternatives_b": "Thiopental, Alfentanil, Remifentanil, Sodium oxybate, Methohexital, Fentanyl, Nitrous oxide, Sufentanil, Propofol, Etomidate", "updated_at": 1767369485}, {"id": 242165, "ingredient1": "Isradipine", "ingredient2": "Dexmethylphenidate", "severity": "Moderate", "effect": "Methylphenidate and other derivative amphetamines may decrease the therapeutic effects of antihypertensive drugs.", "source": "DDInter", "management_text": "Caution and monitoring of blood pressure is recommended if methylphenidate, dexmethylphenidate or serdexmethylphenidate are administered with antihypertensives agents such as:  potassium-sparing and thiazide diuretics, calcium channel blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers or centrally acting alpha-2 receptor agonists.  The dosage of the antihypertensive drug should be adjusted as needed.", "mechanism_text": "Antagonism", "recommendation": "Caution and monitoring of blood pressure is recommended if methylphenidate, dexmethylphenidate or serdexmethylphenidate are administered with antihypertensives agents such as:  potassium-sparing and thiazide diuretics, calcium channel blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers or centrally acting alpha-2 receptor agonists.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272894/", "reference_text": "[1] \"Product Information. Ritalin (methylphenidate).\" Novartis Pharmaceuticals  (2001):[2] \"Product Information. Metadate CD (methylphenidate).\" Celltech Pharmaceuticals Inc  (2022):[3] \"Product Information. Focalin (dexmethylphenidate).\" Mikart Inc  (2001):[4] \"Product Information. Metadate ER (methylphenidate).\" Celltech Pharmaceuticals Inc  (2002):[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Ritalin LA (methylphenidate).\" Quality Care Products/Lake Erie Medical  (2013):[8] \"Product Information. Azstarys (dexmethylphenidate-serdexmethylphenidate).\" Corium, Inc.  (2021):", "alternatives_a": "Amphetamine, Pemoline, Atomoxetine, Metamfetamine, Lisdexamfetamine, Solriamfetol, Caffeine, Dextroamphetamine, Citicoline", "alternatives_b": "Celecoxib", "updated_at": 1767369485}, {"id": 242166, "ingredient1": "Dexmethylphenidate", "ingredient2": "Ketamine", "severity": "Moderate", "effect": "Ketamine can cause hemodynamic instability such as arrhythmias and transient increases or decreases in blood pressure, heart rate, and cardiac index.  Coadministration of ketamine with direct or indirect acting sympathomimetics or vasopressin may enhance the sympathomimetic effects of ketamine leading to additive increases in blood pressure and heart rate.", "source": "DDInter", "management_text": "Close monitoring of vital signs, including blood pressure and heart rate is recommended whenever ketamine is used concomitantly with direct or indirect acting sympathomimetics or vasopressin.  Dosage adjustments should be considered according to the patient's clinical situation.  Some authorities suggest avoiding the use of ketamine in patients receiving drugs with a hypertensive effect such as ergometrine.", "mechanism_text": "Synergism", "recommendation": "Close monitoring of vital signs, including blood pressure and heart rate is recommended whenever ketamine is used concomitantly with direct or indirect acting sympathomimetics or vasopressin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272895/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Ketalar (ketamine).\" JHP Pharmaceuticals  (2009):", "alternatives_a": "Pemoline, Citicoline, Caffeine", "alternatives_b": "Thiopental, Alfentanil, Remifentanil, Sodium oxybate, Methohexital, Fentanyl, Nitrous oxide, Sufentanil, Propofol, Etomidate", "updated_at": 1767369485}, {"id": 242167, "ingredient1": "Dexmethylphenidate", "ingredient2": "Labetalol", "severity": "Moderate", "effect": "Methylphenidate and other derivative amphetamines may decrease the therapeutic effects of antihypertensive drugs.", "source": "DDInter", "management_text": "Caution and monitoring of blood pressure is recommended if methylphenidate, dexmethylphenidate or serdexmethylphenidate are administered with antihypertensives agents such as:  potassium-sparing and thiazide diuretics, calcium channel blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers or centrally acting alpha-2 receptor agonists.  The dosage of the antihypertensive drug should be adjusted as needed.", "mechanism_text": "Antagonism", "recommendation": "Caution and monitoring of blood pressure is recommended if methylphenidate, dexmethylphenidate or serdexmethylphenidate are administered with antihypertensives agents such as:  potassium-sparing and thiazide diuretics, calcium channel blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers or centrally acting alpha-2 receptor agonists.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272896/", "reference_text": "[1] \"Product Information. Ritalin (methylphenidate).\" Novartis Pharmaceuticals  (2001):[2] \"Product Information. Metadate CD (methylphenidate).\" Celltech Pharmaceuticals Inc  (2022):[3] \"Product Information. Focalin (dexmethylphenidate).\" Mikart Inc  (2001):[4] \"Product Information. Metadate ER (methylphenidate).\" Celltech Pharmaceuticals Inc  (2002):[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Ritalin LA (methylphenidate).\" Quality Care Products/Lake Erie Medical  (2013):[8] \"Product Information. Azstarys (dexmethylphenidate-serdexmethylphenidate).\" Corium, Inc.  (2021):", "alternatives_a": "Amphetamine, Pemoline, Atomoxetine, Metamfetamine, Lisdexamfetamine, Solriamfetol, Caffeine, Dextroamphetamine, Armodafinil, Citicoline, Modafinil", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242168, "ingredient1": "Dexmethylphenidate", "ingredient2": "Lisinopril", "severity": "Moderate", "effect": "Methylphenidate and other derivative amphetamines may decrease the therapeutic effects of antihypertensive drugs.", "source": "DDInter", "management_text": "Caution and monitoring of blood pressure is recommended if methylphenidate, dexmethylphenidate or serdexmethylphenidate are administered with antihypertensives agents such as:  potassium-sparing and thiazide diuretics, calcium channel blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers or centrally acting alpha-2 receptor agonists.  The dosage of the antihypertensive drug should be adjusted as needed.", "mechanism_text": "Antagonism", "recommendation": "Caution and monitoring of blood pressure is recommended if methylphenidate, dexmethylphenidate or serdexmethylphenidate are administered with antihypertensives agents such as:  potassium-sparing and thiazide diuretics, calcium channel blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers or centrally acting alpha-2 receptor agonists.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272897/", "reference_text": "[1] \"Product Information. Ritalin (methylphenidate).\" Novartis Pharmaceuticals  (2001):[2] \"Product Information. Metadate CD (methylphenidate).\" Celltech Pharmaceuticals Inc  (2022):[3] \"Product Information. Focalin (dexmethylphenidate).\" Mikart Inc  (2001):[4] \"Product Information. Metadate ER (methylphenidate).\" Celltech Pharmaceuticals Inc  (2002):[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Ritalin LA (methylphenidate).\" Quality Care Products/Lake Erie Medical  (2013):[8] \"Product Information. Azstarys (dexmethylphenidate-serdexmethylphenidate).\" Corium, Inc.  (2021):", "alternatives_a": "Pemoline, Metamfetamine, Lisdexamfetamine, Solriamfetol, Caffeine, Dextroamphetamine, Armodafinil, Citicoline", "alternatives_b": "Atorvastatin, Simvastatin, Lovastatin, Rosuvastatin, Niacin, Pravastatin, Acetylsalicylic acid, Ezetimibe, Bempedoic acid, Fenofibrate", "updated_at": 1767369485}, {"id": 242169, "ingredient1": "Dexmethylphenidate", "ingredient2": "Methoxyflurane", "severity": "Moderate", "effect": "The administration of volatile general anesthetics during therapy with methylphenidate or its derivatives may increase the risk of hypertension and/or arrhythmias during surgery.  The proposed mechanism is anesthetic-induced myocardial sensitization to the stimulation caused by methylphenidate.", "source": "DDInter", "management_text": "When surgery is planned, it is recommended that methylphenidate or its derivatives should not be taken on the day of surgery.", "mechanism_text": "Synergism", "recommendation": "When surgery is planned, it is recommended that methylphenidate or its derivatives should not be taken on the day of surgery.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272899/", "reference_text": "[1] \"Product Information. Ritalin (methylphenidate).\" Novartis Pharmaceuticals  (2001):[2] \"Product Information. Metadate CD (methylphenidate).\" Celltech Pharmaceuticals Inc  (2022):[3] \"Product Information. Focalin (dexmethylphenidate).\" Mikart Inc  (2001):[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ritalin LA (methylphenidate).\" Quality Care Products/Lake Erie Medical  (2013):[7] \"Product Information. Azstarys (dexmethylphenidate-serdexmethylphenidate).\" Corium, Inc.  (2021):", "alternatives_a": "Amphetamine, Pemoline, Atomoxetine, Metamfetamine, Lisdexamfetamine, Solriamfetol, Caffeine, Dextroamphetamine, Armodafinil, Citicoline, Modafinil", "alternatives_b": "Salicylic acid, Acetaminophen, Choline salicylate, Ziconotide, Diflunisal, Salsalate, Acetylsalicylic acid", "updated_at": 1767369485}, {"id": 242170, "ingredient1": "Dexmethylphenidate", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Methylphenidate and other derivative amphetamines may decrease the therapeutic effects of antihypertensive drugs.", "source": "DDInter", "management_text": "Caution and monitoring of blood pressure is recommended if methylphenidate, dexmethylphenidate or serdexmethylphenidate are administered with antihypertensives agents such as:  potassium-sparing and thiazide diuretics, calcium channel blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers or centrally acting alpha-2 receptor agonists.  The dosage of the antihypertensive drug should be adjusted as needed.", "mechanism_text": "Antagonism", "recommendation": "Caution and monitoring of blood pressure is recommended if methylphenidate, dexmethylphenidate or serdexmethylphenidate are administered with antihypertensives agents such as:  potassium-sparing and thiazide diuretics, calcium channel blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers or centrally acting alpha-2 receptor agonists.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272900/", "reference_text": "[1] \"Product Information. Ritalin (methylphenidate).\" Novartis Pharmaceuticals  (2001):[2] \"Product Information. Metadate CD (methylphenidate).\" Celltech Pharmaceuticals Inc  (2022):[3] \"Product Information. Focalin (dexmethylphenidate).\" Mikart Inc  (2001):[4] \"Product Information. Metadate ER (methylphenidate).\" Celltech Pharmaceuticals Inc  (2002):[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Ritalin LA (methylphenidate).\" Quality Care Products/Lake Erie Medical  (2013):[8] \"Product Information. Azstarys (dexmethylphenidate-serdexmethylphenidate).\" Corium, Inc.  (2021):", "alternatives_a": "Amphetamine, Pemoline, Atomoxetine, Metamfetamine, Lisdexamfetamine, Solriamfetol, Caffeine, Dextroamphetamine, Armodafinil, Citicoline", "alternatives_b": "Furosemide, Bumetanide, Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More", "updated_at": 1767369485}, {"id": 242171, "ingredient1": "Dexmethylphenidate", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Methylphenidate and other derivative amphetamines may decrease the therapeutic effects of antihypertensive drugs.", "source": "DDInter", "management_text": "Caution and monitoring of blood pressure is recommended if methylphenidate, dexmethylphenidate or serdexmethylphenidate are administered with antihypertensives agents such as:  potassium-sparing and thiazide diuretics, calcium channel blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers or centrally acting alpha-2 receptor agonists.  The dosage of the antihypertensive drug should be adjusted as needed.", "mechanism_text": "Antagonism", "recommendation": "Caution and monitoring of blood pressure is recommended if methylphenidate, dexmethylphenidate or serdexmethylphenidate are administered with antihypertensives agents such as:  potassium-sparing and thiazide diuretics, calcium channel blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers or centrally acting alpha-2 receptor agonists.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272901/", "reference_text": "[1] \"Product Information. Ritalin (methylphenidate).\" Novartis Pharmaceuticals  (2001):[2] \"Product Information. Metadate CD (methylphenidate).\" Celltech Pharmaceuticals Inc  (2022):[3] \"Product Information. Focalin (dexmethylphenidate).\" Mikart Inc  (2001):[4] \"Product Information. Metadate ER (methylphenidate).\" Celltech Pharmaceuticals Inc  (2002):[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Ritalin LA (methylphenidate).\" Quality Care Products/Lake Erie Medical  (2013):[8] \"Product Information. Azstarys (dexmethylphenidate-serdexmethylphenidate).\" Corium, Inc.  (2021):", "alternatives_a": "Pemoline, Metamfetamine, Lisdexamfetamine, Solriamfetol, Caffeine, Dextroamphetamine, Armodafinil, Citicoline", "alternatives_b": "Acetylsalicylic acid, Ivabradine", "updated_at": 1767369485}, {"id": 242172, "ingredient1": "Dexmethylphenidate", "ingredient2": "Moexipril", "severity": "Moderate", "effect": "Methylphenidate and other derivative amphetamines may decrease the therapeutic effects of antihypertensive drugs.", "source": "DDInter", "management_text": "Caution and monitoring of blood pressure is recommended if methylphenidate, dexmethylphenidate or serdexmethylphenidate are administered with antihypertensives agents such as:  potassium-sparing and thiazide diuretics, calcium channel blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers or centrally acting alpha-2 receptor agonists.  The dosage of the antihypertensive drug should be adjusted as needed.", "mechanism_text": "Antagonism", "recommendation": "Caution and monitoring of blood pressure is recommended if methylphenidate, dexmethylphenidate or serdexmethylphenidate are administered with antihypertensives agents such as:  potassium-sparing and thiazide diuretics, calcium channel blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers or centrally acting alpha-2 receptor agonists.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272904/", "reference_text": "[1] \"Product Information. Ritalin (methylphenidate).\" Novartis Pharmaceuticals  (2001):[2] \"Product Information. Metadate CD (methylphenidate).\" Celltech Pharmaceuticals Inc  (2022):[3] \"Product Information. Focalin (dexmethylphenidate).\" Mikart Inc  (2001):[4] \"Product Information. Metadate ER (methylphenidate).\" Celltech Pharmaceuticals Inc  (2002):[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Ritalin LA (methylphenidate).\" Quality Care Products/Lake Erie Medical  (2013):[8] \"Product Information. Azstarys (dexmethylphenidate-serdexmethylphenidate).\" Corium, Inc.  (2021):", "alternatives_a": "Amphetamine, Pemoline, Atomoxetine, Metamfetamine, Lisdexamfetamine, Solriamfetol, Caffeine, Dextroamphetamine, Armodafinil, Citicoline, Modafinil", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242173, "ingredient1": "Dexmethylphenidate", "ingredient2": "Nimodipine", "severity": "Moderate", "effect": "Methylphenidate and other derivative amphetamines may decrease the therapeutic effects of antihypertensive drugs.", "source": "DDInter", "management_text": "Caution and monitoring of blood pressure is recommended if methylphenidate, dexmethylphenidate or serdexmethylphenidate are administered with antihypertensives agents such as:  potassium-sparing and thiazide diuretics, calcium channel blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers or centrally acting alpha-2 receptor agonists.  The dosage of the antihypertensive drug should be adjusted as needed.", "mechanism_text": "Antagonism", "recommendation": "Caution and monitoring of blood pressure is recommended if methylphenidate, dexmethylphenidate or serdexmethylphenidate are administered with antihypertensives agents such as:  potassium-sparing and thiazide diuretics, calcium channel blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers or centrally acting alpha-2 receptor agonists.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272905/", "reference_text": "[1] \"Product Information. Ritalin (methylphenidate).\" Novartis Pharmaceuticals  (2001):[2] \"Product Information. Metadate CD (methylphenidate).\" Celltech Pharmaceuticals Inc  (2022):[3] \"Product Information. Focalin (dexmethylphenidate).\" Mikart Inc  (2001):[4] \"Product Information. Metadate ER (methylphenidate).\" Celltech Pharmaceuticals Inc  (2002):[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Ritalin LA (methylphenidate).\" Quality Care Products/Lake Erie Medical  (2013):[8] \"Product Information. Azstarys (dexmethylphenidate-serdexmethylphenidate).\" Corium, Inc.  (2021):", "alternatives_a": "Amphetamine, Pemoline, Atomoxetine, Metamfetamine, Lisdexamfetamine, Solriamfetol, Caffeine, Dextroamphetamine, Citicoline", "alternatives_b": "Celecoxib", "updated_at": 1767369485}, {"id": 242174, "ingredient1": "Dexmethylphenidate", "ingredient2": "Penbutolol", "severity": "Moderate", "effect": "Methylphenidate and other derivative amphetamines may decrease the therapeutic effects of antihypertensive drugs.", "source": "DDInter", "management_text": "Caution and monitoring of blood pressure is recommended if methylphenidate, dexmethylphenidate or serdexmethylphenidate are administered with antihypertensives agents such as:  potassium-sparing and thiazide diuretics, calcium channel blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers or centrally acting alpha-2 receptor agonists.  The dosage of the antihypertensive drug should be adjusted as needed.", "mechanism_text": "Antagonism", "recommendation": "Caution and monitoring of blood pressure is recommended if methylphenidate, dexmethylphenidate or serdexmethylphenidate are administered with antihypertensives agents such as:  potassium-sparing and thiazide diuretics, calcium channel blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers or centrally acting alpha-2 receptor agonists.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272906/", "reference_text": "[1] \"Product Information. Ritalin (methylphenidate).\" Novartis Pharmaceuticals  (2001):[2] \"Product Information. Metadate CD (methylphenidate).\" Celltech Pharmaceuticals Inc  (2022):[3] \"Product Information. Focalin (dexmethylphenidate).\" Mikart Inc  (2001):[4] \"Product Information. Metadate ER (methylphenidate).\" Celltech Pharmaceuticals Inc  (2002):[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Ritalin LA (methylphenidate).\" Quality Care Products/Lake Erie Medical  (2013):[8] \"Product Information. Azstarys (dexmethylphenidate-serdexmethylphenidate).\" Corium, Inc.  (2021):", "alternatives_a": "Amphetamine, Pemoline, Atomoxetine, Metamfetamine, Lisdexamfetamine, Solriamfetol, Caffeine, Dextroamphetamine, Armodafinil, Citicoline, Modafinil", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242175, "ingredient1": "Dexmethylphenidate", "ingredient2": "Propranolol", "severity": "Moderate", "effect": "Methylphenidate and other derivative amphetamines may decrease the therapeutic effects of antihypertensive drugs.", "source": "DDInter", "management_text": "Caution and monitoring of blood pressure is recommended if methylphenidate, dexmethylphenidate or serdexmethylphenidate are administered with antihypertensives agents such as:  potassium-sparing and thiazide diuretics, calcium channel blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers or centrally acting alpha-2 receptor agonists.  The dosage of the antihypertensive drug should be adjusted as needed.", "mechanism_text": "Antagonism", "recommendation": "Caution and monitoring of blood pressure is recommended if methylphenidate, dexmethylphenidate or serdexmethylphenidate are administered with antihypertensives agents such as:  potassium-sparing and thiazide diuretics, calcium channel blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers or centrally acting alpha-2 receptor agonists.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272907/", "reference_text": "[1] \"Product Information. Ritalin (methylphenidate).\" Novartis Pharmaceuticals  (2001):[2] \"Product Information. Metadate CD (methylphenidate).\" Celltech Pharmaceuticals Inc  (2022):[3] \"Product Information. Focalin (dexmethylphenidate).\" Mikart Inc  (2001):[4] \"Product Information. Metadate ER (methylphenidate).\" Celltech Pharmaceuticals Inc  (2002):[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Ritalin LA (methylphenidate).\" Quality Care Products/Lake Erie Medical  (2013):[8] \"Product Information. Azstarys (dexmethylphenidate-serdexmethylphenidate).\" Corium, Inc.  (2021):", "alternatives_a": "Amphetamine, Pemoline, Metamfetamine, Lisdexamfetamine, Solriamfetol, Caffeine, Dextroamphetamine, Citicoline", "alternatives_b": "Acetylsalicylic acid, Ivabradine", "updated_at": 1767369485}, {"id": 242176, "ingredient1": "Dexmethylphenidate", "ingredient2": "Telmisartan", "severity": "Moderate", "effect": "Methylphenidate and other derivative amphetamines may decrease the therapeutic effects of antihypertensive drugs.", "source": "DDInter", "management_text": "Caution and monitoring of blood pressure is recommended if methylphenidate, dexmethylphenidate or serdexmethylphenidate are administered with antihypertensives agents such as:  potassium-sparing and thiazide diuretics, calcium channel blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers or centrally acting alpha-2 receptor agonists.  The dosage of the antihypertensive drug should be adjusted as needed.", "mechanism_text": "Antagonism", "recommendation": "Caution and monitoring of blood pressure is recommended if methylphenidate, dexmethylphenidate or serdexmethylphenidate are administered with antihypertensives agents such as:  potassium-sparing and thiazide diuretics, calcium channel blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers or centrally acting alpha-2 receptor agonists.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272909/", "reference_text": "[1] \"Product Information. Ritalin (methylphenidate).\" Novartis Pharmaceuticals  (2001):[2] \"Product Information. Metadate CD (methylphenidate).\" Celltech Pharmaceuticals Inc  (2022):[3] \"Product Information. Focalin (dexmethylphenidate).\" Mikart Inc  (2001):[4] \"Product Information. Metadate ER (methylphenidate).\" Celltech Pharmaceuticals Inc  (2002):[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Ritalin LA (methylphenidate).\" Quality Care Products/Lake Erie Medical  (2013):[8] \"Product Information. Azstarys (dexmethylphenidate-serdexmethylphenidate).\" Corium, Inc.  (2021):", "alternatives_a": "Amphetamine, Pemoline, Atomoxetine, Metamfetamine, Lisdexamfetamine, Solriamfetol, Caffeine, Dextroamphetamine, Armodafinil, Citicoline", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 242177, "ingredient1": "Dexmethylphenidate", "ingredient2": "Trandolapril", "severity": "Moderate", "effect": "Methylphenidate and other derivative amphetamines may decrease the therapeutic effects of antihypertensive drugs.", "source": "DDInter", "management_text": "Caution and monitoring of blood pressure is recommended if methylphenidate, dexmethylphenidate or serdexmethylphenidate are administered with antihypertensives agents such as:  potassium-sparing and thiazide diuretics, calcium channel blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers or centrally acting alpha-2 receptor agonists.  The dosage of the antihypertensive drug should be adjusted as needed.", "mechanism_text": "Antagonism", "recommendation": "Caution and monitoring of blood pressure is recommended if methylphenidate, dexmethylphenidate or serdexmethylphenidate are administered with antihypertensives agents such as:  potassium-sparing and thiazide diuretics, calcium channel blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers or centrally acting alpha-2 receptor agonists.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272910/", "reference_text": "[1] \"Product Information. Ritalin (methylphenidate).\" Novartis Pharmaceuticals  (2001):[2] \"Product Information. Metadate CD (methylphenidate).\" Celltech Pharmaceuticals Inc  (2022):[3] \"Product Information. Focalin (dexmethylphenidate).\" Mikart Inc  (2001):[4] \"Product Information. Metadate ER (methylphenidate).\" Celltech Pharmaceuticals Inc  (2002):[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Ritalin LA (methylphenidate).\" Quality Care Products/Lake Erie Medical  (2013):[8] \"Product Information. Azstarys (dexmethylphenidate-serdexmethylphenidate).\" Corium, Inc.  (2021):", "alternatives_a": "Amphetamine, Pemoline, Atomoxetine, Metamfetamine, Lisdexamfetamine, Solriamfetol, Caffeine, Dextroamphetamine, Armodafinil, Citicoline, Modafinil", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242178, "ingredient1": "Dexmethylphenidate", "ingredient2": "Triamterene", "severity": "Moderate", "effect": "Methylphenidate and other derivative amphetamines may decrease the therapeutic effects of antihypertensive drugs.", "source": "DDInter", "management_text": "Caution and monitoring of blood pressure is recommended if methylphenidate, dexmethylphenidate or serdexmethylphenidate are administered with antihypertensives agents such as:  potassium-sparing and thiazide diuretics, calcium channel blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers or centrally acting alpha-2 receptor agonists.  The dosage of the antihypertensive drug should be adjusted as needed.", "mechanism_text": "Antagonism", "recommendation": "Caution and monitoring of blood pressure is recommended if methylphenidate, dexmethylphenidate or serdexmethylphenidate are administered with antihypertensives agents such as:  potassium-sparing and thiazide diuretics, calcium channel blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers or centrally acting alpha-2 receptor agonists.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272911/", "reference_text": "[1] \"Product Information. Ritalin (methylphenidate).\" Novartis Pharmaceuticals  (2001):[2] \"Product Information. Metadate CD (methylphenidate).\" Celltech Pharmaceuticals Inc  (2022):[3] \"Product Information. Focalin (dexmethylphenidate).\" Mikart Inc  (2001):[4] \"Product Information. Metadate ER (methylphenidate).\" Celltech Pharmaceuticals Inc  (2002):[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Ritalin LA (methylphenidate).\" Quality Care Products/Lake Erie Medical  (2013):[8] \"Product Information. Azstarys (dexmethylphenidate-serdexmethylphenidate).\" Corium, Inc.  (2021):", "alternatives_a": "Amphetamine, Pemoline, Atomoxetine, Metamfetamine, Lisdexamfetamine, Solriamfetol, Caffeine, Dextroamphetamine, Armodafinil, Citicoline, Modafinil", "alternatives_b": "Finerenone", "updated_at": 1767369485}, {"id": 242179, "ingredient1": "Dexmethylphenidate", "ingredient2": "Trichlormethiazide", "severity": "Moderate", "effect": "Methylphenidate and other derivative amphetamines may decrease the therapeutic effects of antihypertensive drugs.", "source": "DDInter", "management_text": "Caution and monitoring of blood pressure is recommended if methylphenidate, dexmethylphenidate or serdexmethylphenidate are administered with antihypertensives agents such as:  potassium-sparing and thiazide diuretics, calcium channel blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers or centrally acting alpha-2 receptor agonists.  The dosage of the antihypertensive drug should be adjusted as needed.", "mechanism_text": "Antagonism", "recommendation": "Caution and monitoring of blood pressure is recommended if methylphenidate, dexmethylphenidate or serdexmethylphenidate are administered with antihypertensives agents such as:  potassium-sparing and thiazide diuretics, calcium channel blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers or centrally acting alpha-2 receptor agonists.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272912/", "reference_text": "[1] \"Product Information. Ritalin (methylphenidate).\" Novartis Pharmaceuticals  (2001):[2] \"Product Information. Metadate CD (methylphenidate).\" Celltech Pharmaceuticals Inc  (2022):[3] \"Product Information. Focalin (dexmethylphenidate).\" Mikart Inc  (2001):[4] \"Product Information. Metadate ER (methylphenidate).\" Celltech Pharmaceuticals Inc  (2002):[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Ritalin LA (methylphenidate).\" Quality Care Products/Lake Erie Medical  (2013):[8] \"Product Information. Azstarys (dexmethylphenidate-serdexmethylphenidate).\" Corium, Inc.  (2021):", "alternatives_a": "Amphetamine, Pemoline, Atomoxetine, Metamfetamine, Lisdexamfetamine, Solriamfetol, Caffeine, Dextroamphetamine, Armodafinil, Citicoline, Modafinil", "alternatives_b": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, More", "updated_at": 1767369485}, {"id": 242180, "ingredient1": "Dexmethylphenidate", "ingredient2": "Trimethaphan", "severity": "Moderate", "effect": "Methylphenidate and other derivative amphetamines may decrease the therapeutic effects of antihypertensive drugs.", "source": "DDInter", "management_text": "Caution and monitoring of blood pressure is recommended if methylphenidate, dexmethylphenidate or serdexmethylphenidate are administered with antihypertensives agents such as:  potassium-sparing and thiazide diuretics, calcium channel blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers or centrally acting alpha-2 receptor agonists.  The dosage of the antihypertensive drug should be adjusted as needed.", "mechanism_text": "Antagonism", "recommendation": "Caution and monitoring of blood pressure is recommended if methylphenidate, dexmethylphenidate or serdexmethylphenidate are administered with antihypertensives agents such as:  potassium-sparing and thiazide diuretics, calcium channel blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers or centrally acting alpha-2 receptor agonists.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272913/", "reference_text": "[1] \"Product Information. Ritalin (methylphenidate).\" Novartis Pharmaceuticals  (2001):[2] \"Product Information. Metadate CD (methylphenidate).\" Celltech Pharmaceuticals Inc  (2022):[3] \"Product Information. Focalin (dexmethylphenidate).\" Mikart Inc  (2001):[4] \"Product Information. Metadate ER (methylphenidate).\" Celltech Pharmaceuticals Inc  (2002):[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Ritalin LA (methylphenidate).\" Quality Care Products/Lake Erie Medical  (2013):[8] \"Product Information. Azstarys (dexmethylphenidate-serdexmethylphenidate).\" Corium, Inc.  (2021):", "alternatives_a": "Amphetamine, Pemoline, Atomoxetine, Metamfetamine, Lisdexamfetamine, Solriamfetol, Caffeine, Dextroamphetamine, Armodafinil, Citicoline, Modafinil", "alternatives_b": "Mecamylamine", "updated_at": 1767369485}, {"id": 242181, "ingredient1": "Dexmethylphenidate", "ingredient2": "Valsartan", "severity": "Moderate", "effect": "Methylphenidate and other derivative amphetamines may decrease the therapeutic effects of antihypertensive drugs.", "source": "DDInter", "management_text": "Caution and monitoring of blood pressure is recommended if methylphenidate, dexmethylphenidate or serdexmethylphenidate are administered with antihypertensives agents such as:  potassium-sparing and thiazide diuretics, calcium channel blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers or centrally acting alpha-2 receptor agonists.  The dosage of the antihypertensive drug should be adjusted as needed.", "mechanism_text": "Antagonism", "recommendation": "Caution and monitoring of blood pressure is recommended if methylphenidate, dexmethylphenidate or serdexmethylphenidate are administered with antihypertensives agents such as:  potassium-sparing and thiazide diuretics, calcium channel blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers or centrally acting alpha-2 receptor agonists.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272914/", "reference_text": "[1] \"Product Information. Ritalin (methylphenidate).\" Novartis Pharmaceuticals  (2001):[2] \"Product Information. Metadate CD (methylphenidate).\" Celltech Pharmaceuticals Inc  (2022):[3] \"Product Information. Focalin (dexmethylphenidate).\" Mikart Inc  (2001):[4] \"Product Information. Metadate ER (methylphenidate).\" Celltech Pharmaceuticals Inc  (2002):[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Ritalin LA (methylphenidate).\" Quality Care Products/Lake Erie Medical  (2013):[8] \"Product Information. Azstarys (dexmethylphenidate-serdexmethylphenidate).\" Corium, Inc.  (2021):", "alternatives_a": "Amphetamine, Pemoline, Metamfetamine, Lisdexamfetamine, Solriamfetol, Caffeine, Dextroamphetamine, Armodafinil, Citicoline", "alternatives_b": "Sacubitril, Aliskiren, Atorvastatin, Simvastatin, Lovastatin, Rosuvastatin, Niacin, Pravastatin, Acetylsalicylic acid, Ezetimibe, Bempedoic acid, Fenofibrate", "updated_at": 1767369485}, {"id": 242182, "ingredient1": "Glyburide", "ingredient2": "Obeticholic acid", "severity": "Moderate", "effect": "Coadministration with inhibitors of the bile salt efflux pump (BSEP) may increase accumulation of conjugated bile salts in the liver, including the glycine and taurine conjugates of obeticholic acid.  Following daily administration of obeticholic acid, there was accumulation of the glycine and taurine conjugates, which have in vitro pharmacological activities similar to the parent drug.  The metabolite-to-parent ratios of the glycine and taurine conjugates of obeticholic acid were 13.8 and 12.3 respectively, with chronic administration.  In vitro data indicate that the taurine conjugate of obeticholic acid (tauro-obeticholic acid) is a substrate of BSEP.  Consequently, concomitant use of medications that inhibit the BSEP, a canalicular membrane bile acid transporter, may result in further accumulation of tauro-obeticholic acid and other conjugated bile salts in the liver.  Clinical symptoms and toxicities may occur.  Additionally, obeticholic acid and its conjugates are selective and potent agonists for the farnesoid X receptor (FXR), the activation of which leads to induction of BSEP.  Thus, inhibitors of BSEP may theoretically diminish the pharmacologic effects of obeticholic acid.", "source": "DDInter", "management_text": "Concomitant use of obeticholic acid with BSEP inhibitors should generally be avoided.  If coadministration is required, serum transaminases and bilirubin should be closely monitored.", "mechanism_text": "Others", "recommendation": "Concomitant use of obeticholic acid with BSEP inhibitors should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272928/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[3] \"Product Information. Ocaliva (obeticholic acid).\" Intercept Pharmaceuticals, Inc.  (2016):", "alternatives_a": "Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Tolazamide, Empagliflozin, Dulaglutide, Exenatide, Tolbutamide, More", "alternatives_b": "Maralixibat, Ursodeoxycholic acid, Cholic Acid, Odevixibat, Chenodeoxycholic acid", "updated_at": 1767369485}, {"id": 242183, "ingredient1": "Glyburide", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272930/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Lixisenatide, Albiglutide, Guar gum, Acarbose, Pramlintide, Canagliflozin, Alogliptin, Liraglutide, Troglitazone, Ertugliflozin, Semaglutide, More", "alternatives_b": "Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Bosutinib, Vemurafenib, Lapatinib, Selumetinib, Ribociclib, More", "updated_at": 1767369485}, {"id": 242184, "ingredient1": "Chlorpropamide", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272952/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Lixisenatide, Albiglutide, Guar gum, Acarbose, Pramlintide, Canagliflozin, Alogliptin, Liraglutide, Troglitazone, Ertugliflozin, Semaglutide, More", "alternatives_b": "Entrectinib, Imatinib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, More", "updated_at": 1767369485}, {"id": 242185, "ingredient1": "Acrivastine", "ingredient2": "Stiripentol", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272960/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Astemizole", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 242186, "ingredient1": "Fenfluramine", "ingredient2": "Stiripentol", "severity": "Moderate", "effect": "Coadministration of fenfluramine with stiripentol and clobazam may increase the plasma concentrations of fenfluramine, which is primarily metabolized by CYP450 1A2, 2B6, and 2D6 in vitro.  Stiripentol is an inhibitor and inducer of CYP450 1A2 and 2B6 in vitro.", "source": "DDInter", "management_text": "For patients taking concomitant stiripentol and clobazam who are tolerating fenfluramine at a dose of 0.1 mg/kg twice daily and require additional seizure reduction, the dose of fenfluramine may be increased up to a maximum recommended maintenance dose of 0.2 mg/kg twice daily (maximum daily dose of 17 mg).", "mechanism_text": "Metabolism", "recommendation": "For patients taking concomitant stiripentol and clobazam who are tolerating fenfluramine at a dose of 0.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272965/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Onfi (clobazam).\" Lundbeck Inc  (2011):[3] \"Product Information. Fintepla (fenfluramine).\" Zogenix, Inc  (2020):", "alternatives_a": "Dexfenfluramine, Naltrexone, Ephedrine, Bupropion, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol, Lacosamide, Stiripentol", "alternatives_b": "Lacosamide, Fenfluramine", "updated_at": 1767369485}, {"id": 242187, "ingredient1": "Ginkgo biloba", "ingredient2": "Stiripentol", "severity": "Moderate", "effect": "Certain preparations of ginkgo biloba have been reported to induce seizures and may antagonize the effects of anticonvulsants.", "source": "DDInter", "management_text": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.  Because of inconsistencies in formulation and potency of commercial herbal preparations, there is no way to verify without laboratory testing if and in what quantity 4'-O-methylpyridoxine may be present in a given ginkgo preparation.  Patients treated with anticonvulsants should preferably avoid the use of products containing ginkgo biloba.", "mechanism_text": "Antagonism", "recommendation": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272970/", "reference_text": "[1] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[2] Gregory PJ \"Seizure associated with Ginkgo biloba?.\" Ann Intern Med 134 (2001):  344[3] Miwa H, Iijima M, Tanaka S, Mizuno Y \"Generalized convulsions after consuming a large amount of Gingko nuts.\" Epilepsia 42 (2001):  280-1[4] Kajiyama Y, Fujii K, Takeuchi H, Manabe Y \"Ginkgo seed poisoning.\" Pediatrics 109 (2002):  325-7[5] Kupiec T, Raj V \"Fatal seizures due to potential herb-drug interactions with Ginkgo biloba.\" J Anal Toxicol 29 (2005):  755-8[6] Harms SL, Garrard J, Schwinghammer P, Eberly LE, Chang Y, Leppik IE \"Ginkgo biloba use in nursing home elderly with epilepsy or seizure disorder.\" Epilepsia 47 (2006):  323-9[7] Granger AS \"Ginkgo biloba precipitating epileptic seizures.\" Age Ageing 30 (2001):  523-5[8] Spinella M \"Herbal medicines and epilepsy: the potential for benefit and adverse effects.\" Epilepsy Behav 2 (2001):  524-32", "alternatives_a": "Rivastigmine, Galantamine, Aducanumab, Memantine, Tacrine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242188, "ingredient1": "Stiripentol", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272972/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Amantadine, Cabergoline", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 242189, "ingredient1": "Stiripentol", "ingredient2": "Melatonin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272975/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam, Zopiclone, Thiopental", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 242190, "ingredient1": "Stiripentol", "ingredient2": "Olopatadine (nasal)", "severity": "Moderate", "effect": "Concurrent use of olopatadine nasal spray with alcohol or other central nervous system (CNS) depressants may result in additive impairment of mental alertness and performance.", "source": "DDInter", "management_text": "Concomitant use of olopatadine nasal spray with alcohol or other CNS depressants should generally be avoided if possible.  In the event that they are used together, patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their doctor if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of olopatadine nasal spray with alcohol or other CNS depressants should generally be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272979/", "reference_text": "[1] \"Product Information. Patanase (olopatadine nasal).\" Alcon Laboratories Inc  (2008):[2] \"Product Information. Ryaltris (mometasone-olopatadine nasal).\" Hikma Americas, Inc  (2022):", "alternatives_a": "Fenfluramine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242191, "ingredient1": "Stiripentol", "ingredient2": "Selegiline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272981/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Amantadine, Cabergoline", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 242192, "ingredient1": "Diazepam", "ingredient2": "Acrivastine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272985/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Dexchlorpheniramine, Astemizole, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242193, "ingredient1": "Diazepam", "ingredient2": "Butalbital", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272987/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Thiopental", "alternatives_b": "Meprobamate, Hydroxyzine", "updated_at": 1767369485}, {"id": 242194, "ingredient1": "Diazepam", "ingredient2": "Chlorcyclizine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272989/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Dexchlorpheniramine, Astemizole, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "Meprobamate, Oxazepam", "updated_at": 1767369485}, {"id": 242195, "ingredient1": "Diazepam", "ingredient2": "Chlormezanone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272990/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Meprobamate, Hydroxyzine, Halazepam", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242196, "ingredient1": "Diazepam", "ingredient2": "Cyclizine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272991/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Dexchlorpheniramine, Astemizole, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "Meprobamate, Halazepam", "updated_at": 1767369485}, {"id": 242197, "ingredient1": "Dimenhydrinate", "ingredient2": "Diazepam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272995/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Dexchlorpheniramine, Astemizole, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242198, "ingredient1": "Doxepin", "ingredient2": "Diazepam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272996/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Meprobamate", "alternatives_b": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone, Pheniramine", "updated_at": 1767369485}, {"id": 242199, "ingredient1": "Ethosuximide", "ingredient2": "Diazepam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/272998/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Methsuximide, Paramethadione, Phensuximide, Phenacemide, Trimethadione, Lacosamide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242200, "ingredient1": "Felbamate", "ingredient2": "Diazepam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273000/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Methsuximide, Paramethadione, Phensuximide, Phenacemide, Trimethadione, Lacosamide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242201, "ingredient1": "Fenfluramine", "ingredient2": "Diazepam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273001/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Dexfenfluramine, Ephedrine, Lorcaserin, Diethylpropion, Mazindol, Methsuximide, Paramethadione, Phensuximide, Phenacemide, Trimethadione, Lacosamide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242202, "ingredient1": "Diazepam", "ingredient2": "Methylphenobarbital", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273007/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Meprobamate, Hydroxyzine", "alternatives_b": "Methsuximide, Paramethadione, Phensuximide, Phenacemide, Trimethadione, Lacosamide, Thiopental", "updated_at": 1767369485}, {"id": 242203, "ingredient1": "Diazepam", "ingredient2": "Osilodrostat", "severity": "Moderate", "effect": "Coadministration with osilodrostat may increase the plasma concentrations of drugs that are metabolized by CYP450 1A2, 2C19, 2D6, and/or 3A4.  Osilodrostat has been shown to be a moderate inhibitor of CYP450 1A2, a mild to borderline moderate inhibitor of CYP450 2C19, and a weak inhibitor of CYP450 2D6 and 3A4.", "source": "DDInter", "management_text": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever osilodrostat is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273010/", "reference_text": "[1] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Inc  (2020):[2] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Australia Pty Ltd  (2022):[3] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases UK Ltd  (2021):", "alternatives_a": "Meprobamate, Lorazepam, Halazepam, Chlordiazepoxide, Oxazepam", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242204, "ingredient1": "Diazepam", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273012/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Meprobamate, Lorazepam, Halazepam, Chlordiazepoxide, Oxazepam", "alternatives_b": "Entrectinib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, More", "updated_at": 1767369485}, {"id": 242205, "ingredient1": "Hydroxyurea", "ingredient2": "Cinchocaine (topical)", "severity": "Moderate", "effect": "Some topical anesthetics can be systemically absorbed and cause methemoglobinemia, particularly when applied to mucous membranes.  Coadministration with other oxidizing agents that can also induce methemoglobinemia such as injectable local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents.  Clinicians should be aware of the potential for methemoglobinemia, particularly when topical anesthetics are applied to mucous membranes or given via the oropharyngeal route.  Signs and symptoms of methemoglobinemia may be delayed some hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273033/", "reference_text": "[1] Karim A, Ahmed S, Siddiqui R, Mattana J \"Methemoglobinemia complicating topical lidocaine used during endoscopic procedures.\" Am J Med 111 (2001):  150-3[2] \"Product Information. Hurricaine (benzocaine topical).\" Beutlich  (2005):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[6] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[7] \"Product Information. Chloraseptic (benzocaine-menthol topical).\" Prestige Brands (formerly MedTech)  (2020):[8] \"Product Information. Diclona (diclofenac-lidocaine topical).\" Terrain Pharmaceuticals  (2022):", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242206, "ingredient1": "Ifosfamide", "ingredient2": "Cinchocaine (topical)", "severity": "Moderate", "effect": "Some topical anesthetics can be systemically absorbed and cause methemoglobinemia, particularly when applied to mucous membranes.  Coadministration with other oxidizing agents that can also induce methemoglobinemia such as injectable local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents.  Clinicians should be aware of the potential for methemoglobinemia, particularly when topical anesthetics are applied to mucous membranes or given via the oropharyngeal route.  Signs and symptoms of methemoglobinemia may be delayed some hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273034/", "reference_text": "[1] Karim A, Ahmed S, Siddiqui R, Mattana J \"Methemoglobinemia complicating topical lidocaine used during endoscopic procedures.\" Am J Med 111 (2001):  150-3[2] \"Product Information. Hurricaine (benzocaine topical).\" Beutlich  (2005):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[6] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[7] \"Product Information. Chloraseptic (benzocaine-menthol topical).\" Prestige Brands (formerly MedTech)  (2020):[8] \"Product Information. Diclona (diclofenac-lidocaine topical).\" Terrain Pharmaceuticals  (2022):", "alternatives_a": "Temozolomide, Thiotepa, Carmustine, Busulfan, Streptozocin, Chlorambucil, Lomustine, Dacarbazine, Mechlorethamine, Bendamustine, Melphalan, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242207, "ingredient1": "Etidronic acid", "ingredient2": "Moxetumomab Pasudotox", "severity": "Moderate", "effect": "Coadministration of bisphosphonates with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the kidney.", "source": "DDInter", "management_text": "Caution is advised if pamidronate, zoledronic acid, or other intravenous formulations of bisphosphonates must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.g., aminoglycosides, polypeptide and polymyxin antibiotics, vancomycin, amphotericin B, adefovir, cidofovir, tenofovir, foscarnet, cisplatin, gallium nitrate, lithium, mesalamine, certain immunosuppressants, intravenous pentamidine, high intravenous dosages of methotrexate, high dosages of nonsteroidal anti-inflammatory agents).  Renal function and serum electrolytes should be monitored.  Patients should have serum creatinine assessed prior to each treatment, and treatment should be withheld for renal deterioration.  In those treated for bone metastases, treatment should not be resumed until renal function returns to baseline.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if pamidronate, zoledronic acid, or other intravenous formulations of bisphosphonates must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273077/", "reference_text": "[1] Kanis JA, Preston CJ, Yates AJ, Percival RC, Mundy KI, Russell RG \"Effects of intravenous diphosphonates on renal function.\" Lancet 1 (1983):  1328[2] \"Product Information. Aredia (pamidronate).\" Novartis Pharmaceuticals  (2001):[3] Osullivan TL, Akbari A, Cadnapaphornchai P \"Acute renal failure associated with the administration of parenteral etidronate.\" Ren Fail 16 (1994):  767-73[4] Zazgornik J, Grafinger P, Biesenbach G, Hubmann R, Fridrik M \"Acute renal failure and alendronate.\" Nephrol Dial Transplant 12 (1997):  2797-8[5] \"Product Information. Zometa (zoledronic acid).\" Novartis Pharmaceuticals  (2001):[6] Janssen Van Doorn K, Neyns B, Van Der Niepen P, Verbeelen D \"Pamidronate-related nephrotoxicity (tubulointerstitial nephritis) in a patient with osteolytic bone metastases.\" Nephron 89 (2001):  467-8[7] Lockridge L, Papac RJ, Perazella MA \"Pamidronate-associated nephrotoxicity in a patient with Langerhans's histiocytosis.\" Am J Kidney Dis 40 (2002):  E2[8] Markowitz GS, Fine PL, Stack JI, et al. \"Toxic acute tubular necrosis following treatment with zoledronate (Zometa).\" Kidney Int 64 (2003):  281-289[9] Banerjee D, Asif A, Striker L, Preston RA, Bourgoignie JJ, Roth D \"Short-term, high-dose pamidronate-induced acute tubular necrosis: The postulated mechanisms of bisphosphonate nephrotoxicity.\" Am J Kidney Dis 41 (2003):  E18[10] Chang JT, Green L, Beitz J \"Renal failure with the use of zoledronic acid.\" N Engl J Med 349 (2003):  1676-9; discussion 1676-9[11] \"Product Information. Ostac (clodronate).\" Hoffmann-La Roche Limited  (2004):[12] \"Product Information. Boniva (ibandronate).\" Roche Laboratories  (2005):", "alternatives_a": "Tiludronic acid, Alendronic acid, Vosoritide, Denosumab, Cholecalciferol, Burosumab, Risedronic acid, Romosozumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242208, "ingredient1": "Diethylpropion", "ingredient2": "Ketamine", "severity": "Moderate", "effect": "Ketamine can cause hemodynamic instability such as arrhythmias and transient increases or decreases in blood pressure, heart rate, and cardiac index.  Coadministration of ketamine with direct or indirect acting sympathomimetics or vasopressin may enhance the sympathomimetic effects of ketamine leading to additive increases in blood pressure and heart rate.", "source": "DDInter", "management_text": "Close monitoring of vital signs, including blood pressure and heart rate is recommended whenever ketamine is used concomitantly with direct or indirect acting sympathomimetics or vasopressin.  Dosage adjustments should be considered according to the patient's clinical situation.  Some authorities suggest avoiding the use of ketamine in patients receiving drugs with a hypertensive effect such as ergometrine.", "mechanism_text": "Synergism", "recommendation": "Close monitoring of vital signs, including blood pressure and heart rate is recommended whenever ketamine is used concomitantly with direct or indirect acting sympathomimetics or vasopressin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273092/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Ketalar (ketamine).\" JHP Pharmaceuticals  (2009):", "alternatives_a": "Dexfenfluramine, Naltrexone, Bupropion, Orlistat, Lorcaserin", "alternatives_b": "Halothane, Thiopental, Alfentanil, Remifentanil, Isoflurane, Sodium oxybate, Methohexital, Fentanyl, Desflurane, Nitrous oxide, Sufentanil, More", "updated_at": 1767369485}, {"id": 242209, "ingredient1": "Fidaxomicin", "ingredient2": "Alvimopan", "severity": "Moderate", "effect": "Coadministration with fidaxomicin may increase the plasma concentrations of some orally administered drugs that are substrates of the P-glycoprotein (P-gp) transporter.  In vitro, fidaxomicin and its main metabolite are substrates and inhibitors of P-gp, an efflux transporter expressed in the gastrointestinal tract.", "source": "DDInter", "management_text": "Caution is advised when fidaxomicin is used in combination with P-gp substrates that may be sensitive to intestinal P-gp inhibition.", "mechanism_text": "Absorption", "recommendation": "Caution is advised when fidaxomicin is used in combination with P-gp substrates that may be sensitive to intestinal P-gp inhibition.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273213/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Dificid (fidaxomicin).\" Optimer Pharmaceuticals  (2011):[4] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):", "alternatives_a": "Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, Linaclotide, More", "alternatives_b": "Rifamycin, Kanamycin, Amphotericin B, Miconazole, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Rifaximin, Paromomycin, Neomycin", "updated_at": 1767369485}, {"id": 242210, "ingredient1": "Fidaxomicin", "ingredient2": "Lurasidone", "severity": "Moderate", "effect": "Coadministration with fidaxomicin may increase the plasma concentrations of some orally administered drugs that are substrates of the P-glycoprotein (P-gp) transporter.  In vitro, fidaxomicin and its main metabolite are substrates and inhibitors of P-gp, an efflux transporter expressed in the gastrointestinal tract.", "source": "DDInter", "management_text": "Caution is advised when fidaxomicin is used in combination with P-gp substrates that may be sensitive to intestinal P-gp inhibition.", "mechanism_text": "Absorption", "recommendation": "Caution is advised when fidaxomicin is used in combination with P-gp substrates that may be sensitive to intestinal P-gp inhibition.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273220/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Dificid (fidaxomicin).\" Optimer Pharmaceuticals  (2011):[4] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Rifaximin, Paromomycin, Neomycin", "alternatives_b": "Fluphenazine, Haloperidol, Thiothixene, Risperidone, Amisulpride, Quetiapine, Prochlorperazine, Promazine, Thioridazine, Lumateperone, Pimozide, More", "updated_at": 1767369485}, {"id": 242211, "ingredient1": "Fidaxomicin", "ingredient2": "Maraviroc", "severity": "Moderate", "effect": "Coadministration with fidaxomicin may increase the plasma concentrations of some orally administered drugs that are substrates of the P-glycoprotein (P-gp) transporter.  In vitro, fidaxomicin and its main metabolite are substrates and inhibitors of P-gp, an efflux transporter expressed in the gastrointestinal tract.", "source": "DDInter", "management_text": "Caution is advised when fidaxomicin is used in combination with P-gp substrates that may be sensitive to intestinal P-gp inhibition.", "mechanism_text": "Absorption", "recommendation": "Caution is advised when fidaxomicin is used in combination with P-gp substrates that may be sensitive to intestinal P-gp inhibition.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273221/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Dificid (fidaxomicin).\" Optimer Pharmaceuticals  (2011):[4] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Rifaximin, Paromomycin, Neomycin", "alternatives_b": "Lamivudine, Simeprevir, Amprenavir, Cabotegravir, Zanamivir, Valaciclovir, Rilpivirine, Etravirine, Dolutegravir, Oseltamivir, Cobicistat, More", "updated_at": 1767369485}, {"id": 242212, "ingredient1": "Fidaxomicin", "ingredient2": "Mirabegron", "severity": "Moderate", "effect": "Coadministration with fidaxomicin may increase the plasma concentrations of some orally administered drugs that are substrates of the P-glycoprotein (P-gp) transporter.  In vitro, fidaxomicin and its main metabolite are substrates and inhibitors of P-gp, an efflux transporter expressed in the gastrointestinal tract.", "source": "DDInter", "management_text": "Caution is advised when fidaxomicin is used in combination with P-gp substrates that may be sensitive to intestinal P-gp inhibition.", "mechanism_text": "Absorption", "recommendation": "Caution is advised when fidaxomicin is used in combination with P-gp substrates that may be sensitive to intestinal P-gp inhibition.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273223/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Dificid (fidaxomicin).\" Optimer Pharmaceuticals  (2011):[4] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Rifaximin, Paromomycin, Neomycin", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "updated_at": 1767369485}, {"id": 242213, "ingredient1": "Fidaxomicin", "ingredient2": "Nintedanib", "severity": "Moderate", "effect": "Coadministration with fidaxomicin may increase the plasma concentrations of some orally administered drugs that are substrates of the P-glycoprotein (P-gp) transporter.  In vitro, fidaxomicin and its main metabolite are substrates and inhibitors of P-gp, an efflux transporter expressed in the gastrointestinal tract.", "source": "DDInter", "management_text": "Caution is advised when fidaxomicin is used in combination with P-gp substrates that may be sensitive to intestinal P-gp inhibition.", "mechanism_text": "Absorption", "recommendation": "Caution is advised when fidaxomicin is used in combination with P-gp substrates that may be sensitive to intestinal P-gp inhibition.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273225/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Dificid (fidaxomicin).\" Optimer Pharmaceuticals  (2011):[4] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Miconazole, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Rifaximin, Paromomycin, Neomycin", "alternatives_b": "Entrectinib, Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Fedratinib, Avapritinib, Selumetinib, Ribociclib, Vandetanib, Duvelisib, More", "updated_at": 1767369485}, {"id": 242214, "ingredient1": "Fidaxomicin", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with fidaxomicin may increase the plasma concentrations of some orally administered drugs that are substrates of the P-glycoprotein (P-gp) transporter.  In vitro, fidaxomicin and its main metabolite are substrates and inhibitors of P-gp, an efflux transporter expressed in the gastrointestinal tract.", "source": "DDInter", "management_text": "Caution is advised when fidaxomicin is used in combination with P-gp substrates that may be sensitive to intestinal P-gp inhibition.", "mechanism_text": "Absorption", "recommendation": "Caution is advised when fidaxomicin is used in combination with P-gp substrates that may be sensitive to intestinal P-gp inhibition.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273227/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Dificid (fidaxomicin).\" Optimer Pharmaceuticals  (2011):[4] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Miconazole, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Paromomycin, Neomycin", "alternatives_b": "Entrectinib, Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Fedratinib, Avapritinib, Selumetinib, Ribociclib, Vandetanib, Duvelisib, More", "updated_at": 1767369485}, {"id": 242215, "ingredient1": "Fidaxomicin", "ingredient2": "Rucaparib", "severity": "Moderate", "effect": "Coadministration with fidaxomicin may increase the plasma concentrations of some orally administered drugs that are substrates of the P-glycoprotein (P-gp) transporter.  In vitro, fidaxomicin and its main metabolite are substrates and inhibitors of P-gp, an efflux transporter expressed in the gastrointestinal tract.", "source": "DDInter", "management_text": "Caution is advised when fidaxomicin is used in combination with P-gp substrates that may be sensitive to intestinal P-gp inhibition.", "mechanism_text": "Absorption", "recommendation": "Caution is advised when fidaxomicin is used in combination with P-gp substrates that may be sensitive to intestinal P-gp inhibition.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273228/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Dificid (fidaxomicin).\" Optimer Pharmaceuticals  (2011):[4] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Miconazole, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Rifaximin, Paromomycin, Neomycin", "alternatives_b": "Pertuzumab, Olaparib, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, More", "updated_at": 1767369485}, {"id": 242216, "ingredient1": "Fidaxomicin", "ingredient2": "Topotecan", "severity": "Moderate", "effect": "Coadministration with fidaxomicin may increase the plasma concentrations of some orally administered drugs that are substrates of the P-glycoprotein (P-gp) transporter.  In vitro, fidaxomicin and its main metabolite are substrates and inhibitors of P-gp, an efflux transporter expressed in the gastrointestinal tract.", "source": "DDInter", "management_text": "Caution is advised when fidaxomicin is used in combination with P-gp substrates that may be sensitive to intestinal P-gp inhibition.", "mechanism_text": "Absorption", "recommendation": "Caution is advised when fidaxomicin is used in combination with P-gp substrates that may be sensitive to intestinal P-gp inhibition.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273233/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Dificid (fidaxomicin).\" Optimer Pharmaceuticals  (2011):[4] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Miconazole, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Rifaximin, Paromomycin, Neomycin", "alternatives_b": "Trabectedin, Cabazitaxel, Vinblastine, Paclitaxel, Vincristine, Teniposide, Irinotecan, Vinorelbine, Etoposide, Docetaxel", "updated_at": 1767369485}, {"id": 242217, "ingredient1": "Fidaxomicin", "ingredient2": "Vemurafenib", "severity": "Moderate", "effect": "Coadministration with fidaxomicin may increase the plasma concentrations of some orally administered drugs that are substrates of the P-glycoprotein (P-gp) transporter.  In vitro, fidaxomicin and its main metabolite are substrates and inhibitors of P-gp, an efflux transporter expressed in the gastrointestinal tract.", "source": "DDInter", "management_text": "Caution is advised when fidaxomicin is used in combination with P-gp substrates that may be sensitive to intestinal P-gp inhibition.", "mechanism_text": "Absorption", "recommendation": "Caution is advised when fidaxomicin is used in combination with P-gp substrates that may be sensitive to intestinal P-gp inhibition.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273234/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Dificid (fidaxomicin).\" Optimer Pharmaceuticals  (2011):[4] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Miconazole, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Rifaximin, Paromomycin, Neomycin", "alternatives_b": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, More", "updated_at": 1767369485}, {"id": 242218, "ingredient1": "Ginkgo biloba", "ingredient2": "Diflunisal", "severity": "Moderate", "effect": "Ginkgo may potentiate the risk of bleeding associated with anticoagulants, platelet inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), and thrombolytic agents.  Ginkgolide B, a component of ginkgo, inhibits platelet-activating factor by displacing it from its receptor-binding site, resulting in reduced platelet aggregation.", "source": "DDInter", "management_text": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.  In general, consumption of ginkgo should be avoided during use of coagulation-modifying agents and at least two weeks prior to surgery.  In patients who have used this herb extensively prior to receiving anticoagulation, antiplatelet, NSAID or thrombolytic therapy, the potential for an interaction should be considered.  Close clinical and laboratory observation for hematologic complications is recommended.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273239/", "reference_text": "[1] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[2] Rosenblatt M, Mindel J \"Spontaneous hyphema associated with ingestion of Ginkgo biloba extract.\" N Engl J Med 336 (1997):  1108[3] Rowin J, Lewis SL \"Spontaneous bilateral subdural hematomas associated with chronic Gingko biloba ingestion.\" Neurology 46 (1996):  1775-6[4] Chung KF, McCusker M, Page CP, Dent G, Guinot P, Barnes PJ \"Effect of ginkgolide mixture (BN 52063) in antagonising skin and platelet responses to platelet acitivating factor in man.\" Lancet 1 (1987):  248-51[5] Fugh-Berman A \"Herb-drug interactions.\" Lancet 355 (2000):  134-8[6] Heck AM, DeWitt BA, Lukes AL \"Potential interactions between alternative therapies and warfarin.\" Am J Health Syst Pharm 57 (2000):  1221-7; quiz 1228-30[7] Vaes LP, Chyka PA \"Interactions of warfarin with garlic, ginger, or ginseng: nature of evidence.\" Ann Pharmacother 34 (2000):  1478-82[8] Fessenden JM, Wittenborn W, Clarke L \"Gingko biloba: A case report of herbal medicine and bleeding postoperatively from a laparoscopic cholecystectomy.\" Am Surg 67 (2001):  33-5[9] Benjamin J, Muir T, Briggs K, Pentland B \"A case of cerebral haemorrhage - can Ginkgo biloba be implicated?.\" Postgrad Med J 77 (2001):  112-3[10] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001):  2163-75[11] Evans V \"Herbs and the brain: friend or foe? The effects of ginkgo and garlic on warfarin use.\" J Neurosci Nurs 32 (2000):  229-32[12] Cupp MJ \"Herbal remedies: adverse effects and drug interactions.\" Am Fam Physician 59 (1999):  1239-45[13] Matthews MK Jr \"Association of Ginko biloba with intracerebral hemorrhage.\" Neurology 50 (1998):  1933-4[14] Engelsen J, Nielsen JD, Winther K \"Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in stable, long-term warfarin treated outpatients. A randomised, double blind, placebo-crossover trial.\" Thromb Haemost 87 (2002):  1075-6[15] Fong KC, Kinnear PE \"Retrobulbar haemorrhage associated with chronic Gingko biloba ingestion.\" Postgrad Med J 79 (2003):  531-2[16] Sierpina VS, Wollschlaeger B, Blumenthal M \"Ginkgo biloba.\" Am Fam Physician 68 (2003):  923-6[17] Jiang X, Williams KM, Liauw WS, et al. \"Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.\" Br J Clin Pharmacol 59 (2005):  425-32[18] Jayasekera N, Moghal A, Kashif F, Karalliedde L \"Herbal medicines and postoperative haemorrhage.\" Anaesthesia 60 (2005):  725-6[19] Wolf HR \"Does Ginkgo biloba special extract EGb 761 provide additional effects on coagulation and bleeding when added to acetylsalicylic acid 500 mg daily?\" Drugs R D 7 (2006):  163-72", "alternatives_a": "Salicylic acid, Acetaminophen, Choline salicylate, Ziconotide, Methoxyflurane, Salsalate", "alternatives_b": "Rivastigmine, Galantamine, Aducanumab, Memantine, Tacrine", "updated_at": 1767369485}, {"id": 242219, "ingredient1": "Heparin (flush)", "ingredient2": "Diflunisal", "severity": "Moderate", "effect": "Concomitant use of heparin flush and drugs that interfere with platelet function or coagulation or drugs that commonly cause thrombocytopenia may potentiate the risk of bleeding complications.  Although uncommon, inadvertent anticoagulation resulting in hemorrhagic events may occur with heparin flushes, particularly during repeated or excessive use or administration of higher concentration flush solutions.", "source": "DDInter", "management_text": "Caution and monitoring (e.g., platelet counts, hematocrits, tests for occult blood in stools) are advised when heparin flushes are given to patients receiving systemic anticoagulants, platelet inhibitors, antithrombotic agents, thrombolytics, or drugs with known risks of thrombocytopenia or bleeding.  An unexplained fall in hematocrit, fall in blood pressure, or any other unexplained symptom should lead to serious consideration of a hemorrhagic event.", "mechanism_text": "Synergism", "recommendation": "Caution and monitoring (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273240/", "reference_text": "[1] Passannante A, Macik BG \"The heparin flush syndrome: a cause of iatrogenic hemorrhage.\" Am J Med Sci 296 (1988):  71-3[2] \"Product Information. Heparin Sodium in Sodium Chloride (heparin flush).\" Baxter Healthcare Corporation  (2022):[3] \"Product Information. Canusal (heparin flush).\" Wockhardt UK Ltd  (2018):[4] \"Product Information. Heparinised Saline (Pfizer) (heparinised saline).\" Pfizer Australia Pty Ltd  (2022):", "alternatives_a": "Salicylic acid, Acetaminophen, Choline salicylate, Ziconotide, Methoxyflurane, Salsalate", "alternatives_b": "Protein C, Acenocoumarol, Selexipag, Pentosan polysulfate, Vitamin A, Ascorbic acid, Nandrolone, Acetylcysteine", "updated_at": 1767369485}, {"id": 242220, "ingredient1": "Digoxin", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273274/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Digitoxin", "alternatives_b": "Entrectinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, Selumetinib, Ribociclib, More", "updated_at": 1767369485}, {"id": 242221, "ingredient1": "Digoxin", "ingredient2": "Pyrophosphoric acid", "severity": "Moderate", "effect": "Medicinal products including sodium heparin, prazosin, methyldopa, hydralazine, quinidine, beta blockers, calcium channel blockers, digitalis glycosides, nitrates, anthracyclines, and iodinated contrast agents may interfere with the blood pool images taken using Technetium Tc 99m pyrophosphate.  This is characterized by a reduction in the amount of injected radioactivity remaining in the blood pool.", "source": "DDInter", "management_text": "Clinicians should be aware of the possibility of a diagnostic interference.  When use of iodinated contrast media is anticipated, it is recommended to perform the scintigraphy with (99mTc)-labeled red blood cells prior to administration of the iodinated contrast media to avoid adversely affecting the red blood cell labeling.", "mechanism_text": "Distribution", "recommendation": "Clinicians should be aware of the possibility of a diagnostic interference.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273275/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Pyrophosphate (pyrophosphate).\" Pharmalucence Inc  (2012):", "alternatives_a": "Digitoxin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242222, "ingredient1": "Digoxin", "ingredient2": "Relugolix", "severity": "Moderate", "effect": "Concomitant use with relugolix may lead to increased plasma concentrations of substrates of the intestinal efflux transporter, P-glycoprotein (P-gp).  According to the manufacturer, a relugolix dose of 40 mg may lead to saturation of intestinal P-gp.  In addition, relugolix exhibits more than dose-proportional pharmacokinetics over a dose range of 10 mg to 120 mg, which may lead to increased absorption of coadministered medicines that are sensitive substrates of P-gp.", "source": "DDInter", "management_text": "Some authorities advise that the coadministration of relugolix with sensitive substrates of P-glycoprotein, such as dabigatran etexilate, should be avoided.", "mechanism_text": "Absorption", "recommendation": "Some authorities advise that the coadministration of relugolix with sensitive substrates of P-glycoprotein, such as dabigatran etexilate, should be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273277/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Orgovyx (relugolix).\" Myovant Sciences, Inc.  (2021):[3] \"Product Information. Myfembree (estradiol/norethindrone/relugolix).\" Myovant Sciences, Inc.  (2021):", "alternatives_a": "Digitoxin", "alternatives_b": "Norethisterone, Nafarelin, Cetrorelix, Ganirelix, Gonadorelin, Darolutamide, Toremifene, Abarelix, Degarelix, Nilutamide, Aminoglutethimide, Abiraterone", "updated_at": 1767369485}, {"id": 242223, "ingredient1": "Dihydroergotamine", "ingredient2": "Ketamine", "severity": "Moderate", "effect": "Ketamine can cause hemodynamic instability such as arrhythmias and transient increases or decreases in blood pressure, heart rate, and cardiac index.  Coadministration of ketamine with direct or indirect acting sympathomimetics or vasopressin may enhance the sympathomimetic effects of ketamine leading to additive increases in blood pressure and heart rate.", "source": "DDInter", "management_text": "Close monitoring of vital signs, including blood pressure and heart rate is recommended whenever ketamine is used concomitantly with direct or indirect acting sympathomimetics or vasopressin.  Dosage adjustments should be considered according to the patient's clinical situation.  Some authorities suggest avoiding the use of ketamine in patients receiving drugs with a hypertensive effect such as ergometrine.", "mechanism_text": "Synergism", "recommendation": "Close monitoring of vital signs, including blood pressure and heart rate is recommended whenever ketamine is used concomitantly with direct or indirect acting sympathomimetics or vasopressin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273286/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Ketalar (ketamine).\" JHP Pharmaceuticals  (2009):", "alternatives_a": "Frovatriptan, Rimegepant, Eptinezumab, Lasmiditan, Atogepant, Eletriptan, Rizatriptan, Ubrogepant, Naratriptan, Galcanezumab, Zolmitriptan, More", "alternatives_b": "Halothane, Thiopental, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, Sevoflurane, Etomidate", "updated_at": 1767369485}, {"id": 242224, "ingredient1": "Dihydroergotamine", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273298/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Frovatriptan, Eptinezumab, Lasmiditan, Rizatriptan, Naratriptan, Galcanezumab, Zolmitriptan, Sumatriptan, Clonidine, Erenumab, Fremanezumab", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More", "updated_at": 1767369485}, {"id": 242225, "ingredient1": "Acrivastine", "ingredient2": "Phenytoin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273304/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Chlorcyclizine, Dexchlorpheniramine, Astemizole, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 242226, "ingredient1": "Dimenhydrinate", "ingredient2": "Phenytoin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273310/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Chlorcyclizine, Dexchlorpheniramine, Astemizole, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 242227, "ingredient1": "Etidocaine", "ingredient2": "Phenytoin", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273312/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242228, "ingredient1": "Fenfluramine", "ingredient2": "Phenytoin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273314/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Dexfenfluramine, Ephedrine, Phentermine, Lorcaserin, Diethylpropion, Mazindol, Ethotoin, Paramethadione, Phenacemide, Phenytoin, Trimethadione, Mephenytoin", "alternatives_b": "Lacosamide, Fenfluramine", "updated_at": 1767369485}, {"id": 242229, "ingredient1": "Phenytoin", "ingredient2": "Melatonin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273328/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Thiopental", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 242230, "ingredient1": "Procaine", "ingredient2": "Phenytoin", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273336/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, More", "alternatives_b": "Zinc sulfate, Zinc acetate, Fluocinolone acetonide, Fluocinonide, Zinc chloride, Fluorometholone, Zinc gluconate", "updated_at": 1767369485}, {"id": 242231, "ingredient1": "Ropivacaine", "ingredient2": "Phenytoin", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273339/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242232, "ingredient1": "Selegiline", "ingredient2": "Phenytoin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273340/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Lacosamide", "alternatives_b": "Cabergoline", "updated_at": 1767369485}, {"id": 242233, "ingredient1": "Silver nitrate (topical)", "ingredient2": "Phenytoin", "severity": "Moderate", "effect": "Topical nitrate and silver (e.g., cerium nitrate, silver nitrate, silver sulfadiazine) preparations can be systemically absorbed and have been associated with rare reports of methemoglobinemia, primarily in burn patients.  In addition, bacterial conversion of nitrate to nitrite can contribute to methemoglobinemia.  Coadministration with other oxidizing agents that can also induce methemoglobinemia such as ester and amide local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), systemic nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Depending on the circumstances, caution may be advisable when topical nitrate and silver preparations are used concomitantly with other methemoglobin-inducing agents.  Clinicians should be aware of the potential for methemoglobinemia, particularly when treating burn patients.  Signs and symptoms of methemoglobinemia may be delayed some hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Depending on the circumstances, caution may be advisable when topical nitrate and silver preparations are used concomitantly with other methemoglobin-inducing agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273341/", "reference_text": "[1] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[2] Geffner ME, Powars DR, Choctaw WT \"Acquired methemoglobinemia.\" West J Med 134 (1981):  7-10[3] Poredos P, Gradisek P, Testen C, Derganc M \"Severe methemoglobinaemia due to benzocaine-containing 'burn cream': two case reports in an adult and in a child.\" Burns 37 (2011):  e63-6[4] Gala HC, Madave A \"An unusual case of neonatal methemoglobinemia.\" Indian Pediatr 54 (2017):  163[5] Reese AD, Keyloun JW, Garg G, et.a \"Compounded cerium nitrate-silver sulfadiazine cream is safe and effective for the treatment of burn wounds: a burn center's four-year experience.\" J Burn Care Res 20 (2021):  Epub ahead of print[6] Cartotto R \"Topical antimicrobial agents for pediatric burns.\" Burns Trauma 5 (2017):  33", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242234, "ingredient1": "Silver sulfadiazine (topical)", "ingredient2": "Phenytoin", "severity": "Moderate", "effect": "Topical nitrate and silver (e.g., cerium nitrate, silver nitrate, silver sulfadiazine) preparations can be systemically absorbed and have been associated with rare reports of methemoglobinemia, primarily in burn patients.  In addition, bacterial conversion of nitrate to nitrite can contribute to methemoglobinemia.  Coadministration with other oxidizing agents that can also induce methemoglobinemia such as ester and amide local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), systemic nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Depending on the circumstances, caution may be advisable when topical nitrate and silver preparations are used concomitantly with other methemoglobin-inducing agents.  Clinicians should be aware of the potential for methemoglobinemia, particularly when treating burn patients.  Signs and symptoms of methemoglobinemia may be delayed some hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Depending on the circumstances, caution may be advisable when topical nitrate and silver preparations are used concomitantly with other methemoglobin-inducing agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273342/", "reference_text": "[1] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[2] Geffner ME, Powars DR, Choctaw WT \"Acquired methemoglobinemia.\" West J Med 134 (1981):  7-10[3] Poredos P, Gradisek P, Testen C, Derganc M \"Severe methemoglobinaemia due to benzocaine-containing 'burn cream': two case reports in an adult and in a child.\" Burns 37 (2011):  e63-6[4] Gala HC, Madave A \"An unusual case of neonatal methemoglobinemia.\" Indian Pediatr 54 (2017):  163[5] Reese AD, Keyloun JW, Garg G, et.a \"Compounded cerium nitrate-silver sulfadiazine cream is safe and effective for the treatment of burn wounds: a burn center's four-year experience.\" J Burn Care Res 20 (2021):  Epub ahead of print[6] Cartotto R \"Topical antimicrobial agents for pediatric burns.\" Burns Trauma 5 (2017):  33", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242235, "ingredient1": "Tivozanib", "ingredient2": "Phenytoin", "severity": "Major", "effect": "Coadministration of tivozanib with strong CYP450 3A4 inducers may decrease the plasma concentrations and therapeutic effects of tivozanib, which has been shown to be a substrate of the isoenzyme.", "source": "DDInter", "management_text": "Due to the potential for reduced anti-tumor activity, concomitant use of tivozanib with a strong CYP450 3A4 inducer should generally be avoided.  If coadministration is necessary, some authorities advise caution, with clinical and laboratory monitoring to be considered whenever a strong CYP450 3A4 inducer is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Due to the potential for reduced anti-tumor activity, concomitant use of tivozanib with a strong CYP450 3A4 inducer should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273351/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Fotivda (tivozanib).\" Aveo Pharmaceuticals, Inc.  (2021):", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, More", "alternatives_b": "Alectinib, Lenvatinib, Trametinib, Dacomitinib", "updated_at": 1767369485}, {"id": 242236, "ingredient1": "Hydromorphone", "ingredient2": "Acrivastine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273354/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Naltrexone, Acetaminophen, Dextropropoxyphene, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 242237, "ingredient1": "Hydromorphone", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273363/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "alternatives_b": "Amantadine", "updated_at": 1767369485}, {"id": 242238, "ingredient1": "Hydromorphone", "ingredient2": "Melatonin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273364/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Naltrexone, Acetaminophen, Dextropropoxyphene, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "alternatives_b": "Nitrazepam", "updated_at": 1767369485}, {"id": 242239, "ingredient1": "Hydromorphone", "ingredient2": "Selegiline", "severity": "Major", "effect": "Coadministration of monoamine oxidase inhibitors (MAOIs), such as selegiline (an MAO-B inhibitor), with opioid analgesics may result in serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5HT1A receptors.", "source": "DDInter", "management_text": "Concomitant use of MAOIs, such as selegiline, with opioid analgesics should generally be avoided.  At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with an opioid analgesic.  If coadministration is unavoidable, patients should be monitored for signs and symptoms of serotonin syndrome which may include mental status changes such as irritability, altered consciousness, confusion, hallucinations, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.  Some authorities consider the use of selegiline with opioid analgesics to be contraindicated (UK).", "mechanism_text": "Synergism", "recommendation": "Concomitant use of MAOIs, such as selegiline, with opioid analgesics should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273367/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Zelapar (selegiline).\" Valeant Pharmaceuticals  (2006):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Naloxone, Naltrexone, Celecoxib", "alternatives_b": "Amantadine", "updated_at": 1767369485}, {"id": 242240, "ingredient1": "Hydromorphone", "ingredient2": "Tolevamer", "severity": "Moderate", "effect": "Coadministration with medications that can cause constipation such as opioids may increase the risk of intestinal injuries associated with the use of sodium polystyrene sulfonate.", "source": "DDInter", "management_text": "Because opioids commonly cause constipation, caution is advised when used during treatment with sodium polystyrene sulfonate.  The prescribing information recommends avoiding the use of sodium polystyrene sulfonate in patients who are at risk for developing constipation or impaction, including those with a history of impaction, chronic constipation, inflammatory bowel disease, ischemic colitis, vascular intestinal atherosclerosis, previous bowel resection, or bowel obstruction, as well as those who have not had a bowel movement post-surgery.  If clinically significant constipation develops, treatment with sodium polystyrene sulfonate should be discontinued until normal bowel motion is resumed.  Concomitant administration of sorbitol is not recommended.", "mechanism_text": "Synergism", "recommendation": "Because opioids commonly cause constipation, caution is advised when used during treatment with sodium polystyrene sulfonate.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273368/", "reference_text": "[1] Foresti V \"Intestinal obstruction due to kayexalate in a patient concurrently treated with aluminum hydroxide and morphine sulfate.\" Clin Nephrol 41 (1994):  252[2] \"Product Information. Kayexalate (sodium polystyrene sulfonate).\" Sanofi Winthrop Pharmaceuticals  (2001):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):", "alternatives_a": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "alternatives_b": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Cobicistat, Deferoxamine, Levoleucovorin, Arginine, More", "updated_at": 1767369485}, {"id": 242241, "ingredient1": "Dimenhydrinate", "ingredient2": "Butalbital", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273375/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "Ketotifen, Chlorcyclizine, Azelastine, Fexofenadine, Dexchlorpheniramine, Loratadine, Phenindamine, Astemizole, Desloratadine, Meclizine, Cyclizine, More", "updated_at": 1767369485}, {"id": 242242, "ingredient1": "Dimenhydrinate", "ingredient2": "Chlormezanone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273377/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Methdilazine, Azatadine, Ketotifen, Alimemazine, Chlorcyclizine, Fexofenadine, Dexchlorpheniramine, Loratadine, Phenindamine, Astemizole, Desloratadine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242243, "ingredient1": "Dimenhydrinate", "ingredient2": "Chlorphenesin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273378/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Salicylic acid, Fluconazole, Selenium Sulfide, Thiabendazole, Miconazole, Nystatin, Ciclopirox, Griseofulvin, Ketoconazole, Terbinafine, Econazole, More", "alternatives_b": "Methdilazine, Azatadine, Ketotifen, Alimemazine, Chlorcyclizine, Fexofenadine, Thiethylperazine, Loratadine, Phenindamine, Astemizole, Desloratadine, More", "updated_at": 1767369485}, {"id": 242244, "ingredient1": "Dronabinol", "ingredient2": "Dimenhydrinate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273379/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Granisetron, Rolapitant, Aprepitant, Dolasetron, Ondansetron, Palonosetron", "updated_at": 1767369485}, {"id": 242245, "ingredient1": "Estazolam", "ingredient2": "Dimenhydrinate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273381/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Methdilazine, Ketotifen, Chlorcyclizine, Fexofenadine, Thiethylperazine, Phenindamine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 242246, "ingredient1": "Ethchlorvynol", "ingredient2": "Dimenhydrinate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273382/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Chlorcyclizine, Triprolidine, Tripelennamine, Azelastine, Promethazine, Fexofenadine, Meclizine, Azatadine, Alimemazine, Loratadine, More", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 242247, "ingredient1": "Ethosuximide", "ingredient2": "Dimenhydrinate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273383/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 242248, "ingredient1": "Ethotoin", "ingredient2": "Dimenhydrinate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273384/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Methdilazine, Ketotifen, Chlorcyclizine, Azelastine, Fexofenadine, Thiethylperazine, Dexchlorpheniramine, Loratadine, Phenindamine, Astemizole, Desloratadine, More", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 242249, "ingredient1": "Felbamate", "ingredient2": "Dimenhydrinate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273385/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Methdilazine, Ketotifen, Chlorcyclizine, Fexofenadine, Thiethylperazine, Dexchlorpheniramine, Loratadine, Phenindamine, Astemizole, Desloratadine, Azelastine, More", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 242250, "ingredient1": "Fenfluramine", "ingredient2": "Dimenhydrinate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273386/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Dexfenfluramine, Naltrexone, Ephedrine, Bupropion, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol, Lacosamide", "updated_at": 1767369485}, {"id": 242251, "ingredient1": "Fluoxetine", "ingredient2": "Dimenhydrinate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273387/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Chlorcyclizine, Dexchlorpheniramine, Azelastine, Pheniramine", "alternatives_b": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "updated_at": 1767369485}, {"id": 242252, "ingredient1": "Fluvoxamine", "ingredient2": "Dimenhydrinate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273388/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Methdilazine, Ketotifen, Meclizine, Chlorcyclizine, Thiethylperazine, Dexchlorpheniramine, Phenindamine, Desloratadine, Azelastine, Pheniramine", "alternatives_b": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "updated_at": 1767369485}, {"id": 242253, "ingredient1": "Gabapentin", "ingredient2": "Dimenhydrinate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273389/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Terfenadine, Astemizole", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 242254, "ingredient1": "Halazepam", "ingredient2": "Dimenhydrinate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273392/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Methdilazine, Azatadine, Ketotifen, Meclizine, Alimemazine, Fexofenadine, Thiethylperazine, Dexchlorpheniramine, Loratadine, Phenindamine, Astemizole, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242255, "ingredient1": "Dimenhydrinate", "ingredient2": "Lamotrigine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273393/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Methdilazine, Azatadine, Ketotifen, Meclizine, Thiethylperazine, Dexchlorpheniramine, Phenindamine, Astemizole, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 242256, "ingredient1": "Dimenhydrinate", "ingredient2": "Levetiracetam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273394/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Meclizine, Azelastine, Thiethylperazine, Dexchlorpheniramine, Phenindamine, Astemizole, Methdilazine, Terfenadine, Pheniramine", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 242257, "ingredient1": "Dimenhydrinate", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273395/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Cabergoline", "updated_at": 1767369485}, {"id": 242258, "ingredient1": "Dimenhydrinate", "ingredient2": "Lithium carbonate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273396/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Chlorcyclizine, Fexofenadine, Dexchlorpheniramine, Loratadine, Desloratadine, Azelastine, Pheniramine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242259, "ingredient1": "Dimenhydrinate", "ingredient2": "Melatonin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273397/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 242260, "ingredient1": "Dimenhydrinate", "ingredient2": "Mephenytoin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273398/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Methdilazine, Ketotifen, Chlorcyclizine, Azelastine, Fexofenadine, Thiethylperazine, Dexchlorpheniramine, Loratadine, Phenindamine, Astemizole, Desloratadine, More", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 242261, "ingredient1": "Dimenhydrinate", "ingredient2": "Methylphenobarbital", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273399/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Chlorcyclizine, Azelastine, Fexofenadine, Dexchlorpheniramine, Loratadine, Phenindamine, Astemizole, Desloratadine, Meclizine, Cyclizine, More", "alternatives_b": "Lacosamide, Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 242262, "ingredient1": "Dimenhydrinate", "ingredient2": "Meprobamate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273400/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Chlorcyclizine, Fexofenadine, Dexchlorpheniramine, Loratadine, Astemizole, Desloratadine, Azelastine, Cyclizine, Terfenadine, Pheniramine", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 242263, "ingredient1": "Dimenhydrinate", "ingredient2": "Metaxalone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273401/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Methdilazine, Ketotifen, Chlorcyclizine, Azelastine, Fexofenadine, Thiethylperazine, Dexchlorpheniramine, Loratadine, Phenindamine, Astemizole, Desloratadine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242264, "ingredient1": "Dimenhydrinate", "ingredient2": "Methocarbamol", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273402/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Meclizine, Azelastine, Thiethylperazine, Dexchlorpheniramine, Phenindamine, Astemizole, Methdilazine, Terfenadine, Pheniramine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242265, "ingredient1": "Dimenhydrinate", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273403/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Fexofenadine, Dexchlorpheniramine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 242266, "ingredient1": "Dimenhydrinate", "ingredient2": "Mirtazapine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273404/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Meclizine, Azelastine, Thiethylperazine, Dexchlorpheniramine, Phenindamine, Methdilazine, Pheniramine", "alternatives_b": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "updated_at": 1767369485}, {"id": 242267, "ingredient1": "Dimenhydrinate", "ingredient2": "Botulinum toxin type A", "severity": "Moderate", "effect": "Use of anticholinergic drugs after administration of botulinum toxin may potentiate systemic anticholinergic effects such as dry mouth, blurred vision, and urinary disorders.  Botulinum toxin inhibits the release of acetylcholine from peripheral cholinergic nerve endings, thus additive or synergistic anticholinergic effects may occur when these agents are used together.", "source": "DDInter", "management_text": "Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) are used after administration of botulinum toxin.", "mechanism_text": "Synergism", "recommendation": "Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273405/", "reference_text": "[1] \"Product Information. Myobloc (rimabotulinumtoxinB).\" Elan Pharmaceuticals[2] \"Product Information. Dysport (abobotulinumtoxinA).\" Tercica Inc[3] \"Product Information. Botox (onabotulinumtoxinA).\" Allergan Inc[4] \"Product Information. Xeomin (incobotulinumtoxinA).\" Merz Pharmaceuticals  (2022):[5] \"Product Information. Jeuveau (prabotulinumtoxinA).\" Evolus, Inc.  (2022):[6] \"Product Information. Daxxify (daxibotulinumtoxinA).\" Revance Therapeutics, Inc.  (2022):", "alternatives_a": "Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Atracurium, Doxacurium, Succinylcholine, Rocuronium, Vecuronium, Tubocurarine, Mivacurium, Pancuronium, Pipecuronium, Cisatracurium", "updated_at": 1767369485}, {"id": 242268, "ingredient1": "Dimenhydrinate", "ingredient2": "Paraldehyde", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273406/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Methdilazine, Azatadine, Ketotifen, Meclizine, Alimemazine, Chlorcyclizine, Fexofenadine, Thiethylperazine, Dexchlorpheniramine, Loratadine, Phenindamine, More", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 242269, "ingredient1": "Dimenhydrinate", "ingredient2": "Paramethadione", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273407/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Methdilazine, Azatadine, Ketotifen, Meclizine, Alimemazine, Chlorcyclizine, Fexofenadine, Thiethylperazine, Dexchlorpheniramine, Loratadine, Phenindamine, More", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 242270, "ingredient1": "Dimenhydrinate", "ingredient2": "Pentobarbital", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273408/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Chlorcyclizine, Fexofenadine, Loratadine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 242271, "ingredient1": "Dimenhydrinate", "ingredient2": "Phenacemide", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273409/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Methdilazine, Azatadine, Ketotifen, Meclizine, Alimemazine, Chlorcyclizine, Fexofenadine, Thiethylperazine, Dexchlorpheniramine, Loratadine, Phenindamine, More", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 242272, "ingredient1": "Dimenhydrinate", "ingredient2": "Phensuximide", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273410/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Methdilazine, Azatadine, Ketotifen, Meclizine, Alimemazine, Chlorcyclizine, Fexofenadine, Thiethylperazine, Dexchlorpheniramine, Loratadine, Phenindamine, More", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 242273, "ingredient1": "Dimenhydrinate", "ingredient2": "Pramipexole", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273411/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Phenindamine, Meclizine, Terfenadine, Astemizole", "alternatives_b": "Cabergoline", "updated_at": 1767369485}, {"id": 242274, "ingredient1": "Dimenhydrinate", "ingredient2": "Quazepam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273412/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Meclizine, Azelastine, Thiethylperazine, Dexchlorpheniramine, Phenindamine, Astemizole, Methdilazine, Terfenadine, Pheniramine", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 242275, "ingredient1": "Dimenhydrinate", "ingredient2": "Botulinum toxin type B", "severity": "Moderate", "effect": "Use of anticholinergic drugs after administration of botulinum toxin may potentiate systemic anticholinergic effects such as dry mouth, blurred vision, and urinary disorders.  Botulinum toxin inhibits the release of acetylcholine from peripheral cholinergic nerve endings, thus additive or synergistic anticholinergic effects may occur when these agents are used together.", "source": "DDInter", "management_text": "Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) are used after administration of botulinum toxin.", "mechanism_text": "Synergism", "recommendation": "Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273413/", "reference_text": "[1] \"Product Information. Myobloc (rimabotulinumtoxinB).\" Elan Pharmaceuticals[2] \"Product Information. Dysport (abobotulinumtoxinA).\" Tercica Inc[3] \"Product Information. Botox (onabotulinumtoxinA).\" Allergan Inc[4] \"Product Information. Xeomin (incobotulinumtoxinA).\" Merz Pharmaceuticals  (2022):[5] \"Product Information. Jeuveau (prabotulinumtoxinA).\" Evolus, Inc.  (2022):[6] \"Product Information. Daxxify (daxibotulinumtoxinA).\" Revance Therapeutics, Inc.  (2022):", "alternatives_a": "Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242276, "ingredient1": "Dimenhydrinate", "ingredient2": "Ropinirole", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273414/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Dexchlorpheniramine, Phenindamine, Astemizole, Meclizine, Terfenadine, Pheniramine", "alternatives_b": "Cabergoline", "updated_at": 1767369485}, {"id": 242277, "ingredient1": "Dimenhydrinate", "ingredient2": "Selegiline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273415/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Clemastine, Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Cabergoline", "updated_at": 1767369485}, {"id": 242278, "ingredient1": "Dimenhydrinate", "ingredient2": "Sibutramine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273416/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Azatadine, Ketotifen, Meclizine, Chlorcyclizine, Thiethylperazine, Dexchlorpheniramine, Phenindamine, Astemizole, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "Dexfenfluramine, Naltrexone, Ephedrine, Bupropion, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol", "updated_at": 1767369485}, {"id": 242279, "ingredient1": "Dimenhydrinate", "ingredient2": "Thiopental", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273418/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Azatadine, Ketotifen, Azelastine, Fexofenadine, Triprolidine, Loratadine, Dexchlorpheniramine, Astemizole, Desloratadine, Meclizine, Terfenadine, Pheniramine", "alternatives_b": "Halothane, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate, Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 242280, "ingredient1": "Dimenhydrinate", "ingredient2": "Tiagabine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273419/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Methdilazine, Azatadine, Ketotifen, Meclizine, Thiethylperazine, Dexchlorpheniramine, Phenindamine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 242281, "ingredient1": "Dimenhydrinate", "ingredient2": "Triazolam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273420/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 242282, "ingredient1": "Dimenhydrinate", "ingredient2": "Venlafaxine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273421/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Meclizine, Chlorcyclizine, Thiethylperazine, Dexchlorpheniramine, Phenindamine, Methdilazine, Pheniramine", "alternatives_b": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "updated_at": 1767369485}, {"id": 242283, "ingredient1": "Dimethyl fumarate", "ingredient2": "Bacillus calmette-guerin substrain tice live antigen", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273423/", "reference_text": "[1] \"Product Information. Meruvax II (rubella virus vaccine).\" Merck & Co., Inc  (2022):[2] \"Product Information. Attenuvax (measles virus vaccine).\" Merck & Co., Inc  (2022):[3] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD \"Harrison's Principles of Internal Medicine.\" New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] \"Product Information. DENGVAXIA (dengue vaccine).\" sanofi pasteur  (2022):", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242284, "ingredient1": "Echinacea", "ingredient2": "Dimethyl fumarate", "severity": "Minor", "effect": "Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat's claw, and zinc may antagonize the pharmacologic effects of immunosuppressants.  However, clinical cases of drug interactions have not been reported.", "source": "DDInter", "management_text": "The effect of this interaction is not well established, and the possibility of an interaction should be considered if an adverse event occurs when combining Cat's Claw with an immune-related drug.", "mechanism_text": "Others", "recommendation": "The effect of this interaction is not well established, and the possibility of an interaction should be considered if an adverse event occurs when combining Cat's Claw with an immune-related drug.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273426/", "reference_text": "[1] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[2] Pepping J \"Echinacea.\" Am J Health Syst Pharm 56 (1999):  121-2[3] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001):  2163-75[4] Therapeutic Research Faculty \"Natural Medicines Comprehensive Database.  http://www.naturaldatabase.com\"   (2008):", "alternatives_a": "Methotrexate, Alemtuzumab, Pegcetacoplan, Cladribine, Belumosudil, Ozanimod, Teprotumumab, Thalidomide, Emapalumab, Ofatumumab, Baricitinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242285, "ingredient1": "Dimethyl fumarate", "ingredient2": "Melphalan flufenamide", "severity": "Moderate", "effect": "The use of monomethyl fumarate (MMF) or its prodrugs, dimethyl fumarate and diroximel fumarate, with other immunosuppressive or myelosuppressive agents may increase the risk of infections.  Treatment with MMF or its prodrugs can cause lymphopenia as well as serious and potentially life-threatening opportunistic infections (e.g., progressive multifocal leukoencephalopathy (PML), herpes zoster, herpes simplex, West Nile virus, cytomegalovirus, Candida, Aspergillus, Nocardia, Listeria monocytogenes, Mycobacterium tuberculosis), and the risk may be theoretically potentiated in the presence of other agents that also suppress the immune system or bone marrow function.", "source": "DDInter", "management_text": "The safety and efficacy of monomethyl fumarate, dimethyl fumarate, or diroximel fumarate in combination with other immunosuppressive or myelosuppressive agents have not been evaluated.  Until further information is available, concomitant use should be avoided if possible.", "mechanism_text": "Synergism", "recommendation": "The safety and efficacy of monomethyl fumarate, dimethyl fumarate, or diroximel fumarate in combination with other immunosuppressive or myelosuppressive agents have not been evaluated.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273442/", "reference_text": "[1] \"Product Information. Vumerity (diroximel fumarate).\" Alkermes, Inc  (2019):", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242286, "ingredient1": "Dimethyl fumarate", "ingredient2": "Promazine", "severity": "Moderate", "effect": "The use of monomethyl fumarate (MMF) or its prodrugs, dimethyl fumarate and diroximel fumarate, with other immunosuppressive or myelosuppressive agents may increase the risk of infections.  Treatment with MMF or its prodrugs can cause lymphopenia as well as serious and potentially life-threatening opportunistic infections (e.g., progressive multifocal leukoencephalopathy (PML), herpes zoster, herpes simplex, West Nile virus, cytomegalovirus, Candida, Aspergillus, Nocardia, Listeria monocytogenes, Mycobacterium tuberculosis), and the risk may be theoretically potentiated in the presence of other agents that also suppress the immune system or bone marrow function.", "source": "DDInter", "management_text": "The safety and efficacy of monomethyl fumarate, dimethyl fumarate, or diroximel fumarate in combination with other immunosuppressive or myelosuppressive agents have not been evaluated.  Until further information is available, concomitant use should be avoided if possible.", "mechanism_text": "Synergism", "recommendation": "The safety and efficacy of monomethyl fumarate, dimethyl fumarate, or diroximel fumarate in combination with other immunosuppressive or myelosuppressive agents have not been evaluated.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273455/", "reference_text": "[1] \"Product Information. Vumerity (diroximel fumarate).\" Alkermes, Inc  (2019):", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "Fluphenazine, Haloperidol, Thiothixene, Risperidone, Amisulpride, Quetiapine, Prochlorperazine, Thioridazine, Lumateperone, Pimozide, Trifluoperazine, More", "updated_at": 1767369485}, {"id": 242287, "ingredient1": "Dimethyl fumarate", "ingredient2": "Zinc acetate", "severity": "Minor", "effect": "Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat's claw, and zinc may antagonize the pharmacologic effects of immunosuppressants.  However, clinical cases of drug interactions have not been reported.", "source": "DDInter", "management_text": "The effect of this interaction is not well established, and the possibility of an interaction should be considered if an adverse event occurs when combining Cat's Claw with an immune-related drug.", "mechanism_text": "Others", "recommendation": "The effect of this interaction is not well established, and the possibility of an interaction should be considered if an adverse event occurs when combining Cat's Claw with an immune-related drug.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273482/", "reference_text": "[1] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[2] Pepping J \"Echinacea.\" Am J Health Syst Pharm 56 (1999):  121-2[3] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001):  2163-75[4] Therapeutic Research Faculty \"Natural Medicines Comprehensive Database.  http://www.naturaldatabase.com\"   (2008):", "alternatives_a": "Ravulizumab, Methotrexate, Siponimod, Apremilast, Cladribine, Belumosudil, Ozanimod, Thalidomide, Emapalumab, Fingolimod, Alemtuzumab, More", "alternatives_b": "Lidocaine, Diltiazem, Tetracaine, Fluocinolone acetonide, Fluocinonide, Isosorbide dinitrate, Procaine, Fluorometholone, Nitroglycerin, Teduglutide, Lonafarnib, More", "updated_at": 1767369485}, {"id": 242288, "ingredient1": "Dimethyl fumarate", "ingredient2": "Zinc chloride", "severity": "Minor", "effect": "Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat's claw, and zinc may antagonize the pharmacologic effects of immunosuppressants.  However, clinical cases of drug interactions have not been reported.", "source": "DDInter", "management_text": "The effect of this interaction is not well established, and the possibility of an interaction should be considered if an adverse event occurs when combining Cat's Claw with an immune-related drug.", "mechanism_text": "Others", "recommendation": "The effect of this interaction is not well established, and the possibility of an interaction should be considered if an adverse event occurs when combining Cat's Claw with an immune-related drug.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273483/", "reference_text": "[1] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[2] Pepping J \"Echinacea.\" Am J Health Syst Pharm 56 (1999):  121-2[3] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001):  2163-75[4] Therapeutic Research Faculty \"Natural Medicines Comprehensive Database.  http://www.naturaldatabase.com\"   (2008):", "alternatives_a": "Ravulizumab, Methotrexate, Siponimod, Apremilast, Cladribine, Belumosudil, Ozanimod, Thalidomide, Emapalumab, Fingolimod, Alemtuzumab, More", "alternatives_b": "Lidocaine, Diltiazem, Tetracaine, Fluocinolone acetonide, Fluocinonide, Isosorbide dinitrate, Procaine, Fluorometholone, Nitroglycerin, Calcium chloride, Potassium chloride, More", "updated_at": 1767369485}, {"id": 242289, "ingredient1": "Dimethyl fumarate", "ingredient2": "Varicella Zoster Vaccine (Recombinant)", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual's risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, the U.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273484/", "reference_text": "[1] \"Product Information. Fluzone (influenza virus vaccine, inactivated).\" Connaught Laboratories Inc[2] \"Product Information. Omnihib (haemophilus b conjugate vaccine (obsolete)).\" SmithKline Beecham[3] \"Product Information. Havrix (hepatitis A adult vaccine).\" SmithKline Beecham[4] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[5] \"Product Information. Imovax Rabies (rabies vaccine, human diploid cell).\" sanofi pasteur  (2022):[6] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc.  (2003):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline  (2022):[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations.  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf\"   (2019):[11] CDC Centers for Disease Control and Prevention \"Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html\"   (2022):", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242290, "ingredient1": "Dinutuximab", "ingredient2": "Bacillus calmette-guerin substrain tice live antigen", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273486/", "reference_text": "[1] \"Product Information. Meruvax II (rubella virus vaccine).\" Merck & Co., Inc  (2022):[2] \"Product Information. Attenuvax (measles virus vaccine).\" Merck & Co., Inc  (2022):[3] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD \"Harrison's Principles of Internal Medicine.\" New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] \"Product Information. DENGVAXIA (dengue vaccine).\" sanofi pasteur  (2022):", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242291, "ingredient1": "Dinutuximab", "ingredient2": "Varicella Zoster Vaccine (Recombinant)", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual's risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, the U.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273539/", "reference_text": "[1] \"Product Information. Fluzone (influenza virus vaccine, inactivated).\" Connaught Laboratories Inc[2] \"Product Information. Omnihib (haemophilus b conjugate vaccine (obsolete)).\" SmithKline Beecham[3] \"Product Information. Havrix (hepatitis A adult vaccine).\" SmithKline Beecham[4] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[5] \"Product Information. Imovax Rabies (rabies vaccine, human diploid cell).\" sanofi pasteur  (2022):[6] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc.  (2003):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline  (2022):[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations.  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf\"   (2019):[11] CDC Centers for Disease Control and Prevention \"Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html\"   (2022):", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242292, "ingredient1": "Butalbital", "ingredient2": "Valsartan", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273541/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Suvorexant, Thiopental, Eszopiclone, Ramelteon, Scopolamine, Lemborexant, Methohexital, Tasimelteon, Melatonin, Valerian", "alternatives_b": "Irbesartan, Hydrochlorothiazide, Olmesartan, Candesartan, Eprosartan, Sacubitril, Aliskiren, Ramipril, Simvastatin, Lovastatin, Rosuvastatin, More", "updated_at": 1767369485}, {"id": 242293, "ingredient1": "Dezocine", "ingredient2": "Valsartan", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273543/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Naloxone, Naltrexone, Tapentadol", "alternatives_b": "Amlodipine, Irbesartan, Hydrochlorothiazide, Losartan, Olmesartan, Candesartan, Sacubitril, Aliskiren, Eprosartan, Amlodipine, Ramipril, More", "updated_at": 1767369485}, {"id": 242294, "ingredient1": "Ethchlorvynol", "ingredient2": "Valsartan", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273545/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Suvorexant, Thiopental, Eszopiclone, Ramelteon, Scopolamine, Lemborexant, Methohexital, Tasimelteon, Melatonin, Valerian", "alternatives_b": "Amlodipine, Irbesartan, Hydrochlorothiazide, Losartan, Olmesartan, Candesartan, Sacubitril, Aliskiren, Eprosartan, Amlodipine, Ramipril, More", "updated_at": 1767369485}, {"id": 242295, "ingredient1": "Valsartan", "ingredient2": "Levacetylmethadol", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273549/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Nalmefene, Disulfiram, Acamprosate, Naltrexone", "alternatives_b": "Amlodipine, Irbesartan, Losartan, Olmesartan, Candesartan, Sacubitril, Aliskiren, Eprosartan, Amlodipine, Ramipril, Atorvastatin, More", "updated_at": 1767369485}, {"id": 242296, "ingredient1": "Valsartan", "ingredient2": "Levorphanol", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273550/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Amlodipine, Irbesartan, Hydrochlorothiazide, Losartan, Olmesartan, Candesartan, Sacubitril, Aliskiren, Eprosartan, Amlodipine, Ramipril, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242297, "ingredient1": "Valsartan", "ingredient2": "Methylphenobarbital", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273553/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Brivaracetam, Ezogabine, Cenobamate, Ethosuximide, Lacosamide, Tiagabine, Ethotoin, Rufinamide, Paramethadione, Perampanel, Ganaxolone, More", "alternatives_b": "Irbesartan, Hydrochlorothiazide, Olmesartan, Candesartan, Eprosartan, Sacubitril, Aliskiren, Ramipril, Simvastatin, Lovastatin, Rosuvastatin, More", "updated_at": 1767369485}, {"id": 242298, "ingredient1": "Valsartan", "ingredient2": "Metaxalone", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273554/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Amlodipine, Irbesartan, Hydrochlorothiazide, Losartan, Olmesartan, Candesartan, Sacubitril, Aliskiren, Eprosartan, Amlodipine, Ramipril, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242299, "ingredient1": "Valsartan", "ingredient2": "Oxymorphone", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273555/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Naloxone, Naltrexone, Tapentadol", "alternatives_b": "Amlodipine, Irbesartan, Hydrochlorothiazide, Losartan, Olmesartan, Candesartan, Sacubitril, Aliskiren, Eprosartan, Amlodipine, Ramipril, More", "updated_at": 1767369485}, {"id": 242300, "ingredient1": "Valsartan", "ingredient2": "Pentobarbital", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273557/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Suvorexant, Thiopental, Eszopiclone, Ramelteon, Scopolamine, Lemborexant, Methohexital, Tasimelteon, Melatonin, Valerian", "alternatives_b": "Irbesartan, Hydrochlorothiazide, Olmesartan, Candesartan, Eprosartan, Sacubitril, Aliskiren, Ramipril, Simvastatin, Lovastatin, Rosuvastatin, More", "updated_at": 1767369485}, {"id": 242301, "ingredient1": "Valsartan", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may increase the plasma concentrations of drugs that are P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), organic anion transporting polypeptide 1B1 (OATP1B1), OATP1B3, organic anion transporter 1 (OAT1), multidrug and toxin extrusion 1 (MATE1), and/or MATE2-K substrates.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of P-gp, BCRP, OATP1B1, OATP1B3, OAT1, MATE1, and/or MATE2-K, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with substrates of these transporters for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism, Excretion", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of P-gp, BCRP, OATP1B1, OATP1B3, OAT1, MATE1, and/or MATE2-K, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273558/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Asciminib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, Vemurafenib, Lapatinib, More", "alternatives_b": "Eprosartan, Nebivolol, Hydrochlorothiazide, Telmisartan, Ramipril, Lisinopril, Perindopril, Pravastatin, Acetylsalicylic acid, Niacin, Bempedoic acid, More", "updated_at": 1767369485}, {"id": 242302, "ingredient1": "Olsalazine", "ingredient2": "Moxetumomab Pasudotox", "severity": "Moderate", "effect": "Coadministration of 5-aminosalicylate with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the kidney.", "source": "DDInter", "management_text": "Caution is advised when 5-aminosalicylate preparations are prescribed to patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents).  Renal function should be evaluated prior to and during 5-aminosalicylate therapy.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when 5-aminosalicylate preparations are prescribed to patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273570/", "reference_text": "[1] Novis BH, Korzets Z, Chen P, Bernheim J \"Nephrotic syndrome after treatment with 5-aminosalicylic acid.\" Br Med J (Clin Res Ed) 296 (1988):  1442[2] \"Product Information. Canasa (mesalamine).\" Axcan Pharma US Inc[3] \"Product Information. Lialda (mesalamine).\" Shire US Inc  (2022):[4] Schreiber S. Hamling J, Zehnter E, et al. \"Renal tubular dysfunction in patients with inflammatory bowel disease treated with aminosalicylate.\" Gut 40 (1997):  761-6", "alternatives_a": "Budesonide, Hydrocortisone, Cromoglicic acid, Prednisone, Prednisolone, Betamethasone, Beclomethasone dipropionate", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242303, "ingredient1": "Dipivefrin (ophthalmic)", "ingredient2": "Ketamine", "severity": "Moderate", "effect": "Ketamine can cause hemodynamic instability such as arrhythmias and transient increases or decreases in blood pressure, heart rate, and cardiac index.  Coadministration of ketamine with direct or indirect acting sympathomimetics or vasopressin may enhance the sympathomimetic effects of ketamine leading to additive increases in blood pressure and heart rate.", "source": "DDInter", "management_text": "Close monitoring of vital signs, including blood pressure and heart rate is recommended whenever ketamine is used concomitantly with direct or indirect acting sympathomimetics or vasopressin.  Dosage adjustments should be considered according to the patient's clinical situation.  Some authorities suggest avoiding the use of ketamine in patients receiving drugs with a hypertensive effect such as ergometrine.", "mechanism_text": "Synergism", "recommendation": "Close monitoring of vital signs, including blood pressure and heart rate is recommended whenever ketamine is used concomitantly with direct or indirect acting sympathomimetics or vasopressin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273578/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Ketalar (ketamine).\" JHP Pharmaceuticals  (2009):", "alternatives_a": "Halothane, Thiopental, Alfentanil, Remifentanil, Isoflurane, Sodium oxybate, Methohexital, Fentanyl, Desflurane, Nitrous oxide, Sufentanil, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242304, "ingredient1": "Heparin (flush)", "ingredient2": "Dipyridamole", "severity": "Moderate", "effect": "Concomitant use of heparin flush and drugs that interfere with platelet function or coagulation or drugs that commonly cause thrombocytopenia may potentiate the risk of bleeding complications.  Although uncommon, inadvertent anticoagulation resulting in hemorrhagic events may occur with heparin flushes, particularly during repeated or excessive use or administration of higher concentration flush solutions.", "source": "DDInter", "management_text": "Caution and monitoring (e.g., platelet counts, hematocrits, tests for occult blood in stools) are advised when heparin flushes are given to patients receiving systemic anticoagulants, platelet inhibitors, antithrombotic agents, thrombolytics, or drugs with known risks of thrombocytopenia or bleeding.  An unexplained fall in hematocrit, fall in blood pressure, or any other unexplained symptom should lead to serious consideration of a hemorrhagic event.", "mechanism_text": "Synergism", "recommendation": "Caution and monitoring (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273582/", "reference_text": "[1] Passannante A, Macik BG \"The heparin flush syndrome: a cause of iatrogenic hemorrhage.\" Am J Med Sci 296 (1988):  71-3[2] \"Product Information. Heparin Sodium in Sodium Chloride (heparin flush).\" Baxter Healthcare Corporation  (2022):[3] \"Product Information. Canusal (heparin flush).\" Wockhardt UK Ltd  (2018):[4] \"Product Information. Heparinised Saline (Pfizer) (heparinised saline).\" Pfizer Australia Pty Ltd  (2022):", "alternatives_a": "Acenocoumarol, Selexipag", "alternatives_b": "Dipyridamole, Antithrombin III human, Protein C, Acenocoumarol, Selexipag, Ticlopidine, Ascorbic acid, Sirolimus, Vitamin A, Potassium Iodide, Acetylcysteine, Nandrolone", "updated_at": 1767369485}, {"id": 242305, "ingredient1": "Diroximel fumarate", "ingredient2": "Bacillus calmette-guerin substrain tice live antigen", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273591/", "reference_text": "[1] \"Product Information. Meruvax II (rubella virus vaccine).\" Merck & Co., Inc  (2022):[2] \"Product Information. Attenuvax (measles virus vaccine).\" Merck & Co., Inc  (2022):[3] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD \"Harrison's Principles of Internal Medicine.\" New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] \"Product Information. DENGVAXIA (dengue vaccine).\" sanofi pasteur  (2022):", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242306, "ingredient1": "Echinacea", "ingredient2": "Diroximel fumarate", "severity": "Minor", "effect": "Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat's claw, and zinc may antagonize the pharmacologic effects of immunosuppressants.  However, clinical cases of drug interactions have not been reported.", "source": "DDInter", "management_text": "The effect of this interaction is not well established, and the possibility of an interaction should be considered if an adverse event occurs when combining Cat's Claw with an immune-related drug.", "mechanism_text": "Others", "recommendation": "The effect of this interaction is not well established, and the possibility of an interaction should be considered if an adverse event occurs when combining Cat's Claw with an immune-related drug.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273594/", "reference_text": "[1] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[2] Pepping J \"Echinacea.\" Am J Health Syst Pharm 56 (1999):  121-2[3] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001):  2163-75[4] Therapeutic Research Faculty \"Natural Medicines Comprehensive Database.  http://www.naturaldatabase.com\"   (2008):", "alternatives_a": "Methotrexate, Alemtuzumab, Pegcetacoplan, Cladribine, Belumosudil, Ozanimod, Teprotumumab, Thalidomide, Emapalumab, Ofatumumab, Baricitinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242307, "ingredient1": "Diroximel fumarate", "ingredient2": "Melphalan flufenamide", "severity": "Moderate", "effect": "The use of monomethyl fumarate (MMF) or its prodrugs, dimethyl fumarate and diroximel fumarate, with other immunosuppressive or myelosuppressive agents may increase the risk of infections.  Treatment with MMF or its prodrugs can cause lymphopenia as well as serious and potentially life-threatening opportunistic infections (e.g., progressive multifocal leukoencephalopathy (PML), herpes zoster, herpes simplex, West Nile virus, cytomegalovirus, Candida, Aspergillus, Nocardia, Listeria monocytogenes, Mycobacterium tuberculosis), and the risk may be theoretically potentiated in the presence of other agents that also suppress the immune system or bone marrow function.", "source": "DDInter", "management_text": "The safety and efficacy of monomethyl fumarate, dimethyl fumarate, or diroximel fumarate in combination with other immunosuppressive or myelosuppressive agents have not been evaluated.  Until further information is available, concomitant use should be avoided if possible.", "mechanism_text": "Synergism", "recommendation": "The safety and efficacy of monomethyl fumarate, dimethyl fumarate, or diroximel fumarate in combination with other immunosuppressive or myelosuppressive agents have not been evaluated.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273610/", "reference_text": "[1] \"Product Information. Vumerity (diroximel fumarate).\" Alkermes, Inc  (2019):", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242308, "ingredient1": "Diroximel fumarate", "ingredient2": "Promazine", "severity": "Moderate", "effect": "The use of monomethyl fumarate (MMF) or its prodrugs, dimethyl fumarate and diroximel fumarate, with other immunosuppressive or myelosuppressive agents may increase the risk of infections.  Treatment with MMF or its prodrugs can cause lymphopenia as well as serious and potentially life-threatening opportunistic infections (e.g., progressive multifocal leukoencephalopathy (PML), herpes zoster, herpes simplex, West Nile virus, cytomegalovirus, Candida, Aspergillus, Nocardia, Listeria monocytogenes, Mycobacterium tuberculosis), and the risk may be theoretically potentiated in the presence of other agents that also suppress the immune system or bone marrow function.", "source": "DDInter", "management_text": "The safety and efficacy of monomethyl fumarate, dimethyl fumarate, or diroximel fumarate in combination with other immunosuppressive or myelosuppressive agents have not been evaluated.  Until further information is available, concomitant use should be avoided if possible.", "mechanism_text": "Synergism", "recommendation": "The safety and efficacy of monomethyl fumarate, dimethyl fumarate, or diroximel fumarate in combination with other immunosuppressive or myelosuppressive agents have not been evaluated.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273623/", "reference_text": "[1] \"Product Information. Vumerity (diroximel fumarate).\" Alkermes, Inc  (2019):", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "Fluphenazine, Haloperidol, Thiothixene, Risperidone, Amisulpride, Quetiapine, Prochlorperazine, Thioridazine, Lumateperone, Pimozide, Trifluoperazine, More", "updated_at": 1767369485}, {"id": 242309, "ingredient1": "Diroximel fumarate", "ingredient2": "Zinc acetate", "severity": "Minor", "effect": "Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat's claw, and zinc may antagonize the pharmacologic effects of immunosuppressants.  However, clinical cases of drug interactions have not been reported.", "source": "DDInter", "management_text": "The effect of this interaction is not well established, and the possibility of an interaction should be considered if an adverse event occurs when combining Cat's Claw with an immune-related drug.", "mechanism_text": "Others", "recommendation": "The effect of this interaction is not well established, and the possibility of an interaction should be considered if an adverse event occurs when combining Cat's Claw with an immune-related drug.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273650/", "reference_text": "[1] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[2] Pepping J \"Echinacea.\" Am J Health Syst Pharm 56 (1999):  121-2[3] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001):  2163-75[4] Therapeutic Research Faculty \"Natural Medicines Comprehensive Database.  http://www.naturaldatabase.com\"   (2008):", "alternatives_a": "Ravulizumab, Methotrexate, Siponimod, Apremilast, Cladribine, Belumosudil, Ozanimod, Thalidomide, Emapalumab, Fingolimod, Alemtuzumab, More", "alternatives_b": "Lidocaine, Diltiazem, Tetracaine, Fluocinolone acetonide, Fluocinonide, Isosorbide dinitrate, Procaine, Fluorometholone, Nitroglycerin, Teduglutide, Lonafarnib, More", "updated_at": 1767369485}, {"id": 242310, "ingredient1": "Diroximel fumarate", "ingredient2": "Zinc chloride", "severity": "Minor", "effect": "Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat's claw, and zinc may antagonize the pharmacologic effects of immunosuppressants.  However, clinical cases of drug interactions have not been reported.", "source": "DDInter", "management_text": "The effect of this interaction is not well established, and the possibility of an interaction should be considered if an adverse event occurs when combining Cat's Claw with an immune-related drug.", "mechanism_text": "Others", "recommendation": "The effect of this interaction is not well established, and the possibility of an interaction should be considered if an adverse event occurs when combining Cat's Claw with an immune-related drug.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273651/", "reference_text": "[1] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[2] Pepping J \"Echinacea.\" Am J Health Syst Pharm 56 (1999):  121-2[3] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001):  2163-75[4] Therapeutic Research Faculty \"Natural Medicines Comprehensive Database.  http://www.naturaldatabase.com\"   (2008):", "alternatives_a": "Ravulizumab, Methotrexate, Siponimod, Apremilast, Cladribine, Belumosudil, Ozanimod, Thalidomide, Emapalumab, Fingolimod, Alemtuzumab, More", "alternatives_b": "Lidocaine, Diltiazem, Tetracaine, Fluocinolone acetonide, Fluocinonide, Isosorbide dinitrate, Procaine, Fluorometholone, Nitroglycerin, Calcium chloride, Potassium chloride, More", "updated_at": 1767369485}, {"id": 242311, "ingredient1": "Diroximel fumarate", "ingredient2": "Varicella Zoster Vaccine (Recombinant)", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual's risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, the U.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273652/", "reference_text": "[1] \"Product Information. Fluzone (influenza virus vaccine, inactivated).\" Connaught Laboratories Inc[2] \"Product Information. Omnihib (haemophilus b conjugate vaccine (obsolete)).\" SmithKline Beecham[3] \"Product Information. Havrix (hepatitis A adult vaccine).\" SmithKline Beecham[4] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[5] \"Product Information. Imovax Rabies (rabies vaccine, human diploid cell).\" sanofi pasteur  (2022):[6] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc.  (2003):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline  (2022):[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations.  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf\"   (2019):[11] CDC Centers for Disease Control and Prevention \"Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html\"   (2022):", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242312, "ingredient1": "Acrivastine", "ingredient2": "Methadone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273654/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Azelastine, Ketotifen, Loratadine, Desloratadine", "alternatives_b": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine, Naltrexone, Acetaminophen, Dextropropoxyphene, Ibuprofen, Celecoxib, More", "updated_at": 1767369485}, {"id": 242313, "ingredient1": "Methadone", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273667/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Amantadine, Cabergoline", "alternatives_b": "Acamprosate, Naltrexone, Varenicline, Nalmefene, Nicotine, Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 242314, "ingredient1": "Methadone", "ingredient2": "Melatonin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273670/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam", "alternatives_b": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine, Naltrexone, Acetaminophen, Dextropropoxyphene, Ibuprofen, Celecoxib, More", "updated_at": 1767369485}, {"id": 242315, "ingredient1": "Palbociclib", "ingredient2": "Methadone", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of methadone, which is metabolized primarily by CYP450 3A4, 2B6, 2C19, and to a lesser extent by CYP450 2C9 and 2D6.", "source": "DDInter", "management_text": "Caution is advised if methadone is prescribed in combination with CYP450 3A4 inhibitors.  Pharmacologic response to methadone should be closely monitored and the dosage adjusted accordingly, particularly following initiation or discontinuation of the CYP450 3A4 inhibitor in patients who are stabilized on their methadone regimen.  Patients should be advised to report excessive drowsiness, nausea, or asthenia to their physician, and to seek immediate medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.  ECG monitoring should be considered for patients on methadone with heart or liver disease; conduction abnormalities; electrolyte disturbances (i.e., hypokalemia, hypomagnesemia); concomitant use of drugs that may cause QT prolongation or electrolyte loss; concomitant use of CYP450 3A4 inhibitors; or use of methadone at dosages greater than 200 mg daily.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if methadone is prescribed in combination with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273677/", "reference_text": "[1] Bell J, Seres V, Bowron P, Lewis J, Batey R \"The use of serum methadone levels in patients receiving methadone maintenance.\" Clin Pharmacol Ther 43 (1988):  623-9[2] Iribarne C, Berthou F, Baird S, Dreano Y, Picart D, Bail JP, Beaune P, Menez JF \"Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes.\" Chem Res Toxicol 9 (1996):  365-73[3] Oda Y, Kharasch ED \"Metabolism of methadone and levo-alpha-acetylmethadol (LAAM) by human intestinal cytochrome P450 3A4 (CYP3A4): potential contribution of intestinal metabolism to presystemic clearance and bioactivation.\" J Pharmacol Exp Ther 298 (2001):  1021-32[4] Krantz MJ, Lewkowiez L, Hays H, et al. \"Torsade de pointes associated with very-high-dose methadone.\" Ann Intern Med 137 (2002):  501-4[5] Foster DJ, Somogyi AA, Bochner F \"Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4.\" Br J Clin Pharmacol 47 (1999):  403-12[6] Ehret GB, Desmeules JA, Broers B \"Methadone-associated long QT syndrome: improving pharmacotherapy for dependence on illegal opioids and lessons learned for pharmacology.\" Expert Opin Drug Saf 6 (2007):  289-303[7] Moody DE, Alburges ME, Parker RJ, Collings JM, Strong JM \"The involvement of cytochrome P450 3A4 in the N-demethylation of L-alpha-acetylmethadol (LAAM), norLAAM, and methadone.\" Drug Metab Dispos 25 (1997):  1347-53[8] \"Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov).\" Gilead Sciences  (2012):", "alternatives_a": "Diamorphine, Acamprosate, Lofexidine, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine, Codeine, Naltrexone, Oxymorphone, More", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, Zanubrutinib, More", "updated_at": 1767369485}, {"id": 242316, "ingredient1": "Pralsetinib", "ingredient2": "Methadone", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273680/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Diamorphine, Acamprosate, Lofexidine, Varenicline, Nalmefene, Nicotine, Oxymorphone, Tapentadol, Butorphanol, Hydromorphone, Dezocine, More", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, Zanubrutinib, More", "updated_at": 1767369485}, {"id": 242317, "ingredient1": "Tolevamer", "ingredient2": "Methadone", "severity": "Moderate", "effect": "Coadministration with medications that can cause constipation such as opioids may increase the risk of intestinal injuries associated with the use of sodium polystyrene sulfonate.", "source": "DDInter", "management_text": "Because opioids commonly cause constipation, caution is advised when used during treatment with sodium polystyrene sulfonate.  The prescribing information recommends avoiding the use of sodium polystyrene sulfonate in patients who are at risk for developing constipation or impaction, including those with a history of impaction, chronic constipation, inflammatory bowel disease, ischemic colitis, vascular intestinal atherosclerosis, previous bowel resection, or bowel obstruction, as well as those who have not had a bowel movement post-surgery.  If clinically significant constipation develops, treatment with sodium polystyrene sulfonate should be discontinued until normal bowel motion is resumed.  Concomitant administration of sorbitol is not recommended.", "mechanism_text": "Synergism", "recommendation": "Because opioids commonly cause constipation, caution is advised when used during treatment with sodium polystyrene sulfonate.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273681/", "reference_text": "[1] Foresti V \"Intestinal obstruction due to kayexalate in a patient concurrently treated with aluminum hydroxide and morphine sulfate.\" Clin Nephrol 41 (1994):  252[2] \"Product Information. Kayexalate (sodium polystyrene sulfonate).\" Sanofi Winthrop Pharmaceuticals  (2001):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):", "alternatives_a": "Diamorphine, Acamprosate, Lofexidine, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine, Naltrexone, Acetaminophen, Ibuprofen, More", "alternatives_b": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Cobicistat, Deferoxamine, Levoleucovorin, Arginine, More", "updated_at": 1767369485}, {"id": 242318, "ingredient1": "Isocarboxazid", "ingredient2": "Disopyramide", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273693/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Amiodarone, Dronedarone, Tocainide, Lidocaine, Propafenone, Flecainide, Mexiletine, Dofetilide, Bretylium, Moricizine, Ibutilide", "alternatives_b": "Duloxetine, Vilazodone, Desvenlafaxine, St. John's Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion, More", "updated_at": 1767369485}, {"id": 242319, "ingredient1": "Disopyramide", "ingredient2": "Botulinum toxin type A", "severity": "Moderate", "effect": "Use of anticholinergic drugs after administration of botulinum toxin may potentiate systemic anticholinergic effects such as dry mouth, blurred vision, and urinary disorders.  Botulinum toxin inhibits the release of acetylcholine from peripheral cholinergic nerve endings, thus additive or synergistic anticholinergic effects may occur when these agents are used together.", "source": "DDInter", "management_text": "Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) are used after administration of botulinum toxin.", "mechanism_text": "Synergism", "recommendation": "Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273702/", "reference_text": "[1] \"Product Information. Myobloc (rimabotulinumtoxinB).\" Elan Pharmaceuticals[2] \"Product Information. Dysport (abobotulinumtoxinA).\" Tercica Inc[3] \"Product Information. Botox (onabotulinumtoxinA).\" Allergan Inc[4] \"Product Information. Xeomin (incobotulinumtoxinA).\" Merz Pharmaceuticals  (2022):[5] \"Product Information. Jeuveau (prabotulinumtoxinA).\" Evolus, Inc.  (2022):[6] \"Product Information. Daxxify (daxibotulinumtoxinA).\" Revance Therapeutics, Inc.  (2022):", "alternatives_a": "Quinidine, Amiodarone, Dronedarone, Lidocaine, Propafenone, Procainamide, Tocainide, Flecainide, Mexiletine, Dofetilide, Bretylium, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242320, "ingredient1": "Disopyramide", "ingredient2": "Phenelzine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273703/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Amiodarone, Dronedarone, Tocainide, Lidocaine, Propafenone, Flecainide, Mexiletine, Dofetilide, Bretylium, Moricizine, Ibutilide", "alternatives_b": "Duloxetine, Vilazodone, Desvenlafaxine, St. John's Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion, More", "updated_at": 1767369485}, {"id": 242321, "ingredient1": "Disopyramide", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273706/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Moricizine, Tocainide, Bretylium, Mexiletine", "alternatives_b": "Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More", "updated_at": 1767369485}, {"id": 242322, "ingredient1": "Disopyramide", "ingredient2": "Botulinum toxin type B", "severity": "Moderate", "effect": "Use of anticholinergic drugs after administration of botulinum toxin may potentiate systemic anticholinergic effects such as dry mouth, blurred vision, and urinary disorders.  Botulinum toxin inhibits the release of acetylcholine from peripheral cholinergic nerve endings, thus additive or synergistic anticholinergic effects may occur when these agents are used together.", "source": "DDInter", "management_text": "Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) are used after administration of botulinum toxin.", "mechanism_text": "Synergism", "recommendation": "Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273707/", "reference_text": "[1] \"Product Information. Myobloc (rimabotulinumtoxinB).\" Elan Pharmaceuticals[2] \"Product Information. Dysport (abobotulinumtoxinA).\" Tercica Inc[3] \"Product Information. Botox (onabotulinumtoxinA).\" Allergan Inc[4] \"Product Information. Xeomin (incobotulinumtoxinA).\" Merz Pharmaceuticals  (2022):[5] \"Product Information. Jeuveau (prabotulinumtoxinA).\" Evolus, Inc.  (2022):[6] \"Product Information. Daxxify (daxibotulinumtoxinA).\" Revance Therapeutics, Inc.  (2022):", "alternatives_a": "Quinidine, Amiodarone, Dronedarone, Lidocaine, Propafenone, Procainamide, Tocainide, Flecainide, Mexiletine, Dofetilide, Bretylium, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242323, "ingredient1": "Docetaxel", "ingredient2": "Bacillus calmette-guerin substrain tice live antigen", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273827/", "reference_text": "[1] \"Product Information. Meruvax II (rubella virus vaccine).\" Merck & Co., Inc  (2022):[2] \"Product Information. Attenuvax (measles virus vaccine).\" Merck & Co., Inc  (2022):[3] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD \"Harrison's Principles of Internal Medicine.\" New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] \"Product Information. DENGVAXIA (dengue vaccine).\" sanofi pasteur  (2022):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242324, "ingredient1": "Ibritumomab tiuxetan", "ingredient2": "Docetaxel", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.  Dosing adjustments may be necessary.  The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273837/", "reference_text": "[1] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb  (2001):[2] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb  (2001):[3] \"Product Information. Fluorouracil (fluorouracil).\" Roche Laboratories  (2022):[4] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn  (2001):[5] \"Product Information. Ellence (epirubicin).\" Pharmacia and Upjohn  (2001):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] Agencia Espala de Medicamentos y Productos Sanitarios Healthcare \"Centro de informaci online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):", "alternatives_a": "Trabectedin, Cabazitaxel, Vincristine, Paclitaxel, Teniposide, Irinotecan", "alternatives_b": "Tositumomab, Iodide I-131", "updated_at": 1767369485}, {"id": 242325, "ingredient1": "Docetaxel", "ingredient2": "Melphalan flufenamide", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.  Dosing adjustments may be necessary.  The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273849/", "reference_text": "[1] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb  (2001):[2] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb  (2001):[3] \"Product Information. Fluorouracil (fluorouracil).\" Roche Laboratories  (2022):[4] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn  (2001):[5] \"Product Information. Ellence (epirubicin).\" Pharmacia and Upjohn  (2001):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] Agencia Espala de Medicamentos y Productos Sanitarios Healthcare \"Centro de informaci online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):", "alternatives_a": "Trabectedin, Cabazitaxel, Vincristine, Paclitaxel, Teniposide, Irinotecan", "alternatives_b": "Carmustine, Mechlorethamine, Uracil mustard", "updated_at": 1767369485}, {"id": 242326, "ingredient1": "Docetaxel", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273866/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Ibrutinib, Afatinib, Tivozanib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242327, "ingredient1": "Docetaxel", "ingredient2": "Varicella Zoster Vaccine (Recombinant)", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual's risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, the U.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273895/", "reference_text": "[1] \"Product Information. Fluzone (influenza virus vaccine, inactivated).\" Connaught Laboratories Inc[2] \"Product Information. Omnihib (haemophilus b conjugate vaccine (obsolete)).\" SmithKline Beecham[3] \"Product Information. Havrix (hepatitis A adult vaccine).\" SmithKline Beecham[4] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[5] \"Product Information. Imovax Rabies (rabies vaccine, human diploid cell).\" sanofi pasteur  (2022):[6] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc.  (2003):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline  (2022):[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations.  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf\"   (2019):[11] CDC Centers for Disease Control and Prevention \"Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html\"   (2022):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242328, "ingredient1": "Dofetilide", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273910/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Moricizine, Tocainide, Bretylium, Mexiletine", "alternatives_b": "Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More", "updated_at": 1767369485}, {"id": 242329, "ingredient1": "Fedratinib", "ingredient2": "Dolutegravir", "severity": "Minor", "effect": "Theoretically, coadministration with inhibitors of UGT1A or CYP450 3A4 isoenzymes may increase the plasma concentrations of dolutegravir, which is primarily metabolized by UGT1A1 with some contribution from CYP450 3A4.", "source": "DDInter", "management_text": "Because safety data regarding increased dolutegravir exposures are limited, caution may be advisable if dolutegravir is used in combination with both a UGT1A1 inhibitor and a CYP450 3A4 inhibitor.", "mechanism_text": "Metabolism", "recommendation": "Because safety data regarding increased dolutegravir exposures are limited, caution may be advisable if dolutegravir is used in combination with both a UGT1A1 inhibitor and a CYP450 3A4 inhibitor.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273920/", "reference_text": "[1] \"Product Information. Tivicay (dolutegravir).\" ViiV Healthcare  (2013):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Oseltamivir, Acyclovir, Brincidofovir, More", "alternatives_b": "Entrectinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Avapritinib, Larotrectinib, Bosutinib, More", "updated_at": 1767369485}, {"id": 242330, "ingredient1": "Dolutegravir", "ingredient2": "Zinc acetate", "severity": "Major", "effect": "Coadministration with medications or supplements containing polyvalent cations such as zinc may decrease the plasma concentrations of integrase strand transfer inhibitors (INSTIs).  The proposed mechanism involves chelation of the INSTI by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.", "source": "DDInter", "management_text": "If concomitant use is required, monitor for virologic efficacy and administer the INSTI at least 2 hours before or 6 hours after products containing polyvalent cations such as zinc.", "mechanism_text": "Absorption", "recommendation": "If concomitant use is required, monitor for virologic efficacy and administer the INSTI at least 2 hours before or 6 hours after products containing polyvalent cations such as zinc.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273935/", "reference_text": "[1] \"Product Information. Tivicay (dolutegravir).\" ViiV Healthcare  (2013):[2] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):[3] US National Library of Medicine \"Guidelines for the use of antiretroviral agents in adults and adolescents with HIV.  https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv-guidelines/287/insti-drug-interactions\"   (2019):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, More", "alternatives_b": "Lidocaine, Tetracaine, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Isosorbide dinitrate, Zinc chloride, Procaine, Prednisolone, Betamethasone, Fluorometholone, More", "updated_at": 1767369485}, {"id": 242331, "ingredient1": "Etoposide", "ingredient2": "Bacillus calmette-guerin substrain tice live antigen", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273936/", "reference_text": "[1] \"Product Information. Meruvax II (rubella virus vaccine).\" Merck & Co., Inc  (2022):[2] \"Product Information. Attenuvax (measles virus vaccine).\" Merck & Co., Inc  (2022):[3] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD \"Harrison's Principles of Internal Medicine.\" New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] \"Product Information. DENGVAXIA (dengue vaccine).\" sanofi pasteur  (2022):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242332, "ingredient1": "Ibritumomab tiuxetan", "ingredient2": "Etoposide", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.  Dosing adjustments may be necessary.  The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273946/", "reference_text": "[1] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb  (2001):[2] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb  (2001):[3] \"Product Information. Fluorouracil (fluorouracil).\" Roche Laboratories  (2022):[4] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn  (2001):[5] \"Product Information. Ellence (epirubicin).\" Pharmacia and Upjohn  (2001):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] Agencia Espala de Medicamentos y Productos Sanitarios Healthcare \"Centro de informaci online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):", "alternatives_a": "Trabectedin, Cabazitaxel, Vincristine, Paclitaxel, Teniposide, Irinotecan", "alternatives_b": "Tositumomab, Iodide I-131", "updated_at": 1767369485}, {"id": 242333, "ingredient1": "Etoposide", "ingredient2": "Melphalan flufenamide", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.  Dosing adjustments may be necessary.  The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273957/", "reference_text": "[1] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb  (2001):[2] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb  (2001):[3] \"Product Information. Fluorouracil (fluorouracil).\" Roche Laboratories  (2022):[4] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn  (2001):[5] \"Product Information. Ellence (epirubicin).\" Pharmacia and Upjohn  (2001):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] Agencia Espala de Medicamentos y Productos Sanitarios Healthcare \"Centro de informaci online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):", "alternatives_a": "Trabectedin, Cabazitaxel, Vincristine, Paclitaxel, Teniposide, Irinotecan", "alternatives_b": "Uracil mustard", "updated_at": 1767369485}, {"id": 242334, "ingredient1": "Etoposide", "ingredient2": "Osilodrostat", "severity": "Moderate", "effect": "Coadministration with osilodrostat may increase the plasma concentrations of drugs that are metabolized by CYP450 1A2, 2C19, 2D6, and/or 3A4.  Osilodrostat has been shown to be a moderate inhibitor of CYP450 1A2, a mild to borderline moderate inhibitor of CYP450 2C19, and a weak inhibitor of CYP450 2D6 and 3A4.", "source": "DDInter", "management_text": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever osilodrostat is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273966/", "reference_text": "[1] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Inc  (2020):[2] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Australia Pty Ltd  (2022):[3] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases UK Ltd  (2021):", "alternatives_a": "Topotecan, Trabectedin, Cabazitaxel", "alternatives_b": "Ketoconazole", "updated_at": 1767369485}, {"id": 242335, "ingredient1": "Etoposide", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/273976/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Entrectinib, Acalabrutinib, Dacomitinib, Pexidartinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, Cobimetinib, Ibrutinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242336, "ingredient1": "Etoposide", "ingredient2": "Varicella Zoster Vaccine (Recombinant)", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual's risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, the U.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274004/", "reference_text": "[1] \"Product Information. Fluzone (influenza virus vaccine, inactivated).\" Connaught Laboratories Inc[2] \"Product Information. Omnihib (haemophilus b conjugate vaccine (obsolete)).\" SmithKline Beecham[3] \"Product Information. Havrix (hepatitis A adult vaccine).\" SmithKline Beecham[4] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[5] \"Product Information. Imovax Rabies (rabies vaccine, human diploid cell).\" sanofi pasteur  (2022):[6] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc.  (2003):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline  (2022):[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations.  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf\"   (2019):[11] CDC Centers for Disease Control and Prevention \"Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html\"   (2022):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242337, "ingredient1": "Dopamine", "ingredient2": "Ketamine", "severity": "Moderate", "effect": "Ketamine can cause hemodynamic instability such as arrhythmias and transient increases or decreases in blood pressure, heart rate, and cardiac index.  Coadministration of ketamine with direct or indirect acting sympathomimetics or vasopressin may enhance the sympathomimetic effects of ketamine leading to additive increases in blood pressure and heart rate.", "source": "DDInter", "management_text": "Close monitoring of vital signs, including blood pressure and heart rate is recommended whenever ketamine is used concomitantly with direct or indirect acting sympathomimetics or vasopressin.  Dosage adjustments should be considered according to the patient's clinical situation.  Some authorities suggest avoiding the use of ketamine in patients receiving drugs with a hypertensive effect such as ergometrine.", "mechanism_text": "Synergism", "recommendation": "Close monitoring of vital signs, including blood pressure and heart rate is recommended whenever ketamine is used concomitantly with direct or indirect acting sympathomimetics or vasopressin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274023/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Ketalar (ketamine).\" JHP Pharmaceuticals  (2009):", "alternatives_a": "Arbutamine, Amrinone, Milrinone, Angiotensin II", "alternatives_b": "Halothane, Thiopental, Alfentanil, Remifentanil, Isoflurane, Sodium oxybate, Methohexital, Fentanyl, Desflurane, Nitrous oxide, Sufentanil, More", "updated_at": 1767369485}, {"id": 242338, "ingredient1": "Doxapram", "ingredient2": "Ketamine", "severity": "Moderate", "effect": "Ketamine can cause hemodynamic instability such as arrhythmias and transient increases or decreases in blood pressure, heart rate, and cardiac index.  Coadministration of ketamine with direct or indirect acting sympathomimetics or vasopressin may enhance the sympathomimetic effects of ketamine leading to additive increases in blood pressure and heart rate.", "source": "DDInter", "management_text": "Close monitoring of vital signs, including blood pressure and heart rate is recommended whenever ketamine is used concomitantly with direct or indirect acting sympathomimetics or vasopressin.  Dosage adjustments should be considered according to the patient's clinical situation.  Some authorities suggest avoiding the use of ketamine in patients receiving drugs with a hypertensive effect such as ergometrine.", "mechanism_text": "Synergism", "recommendation": "Close monitoring of vital signs, including blood pressure and heart rate is recommended whenever ketamine is used concomitantly with direct or indirect acting sympathomimetics or vasopressin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274031/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Ketalar (ketamine).\" JHP Pharmaceuticals  (2009):", "alternatives_a": "Nitric Oxide, Ivacaftor, Elexacaftor", "alternatives_b": "Halothane, Thiopental, Alfentanil, Remifentanil, Isoflurane, Sodium oxybate, Methohexital, Fentanyl, Desflurane, Nitrous oxide, Sufentanil, More", "updated_at": 1767369485}, {"id": 242339, "ingredient1": "Acrivastine", "ingredient2": "Quazepam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274035/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Meclizine, Azelastine, Thiethylperazine, Dexchlorpheniramine, Phenindamine, Astemizole, Methdilazine, Terfenadine, Pheniramine", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 242340, "ingredient1": "Chlorcyclizine", "ingredient2": "Quazepam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274038/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Meclizine, Azelastine, Thiethylperazine, Dexchlorpheniramine, Phenindamine, Astemizole, Methdilazine, Terfenadine, Pheniramine", "alternatives_b": "Temazepam, Butabarbital, Chloral hydrate, Nitrazepam, Paraldehyde, Amobarbital, Meprobamate, Butalbital, Eszopiclone, Estazolam, Methylphenobarbital, More", "updated_at": 1767369485}, {"id": 242341, "ingredient1": "Chlormezanone", "ingredient2": "Quazepam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274039/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Butabarbital, Chloral hydrate, Nitrazepam, Paraldehyde, Butalbital, Propiomazine, Meprobamate, Methylphenobarbital, Zolpidem, Ethchlorvynol, Zopiclone, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242342, "ingredient1": "Ethchlorvynol", "ingredient2": "Quazepam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274042/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Zopiclone, Quazepam", "alternatives_b": "Butabarbital, Nitrazepam, Thiopental, Paraldehyde, Butalbital, Propiomazine, Meprobamate, Dexmedetomidine, Methylphenobarbital, Zolpidem, Ethchlorvynol, More", "updated_at": 1767369485}, {"id": 242343, "ingredient1": "Fenfluramine", "ingredient2": "Quazepam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274043/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Dexfenfluramine, Naltrexone, Ephedrine, Phentermine, Lorcaserin, Diethylpropion, Mazindol, Lacosamide", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 242344, "ingredient1": "Quazepam", "ingredient2": "Paraldehyde", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274051/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Zopiclone, Quazepam", "alternatives_b": "Chloral hydrate, Nitrazepam, Thiopental, Paraldehyde, Propiomazine, Ethchlorvynol, Zolpidem, Zopiclone, Pentobarbital, Zaleplon", "updated_at": 1767369485}, {"id": 242345, "ingredient1": "Quazepam", "ingredient2": "Pentobarbital", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274052/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Zopiclone, Quazepam", "alternatives_b": "Nitrazepam, Paraldehyde, Ethchlorvynol, Zopiclone, Pentobarbital, Zaleplon", "updated_at": 1767369485}, {"id": 242346, "ingredient1": "Quazepam", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274054/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Entrectinib, Imatinib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, More", "alternatives_b": "Methohexital, Methylphenobarbital, Pentobarbital, Dichloralphenazone, Valerian, Temazepam, Butabarbital, Secobarbital, Chloral hydrate, Paraldehyde, Ethchlorvynol, More", "updated_at": 1767369485}, {"id": 242347, "ingredient1": "Selegiline", "ingredient2": "Quazepam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274056/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam", "alternatives_b": "Cabergoline", "updated_at": 1767369485}, {"id": 242348, "ingredient1": "Doravirine", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274069/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Lamivudine, Cabotegravir, Zanamivir, Valaciclovir, Dolutegravir, Oseltamivir, Acyclovir, Stavudine, Remdesivir, Elbasvir, Famciclovir, More", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Vandetanib, Cobimetinib, Ibrutinib, Afatinib, Tivozanib, Encorafenib, More", "updated_at": 1767369485}, {"id": 242349, "ingredient1": "Doxepin (topical)", "ingredient2": "Doxepin", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274077/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Viloxazine, Lidocaine, Tetracaine", "alternatives_b": "Viloxazine, Doxepin, Tetracaine, Doxepin", "updated_at": 1767369485}, {"id": 242350, "ingredient1": "Eletriptan", "ingredient2": "Doxepin", "severity": "Major", "effect": "Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John's wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.", "source": "DDInter", "management_text": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.  Patients should be closely monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.  For example, some experts suggest a 5-week washout period following use of fluoxetine and 3 weeks following the use of vortioxetine before administering another serotonergic agent.  Individual product labeling for washout periods should be consulted for current recommendations.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.", "mechanism_text": "Synergism", "recommendation": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274078/", "reference_text": "[1] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[2] Achamallah NS \"Visual hallucinations after combining fluoxetine and dextromethorphan .\" Am J Psychiatry 149 (1992):  1406[3] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993):  84-8[4] Metz A \"Interaction between fluoxetine and buspirone.\" Can J Psychiatry 35 (1990):  722-3[5] Goldberg RJ, Huk M \"Serotonin syndrome from trazodone and buspirone.\" Psychosomatics 33 (1992):  235-6[6] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation  (2002):[7] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[8] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990):  213-7[9] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics.\" J Clin Psychopharmacol 10 (1990):  48-50[10] \"Product Information. Zoloft (sertraline).\" Roerig Division  (2001):[11] \"Product Information. Prozac (fluoxetine).\" Dista Products Company  (2001):[12] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[13] Insel TR, Roy BF, Cohen RM, Murphy DL \"Possible development of the serotonin syndrome in man.\" Am J Psychiatry 139 (1982):  954-5[14] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories  (2001):[15] Gilman AG, eds., Nies AS, Rall TW, Taylor P \"Goodman and Gilman's the Pharmacological Basis of Therapeutics.\" New York, NY: Pergamon Press Inc.  (1990):[16] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline  (2001):[17] \"Product Information. Flexeril (cyclobenzaprine).\" Merck & Co., Inc  (2001):[18] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[19] \"Product Information. Imitrex (sumatriptan).\" Glaxo Wellcome  (2001):[20] Ruiz F \"Fluoxetine and the serotonin syndrome.\" Ann Emerg Med 24 (1994):  983-5[21] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc  (2001):[22] Reeves RR, Bullen JA \"Serotonin syndrome produced by paroxetine and low-dose trazodone.\" Psychosomatics 36 (1995):  159-60[23] Harvey AT, Preskorn SH \"Interactions of serotonin reuptake inhibitors with tricyclic antidepressants.\" Arch Gen Psychiatry 52 (1995):  783-4[24] Baetz M, Malcolm D \"Serotonin syndrome from fluvoxamine and buspirone.\" Can J Psychiatry 40 (1995):  428-9[25] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995):  440-2[26] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995):  481-2[27] George TP, Godleski LS \"Possible serotonin syndrome with trazodone addition to fluoxetine.\" Biol Psychiatry 39 (1996):  384-5[28] Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM \"The serotonin syndrome associated wtih paroxetine, an over-the-counter cold remedy, and vascular disease.\" Am J Emerg Med 12 (1994):  642-4[29] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[30] John L, Perreault MM, Tao T, Blew PG \"Serotonin syndrome associated with nefazodone and paroxetine.\" Ann Emerg Med 29 (1997):  287-9[31] \"Product Information. Zomig (zolmitriptan).\" Astra-Zeneca Pharmaceuticals  (2001):[32] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[33] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[34] Bhatara VS, Magnus RD, Paul KL, Preskorn SH \"Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms.\" Ann Pharmacother 32 (1998):  432-6[35] \"Product Information. Maxalt (rizatriptan).\" Merck & Co., Inc  (2001):[36] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals  (2001):[37] Gardner DM, Lynd LD \"Sumatriptan contraindications and the serotonin syndrome.\" Ann Pharmacother 32 (1998):  33-8[38] Mathew NT, Tietjen GE, Lucker C \"Serotonin syndrome complicating migraine pharmacotherapy.\" Cephalalgia 16 (1996):  323-7[39] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[40] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[41] Weiner AL \"Meperidine as a potential cause of serotonin syndrome in the emergency department.\" Acad Emerg Med 6 (1999):  156-8[42] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[43] Gordon JB \"SSRI's and St. John's Wort: possible toxicity?\" Am Fam Physician 57 (1998):  950,953[44] Lantz MS, Buchalter E, Giambanco V \"St. John's wort and antidepressant drug interactions in the elderly.\" J Geriatr Psychiatr Neurol 12 (1999):  7-10[45] Fugh-Berman A \"Herb-drug interactions.\" Lancet 355 (2000):  134-8[46] \"Product Information. Zyvox (linezolid).\" Pharmacia and Upjohn  (2001):[47] Perry NK \"Venlafaxine-induced serotonin syndrome with relapse following amitriptyline.\" Postgrad Med J 76 (2000):  254-6[48] Manos GH \"Possible serotonin syndrome associated with buspirone added to fluoxetine.\" Ann Pharmacother 34 (2000):  871-4[49] Nijhawan PK, Katz G, Winter S \"Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission.\" Crit Care Med 24 (1996):  1086-9[50] Laird LK \"Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder.\" Psychopharmacol Bull 32 (1996):  569-78[51] Margolese HC, Chouinard G \"Serotonin syndrome from addition of low-dose trazodone to nefazodone.\" Am J Psychiatry 157 (2000):  1022[52] Mackay FJ, Dunn NR, Mann RD \"Antidepressants and the serotonin syndrome in general practice.\" Br J Gen Pract 49 (1999):  871-4[53] Smith DL, Wenegrat BG \"A case report of serotonin syndrome associated with combined nefazodone and fluoxetine.\" J Clin Psychiatry 61 (2000):  146[54] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[55] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001):  2163-75[56] Duggal HS, Fetchko J \"Serotonin syndrome and atypical antipsychotics.\" Am J Psychiatry 159 (2002):  672-3[57] Wigen CL, Goetz MB \"Serotonin syndrome and linezolid.\" Clin Infect Dis 34 (2002):  1651-2[58] Hammerness P, Parada H, Abrams A \"Linezolid: MAOI Activity and Potential Drug Interactions.\" Psychosomatics 43 (2002):  248-9[59] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[60] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[61] Turkel SB, Nadala JG, Wincor MZ \"Possible serotonin syndrome in association with 5-HT3 antagonist agents.\" Psychosomatics 42 (2001):  258-60[62] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[63] Lavery S, Ravi H, McDaniel WW, Pushkin YR \"Linezolid and serotonin syndrome.\" Psychosomatics 42 (2001):  432-4[64] Lane R, Baldwin D \"Selective serotonin reuptake inhibitor--induced serotonin syndrome: review.\" J Clin Psychopharmacol 17 (1997):  208-21[65] Bernard L, Stern R, Lew D, Hoffmeyer P \"Serotonin syndrome after concomitant treatment with linezolid and citalopram.\" Clin Infect Dis 36 (2003):  1197[66] Dannawi M \"Possible serotonin syndrome after combination of buspirone and St John's Wort.\" J Psychopharmacol 16 (2002):  401[67] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[68] Hachem RY, Hicks K, Huen A, Raad I \"Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients.\" Clin Infect Dis 37 (2003):  E8-E11[69] Gillman PK \"Linezolid and serotonin toxicity.\" Clin Infect Dis 37 (2003):  1274-5[70] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[71] Giese SY, Neborsky R \"Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl.\" Plast Reconstr Surg 107 (2001):  293-4[72] Jones SL, Athan E, O'Brien D \"Serotonin syndrome due to co-administration of linezolid and venlafaxine.\" J Antimicrob Chemother 54 (2004):  289-90[73] Tahir N \"Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram.\" J Am Med Dir Assoc 5 (2004):  111-3[74] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company  (2004):[75] Thomas CR, Rosenberg M, Blythe V, Meyer WJ 3rd \"Serotonin syndrome and linezolid.\" J Am Acad Child Adolesc Psychiatry 43 (2004):  790[76] Boyer EW, Shannon M \"The serotonin syndrome.\" N Engl J Med 352 (2005):  1112-20[77] Bergeron L, Boule M, Perreault S \"Serotonin toxicity associated with concomitant use of linezolid.\" Ann Pharmacother 39 (2005):  956-61[78] Morales N, Vermette H \"Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine.\" Psychosomatics 46 (2005):  274-5[79] Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M, Grau S \"Linezolid-associated serotonin syndrome: what we can learn from cases reported so far.\" J Antimicrob Chemother 56 (2005):  1176-8[80] DeBellis RJ, Schaefer OP, Liquori M, Volturo GA \"Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient.\" J Intensive Care Med 20 (2005):  351-3[81] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[82] Taylor JJ, Wilson JW, Estes LL \"Linezolid and serotonergic drug interactions: a retrospective survey.\" Clin Infect Dis 43 (2006):  180-7[83] Strouse TB, Kerrihard TN, Forscher CA, Zakowski P \"Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine.\" J Clin Psychopharmacol 26 (2006):  681-683[84] Keegan MT, Brown DR, Rabinstein AA \"Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs.\" Anesth Analg 103 (2006):  1466-8[85] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S \"Rare case of serotonin syndrome with therapeutic doses of paroxetine.\" Am J Ther 13 (2006):  550-552[86] Steinberg M, Morin AK \"Mild serotonin syndrome associated with concurrent linezolid and fluoxetine.\" Am J Health Syst Pharm 64 (2007):  59-62[87] Packer S, Berman SA \"Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid.\" Am J Psychiatry 164 (2007):  346-7[88] Shapiro RE, Tepper SJ \"The serotonin syndrome, triptans, and the potential for drug-drug interactions.\" Headache 47 (2007):  266-9[89] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[90] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories  (2008):[91] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[92] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals  (2009):[93] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals  (2009):[94] Lee J, Franz L, Goforth HW \"Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine.\" Psychosomatics 50 (2009):  638-9[95] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC  (2011):[96] Mugele J, Nanagas KA, Tormoehlen LM \"Serotonin Syndrome Associated With MDPV Use: A Case Report.\" Ann Emerg Med  (2012):[97] \"Product Information. Oleptro (trazodone).\" Labopharm Inc  (2012):[98] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals  (2013):[99] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America  (2013):", "alternatives_a": "Esketamine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Pheniramine", "alternatives_b": "Rimegepant, Eptinezumab, Ubrogepant, Galcanezumab, Atogepant, Methysergide, Erenumab, Fremanezumab", "updated_at": 1767369485}, {"id": 242351, "ingredient1": "Ergotamine", "ingredient2": "Doxepin", "severity": "Major", "effect": "Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John's wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.", "source": "DDInter", "management_text": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.  Patients should be closely monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.  For example, some experts suggest a 5-week washout period following use of fluoxetine and 3 weeks following the use of vortioxetine before administering another serotonergic agent.  Individual product labeling for washout periods should be consulted for current recommendations.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.", "mechanism_text": "Synergism", "recommendation": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274080/", "reference_text": "[1] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[2] Achamallah NS \"Visual hallucinations after combining fluoxetine and dextromethorphan .\" Am J Psychiatry 149 (1992):  1406[3] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993):  84-8[4] Metz A \"Interaction between fluoxetine and buspirone.\" Can J Psychiatry 35 (1990):  722-3[5] Goldberg RJ, Huk M \"Serotonin syndrome from trazodone and buspirone.\" Psychosomatics 33 (1992):  235-6[6] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation  (2002):[7] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[8] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990):  213-7[9] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics.\" J Clin Psychopharmacol 10 (1990):  48-50[10] \"Product Information. Zoloft (sertraline).\" Roerig Division  (2001):[11] \"Product Information. Prozac (fluoxetine).\" Dista Products Company  (2001):[12] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[13] Insel TR, Roy BF, Cohen RM, Murphy DL \"Possible development of the serotonin syndrome in man.\" Am J Psychiatry 139 (1982):  954-5[14] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories  (2001):[15] Gilman AG, eds., Nies AS, Rall TW, Taylor P \"Goodman and Gilman's the Pharmacological Basis of Therapeutics.\" New York, NY: Pergamon Press Inc.  (1990):[16] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline  (2001):[17] \"Product Information. Flexeril (cyclobenzaprine).\" Merck & Co., Inc  (2001):[18] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[19] \"Product Information. Imitrex (sumatriptan).\" Glaxo Wellcome  (2001):[20] Ruiz F \"Fluoxetine and the serotonin syndrome.\" Ann Emerg Med 24 (1994):  983-5[21] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc  (2001):[22] Reeves RR, Bullen JA \"Serotonin syndrome produced by paroxetine and low-dose trazodone.\" Psychosomatics 36 (1995):  159-60[23] Harvey AT, Preskorn SH \"Interactions of serotonin reuptake inhibitors with tricyclic antidepressants.\" Arch Gen Psychiatry 52 (1995):  783-4[24] Baetz M, Malcolm D \"Serotonin syndrome from fluvoxamine and buspirone.\" Can J Psychiatry 40 (1995):  428-9[25] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995):  440-2[26] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995):  481-2[27] George TP, Godleski LS \"Possible serotonin syndrome with trazodone addition to fluoxetine.\" Biol Psychiatry 39 (1996):  384-5[28] Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM \"The serotonin syndrome associated wtih paroxetine, an over-the-counter cold remedy, and vascular disease.\" Am J Emerg Med 12 (1994):  642-4[29] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[30] John L, Perreault MM, Tao T, Blew PG \"Serotonin syndrome associated with nefazodone and paroxetine.\" Ann Emerg Med 29 (1997):  287-9[31] \"Product Information. Zomig (zolmitriptan).\" Astra-Zeneca Pharmaceuticals  (2001):[32] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[33] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[34] Bhatara VS, Magnus RD, Paul KL, Preskorn SH \"Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms.\" Ann Pharmacother 32 (1998):  432-6[35] \"Product Information. Maxalt (rizatriptan).\" Merck & Co., Inc  (2001):[36] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals  (2001):[37] Gardner DM, Lynd LD \"Sumatriptan contraindications and the serotonin syndrome.\" Ann Pharmacother 32 (1998):  33-8[38] Mathew NT, Tietjen GE, Lucker C \"Serotonin syndrome complicating migraine pharmacotherapy.\" Cephalalgia 16 (1996):  323-7[39] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[40] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[41] Weiner AL \"Meperidine as a potential cause of serotonin syndrome in the emergency department.\" Acad Emerg Med 6 (1999):  156-8[42] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[43] Gordon JB \"SSRI's and St. John's Wort: possible toxicity?\" Am Fam Physician 57 (1998):  950,953[44] Lantz MS, Buchalter E, Giambanco V \"St. John's wort and antidepressant drug interactions in the elderly.\" J Geriatr Psychiatr Neurol 12 (1999):  7-10[45] Fugh-Berman A \"Herb-drug interactions.\" Lancet 355 (2000):  134-8[46] \"Product Information. Zyvox (linezolid).\" Pharmacia and Upjohn  (2001):[47] Perry NK \"Venlafaxine-induced serotonin syndrome with relapse following amitriptyline.\" Postgrad Med J 76 (2000):  254-6[48] Manos GH \"Possible serotonin syndrome associated with buspirone added to fluoxetine.\" Ann Pharmacother 34 (2000):  871-4[49] Nijhawan PK, Katz G, Winter S \"Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission.\" Crit Care Med 24 (1996):  1086-9[50] Laird LK \"Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder.\" Psychopharmacol Bull 32 (1996):  569-78[51] Margolese HC, Chouinard G \"Serotonin syndrome from addition of low-dose trazodone to nefazodone.\" Am J Psychiatry 157 (2000):  1022[52] Mackay FJ, Dunn NR, Mann RD \"Antidepressants and the serotonin syndrome in general practice.\" Br J Gen Pract 49 (1999):  871-4[53] Smith DL, Wenegrat BG \"A case report of serotonin syndrome associated with combined nefazodone and fluoxetine.\" J Clin Psychiatry 61 (2000):  146[54] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[55] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001):  2163-75[56] Duggal HS, Fetchko J \"Serotonin syndrome and atypical antipsychotics.\" Am J Psychiatry 159 (2002):  672-3[57] Wigen CL, Goetz MB \"Serotonin syndrome and linezolid.\" Clin Infect Dis 34 (2002):  1651-2[58] Hammerness P, Parada H, Abrams A \"Linezolid: MAOI Activity and Potential Drug Interactions.\" Psychosomatics 43 (2002):  248-9[59] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[60] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[61] Turkel SB, Nadala JG, Wincor MZ \"Possible serotonin syndrome in association with 5-HT3 antagonist agents.\" Psychosomatics 42 (2001):  258-60[62] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[63] Lavery S, Ravi H, McDaniel WW, Pushkin YR \"Linezolid and serotonin syndrome.\" Psychosomatics 42 (2001):  432-4[64] Lane R, Baldwin D \"Selective serotonin reuptake inhibitor--induced serotonin syndrome: review.\" J Clin Psychopharmacol 17 (1997):  208-21[65] Bernard L, Stern R, Lew D, Hoffmeyer P \"Serotonin syndrome after concomitant treatment with linezolid and citalopram.\" Clin Infect Dis 36 (2003):  1197[66] Dannawi M \"Possible serotonin syndrome after combination of buspirone and St John's Wort.\" J Psychopharmacol 16 (2002):  401[67] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[68] Hachem RY, Hicks K, Huen A, Raad I \"Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients.\" Clin Infect Dis 37 (2003):  E8-E11[69] Gillman PK \"Linezolid and serotonin toxicity.\" Clin Infect Dis 37 (2003):  1274-5[70] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[71] Giese SY, Neborsky R \"Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl.\" Plast Reconstr Surg 107 (2001):  293-4[72] Jones SL, Athan E, O'Brien D \"Serotonin syndrome due to co-administration of linezolid and venlafaxine.\" J Antimicrob Chemother 54 (2004):  289-90[73] Tahir N \"Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram.\" J Am Med Dir Assoc 5 (2004):  111-3[74] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company  (2004):[75] Thomas CR, Rosenberg M, Blythe V, Meyer WJ 3rd \"Serotonin syndrome and linezolid.\" J Am Acad Child Adolesc Psychiatry 43 (2004):  790[76] Boyer EW, Shannon M \"The serotonin syndrome.\" N Engl J Med 352 (2005):  1112-20[77] Bergeron L, Boule M, Perreault S \"Serotonin toxicity associated with concomitant use of linezolid.\" Ann Pharmacother 39 (2005):  956-61[78] Morales N, Vermette H \"Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine.\" Psychosomatics 46 (2005):  274-5[79] Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M, Grau S \"Linezolid-associated serotonin syndrome: what we can learn from cases reported so far.\" J Antimicrob Chemother 56 (2005):  1176-8[80] DeBellis RJ, Schaefer OP, Liquori M, Volturo GA \"Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient.\" J Intensive Care Med 20 (2005):  351-3[81] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[82] Taylor JJ, Wilson JW, Estes LL \"Linezolid and serotonergic drug interactions: a retrospective survey.\" Clin Infect Dis 43 (2006):  180-7[83] Strouse TB, Kerrihard TN, Forscher CA, Zakowski P \"Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine.\" J Clin Psychopharmacol 26 (2006):  681-683[84] Keegan MT, Brown DR, Rabinstein AA \"Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs.\" Anesth Analg 103 (2006):  1466-8[85] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S \"Rare case of serotonin syndrome with therapeutic doses of paroxetine.\" Am J Ther 13 (2006):  550-552[86] Steinberg M, Morin AK \"Mild serotonin syndrome associated with concurrent linezolid and fluoxetine.\" Am J Health Syst Pharm 64 (2007):  59-62[87] Packer S, Berman SA \"Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid.\" Am J Psychiatry 164 (2007):  346-7[88] Shapiro RE, Tepper SJ \"The serotonin syndrome, triptans, and the potential for drug-drug interactions.\" Headache 47 (2007):  266-9[89] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[90] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories  (2008):[91] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[92] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals  (2009):[93] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals  (2009):[94] Lee J, Franz L, Goforth HW \"Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine.\" Psychosomatics 50 (2009):  638-9[95] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC  (2011):[96] Mugele J, Nanagas KA, Tormoehlen LM \"Serotonin Syndrome Associated With MDPV Use: A Case Report.\" Ann Emerg Med  (2012):[97] \"Product Information. Oleptro (trazodone).\" Labopharm Inc  (2012):[98] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals  (2013):[99] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America  (2013):", "alternatives_a": "Desipramine, Esketamine, Lidocaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Pheniramine, Promethazine", "alternatives_b": "Rimegepant, Eptinezumab, Ubrogepant, Galcanezumab, Atogepant, Methysergide, Erenumab, Fremanezumab", "updated_at": 1767369485}, {"id": 242352, "ingredient1": "Frovatriptan", "ingredient2": "Doxepin", "severity": "Major", "effect": "Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John's wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.", "source": "DDInter", "management_text": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.  Patients should be closely monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.  For example, some experts suggest a 5-week washout period following use of fluoxetine and 3 weeks following the use of vortioxetine before administering another serotonergic agent.  Individual product labeling for washout periods should be consulted for current recommendations.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.", "mechanism_text": "Synergism", "recommendation": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274083/", "reference_text": "[1] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[2] Achamallah NS \"Visual hallucinations after combining fluoxetine and dextromethorphan .\" Am J Psychiatry 149 (1992):  1406[3] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993):  84-8[4] Metz A \"Interaction between fluoxetine and buspirone.\" Can J Psychiatry 35 (1990):  722-3[5] Goldberg RJ, Huk M \"Serotonin syndrome from trazodone and buspirone.\" Psychosomatics 33 (1992):  235-6[6] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation  (2002):[7] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[8] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990):  213-7[9] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics.\" J Clin Psychopharmacol 10 (1990):  48-50[10] \"Product Information. Zoloft (sertraline).\" Roerig Division  (2001):[11] \"Product Information. Prozac (fluoxetine).\" Dista Products Company  (2001):[12] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[13] Insel TR, Roy BF, Cohen RM, Murphy DL \"Possible development of the serotonin syndrome in man.\" Am J Psychiatry 139 (1982):  954-5[14] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories  (2001):[15] Gilman AG, eds., Nies AS, Rall TW, Taylor P \"Goodman and Gilman's the Pharmacological Basis of Therapeutics.\" New York, NY: Pergamon Press Inc.  (1990):[16] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline  (2001):[17] \"Product Information. Flexeril (cyclobenzaprine).\" Merck & Co., Inc  (2001):[18] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[19] \"Product Information. Imitrex (sumatriptan).\" Glaxo Wellcome  (2001):[20] Ruiz F \"Fluoxetine and the serotonin syndrome.\" Ann Emerg Med 24 (1994):  983-5[21] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc  (2001):[22] Reeves RR, Bullen JA \"Serotonin syndrome produced by paroxetine and low-dose trazodone.\" Psychosomatics 36 (1995):  159-60[23] Harvey AT, Preskorn SH \"Interactions of serotonin reuptake inhibitors with tricyclic antidepressants.\" Arch Gen Psychiatry 52 (1995):  783-4[24] Baetz M, Malcolm D \"Serotonin syndrome from fluvoxamine and buspirone.\" Can J Psychiatry 40 (1995):  428-9[25] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995):  440-2[26] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995):  481-2[27] George TP, Godleski LS \"Possible serotonin syndrome with trazodone addition to fluoxetine.\" Biol Psychiatry 39 (1996):  384-5[28] Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM \"The serotonin syndrome associated wtih paroxetine, an over-the-counter cold remedy, and vascular disease.\" Am J Emerg Med 12 (1994):  642-4[29] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[30] John L, Perreault MM, Tao T, Blew PG \"Serotonin syndrome associated with nefazodone and paroxetine.\" Ann Emerg Med 29 (1997):  287-9[31] \"Product Information. Zomig (zolmitriptan).\" Astra-Zeneca Pharmaceuticals  (2001):[32] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[33] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[34] Bhatara VS, Magnus RD, Paul KL, Preskorn SH \"Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms.\" Ann Pharmacother 32 (1998):  432-6[35] \"Product Information. Maxalt (rizatriptan).\" Merck & Co., Inc  (2001):[36] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals  (2001):[37] Gardner DM, Lynd LD \"Sumatriptan contraindications and the serotonin syndrome.\" Ann Pharmacother 32 (1998):  33-8[38] Mathew NT, Tietjen GE, Lucker C \"Serotonin syndrome complicating migraine pharmacotherapy.\" Cephalalgia 16 (1996):  323-7[39] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[40] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[41] Weiner AL \"Meperidine as a potential cause of serotonin syndrome in the emergency department.\" Acad Emerg Med 6 (1999):  156-8[42] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[43] Gordon JB \"SSRI's and St. John's Wort: possible toxicity?\" Am Fam Physician 57 (1998):  950,953[44] Lantz MS, Buchalter E, Giambanco V \"St. John's wort and antidepressant drug interactions in the elderly.\" J Geriatr Psychiatr Neurol 12 (1999):  7-10[45] Fugh-Berman A \"Herb-drug interactions.\" Lancet 355 (2000):  134-8[46] \"Product Information. Zyvox (linezolid).\" Pharmacia and Upjohn  (2001):[47] Perry NK \"Venlafaxine-induced serotonin syndrome with relapse following amitriptyline.\" Postgrad Med J 76 (2000):  254-6[48] Manos GH \"Possible serotonin syndrome associated with buspirone added to fluoxetine.\" Ann Pharmacother 34 (2000):  871-4[49] Nijhawan PK, Katz G, Winter S \"Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission.\" Crit Care Med 24 (1996):  1086-9[50] Laird LK \"Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder.\" Psychopharmacol Bull 32 (1996):  569-78[51] Margolese HC, Chouinard G \"Serotonin syndrome from addition of low-dose trazodone to nefazodone.\" Am J Psychiatry 157 (2000):  1022[52] Mackay FJ, Dunn NR, Mann RD \"Antidepressants and the serotonin syndrome in general practice.\" Br J Gen Pract 49 (1999):  871-4[53] Smith DL, Wenegrat BG \"A case report of serotonin syndrome associated with combined nefazodone and fluoxetine.\" J Clin Psychiatry 61 (2000):  146[54] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[55] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001):  2163-75[56] Duggal HS, Fetchko J \"Serotonin syndrome and atypical antipsychotics.\" Am J Psychiatry 159 (2002):  672-3[57] Wigen CL, Goetz MB \"Serotonin syndrome and linezolid.\" Clin Infect Dis 34 (2002):  1651-2[58] Hammerness P, Parada H, Abrams A \"Linezolid: MAOI Activity and Potential Drug Interactions.\" Psychosomatics 43 (2002):  248-9[59] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[60] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[61] Turkel SB, Nadala JG, Wincor MZ \"Possible serotonin syndrome in association with 5-HT3 antagonist agents.\" Psychosomatics 42 (2001):  258-60[62] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[63] Lavery S, Ravi H, McDaniel WW, Pushkin YR \"Linezolid and serotonin syndrome.\" Psychosomatics 42 (2001):  432-4[64] Lane R, Baldwin D \"Selective serotonin reuptake inhibitor--induced serotonin syndrome: review.\" J Clin Psychopharmacol 17 (1997):  208-21[65] Bernard L, Stern R, Lew D, Hoffmeyer P \"Serotonin syndrome after concomitant treatment with linezolid and citalopram.\" Clin Infect Dis 36 (2003):  1197[66] Dannawi M \"Possible serotonin syndrome after combination of buspirone and St John's Wort.\" J Psychopharmacol 16 (2002):  401[67] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[68] Hachem RY, Hicks K, Huen A, Raad I \"Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients.\" Clin Infect Dis 37 (2003):  E8-E11[69] Gillman PK \"Linezolid and serotonin toxicity.\" Clin Infect Dis 37 (2003):  1274-5[70] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[71] Giese SY, Neborsky R \"Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl.\" Plast Reconstr Surg 107 (2001):  293-4[72] Jones SL, Athan E, O'Brien D \"Serotonin syndrome due to co-administration of linezolid and venlafaxine.\" J Antimicrob Chemother 54 (2004):  289-90[73] Tahir N \"Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram.\" J Am Med Dir Assoc 5 (2004):  111-3[74] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company  (2004):[75] Thomas CR, Rosenberg M, Blythe V, Meyer WJ 3rd \"Serotonin syndrome and linezolid.\" J Am Acad Child Adolesc Psychiatry 43 (2004):  790[76] Boyer EW, Shannon M \"The serotonin syndrome.\" N Engl J Med 352 (2005):  1112-20[77] Bergeron L, Boule M, Perreault S \"Serotonin toxicity associated with concomitant use of linezolid.\" Ann Pharmacother 39 (2005):  956-61[78] Morales N, Vermette H \"Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine.\" Psychosomatics 46 (2005):  274-5[79] Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M, Grau S \"Linezolid-associated serotonin syndrome: what we can learn from cases reported so far.\" J Antimicrob Chemother 56 (2005):  1176-8[80] DeBellis RJ, Schaefer OP, Liquori M, Volturo GA \"Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient.\" J Intensive Care Med 20 (2005):  351-3[81] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[82] Taylor JJ, Wilson JW, Estes LL \"Linezolid and serotonergic drug interactions: a retrospective survey.\" Clin Infect Dis 43 (2006):  180-7[83] Strouse TB, Kerrihard TN, Forscher CA, Zakowski P \"Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine.\" J Clin Psychopharmacol 26 (2006):  681-683[84] Keegan MT, Brown DR, Rabinstein AA \"Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs.\" Anesth Analg 103 (2006):  1466-8[85] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S \"Rare case of serotonin syndrome with therapeutic doses of paroxetine.\" Am J Ther 13 (2006):  550-552[86] Steinberg M, Morin AK \"Mild serotonin syndrome associated with concurrent linezolid and fluoxetine.\" Am J Health Syst Pharm 64 (2007):  59-62[87] Packer S, Berman SA \"Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid.\" Am J Psychiatry 164 (2007):  346-7[88] Shapiro RE, Tepper SJ \"The serotonin syndrome, triptans, and the potential for drug-drug interactions.\" Headache 47 (2007):  266-9[89] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[90] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories  (2008):[91] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[92] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals  (2009):[93] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals  (2009):[94] Lee J, Franz L, Goforth HW \"Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine.\" Psychosomatics 50 (2009):  638-9[95] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC  (2011):[96] Mugele J, Nanagas KA, Tormoehlen LM \"Serotonin Syndrome Associated With MDPV Use: A Case Report.\" Ann Emerg Med  (2012):[97] \"Product Information. Oleptro (trazodone).\" Labopharm Inc  (2012):[98] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals  (2013):[99] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America  (2013):", "alternatives_a": "Bupropion, Viloxazine, Esketamine, Lidocaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Pheniramine, Promethazine", "alternatives_b": "Rimegepant, Eptinezumab, Ubrogepant, Galcanezumab, Atogepant, Methysergide, Erenumab, Fremanezumab", "updated_at": 1767369485}, {"id": 242353, "ingredient1": "Doxepin", "ingredient2": "Melatonin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274091/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Vilazodone, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Bupropion, Esketamine, Lidocaine, Tetracaine", "alternatives_b": "Meprobamate, Nitrazepam, Dichloralphenazone", "updated_at": 1767369485}, {"id": 242354, "ingredient1": "Doxepin", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274094/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Levomilnacipran, Oxitriptan, Vortioxetine, Milnacipran, Tryptophan, Vilazodone, Pheniramine", "alternatives_b": "Meprobamate, Nitrazepam, Dichloralphenazone", "updated_at": 1767369485}, {"id": 242355, "ingredient1": "Doxepin", "ingredient2": "Botulinum toxin type A", "severity": "Moderate", "effect": "Use of anticholinergic drugs after administration of botulinum toxin may potentiate systemic anticholinergic effects such as dry mouth, blurred vision, and urinary disorders.  Botulinum toxin inhibits the release of acetylcholine from peripheral cholinergic nerve endings, thus additive or synergistic anticholinergic effects may occur when these agents are used together.", "source": "DDInter", "management_text": "Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) are used after administration of botulinum toxin.", "mechanism_text": "Synergism", "recommendation": "Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274098/", "reference_text": "[1] \"Product Information. Myobloc (rimabotulinumtoxinB).\" Elan Pharmaceuticals[2] \"Product Information. Dysport (abobotulinumtoxinA).\" Tercica Inc[3] \"Product Information. Botox (onabotulinumtoxinA).\" Allergan Inc[4] \"Product Information. Xeomin (incobotulinumtoxinA).\" Merz Pharmaceuticals  (2022):[5] \"Product Information. Jeuveau (prabotulinumtoxinA).\" Evolus, Inc.  (2022):[6] \"Product Information. Daxxify (daxibotulinumtoxinA).\" Revance Therapeutics, Inc.  (2022):", "alternatives_a": "Citalopram, Sertraline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Isocarboxazid, Viloxazine, Esketamine, More", "alternatives_b": "Atracurium, Doxacurium, Succinylcholine, Rocuronium, Vecuronium, Tubocurarine, Mivacurium, Pancuronium, Pipecuronium, Cisatracurium", "updated_at": 1767369485}, {"id": 242356, "ingredient1": "Doxepin", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274102/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Phenelzine, Duloxetine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Bupropion, More", "alternatives_b": "Dabrafenib, Acalabrutinib, Pexidartinib, Tepotinib, Avapritinib, Larotrectinib, Bosutinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, More", "updated_at": 1767369485}, {"id": 242357, "ingredient1": "Doxepin", "ingredient2": "Botulinum toxin type B", "severity": "Moderate", "effect": "Use of anticholinergic drugs after administration of botulinum toxin may potentiate systemic anticholinergic effects such as dry mouth, blurred vision, and urinary disorders.  Botulinum toxin inhibits the release of acetylcholine from peripheral cholinergic nerve endings, thus additive or synergistic anticholinergic effects may occur when these agents are used together.", "source": "DDInter", "management_text": "Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) are used after administration of botulinum toxin.", "mechanism_text": "Synergism", "recommendation": "Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274105/", "reference_text": "[1] \"Product Information. Myobloc (rimabotulinumtoxinB).\" Elan Pharmaceuticals[2] \"Product Information. Dysport (abobotulinumtoxinA).\" Tercica Inc[3] \"Product Information. Botox (onabotulinumtoxinA).\" Allergan Inc[4] \"Product Information. Xeomin (incobotulinumtoxinA).\" Merz Pharmaceuticals  (2022):[5] \"Product Information. Jeuveau (prabotulinumtoxinA).\" Evolus, Inc.  (2022):[6] \"Product Information. Daxxify (daxibotulinumtoxinA).\" Revance Therapeutics, Inc.  (2022):", "alternatives_a": "Citalopram, Sertraline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Isocarboxazid, Viloxazine, Esketamine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242358, "ingredient1": "Eletriptan", "ingredient2": "Doxepin (topical)", "severity": "Major", "effect": "Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John's wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.", "source": "DDInter", "management_text": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.  Patients should be closely monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.  For example, some experts suggest a 5-week washout period following use of fluoxetine and 3 weeks following the use of vortioxetine before administering another serotonergic agent.  Individual product labeling for washout periods should be consulted for current recommendations.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.", "mechanism_text": "Synergism", "recommendation": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274114/", "reference_text": "[1] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[2] Achamallah NS \"Visual hallucinations after combining fluoxetine and dextromethorphan .\" Am J Psychiatry 149 (1992):  1406[3] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993):  84-8[4] Metz A \"Interaction between fluoxetine and buspirone.\" Can J Psychiatry 35 (1990):  722-3[5] Goldberg RJ, Huk M \"Serotonin syndrome from trazodone and buspirone.\" Psychosomatics 33 (1992):  235-6[6] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation  (2002):[7] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[8] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990):  213-7[9] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics.\" J Clin Psychopharmacol 10 (1990):  48-50[10] \"Product Information. Zoloft (sertraline).\" Roerig Division  (2001):[11] \"Product Information. Prozac (fluoxetine).\" Dista Products Company  (2001):[12] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[13] Insel TR, Roy BF, Cohen RM, Murphy DL \"Possible development of the serotonin syndrome in man.\" Am J Psychiatry 139 (1982):  954-5[14] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories  (2001):[15] Gilman AG, eds., Nies AS, Rall TW, Taylor P \"Goodman and Gilman's the Pharmacological Basis of Therapeutics.\" New York, NY: Pergamon Press Inc.  (1990):[16] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline  (2001):[17] \"Product Information. Flexeril (cyclobenzaprine).\" Merck & Co., Inc  (2001):[18] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[19] \"Product Information. Imitrex (sumatriptan).\" Glaxo Wellcome  (2001):[20] Ruiz F \"Fluoxetine and the serotonin syndrome.\" Ann Emerg Med 24 (1994):  983-5[21] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc  (2001):[22] Reeves RR, Bullen JA \"Serotonin syndrome produced by paroxetine and low-dose trazodone.\" Psychosomatics 36 (1995):  159-60[23] Harvey AT, Preskorn SH \"Interactions of serotonin reuptake inhibitors with tricyclic antidepressants.\" Arch Gen Psychiatry 52 (1995):  783-4[24] Baetz M, Malcolm D \"Serotonin syndrome from fluvoxamine and buspirone.\" Can J Psychiatry 40 (1995):  428-9[25] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995):  440-2[26] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995):  481-2[27] George TP, Godleski LS \"Possible serotonin syndrome with trazodone addition to fluoxetine.\" Biol Psychiatry 39 (1996):  384-5[28] Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM \"The serotonin syndrome associated wtih paroxetine, an over-the-counter cold remedy, and vascular disease.\" Am J Emerg Med 12 (1994):  642-4[29] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[30] John L, Perreault MM, Tao T, Blew PG \"Serotonin syndrome associated with nefazodone and paroxetine.\" Ann Emerg Med 29 (1997):  287-9[31] \"Product Information. Zomig (zolmitriptan).\" Astra-Zeneca Pharmaceuticals  (2001):[32] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[33] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[34] Bhatara VS, Magnus RD, Paul KL, Preskorn SH \"Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms.\" Ann Pharmacother 32 (1998):  432-6[35] \"Product Information. Maxalt (rizatriptan).\" Merck & Co., Inc  (2001):[36] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals  (2001):[37] Gardner DM, Lynd LD \"Sumatriptan contraindications and the serotonin syndrome.\" Ann Pharmacother 32 (1998):  33-8[38] Mathew NT, Tietjen GE, Lucker C \"Serotonin syndrome complicating migraine pharmacotherapy.\" Cephalalgia 16 (1996):  323-7[39] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[40] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[41] Weiner AL \"Meperidine as a potential cause of serotonin syndrome in the emergency department.\" Acad Emerg Med 6 (1999):  156-8[42] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[43] Gordon JB \"SSRI's and St. John's Wort: possible toxicity?\" Am Fam Physician 57 (1998):  950,953[44] Lantz MS, Buchalter E, Giambanco V \"St. John's wort and antidepressant drug interactions in the elderly.\" J Geriatr Psychiatr Neurol 12 (1999):  7-10[45] Fugh-Berman A \"Herb-drug interactions.\" Lancet 355 (2000):  134-8[46] \"Product Information. Zyvox (linezolid).\" Pharmacia and Upjohn  (2001):[47] Perry NK \"Venlafaxine-induced serotonin syndrome with relapse following amitriptyline.\" Postgrad Med J 76 (2000):  254-6[48] Manos GH \"Possible serotonin syndrome associated with buspirone added to fluoxetine.\" Ann Pharmacother 34 (2000):  871-4[49] Nijhawan PK, Katz G, Winter S \"Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission.\" Crit Care Med 24 (1996):  1086-9[50] Laird LK \"Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder.\" Psychopharmacol Bull 32 (1996):  569-78[51] Margolese HC, Chouinard G \"Serotonin syndrome from addition of low-dose trazodone to nefazodone.\" Am J Psychiatry 157 (2000):  1022[52] Mackay FJ, Dunn NR, Mann RD \"Antidepressants and the serotonin syndrome in general practice.\" Br J Gen Pract 49 (1999):  871-4[53] Smith DL, Wenegrat BG \"A case report of serotonin syndrome associated with combined nefazodone and fluoxetine.\" J Clin Psychiatry 61 (2000):  146[54] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[55] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001):  2163-75[56] Duggal HS, Fetchko J \"Serotonin syndrome and atypical antipsychotics.\" Am J Psychiatry 159 (2002):  672-3[57] Wigen CL, Goetz MB \"Serotonin syndrome and linezolid.\" Clin Infect Dis 34 (2002):  1651-2[58] Hammerness P, Parada H, Abrams A \"Linezolid: MAOI Activity and Potential Drug Interactions.\" Psychosomatics 43 (2002):  248-9[59] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[60] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[61] Turkel SB, Nadala JG, Wincor MZ \"Possible serotonin syndrome in association with 5-HT3 antagonist agents.\" Psychosomatics 42 (2001):  258-60[62] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[63] Lavery S, Ravi H, McDaniel WW, Pushkin YR \"Linezolid and serotonin syndrome.\" Psychosomatics 42 (2001):  432-4[64] Lane R, Baldwin D \"Selective serotonin reuptake inhibitor--induced serotonin syndrome: review.\" J Clin Psychopharmacol 17 (1997):  208-21[65] Bernard L, Stern R, Lew D, Hoffmeyer P \"Serotonin syndrome after concomitant treatment with linezolid and citalopram.\" Clin Infect Dis 36 (2003):  1197[66] Dannawi M \"Possible serotonin syndrome after combination of buspirone and St John's Wort.\" J Psychopharmacol 16 (2002):  401[67] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[68] Hachem RY, Hicks K, Huen A, Raad I \"Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients.\" Clin Infect Dis 37 (2003):  E8-E11[69] Gillman PK \"Linezolid and serotonin toxicity.\" Clin Infect Dis 37 (2003):  1274-5[70] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[71] Giese SY, Neborsky R \"Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl.\" Plast Reconstr Surg 107 (2001):  293-4[72] Jones SL, Athan E, O'Brien D \"Serotonin syndrome due to co-administration of linezolid and venlafaxine.\" J Antimicrob Chemother 54 (2004):  289-90[73] Tahir N \"Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram.\" J Am Med Dir Assoc 5 (2004):  111-3[74] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company  (2004):[75] Thomas CR, Rosenberg M, Blythe V, Meyer WJ 3rd \"Serotonin syndrome and linezolid.\" J Am Acad Child Adolesc Psychiatry 43 (2004):  790[76] Boyer EW, Shannon M \"The serotonin syndrome.\" N Engl J Med 352 (2005):  1112-20[77] Bergeron L, Boule M, Perreault S \"Serotonin toxicity associated with concomitant use of linezolid.\" Ann Pharmacother 39 (2005):  956-61[78] Morales N, Vermette H \"Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine.\" Psychosomatics 46 (2005):  274-5[79] Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M, Grau S \"Linezolid-associated serotonin syndrome: what we can learn from cases reported so far.\" J Antimicrob Chemother 56 (2005):  1176-8[80] DeBellis RJ, Schaefer OP, Liquori M, Volturo GA \"Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient.\" J Intensive Care Med 20 (2005):  351-3[81] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[82] Taylor JJ, Wilson JW, Estes LL \"Linezolid and serotonergic drug interactions: a retrospective survey.\" Clin Infect Dis 43 (2006):  180-7[83] Strouse TB, Kerrihard TN, Forscher CA, Zakowski P \"Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine.\" J Clin Psychopharmacol 26 (2006):  681-683[84] Keegan MT, Brown DR, Rabinstein AA \"Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs.\" Anesth Analg 103 (2006):  1466-8[85] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S \"Rare case of serotonin syndrome with therapeutic doses of paroxetine.\" Am J Ther 13 (2006):  550-552[86] Steinberg M, Morin AK \"Mild serotonin syndrome associated with concurrent linezolid and fluoxetine.\" Am J Health Syst Pharm 64 (2007):  59-62[87] Packer S, Berman SA \"Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid.\" Am J Psychiatry 164 (2007):  346-7[88] Shapiro RE, Tepper SJ \"The serotonin syndrome, triptans, and the potential for drug-drug interactions.\" Headache 47 (2007):  266-9[89] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[90] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories  (2008):[91] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[92] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals  (2009):[93] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals  (2009):[94] Lee J, Franz L, Goforth HW \"Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine.\" Psychosomatics 50 (2009):  638-9[95] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC  (2011):[96] Mugele J, Nanagas KA, Tormoehlen LM \"Serotonin Syndrome Associated With MDPV Use: A Case Report.\" Ann Emerg Med  (2012):[97] \"Product Information. Oleptro (trazodone).\" Labopharm Inc  (2012):[98] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals  (2013):[99] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America  (2013):", "alternatives_a": "Esketamine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Pheniramine", "alternatives_b": "Rimegepant, Eptinezumab, Ubrogepant, Galcanezumab, Atogepant, Methysergide, Erenumab, Fremanezumab", "updated_at": 1767369485}, {"id": 242359, "ingredient1": "Ergotamine", "ingredient2": "Doxepin (topical)", "severity": "Major", "effect": "Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John's wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.", "source": "DDInter", "management_text": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.  Patients should be closely monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.  For example, some experts suggest a 5-week washout period following use of fluoxetine and 3 weeks following the use of vortioxetine before administering another serotonergic agent.  Individual product labeling for washout periods should be consulted for current recommendations.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.", "mechanism_text": "Synergism", "recommendation": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274116/", "reference_text": "[1] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[2] Achamallah NS \"Visual hallucinations after combining fluoxetine and dextromethorphan .\" Am J Psychiatry 149 (1992):  1406[3] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993):  84-8[4] Metz A \"Interaction between fluoxetine and buspirone.\" Can J Psychiatry 35 (1990):  722-3[5] Goldberg RJ, Huk M \"Serotonin syndrome from trazodone and buspirone.\" Psychosomatics 33 (1992):  235-6[6] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation  (2002):[7] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[8] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990):  213-7[9] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics.\" J Clin Psychopharmacol 10 (1990):  48-50[10] \"Product Information. Zoloft (sertraline).\" Roerig Division  (2001):[11] \"Product Information. Prozac (fluoxetine).\" Dista Products Company  (2001):[12] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[13] Insel TR, Roy BF, Cohen RM, Murphy DL \"Possible development of the serotonin syndrome in man.\" Am J Psychiatry 139 (1982):  954-5[14] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories  (2001):[15] Gilman AG, eds., Nies AS, Rall TW, Taylor P \"Goodman and Gilman's the Pharmacological Basis of Therapeutics.\" New York, NY: Pergamon Press Inc.  (1990):[16] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline  (2001):[17] \"Product Information. Flexeril (cyclobenzaprine).\" Merck & Co., Inc  (2001):[18] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[19] \"Product Information. Imitrex (sumatriptan).\" Glaxo Wellcome  (2001):[20] Ruiz F \"Fluoxetine and the serotonin syndrome.\" Ann Emerg Med 24 (1994):  983-5[21] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc  (2001):[22] Reeves RR, Bullen JA \"Serotonin syndrome produced by paroxetine and low-dose trazodone.\" Psychosomatics 36 (1995):  159-60[23] Harvey AT, Preskorn SH \"Interactions of serotonin reuptake inhibitors with tricyclic antidepressants.\" Arch Gen Psychiatry 52 (1995):  783-4[24] Baetz M, Malcolm D \"Serotonin syndrome from fluvoxamine and buspirone.\" Can J Psychiatry 40 (1995):  428-9[25] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995):  440-2[26] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995):  481-2[27] George TP, Godleski LS \"Possible serotonin syndrome with trazodone addition to fluoxetine.\" Biol Psychiatry 39 (1996):  384-5[28] Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM \"The serotonin syndrome associated wtih paroxetine, an over-the-counter cold remedy, and vascular disease.\" Am J Emerg Med 12 (1994):  642-4[29] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[30] John L, Perreault MM, Tao T, Blew PG \"Serotonin syndrome associated with nefazodone and paroxetine.\" Ann Emerg Med 29 (1997):  287-9[31] \"Product Information. Zomig (zolmitriptan).\" Astra-Zeneca Pharmaceuticals  (2001):[32] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[33] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[34] Bhatara VS, Magnus RD, Paul KL, Preskorn SH \"Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms.\" Ann Pharmacother 32 (1998):  432-6[35] \"Product Information. Maxalt (rizatriptan).\" Merck & Co., Inc  (2001):[36] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals  (2001):[37] Gardner DM, Lynd LD \"Sumatriptan contraindications and the serotonin syndrome.\" Ann Pharmacother 32 (1998):  33-8[38] Mathew NT, Tietjen GE, Lucker C \"Serotonin syndrome complicating migraine pharmacotherapy.\" Cephalalgia 16 (1996):  323-7[39] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[40] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[41] Weiner AL \"Meperidine as a potential cause of serotonin syndrome in the emergency department.\" Acad Emerg Med 6 (1999):  156-8[42] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[43] Gordon JB \"SSRI's and St. John's Wort: possible toxicity?\" Am Fam Physician 57 (1998):  950,953[44] Lantz MS, Buchalter E, Giambanco V \"St. John's wort and antidepressant drug interactions in the elderly.\" J Geriatr Psychiatr Neurol 12 (1999):  7-10[45] Fugh-Berman A \"Herb-drug interactions.\" Lancet 355 (2000):  134-8[46] \"Product Information. Zyvox (linezolid).\" Pharmacia and Upjohn  (2001):[47] Perry NK \"Venlafaxine-induced serotonin syndrome with relapse following amitriptyline.\" Postgrad Med J 76 (2000):  254-6[48] Manos GH \"Possible serotonin syndrome associated with buspirone added to fluoxetine.\" Ann Pharmacother 34 (2000):  871-4[49] Nijhawan PK, Katz G, Winter S \"Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission.\" Crit Care Med 24 (1996):  1086-9[50] Laird LK \"Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder.\" Psychopharmacol Bull 32 (1996):  569-78[51] Margolese HC, Chouinard G \"Serotonin syndrome from addition of low-dose trazodone to nefazodone.\" Am J Psychiatry 157 (2000):  1022[52] Mackay FJ, Dunn NR, Mann RD \"Antidepressants and the serotonin syndrome in general practice.\" Br J Gen Pract 49 (1999):  871-4[53] Smith DL, Wenegrat BG \"A case report of serotonin syndrome associated with combined nefazodone and fluoxetine.\" J Clin Psychiatry 61 (2000):  146[54] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[55] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001):  2163-75[56] Duggal HS, Fetchko J \"Serotonin syndrome and atypical antipsychotics.\" Am J Psychiatry 159 (2002):  672-3[57] Wigen CL, Goetz MB \"Serotonin syndrome and linezolid.\" Clin Infect Dis 34 (2002):  1651-2[58] Hammerness P, Parada H, Abrams A \"Linezolid: MAOI Activity and Potential Drug Interactions.\" Psychosomatics 43 (2002):  248-9[59] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[60] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[61] Turkel SB, Nadala JG, Wincor MZ \"Possible serotonin syndrome in association with 5-HT3 antagonist agents.\" Psychosomatics 42 (2001):  258-60[62] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[63] Lavery S, Ravi H, McDaniel WW, Pushkin YR \"Linezolid and serotonin syndrome.\" Psychosomatics 42 (2001):  432-4[64] Lane R, Baldwin D \"Selective serotonin reuptake inhibitor--induced serotonin syndrome: review.\" J Clin Psychopharmacol 17 (1997):  208-21[65] Bernard L, Stern R, Lew D, Hoffmeyer P \"Serotonin syndrome after concomitant treatment with linezolid and citalopram.\" Clin Infect Dis 36 (2003):  1197[66] Dannawi M \"Possible serotonin syndrome after combination of buspirone and St John's Wort.\" J Psychopharmacol 16 (2002):  401[67] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[68] Hachem RY, Hicks K, Huen A, Raad I \"Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients.\" Clin Infect Dis 37 (2003):  E8-E11[69] Gillman PK \"Linezolid and serotonin toxicity.\" Clin Infect Dis 37 (2003):  1274-5[70] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[71] Giese SY, Neborsky R \"Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl.\" Plast Reconstr Surg 107 (2001):  293-4[72] Jones SL, Athan E, O'Brien D \"Serotonin syndrome due to co-administration of linezolid and venlafaxine.\" J Antimicrob Chemother 54 (2004):  289-90[73] Tahir N \"Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram.\" J Am Med Dir Assoc 5 (2004):  111-3[74] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company  (2004):[75] Thomas CR, Rosenberg M, Blythe V, Meyer WJ 3rd \"Serotonin syndrome and linezolid.\" J Am Acad Child Adolesc Psychiatry 43 (2004):  790[76] Boyer EW, Shannon M \"The serotonin syndrome.\" N Engl J Med 352 (2005):  1112-20[77] Bergeron L, Boule M, Perreault S \"Serotonin toxicity associated with concomitant use of linezolid.\" Ann Pharmacother 39 (2005):  956-61[78] Morales N, Vermette H \"Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine.\" Psychosomatics 46 (2005):  274-5[79] Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M, Grau S \"Linezolid-associated serotonin syndrome: what we can learn from cases reported so far.\" J Antimicrob Chemother 56 (2005):  1176-8[80] DeBellis RJ, Schaefer OP, Liquori M, Volturo GA \"Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient.\" J Intensive Care Med 20 (2005):  351-3[81] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[82] Taylor JJ, Wilson JW, Estes LL \"Linezolid and serotonergic drug interactions: a retrospective survey.\" Clin Infect Dis 43 (2006):  180-7[83] Strouse TB, Kerrihard TN, Forscher CA, Zakowski P \"Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine.\" J Clin Psychopharmacol 26 (2006):  681-683[84] Keegan MT, Brown DR, Rabinstein AA \"Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs.\" Anesth Analg 103 (2006):  1466-8[85] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S \"Rare case of serotonin syndrome with therapeutic doses of paroxetine.\" Am J Ther 13 (2006):  550-552[86] Steinberg M, Morin AK \"Mild serotonin syndrome associated with concurrent linezolid and fluoxetine.\" Am J Health Syst Pharm 64 (2007):  59-62[87] Packer S, Berman SA \"Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid.\" Am J Psychiatry 164 (2007):  346-7[88] Shapiro RE, Tepper SJ \"The serotonin syndrome, triptans, and the potential for drug-drug interactions.\" Headache 47 (2007):  266-9[89] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[90] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories  (2008):[91] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[92] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals  (2009):[93] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals  (2009):[94] Lee J, Franz L, Goforth HW \"Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine.\" Psychosomatics 50 (2009):  638-9[95] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC  (2011):[96] Mugele J, Nanagas KA, Tormoehlen LM \"Serotonin Syndrome Associated With MDPV Use: A Case Report.\" Ann Emerg Med  (2012):[97] \"Product Information. Oleptro (trazodone).\" Labopharm Inc  (2012):[98] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals  (2013):[99] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America  (2013):", "alternatives_a": "Desipramine, Esketamine, Lidocaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Pheniramine, Promethazine", "alternatives_b": "Rimegepant, Eptinezumab, Ubrogepant, Galcanezumab, Atogepant, Methysergide, Erenumab, Fremanezumab", "updated_at": 1767369485}, {"id": 242360, "ingredient1": "Frovatriptan", "ingredient2": "Doxepin (topical)", "severity": "Major", "effect": "Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John's wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.", "source": "DDInter", "management_text": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.  Patients should be closely monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.  For example, some experts suggest a 5-week washout period following use of fluoxetine and 3 weeks following the use of vortioxetine before administering another serotonergic agent.  Individual product labeling for washout periods should be consulted for current recommendations.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.", "mechanism_text": "Synergism", "recommendation": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274119/", "reference_text": "[1] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[2] Achamallah NS \"Visual hallucinations after combining fluoxetine and dextromethorphan .\" Am J Psychiatry 149 (1992):  1406[3] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993):  84-8[4] Metz A \"Interaction between fluoxetine and buspirone.\" Can J Psychiatry 35 (1990):  722-3[5] Goldberg RJ, Huk M \"Serotonin syndrome from trazodone and buspirone.\" Psychosomatics 33 (1992):  235-6[6] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation  (2002):[7] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[8] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990):  213-7[9] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics.\" J Clin Psychopharmacol 10 (1990):  48-50[10] \"Product Information. Zoloft (sertraline).\" Roerig Division  (2001):[11] \"Product Information. Prozac (fluoxetine).\" Dista Products Company  (2001):[12] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[13] Insel TR, Roy BF, Cohen RM, Murphy DL \"Possible development of the serotonin syndrome in man.\" Am J Psychiatry 139 (1982):  954-5[14] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories  (2001):[15] Gilman AG, eds., Nies AS, Rall TW, Taylor P \"Goodman and Gilman's the Pharmacological Basis of Therapeutics.\" New York, NY: Pergamon Press Inc.  (1990):[16] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline  (2001):[17] \"Product Information. Flexeril (cyclobenzaprine).\" Merck & Co., Inc  (2001):[18] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[19] \"Product Information. Imitrex (sumatriptan).\" Glaxo Wellcome  (2001):[20] Ruiz F \"Fluoxetine and the serotonin syndrome.\" Ann Emerg Med 24 (1994):  983-5[21] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc  (2001):[22] Reeves RR, Bullen JA \"Serotonin syndrome produced by paroxetine and low-dose trazodone.\" Psychosomatics 36 (1995):  159-60[23] Harvey AT, Preskorn SH \"Interactions of serotonin reuptake inhibitors with tricyclic antidepressants.\" Arch Gen Psychiatry 52 (1995):  783-4[24] Baetz M, Malcolm D \"Serotonin syndrome from fluvoxamine and buspirone.\" Can J Psychiatry 40 (1995):  428-9[25] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995):  440-2[26] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995):  481-2[27] George TP, Godleski LS \"Possible serotonin syndrome with trazodone addition to fluoxetine.\" Biol Psychiatry 39 (1996):  384-5[28] Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM \"The serotonin syndrome associated wtih paroxetine, an over-the-counter cold remedy, and vascular disease.\" Am J Emerg Med 12 (1994):  642-4[29] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[30] John L, Perreault MM, Tao T, Blew PG \"Serotonin syndrome associated with nefazodone and paroxetine.\" Ann Emerg Med 29 (1997):  287-9[31] \"Product Information. Zomig (zolmitriptan).\" Astra-Zeneca Pharmaceuticals  (2001):[32] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[33] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[34] Bhatara VS, Magnus RD, Paul KL, Preskorn SH \"Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms.\" Ann Pharmacother 32 (1998):  432-6[35] \"Product Information. Maxalt (rizatriptan).\" Merck & Co., Inc  (2001):[36] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals  (2001):[37] Gardner DM, Lynd LD \"Sumatriptan contraindications and the serotonin syndrome.\" Ann Pharmacother 32 (1998):  33-8[38] Mathew NT, Tietjen GE, Lucker C \"Serotonin syndrome complicating migraine pharmacotherapy.\" Cephalalgia 16 (1996):  323-7[39] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[40] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[41] Weiner AL \"Meperidine as a potential cause of serotonin syndrome in the emergency department.\" Acad Emerg Med 6 (1999):  156-8[42] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[43] Gordon JB \"SSRI's and St. John's Wort: possible toxicity?\" Am Fam Physician 57 (1998):  950,953[44] Lantz MS, Buchalter E, Giambanco V \"St. John's wort and antidepressant drug interactions in the elderly.\" J Geriatr Psychiatr Neurol 12 (1999):  7-10[45] Fugh-Berman A \"Herb-drug interactions.\" Lancet 355 (2000):  134-8[46] \"Product Information. Zyvox (linezolid).\" Pharmacia and Upjohn  (2001):[47] Perry NK \"Venlafaxine-induced serotonin syndrome with relapse following amitriptyline.\" Postgrad Med J 76 (2000):  254-6[48] Manos GH \"Possible serotonin syndrome associated with buspirone added to fluoxetine.\" Ann Pharmacother 34 (2000):  871-4[49] Nijhawan PK, Katz G, Winter S \"Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission.\" Crit Care Med 24 (1996):  1086-9[50] Laird LK \"Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder.\" Psychopharmacol Bull 32 (1996):  569-78[51] Margolese HC, Chouinard G \"Serotonin syndrome from addition of low-dose trazodone to nefazodone.\" Am J Psychiatry 157 (2000):  1022[52] Mackay FJ, Dunn NR, Mann RD \"Antidepressants and the serotonin syndrome in general practice.\" Br J Gen Pract 49 (1999):  871-4[53] Smith DL, Wenegrat BG \"A case report of serotonin syndrome associated with combined nefazodone and fluoxetine.\" J Clin Psychiatry 61 (2000):  146[54] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[55] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001):  2163-75[56] Duggal HS, Fetchko J \"Serotonin syndrome and atypical antipsychotics.\" Am J Psychiatry 159 (2002):  672-3[57] Wigen CL, Goetz MB \"Serotonin syndrome and linezolid.\" Clin Infect Dis 34 (2002):  1651-2[58] Hammerness P, Parada H, Abrams A \"Linezolid: MAOI Activity and Potential Drug Interactions.\" Psychosomatics 43 (2002):  248-9[59] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[60] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[61] Turkel SB, Nadala JG, Wincor MZ \"Possible serotonin syndrome in association with 5-HT3 antagonist agents.\" Psychosomatics 42 (2001):  258-60[62] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[63] Lavery S, Ravi H, McDaniel WW, Pushkin YR \"Linezolid and serotonin syndrome.\" Psychosomatics 42 (2001):  432-4[64] Lane R, Baldwin D \"Selective serotonin reuptake inhibitor--induced serotonin syndrome: review.\" J Clin Psychopharmacol 17 (1997):  208-21[65] Bernard L, Stern R, Lew D, Hoffmeyer P \"Serotonin syndrome after concomitant treatment with linezolid and citalopram.\" Clin Infect Dis 36 (2003):  1197[66] Dannawi M \"Possible serotonin syndrome after combination of buspirone and St John's Wort.\" J Psychopharmacol 16 (2002):  401[67] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[68] Hachem RY, Hicks K, Huen A, Raad I \"Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients.\" Clin Infect Dis 37 (2003):  E8-E11[69] Gillman PK \"Linezolid and serotonin toxicity.\" Clin Infect Dis 37 (2003):  1274-5[70] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[71] Giese SY, Neborsky R \"Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl.\" Plast Reconstr Surg 107 (2001):  293-4[72] Jones SL, Athan E, O'Brien D \"Serotonin syndrome due to co-administration of linezolid and venlafaxine.\" J Antimicrob Chemother 54 (2004):  289-90[73] Tahir N \"Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram.\" J Am Med Dir Assoc 5 (2004):  111-3[74] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company  (2004):[75] Thomas CR, Rosenberg M, Blythe V, Meyer WJ 3rd \"Serotonin syndrome and linezolid.\" J Am Acad Child Adolesc Psychiatry 43 (2004):  790[76] Boyer EW, Shannon M \"The serotonin syndrome.\" N Engl J Med 352 (2005):  1112-20[77] Bergeron L, Boule M, Perreault S \"Serotonin toxicity associated with concomitant use of linezolid.\" Ann Pharmacother 39 (2005):  956-61[78] Morales N, Vermette H \"Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine.\" Psychosomatics 46 (2005):  274-5[79] Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M, Grau S \"Linezolid-associated serotonin syndrome: what we can learn from cases reported so far.\" J Antimicrob Chemother 56 (2005):  1176-8[80] DeBellis RJ, Schaefer OP, Liquori M, Volturo GA \"Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient.\" J Intensive Care Med 20 (2005):  351-3[81] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[82] Taylor JJ, Wilson JW, Estes LL \"Linezolid and serotonergic drug interactions: a retrospective survey.\" Clin Infect Dis 43 (2006):  180-7[83] Strouse TB, Kerrihard TN, Forscher CA, Zakowski P \"Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine.\" J Clin Psychopharmacol 26 (2006):  681-683[84] Keegan MT, Brown DR, Rabinstein AA \"Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs.\" Anesth Analg 103 (2006):  1466-8[85] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S \"Rare case of serotonin syndrome with therapeutic doses of paroxetine.\" Am J Ther 13 (2006):  550-552[86] Steinberg M, Morin AK \"Mild serotonin syndrome associated with concurrent linezolid and fluoxetine.\" Am J Health Syst Pharm 64 (2007):  59-62[87] Packer S, Berman SA \"Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid.\" Am J Psychiatry 164 (2007):  346-7[88] Shapiro RE, Tepper SJ \"The serotonin syndrome, triptans, and the potential for drug-drug interactions.\" Headache 47 (2007):  266-9[89] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[90] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories  (2008):[91] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[92] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals  (2009):[93] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals  (2009):[94] Lee J, Franz L, Goforth HW \"Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine.\" Psychosomatics 50 (2009):  638-9[95] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC  (2011):[96] Mugele J, Nanagas KA, Tormoehlen LM \"Serotonin Syndrome Associated With MDPV Use: A Case Report.\" Ann Emerg Med  (2012):[97] \"Product Information. Oleptro (trazodone).\" Labopharm Inc  (2012):[98] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals  (2013):[99] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America  (2013):", "alternatives_a": "Bupropion, Viloxazine, Esketamine, Lidocaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Pheniramine, Promethazine", "alternatives_b": "Rimegepant, Eptinezumab, Ubrogepant, Galcanezumab, Atogepant, Methysergide, Erenumab, Fremanezumab", "updated_at": 1767369485}, {"id": 242361, "ingredient1": "Doxepin (topical)", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274124/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone, Lidocaine, Tetracaine", "alternatives_b": "Tolcapone, Entacapone, Cabergoline", "updated_at": 1767369485}, {"id": 242362, "ingredient1": "Doxepin (topical)", "ingredient2": "Melatonin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274127/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Vilazodone, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Bupropion, Esketamine, Lidocaine, Tetracaine", "alternatives_b": "Nitrazepam, Ethchlorvynol, Zopiclone, Zaleplon, Dichloralphenazone", "updated_at": 1767369485}, {"id": 242363, "ingredient1": "Doxepin (topical)", "ingredient2": "Botulinum toxin type A", "severity": "Moderate", "effect": "Use of anticholinergic drugs after administration of botulinum toxin may potentiate systemic anticholinergic effects such as dry mouth, blurred vision, and urinary disorders.  Botulinum toxin inhibits the release of acetylcholine from peripheral cholinergic nerve endings, thus additive or synergistic anticholinergic effects may occur when these agents are used together.", "source": "DDInter", "management_text": "Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) are used after administration of botulinum toxin.", "mechanism_text": "Synergism", "recommendation": "Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274132/", "reference_text": "[1] \"Product Information. Myobloc (rimabotulinumtoxinB).\" Elan Pharmaceuticals[2] \"Product Information. Dysport (abobotulinumtoxinA).\" Tercica Inc[3] \"Product Information. Botox (onabotulinumtoxinA).\" Allergan Inc[4] \"Product Information. Xeomin (incobotulinumtoxinA).\" Merz Pharmaceuticals  (2022):[5] \"Product Information. Jeuveau (prabotulinumtoxinA).\" Evolus, Inc.  (2022):[6] \"Product Information. Daxxify (daxibotulinumtoxinA).\" Revance Therapeutics, Inc.  (2022):", "alternatives_a": "Citalopram, Sertraline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Isocarboxazid, Viloxazine, Esketamine, More", "alternatives_b": "Atracurium, Doxacurium, Succinylcholine, Rocuronium, Vecuronium, Tubocurarine, Mivacurium, Pancuronium, Pipecuronium, Cisatracurium", "updated_at": 1767369485}, {"id": 242364, "ingredient1": "Doxepin (topical)", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274135/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Phenelzine, Duloxetine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Bupropion, More", "alternatives_b": "Dabrafenib, Acalabrutinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Lapatinib, Selumetinib, Ribociclib, Cobimetinib, More", "updated_at": 1767369485}, {"id": 242365, "ingredient1": "Doxepin (topical)", "ingredient2": "Botulinum toxin type B", "severity": "Moderate", "effect": "Use of anticholinergic drugs after administration of botulinum toxin may potentiate systemic anticholinergic effects such as dry mouth, blurred vision, and urinary disorders.  Botulinum toxin inhibits the release of acetylcholine from peripheral cholinergic nerve endings, thus additive or synergistic anticholinergic effects may occur when these agents are used together.", "source": "DDInter", "management_text": "Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) are used after administration of botulinum toxin.", "mechanism_text": "Synergism", "recommendation": "Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274137/", "reference_text": "[1] \"Product Information. Myobloc (rimabotulinumtoxinB).\" Elan Pharmaceuticals[2] \"Product Information. Dysport (abobotulinumtoxinA).\" Tercica Inc[3] \"Product Information. Botox (onabotulinumtoxinA).\" Allergan Inc[4] \"Product Information. Xeomin (incobotulinumtoxinA).\" Merz Pharmaceuticals  (2022):[5] \"Product Information. Jeuveau (prabotulinumtoxinA).\" Evolus, Inc.  (2022):[6] \"Product Information. Daxxify (daxibotulinumtoxinA).\" Revance Therapeutics, Inc.  (2022):", "alternatives_a": "Citalopram, Sertraline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Isocarboxazid, Viloxazine, Esketamine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242366, "ingredient1": "Doxepin (topical)", "ingredient2": "Rizatriptan", "severity": "Major", "effect": "Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John's wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.", "source": "DDInter", "management_text": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.  Patients should be closely monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.  For example, some experts suggest a 5-week washout period following use of fluoxetine and 3 weeks following the use of vortioxetine before administering another serotonergic agent.  Individual product labeling for washout periods should be consulted for current recommendations.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.", "mechanism_text": "Synergism", "recommendation": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274138/", "reference_text": "[1] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[2] Achamallah NS \"Visual hallucinations after combining fluoxetine and dextromethorphan .\" Am J Psychiatry 149 (1992):  1406[3] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993):  84-8[4] Metz A \"Interaction between fluoxetine and buspirone.\" Can J Psychiatry 35 (1990):  722-3[5] Goldberg RJ, Huk M \"Serotonin syndrome from trazodone and buspirone.\" Psychosomatics 33 (1992):  235-6[6] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation  (2002):[7] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[8] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990):  213-7[9] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics.\" J Clin Psychopharmacol 10 (1990):  48-50[10] \"Product Information. Zoloft (sertraline).\" Roerig Division  (2001):[11] \"Product Information. Prozac (fluoxetine).\" Dista Products Company  (2001):[12] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[13] Insel TR, Roy BF, Cohen RM, Murphy DL \"Possible development of the serotonin syndrome in man.\" Am J Psychiatry 139 (1982):  954-5[14] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories  (2001):[15] Gilman AG, eds., Nies AS, Rall TW, Taylor P \"Goodman and Gilman's the Pharmacological Basis of Therapeutics.\" New York, NY: Pergamon Press Inc.  (1990):[16] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline  (2001):[17] \"Product Information. Flexeril (cyclobenzaprine).\" Merck & Co., Inc  (2001):[18] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[19] \"Product Information. Imitrex (sumatriptan).\" Glaxo Wellcome  (2001):[20] Ruiz F \"Fluoxetine and the serotonin syndrome.\" Ann Emerg Med 24 (1994):  983-5[21] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc  (2001):[22] Reeves RR, Bullen JA \"Serotonin syndrome produced by paroxetine and low-dose trazodone.\" Psychosomatics 36 (1995):  159-60[23] Harvey AT, Preskorn SH \"Interactions of serotonin reuptake inhibitors with tricyclic antidepressants.\" Arch Gen Psychiatry 52 (1995):  783-4[24] Baetz M, Malcolm D \"Serotonin syndrome from fluvoxamine and buspirone.\" Can J Psychiatry 40 (1995):  428-9[25] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995):  440-2[26] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995):  481-2[27] George TP, Godleski LS \"Possible serotonin syndrome with trazodone addition to fluoxetine.\" Biol Psychiatry 39 (1996):  384-5[28] Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM \"The serotonin syndrome associated wtih paroxetine, an over-the-counter cold remedy, and vascular disease.\" Am J Emerg Med 12 (1994):  642-4[29] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[30] John L, Perreault MM, Tao T, Blew PG \"Serotonin syndrome associated with nefazodone and paroxetine.\" Ann Emerg Med 29 (1997):  287-9[31] \"Product Information. Zomig (zolmitriptan).\" Astra-Zeneca Pharmaceuticals  (2001):[32] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[33] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[34] Bhatara VS, Magnus RD, Paul KL, Preskorn SH \"Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms.\" Ann Pharmacother 32 (1998):  432-6[35] \"Product Information. Maxalt (rizatriptan).\" Merck & Co., Inc  (2001):[36] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals  (2001):[37] Gardner DM, Lynd LD \"Sumatriptan contraindications and the serotonin syndrome.\" Ann Pharmacother 32 (1998):  33-8[38] Mathew NT, Tietjen GE, Lucker C \"Serotonin syndrome complicating migraine pharmacotherapy.\" Cephalalgia 16 (1996):  323-7[39] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[40] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[41] Weiner AL \"Meperidine as a potential cause of serotonin syndrome in the emergency department.\" Acad Emerg Med 6 (1999):  156-8[42] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[43] Gordon JB \"SSRI's and St. John's Wort: possible toxicity?\" Am Fam Physician 57 (1998):  950,953[44] Lantz MS, Buchalter E, Giambanco V \"St. John's wort and antidepressant drug interactions in the elderly.\" J Geriatr Psychiatr Neurol 12 (1999):  7-10[45] Fugh-Berman A \"Herb-drug interactions.\" Lancet 355 (2000):  134-8[46] \"Product Information. Zyvox (linezolid).\" Pharmacia and Upjohn  (2001):[47] Perry NK \"Venlafaxine-induced serotonin syndrome with relapse following amitriptyline.\" Postgrad Med J 76 (2000):  254-6[48] Manos GH \"Possible serotonin syndrome associated with buspirone added to fluoxetine.\" Ann Pharmacother 34 (2000):  871-4[49] Nijhawan PK, Katz G, Winter S \"Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission.\" Crit Care Med 24 (1996):  1086-9[50] Laird LK \"Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder.\" Psychopharmacol Bull 32 (1996):  569-78[51] Margolese HC, Chouinard G \"Serotonin syndrome from addition of low-dose trazodone to nefazodone.\" Am J Psychiatry 157 (2000):  1022[52] Mackay FJ, Dunn NR, Mann RD \"Antidepressants and the serotonin syndrome in general practice.\" Br J Gen Pract 49 (1999):  871-4[53] Smith DL, Wenegrat BG \"A case report of serotonin syndrome associated with combined nefazodone and fluoxetine.\" J Clin Psychiatry 61 (2000):  146[54] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[55] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001):  2163-75[56] Duggal HS, Fetchko J \"Serotonin syndrome and atypical antipsychotics.\" Am J Psychiatry 159 (2002):  672-3[57] Wigen CL, Goetz MB \"Serotonin syndrome and linezolid.\" Clin Infect Dis 34 (2002):  1651-2[58] Hammerness P, Parada H, Abrams A \"Linezolid: MAOI Activity and Potential Drug Interactions.\" Psychosomatics 43 (2002):  248-9[59] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[60] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[61] Turkel SB, Nadala JG, Wincor MZ \"Possible serotonin syndrome in association with 5-HT3 antagonist agents.\" Psychosomatics 42 (2001):  258-60[62] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[63] Lavery S, Ravi H, McDaniel WW, Pushkin YR \"Linezolid and serotonin syndrome.\" Psychosomatics 42 (2001):  432-4[64] Lane R, Baldwin D \"Selective serotonin reuptake inhibitor--induced serotonin syndrome: review.\" J Clin Psychopharmacol 17 (1997):  208-21[65] Bernard L, Stern R, Lew D, Hoffmeyer P \"Serotonin syndrome after concomitant treatment with linezolid and citalopram.\" Clin Infect Dis 36 (2003):  1197[66] Dannawi M \"Possible serotonin syndrome after combination of buspirone and St John's Wort.\" J Psychopharmacol 16 (2002):  401[67] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[68] Hachem RY, Hicks K, Huen A, Raad I \"Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients.\" Clin Infect Dis 37 (2003):  E8-E11[69] Gillman PK \"Linezolid and serotonin toxicity.\" Clin Infect Dis 37 (2003):  1274-5[70] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[71] Giese SY, Neborsky R \"Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl.\" Plast Reconstr Surg 107 (2001):  293-4[72] Jones SL, Athan E, O'Brien D \"Serotonin syndrome due to co-administration of linezolid and venlafaxine.\" J Antimicrob Chemother 54 (2004):  289-90[73] Tahir N \"Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram.\" J Am Med Dir Assoc 5 (2004):  111-3[74] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company  (2004):[75] Thomas CR, Rosenberg M, Blythe V, Meyer WJ 3rd \"Serotonin syndrome and linezolid.\" J Am Acad Child Adolesc Psychiatry 43 (2004):  790[76] Boyer EW, Shannon M \"The serotonin syndrome.\" N Engl J Med 352 (2005):  1112-20[77] Bergeron L, Boule M, Perreault S \"Serotonin toxicity associated with concomitant use of linezolid.\" Ann Pharmacother 39 (2005):  956-61[78] Morales N, Vermette H \"Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine.\" Psychosomatics 46 (2005):  274-5[79] Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M, Grau S \"Linezolid-associated serotonin syndrome: what we can learn from cases reported so far.\" J Antimicrob Chemother 56 (2005):  1176-8[80] DeBellis RJ, Schaefer OP, Liquori M, Volturo GA \"Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient.\" J Intensive Care Med 20 (2005):  351-3[81] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[82] Taylor JJ, Wilson JW, Estes LL \"Linezolid and serotonergic drug interactions: a retrospective survey.\" Clin Infect Dis 43 (2006):  180-7[83] Strouse TB, Kerrihard TN, Forscher CA, Zakowski P \"Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine.\" J Clin Psychopharmacol 26 (2006):  681-683[84] Keegan MT, Brown DR, Rabinstein AA \"Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs.\" Anesth Analg 103 (2006):  1466-8[85] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S \"Rare case of serotonin syndrome with therapeutic doses of paroxetine.\" Am J Ther 13 (2006):  550-552[86] Steinberg M, Morin AK \"Mild serotonin syndrome associated with concurrent linezolid and fluoxetine.\" Am J Health Syst Pharm 64 (2007):  59-62[87] Packer S, Berman SA \"Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid.\" Am J Psychiatry 164 (2007):  346-7[88] Shapiro RE, Tepper SJ \"The serotonin syndrome, triptans, and the potential for drug-drug interactions.\" Headache 47 (2007):  266-9[89] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[90] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories  (2008):[91] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[92] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals  (2009):[93] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals  (2009):[94] Lee J, Franz L, Goforth HW \"Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine.\" Psychosomatics 50 (2009):  638-9[95] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC  (2011):[96] Mugele J, Nanagas KA, Tormoehlen LM \"Serotonin Syndrome Associated With MDPV Use: A Case Report.\" Ann Emerg Med  (2012):[97] \"Product Information. Oleptro (trazodone).\" Labopharm Inc  (2012):[98] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals  (2013):[99] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America  (2013):", "alternatives_a": "Viloxazine, Esketamine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Pheniramine", "alternatives_b": "Rimegepant, Eptinezumab, Ubrogepant, Galcanezumab, Atogepant, Methysergide, Erenumab, Fremanezumab", "updated_at": 1767369485}, {"id": 242367, "ingredient1": "Doxercalciferol", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274155/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Etelcalcetide, Salmon calcitonin, Calcifediol", "alternatives_b": "Entrectinib, Imatinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, More", "updated_at": 1767369485}, {"id": 242368, "ingredient1": "Ethotoin", "ingredient2": "Doxorubicin", "severity": "Moderate", "effect": "Cases have been reported in which patients receiving chemotherapy have experienced markedly reduced plasma phenytoin concentrations and seizures.", "source": "DDInter", "management_text": "It may be necessary to increase phenytoin dosage during chemotherapy and to decrease it after or between courses of chemotherapy.  Intravenous phenytoin may be less likely to interact with chemotherapy.  Careful monitoring of patients for seizure activity is recommended, as is monitoring of plasma phenytoin levels.", "mechanism_text": "Others", "recommendation": "It may be necessary to increase phenytoin dosage during chemotherapy and to decrease it after or between courses of chemotherapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274157/", "reference_text": "[1] Jarosinski PF, Moscow JA, Alexander MS, et al. \"Altered phenytoin clearance during intensive chemotherapy for acute lymphoblastic leukemia.\" J Pediatr 112 (1988):  996-9[2] Bollini P, Riva R, Albani F, Ida, et al. \"Decreased phenytoin level during antineoplastic therapy: a case report.\" Epilepsia 24 (1983):  75-8[3] Dofferhoff AS, Berendsen HH \"Decreased phenytoin level after carboplatin treatment.\" Am J Med 89 (1990):  247[4] Fincham RW, Schottelius DD \"Decreased phenytoin levels in antineoplastic therapy.\" Ther Drug Monit 1 (1979):  277-83[5] Sylvester RK, Lewis FB, Caldwell KC, Lobell M, Perri R, Sawchuk RA \"Impaired phenytoin bioavailability secondary to cisplantin, vinblastine, and bleomycin.\" Ther Drug Monit 6 (1984):  302-5[6] Neef C, de Voogd-van der Straaten \"An interaction between cytostatic and anticonvulsant drugs.\" Clin Pharmacol Ther 43 (1988):  372-5[7] Grossman SA, Sheidler VR, Gilbert MR \"Decreased phenytoin levels in patients receiving chemotherapy.\" Am J Med 87 (1989):  505-10[8] \"Product Information. Oncovin (vincristine).\" Lilly, Eli and Company  (2001):", "alternatives_a": "Idarubicin, Valrubicin, Plicamycin, Ixabepilone, Mitoxantrone, Mitomycin, Daunorubicin, Dactinomycin, Epirubicin", "alternatives_b": "Tiagabine, Brivaracetam, Cannabidiol, Methsuximide, Paramethadione, Zonisamide, Perampanel, Fenfluramine, Phensuximide, Ganaxolone, Phenacemide, More", "updated_at": 1767369485}, {"id": 242369, "ingredient1": "Doxorubicin", "ingredient2": "Mephenytoin", "severity": "Moderate", "effect": "Cases have been reported in which patients receiving chemotherapy have experienced markedly reduced plasma phenytoin concentrations and seizures.", "source": "DDInter", "management_text": "It may be necessary to increase phenytoin dosage during chemotherapy and to decrease it after or between courses of chemotherapy.  Intravenous phenytoin may be less likely to interact with chemotherapy.  Careful monitoring of patients for seizure activity is recommended, as is monitoring of plasma phenytoin levels.", "mechanism_text": "Others", "recommendation": "It may be necessary to increase phenytoin dosage during chemotherapy and to decrease it after or between courses of chemotherapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274158/", "reference_text": "[1] Jarosinski PF, Moscow JA, Alexander MS, et al. \"Altered phenytoin clearance during intensive chemotherapy for acute lymphoblastic leukemia.\" J Pediatr 112 (1988):  996-9[2] Bollini P, Riva R, Albani F, Ida, et al. \"Decreased phenytoin level during antineoplastic therapy: a case report.\" Epilepsia 24 (1983):  75-8[3] Dofferhoff AS, Berendsen HH \"Decreased phenytoin level after carboplatin treatment.\" Am J Med 89 (1990):  247[4] Fincham RW, Schottelius DD \"Decreased phenytoin levels in antineoplastic therapy.\" Ther Drug Monit 1 (1979):  277-83[5] Sylvester RK, Lewis FB, Caldwell KC, Lobell M, Perri R, Sawchuk RA \"Impaired phenytoin bioavailability secondary to cisplantin, vinblastine, and bleomycin.\" Ther Drug Monit 6 (1984):  302-5[6] Neef C, de Voogd-van der Straaten \"An interaction between cytostatic and anticonvulsant drugs.\" Clin Pharmacol Ther 43 (1988):  372-5[7] Grossman SA, Sheidler VR, Gilbert MR \"Decreased phenytoin levels in patients receiving chemotherapy.\" Am J Med 87 (1989):  505-10[8] \"Product Information. Oncovin (vincristine).\" Lilly, Eli and Company  (2001):", "alternatives_a": "Idarubicin, Valrubicin, Plicamycin, Ixabepilone, Mitoxantrone, Mitomycin, Daunorubicin, Dactinomycin, Epirubicin", "alternatives_b": "Tiagabine, Brivaracetam, Cannabidiol, Methsuximide, Paramethadione, Zonisamide, Perampanel, Fenfluramine, Phensuximide, Ganaxolone, Phenacemide, More", "updated_at": 1767369485}, {"id": 242370, "ingredient1": "Doxorubicin", "ingredient2": "Pegloticase", "severity": "Moderate", "effect": "Antibodies that develop during pegloticase therapy may theoretically affect the pharmacologic effects of other pegylated agents.", "source": "DDInter", "management_text": "Clinicians should be aware of the potential for diminished effects of other pegylated agents (including certain formulations of recombinant antihemophilic factor and coagulation factor IX as well as some liposomal formulations of chemotherapeutic agents such as doxorubicin and irinotecan) following treatment with pegloticase.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of the potential for diminished effects of other pegylated agents (including certain formulations of recombinant antihemophilic factor and coagulation factor IX as well as some liposomal formulations of chemotherapeutic agents such as doxorubicin and irinotecan) following treatment with pegloticase.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274159/", "reference_text": "[1] \"Product Information. Krystexxa (pegloticase).\" Savient Pharmaceuticals  (2010):", "alternatives_a": "Idarubicin, Valrubicin, Plicamycin, Ixabepilone, Mitoxantrone, Bleomycin, Mitomycin, Daunorubicin, Dactinomycin, Epirubicin", "alternatives_b": "Lesinurad, Febuxostat, Colchicine, Rasburicase, Probenecid", "updated_at": 1767369485}, {"id": 242371, "ingredient1": "Doxorubicin", "ingredient2": "Pegvaliase", "severity": "Moderate", "effect": "Coadministration of pegvaliase with other PEGylated products may increase the risk of hypersensitivity reactions, including anaphylaxis.", "source": "DDInter", "management_text": "Close monitoring for anaphylaxis and other hypersensitivity reactions is recommended during concomitant use of pegvaliase with other PEGylated products or products that contain polyethylene glycol (e.g., certolizumab pegol; doxorubicin liposomal; eflapegrastim; epoetin beta-methoxy polyethylene glycol; irinotecan liposomal; medroxyprogesterone acetate suspension; naloxegol; pegademase bovine; pegaptanib; pegaspargase; pegfilgrastim; peginesatide; peginterferons; pegloticase; pegvisomant; certain formulations of recombinant antihemophilic factor and coagulation factor IX).", "mechanism_text": "Synergism", "recommendation": "Close monitoring for anaphylaxis and other hypersensitivity reactions is recommended during concomitant use of pegvaliase with other PEGylated products or products that contain polyethylene glycol (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274160/", "reference_text": "[1] \"Product Information. Palynziq (pegvaliase).\" BioMarin Pharmaceutical Inc  (2018):", "alternatives_a": "Idarubicin, Valrubicin, Plicamycin, Ixabepilone, Mitoxantrone, Bleomycin, Mitomycin, Daunorubicin, Dactinomycin, Epirubicin", "alternatives_b": "Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Zinc acetate, Nitisinone, Levocarnitine, Laronidase, More", "updated_at": 1767369485}, {"id": 242372, "ingredient1": "Fenfluramine", "ingredient2": "Doxylamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274164/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Dexfenfluramine, Naltrexone, Ephedrine, Bupropion, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol, Lacosamide", "updated_at": 1767369485}, {"id": 242373, "ingredient1": "Guanfacine", "ingredient2": "Doxylamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274168/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Levocetirizine, Chlorcyclizine, Cetirizine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, Fexofenadine, Meclizine, More", "alternatives_b": "Rauwolfia serpentina root, Reserpine, Deserpidine", "updated_at": 1767369485}, {"id": 242374, "ingredient1": "Doxylamine", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274169/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Cabergoline", "updated_at": 1767369485}, {"id": 242375, "ingredient1": "Doxylamine", "ingredient2": "Melatonin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274170/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 242376, "ingredient1": "Doxylamine", "ingredient2": "Botulinum toxin type A", "severity": "Moderate", "effect": "Use of anticholinergic drugs after administration of botulinum toxin may potentiate systemic anticholinergic effects such as dry mouth, blurred vision, and urinary disorders.  Botulinum toxin inhibits the release of acetylcholine from peripheral cholinergic nerve endings, thus additive or synergistic anticholinergic effects may occur when these agents are used together.", "source": "DDInter", "management_text": "Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) are used after administration of botulinum toxin.", "mechanism_text": "Synergism", "recommendation": "Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274171/", "reference_text": "[1] \"Product Information. Myobloc (rimabotulinumtoxinB).\" Elan Pharmaceuticals[2] \"Product Information. Dysport (abobotulinumtoxinA).\" Tercica Inc[3] \"Product Information. Botox (onabotulinumtoxinA).\" Allergan Inc[4] \"Product Information. Xeomin (incobotulinumtoxinA).\" Merz Pharmaceuticals  (2022):[5] \"Product Information. Jeuveau (prabotulinumtoxinA).\" Evolus, Inc.  (2022):[6] \"Product Information. Daxxify (daxibotulinumtoxinA).\" Revance Therapeutics, Inc.  (2022):", "alternatives_a": "Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Atracurium, Doxacurium, Succinylcholine, Rocuronium, Vecuronium, Tubocurarine, Mivacurium, Pancuronium, Pipecuronium, Cisatracurium", "updated_at": 1767369485}, {"id": 242377, "ingredient1": "Doxylamine", "ingredient2": "Procainamide", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274172/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, More", "alternatives_b": "Amiodarone, Dronedarone, Tocainide, Lidocaine, Propafenone, Flecainide, Mexiletine, Dofetilide, Bretylium, Moricizine, Ibutilide", "updated_at": 1767369485}, {"id": 242378, "ingredient1": "Doxylamine", "ingredient2": "Botulinum toxin type B", "severity": "Moderate", "effect": "Use of anticholinergic drugs after administration of botulinum toxin may potentiate systemic anticholinergic effects such as dry mouth, blurred vision, and urinary disorders.  Botulinum toxin inhibits the release of acetylcholine from peripheral cholinergic nerve endings, thus additive or synergistic anticholinergic effects may occur when these agents are used together.", "source": "DDInter", "management_text": "Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) are used after administration of botulinum toxin.", "mechanism_text": "Synergism", "recommendation": "Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274173/", "reference_text": "[1] \"Product Information. Myobloc (rimabotulinumtoxinB).\" Elan Pharmaceuticals[2] \"Product Information. Dysport (abobotulinumtoxinA).\" Tercica Inc[3] \"Product Information. Botox (onabotulinumtoxinA).\" Allergan Inc[4] \"Product Information. Xeomin (incobotulinumtoxinA).\" Merz Pharmaceuticals  (2022):[5] \"Product Information. Jeuveau (prabotulinumtoxinA).\" Evolus, Inc.  (2022):[6] \"Product Information. Daxxify (daxibotulinumtoxinA).\" Revance Therapeutics, Inc.  (2022):", "alternatives_a": "Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242379, "ingredient1": "Dronabinol", "ingredient2": "Acrivastine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274175/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Granisetron, Rolapitant, Aprepitant, Dolasetron, Ondansetron, Palonosetron", "updated_at": 1767369485}, {"id": 242380, "ingredient1": "Fenfluramine", "ingredient2": "Dronabinol", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274179/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Aprepitant", "alternatives_b": "Dexfenfluramine, Naltrexone, Ephedrine, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol, Lacosamide", "updated_at": 1767369485}, {"id": 242381, "ingredient1": "Dronabinol", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274184/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Granisetron, Rolapitant, Aprepitant, Dolasetron, Ondansetron, Palonosetron", "alternatives_b": "Amantadine, Cabergoline", "updated_at": 1767369485}, {"id": 242382, "ingredient1": "Dronabinol", "ingredient2": "Melatonin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274186/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Granisetron, Rolapitant, Aprepitant, Dolasetron, Ondansetron, Palonosetron", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 242383, "ingredient1": "Dronabinol", "ingredient2": "Methotrimeprazine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274187/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Aprepitant", "alternatives_b": "Amisulpride, Pimavanserin", "updated_at": 1767369485}, {"id": 242384, "ingredient1": "Dronabinol", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274192/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Scopolamine, Nabilone", "alternatives_b": "Entrectinib, Imatinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, More", "updated_at": 1767369485}, {"id": 242385, "ingredient1": "Dronabinol", "ingredient2": "Selegiline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274194/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Granisetron, Rolapitant, Aprepitant, Dolasetron, Palonosetron", "alternatives_b": "Amantadine, Cabergoline", "updated_at": 1767369485}, {"id": 242386, "ingredient1": "Drospirenone", "ingredient2": "Dronedarone", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of drospirenone, which is partially metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution and close clinical monitoring are recommended when drospirenone is prescribed with CYP450 3A4 inhibitors, particularly in patients requiring long-term concomitant use and those with other risk factors for hyperkalemia (e.g., renal insufficiency; coadministration with medications that can increase potassium such as aldosterone antagonists, angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, nonsteroidal anti-inflammatory drugs (NSAIDs), potassium-sparing diuretics, potassium supplements, and heparin).  Consider checking serum potassium levels during the first treatment cycle and periodically thereafter as indicated.", "mechanism_text": "Metabolism", "recommendation": "Caution and close clinical monitoring are recommended when drospirenone is prescribed with CYP450 3A4 inhibitors, particularly in patients requiring long-term concomitant use and those with other risk factors for hyperkalemia (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274199/", "reference_text": "[1] \"Product Information. Victrelis (boceprevir).\" Schering-Plough Corporation  (2011):[2] \"Product Information. Slynd (drospirenone).\" Exeltis USA, Inc.  (2022):[3] \"Product Information. Angeliq (drospirenone-estradiol).\" Bayer Pharmaceutical Inc  (2017):[4] \"Product Information. Slinda (drospirenone).\" Besins Healthcare Australia Pty Ltd  (2021):[5] \"Product Information. Angeliq 1/2 (drospirenone-estradiol).\" Bayer Australia Limited  (2021):[6] \"Product Information. Slynd (drospirenone).\" Duchesnay Inc  (2021):[7] \"Product Information. Evotaz (atazanavir-cobicistat).\" Bristol-Myers Squibb  (2022):[8] \"Product Information. Evotaz (atazanavir-cobicistat).\" Bristol-Myers Squibb Australia Pty Ltd  (2023):[9] \"Product Information. Evotaz (atazanavir-cobicistat).\" Bristol-Myers Squibb Pharmaceuticals Ltd  (2021):", "alternatives_a": "Quinidine, Lidocaine, Tocainide, Propafenone, Procainamide, Flecainide, Disopyramide, Mexiletine, Dofetilide, Bretylium, Moricizine, Ibutilide", "alternatives_b": "Dienogest, Estetrol, Etynodiol, Dienogest, Etynodiol", "updated_at": 1767369485}, {"id": 242387, "ingredient1": "Droperidol", "ingredient2": "Acrivastine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274225/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine", "alternatives_b": "Amisulpride, Pimavanserin", "updated_at": 1767369485}, {"id": 242388, "ingredient1": "Droperidol", "ingredient2": "Chlorcyclizine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274228/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine", "alternatives_b": "Amisulpride, Pimavanserin", "updated_at": 1767369485}, {"id": 242389, "ingredient1": "Fenfluramine", "ingredient2": "Droperidol", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274229/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Amisulpride, Pimavanserin", "alternatives_b": "Dexfenfluramine, Ephedrine, Phentermine, Orlistat, Bupropion, Diethylpropion, Mazindol, Lacosamide", "updated_at": 1767369485}, {"id": 242390, "ingredient1": "Droperidol", "ingredient2": "Melatonin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274235/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Amisulpride, Pimavanserin", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 242391, "ingredient1": "Droperidol", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274241/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Amisulpride, Loxapine, Molindone, Thiothixene", "alternatives_b": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Tepotinib, Fedratinib, Avapritinib, Selumetinib, Cobimetinib, Ibrutinib, Afatinib, More", "updated_at": 1767369485}, {"id": 242392, "ingredient1": "Eplerenone", "ingredient2": "Drospirenone", "severity": "Moderate", "effect": "The use of drospirenone may potentiate the risk of hyperkalemia in patients receiving chronic treatment with drugs that can increase serum potassium such as angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, potassium-sparing diuretics, aldosterone antagonists, nonsteroidal anti-inflammatory drugs (NSAIDs), potassium preparations, and miscellaneous agents like cyclosporine, heparin, tacrolimus, and trimethoprim.  Drospirenone has antimineralocorticoid activity and may induce hyperkalemia in susceptible patients.", "source": "DDInter", "management_text": "Serum potassium levels should be checked regularly during concomitant therapy with drospirenone and other agents that can increase serum potassium.  Particular caution is warranted in patients with renal impairment, diabetes, old age, severe or worsening heart failure, or dehydration.  Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Serum potassium levels should be checked regularly during concomitant therapy with drospirenone and other agents that can increase serum potassium.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274247/", "reference_text": "[1] Ponce SP, Jennings AE, Madias NE, Harrington JT \"Drug-induced hyperkalemia.\" Medicine (Baltimore) 64 (1985):  357-70[2] \"Product Information. Yasmin (drospirenone-ethinyl estradiol).\" Berlex Laboratories  (2001):", "alternatives_a": "Ulipristal, Norethisterone, Norelgestromin, Etonogestrel, Megestrol acetate, Norgestimate, Etynodiol, Estradiol, Levonorgestrel, Medroxyprogesterone acetate, Desogestrel, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242393, "ingredient1": "Fedratinib", "ingredient2": "Drospirenone", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of drospirenone, which is partially metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution and close clinical monitoring are recommended when drospirenone is prescribed with CYP450 3A4 inhibitors, particularly in patients requiring long-term concomitant use and those with other risk factors for hyperkalemia (e.g., renal insufficiency; coadministration with medications that can increase potassium such as aldosterone antagonists, angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, nonsteroidal anti-inflammatory drugs (NSAIDs), potassium-sparing diuretics, potassium supplements, and heparin).  Consider checking serum potassium levels during the first treatment cycle and periodically thereafter as indicated.", "mechanism_text": "Metabolism", "recommendation": "Caution and close clinical monitoring are recommended when drospirenone is prescribed with CYP450 3A4 inhibitors, particularly in patients requiring long-term concomitant use and those with other risk factors for hyperkalemia (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274248/", "reference_text": "[1] \"Product Information. Victrelis (boceprevir).\" Schering-Plough Corporation  (2011):[2] \"Product Information. Slynd (drospirenone).\" Exeltis USA, Inc.  (2022):[3] \"Product Information. Angeliq (drospirenone-estradiol).\" Bayer Pharmaceutical Inc  (2017):[4] \"Product Information. Slinda (drospirenone).\" Besins Healthcare Australia Pty Ltd  (2021):[5] \"Product Information. Angeliq 1/2 (drospirenone-estradiol).\" Bayer Australia Limited  (2021):[6] \"Product Information. Slynd (drospirenone).\" Duchesnay Inc  (2021):[7] \"Product Information. Evotaz (atazanavir-cobicistat).\" Bristol-Myers Squibb  (2022):[8] \"Product Information. Evotaz (atazanavir-cobicistat).\" Bristol-Myers Squibb Australia Pty Ltd  (2023):[9] \"Product Information. Evotaz (atazanavir-cobicistat).\" Bristol-Myers Squibb Pharmaceuticals Ltd  (2021):", "alternatives_a": "Dienogest, Estetrol, Etynodiol, Dienogest, Etynodiol", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Zanubrutinib, More", "updated_at": 1767369485}, {"id": 242394, "ingredient1": "Fluvoxamine", "ingredient2": "Drospirenone", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of drospirenone, which is partially metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution and close clinical monitoring are recommended when drospirenone is prescribed with CYP450 3A4 inhibitors, particularly in patients requiring long-term concomitant use and those with other risk factors for hyperkalemia (e.g., renal insufficiency; coadministration with medications that can increase potassium such as aldosterone antagonists, angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, nonsteroidal anti-inflammatory drugs (NSAIDs), potassium-sparing diuretics, potassium supplements, and heparin).  Consider checking serum potassium levels during the first treatment cycle and periodically thereafter as indicated.", "mechanism_text": "Metabolism", "recommendation": "Caution and close clinical monitoring are recommended when drospirenone is prescribed with CYP450 3A4 inhibitors, particularly in patients requiring long-term concomitant use and those with other risk factors for hyperkalemia (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274251/", "reference_text": "[1] \"Product Information. Victrelis (boceprevir).\" Schering-Plough Corporation  (2011):[2] \"Product Information. Slynd (drospirenone).\" Exeltis USA, Inc.  (2022):[3] \"Product Information. Angeliq (drospirenone-estradiol).\" Bayer Pharmaceutical Inc  (2017):[4] \"Product Information. Slinda (drospirenone).\" Besins Healthcare Australia Pty Ltd  (2021):[5] \"Product Information. Angeliq 1/2 (drospirenone-estradiol).\" Bayer Australia Limited  (2021):[6] \"Product Information. Slynd (drospirenone).\" Duchesnay Inc  (2021):[7] \"Product Information. Evotaz (atazanavir-cobicistat).\" Bristol-Myers Squibb  (2022):[8] \"Product Information. Evotaz (atazanavir-cobicistat).\" Bristol-Myers Squibb Australia Pty Ltd  (2023):[9] \"Product Information. Evotaz (atazanavir-cobicistat).\" Bristol-Myers Squibb Pharmaceuticals Ltd  (2021):", "alternatives_a": "Norelgestromin, Megestrol acetate, Etynodiol, Dienogest, Estetrol, Megestrol acetate, Dienogest, Etynodiol", "alternatives_b": "Citalopram, Sertraline, Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Isocarboxazid, Amoxapine, More", "updated_at": 1767369485}, {"id": 242395, "ingredient1": "Goldenseal", "ingredient2": "Drospirenone", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of drospirenone, which is partially metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution and close clinical monitoring are recommended when drospirenone is prescribed with CYP450 3A4 inhibitors, particularly in patients requiring long-term concomitant use and those with other risk factors for hyperkalemia (e.g., renal insufficiency; coadministration with medications that can increase potassium such as aldosterone antagonists, angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, nonsteroidal anti-inflammatory drugs (NSAIDs), potassium-sparing diuretics, potassium supplements, and heparin).  Consider checking serum potassium levels during the first treatment cycle and periodically thereafter as indicated.", "mechanism_text": "Metabolism", "recommendation": "Caution and close clinical monitoring are recommended when drospirenone is prescribed with CYP450 3A4 inhibitors, particularly in patients requiring long-term concomitant use and those with other risk factors for hyperkalemia (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274253/", "reference_text": "[1] \"Product Information. Victrelis (boceprevir).\" Schering-Plough Corporation  (2011):[2] \"Product Information. Slynd (drospirenone).\" Exeltis USA, Inc.  (2022):[3] \"Product Information. Angeliq (drospirenone-estradiol).\" Bayer Pharmaceutical Inc  (2017):[4] \"Product Information. Slinda (drospirenone).\" Besins Healthcare Australia Pty Ltd  (2021):[5] \"Product Information. Angeliq 1/2 (drospirenone-estradiol).\" Bayer Australia Limited  (2021):[6] \"Product Information. Slynd (drospirenone).\" Duchesnay Inc  (2021):[7] \"Product Information. Evotaz (atazanavir-cobicistat).\" Bristol-Myers Squibb  (2022):[8] \"Product Information. Evotaz (atazanavir-cobicistat).\" Bristol-Myers Squibb Australia Pty Ltd  (2023):[9] \"Product Information. Evotaz (atazanavir-cobicistat).\" Bristol-Myers Squibb Pharmaceuticals Ltd  (2021):", "alternatives_a": "Norelgestromin, Norethisterone, Etonogestrel, Megestrol acetate, Norgestimate, Etynodiol, Estradiol, Levonorgestrel, Medroxyprogesterone acetate, Desogestrel, Dienogest, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242396, "ingredient1": "Grepafloxacin", "ingredient2": "Drospirenone", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of drospirenone, which is partially metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution and close clinical monitoring are recommended when drospirenone is prescribed with CYP450 3A4 inhibitors, particularly in patients requiring long-term concomitant use and those with other risk factors for hyperkalemia (e.g., renal insufficiency; coadministration with medications that can increase potassium such as aldosterone antagonists, angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, nonsteroidal anti-inflammatory drugs (NSAIDs), potassium-sparing diuretics, potassium supplements, and heparin).  Consider checking serum potassium levels during the first treatment cycle and periodically thereafter as indicated.", "mechanism_text": "Metabolism", "recommendation": "Caution and close clinical monitoring are recommended when drospirenone is prescribed with CYP450 3A4 inhibitors, particularly in patients requiring long-term concomitant use and those with other risk factors for hyperkalemia (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274254/", "reference_text": "[1] \"Product Information. Victrelis (boceprevir).\" Schering-Plough Corporation  (2011):[2] \"Product Information. Slynd (drospirenone).\" Exeltis USA, Inc.  (2022):[3] \"Product Information. Angeliq (drospirenone-estradiol).\" Bayer Pharmaceutical Inc  (2017):[4] \"Product Information. Slinda (drospirenone).\" Besins Healthcare Australia Pty Ltd  (2021):[5] \"Product Information. Angeliq 1/2 (drospirenone-estradiol).\" Bayer Australia Limited  (2021):[6] \"Product Information. Slynd (drospirenone).\" Duchesnay Inc  (2021):[7] \"Product Information. Evotaz (atazanavir-cobicistat).\" Bristol-Myers Squibb  (2022):[8] \"Product Information. Evotaz (atazanavir-cobicistat).\" Bristol-Myers Squibb Australia Pty Ltd  (2023):[9] \"Product Information. Evotaz (atazanavir-cobicistat).\" Bristol-Myers Squibb Pharmaceuticals Ltd  (2021):", "alternatives_a": "Norelgestromin, Megestrol acetate, Norgestimate, Etynodiol, Estradiol, Levonorgestrel, Desogestrel, Dienogest, Estetrol, Etonogestrel, Norgestrel, More", "alternatives_b": "Enoxacin, Gatifloxacin, Norfloxacin, Levofloxacin, Nalidixic acid, Gemifloxacin, Lomefloxacin, Moxifloxacin, Cinoxacin, Trovafloxacin, Delafloxacin, More", "updated_at": 1767369485}, {"id": 242397, "ingredient1": "Imatinib", "ingredient2": "Drospirenone", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of drospirenone, which is partially metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution and close clinical monitoring are recommended when drospirenone is prescribed with CYP450 3A4 inhibitors, particularly in patients requiring long-term concomitant use and those with other risk factors for hyperkalemia (e.g., renal insufficiency; coadministration with medications that can increase potassium such as aldosterone antagonists, angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, nonsteroidal anti-inflammatory drugs (NSAIDs), potassium-sparing diuretics, potassium supplements, and heparin).  Consider checking serum potassium levels during the first treatment cycle and periodically thereafter as indicated.", "mechanism_text": "Metabolism", "recommendation": "Caution and close clinical monitoring are recommended when drospirenone is prescribed with CYP450 3A4 inhibitors, particularly in patients requiring long-term concomitant use and those with other risk factors for hyperkalemia (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274255/", "reference_text": "[1] \"Product Information. Victrelis (boceprevir).\" Schering-Plough Corporation  (2011):[2] \"Product Information. Slynd (drospirenone).\" Exeltis USA, Inc.  (2022):[3] \"Product Information. Angeliq (drospirenone-estradiol).\" Bayer Pharmaceutical Inc  (2017):[4] \"Product Information. Slinda (drospirenone).\" Besins Healthcare Australia Pty Ltd  (2021):[5] \"Product Information. Angeliq 1/2 (drospirenone-estradiol).\" Bayer Australia Limited  (2021):[6] \"Product Information. Slynd (drospirenone).\" Duchesnay Inc  (2021):[7] \"Product Information. Evotaz (atazanavir-cobicistat).\" Bristol-Myers Squibb  (2022):[8] \"Product Information. Evotaz (atazanavir-cobicistat).\" Bristol-Myers Squibb Australia Pty Ltd  (2023):[9] \"Product Information. Evotaz (atazanavir-cobicistat).\" Bristol-Myers Squibb Pharmaceuticals Ltd  (2021):", "alternatives_a": "Norelgestromin, Megestrol acetate, Norgestimate, Etynodiol, Levonorgestrel, Desogestrel, Dienogest, Estetrol, Etonogestrel, Norgestrel, Megestrol acetate, More", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Zanubrutinib, More", "updated_at": 1767369485}, {"id": 242398, "ingredient1": "Isoniazid", "ingredient2": "Drospirenone", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of drospirenone, which is partially metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution and close clinical monitoring are recommended when drospirenone is prescribed with CYP450 3A4 inhibitors, particularly in patients requiring long-term concomitant use and those with other risk factors for hyperkalemia (e.g., renal insufficiency; coadministration with medications that can increase potassium such as aldosterone antagonists, angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, nonsteroidal anti-inflammatory drugs (NSAIDs), potassium-sparing diuretics, potassium supplements, and heparin).  Consider checking serum potassium levels during the first treatment cycle and periodically thereafter as indicated.", "mechanism_text": "Metabolism", "recommendation": "Caution and close clinical monitoring are recommended when drospirenone is prescribed with CYP450 3A4 inhibitors, particularly in patients requiring long-term concomitant use and those with other risk factors for hyperkalemia (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274256/", "reference_text": "[1] \"Product Information. Victrelis (boceprevir).\" Schering-Plough Corporation  (2011):[2] \"Product Information. Slynd (drospirenone).\" Exeltis USA, Inc.  (2022):[3] \"Product Information. Angeliq (drospirenone-estradiol).\" Bayer Pharmaceutical Inc  (2017):[4] \"Product Information. Slinda (drospirenone).\" Besins Healthcare Australia Pty Ltd  (2021):[5] \"Product Information. Angeliq 1/2 (drospirenone-estradiol).\" Bayer Australia Limited  (2021):[6] \"Product Information. Slynd (drospirenone).\" Duchesnay Inc  (2021):[7] \"Product Information. Evotaz (atazanavir-cobicistat).\" Bristol-Myers Squibb  (2022):[8] \"Product Information. Evotaz (atazanavir-cobicistat).\" Bristol-Myers Squibb Australia Pty Ltd  (2023):[9] \"Product Information. Evotaz (atazanavir-cobicistat).\" Bristol-Myers Squibb Pharmaceuticals Ltd  (2021):", "alternatives_a": "Norelgestromin, Norethisterone, Etonogestrel, Megestrol acetate, Norgestimate, Etynodiol, Estradiol, Levonorgestrel, Medroxyprogesterone acetate, Desogestrel, Dienogest, More", "alternatives_b": "Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Streptomycin, Cycloserine, Ethambutol, Pyridoxine, Ethionamide, Pretomanid, Aminosalicylic acid", "updated_at": 1767369485}, {"id": 242399, "ingredient1": "Ivacaftor", "ingredient2": "Drospirenone", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of drospirenone, which is partially metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution and close clinical monitoring are recommended when drospirenone is prescribed with CYP450 3A4 inhibitors, particularly in patients requiring long-term concomitant use and those with other risk factors for hyperkalemia (e.g., renal insufficiency; coadministration with medications that can increase potassium such as aldosterone antagonists, angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, nonsteroidal anti-inflammatory drugs (NSAIDs), potassium-sparing diuretics, potassium supplements, and heparin).  Consider checking serum potassium levels during the first treatment cycle and periodically thereafter as indicated.", "mechanism_text": "Metabolism", "recommendation": "Caution and close clinical monitoring are recommended when drospirenone is prescribed with CYP450 3A4 inhibitors, particularly in patients requiring long-term concomitant use and those with other risk factors for hyperkalemia (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274257/", "reference_text": "[1] \"Product Information. Victrelis (boceprevir).\" Schering-Plough Corporation  (2011):[2] \"Product Information. Slynd (drospirenone).\" Exeltis USA, Inc.  (2022):[3] \"Product Information. Angeliq (drospirenone-estradiol).\" Bayer Pharmaceutical Inc  (2017):[4] \"Product Information. Slinda (drospirenone).\" Besins Healthcare Australia Pty Ltd  (2021):[5] \"Product Information. Angeliq 1/2 (drospirenone-estradiol).\" Bayer Australia Limited  (2021):[6] \"Product Information. Slynd (drospirenone).\" Duchesnay Inc  (2021):[7] \"Product Information. Evotaz (atazanavir-cobicistat).\" Bristol-Myers Squibb  (2022):[8] \"Product Information. Evotaz (atazanavir-cobicistat).\" Bristol-Myers Squibb Australia Pty Ltd  (2023):[9] \"Product Information. Evotaz (atazanavir-cobicistat).\" Bristol-Myers Squibb Pharmaceuticals Ltd  (2021):", "alternatives_a": "Ulipristal, Norethisterone, Norelgestromin, Norgestimate, Etynodiol, Dienogest, Estetrol, Norgestrel, Norethisterone, Progesterone, Norgestimate, More", "alternatives_b": "Nitric Oxide, Doxapram", "updated_at": 1767369485}, {"id": 242400, "ingredient1": "Drospirenone", "ingredient2": "Lanreotide", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of drospirenone, which is partially metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution and close clinical monitoring are recommended when drospirenone is prescribed with CYP450 3A4 inhibitors, particularly in patients requiring long-term concomitant use and those with other risk factors for hyperkalemia (e.g., renal insufficiency; coadministration with medications that can increase potassium such as aldosterone antagonists, angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, nonsteroidal anti-inflammatory drugs (NSAIDs), potassium-sparing diuretics, potassium supplements, and heparin).  Consider checking serum potassium levels during the first treatment cycle and periodically thereafter as indicated.", "mechanism_text": "Metabolism", "recommendation": "Caution and close clinical monitoring are recommended when drospirenone is prescribed with CYP450 3A4 inhibitors, particularly in patients requiring long-term concomitant use and those with other risk factors for hyperkalemia (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274258/", "reference_text": "[1] \"Product Information. Victrelis (boceprevir).\" Schering-Plough Corporation  (2011):[2] \"Product Information. Slynd (drospirenone).\" Exeltis USA, Inc.  (2022):[3] \"Product Information. Angeliq (drospirenone-estradiol).\" Bayer Pharmaceutical Inc  (2017):[4] \"Product Information. Slinda (drospirenone).\" Besins Healthcare Australia Pty Ltd  (2021):[5] \"Product Information. Angeliq 1/2 (drospirenone-estradiol).\" Bayer Australia Limited  (2021):[6] \"Product Information. Slynd (drospirenone).\" Duchesnay Inc  (2021):[7] \"Product Information. Evotaz (atazanavir-cobicistat).\" Bristol-Myers Squibb  (2022):[8] \"Product Information. Evotaz (atazanavir-cobicistat).\" Bristol-Myers Squibb Australia Pty Ltd  (2023):[9] \"Product Information. Evotaz (atazanavir-cobicistat).\" Bristol-Myers Squibb Pharmaceuticals Ltd  (2021):", "alternatives_a": "Ulipristal, Norethisterone, Norelgestromin, Etonogestrel, Megestrol acetate, Norgestimate, Etynodiol, Estradiol, Levonorgestrel, Medroxyprogesterone acetate, Desogestrel, More", "alternatives_b": "Norethisterone, Nafarelin, Cetrorelix, Estradiol, Ganirelix, Relugolix, Gonadorelin", "updated_at": 1767369485}, {"id": 242401, "ingredient1": "Drospirenone", "ingredient2": "Osilodrostat", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of drospirenone, which is partially metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution and close clinical monitoring are recommended when drospirenone is prescribed with CYP450 3A4 inhibitors, particularly in patients requiring long-term concomitant use and those with other risk factors for hyperkalemia (e.g., renal insufficiency; coadministration with medications that can increase potassium such as aldosterone antagonists, angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, nonsteroidal anti-inflammatory drugs (NSAIDs), potassium-sparing diuretics, potassium supplements, and heparin).  Consider checking serum potassium levels during the first treatment cycle and periodically thereafter as indicated.", "mechanism_text": "Metabolism", "recommendation": "Caution and close clinical monitoring are recommended when drospirenone is prescribed with CYP450 3A4 inhibitors, particularly in patients requiring long-term concomitant use and those with other risk factors for hyperkalemia (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274267/", "reference_text": "[1] \"Product Information. Victrelis (boceprevir).\" Schering-Plough Corporation  (2011):[2] \"Product Information. Slynd (drospirenone).\" Exeltis USA, Inc.  (2022):[3] \"Product Information. Angeliq (drospirenone-estradiol).\" Bayer Pharmaceutical Inc  (2017):[4] \"Product Information. Slinda (drospirenone).\" Besins Healthcare Australia Pty Ltd  (2021):[5] \"Product Information. Angeliq 1/2 (drospirenone-estradiol).\" Bayer Australia Limited  (2021):[6] \"Product Information. Slynd (drospirenone).\" Duchesnay Inc  (2021):[7] \"Product Information. Evotaz (atazanavir-cobicistat).\" Bristol-Myers Squibb  (2022):[8] \"Product Information. Evotaz (atazanavir-cobicistat).\" Bristol-Myers Squibb Australia Pty Ltd  (2023):[9] \"Product Information. Evotaz (atazanavir-cobicistat).\" Bristol-Myers Squibb Pharmaceuticals Ltd  (2021):", "alternatives_a": "Dienogest, Estetrol, Etynodiol, Dienogest, Etynodiol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242402, "ingredient1": "Drospirenone", "ingredient2": "Palbociclib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of drospirenone, which is partially metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution and close clinical monitoring are recommended when drospirenone is prescribed with CYP450 3A4 inhibitors, particularly in patients requiring long-term concomitant use and those with other risk factors for hyperkalemia (e.g., renal insufficiency; coadministration with medications that can increase potassium such as aldosterone antagonists, angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, nonsteroidal anti-inflammatory drugs (NSAIDs), potassium-sparing diuretics, potassium supplements, and heparin).  Consider checking serum potassium levels during the first treatment cycle and periodically thereafter as indicated.", "mechanism_text": "Metabolism", "recommendation": "Caution and close clinical monitoring are recommended when drospirenone is prescribed with CYP450 3A4 inhibitors, particularly in patients requiring long-term concomitant use and those with other risk factors for hyperkalemia (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274268/", "reference_text": "[1] \"Product Information. Victrelis (boceprevir).\" Schering-Plough Corporation  (2011):[2] \"Product Information. Slynd (drospirenone).\" Exeltis USA, Inc.  (2022):[3] \"Product Information. Angeliq (drospirenone-estradiol).\" Bayer Pharmaceutical Inc  (2017):[4] \"Product Information. Slinda (drospirenone).\" Besins Healthcare Australia Pty Ltd  (2021):[5] \"Product Information. Angeliq 1/2 (drospirenone-estradiol).\" Bayer Australia Limited  (2021):[6] \"Product Information. Slynd (drospirenone).\" Duchesnay Inc  (2021):[7] \"Product Information. Evotaz (atazanavir-cobicistat).\" Bristol-Myers Squibb  (2022):[8] \"Product Information. Evotaz (atazanavir-cobicistat).\" Bristol-Myers Squibb Australia Pty Ltd  (2023):[9] \"Product Information. Evotaz (atazanavir-cobicistat).\" Bristol-Myers Squibb Pharmaceuticals Ltd  (2021):", "alternatives_a": "Norelgestromin, Norethisterone, Etonogestrel, Megestrol acetate, Norgestimate, Etynodiol, Estradiol, Levonorgestrel, Medroxyprogesterone acetate, Desogestrel, Dienogest, More", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Zanubrutinib, More", "updated_at": 1767369485}, {"id": 242403, "ingredient1": "Drospirenone", "ingredient2": "Ribociclib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of drospirenone, which is partially metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution and close clinical monitoring are recommended when drospirenone is prescribed with CYP450 3A4 inhibitors, particularly in patients requiring long-term concomitant use and those with other risk factors for hyperkalemia (e.g., renal insufficiency; coadministration with medications that can increase potassium such as aldosterone antagonists, angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, nonsteroidal anti-inflammatory drugs (NSAIDs), potassium-sparing diuretics, potassium supplements, and heparin).  Consider checking serum potassium levels during the first treatment cycle and periodically thereafter as indicated.", "mechanism_text": "Metabolism", "recommendation": "Caution and close clinical monitoring are recommended when drospirenone is prescribed with CYP450 3A4 inhibitors, particularly in patients requiring long-term concomitant use and those with other risk factors for hyperkalemia (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274272/", "reference_text": "[1] \"Product Information. Victrelis (boceprevir).\" Schering-Plough Corporation  (2011):[2] \"Product Information. Slynd (drospirenone).\" Exeltis USA, Inc.  (2022):[3] \"Product Information. Angeliq (drospirenone-estradiol).\" Bayer Pharmaceutical Inc  (2017):[4] \"Product Information. Slinda (drospirenone).\" Besins Healthcare Australia Pty Ltd  (2021):[5] \"Product Information. Angeliq 1/2 (drospirenone-estradiol).\" Bayer Australia Limited  (2021):[6] \"Product Information. Slynd (drospirenone).\" Duchesnay Inc  (2021):[7] \"Product Information. Evotaz (atazanavir-cobicistat).\" Bristol-Myers Squibb  (2022):[8] \"Product Information. Evotaz (atazanavir-cobicistat).\" Bristol-Myers Squibb Australia Pty Ltd  (2023):[9] \"Product Information. Evotaz (atazanavir-cobicistat).\" Bristol-Myers Squibb Pharmaceuticals Ltd  (2021):", "alternatives_a": "Norelgestromin, Norethisterone, Etonogestrel, Megestrol acetate, Norgestimate, Etynodiol, Estradiol, Levonorgestrel, Medroxyprogesterone acetate, Desogestrel, Dienogest, More", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Zanubrutinib, More", "updated_at": 1767369485}, {"id": 242404, "ingredient1": "Drospirenone", "ingredient2": "Rucaparib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of drospirenone, which is partially metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution and close clinical monitoring are recommended when drospirenone is prescribed with CYP450 3A4 inhibitors, particularly in patients requiring long-term concomitant use and those with other risk factors for hyperkalemia (e.g., renal insufficiency; coadministration with medications that can increase potassium such as aldosterone antagonists, angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, nonsteroidal anti-inflammatory drugs (NSAIDs), potassium-sparing diuretics, potassium supplements, and heparin).  Consider checking serum potassium levels during the first treatment cycle and periodically thereafter as indicated.", "mechanism_text": "Metabolism", "recommendation": "Caution and close clinical monitoring are recommended when drospirenone is prescribed with CYP450 3A4 inhibitors, particularly in patients requiring long-term concomitant use and those with other risk factors for hyperkalemia (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274273/", "reference_text": "[1] \"Product Information. Victrelis (boceprevir).\" Schering-Plough Corporation  (2011):[2] \"Product Information. Slynd (drospirenone).\" Exeltis USA, Inc.  (2022):[3] \"Product Information. Angeliq (drospirenone-estradiol).\" Bayer Pharmaceutical Inc  (2017):[4] \"Product Information. Slinda (drospirenone).\" Besins Healthcare Australia Pty Ltd  (2021):[5] \"Product Information. Angeliq 1/2 (drospirenone-estradiol).\" Bayer Australia Limited  (2021):[6] \"Product Information. Slynd (drospirenone).\" Duchesnay Inc  (2021):[7] \"Product Information. Evotaz (atazanavir-cobicistat).\" Bristol-Myers Squibb  (2022):[8] \"Product Information. Evotaz (atazanavir-cobicistat).\" Bristol-Myers Squibb Australia Pty Ltd  (2023):[9] \"Product Information. Evotaz (atazanavir-cobicistat).\" Bristol-Myers Squibb Pharmaceuticals Ltd  (2021):", "alternatives_a": "Etynodiol, Levonorgestrel, Medroxyprogesterone acetate, Dienogest, Estetrol, Dienogest, Levonorgestrel, Etynodiol, Medroxyprogesterone acetate", "alternatives_b": "Pertuzumab, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Ixazomib, Porfimer sodium, Niraparib, More", "updated_at": 1767369485}, {"id": 242405, "ingredient1": "Drospirenone", "ingredient2": "Selumetinib", "severity": "Moderate", "effect": "Coadministration with selumetinib may reduce the effectiveness of hormonal contraceptives.", "source": "DDInter", "management_text": "Until further data are available, females of reproductive potential using hormonal contraceptives should be advised to add a barrier method during treatment with selumetinib and for 1 week after the final dose.  In addition, men with female partners of reproductive potential should also use effective contraception during treatment with selumetinib and for 1 week after the last dose.", "mechanism_text": "Antagonism", "recommendation": "Until further data are available, females of reproductive potential using hormonal contraceptives should be advised to add a barrier method during treatment with selumetinib and for 1 week after the final dose.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274274/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Megestrol acetate, Ulipristal, Estradiol, Megestrol acetate, Progesterone, Estradiol", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Zanubrutinib, More", "updated_at": 1767369485}, {"id": 242406, "ingredient1": "Drospirenone", "ingredient2": "Tivozanib", "severity": "Moderate", "effect": "Coadministration with tivozanib may decrease the efficacy of contraceptive hormones.", "source": "DDInter", "management_text": "Until more information is known, caution is advised when tivozanib is prescribed concomitantly with hormonal contraceptives.  Some authorities recommend that female patients of childbearing potential use an additional method of contraception.  An acceptable barrier method (e.g., diaphragm with spermicide, cervical cap with spermicide, contraceptive sponge, male condom, female condom) in addition to the hormonal contraceptive of choice may be advisable during the duration of tivozanib therapy and for at least one month after completing therapy.", "mechanism_text": "Antagonism", "recommendation": "Until more information is known, caution is advised when tivozanib is prescribed concomitantly with hormonal contraceptives.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274280/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Fotivda (tivozanib).\" Aveo Pharmaceuticals, Inc.  (2021):", "alternatives_a": "Megestrol acetate, Estetrol, Ulipristal, Estradiol, Megestrol acetate, Progesterone, Estradiol", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Zanubrutinib, More", "updated_at": 1767369485}, {"id": 242407, "ingredient1": "Drospirenone", "ingredient2": "Topiramate", "severity": "Major", "effect": "Coadministration with topiramate, particularly at dosages above 200 mg/day, may decrease the plasma concentrations and efficacy of contraceptive hormones.  The proposed mechanism is topiramate induction of CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of steroidal hormones.", "source": "DDInter", "management_text": "The potential for decreased contraceptive efficacy and increased breakthrough bleeding should be considered in patients using hormonal contraceptives (including oral, injectable, transdermal, and implantable forms) during treatment with topiramate, particularly at dosages above 200 mg/day.  Some clinicians and manufacturers recommend that patients on topiramate dosages at or above 200 mg/day who are taking oral contraceptives should receive a preparation containing no less than 30 or 35 mcg of estrogen, while others recommend at least 50 mcg.  Intrauterine systems are unlikely to be significantly affected because of their local action, thus they may be preferable to other routes of administration.  Patients should be advised to report any change in their bleeding patterns, although contraceptive efficacy can be decreased even in the absence of breakthrough bleeding.  Because use of topiramate can cause fetal harm, it is particularly important that patients not become pregnant during treatment.  Counseling should be provided regarding the use of alternative (non-hormonal) or additional (back-up) pregnancy prevention methods during and for at least 28 days after discontinuing topiramate.  Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.  Alternative, nonenzyme-inducing anticonvulsants that are not believed to interact significantly with hormonal contraceptives include clonazepam, ethosuximide, gabapentin, levetiracetam, pregabalin, tiagabine, valproic acid, vigabatrin, and zonisamide.", "mechanism_text": "Metabolism", "recommendation": "The potential for decreased contraceptive efficacy and increased breakthrough bleeding should be considered in patients using hormonal contraceptives (including oral, injectable, transdermal, and implantable forms) during treatment with topiramate, particularly at dosages above 200 mg/day.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274281/", "reference_text": "[1] \"Product Information. Depo-Provera (medroxyprogesterone).\" Pharmacia and Upjohn  (2001):[2] \"Product Information. Topamax (topiramate).\" Ortho McNeil Pharmaceutical  (2001):[3] Wilbur K, Ensom MHH \"Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants.\" Clin Pharmacokinet 38 (2000):  355-65[4] Rosenfeld WE, Doose DR, Walker SA, Nayak RK \"Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy.\" Epilepsia 38 (1997):  317-23[5] Patsalos PN, Froscher W, Pisani F, van Rijn CM \"The importance of drug interactions in epilepsy therapy.\" Epilepsia 43 (2002):  365-85[6] Doose DR, Wang SS, Padmanabhan M, Schwabe S, Jacobs D, Bialer M \"Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects.\" Epilepsia 44 (2003):  540-9[7] Nallani SC, Glauser TA, Hariparsad N, et al. \"Dose-dependent induction of cytochrome P450 (CYP) 3A4 and activation of pregnane X receptor by topiramate.\" Epilepsia 44 (2003):  1521-8[8] Bialer M, Doose DR, Murthy B, et al. \"Pharmacokinetic interactions of topiramate.\" Clin Pharmacokinet 43 (2004):  763-80[9] \"FFPRHC Guidance (April 2005). Drug interactions with hormonal contraception.\" J Fam Plann Reprod Health Care 31 (2005):  139-51[10] Perucca E \"Clinically relevant drug interactions with antiepileptic drugs.\" Br J Clin Pharmacol 61 (2006):  246-255[11] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[12] Harden CL, Leppik I \"Optimizing therapy of seizures in women who use oral contraceptives.\" Neurology 67(12 Suppl 4) (2006):  S56-8[13] Cerner Multum, Inc. \"Australian Product Information.\" O 0[14] \"Product Information. Qsymia (phentermine-topiramate).\" Vivus Inc  (2012):[15] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[16] \"Product Information. Nexplanon (etonogestrel).\" Organon Pharmaceuticals  (2017):[17] Sunaga T, Cicali B, Schmidt S, Brown J \"Comparison of contraceptive failures associated with CYP3A4-inducing drug-drug interactions by route of hormonal contraceptive in an adverse event reporting system.\" Contraception 103(Issue 4) (2021):  222-4[18] Doodipala SR \"Clinical pharmacokinetic interactions between antiepileptic drugs and hormonal contraceptives.\" Expert Rev Clin Pharmacol 3 (2010):  183-92", "alternatives_a": "Megestrol acetate, Estetrol, Megestrol acetate", "alternatives_b": "Ezogabine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, Ganaxolone, Vigabatrin, Mephenytoin, More", "updated_at": 1767369485}, {"id": 242408, "ingredient1": "Hydroxyurea", "ingredient2": "Bacillus calmette-guerin substrain tice live antigen", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274284/", "reference_text": "[1] \"Product Information. Meruvax II (rubella virus vaccine).\" Merck & Co., Inc  (2022):[2] \"Product Information. Attenuvax (measles virus vaccine).\" Merck & Co., Inc  (2022):[3] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD \"Harrison's Principles of Internal Medicine.\" New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] \"Product Information. DENGVAXIA (dengue vaccine).\" sanofi pasteur  (2022):", "alternatives_a": "Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, Anagrelide, Ivosidenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242409, "ingredient1": "Hydroxyurea", "ingredient2": "Oxybuprocaine (ophthalmic)", "severity": "Moderate", "effect": "Some topical anesthetics can be systemically absorbed and cause methemoglobinemia, particularly when applied to mucous membranes.  Coadministration with other oxidizing agents that can also induce methemoglobinemia such as injectable local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents.  Clinicians should be aware of the potential for methemoglobinemia, particularly when topical anesthetics are applied to mucous membranes or given via the oropharyngeal route.  Signs and symptoms of methemoglobinemia may be delayed some hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274285/", "reference_text": "[1] Karim A, Ahmed S, Siddiqui R, Mattana J \"Methemoglobinemia complicating topical lidocaine used during endoscopic procedures.\" Am J Med 111 (2001):  150-3[2] \"Product Information. Hurricaine (benzocaine topical).\" Beutlich  (2005):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[6] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[7] \"Product Information. Chloraseptic (benzocaine-menthol topical).\" Prestige Brands (formerly MedTech)  (2020):[8] \"Product Information. Diclona (diclofenac-lidocaine topical).\" Terrain Pharmaceuticals  (2022):", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242410, "ingredient1": "Hydroxyurea", "ingredient2": "Etidocaine", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274289/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242411, "ingredient1": "Ibritumomab tiuxetan", "ingredient2": "Hydroxyurea", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.  Dosing adjustments may be necessary.  The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274294/", "reference_text": "[1] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb  (2001):[2] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb  (2001):[3] \"Product Information. Fluorouracil (fluorouracil).\" Roche Laboratories  (2022):[4] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn  (2001):[5] \"Product Information. Ellence (epirubicin).\" Pharmacia and Upjohn  (2001):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] Agencia Espala de Medicamentos y Productos Sanitarios Healthcare \"Centro de informaci online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):", "alternatives_a": "Pertuzumab, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, More", "alternatives_b": "Tositumomab, Iodide I-131", "updated_at": 1767369485}, {"id": 242412, "ingredient1": "Hydroxyurea", "ingredient2": "Levobupivacaine", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274302/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Pertuzumab, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Enasidenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242413, "ingredient1": "Hydroxyurea", "ingredient2": "Lidocaine (ophthalmic)", "severity": "Moderate", "effect": "Some topical anesthetics can be systemically absorbed and cause methemoglobinemia, particularly when applied to mucous membranes.  Coadministration with other oxidizing agents that can also induce methemoglobinemia such as injectable local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents.  Clinicians should be aware of the potential for methemoglobinemia, particularly when topical anesthetics are applied to mucous membranes or given via the oropharyngeal route.  Signs and symptoms of methemoglobinemia may be delayed some hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274303/", "reference_text": "[1] Karim A, Ahmed S, Siddiqui R, Mattana J \"Methemoglobinemia complicating topical lidocaine used during endoscopic procedures.\" Am J Med 111 (2001):  150-3[2] \"Product Information. Hurricaine (benzocaine topical).\" Beutlich  (2005):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[6] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[7] \"Product Information. Chloraseptic (benzocaine-menthol topical).\" Prestige Brands (formerly MedTech)  (2020):[8] \"Product Information. Diclona (diclofenac-lidocaine topical).\" Terrain Pharmaceuticals  (2022):", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, More", "alternatives_b": "Clemastine, Mepyramine, Diphenhydramine, Tripelennamine, Doxepin, Pheniramine, Bacitracin, Flurbiprofen, Chlorhexidine, Povidone-iodine, Neomycin, More", "updated_at": 1767369485}, {"id": 242414, "ingredient1": "Hydroxyurea", "ingredient2": "Melphalan flufenamide", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.  Dosing adjustments may be necessary.  The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274305/", "reference_text": "[1] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb  (2001):[2] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb  (2001):[3] \"Product Information. Fluorouracil (fluorouracil).\" Roche Laboratories  (2022):[4] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn  (2001):[5] \"Product Information. Ellence (epirubicin).\" Pharmacia and Upjohn  (2001):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] Agencia Espala de Medicamentos y Productos Sanitarios Healthcare \"Centro de informaci online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):", "alternatives_a": "Pertuzumab, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, More", "alternatives_b": "Uracil mustard", "updated_at": 1767369485}, {"id": 242415, "ingredient1": "Hydroxyurea", "ingredient2": "Procaine", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274316/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, More", "alternatives_b": "Zinc sulfate, Zinc acetate, Fluocinolone acetonide, Fluocinonide, Isosorbide dinitrate, Zinc chloride, Betamethasone, Fluorometholone, Zinc gluconate", "updated_at": 1767369485}, {"id": 242416, "ingredient1": "Hydroxyurea", "ingredient2": "Proparacaine (ophthalmic)", "severity": "Moderate", "effect": "Some topical anesthetics can be systemically absorbed and cause methemoglobinemia, particularly when applied to mucous membranes.  Coadministration with other oxidizing agents that can also induce methemoglobinemia such as injectable local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents.  Clinicians should be aware of the potential for methemoglobinemia, particularly when topical anesthetics are applied to mucous membranes or given via the oropharyngeal route.  Signs and symptoms of methemoglobinemia may be delayed some hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274318/", "reference_text": "[1] Karim A, Ahmed S, Siddiqui R, Mattana J \"Methemoglobinemia complicating topical lidocaine used during endoscopic procedures.\" Am J Med 111 (2001):  150-3[2] \"Product Information. Hurricaine (benzocaine topical).\" Beutlich  (2005):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[6] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[7] \"Product Information. Chloraseptic (benzocaine-menthol topical).\" Prestige Brands (formerly MedTech)  (2020):[8] \"Product Information. Diclona (diclofenac-lidocaine topical).\" Terrain Pharmaceuticals  (2022):", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242417, "ingredient1": "Hydroxyurea", "ingredient2": "Ropivacaine", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274321/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Pertuzumab, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242418, "ingredient1": "Hydroxyurea", "ingredient2": "Tetracaine (ophthalmic)", "severity": "Moderate", "effect": "Some topical anesthetics can be systemically absorbed and cause methemoglobinemia, particularly when applied to mucous membranes.  Coadministration with other oxidizing agents that can also induce methemoglobinemia such as injectable local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents.  Clinicians should be aware of the potential for methemoglobinemia, particularly when topical anesthetics are applied to mucous membranes or given via the oropharyngeal route.  Signs and symptoms of methemoglobinemia may be delayed some hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274340/", "reference_text": "[1] Karim A, Ahmed S, Siddiqui R, Mattana J \"Methemoglobinemia complicating topical lidocaine used during endoscopic procedures.\" Am J Med 111 (2001):  150-3[2] \"Product Information. Hurricaine (benzocaine topical).\" Beutlich  (2005):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[6] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[7] \"Product Information. Chloraseptic (benzocaine-menthol topical).\" Prestige Brands (formerly MedTech)  (2020):[8] \"Product Information. Diclona (diclofenac-lidocaine topical).\" Terrain Pharmaceuticals  (2022):", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, More", "alternatives_b": "Zinc sulfate, Zinc acetate, Fluocinolone acetonide, Fluocinonide, Isosorbide dinitrate, Zinc chloride, Betamethasone, Fluorometholone, Zinc gluconate, Clemastine, Mepyramine, More", "updated_at": 1767369485}, {"id": 242419, "ingredient1": "Hydroxyurea", "ingredient2": "Varicella Zoster Vaccine (Recombinant)", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual's risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, the U.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274346/", "reference_text": "[1] \"Product Information. Fluzone (influenza virus vaccine, inactivated).\" Connaught Laboratories Inc[2] \"Product Information. Omnihib (haemophilus b conjugate vaccine (obsolete)).\" SmithKline Beecham[3] \"Product Information. Havrix (hepatitis A adult vaccine).\" SmithKline Beecham[4] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[5] \"Product Information. Imovax Rabies (rabies vaccine, human diploid cell).\" sanofi pasteur  (2022):[6] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc.  (2003):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline  (2022):[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations.  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf\"   (2019):[11] CDC Centers for Disease Control and Prevention \"Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html\"   (2022):", "alternatives_a": "Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, Anagrelide, Ivosidenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242420, "ingredient1": "Droxidopa", "ingredient2": "Ketamine", "severity": "Moderate", "effect": "Ketamine can cause hemodynamic instability such as arrhythmias and transient increases or decreases in blood pressure, heart rate, and cardiac index.  Coadministration of ketamine with direct or indirect acting sympathomimetics or vasopressin may enhance the sympathomimetic effects of ketamine leading to additive increases in blood pressure and heart rate.", "source": "DDInter", "management_text": "Close monitoring of vital signs, including blood pressure and heart rate is recommended whenever ketamine is used concomitantly with direct or indirect acting sympathomimetics or vasopressin.  Dosage adjustments should be considered according to the patient's clinical situation.  Some authorities suggest avoiding the use of ketamine in patients receiving drugs with a hypertensive effect such as ergometrine.", "mechanism_text": "Synergism", "recommendation": "Close monitoring of vital signs, including blood pressure and heart rate is recommended whenever ketamine is used concomitantly with direct or indirect acting sympathomimetics or vasopressin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274349/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Ketalar (ketamine).\" JHP Pharmaceuticals  (2009):", "alternatives_a": "Arbutamine, Amrinone, Milrinone, Angiotensin II", "alternatives_b": "Halothane, Thiopental, Alfentanil, Remifentanil, Isoflurane, Sodium oxybate, Methohexital, Fentanyl, Desflurane, Nitrous oxide, Sufentanil, More", "updated_at": 1767369485}, {"id": 242421, "ingredient1": "Dupilumab", "ingredient2": "Bacillus calmette-guerin substrain tice live antigen", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274358/", "reference_text": "[1] \"Product Information. Meruvax II (rubella virus vaccine).\" Merck & Co., Inc  (2022):[2] \"Product Information. Attenuvax (measles virus vaccine).\" Merck & Co., Inc  (2022):[3] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD \"Harrison's Principles of Internal Medicine.\" New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] \"Product Information. DENGVAXIA (dengue vaccine).\" sanofi pasteur  (2022):", "alternatives_a": "Minoxidil, Deoxycholic acid, Calcium gluconate, Magnesium sulfate, Glycopyrronium, Pimecrolimus, Aminobenzoic acid, Ivermectin, Caffeine, Diclofenac, Cromoglicic acid, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242422, "ingredient1": "Durvalumab", "ingredient2": "Bacillus calmette-guerin substrain tice live antigen", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274373/", "reference_text": "[1] \"Product Information. Meruvax II (rubella virus vaccine).\" Merck & Co., Inc  (2022):[2] \"Product Information. Attenuvax (measles virus vaccine).\" Merck & Co., Inc  (2022):[3] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD \"Harrison's Principles of Internal Medicine.\" New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] \"Product Information. DENGVAXIA (dengue vaccine).\" sanofi pasteur  (2022):", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242423, "ingredient1": "Durvalumab", "ingredient2": "Varicella Zoster Vaccine (Recombinant)", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual's risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, the U.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274423/", "reference_text": "[1] \"Product Information. Fluzone (influenza virus vaccine, inactivated).\" Connaught Laboratories Inc[2] \"Product Information. Omnihib (haemophilus b conjugate vaccine (obsolete)).\" SmithKline Beecham[3] \"Product Information. Havrix (hepatitis A adult vaccine).\" SmithKline Beecham[4] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[5] \"Product Information. Imovax Rabies (rabies vaccine, human diploid cell).\" sanofi pasteur  (2022):[6] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc.  (2003):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline  (2022):[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations.  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf\"   (2019):[11] CDC Centers for Disease Control and Prevention \"Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html\"   (2022):", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242424, "ingredient1": "Isradipine", "ingredient2": "Osilodrostat", "severity": "Moderate", "effect": "Coadministration with osilodrostat may increase the plasma concentrations of drugs that are metabolized by CYP450 1A2, 2C19, 2D6, and/or 3A4.  Osilodrostat has been shown to be a moderate inhibitor of CYP450 1A2, a mild to borderline moderate inhibitor of CYP450 2C19, and a weak inhibitor of CYP450 2D6 and 3A4.", "source": "DDInter", "management_text": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever osilodrostat is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274440/", "reference_text": "[1] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Inc  (2020):[2] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Australia Pty Ltd  (2022):[3] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases UK Ltd  (2021):", "alternatives_a": "Clevidipine, Celecoxib", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242425, "ingredient1": "Isradipine", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274443/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Clevidipine, Levamlodipine", "alternatives_b": "Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, More", "updated_at": 1767369485}, {"id": 242426, "ingredient1": "Isradipine", "ingredient2": "Pyrophosphoric acid", "severity": "Moderate", "effect": "Medicinal products including sodium heparin, prazosin, methyldopa, hydralazine, quinidine, beta blockers, calcium channel blockers, digitalis glycosides, nitrates, anthracyclines, and iodinated contrast agents may interfere with the blood pool images taken using Technetium Tc 99m pyrophosphate.  This is characterized by a reduction in the amount of injected radioactivity remaining in the blood pool.", "source": "DDInter", "management_text": "Clinicians should be aware of the possibility of a diagnostic interference.  When use of iodinated contrast media is anticipated, it is recommended to perform the scintigraphy with (99mTc)-labeled red blood cells prior to administration of the iodinated contrast media to avoid adversely affecting the red blood cell labeling.", "mechanism_text": "Distribution", "recommendation": "Clinicians should be aware of the possibility of a diagnostic interference.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274444/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Pyrophosphate (pyrophosphate).\" Pharmalucence Inc  (2012):", "alternatives_a": "Mibefradil, Celecoxib", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242427, "ingredient1": "Echinacea", "ingredient2": "Axicabtagene ciloleucel", "severity": "Minor", "effect": "Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat's claw, and zinc may antagonize the pharmacologic effects of immunosuppressants.  However, clinical cases of drug interactions have not been reported.", "source": "DDInter", "management_text": "The effect of this interaction is not well established, and the possibility of an interaction should be considered if an adverse event occurs when combining Cat's Claw with an immune-related drug.", "mechanism_text": "Others", "recommendation": "The effect of this interaction is not well established, and the possibility of an interaction should be considered if an adverse event occurs when combining Cat's Claw with an immune-related drug.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274469/", "reference_text": "[1] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[2] Pepping J \"Echinacea.\" Am J Health Syst Pharm 56 (1999):  121-2[3] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001):  2163-75[4] Therapeutic Research Faculty \"Natural Medicines Comprehensive Database.  http://www.naturaldatabase.com\"   (2008):", "alternatives_a": "Pertuzumab, Oxaliplatin, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Sotorasib, Enasidenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242428, "ingredient1": "Etacrynic acid", "ingredient2": "Polymyxin B", "severity": "Moderate", "effect": "Increased adverse effects are possible when glycopeptide, polypeptide, or polymyxin antibiotics are administered concomitantly with other potentially nephrotoxic and neurotoxic drugs.", "source": "DDInter", "management_text": "If these drugs must be used together, renal function, auditory and vestibular function, and serum drug concentrations should be monitored.", "mechanism_text": "Synergism", "recommendation": "If these drugs must be used together, renal function, auditory and vestibular function, and serum drug concentrations should be monitored.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274490/", "reference_text": "[1] \"Product Information. Vancocin (vancomycin).\" Lilly, Eli and Company  (2001):[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015):  1903-7", "alternatives_a": "Torasemide, Bumetanide", "alternatives_b": "Chloramphenicol, Rifamycin, Chlorhexidine, Miconazole, Chloramphenicol, Chlorhexidine, Tinidazole, Bacitracin, Oritavancin, Daptomycin, Metronidazole, More", "updated_at": 1767369485}, {"id": 242429, "ingredient1": "Etacrynic acid", "ingredient2": "Telavancin", "severity": "Moderate", "effect": "Increased adverse effects are possible when glycopeptide, polypeptide, or polymyxin antibiotics are administered concomitantly with other potentially nephrotoxic and neurotoxic drugs.", "source": "DDInter", "management_text": "If these drugs must be used together, renal function, auditory and vestibular function, and serum drug concentrations should be monitored.", "mechanism_text": "Synergism", "recommendation": "If these drugs must be used together, renal function, auditory and vestibular function, and serum drug concentrations should be monitored.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274494/", "reference_text": "[1] \"Product Information. Vancocin (vancomycin).\" Lilly, Eli and Company  (2001):[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015):  1903-7", "alternatives_a": "Torasemide, Bumetanide", "alternatives_b": "Tinidazole, Bacitracin, Oritavancin, Daptomycin, Metronidazole, Methenamine, Spectinomycin, Lefamulin, Nitrofurantoin, Fosfomycin, Tedizolid, Dalbavancin", "updated_at": 1767369485}, {"id": 242430, "ingredient1": "Heparin (flush)", "ingredient2": "Edoxaban", "severity": "Moderate", "effect": "Concomitant use of heparin flush and drugs that interfere with platelet function or coagulation or drugs that commonly cause thrombocytopenia may potentiate the risk of bleeding complications.  Although uncommon, inadvertent anticoagulation resulting in hemorrhagic events may occur with heparin flushes, particularly during repeated or excessive use or administration of higher concentration flush solutions.", "source": "DDInter", "management_text": "Caution and monitoring (e.g., platelet counts, hematocrits, tests for occult blood in stools) are advised when heparin flushes are given to patients receiving systemic anticoagulants, platelet inhibitors, antithrombotic agents, thrombolytics, or drugs with known risks of thrombocytopenia or bleeding.  An unexplained fall in hematocrit, fall in blood pressure, or any other unexplained symptom should lead to serious consideration of a hemorrhagic event.", "mechanism_text": "Synergism", "recommendation": "Caution and monitoring (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274501/", "reference_text": "[1] Passannante A, Macik BG \"The heparin flush syndrome: a cause of iatrogenic hemorrhage.\" Am J Med Sci 296 (1988):  71-3[2] \"Product Information. Heparin Sodium in Sodium Chloride (heparin flush).\" Baxter Healthcare Corporation  (2022):[3] \"Product Information. Canusal (heparin flush).\" Wockhardt UK Ltd  (2018):[4] \"Product Information. Heparinised Saline (Pfizer) (heparinised saline).\" Pfizer Australia Pty Ltd  (2022):", "alternatives_a": "Acenocoumarol, Selexipag", "alternatives_b": "Acenocoumarol, Selexipag, Edoxaban, Ascorbic acid, Sirolimus, Vitamin A, Potassium Iodide, Acetylcysteine, Nandrolone", "updated_at": 1767369485}, {"id": 242431, "ingredient1": "Edoxaban", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may increase the plasma concentrations of drugs that are P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), organic anion transporting polypeptide 1B1 (OATP1B1), OATP1B3, organic anion transporter 1 (OAT1), multidrug and toxin extrusion 1 (MATE1), and/or MATE2-K substrates.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of P-gp, BCRP, OATP1B1, OATP1B3, OAT1, MATE1, and/or MATE2-K, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with substrates of these transporters for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism, Excretion", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of P-gp, BCRP, OATP1B1, OATP1B3, OAT1, MATE1, and/or MATE2-K, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274510/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Caplacizumab, Argatroban, Prasugrel, Desirudin, Eptifibatide, More", "alternatives_b": "Entrectinib, Imatinib, Dabrafenib, Dacomitinib, Pexidartinib, Larotrectinib, Bosutinib, Ribociclib, Vandetanib, Cobimetinib, Afatinib, More", "updated_at": 1767369485}, {"id": 242432, "ingredient1": "Guanidine", "ingredient2": "Edrophonium", "severity": "Moderate", "effect": "A synergistic effect may be expected when acetylcholinesterase inhibitors are administered concurrently with other cholinesterase inhibitors or cholinergic agonists.", "source": "DDInter", "management_text": "Monitoring for excessive cholinergic effects and seizure activity is recommended.  Patients should be advised to notify their physician if they experience nausea, vomiting, diarrhea, abdominal pain, increased salivation, cold sweats, slow or irregular heartbeat, muscle weakness or cramps, dizziness, headache, seizures, or respiratory distress.", "mechanism_text": "Synergism", "recommendation": "Monitoring for excessive cholinergic effects and seizure activity is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274516/", "reference_text": "[1] \"Product Information. Cognex (tacrine).\" Parke-Davis  (2001):[2] \"Product Information. Aricept (donepezil).\" Pfizer U.S. Pharmaceuticals  (2001):[3] \"Product Information. Reminyl (galantamine).\" Janssen Pharmaceuticals  (2001):", "alternatives_a": "Sorbitol, Caffeine, Indocyanine green, Tolbutamide, Inulin, Hexaminolevulinate, Secretin human, Galactose, Corticorelin, Macimorelin, Methacholine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242433, "ingredient1": "Rilpivirine", "ingredient2": "Magnesium sulfate", "severity": "Moderate", "effect": "Coadministration with antacids may decrease the oral bioavailability of rilpivirine.  The proposed mechanism involves a pH-dependent reduction in dissolution and absorption of rilpivirine, which is poorly soluble over a wide pH range.", "source": "DDInter", "management_text": "To minimize the risk of reduced viral susceptibility and resistance development associated with subtherapeutic levels of rilpivirine, antacids or other medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution) should be administered at least 2 hours before or 4 hours after the rilpivirine dose.", "mechanism_text": "Absorption", "recommendation": "To minimize the risk of reduced viral susceptibility and resistance development associated with subtherapeutic levels of rilpivirine, antacids or other medications that contain antacids (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274526/", "reference_text": "[1] \"Product Information. Edurant (rilpivirine).\" Tibotec Pharmaceuticals  (2011):", "alternatives_a": "Alvimopan, Sorbitol, Methylnaltrexone, Tegaserod, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, Prucalopride, More", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, More", "updated_at": 1767369485}, {"id": 242434, "ingredient1": "Rilpivirine", "ingredient2": "Potassium bicarbonate", "severity": "Moderate", "effect": "Coadministration with antacids may decrease the oral bioavailability of rilpivirine.  The proposed mechanism involves a pH-dependent reduction in dissolution and absorption of rilpivirine, which is poorly soluble over a wide pH range.", "source": "DDInter", "management_text": "To minimize the risk of reduced viral susceptibility and resistance development associated with subtherapeutic levels of rilpivirine, antacids or other medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution) should be administered at least 2 hours before or 4 hours after the rilpivirine dose.", "mechanism_text": "Absorption", "recommendation": "To minimize the risk of reduced viral susceptibility and resistance development associated with subtherapeutic levels of rilpivirine, antacids or other medications that contain antacids (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274532/", "reference_text": "[1] \"Product Information. Edurant (rilpivirine).\" Tibotec Pharmaceuticals  (2011):", "alternatives_a": "Potassium citrate, Potassium chloride, Potassium gluconate", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More", "updated_at": 1767369485}, {"id": 242435, "ingredient1": "Rilpivirine", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274533/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, Zanubrutinib, More", "alternatives_b": "Lamivudine, Cabotegravir, Zanamivir, Valaciclovir, Dolutegravir, Oseltamivir, Acyclovir, Stavudine, Remdesivir, Elbasvir, Famciclovir, More", "updated_at": 1767369485}, {"id": 242436, "ingredient1": "Acrivastine", "ingredient2": "Venlafaxine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274578/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Meclizine, Chlorcyclizine, Thiethylperazine, Dexchlorpheniramine, Phenindamine, Methdilazine, Pheniramine", "alternatives_b": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "updated_at": 1767369485}, {"id": 242437, "ingredient1": "Cyclizine", "ingredient2": "Venlafaxine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274581/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Meclizine, Chlorcyclizine, Thiethylperazine, Dexchlorpheniramine, Phenindamine, Methdilazine, Pheniramine", "alternatives_b": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "updated_at": 1767369485}, {"id": 242438, "ingredient1": "Venlafaxine", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274589/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Amantadine", "alternatives_b": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "updated_at": 1767369485}, {"id": 242439, "ingredient1": "Venlafaxine", "ingredient2": "Melatonin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274593/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Thiopental, Ethchlorvynol, Dichloralphenazone", "alternatives_b": "Vilazodone, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Bupropion, Esketamine", "updated_at": 1767369485}, {"id": 242440, "ingredient1": "Venlafaxine", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274601/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Dabrafenib, Dacomitinib, Tepotinib, Bosutinib, Selumetinib, Cobimetinib, Capmatinib, Afatinib, Tivozanib, Brigatinib, Axitinib, More", "alternatives_b": "Phenelzine, Duloxetine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Bupropion, More", "updated_at": 1767369485}, {"id": 242441, "ingredient1": "Heparin (flush)", "ingredient2": "Prasugrel", "severity": "Moderate", "effect": "Concomitant use of heparin flush and drugs that interfere with platelet function or coagulation or drugs that commonly cause thrombocytopenia may potentiate the risk of bleeding complications.  Although uncommon, inadvertent anticoagulation resulting in hemorrhagic events may occur with heparin flushes, particularly during repeated or excessive use or administration of higher concentration flush solutions.", "source": "DDInter", "management_text": "Caution and monitoring (e.g., platelet counts, hematocrits, tests for occult blood in stools) are advised when heparin flushes are given to patients receiving systemic anticoagulants, platelet inhibitors, antithrombotic agents, thrombolytics, or drugs with known risks of thrombocytopenia or bleeding.  An unexplained fall in hematocrit, fall in blood pressure, or any other unexplained symptom should lead to serious consideration of a hemorrhagic event.", "mechanism_text": "Synergism", "recommendation": "Caution and monitoring (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274609/", "reference_text": "[1] Passannante A, Macik BG \"The heparin flush syndrome: a cause of iatrogenic hemorrhage.\" Am J Med Sci 296 (1988):  71-3[2] \"Product Information. Heparin Sodium in Sodium Chloride (heparin flush).\" Baxter Healthcare Corporation  (2022):[3] \"Product Information. Canusal (heparin flush).\" Wockhardt UK Ltd  (2018):[4] \"Product Information. Heparinised Saline (Pfizer) (heparinised saline).\" Pfizer Australia Pty Ltd  (2022):", "alternatives_a": "Prasugrel, Protein C, Acenocoumarol, Selexipag, Ascorbic acid, Cyclosporine, Sirolimus, Potassium Iodide, Vitamin A, Acetylcysteine, Nandrolone", "alternatives_b": "Acenocoumarol, Selexipag", "updated_at": 1767369485}, {"id": 242442, "ingredient1": "Fedratinib", "ingredient2": "Elagolix", "severity": "Moderate", "effect": "Coadministration with inhibitors of the OATP 1B1 hepatic uptake transporter, CYP450 3A4 metabolic isoenzyme, and/or P-glycoprotein (P-gp) efflux transporter may increase the plasma concentrations of elagolix.", "source": "DDInter", "management_text": "Caution is advised when elagolix is used with OATP 1B1, CYP450 3A4, and/or P-gp inhibitors.  Patients should be monitored for potentially altered effects of elagolix following the initiation or discontinuation of these inhibitors, and the elagolix dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when elagolix is used with OATP 1B1, CYP450 3A4, and/or P-gp inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274931/", "reference_text": "[1] \"Product Information. Orilissa (elagolix).\" AbbVie US LLC  (2018):", "alternatives_a": "Nafarelin, Octreotide, Cetrorelix, Pasireotide, Ganirelix, Relugolix, Lanreotide, Gonadorelin", "alternatives_b": "Futibatinib, Regorafenib, Lenvatinib, Erdafitinib, Pralsetinib, Asciminib, Vandetanib, Neratinib, Nintedanib, Dacomitinib, Tivozanib, Alectinib", "updated_at": 1767369485}, {"id": 242443, "ingredient1": "Elagolix", "ingredient2": "Ulipristal", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ulipristal acetate and its pharmacologically active metabolite.  Based on in vitro and pharmacokinetic data, ulipristal acetate is thought to be primarily metabolized by CYP450 3A4 to mono-demethylated and di-demethylated metabolites.", "source": "DDInter", "management_text": "When used to prevent pregnancy, ulipristal acetate should not be coadministered with CYP450 3A4 inducers due to the potential for loss of therapeutic efficacy.  For patients who have used enzyme-inducing drugs within the past 4 weeks and are seeking emergency contraception, ulipristal acetate is not recommended and a non-hormonal method (i.e.  a copper intrauterine device (Cu-IUD)) should be considered.", "mechanism_text": "Metabolism", "recommendation": "When used to prevent pregnancy, ulipristal acetate should not be coadministered with CYP450 3A4 inducers due to the potential for loss of therapeutic efficacy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/274948/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[3] \"Product Information. Esmya (ulipristal).\" Gedeon Richter (UK) Ltd  (2021):[4] \"Product Information. EllaOne (ulipristal).\" HRA Pharma UK & Ireland Ltd  (2021):", "alternatives_a": "Nafarelin, Octreotide, Cetrorelix, Pasireotide, Estradiol, Ganirelix, Lanreotide, Gonadorelin", "alternatives_b": "Ospemifene, Raloxifene, Bazedoxifene", "updated_at": 1767369485}, {"id": 242444, "ingredient1": "Acrivastine", "ingredient2": "Selegiline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275007/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Clemastine, Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Cabergoline", "updated_at": 1767369485}, {"id": 242445, "ingredient1": "Selegiline", "ingredient2": "Azatadine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275008/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Clemastine, Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Entacapone, Cabergoline", "updated_at": 1767369485}, {"id": 242446, "ingredient1": "Butalbital", "ingredient2": "Selegiline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275010/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam", "alternatives_b": "Amantadine, Cabergoline", "updated_at": 1767369485}, {"id": 242447, "ingredient1": "Chloral hydrate", "ingredient2": "Selegiline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275012/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam", "alternatives_b": "Amantadine, Cabergoline", "updated_at": 1767369485}, {"id": 242448, "ingredient1": "Chlorcyclizine", "ingredient2": "Selegiline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275013/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Clemastine, Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Cabergoline", "updated_at": 1767369485}, {"id": 242449, "ingredient1": "Chlormezanone", "ingredient2": "Selegiline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275014/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Tizanidine", "alternatives_b": "Amantadine, Cabergoline", "updated_at": 1767369485}, {"id": 242450, "ingredient1": "Chlorphenesin", "ingredient2": "Selegiline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275015/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Salicylic acid, Fluconazole, Selenium Sulfide, Thiabendazole, Miconazole, Nystatin, Ciclopirox, Griseofulvin, Ketoconazole, Terbinafine, Econazole, More", "alternatives_b": "Amantadine, Cabergoline", "updated_at": 1767369485}, {"id": 242451, "ingredient1": "Cyclizine", "ingredient2": "Selegiline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275016/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Clemastine, Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Cabergoline", "updated_at": 1767369485}, {"id": 242452, "ingredient1": "Dezocine", "ingredient2": "Selegiline", "severity": "Major", "effect": "Coadministration of monoamine oxidase inhibitors (MAOIs), such as selegiline (an MAO-B inhibitor), with opioid analgesics may result in serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5HT1A receptors.", "source": "DDInter", "management_text": "Concomitant use of MAOIs, such as selegiline, with opioid analgesics should generally be avoided.  At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with an opioid analgesic.  If coadministration is unavoidable, patients should be monitored for signs and symptoms of serotonin syndrome which may include mental status changes such as irritability, altered consciousness, confusion, hallucinations, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.  Some authorities consider the use of selegiline with opioid analgesics to be contraindicated (UK).", "mechanism_text": "Synergism", "recommendation": "Concomitant use of MAOIs, such as selegiline, with opioid analgesics should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275017/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Zelapar (selegiline).\" Valeant Pharmaceuticals  (2006):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Naloxone, Naltrexone, Celecoxib", "alternatives_b": "Amantadine, Cabergoline", "updated_at": 1767369485}, {"id": 242453, "ingredient1": "Estazolam", "ingredient2": "Selegiline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275019/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam", "alternatives_b": "Amantadine, Cabergoline", "updated_at": 1767369485}, {"id": 242454, "ingredient1": "Eszopiclone", "ingredient2": "Selegiline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275020/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam", "alternatives_b": "Amantadine, Cabergoline", "updated_at": 1767369485}, {"id": 242455, "ingredient1": "Ethchlorvynol", "ingredient2": "Selegiline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275022/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam", "alternatives_b": "Ropinirole, Cabergoline, Tolcapone, Entacapone, Pramipexole, Amantadine", "updated_at": 1767369485}, {"id": 242456, "ingredient1": "Ethosuximide", "ingredient2": "Selegiline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275023/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Lacosamide", "alternatives_b": "Amantadine, Cabergoline", "updated_at": 1767369485}, {"id": 242457, "ingredient1": "Ethotoin", "ingredient2": "Selegiline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275024/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Lacosamide", "alternatives_b": "Amantadine, Cabergoline", "updated_at": 1767369485}, {"id": 242458, "ingredient1": "Ezogabine", "ingredient2": "Selegiline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275025/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Lacosamide", "alternatives_b": "Amantadine, Cabergoline", "updated_at": 1767369485}, {"id": 242459, "ingredient1": "Felbamate", "ingredient2": "Selegiline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275026/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Lacosamide", "alternatives_b": "Amantadine, Cabergoline", "updated_at": 1767369485}, {"id": 242460, "ingredient1": "Flavoxate", "ingredient2": "Selegiline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275028/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Apomorphine, Fesoterodine, Pentosan polysulfate, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Mirabegron, Alprostadil, Acetohydroxamic acid, Darifenacin, More", "alternatives_b": "Cabergoline", "updated_at": 1767369485}, {"id": 242461, "ingredient1": "Halazepam", "ingredient2": "Selegiline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275032/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Amantadine, Cabergoline", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242462, "ingredient1": "Diamorphine", "ingredient2": "Selegiline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275033/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Acamprosate, Naltrexone, Varenicline, Nalmefene, Nicotine", "alternatives_b": "Amantadine, Cabergoline", "updated_at": 1767369485}, {"id": 242463, "ingredient1": "Hydrocodone", "ingredient2": "Selegiline", "severity": "Major", "effect": "Coadministration of monoamine oxidase inhibitors (MAOIs), such as selegiline (an MAO-B inhibitor), with opioid analgesics may result in serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5HT1A receptors.", "source": "DDInter", "management_text": "Concomitant use of MAOIs, such as selegiline, with opioid analgesics should generally be avoided.  At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with an opioid analgesic.  If coadministration is unavoidable, patients should be monitored for signs and symptoms of serotonin syndrome which may include mental status changes such as irritability, altered consciousness, confusion, hallucinations, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.  Some authorities consider the use of selegiline with opioid analgesics to be contraindicated (UK).", "mechanism_text": "Synergism", "recommendation": "Concomitant use of MAOIs, such as selegiline, with opioid analgesics should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275035/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Zelapar (selegiline).\" Valeant Pharmaceuticals  (2006):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Benzonatate", "alternatives_b": "Amantadine, Cabergoline", "updated_at": 1767369485}, {"id": 242464, "ingredient1": "Iloperidone", "ingredient2": "Selegiline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275037/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Amisulpride, Pimavanserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242465, "ingredient1": "Selegiline", "ingredient2": "Kava", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275038/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Amantadine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242466, "ingredient1": "Selegiline", "ingredient2": "Levetiracetam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275039/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Lacosamide", "alternatives_b": "Amantadine", "updated_at": 1767369485}, {"id": 242467, "ingredient1": "Selegiline", "ingredient2": "Levacetylmethadol", "severity": "Major", "effect": "Coadministration of monoamine oxidase inhibitors (MAOIs), such as selegiline (an MAO-B inhibitor), with opioid analgesics may result in serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5HT1A receptors.", "source": "DDInter", "management_text": "Concomitant use of MAOIs, such as selegiline, with opioid analgesics should generally be avoided.  At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with an opioid analgesic.  If coadministration is unavoidable, patients should be monitored for signs and symptoms of serotonin syndrome which may include mental status changes such as irritability, altered consciousness, confusion, hallucinations, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.  Some authorities consider the use of selegiline with opioid analgesics to be contraindicated (UK).", "mechanism_text": "Synergism", "recommendation": "Concomitant use of MAOIs, such as selegiline, with opioid analgesics should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275040/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Zelapar (selegiline).\" Valeant Pharmaceuticals  (2006):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Acamprosate, Naltrexone, Varenicline, Nalmefene, Nicotine", "alternatives_b": "Amantadine, Cabergoline", "updated_at": 1767369485}, {"id": 242468, "ingredient1": "Selegiline", "ingredient2": "Levorphanol", "severity": "Major", "effect": "Coadministration of monoamine oxidase inhibitors (MAOIs), such as selegiline (an MAO-B inhibitor), with opioid analgesics may result in serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5HT1A receptors.", "source": "DDInter", "management_text": "Concomitant use of MAOIs, such as selegiline, with opioid analgesics should generally be avoided.  At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with an opioid analgesic.  If coadministration is unavoidable, patients should be monitored for signs and symptoms of serotonin syndrome which may include mental status changes such as irritability, altered consciousness, confusion, hallucinations, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.  Some authorities consider the use of selegiline with opioid analgesics to be contraindicated (UK).", "mechanism_text": "Synergism", "recommendation": "Concomitant use of MAOIs, such as selegiline, with opioid analgesics should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275041/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Zelapar (selegiline).\" Valeant Pharmaceuticals  (2006):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Amantadine, Cabergoline", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242469, "ingredient1": "Selegiline", "ingredient2": "Lithium carbonate", "severity": "Moderate", "effect": "Concomitant administration of lithium with serotonergic drugs (e.g., selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, tricyclic antidepressants, triptans (5-HT1 agonists), buspirone, fentanyl, St. John's wort, tramadol, tryptophan) or drugs that impair metabolism of serotonin (e.g., monoamine oxidase inhibitors) can precipitate serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.", "source": "DDInter", "management_text": "Close monitoring for potential serotonin toxicity and excessive CNS depression is advised when lithium is used with other serotonergic agents or monoamine oxidase inhibitors.  Particular caution is advised when increasing the dosages of these agents.  Patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for potential serotonin toxicity and excessive CNS depression is advised when lithium is used with other serotonergic agents or monoamine oxidase inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275042/", "reference_text": "[1] \"Product Information. Lithobid (lithium).\" Ciba-Geigy Pharmaceuticals  (2002):[2] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[3] Sobanski T, Bagli M, Laux G, Rao ML \"Serotonin syndrome after lithium add-on medication to paroxetine.\" Pharmacopsychiatry 30 (1997):  106-7[4] Gardner DM, Lynd LD \"Sumatriptan contraindications and the serotonin syndrome.\" Ann Pharmacother 32 (1998):  33-8[5] Mathew NT, Tietjen GE, Lucker C \"Serotonin syndrome complicating migraine pharmacotherapy.\" Cephalalgia 16 (1996):  323-7[6] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):", "alternatives_a": "Amantadine, Cabergoline", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242470, "ingredient1": "Selegiline", "ingredient2": "Lurasidone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275044/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Amisulpride, Pimavanserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242471, "ingredient1": "Selegiline", "ingredient2": "Melatonin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275046/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam", "alternatives_b": "Apomorphine, Amantadine, Cabergoline", "updated_at": 1767369485}, {"id": 242472, "ingredient1": "Selegiline", "ingredient2": "Mephenytoin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275047/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Lacosamide", "alternatives_b": "Amantadine, Cabergoline", "updated_at": 1767369485}, {"id": 242473, "ingredient1": "Selegiline", "ingredient2": "Methylphenobarbital", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275048/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Lacosamide, Nitrazepam", "alternatives_b": "Amantadine, Cabergoline", "updated_at": 1767369485}, {"id": 242474, "ingredient1": "Selegiline", "ingredient2": "Meprobamate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275049/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam", "alternatives_b": "Amantadine, Cabergoline", "updated_at": 1767369485}, {"id": 242475, "ingredient1": "Selegiline", "ingredient2": "Metaxalone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275050/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Amantadine, Cabergoline", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242476, "ingredient1": "Selegiline", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275051/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam", "alternatives_b": "Amantadine, Cabergoline", "updated_at": 1767369485}, {"id": 242477, "ingredient1": "Selegiline", "ingredient2": "Molindone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275054/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Amisulpride, Pimavanserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242478, "ingredient1": "Selegiline", "ingredient2": "Nalbuphine", "severity": "Major", "effect": "Coadministration of monoamine oxidase inhibitors (MAOIs), such as selegiline (an MAO-B inhibitor), with opioid analgesics may result in serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5HT1A receptors.", "source": "DDInter", "management_text": "Concomitant use of MAOIs, such as selegiline, with opioid analgesics should generally be avoided.  At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with an opioid analgesic.  If coadministration is unavoidable, patients should be monitored for signs and symptoms of serotonin syndrome which may include mental status changes such as irritability, altered consciousness, confusion, hallucinations, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.  Some authorities consider the use of selegiline with opioid analgesics to be contraindicated (UK).", "mechanism_text": "Synergism", "recommendation": "Concomitant use of MAOIs, such as selegiline, with opioid analgesics should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275055/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Zelapar (selegiline).\" Valeant Pharmaceuticals  (2006):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Naloxone, Naltrexone, Celecoxib", "alternatives_b": "Safinamide, Amantadine, Cabergoline", "updated_at": 1767369485}, {"id": 242479, "ingredient1": "Selegiline", "ingredient2": "Opicapone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275056/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Apomorphine, Safinamide, Selegiline", "alternatives_b": "Amantadine, Opicapone, Cabergoline", "updated_at": 1767369485}, {"id": 242480, "ingredient1": "Selegiline", "ingredient2": "Oxymorphone", "severity": "Major", "effect": "Coadministration of monoamine oxidase inhibitors (MAOIs), such as selegiline (an MAO-B inhibitor), with opioid analgesics may result in serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5HT1A receptors.", "source": "DDInter", "management_text": "Concomitant use of MAOIs, such as selegiline, with opioid analgesics should generally be avoided.  At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with an opioid analgesic.  If coadministration is unavoidable, patients should be monitored for signs and symptoms of serotonin syndrome which may include mental status changes such as irritability, altered consciousness, confusion, hallucinations, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.  Some authorities consider the use of selegiline with opioid analgesics to be contraindicated (UK).", "mechanism_text": "Synergism", "recommendation": "Concomitant use of MAOIs, such as selegiline, with opioid analgesics should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275057/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Zelapar (selegiline).\" Valeant Pharmaceuticals  (2006):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Naloxone, Naltrexone, Celecoxib", "alternatives_b": "Amantadine, Cabergoline", "updated_at": 1767369485}, {"id": 242481, "ingredient1": "Selegiline", "ingredient2": "Paliperidone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275058/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Amisulpride, Pimavanserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242482, "ingredient1": "Selegiline", "ingredient2": "Paraldehyde", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275059/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam", "alternatives_b": "Amantadine, Cabergoline", "updated_at": 1767369485}, {"id": 242483, "ingredient1": "Selegiline", "ingredient2": "Paramethadione", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275060/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Lacosamide", "alternatives_b": "Amantadine, Cabergoline", "updated_at": 1767369485}, {"id": 242484, "ingredient1": "Selegiline", "ingredient2": "Pentobarbital", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275062/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam", "alternatives_b": "Amantadine, Cabergoline", "updated_at": 1767369485}, {"id": 242485, "ingredient1": "Selegiline", "ingredient2": "Perampanel", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275063/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Lacosamide", "alternatives_b": "Amantadine, Cabergoline", "updated_at": 1767369485}, {"id": 242486, "ingredient1": "Selegiline", "ingredient2": "Phenacemide", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275064/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Lacosamide", "alternatives_b": "Amantadine, Cabergoline", "updated_at": 1767369485}, {"id": 242487, "ingredient1": "Selegiline", "ingredient2": "Phenindamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275065/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Clemastine, Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Ropinirole, Cabergoline, Tolcapone, Entacapone, Pramipexole", "updated_at": 1767369485}, {"id": 242488, "ingredient1": "Selegiline", "ingredient2": "Phensuximide", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275066/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Lacosamide", "alternatives_b": "Amantadine, Cabergoline", "updated_at": 1767369485}, {"id": 242489, "ingredient1": "Selegiline", "ingredient2": "Pimozide", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275067/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Amisulpride, Pimavanserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242490, "ingredient1": "Selegiline", "ingredient2": "Primidone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275068/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam, Lacosamide", "alternatives_b": "Amantadine, Cabergoline", "updated_at": 1767369485}, {"id": 242491, "ingredient1": "Selegiline", "ingredient2": "Procyclidine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275069/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Apomorphine, Ropinirole, Cabergoline, Tolcapone, Entacapone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242492, "ingredient1": "Selegiline", "ingredient2": "Mepyramine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275070/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Lidocaine, Tetracaine, Clemastine, Clemastine, Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Desloratadine, Azelastine, More", "alternatives_b": "Cabergoline", "updated_at": 1767369485}, {"id": 242493, "ingredient1": "Selegiline", "ingredient2": "Ramelteon", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275072/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam", "alternatives_b": "Amantadine, Cabergoline", "updated_at": 1767369485}, {"id": 242494, "ingredient1": "Selegiline", "ingredient2": "Rotigotine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275074/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Apomorphine, Safinamide, Selegiline", "alternatives_b": "Levodopa, Amantadine, Rotigotine, Cabergoline", "updated_at": 1767369485}, {"id": 242495, "ingredient1": "Tasimelteon", "ingredient2": "Selegiline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275076/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Amantadine, Cabergoline", "alternatives_b": "Nitrazepam", "updated_at": 1767369485}, {"id": 242496, "ingredient1": "Tiagabine", "ingredient2": "Selegiline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275077/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Amantadine, Entacapone, Cabergoline", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 242497, "ingredient1": "Triazolam", "ingredient2": "Selegiline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275079/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242498, "ingredient1": "Tripelennamine", "ingredient2": "Selegiline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275080/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Cabergoline", "alternatives_b": "Clemastine, Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole, Lidocaine, More", "updated_at": 1767369485}, {"id": 242499, "ingredient1": "Triprolidine", "ingredient2": "Selegiline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275081/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Cabergoline", "alternatives_b": "Clemastine, Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "updated_at": 1767369485}, {"id": 242500, "ingredient1": "Valerian", "ingredient2": "Selegiline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275083/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Amantadine, Cabergoline", "alternatives_b": "Nitrazepam", "updated_at": 1767369485}, {"id": 242501, "ingredient1": "Vigabatrin", "ingredient2": "Selegiline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275084/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Amantadine, Cabergoline", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 242502, "ingredient1": "Acrivastine", "ingredient2": "Levetiracetam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275087/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Meclizine, Azelastine, Thiethylperazine, Dexchlorpheniramine, Phenindamine, Astemizole, Methdilazine, Terfenadine, Pheniramine", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 242503, "ingredient1": "Chlorcyclizine", "ingredient2": "Levetiracetam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275089/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Meclizine, Azelastine, Thiethylperazine, Dexchlorpheniramine, Phenindamine, Astemizole, Methdilazine, Terfenadine, Pheniramine", "alternatives_b": "Oxcarbazepine, Ethotoin, Methsuximide, Paramethadione, Carbamazepine, Phensuximide, Fosphenytoin, Methylphenobarbital, Phenacemide, Phenytoin, Felbamate, More", "updated_at": 1767369485}, {"id": 242504, "ingredient1": "Cyclizine", "ingredient2": "Levetiracetam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275090/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Meclizine, Azelastine, Thiethylperazine, Dexchlorpheniramine, Phenindamine, Astemizole, Methdilazine, Terfenadine, Pheniramine", "alternatives_b": "Methsuximide, Paramethadione, Phensuximide, Methylphenobarbital, Phenacemide, Trimethadione, Lacosamide", "updated_at": 1767369485}, {"id": 242505, "ingredient1": "Felbamate", "ingredient2": "Levetiracetam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275092/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ethotoin, Methsuximide, Paramethadione, Mephenytoin, Phensuximide, Methylphenobarbital, Phenacemide, Trimethadione, Lacosamide, Levetiracetam", "alternatives_b": "Paramethadione, Phensuximide, Methylphenobarbital, Phenacemide, Felbamate, Lacosamide, Trimethadione", "updated_at": 1767369485}, {"id": 242506, "ingredient1": "Fenfluramine", "ingredient2": "Levetiracetam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275093/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Dexfenfluramine, Naltrexone, Ephedrine, Phentermine, Lorcaserin, Diethylpropion, Mazindol, Ethotoin, Methsuximide, Paramethadione, Mephenytoin, More", "alternatives_b": "Lacosamide, Fenfluramine", "updated_at": 1767369485}, {"id": 242507, "ingredient1": "Levodopa", "ingredient2": "Levetiracetam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275096/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Lacosamide", "alternatives_b": "Amantadine", "updated_at": 1767369485}, {"id": 242508, "ingredient1": "Melatonin", "ingredient2": "Levetiracetam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275097/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Lacosamide", "alternatives_b": "Nitrazepam, Thiopental, Ethchlorvynol, Methylphenobarbital, Dichloralphenazone", "updated_at": 1767369485}, {"id": 242509, "ingredient1": "Imipramine", "ingredient2": "Eletriptan", "severity": "Major", "effect": "Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John's wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.", "source": "DDInter", "management_text": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.  Patients should be closely monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.  For example, some experts suggest a 5-week washout period following use of fluoxetine and 3 weeks following the use of vortioxetine before administering another serotonergic agent.  Individual product labeling for washout periods should be consulted for current recommendations.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.", "mechanism_text": "Synergism", "recommendation": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275100/", "reference_text": "[1] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[2] Achamallah NS \"Visual hallucinations after combining fluoxetine and dextromethorphan .\" Am J Psychiatry 149 (1992):  1406[3] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993):  84-8[4] Metz A \"Interaction between fluoxetine and buspirone.\" Can J Psychiatry 35 (1990):  722-3[5] Goldberg RJ, Huk M \"Serotonin syndrome from trazodone and buspirone.\" Psychosomatics 33 (1992):  235-6[6] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation  (2002):[7] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[8] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990):  213-7[9] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics.\" J Clin Psychopharmacol 10 (1990):  48-50[10] \"Product Information. Zoloft (sertraline).\" Roerig Division  (2001):[11] \"Product Information. Prozac (fluoxetine).\" Dista Products Company  (2001):[12] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[13] Insel TR, Roy BF, Cohen RM, Murphy DL \"Possible development of the serotonin syndrome in man.\" Am J Psychiatry 139 (1982):  954-5[14] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories  (2001):[15] Gilman AG, eds., Nies AS, Rall TW, Taylor P \"Goodman and Gilman's the Pharmacological Basis of Therapeutics.\" New York, NY: Pergamon Press Inc.  (1990):[16] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline  (2001):[17] \"Product Information. Flexeril (cyclobenzaprine).\" Merck & Co., Inc  (2001):[18] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[19] \"Product Information. Imitrex (sumatriptan).\" Glaxo Wellcome  (2001):[20] Ruiz F \"Fluoxetine and the serotonin syndrome.\" Ann Emerg Med 24 (1994):  983-5[21] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc  (2001):[22] Reeves RR, Bullen JA \"Serotonin syndrome produced by paroxetine and low-dose trazodone.\" Psychosomatics 36 (1995):  159-60[23] Harvey AT, Preskorn SH \"Interactions of serotonin reuptake inhibitors with tricyclic antidepressants.\" Arch Gen Psychiatry 52 (1995):  783-4[24] Baetz M, Malcolm D \"Serotonin syndrome from fluvoxamine and buspirone.\" Can J Psychiatry 40 (1995):  428-9[25] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995):  440-2[26] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995):  481-2[27] George TP, Godleski LS \"Possible serotonin syndrome with trazodone addition to fluoxetine.\" Biol Psychiatry 39 (1996):  384-5[28] Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM \"The serotonin syndrome associated wtih paroxetine, an over-the-counter cold remedy, and vascular disease.\" Am J Emerg Med 12 (1994):  642-4[29] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[30] John L, Perreault MM, Tao T, Blew PG \"Serotonin syndrome associated with nefazodone and paroxetine.\" Ann Emerg Med 29 (1997):  287-9[31] \"Product Information. Zomig (zolmitriptan).\" Astra-Zeneca Pharmaceuticals  (2001):[32] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[33] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[34] Bhatara VS, Magnus RD, Paul KL, Preskorn SH \"Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms.\" Ann Pharmacother 32 (1998):  432-6[35] \"Product Information. Maxalt (rizatriptan).\" Merck & Co., Inc  (2001):[36] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals  (2001):[37] Gardner DM, Lynd LD \"Sumatriptan contraindications and the serotonin syndrome.\" Ann Pharmacother 32 (1998):  33-8[38] Mathew NT, Tietjen GE, Lucker C \"Serotonin syndrome complicating migraine pharmacotherapy.\" Cephalalgia 16 (1996):  323-7[39] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[40] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[41] Weiner AL \"Meperidine as a potential cause of serotonin syndrome in the emergency department.\" Acad Emerg Med 6 (1999):  156-8[42] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[43] Gordon JB \"SSRI's and St. John's Wort: possible toxicity?\" Am Fam Physician 57 (1998):  950,953[44] Lantz MS, Buchalter E, Giambanco V \"St. John's wort and antidepressant drug interactions in the elderly.\" J Geriatr Psychiatr Neurol 12 (1999):  7-10[45] Fugh-Berman A \"Herb-drug interactions.\" Lancet 355 (2000):  134-8[46] \"Product Information. Zyvox (linezolid).\" Pharmacia and Upjohn  (2001):[47] Perry NK \"Venlafaxine-induced serotonin syndrome with relapse following amitriptyline.\" Postgrad Med J 76 (2000):  254-6[48] Manos GH \"Possible serotonin syndrome associated with buspirone added to fluoxetine.\" Ann Pharmacother 34 (2000):  871-4[49] Nijhawan PK, Katz G, Winter S \"Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission.\" Crit Care Med 24 (1996):  1086-9[50] Laird LK \"Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder.\" Psychopharmacol Bull 32 (1996):  569-78[51] Margolese HC, Chouinard G \"Serotonin syndrome from addition of low-dose trazodone to nefazodone.\" Am J Psychiatry 157 (2000):  1022[52] Mackay FJ, Dunn NR, Mann RD \"Antidepressants and the serotonin syndrome in general practice.\" Br J Gen Pract 49 (1999):  871-4[53] Smith DL, Wenegrat BG \"A case report of serotonin syndrome associated with combined nefazodone and fluoxetine.\" J Clin Psychiatry 61 (2000):  146[54] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[55] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001):  2163-75[56] Duggal HS, Fetchko J \"Serotonin syndrome and atypical antipsychotics.\" Am J Psychiatry 159 (2002):  672-3[57] Wigen CL, Goetz MB \"Serotonin syndrome and linezolid.\" Clin Infect Dis 34 (2002):  1651-2[58] Hammerness P, Parada H, Abrams A \"Linezolid: MAOI Activity and Potential Drug Interactions.\" Psychosomatics 43 (2002):  248-9[59] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[60] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[61] Turkel SB, Nadala JG, Wincor MZ \"Possible serotonin syndrome in association with 5-HT3 antagonist agents.\" Psychosomatics 42 (2001):  258-60[62] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[63] Lavery S, Ravi H, McDaniel WW, Pushkin YR \"Linezolid and serotonin syndrome.\" Psychosomatics 42 (2001):  432-4[64] Lane R, Baldwin D \"Selective serotonin reuptake inhibitor--induced serotonin syndrome: review.\" J Clin Psychopharmacol 17 (1997):  208-21[65] Bernard L, Stern R, Lew D, Hoffmeyer P \"Serotonin syndrome after concomitant treatment with linezolid and citalopram.\" Clin Infect Dis 36 (2003):  1197[66] Dannawi M \"Possible serotonin syndrome after combination of buspirone and St John's Wort.\" J Psychopharmacol 16 (2002):  401[67] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[68] Hachem RY, Hicks K, Huen A, Raad I \"Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients.\" Clin Infect Dis 37 (2003):  E8-E11[69] Gillman PK \"Linezolid and serotonin toxicity.\" Clin Infect Dis 37 (2003):  1274-5[70] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[71] Giese SY, Neborsky R \"Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl.\" Plast Reconstr Surg 107 (2001):  293-4[72] Jones SL, Athan E, O'Brien D \"Serotonin syndrome due to co-administration of linezolid and venlafaxine.\" J Antimicrob Chemother 54 (2004):  289-90[73] Tahir N \"Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram.\" J Am Med Dir Assoc 5 (2004):  111-3[74] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company  (2004):[75] Thomas CR, Rosenberg M, Blythe V, Meyer WJ 3rd \"Serotonin syndrome and linezolid.\" J Am Acad Child Adolesc Psychiatry 43 (2004):  790[76] Boyer EW, Shannon M \"The serotonin syndrome.\" N Engl J Med 352 (2005):  1112-20[77] Bergeron L, Boule M, Perreault S \"Serotonin toxicity associated with concomitant use of linezolid.\" Ann Pharmacother 39 (2005):  956-61[78] Morales N, Vermette H \"Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine.\" Psychosomatics 46 (2005):  274-5[79] Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M, Grau S \"Linezolid-associated serotonin syndrome: what we can learn from cases reported so far.\" J Antimicrob Chemother 56 (2005):  1176-8[80] DeBellis RJ, Schaefer OP, Liquori M, Volturo GA \"Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient.\" J Intensive Care Med 20 (2005):  351-3[81] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[82] Taylor JJ, Wilson JW, Estes LL \"Linezolid and serotonergic drug interactions: a retrospective survey.\" Clin Infect Dis 43 (2006):  180-7[83] Strouse TB, Kerrihard TN, Forscher CA, Zakowski P \"Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine.\" J Clin Psychopharmacol 26 (2006):  681-683[84] Keegan MT, Brown DR, Rabinstein AA \"Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs.\" Anesth Analg 103 (2006):  1466-8[85] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S \"Rare case of serotonin syndrome with therapeutic doses of paroxetine.\" Am J Ther 13 (2006):  550-552[86] Steinberg M, Morin AK \"Mild serotonin syndrome associated with concurrent linezolid and fluoxetine.\" Am J Health Syst Pharm 64 (2007):  59-62[87] Packer S, Berman SA \"Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid.\" Am J Psychiatry 164 (2007):  346-7[88] Shapiro RE, Tepper SJ \"The serotonin syndrome, triptans, and the potential for drug-drug interactions.\" Headache 47 (2007):  266-9[89] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[90] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories  (2008):[91] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[92] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals  (2009):[93] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals  (2009):[94] Lee J, Franz L, Goforth HW \"Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine.\" Psychosomatics 50 (2009):  638-9[95] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC  (2011):[96] Mugele J, Nanagas KA, Tormoehlen LM \"Serotonin Syndrome Associated With MDPV Use: A Case Report.\" Ann Emerg Med  (2012):[97] \"Product Information. Oleptro (trazodone).\" Labopharm Inc  (2012):[98] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals  (2013):[99] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America  (2013):", "alternatives_a": "Rimegepant, Eptinezumab, Ubrogepant, Galcanezumab, Atogepant, Methysergide, Erenumab, Fremanezumab", "alternatives_b": "Esketamine", "updated_at": 1767369485}, {"id": 242510, "ingredient1": "Eletriptan", "ingredient2": "Lithium carbonate", "severity": "Moderate", "effect": "Concomitant administration of lithium with serotonergic drugs (e.g., selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, tricyclic antidepressants, triptans (5-HT1 agonists), buspirone, fentanyl, St. John's wort, tramadol, tryptophan) or drugs that impair metabolism of serotonin (e.g., monoamine oxidase inhibitors) can precipitate serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.", "source": "DDInter", "management_text": "Close monitoring for potential serotonin toxicity and excessive CNS depression is advised when lithium is used with other serotonergic agents or monoamine oxidase inhibitors.  Particular caution is advised when increasing the dosages of these agents.  Patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for potential serotonin toxicity and excessive CNS depression is advised when lithium is used with other serotonergic agents or monoamine oxidase inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275103/", "reference_text": "[1] \"Product Information. Lithobid (lithium).\" Ciba-Geigy Pharmaceuticals  (2002):[2] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[3] Sobanski T, Bagli M, Laux G, Rao ML \"Serotonin syndrome after lithium add-on medication to paroxetine.\" Pharmacopsychiatry 30 (1997):  106-7[4] Gardner DM, Lynd LD \"Sumatriptan contraindications and the serotonin syndrome.\" Ann Pharmacother 32 (1998):  33-8[5] Mathew NT, Tietjen GE, Lucker C \"Serotonin syndrome complicating migraine pharmacotherapy.\" Cephalalgia 16 (1996):  323-7[6] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):", "alternatives_a": "Rimegepant, Eptinezumab, Dihydroergotamine, Ubrogepant, Ergotamine, Galcanezumab, Atogepant, Methysergide, Erenumab, Fremanezumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242511, "ingredient1": "Eletriptan", "ingredient2": "Maprotiline", "severity": "Major", "effect": "Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John's wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.", "source": "DDInter", "management_text": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.  Patients should be closely monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.  For example, some experts suggest a 5-week washout period following use of fluoxetine and 3 weeks following the use of vortioxetine before administering another serotonergic agent.  Individual product labeling for washout periods should be consulted for current recommendations.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.", "mechanism_text": "Synergism", "recommendation": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275105/", "reference_text": "[1] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[2] Achamallah NS \"Visual hallucinations after combining fluoxetine and dextromethorphan .\" Am J Psychiatry 149 (1992):  1406[3] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993):  84-8[4] Metz A \"Interaction between fluoxetine and buspirone.\" Can J Psychiatry 35 (1990):  722-3[5] Goldberg RJ, Huk M \"Serotonin syndrome from trazodone and buspirone.\" Psychosomatics 33 (1992):  235-6[6] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation  (2002):[7] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[8] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990):  213-7[9] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics.\" J Clin Psychopharmacol 10 (1990):  48-50[10] \"Product Information. Zoloft (sertraline).\" Roerig Division  (2001):[11] \"Product Information. Prozac (fluoxetine).\" Dista Products Company  (2001):[12] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[13] Insel TR, Roy BF, Cohen RM, Murphy DL \"Possible development of the serotonin syndrome in man.\" Am J Psychiatry 139 (1982):  954-5[14] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories  (2001):[15] Gilman AG, eds., Nies AS, Rall TW, Taylor P \"Goodman and Gilman's the Pharmacological Basis of Therapeutics.\" New York, NY: Pergamon Press Inc.  (1990):[16] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline  (2001):[17] \"Product Information. Flexeril (cyclobenzaprine).\" Merck & Co., Inc  (2001):[18] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[19] \"Product Information. Imitrex (sumatriptan).\" Glaxo Wellcome  (2001):[20] Ruiz F \"Fluoxetine and the serotonin syndrome.\" Ann Emerg Med 24 (1994):  983-5[21] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc  (2001):[22] Reeves RR, Bullen JA \"Serotonin syndrome produced by paroxetine and low-dose trazodone.\" Psychosomatics 36 (1995):  159-60[23] Harvey AT, Preskorn SH \"Interactions of serotonin reuptake inhibitors with tricyclic antidepressants.\" Arch Gen Psychiatry 52 (1995):  783-4[24] Baetz M, Malcolm D \"Serotonin syndrome from fluvoxamine and buspirone.\" Can J Psychiatry 40 (1995):  428-9[25] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995):  440-2[26] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995):  481-2[27] George TP, Godleski LS \"Possible serotonin syndrome with trazodone addition to fluoxetine.\" Biol Psychiatry 39 (1996):  384-5[28] Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM \"The serotonin syndrome associated wtih paroxetine, an over-the-counter cold remedy, and vascular disease.\" Am J Emerg Med 12 (1994):  642-4[29] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[30] John L, Perreault MM, Tao T, Blew PG \"Serotonin syndrome associated with nefazodone and paroxetine.\" Ann Emerg Med 29 (1997):  287-9[31] \"Product Information. Zomig (zolmitriptan).\" Astra-Zeneca Pharmaceuticals  (2001):[32] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[33] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[34] Bhatara VS, Magnus RD, Paul KL, Preskorn SH \"Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms.\" Ann Pharmacother 32 (1998):  432-6[35] \"Product Information. Maxalt (rizatriptan).\" Merck & Co., Inc  (2001):[36] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals  (2001):[37] Gardner DM, Lynd LD \"Sumatriptan contraindications and the serotonin syndrome.\" Ann Pharmacother 32 (1998):  33-8[38] Mathew NT, Tietjen GE, Lucker C \"Serotonin syndrome complicating migraine pharmacotherapy.\" Cephalalgia 16 (1996):  323-7[39] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[40] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[41] Weiner AL \"Meperidine as a potential cause of serotonin syndrome in the emergency department.\" Acad Emerg Med 6 (1999):  156-8[42] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[43] Gordon JB \"SSRI's and St. John's Wort: possible toxicity?\" Am Fam Physician 57 (1998):  950,953[44] Lantz MS, Buchalter E, Giambanco V \"St. John's wort and antidepressant drug interactions in the elderly.\" J Geriatr Psychiatr Neurol 12 (1999):  7-10[45] Fugh-Berman A \"Herb-drug interactions.\" Lancet 355 (2000):  134-8[46] \"Product Information. Zyvox (linezolid).\" Pharmacia and Upjohn  (2001):[47] Perry NK \"Venlafaxine-induced serotonin syndrome with relapse following amitriptyline.\" Postgrad Med J 76 (2000):  254-6[48] Manos GH \"Possible serotonin syndrome associated with buspirone added to fluoxetine.\" Ann Pharmacother 34 (2000):  871-4[49] Nijhawan PK, Katz G, Winter S \"Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission.\" Crit Care Med 24 (1996):  1086-9[50] Laird LK \"Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder.\" Psychopharmacol Bull 32 (1996):  569-78[51] Margolese HC, Chouinard G \"Serotonin syndrome from addition of low-dose trazodone to nefazodone.\" Am J Psychiatry 157 (2000):  1022[52] Mackay FJ, Dunn NR, Mann RD \"Antidepressants and the serotonin syndrome in general practice.\" Br J Gen Pract 49 (1999):  871-4[53] Smith DL, Wenegrat BG \"A case report of serotonin syndrome associated with combined nefazodone and fluoxetine.\" J Clin Psychiatry 61 (2000):  146[54] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[55] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001):  2163-75[56] Duggal HS, Fetchko J \"Serotonin syndrome and atypical antipsychotics.\" Am J Psychiatry 159 (2002):  672-3[57] Wigen CL, Goetz MB \"Serotonin syndrome and linezolid.\" Clin Infect Dis 34 (2002):  1651-2[58] Hammerness P, Parada H, Abrams A \"Linezolid: MAOI Activity and Potential Drug Interactions.\" Psychosomatics 43 (2002):  248-9[59] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[60] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[61] Turkel SB, Nadala JG, Wincor MZ \"Possible serotonin syndrome in association with 5-HT3 antagonist agents.\" Psychosomatics 42 (2001):  258-60[62] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[63] Lavery S, Ravi H, McDaniel WW, Pushkin YR \"Linezolid and serotonin syndrome.\" Psychosomatics 42 (2001):  432-4[64] Lane R, Baldwin D \"Selective serotonin reuptake inhibitor--induced serotonin syndrome: review.\" J Clin Psychopharmacol 17 (1997):  208-21[65] Bernard L, Stern R, Lew D, Hoffmeyer P \"Serotonin syndrome after concomitant treatment with linezolid and citalopram.\" Clin Infect Dis 36 (2003):  1197[66] Dannawi M \"Possible serotonin syndrome after combination of buspirone and St John's Wort.\" J Psychopharmacol 16 (2002):  401[67] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[68] Hachem RY, Hicks K, Huen A, Raad I \"Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients.\" Clin Infect Dis 37 (2003):  E8-E11[69] Gillman PK \"Linezolid and serotonin toxicity.\" Clin Infect Dis 37 (2003):  1274-5[70] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[71] Giese SY, Neborsky R \"Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl.\" Plast Reconstr Surg 107 (2001):  293-4[72] Jones SL, Athan E, O'Brien D \"Serotonin syndrome due to co-administration of linezolid and venlafaxine.\" J Antimicrob Chemother 54 (2004):  289-90[73] Tahir N \"Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram.\" J Am Med Dir Assoc 5 (2004):  111-3[74] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company  (2004):[75] Thomas CR, Rosenberg M, Blythe V, Meyer WJ 3rd \"Serotonin syndrome and linezolid.\" J Am Acad Child Adolesc Psychiatry 43 (2004):  790[76] Boyer EW, Shannon M \"The serotonin syndrome.\" N Engl J Med 352 (2005):  1112-20[77] Bergeron L, Boule M, Perreault S \"Serotonin toxicity associated with concomitant use of linezolid.\" Ann Pharmacother 39 (2005):  956-61[78] Morales N, Vermette H \"Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine.\" Psychosomatics 46 (2005):  274-5[79] Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M, Grau S \"Linezolid-associated serotonin syndrome: what we can learn from cases reported so far.\" J Antimicrob Chemother 56 (2005):  1176-8[80] DeBellis RJ, Schaefer OP, Liquori M, Volturo GA \"Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient.\" J Intensive Care Med 20 (2005):  351-3[81] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[82] Taylor JJ, Wilson JW, Estes LL \"Linezolid and serotonergic drug interactions: a retrospective survey.\" Clin Infect Dis 43 (2006):  180-7[83] Strouse TB, Kerrihard TN, Forscher CA, Zakowski P \"Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine.\" J Clin Psychopharmacol 26 (2006):  681-683[84] Keegan MT, Brown DR, Rabinstein AA \"Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs.\" Anesth Analg 103 (2006):  1466-8[85] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S \"Rare case of serotonin syndrome with therapeutic doses of paroxetine.\" Am J Ther 13 (2006):  550-552[86] Steinberg M, Morin AK \"Mild serotonin syndrome associated with concurrent linezolid and fluoxetine.\" Am J Health Syst Pharm 64 (2007):  59-62[87] Packer S, Berman SA \"Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid.\" Am J Psychiatry 164 (2007):  346-7[88] Shapiro RE, Tepper SJ \"The serotonin syndrome, triptans, and the potential for drug-drug interactions.\" Headache 47 (2007):  266-9[89] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[90] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories  (2008):[91] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[92] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals  (2009):[93] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals  (2009):[94] Lee J, Franz L, Goforth HW \"Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine.\" Psychosomatics 50 (2009):  638-9[95] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC  (2011):[96] Mugele J, Nanagas KA, Tormoehlen LM \"Serotonin Syndrome Associated With MDPV Use: A Case Report.\" Ann Emerg Med  (2012):[97] \"Product Information. Oleptro (trazodone).\" Labopharm Inc  (2012):[98] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals  (2013):[99] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America  (2013):", "alternatives_a": "Rimegepant, Eptinezumab, Ubrogepant, Galcanezumab, Atogepant, Methysergide, Erenumab, Fremanezumab", "alternatives_b": "Esketamine", "updated_at": 1767369485}, {"id": 242512, "ingredient1": "Eletriptan", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275109/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Frovatriptan, Eptinezumab, Lasmiditan, Rizatriptan, Naratriptan, Galcanezumab, Zolmitriptan, Sumatriptan, Clonidine, Erenumab, Fremanezumab", "alternatives_b": "Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, Cobimetinib, More", "updated_at": 1767369485}, {"id": 242513, "ingredient1": "Eletriptan", "ingredient2": "Remifentanil", "severity": "Major", "effect": "Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John's wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.", "source": "DDInter", "management_text": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.  Patients should be closely monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.  For example, some experts suggest a 5-week washout period following use of fluoxetine and 3 weeks following the use of vortioxetine before administering another serotonergic agent.  Individual product labeling for washout periods should be consulted for current recommendations.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.", "mechanism_text": "Synergism", "recommendation": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275110/", "reference_text": "[1] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[2] Achamallah NS \"Visual hallucinations after combining fluoxetine and dextromethorphan .\" Am J Psychiatry 149 (1992):  1406[3] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993):  84-8[4] Metz A \"Interaction between fluoxetine and buspirone.\" Can J Psychiatry 35 (1990):  722-3[5] Goldberg RJ, Huk M \"Serotonin syndrome from trazodone and buspirone.\" Psychosomatics 33 (1992):  235-6[6] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation  (2002):[7] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[8] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990):  213-7[9] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics.\" J Clin Psychopharmacol 10 (1990):  48-50[10] \"Product Information. Zoloft (sertraline).\" Roerig Division  (2001):[11] \"Product Information. Prozac (fluoxetine).\" Dista Products Company  (2001):[12] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[13] Insel TR, Roy BF, Cohen RM, Murphy DL \"Possible development of the serotonin syndrome in man.\" Am J Psychiatry 139 (1982):  954-5[14] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories  (2001):[15] Gilman AG, eds., Nies AS, Rall TW, Taylor P \"Goodman and Gilman's the Pharmacological Basis of Therapeutics.\" New York, NY: Pergamon Press Inc.  (1990):[16] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline  (2001):[17] \"Product Information. Flexeril (cyclobenzaprine).\" Merck & Co., Inc  (2001):[18] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[19] \"Product Information. Imitrex (sumatriptan).\" Glaxo Wellcome  (2001):[20] Ruiz F \"Fluoxetine and the serotonin syndrome.\" Ann Emerg Med 24 (1994):  983-5[21] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc  (2001):[22] Reeves RR, Bullen JA \"Serotonin syndrome produced by paroxetine and low-dose trazodone.\" Psychosomatics 36 (1995):  159-60[23] Harvey AT, Preskorn SH \"Interactions of serotonin reuptake inhibitors with tricyclic antidepressants.\" Arch Gen Psychiatry 52 (1995):  783-4[24] Baetz M, Malcolm D \"Serotonin syndrome from fluvoxamine and buspirone.\" Can J Psychiatry 40 (1995):  428-9[25] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995):  440-2[26] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995):  481-2[27] George TP, Godleski LS \"Possible serotonin syndrome with trazodone addition to fluoxetine.\" Biol Psychiatry 39 (1996):  384-5[28] Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM \"The serotonin syndrome associated wtih paroxetine, an over-the-counter cold remedy, and vascular disease.\" Am J Emerg Med 12 (1994):  642-4[29] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[30] John L, Perreault MM, Tao T, Blew PG \"Serotonin syndrome associated with nefazodone and paroxetine.\" Ann Emerg Med 29 (1997):  287-9[31] \"Product Information. Zomig (zolmitriptan).\" Astra-Zeneca Pharmaceuticals  (2001):[32] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[33] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[34] Bhatara VS, Magnus RD, Paul KL, Preskorn SH \"Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms.\" Ann Pharmacother 32 (1998):  432-6[35] \"Product Information. Maxalt (rizatriptan).\" Merck & Co., Inc  (2001):[36] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals  (2001):[37] Gardner DM, Lynd LD \"Sumatriptan contraindications and the serotonin syndrome.\" Ann Pharmacother 32 (1998):  33-8[38] Mathew NT, Tietjen GE, Lucker C \"Serotonin syndrome complicating migraine pharmacotherapy.\" Cephalalgia 16 (1996):  323-7[39] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[40] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[41] Weiner AL \"Meperidine as a potential cause of serotonin syndrome in the emergency department.\" Acad Emerg Med 6 (1999):  156-8[42] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[43] Gordon JB \"SSRI's and St. John's Wort: possible toxicity?\" Am Fam Physician 57 (1998):  950,953[44] Lantz MS, Buchalter E, Giambanco V \"St. John's wort and antidepressant drug interactions in the elderly.\" J Geriatr Psychiatr Neurol 12 (1999):  7-10[45] Fugh-Berman A \"Herb-drug interactions.\" Lancet 355 (2000):  134-8[46] \"Product Information. Zyvox (linezolid).\" Pharmacia and Upjohn  (2001):[47] Perry NK \"Venlafaxine-induced serotonin syndrome with relapse following amitriptyline.\" Postgrad Med J 76 (2000):  254-6[48] Manos GH \"Possible serotonin syndrome associated with buspirone added to fluoxetine.\" Ann Pharmacother 34 (2000):  871-4[49] Nijhawan PK, Katz G, Winter S \"Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission.\" Crit Care Med 24 (1996):  1086-9[50] Laird LK \"Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder.\" Psychopharmacol Bull 32 (1996):  569-78[51] Margolese HC, Chouinard G \"Serotonin syndrome from addition of low-dose trazodone to nefazodone.\" Am J Psychiatry 157 (2000):  1022[52] Mackay FJ, Dunn NR, Mann RD \"Antidepressants and the serotonin syndrome in general practice.\" Br J Gen Pract 49 (1999):  871-4[53] Smith DL, Wenegrat BG \"A case report of serotonin syndrome associated with combined nefazodone and fluoxetine.\" J Clin Psychiatry 61 (2000):  146[54] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[55] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001):  2163-75[56] Duggal HS, Fetchko J \"Serotonin syndrome and atypical antipsychotics.\" Am J Psychiatry 159 (2002):  672-3[57] Wigen CL, Goetz MB \"Serotonin syndrome and linezolid.\" Clin Infect Dis 34 (2002):  1651-2[58] Hammerness P, Parada H, Abrams A \"Linezolid: MAOI Activity and Potential Drug Interactions.\" Psychosomatics 43 (2002):  248-9[59] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[60] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[61] Turkel SB, Nadala JG, Wincor MZ \"Possible serotonin syndrome in association with 5-HT3 antagonist agents.\" Psychosomatics 42 (2001):  258-60[62] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[63] Lavery S, Ravi H, McDaniel WW, Pushkin YR \"Linezolid and serotonin syndrome.\" Psychosomatics 42 (2001):  432-4[64] Lane R, Baldwin D \"Selective serotonin reuptake inhibitor--induced serotonin syndrome: review.\" J Clin Psychopharmacol 17 (1997):  208-21[65] Bernard L, Stern R, Lew D, Hoffmeyer P \"Serotonin syndrome after concomitant treatment with linezolid and citalopram.\" Clin Infect Dis 36 (2003):  1197[66] Dannawi M \"Possible serotonin syndrome after combination of buspirone and St John's Wort.\" J Psychopharmacol 16 (2002):  401[67] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[68] Hachem RY, Hicks K, Huen A, Raad I \"Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients.\" Clin Infect Dis 37 (2003):  E8-E11[69] Gillman PK \"Linezolid and serotonin toxicity.\" Clin Infect Dis 37 (2003):  1274-5[70] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[71] Giese SY, Neborsky R \"Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl.\" Plast Reconstr Surg 107 (2001):  293-4[72] Jones SL, Athan E, O'Brien D \"Serotonin syndrome due to co-administration of linezolid and venlafaxine.\" J Antimicrob Chemother 54 (2004):  289-90[73] Tahir N \"Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram.\" J Am Med Dir Assoc 5 (2004):  111-3[74] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company  (2004):[75] Thomas CR, Rosenberg M, Blythe V, Meyer WJ 3rd \"Serotonin syndrome and linezolid.\" J Am Acad Child Adolesc Psychiatry 43 (2004):  790[76] Boyer EW, Shannon M \"The serotonin syndrome.\" N Engl J Med 352 (2005):  1112-20[77] Bergeron L, Boule M, Perreault S \"Serotonin toxicity associated with concomitant use of linezolid.\" Ann Pharmacother 39 (2005):  956-61[78] Morales N, Vermette H \"Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine.\" Psychosomatics 46 (2005):  274-5[79] Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M, Grau S \"Linezolid-associated serotonin syndrome: what we can learn from cases reported so far.\" J Antimicrob Chemother 56 (2005):  1176-8[80] DeBellis RJ, Schaefer OP, Liquori M, Volturo GA \"Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient.\" J Intensive Care Med 20 (2005):  351-3[81] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[82] Taylor JJ, Wilson JW, Estes LL \"Linezolid and serotonergic drug interactions: a retrospective survey.\" Clin Infect Dis 43 (2006):  180-7[83] Strouse TB, Kerrihard TN, Forscher CA, Zakowski P \"Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine.\" J Clin Psychopharmacol 26 (2006):  681-683[84] Keegan MT, Brown DR, Rabinstein AA \"Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs.\" Anesth Analg 103 (2006):  1466-8[85] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S \"Rare case of serotonin syndrome with therapeutic doses of paroxetine.\" Am J Ther 13 (2006):  550-552[86] Steinberg M, Morin AK \"Mild serotonin syndrome associated with concurrent linezolid and fluoxetine.\" Am J Health Syst Pharm 64 (2007):  59-62[87] Packer S, Berman SA \"Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid.\" Am J Psychiatry 164 (2007):  346-7[88] Shapiro RE, Tepper SJ \"The serotonin syndrome, triptans, and the potential for drug-drug interactions.\" Headache 47 (2007):  266-9[89] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[90] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories  (2008):[91] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[92] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals  (2009):[93] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals  (2009):[94] Lee J, Franz L, Goforth HW \"Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine.\" Psychosomatics 50 (2009):  638-9[95] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC  (2011):[96] Mugele J, Nanagas KA, Tormoehlen LM \"Serotonin Syndrome Associated With MDPV Use: A Case Report.\" Ann Emerg Med  (2012):[97] \"Product Information. Oleptro (trazodone).\" Labopharm Inc  (2012):[98] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals  (2013):[99] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America  (2013):", "alternatives_a": "Rimegepant, Eptinezumab, Ubrogepant, Galcanezumab, Atogepant, Methysergide, Erenumab, Fremanezumab", "alternatives_b": "Halothane, Thiopental, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, Sevoflurane, More", "updated_at": 1767369485}, {"id": 242514, "ingredient1": "Pimecrolimus (topical)", "ingredient2": "Lefamulin", "severity": "Minor", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of mirabegron, which has been shown in vitro to be a substrate of the isoenzyme.", "source": "DDInter", "management_text": "No dosage adjustment is recommended when mirabegron is administered in combination with ketoconazole and probably other CYP450 3A4 inhibitors.", "mechanism_text": "Metabolism", "recommendation": "No dosage adjustment is recommended when mirabegron is administered in combination with ketoconazole and probably other CYP450 3A4 inhibitors.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275114/", "reference_text": "[1] \"Product Information. Elidel (pimecrolimus topical).\" Novartis Pharmaceuticals  (2002):", "alternatives_a": "Tinidazole, Linezolid, Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Metronidazole, Telavancin, Methenamine, Spectinomycin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242515, "ingredient1": "Pimecrolimus (topical)", "ingredient2": "Osilodrostat", "severity": "Minor", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of mirabegron, which has been shown in vitro to be a substrate of the isoenzyme.", "source": "DDInter", "management_text": "No dosage adjustment is recommended when mirabegron is administered in combination with ketoconazole and probably other CYP450 3A4 inhibitors.", "mechanism_text": "Metabolism", "recommendation": "No dosage adjustment is recommended when mirabegron is administered in combination with ketoconazole and probably other CYP450 3A4 inhibitors.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275119/", "reference_text": "[1] \"Product Information. Elidel (pimecrolimus topical).\" Novartis Pharmaceuticals  (2002):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242516, "ingredient1": "Pimecrolimus (topical)", "ingredient2": "Palbociclib", "severity": "Minor", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of mirabegron, which has been shown in vitro to be a substrate of the isoenzyme.", "source": "DDInter", "management_text": "No dosage adjustment is recommended when mirabegron is administered in combination with ketoconazole and probably other CYP450 3A4 inhibitors.", "mechanism_text": "Metabolism", "recommendation": "No dosage adjustment is recommended when mirabegron is administered in combination with ketoconazole and probably other CYP450 3A4 inhibitors.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275120/", "reference_text": "[1] \"Product Information. Elidel (pimecrolimus topical).\" Novartis Pharmaceuticals  (2002):", "alternatives_a": "Dabrafenib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, Cobimetinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242517, "ingredient1": "Pralsetinib", "ingredient2": "Pimecrolimus (topical)", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275122/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Dabrafenib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, Cobimetinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242518, "ingredient1": "Theophylline", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275209/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Entrectinib, Imatinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Bosutinib, More", "alternatives_b": "Omalizumab, Tezepelumab, Mercaptopurine, Aminophylline, Benralizumab, Caffeine, Reslizumab, Dyphylline, Oxtriphylline, Mepolizumab, Pentoxifylline, Bromotheophylline", "updated_at": 1767369485}, {"id": 242519, "ingredient1": "Entrectinib", "ingredient2": "Ulipristal", "severity": "Minor", "effect": "Coadministration with CYP450 3A4 inhibitors may increase the plasma concentrations of ulipristal, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Coadministration with CYP450 3A4 inhibitors may increase the plasma concentrations of ulipristal, which is primarily metabolized by the isoenzyme.  The clinical relevance is unknown.", "mechanism_text": "Metabolism", "recommendation": "Coadministration with CYP450 3A4 inhibitors may increase the plasma concentrations of ulipristal, which is primarily metabolized by the isoenzyme.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275212/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Ella (ulipristal).\" Afaxys Inc.  (2022):", "alternatives_a": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, More", "alternatives_b": "Megestrol acetate, Estetrol, Estradiol, Ospemifene, Prasterone, Raloxifene, Bazedoxifene", "updated_at": 1767369485}, {"id": 242520, "ingredient1": "Enzalutamide", "ingredient2": "Ulipristal", "severity": "Major", "effect": "Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of ulipristal acetate and its pharmacologically active metabolite.  Based on in vitro and pharmacokinetic data, ulipristal acetate is thought to be primarily metabolized by CYP450 3A4 to mono-demethylated and di-demethylated metabolites.", "source": "DDInter", "management_text": "Concomitant use of ulipristal acetate with potent and moderate CYP450 3A4 inducers should generally be avoided due to the potential for loss of therapeutic efficacy.  For patients who have used enzyme-inducing drugs within the past 4 weeks and are seeking emergency contraception, ulipristal acetate is not recommended and a non-hormonal method (i.e.  a copper intrauterine device (Cu-IUD)) should be considered.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of ulipristal acetate with potent and moderate CYP450 3A4 inducers should generally be avoided due to the potential for loss of therapeutic efficacy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275213/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Ella (ulipristal).\" Afaxys Inc.  (2022):[4] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[5] \"Product Information. Esmya (ulipristal).\" Gedeon Richter (UK) Ltd  (2021):[6] \"Product Information. EllaOne (ulipristal).\" HRA Pharma UK & Ireland Ltd  (2021):", "alternatives_a": "Darolutamide, Tamoxifen, Anastrozole, Letrozole, Toremifene, Fulvestrant, Abarelix, Flutamide, Bicalutamide, Degarelix, Nilutamide, More", "alternatives_b": "Estetrol, Prasterone, Raloxifene, Bazedoxifene", "updated_at": 1767369485}, {"id": 242521, "ingredient1": "Fedratinib", "ingredient2": "Ulipristal", "severity": "Minor", "effect": "Coadministration with CYP450 3A4 inhibitors may increase the plasma concentrations of ulipristal, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Coadministration with CYP450 3A4 inhibitors may increase the plasma concentrations of ulipristal, which is primarily metabolized by the isoenzyme.  The clinical relevance is unknown.", "mechanism_text": "Metabolism", "recommendation": "Coadministration with CYP450 3A4 inhibitors may increase the plasma concentrations of ulipristal, which is primarily metabolized by the isoenzyme.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275214/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Ella (ulipristal).\" Afaxys Inc.  (2022):", "alternatives_a": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, More", "alternatives_b": "Dienogest, Estetrol, Etynodiol, Ospemifene, Prasterone, Raloxifene, Bazedoxifene", "updated_at": 1767369485}, {"id": 242522, "ingredient1": "Glycerol phenylbutyrate", "ingredient2": "Ulipristal", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ulipristal acetate and its pharmacologically active metabolite.  Based on in vitro and pharmacokinetic data, ulipristal acetate is thought to be primarily metabolized by CYP450 3A4 to mono-demethylated and di-demethylated metabolites.", "source": "DDInter", "management_text": "When used to prevent pregnancy, ulipristal acetate should not be coadministered with CYP450 3A4 inducers due to the potential for loss of therapeutic efficacy.  For patients who have used enzyme-inducing drugs within the past 4 weeks and are seeking emergency contraception, ulipristal acetate is not recommended and a non-hormonal method (i.e.  a copper intrauterine device (Cu-IUD)) should be considered.", "mechanism_text": "Metabolism", "recommendation": "When used to prevent pregnancy, ulipristal acetate should not be coadministered with CYP450 3A4 inducers due to the potential for loss of therapeutic efficacy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275216/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[3] \"Product Information. Esmya (ulipristal).\" Gedeon Richter (UK) Ltd  (2021):[4] \"Product Information. EllaOne (ulipristal).\" HRA Pharma UK & Ireland Ltd  (2021):", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, Agalsidase beta, More", "alternatives_b": "Megestrol acetate, Estetrol, Etynodiol, Norgestrel, Danazol, Mifepristone, Ospemifene, Raloxifene, Bazedoxifene, Prasterone", "updated_at": 1767369485}, {"id": 242523, "ingredient1": "Ulipristal", "ingredient2": "Ivosidenib", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ulipristal acetate and its pharmacologically active metabolite.  Based on in vitro and pharmacokinetic data, ulipristal acetate is thought to be primarily metabolized by CYP450 3A4 to mono-demethylated and di-demethylated metabolites.", "source": "DDInter", "management_text": "When used to prevent pregnancy, ulipristal acetate should not be coadministered with CYP450 3A4 inducers due to the potential for loss of therapeutic efficacy.  For patients who have used enzyme-inducing drugs within the past 4 weeks and are seeking emergency contraception, ulipristal acetate is not recommended and a non-hormonal method (i.e.  a copper intrauterine device (Cu-IUD)) should be considered.", "mechanism_text": "Metabolism", "recommendation": "When used to prevent pregnancy, ulipristal acetate should not be coadministered with CYP450 3A4 inducers due to the potential for loss of therapeutic efficacy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275217/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[3] \"Product Information. Esmya (ulipristal).\" Gedeon Richter (UK) Ltd  (2021):[4] \"Product Information. EllaOne (ulipristal).\" HRA Pharma UK & Ireland Ltd  (2021):", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "alternatives_b": "Estetrol, Danazol, Ospemifene, Raloxifene, Bazedoxifene, Prasterone", "updated_at": 1767369485}, {"id": 242524, "ingredient1": "Ulipristal", "ingredient2": "Lesinurad", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ulipristal acetate and its pharmacologically active metabolite.  Based on in vitro and pharmacokinetic data, ulipristal acetate is thought to be primarily metabolized by CYP450 3A4 to mono-demethylated and di-demethylated metabolites.", "source": "DDInter", "management_text": "When used to prevent pregnancy, ulipristal acetate should not be coadministered with CYP450 3A4 inducers due to the potential for loss of therapeutic efficacy.  For patients who have used enzyme-inducing drugs within the past 4 weeks and are seeking emergency contraception, ulipristal acetate is not recommended and a non-hormonal method (i.e.  a copper intrauterine device (Cu-IUD)) should be considered.", "mechanism_text": "Metabolism", "recommendation": "When used to prevent pregnancy, ulipristal acetate should not be coadministered with CYP450 3A4 inducers due to the potential for loss of therapeutic efficacy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275219/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[3] \"Product Information. Esmya (ulipristal).\" Gedeon Richter (UK) Ltd  (2021):[4] \"Product Information. EllaOne (ulipristal).\" HRA Pharma UK & Ireland Ltd  (2021):", "alternatives_a": "Pegloticase, Febuxostat, Rasburicase, Probenecid, Allopurinol", "alternatives_b": "Megestrol acetate, Estetrol, Estradiol, Danazol, Ospemifene, Raloxifene, Bazedoxifene, Prasterone", "updated_at": 1767369485}, {"id": 242525, "ingredient1": "Ulipristal", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ulipristal acetate and its pharmacologically active metabolite.  Based on in vitro and pharmacokinetic data, ulipristal acetate is thought to be primarily metabolized by CYP450 3A4 to mono-demethylated and di-demethylated metabolites.", "source": "DDInter", "management_text": "When used to prevent pregnancy, ulipristal acetate should not be coadministered with CYP450 3A4 inducers due to the potential for loss of therapeutic efficacy.  For patients who have used enzyme-inducing drugs within the past 4 weeks and are seeking emergency contraception, ulipristal acetate is not recommended and a non-hormonal method (i.e.  a copper intrauterine device (Cu-IUD)) should be considered.", "mechanism_text": "Metabolism", "recommendation": "When used to prevent pregnancy, ulipristal acetate should not be coadministered with CYP450 3A4 inducers due to the potential for loss of therapeutic efficacy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275222/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[3] \"Product Information. Esmya (ulipristal).\" Gedeon Richter (UK) Ltd  (2021):[4] \"Product Information. EllaOne (ulipristal).\" HRA Pharma UK & Ireland Ltd  (2021):", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, Agalsidase beta, More", "alternatives_b": "Megestrol acetate, Estetrol, Estradiol, Danazol, Mifepristone, Ospemifene, Raloxifene, Bazedoxifene, Prasterone", "updated_at": 1767369485}, {"id": 242526, "ingredient1": "Ulipristal", "ingredient2": "Mitotane", "severity": "Major", "effect": "Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of ulipristal acetate and its pharmacologically active metabolite.  Based on in vitro and pharmacokinetic data, ulipristal acetate is thought to be primarily metabolized by CYP450 3A4 to mono-demethylated and di-demethylated metabolites.", "source": "DDInter", "management_text": "Concomitant use of ulipristal acetate with potent and moderate CYP450 3A4 inducers should generally be avoided due to the potential for loss of therapeutic efficacy.  For patients who have used enzyme-inducing drugs within the past 4 weeks and are seeking emergency contraception, ulipristal acetate is not recommended and a non-hormonal method (i.e.  a copper intrauterine device (Cu-IUD)) should be considered.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of ulipristal acetate with potent and moderate CYP450 3A4 inducers should generally be avoided due to the potential for loss of therapeutic efficacy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275225/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Ella (ulipristal).\" Afaxys Inc.  (2022):[4] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[5] \"Product Information. Esmya (ulipristal).\" Gedeon Richter (UK) Ltd  (2021):[6] \"Product Information. EllaOne (ulipristal).\" HRA Pharma UK & Ireland Ltd  (2021):", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "alternatives_b": "Estetrol, Danazol, Mifepristone, Raloxifene, Bazedoxifene, Prasterone", "updated_at": 1767369485}, {"id": 242527, "ingredient1": "Ulipristal", "ingredient2": "Nafcillin", "severity": "Major", "effect": "Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of ulipristal acetate and its pharmacologically active metabolite.  Based on in vitro and pharmacokinetic data, ulipristal acetate is thought to be primarily metabolized by CYP450 3A4 to mono-demethylated and di-demethylated metabolites.", "source": "DDInter", "management_text": "Concomitant use of ulipristal acetate with potent and moderate CYP450 3A4 inducers should generally be avoided due to the potential for loss of therapeutic efficacy.  For patients who have used enzyme-inducing drugs within the past 4 weeks and are seeking emergency contraception, ulipristal acetate is not recommended and a non-hormonal method (i.e.  a copper intrauterine device (Cu-IUD)) should be considered.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of ulipristal acetate with potent and moderate CYP450 3A4 inducers should generally be avoided due to the potential for loss of therapeutic efficacy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275226/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Ella (ulipristal).\" Afaxys Inc.  (2022):[4] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[5] \"Product Information. Esmya (ulipristal).\" Gedeon Richter (UK) Ltd  (2021):[6] \"Product Information. EllaOne (ulipristal).\" HRA Pharma UK & Ireland Ltd  (2021):", "alternatives_a": "Sulbactam, Oxacillin, Dicloxacillin, Piperacillin, Meticillin, Carbenicillin, Bacampicillin, Ticarcillin, Mezlocillin, Tazobactam, Cloxacillin, More", "alternatives_b": "Estetrol, Danazol, Ospemifene, Raloxifene, Bazedoxifene, Prasterone", "updated_at": 1767369485}, {"id": 242528, "ingredient1": "Ulipristal", "ingredient2": "Osilodrostat", "severity": "Minor", "effect": "Coadministration with CYP450 3A4 inhibitors may increase the plasma concentrations of ulipristal, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Coadministration with CYP450 3A4 inhibitors may increase the plasma concentrations of ulipristal, which is primarily metabolized by the isoenzyme.  The clinical relevance is unknown.", "mechanism_text": "Metabolism", "recommendation": "Coadministration with CYP450 3A4 inhibitors may increase the plasma concentrations of ulipristal, which is primarily metabolized by the isoenzyme.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275228/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Ella (ulipristal).\" Afaxys Inc.  (2022):", "alternatives_a": "Dienogest, Estetrol, Etynodiol, Ospemifene, Prasterone, Raloxifene, Bazedoxifene", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242529, "ingredient1": "Ulipristal", "ingredient2": "Palbociclib", "severity": "Minor", "effect": "Coadministration with CYP450 3A4 inhibitors may increase the plasma concentrations of ulipristal, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Coadministration with CYP450 3A4 inhibitors may increase the plasma concentrations of ulipristal, which is primarily metabolized by the isoenzyme.  The clinical relevance is unknown.", "mechanism_text": "Metabolism", "recommendation": "Coadministration with CYP450 3A4 inhibitors may increase the plasma concentrations of ulipristal, which is primarily metabolized by the isoenzyme.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275229/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Ella (ulipristal).\" Afaxys Inc.  (2022):", "alternatives_a": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, More", "alternatives_b": "Norelgestromin, Norethisterone, Etonogestrel, Megestrol acetate, Norgestimate, Etynodiol, Estradiol, Levonorgestrel, Medroxyprogesterone acetate, Desogestrel, Dienogest, More", "updated_at": 1767369485}, {"id": 242530, "ingredient1": "Ulipristal", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275231/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, More", "alternatives_b": "Megestrol acetate, Estetrol, Prasterone, Raloxifene, Bazedoxifene", "updated_at": 1767369485}, {"id": 242531, "ingredient1": "Vemurafenib", "ingredient2": "Ulipristal", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ulipristal acetate and its pharmacologically active metabolite.  Based on in vitro and pharmacokinetic data, ulipristal acetate is thought to be primarily metabolized by CYP450 3A4 to mono-demethylated and di-demethylated metabolites.", "source": "DDInter", "management_text": "When used to prevent pregnancy, ulipristal acetate should not be coadministered with CYP450 3A4 inducers due to the potential for loss of therapeutic efficacy.  For patients who have used enzyme-inducing drugs within the past 4 weeks and are seeking emergency contraception, ulipristal acetate is not recommended and a non-hormonal method (i.e.  a copper intrauterine device (Cu-IUD)) should be considered.", "mechanism_text": "Metabolism", "recommendation": "When used to prevent pregnancy, ulipristal acetate should not be coadministered with CYP450 3A4 inducers due to the potential for loss of therapeutic efficacy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275233/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[3] \"Product Information. Esmya (ulipristal).\" Gedeon Richter (UK) Ltd  (2021):[4] \"Product Information. EllaOne (ulipristal).\" HRA Pharma UK & Ireland Ltd  (2021):", "alternatives_a": "Estetrol, Danazol, Ospemifene, Raloxifene, Bazedoxifene, Prasterone", "alternatives_b": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, More", "updated_at": 1767369485}, {"id": 242532, "ingredient1": "Epirubicin", "ingredient2": "Bacillus calmette-guerin substrain tice live antigen", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275235/", "reference_text": "[1] \"Product Information. Meruvax II (rubella virus vaccine).\" Merck & Co., Inc  (2022):[2] \"Product Information. Attenuvax (measles virus vaccine).\" Merck & Co., Inc  (2022):[3] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD \"Harrison's Principles of Internal Medicine.\" New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] \"Product Information. DENGVAXIA (dengue vaccine).\" sanofi pasteur  (2022):", "alternatives_a": "Valrubicin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242533, "ingredient1": "Epirubicin", "ingredient2": "Bevacizumab", "severity": "Major", "effect": "Coadministration of bevacizumab and anthracyclines may increase the risk of cardiac dysfunction.  Bevacizumab and anthracyclines are individually cardiotoxic and may have additive effects during coadministration.", "source": "DDInter", "management_text": "Bevacizumab is not indicated for use with anthracycline-based chemotherapy.  Some authorities recommend avoiding bevacizumab during and for at least 12 months after stopping anthracycline-containing treatment.", "mechanism_text": "Synergism", "recommendation": "Bevacizumab is not indicated for use with anthracycline-based chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275236/", "reference_text": "[1] \"Product Information. Avastin (bevacizumab).\" Genentech  (2004):[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Necitumumab, Dostarlimab, Amivantamab, Ramucirumab, Atezolizumab, Pembrolizumab, More", "alternatives_b": "Valrubicin, Plicamycin, Ixabepilone, Mitoxantrone, Bleomycin, Mitomycin, Dactinomycin", "updated_at": 1767369485}, {"id": 242534, "ingredient1": "Ibritumomab tiuxetan", "ingredient2": "Epirubicin", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.  Dosing adjustments may be necessary.  The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275248/", "reference_text": "[1] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb  (2001):[2] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb  (2001):[3] \"Product Information. Fluorouracil (fluorouracil).\" Roche Laboratories  (2022):[4] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn  (2001):[5] \"Product Information. Ellence (epirubicin).\" Pharmacia and Upjohn  (2001):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] Agencia Espala de Medicamentos y Productos Sanitarios Healthcare \"Centro de informaci online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):", "alternatives_a": "Ixabepilone, Valrubicin", "alternatives_b": "Tositumomab, Iodide I-131", "updated_at": 1767369485}, {"id": 242535, "ingredient1": "Epirubicin", "ingredient2": "Melphalan flufenamide", "severity": "Minor", "effect": "Limited anecdotal data suggest an increased risk of doxorubicin-induced cardiomyopathy in patients who have previously received melphalan.", "source": "DDInter", "management_text": "Limited anecdotal data suggest an increased risk of doxorubicin-induced cardiomyopathy in patients who have previously received melphalan.  The mechanism of this suspected interaction is unknown.   Although conclusive proof that melphalan sensitizes the myocardium is lacking, anthracyclines should be administered cautiously to patients who have had extensive melphalan therapy.", "mechanism_text": "Synergism", "recommendation": "Limited anecdotal data suggest an increased risk of doxorubicin-induced cardiomyopathy in patients who have previously received melphalan.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275260/", "reference_text": "[1] Bitran JD \"Doxorubicin cardiotoxicity and melphalan\" Ann Intern Med 95 (1981):  243-4", "alternatives_a": "Ixabepilone, Valrubicin, Plicamycin", "alternatives_b": "Cyclophosphamide, Mechlorethamine, Uracil mustard", "updated_at": 1767369485}, {"id": 242536, "ingredient1": "Epirubicin", "ingredient2": "Pyrophosphoric acid", "severity": "Moderate", "effect": "Medicinal products including sodium heparin, prazosin, methyldopa, hydralazine, quinidine, beta blockers, calcium channel blockers, digitalis glycosides, nitrates, anthracyclines, and iodinated contrast agents may interfere with the blood pool images taken using Technetium Tc 99m pyrophosphate.  This is characterized by a reduction in the amount of injected radioactivity remaining in the blood pool.", "source": "DDInter", "management_text": "Clinicians should be aware of the possibility of a diagnostic interference.  When use of iodinated contrast media is anticipated, it is recommended to perform the scintigraphy with (99mTc)-labeled red blood cells prior to administration of the iodinated contrast media to avoid adversely affecting the red blood cell labeling.", "mechanism_text": "Distribution", "recommendation": "Clinicians should be aware of the possibility of a diagnostic interference.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275275/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Pyrophosphate (pyrophosphate).\" Pharmalucence Inc  (2012):", "alternatives_a": "Valrubicin, Plicamycin, Ixabepilone, Mitoxantrone, Bleomycin, Mitomycin, Dactinomycin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242537, "ingredient1": "Epirubicin", "ingredient2": "Varicella Zoster Vaccine (Recombinant)", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual's risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, the U.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275307/", "reference_text": "[1] \"Product Information. Fluzone (influenza virus vaccine, inactivated).\" Connaught Laboratories Inc[2] \"Product Information. Omnihib (haemophilus b conjugate vaccine (obsolete)).\" SmithKline Beecham[3] \"Product Information. Havrix (hepatitis A adult vaccine).\" SmithKline Beecham[4] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[5] \"Product Information. Imovax Rabies (rabies vaccine, human diploid cell).\" sanofi pasteur  (2022):[6] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc.  (2003):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline  (2022):[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations.  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf\"   (2019):[11] CDC Centers for Disease Control and Prevention \"Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html\"   (2022):", "alternatives_a": "Valrubicin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242538, "ingredient1": "Eplerenone", "ingredient2": "Pentosan polysulfate", "severity": "Moderate", "effect": "Heparin and low molecular weight heparins (LMWHs) may cause hyperkalemia.  Concomitant use with potassium-sparing diuretics or aldosterone receptor antagonists may increase the risk and/or severity of hyperkalemia.", "source": "DDInter", "management_text": "Caution is advised when heparin or LMWHs are used with potassium-sparing diuretics or aldosterone receptor antagonists.  Serum potassium levels and renal function should be monitored regularly.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when heparin or LMWHs are used with potassium-sparing diuretics or aldosterone receptor antagonists.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275308/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Agencia Espala de Medicamentos y Productos Sanitarios Healthcare \"Centro de informaci online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):", "alternatives_a": "Fesoterodine, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Flavoxate, Darifenacin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242539, "ingredient1": "Elotuzumab", "ingredient2": "Bacillus calmette-guerin substrain tice live antigen", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275330/", "reference_text": "[1] \"Product Information. Meruvax II (rubella virus vaccine).\" Merck & Co., Inc  (2022):[2] \"Product Information. Attenuvax (measles virus vaccine).\" Merck & Co., Inc  (2022):[3] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD \"Harrison's Principles of Internal Medicine.\" New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] \"Product Information. DENGVAXIA (dengue vaccine).\" sanofi pasteur  (2022):", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242540, "ingredient1": "Elotuzumab", "ingredient2": "Varicella Zoster Vaccine (Recombinant)", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual's risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, the U.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275380/", "reference_text": "[1] \"Product Information. Fluzone (influenza virus vaccine, inactivated).\" Connaught Laboratories Inc[2] \"Product Information. Omnihib (haemophilus b conjugate vaccine (obsolete)).\" SmithKline Beecham[3] \"Product Information. Havrix (hepatitis A adult vaccine).\" SmithKline Beecham[4] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[5] \"Product Information. Imovax Rabies (rabies vaccine, human diploid cell).\" sanofi pasteur  (2022):[6] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc.  (2003):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline  (2022):[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations.  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf\"   (2019):[11] CDC Centers for Disease Control and Prevention \"Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html\"   (2022):", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242541, "ingredient1": "Bacillus calmette-guerin substrain tice live antigen", "ingredient2": "Oxaliplatin", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275381/", "reference_text": "[1] \"Product Information. Meruvax II (rubella virus vaccine).\" Merck & Co., Inc  (2022):[2] \"Product Information. Attenuvax (measles virus vaccine).\" Merck & Co., Inc  (2022):[3] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD \"Harrison's Principles of Internal Medicine.\" New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] \"Product Information. DENGVAXIA (dengue vaccine).\" sanofi pasteur  (2022):", "alternatives_a": "Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, Anagrelide, Ivosidenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242542, "ingredient1": "Fedratinib", "ingredient2": "Oxaliplatin", "severity": "Moderate", "effect": "Coadministration with fedratinib may decrease the renal clearance of drugs that are excreted via organic cation transporter (OCT) 2 and multidrug and toxin extrusion (MATE) 1/2-K.", "source": "DDInter", "management_text": "Caution is advised when fedratinib is used with drugs that are renally excreted via OCT2, MATE1, and MATE2-K.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever fedratinib is added to or withdrawn from therapy, particularly those with a narrow therapeutic index.", "mechanism_text": "Excretion", "recommendation": "Caution is advised when fedratinib is used with drugs that are renally excreted via OCT2, MATE1, and MATE2-K.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275384/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Inrebic (fedratinib).\" Celgene Corporation  (2019):", "alternatives_a": "Dabrafenib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More", "alternatives_b": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Enasidenib, Porfimer sodium, Niraparib, Selinexor, More", "updated_at": 1767369485}, {"id": 242543, "ingredient1": "Ibritumomab tiuxetan", "ingredient2": "Oxaliplatin", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.  Dosing adjustments may be necessary.  The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275390/", "reference_text": "[1] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb  (2001):[2] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb  (2001):[3] \"Product Information. Fluorouracil (fluorouracil).\" Roche Laboratories  (2022):[4] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn  (2001):[5] \"Product Information. Ellence (epirubicin).\" Pharmacia and Upjohn  (2001):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] Agencia Espala de Medicamentos y Productos Sanitarios Healthcare \"Centro de informaci online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):", "alternatives_a": "Tositumomab, Iodide I-131", "alternatives_b": "Pertuzumab, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, More", "updated_at": 1767369485}, {"id": 242544, "ingredient1": "Oxaliplatin", "ingredient2": "Melphalan flufenamide", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.  Dosing adjustments may be necessary.  The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275401/", "reference_text": "[1] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb  (2001):[2] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb  (2001):[3] \"Product Information. Fluorouracil (fluorouracil).\" Roche Laboratories  (2022):[4] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn  (2001):[5] \"Product Information. Ellence (epirubicin).\" Pharmacia and Upjohn  (2001):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] Agencia Espala de Medicamentos y Productos Sanitarios Healthcare \"Centro de informaci online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):", "alternatives_a": "Uracil mustard", "alternatives_b": "Pertuzumab, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, More", "updated_at": 1767369485}, {"id": 242545, "ingredient1": "Oxaliplatin", "ingredient2": "Moxetumomab Pasudotox", "severity": "Moderate", "effect": "Theoretically, coadministration with drugs that are nephrotoxic may delay and/or decrease the clearance of oxaliplatin, which is primarily eliminated unchanged by the kidney.", "source": "DDInter", "management_text": "Caution is advised if oxaliplatin is used in patients who have recently received or are receiving treatment with potentially nephrotoxic drugs (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents).  The potential for increased toxicity of oxaliplatin such as peripheral sensory neuropathies and neutropenia should be considered.  Renal function should be closely monitored during therapy.", "mechanism_text": "Excretion", "recommendation": "Caution is advised if oxaliplatin is used in patients who have recently received or are receiving treatment with potentially nephrotoxic drugs (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275406/", "reference_text": "[1] \"Product Information. Eloxatin (oxaliplatin).\" Sanofi Winthrop Pharmaceuticals  (2002):", "alternatives_a": "Pertuzumab, Olaparib, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242546, "ingredient1": "Pralsetinib", "ingredient2": "Oxaliplatin", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275415/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Enasidenib, Porfimer sodium, Aflibercept, Trastuzumab, Hydroxyurea, More", "alternatives_b": "Dabrafenib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More", "updated_at": 1767369485}, {"id": 242547, "ingredient1": "Varicella Zoster Vaccine (Recombinant)", "ingredient2": "Oxaliplatin", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual's risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, the U.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275446/", "reference_text": "[1] \"Product Information. Fluzone (influenza virus vaccine, inactivated).\" Connaught Laboratories Inc[2] \"Product Information. Omnihib (haemophilus b conjugate vaccine (obsolete)).\" SmithKline Beecham[3] \"Product Information. Havrix (hepatitis A adult vaccine).\" SmithKline Beecham[4] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[5] \"Product Information. Imovax Rabies (rabies vaccine, human diploid cell).\" sanofi pasteur  (2022):[6] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc.  (2003):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline  (2022):[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations.  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf\"   (2019):[11] CDC Centers for Disease Control and Prevention \"Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html\"   (2022):", "alternatives_a": "Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, Anagrelide, Ivosidenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242548, "ingredient1": "Ibritumomab tiuxetan", "ingredient2": "Eltrombopag", "severity": "Moderate", "effect": "The safety and efficacy of hematopoietic growth factors such as colony-stimulating factors (G-CSF and GM-CSF) and stem cell factors (SCF) given simultaneously with radiolabeled ibritumomab tiuxetan have not been established.", "source": "DDInter", "management_text": "Some authorities recommend that patients not receive hematopoietic growth factors for 3 weeks prior to administration of radiolabeled ibritumomab tiuxetan and for 2 weeks following completion of the treatment in order to assess for adequate bone marrow reserve correctly and also because of the potential sensitivity of rapidly dividing myeloid cells to radiation.", "mechanism_text": "Others", "recommendation": "Some authorities recommend that patients not receive hematopoietic growth factors for 3 weeks prior to administration of radiolabeled ibritumomab tiuxetan and for 2 weeks following completion of the treatment in order to assess for adequate bone marrow reserve correctly and also because of the potential sensitivity of rapidly dividing myeloid cells to radiation.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275451/", "reference_text": "[1] \"Product Information. In-111 Zevalin (ibritumomab tiuxetan).\" IDEC Pharmaceuticals Corporation[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Fostamatinib, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Epinephrine, Coagulation Factor IX Human", "alternatives_b": "Tositumomab, Iodide I-131", "updated_at": 1767369485}, {"id": 242549, "ingredient1": "Eltrombopag", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275464/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Romiplostim, Fostamatinib, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Epinephrine, Coagulation Factor IX Human", "alternatives_b": "Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Tepotinib, Fedratinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, More", "updated_at": 1767369485}, {"id": 242550, "ingredient1": "Etanercept", "ingredient2": "Bacillus calmette-guerin substrain tice live antigen", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275645/", "reference_text": "[1] \"Product Information. Meruvax II (rubella virus vaccine).\" Merck & Co., Inc  (2022):[2] \"Product Information. Attenuvax (measles virus vaccine).\" Merck & Co., Inc  (2022):[3] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD \"Harrison's Principles of Internal Medicine.\" New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] \"Product Information. DENGVAXIA (dengue vaccine).\" sanofi pasteur  (2022):", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242551, "ingredient1": "Etanercept", "ingredient2": "Melphalan flufenamide", "severity": "Major", "effect": "The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Concomitant use of TNF blockers with other immunosuppressants such as azathioprine or mercaptopurine may also increase the risk of a rare and often fatal cancer of white blood cells known as hepatosplenic T-Cell lymphoma (HSTCL), which has primarily been reported in adolescent and young adult males receiving treatment for Crohn's disease or ulcerative colitis.", "source": "DDInter", "management_text": "Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections.  TNF blocker therapy should be discontinued if a serious infection or sepsis occurs.  Close monitoring for signs and symptoms of HSTCL (e.g., splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss) is also recommended during use of TNF blockers, particularly in combination with other immunosuppressants such as azathioprine and mercaptopurine.", "mechanism_text": "Synergism", "recommendation": "Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275662/", "reference_text": "[1] \"Product Information. Remicade (infliximab).\" Centocor Inc  (2001):[2] \"Product Information. Enbrel (etanercept).\" Wyeth-Ayerst Laboratories  (2001):[3] \"Product Information. Humira (adalimumab).\" Abbott Pharmaceutical  (2003):[4] \"Product Information. Cimzia (certolizumab).\" UCB Pharma Inc  (2008):[5] \"Product Information. Simponi (golimumab).\" Centocor Inc  (2009):[6] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Drug labels for the Tumor Necrosis Factor-alpha (TNFa) blockers now include warnings about infection with Legionella and Listeria bacteria.  http://www.fda.gov/Drugs/DrugSafety/ucm270849.htm\"   (2012):", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242552, "ingredient1": "Etanercept", "ingredient2": "Promazine", "severity": "Major", "effect": "The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Concomitant use of TNF blockers with other immunosuppressants such as azathioprine or mercaptopurine may also increase the risk of a rare and often fatal cancer of white blood cells known as hepatosplenic T-Cell lymphoma (HSTCL), which has primarily been reported in adolescent and young adult males receiving treatment for Crohn's disease or ulcerative colitis.", "source": "DDInter", "management_text": "Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections.  TNF blocker therapy should be discontinued if a serious infection or sepsis occurs.  Close monitoring for signs and symptoms of HSTCL (e.g., splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss) is also recommended during use of TNF blockers, particularly in combination with other immunosuppressants such as azathioprine and mercaptopurine.", "mechanism_text": "Synergism", "recommendation": "Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275675/", "reference_text": "[1] \"Product Information. Remicade (infliximab).\" Centocor Inc  (2001):[2] \"Product Information. Enbrel (etanercept).\" Wyeth-Ayerst Laboratories  (2001):[3] \"Product Information. Humira (adalimumab).\" Abbott Pharmaceutical  (2003):[4] \"Product Information. Cimzia (certolizumab).\" UCB Pharma Inc  (2008):[5] \"Product Information. Simponi (golimumab).\" Centocor Inc  (2009):[6] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Drug labels for the Tumor Necrosis Factor-alpha (TNFa) blockers now include warnings about infection with Legionella and Listeria bacteria.  http://www.fda.gov/Drugs/DrugSafety/ucm270849.htm\"   (2012):", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "Fluphenazine, Haloperidol, Thiothixene, Risperidone, Amisulpride, Quetiapine, Prochlorperazine, Thioridazine, Lumateperone, Pimozide, Trifluoperazine, More", "updated_at": 1767369485}, {"id": 242553, "ingredient1": "Etanercept", "ingredient2": "Varicella Zoster Vaccine (Recombinant)", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual's risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, the U.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275703/", "reference_text": "[1] \"Product Information. Fluzone (influenza virus vaccine, inactivated).\" Connaught Laboratories Inc[2] \"Product Information. Omnihib (haemophilus b conjugate vaccine (obsolete)).\" SmithKline Beecham[3] \"Product Information. Havrix (hepatitis A adult vaccine).\" SmithKline Beecham[4] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[5] \"Product Information. Imovax Rabies (rabies vaccine, human diploid cell).\" sanofi pasteur  (2022):[6] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc.  (2003):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline  (2022):[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations.  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf\"   (2019):[11] CDC Centers for Disease Control and Prevention \"Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html\"   (2022):", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242554, "ingredient1": "Enfortumab vedotin", "ingredient2": "Bacillus calmette-guerin substrain tice live antigen", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275709/", "reference_text": "[1] \"Product Information. Meruvax II (rubella virus vaccine).\" Merck & Co., Inc  (2022):[2] \"Product Information. Attenuvax (measles virus vaccine).\" Merck & Co., Inc  (2022):[3] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD \"Harrison's Principles of Internal Medicine.\" New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] \"Product Information. DENGVAXIA (dengue vaccine).\" sanofi pasteur  (2022):", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242555, "ingredient1": "Fluvoxamine", "ingredient2": "Enfortumab vedotin", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of unconjugated monomethyl auristatin E (MMAE), the anti-mitotic and cytotoxic component of enfortumab vedotin.", "source": "DDInter", "management_text": "Caution is advised when enfortumab vedotin is used concomitantly with CYP450 3A4 inhibitors.  Patients should be closely monitored for development or exacerbation of toxicities such as peripheral neuropathy, hyperglycaemia, dermatologic reactions (maculopapular rash, pruritus, symmetrical drug-related intertriginous and flexural exanthema (SDRIFE), bullous dermatitis, exfoliative dermatitis, palmar-plantar erythrodysesthesia), and ocular disorders (dry eyes, keratitis, blurred vision, limbal stem cell deficiency), and the dosing of enfortumab vedotin adjusted or withheld as necessary in accordance with the product labeling.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when enfortumab vedotin is used concomitantly with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275712/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Adcetris (brentuximab vedotin).\" Seattle Genetics Inc  (2011):[3] Han TH, Gopal AK, Ramchandren R, et al. \"CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies.\" J Clin Pharmacol 53 (2013):  866-77[4] \"Product Information. Padcev (enfortumab vedotin).\" Seattle Genetics Inc  (2019):", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Amivantamab, Atezolizumab, Pembrolizumab, More", "alternatives_b": "Citalopram, Sertraline, Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Isocarboxazid, Viloxazine, More", "updated_at": 1767369485}, {"id": 242556, "ingredient1": "Enfortumab vedotin", "ingredient2": "Mifepristone", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of unconjugated monomethyl auristatin E (MMAE), the anti-mitotic and cytotoxic component of enfortumab vedotin.  Enfortumab vedotin is an antibody-drug conjugate (ADC) that releases MMAE via proteolytic cleavage, and MMAE has been shown in vitro to be primarily metabolized by CYP450 3A4.", "source": "DDInter", "management_text": "Caution is advised when enfortumab vedotin is used concomitantly with potent CYP450 3A4 inhibitors.  Patients should be closely monitored for development or exacerbation of toxicities such as peripheral neuropathy, hyperglycemia, dermatologic reactions (maculopapular rash, pruritus, symmetrical drug-related intertriginous and flexural exanthema (SDRIFE), bullous dermatitis, exfoliative dermatitis, palmar-plantar erythrodysesthesia), and ocular disorders (dry eyes, keratitis, blurred vision, limbal stem cell deficiency), and the dosing of enfortumab vedotin adjusted or withheld as necessary in accordance with the product labeling.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when enfortumab vedotin is used concomitantly with potent CYP450 3A4 inhibitors.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275727/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Adcetris (brentuximab vedotin).\" Seattle Genetics Inc  (2011):[3] Han TH, Gopal AK, Ramchandren R, et al. \"CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies.\" J Clin Pharmacol 53 (2013):  866-77[4] \"Product Information. Padcev (enfortumab vedotin).\" Seattle Genetics Inc  (2019):", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "alternatives_b": "Ulipristal, Danazol, Ospemifene, Raloxifene, Bazedoxifene, Prasterone", "updated_at": 1767369485}, {"id": 242557, "ingredient1": "Enfortumab vedotin", "ingredient2": "Rifabutin", "severity": "Minor", "effect": "Coadministration with potent inducers of CYP450 3A4 may decrease the plasma concentrations of unconjugated monomethyl auristatin E (MMAE), the anti-mitotic and cytotoxic component of enfortumab vedotin.  Enfortumab vedotin is an antibody-drug conjugate (ADC) that releases MMAE via proteolytic cleavage, and MMAE has been shown in vitro to be primarily metabolized by CYP450 3A4.", "source": "DDInter", "management_text": "However, the interaction is not expected to be clinically relevant, since the intact ADC containing the antibody component is required to bind to Nectin-4, an adhesion protein found on the surface of cells, which allows for internalization and cleavage by lysosomal proteases to enable intracellular delivery of MMAE..", "mechanism_text": "Metabolism", "recommendation": "However, the interaction is not expected to be clinically relevant, since the intact ADC containing the antibody component is required to bind to Nectin-4, an adhesion protein found on the surface of cells, which allows for internalization and cleavage by lysosomal proteases to enable intracellular delivery of MMAE.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275741/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Adcetris (brentuximab vedotin).\" Seattle Genetics Inc  (2011):[3] Han TH, Gopal AK, Ramchandren R, et al. \"CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies.\" J Clin Pharmacol 53 (2013):  866-77[4] \"Product Information. Padcev (enfortumab vedotin).\" Seattle Genetics Inc  (2019):", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "alternatives_b": "Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Streptomycin, Trimethoprim, Cycloserine, Pyridoxine, Pretomanid, Aminosalicylic acid, More", "updated_at": 1767369485}, {"id": 242558, "ingredient1": "Enfortumab vedotin", "ingredient2": "Varicella Zoster Vaccine (Recombinant)", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual's risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, the U.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275766/", "reference_text": "[1] \"Product Information. Fluzone (influenza virus vaccine, inactivated).\" Connaught Laboratories Inc[2] \"Product Information. Omnihib (haemophilus b conjugate vaccine (obsolete)).\" SmithKline Beecham[3] \"Product Information. Havrix (hepatitis A adult vaccine).\" SmithKline Beecham[4] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[5] \"Product Information. Imovax Rabies (rabies vaccine, human diploid cell).\" sanofi pasteur  (2022):[6] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc.  (2003):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline  (2022):[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations.  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf\"   (2019):[11] CDC Centers for Disease Control and Prevention \"Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html\"   (2022):", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242559, "ingredient1": "Eplerenone", "ingredient2": "Enoxaparin", "severity": "Moderate", "effect": "Heparin and low molecular weight heparins (LMWHs) may cause hyperkalemia.  Concomitant use with potassium-sparing diuretics or aldosterone receptor antagonists may increase the risk and/or severity of hyperkalemia.", "source": "DDInter", "management_text": "Caution is advised when heparin or LMWHs are used with potassium-sparing diuretics or aldosterone receptor antagonists.  Serum potassium levels and renal function should be monitored regularly.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when heparin or LMWHs are used with potassium-sparing diuretics or aldosterone receptor antagonists.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275793/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Agencia Espala de Medicamentos y Productos Sanitarios Healthcare \"Centro de informaci online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Caplacizumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242560, "ingredient1": "Heparin (flush)", "ingredient2": "Enoxaparin", "severity": "Moderate", "effect": "Concomitant use of heparin flush and drugs that interfere with platelet function or coagulation or drugs that commonly cause thrombocytopenia may potentiate the risk of bleeding complications.  Although uncommon, inadvertent anticoagulation resulting in hemorrhagic events may occur with heparin flushes, particularly during repeated or excessive use or administration of higher concentration flush solutions.", "source": "DDInter", "management_text": "Caution and monitoring (e.g., platelet counts, hematocrits, tests for occult blood in stools) are advised when heparin flushes are given to patients receiving systemic anticoagulants, platelet inhibitors, antithrombotic agents, thrombolytics, or drugs with known risks of thrombocytopenia or bleeding.  An unexplained fall in hematocrit, fall in blood pressure, or any other unexplained symptom should lead to serious consideration of a hemorrhagic event.", "mechanism_text": "Synergism", "recommendation": "Caution and monitoring (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275797/", "reference_text": "[1] Passannante A, Macik BG \"The heparin flush syndrome: a cause of iatrogenic hemorrhage.\" Am J Med Sci 296 (1988):  71-3[2] \"Product Information. Heparin Sodium in Sodium Chloride (heparin flush).\" Baxter Healthcare Corporation  (2022):[3] \"Product Information. Canusal (heparin flush).\" Wockhardt UK Ltd  (2018):[4] \"Product Information. Heparinised Saline (Pfizer) (heparinised saline).\" Pfizer Australia Pty Ltd  (2022):", "alternatives_a": "Acenocoumarol, Selexipag", "alternatives_b": "Acenocoumarol, Selexipag, Enoxaparin, Ascorbic acid, Cyclosporine, Sirolimus, Potassium Iodide, Vitamin A, Acetylcysteine, Nandrolone", "updated_at": 1767369485}, {"id": 242561, "ingredient1": "Satralizumab", "ingredient2": "Bacillus calmette-guerin substrain tice live antigen", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275807/", "reference_text": "[1] \"Product Information. Meruvax II (rubella virus vaccine).\" Merck & Co., Inc  (2022):[2] \"Product Information. Attenuvax (measles virus vaccine).\" Merck & Co., Inc  (2022):[3] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD \"Harrison's Principles of Internal Medicine.\" New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] \"Product Information. DENGVAXIA (dengue vaccine).\" sanofi pasteur  (2022):", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242562, "ingredient1": "Satralizumab", "ingredient2": "Melphalan flufenamide", "severity": "Moderate", "effect": "The use of interleukin blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections.", "source": "DDInter", "management_text": "Caution is advised when interleukin inhibitors are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges such as immunosuppressants or antineoplastic agents.  Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of interleukin inhibitor therapy, and the dosage(s) of these drugs adjusted accordingly.  Clinicians should note that the effects of interleukin inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when interleukin inhibitors are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges such as immunosuppressants or antineoplastic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275822/", "reference_text": "[1] \"Product Information. Amevive (alefacept).\" Biogen  (2003):[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc  (2008):[4] \"Product Information. Stelara (ustekinumab).\" Centocor Inc  (2009):[5] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals  (2009):[6] \"Product Information. Actemra (tocilizumab).\" Genentech  (2010):[7] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc.  (2014):[8] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals  (2015):[9] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company  (2016):", "alternatives_a": "Temozolomide, Thiotepa, Carmustine, Cyclophosphamide, Busulfan, Chlorambucil, Lomustine, Dacarbazine, Mechlorethamine, Bendamustine, Ifosfamide, More", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More", "updated_at": 1767369485}, {"id": 242563, "ingredient1": "Varicella Zoster Vaccine (Recombinant)", "ingredient2": "Satralizumab", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual's risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, the U.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275858/", "reference_text": "[1] \"Product Information. Fluzone (influenza virus vaccine, inactivated).\" Connaught Laboratories Inc[2] \"Product Information. Omnihib (haemophilus b conjugate vaccine (obsolete)).\" SmithKline Beecham[3] \"Product Information. Havrix (hepatitis A adult vaccine).\" SmithKline Beecham[4] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[5] \"Product Information. Imovax Rabies (rabies vaccine, human diploid cell).\" sanofi pasteur  (2022):[6] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc.  (2003):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline  (2022):[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations.  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf\"   (2019):[11] CDC Centers for Disease Control and Prevention \"Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html\"   (2022):", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242564, "ingredient1": "Abatacept", "ingredient2": "Bacillus calmette-guerin substrain tice live antigen", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275860/", "reference_text": "[1] \"Product Information. Meruvax II (rubella virus vaccine).\" Merck & Co., Inc  (2022):[2] \"Product Information. Attenuvax (measles virus vaccine).\" Merck & Co., Inc  (2022):[3] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD \"Harrison's Principles of Internal Medicine.\" New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] \"Product Information. DENGVAXIA (dengue vaccine).\" sanofi pasteur  (2022):", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242565, "ingredient1": "Abatacept", "ingredient2": "Varicella Zoster Vaccine (Recombinant)", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual's risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, the U.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275909/", "reference_text": "[1] \"Product Information. Fluzone (influenza virus vaccine, inactivated).\" Connaught Laboratories Inc[2] \"Product Information. Omnihib (haemophilus b conjugate vaccine (obsolete)).\" SmithKline Beecham[3] \"Product Information. Havrix (hepatitis A adult vaccine).\" SmithKline Beecham[4] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[5] \"Product Information. Imovax Rabies (rabies vaccine, human diploid cell).\" sanofi pasteur  (2022):[6] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc.  (2003):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline  (2022):[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations.  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf\"   (2019):[11] CDC Centers for Disease Control and Prevention \"Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html\"   (2022):", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242566, "ingredient1": "Fostamatinib", "ingredient2": "Entrectinib", "severity": "Moderate", "effect": "Coadministration of fostamatinib with inhibitors of CYP450 3A4 may increase exposure to the active metabolite known as R406, the predominant moiety in the systemic circulation following fostamatinib administration.  Fostamatinib is metabolized in the gut by alkaline phosphatase to R406, which then undergoes oxidation via CYP450 3A4 and glucuronidation via UGT1A9.  In vitro, R406 is also a substrate of the P-glycoprotein (P-gp) efflux transporter.", "source": "DDInter", "management_text": "Patients should be monitored for toxicities of fostamatinib during concomitant use of potent or moderate CYP450 3A4 inhibitors or dual CYP450 3A4/P-gp inhibitors, and the fostamatinib dosage adjusted as necessary in accordance with the product labeling.", "mechanism_text": "Metabolism", "recommendation": "Patients should be monitored for toxicities of fostamatinib during concomitant use of potent or moderate CYP450 3A4 inhibitors or dual CYP450 3A4/P-gp inhibitors, and the fostamatinib dosage adjusted as necessary in accordance with the product labeling.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275913/", "reference_text": "[1] \"Product Information. Tavalisse (fostamatinib).\" Rigel Pharmaceuticals  (2018):", "alternatives_a": "Pralsetinib, Asciminib, Acalabrutinib, Dacomitinib, Pacritinib, Avapritinib, Selumetinib, Capmatinib, Ibrutinib, Duvelisib, Tivozanib, More", "alternatives_b": "Romiplostim, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Epinephrine, Coagulation Factor IX Human", "updated_at": 1767369485}, {"id": 242567, "ingredient1": "Ibrutinib", "ingredient2": "Entrectinib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ibrutinib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if ibrutinib is prescribed in combination with CYP450 3A4 inhibitors.  Patients should be closely monitored for signs of ibrutinib toxicity such as myelosuppression, bleeding, infection, and renal impairment.  Dosage reduction in accordance with ibrutinib product labeling may be necessary if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if ibrutinib is prescribed in combination with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275915/", "reference_text": "[1] \"Product Information. Imbruvica (ibrutinib).\" Pharmacyclics Inc  (2013):[2] \"Product Information. Qelbree (viloxazine).\" Supernus Pharmaceuticals Inc  (2021):", "alternatives_a": "Dabrafenib, Dacomitinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Tivozanib, Brigatinib, Axitinib, Lenvatinib, More", "alternatives_b": "Futibatinib, Entrectinib, Regorafenib, Copanlisib, Trametinib, Erlotinib, Ponatinib, Neratinib, Erdafitinib, Nintedanib, Capmatinib, More", "updated_at": 1767369485}, {"id": 242568, "ingredient1": "Entrectinib", "ingredient2": "Lurbinectedin", "severity": "Moderate", "effect": "Coadministration with a CYP450 3A4 inhibitor may increase lurbinectedin systemic exposure, which may increase the incidence and severity of adverse reactions to lurbinectedin, such as myelosuppression and hepatotoxicity.", "source": "DDInter", "management_text": "Clinical and laboratory monitoring is advised whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy with lurbinectedin.  Patients should be advised to contact their physician if they experience symptoms suggestive of myelosuppression or hepatotoxicity, such as fever or any other signs of infection, unusual bruising or bleeding; or nausea or vomiting, or pain on the right side of the abdomen.", "mechanism_text": "Metabolism", "recommendation": "Clinical and laboratory monitoring is advised whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy with lurbinectedin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275920/", "reference_text": "[1] \"Product Information. Zepzelca (lurbinectedin).\" Jazz Pharmaceuticals  (2020):", "alternatives_a": "Pralsetinib, Asciminib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, More", "alternatives_b": "Pertuzumab, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Porfimer sodium, Selinexor, More", "updated_at": 1767369485}, {"id": 242569, "ingredient1": "Entrectinib", "ingredient2": "Macitentan", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 or moderate dual or combined inhibitors of CYP450 3A4 and CYP450 2C9 may increase the plasma concentrations of macitentan.  Macitentan is primarily metabolized by CYP450 3A4 and to a minor extent by CYP450 2C8, CYP450 2C9 and CYP450 2C19.", "source": "DDInter", "management_text": "Caution is advisable if macitentan is used with inhibitors of CYP450 3A4.  The product labeling recommends avoiding concomitant use with potent inhibitors (e.g., protease inhibitors, clarithromycin, cobicistat, conivaptan, delavirdine, itraconazole, ketoconazole, nefazodone, posaconazole, voriconazole).  The manufacturer of macitentan also recommends avoiding concomitant use with moderate dual inhibitors of CYP450 3A4 and 2C9 (e.g., fluconazole, amiodarone) or in combination with both a moderate CYP450 3A4 inhibitor and a moderate CYP450 2C9 inhibitor.", "mechanism_text": "Metabolism", "recommendation": "Caution is advisable if macitentan is used with inhibitors of CYP450 3A4.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275921/", "reference_text": "[1] \"Product Information. Opsumit (macitentan).\" Actelion Pharmaceuticals US Inc  (2013):", "alternatives_a": "Dabrafenib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, More", "alternatives_b": "Metyrosine", "updated_at": 1767369485}, {"id": 242570, "ingredient1": "Entrectinib", "ingredient2": "Maraviroc", "severity": "Moderate", "effect": "Coadministration with inhibitors of the CYP450 3A4 isoenzyme and/or P-glycoprotein efflux transporter may increase the plasma concentrations of maraviroc, which is a substrate of both.", "source": "DDInter", "management_text": "Caution is advised when maraviroc is used with inhibitors of CYP450 3A4 and/or P-glycoprotein.  Dosage adjustment for maraviroc may be necessary if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when maraviroc is used with inhibitors of CYP450 3A4 and/or P-glycoprotein.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275922/", "reference_text": "[1] \"Product Information. Selzentry (maraviroc).\" Pfizer U.S. Pharmaceuticals Group  (2007):", "alternatives_a": "Acalabrutinib, Dacomitinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Afatinib, Tivozanib, Zanubrutinib, Axitinib, More", "alternatives_b": "Lamivudine, Tenofovir alafenamide, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Dolutegravir, Oseltamivir, Acyclovir, Stavudine, Elbasvir, More", "updated_at": 1767369485}, {"id": 242571, "ingredient1": "Entrectinib", "ingredient2": "Pemigatinib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of pemigatinib, which is primarily metabolized by the isoenzyme in vitro.", "source": "DDInter", "management_text": "Caution is advised if pemigatinib is coadministered with CYP450 3A4 inhibitors.  Dosage adjustments may be required based on clinical response and tolerance.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pemigatinib is coadministered with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275927/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Pemazyre (pemigatinib).\" Incyte Corporation  (2020):", "alternatives_a": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More", "alternatives_b": "Futibatinib, Entrectinib, Regorafenib, Copanlisib, Trametinib, Erlotinib, Ponatinib, Neratinib, Erdafitinib, Nintedanib, Capmatinib, More", "updated_at": 1767369485}, {"id": 242572, "ingredient1": "Entrectinib", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of pralsetinib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised when pralsetinib is used with CYP450 3A inhibitors.  Monitor closely for adverse effects whenever a CYP450 3A4 inhibitor is added to therapy.  Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when pralsetinib is used with CYP450 3A inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275930/", "reference_text": "[1] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Copanlisib, Abemaciclib, Erdafitinib, Neratinib, Erlotinib, Pralsetinib, Dacomitinib, Alectinib, Binimetinib", "alternatives_b": "Futibatinib, Entrectinib, Regorafenib, Copanlisib, Trametinib, Erlotinib, Ponatinib, Neratinib, Erdafitinib, Nintedanib, Capmatinib, More", "updated_at": 1767369485}, {"id": 242573, "ingredient1": "Entrectinib", "ingredient2": "Selumetinib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of selumetinib, which is primarily metabolized by CYP450 3A4 and to a lesser extent by CYP450 2C19, 1A2, 2C9, 2E1, and 3A5.  Selumetinib also undergoes glucuronidation by UGT1A1 and UGT1A3.", "source": "DDInter", "management_text": "Caution is advised when selumetinib is coadministered with CYP450 3A4 inhibitors.  Dosage adjustments may be required based on clinical response and tolerance.  Please refer to the product labeling for specific guidelines on dosing adjustments.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when selumetinib is coadministered with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275932/", "reference_text": "[1] \"Product Information. Koselugo (selumetinib).\" Astra-Zeneca Pharmaceuticals  (2020):", "alternatives_a": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More", "alternatives_b": "Futibatinib, Entrectinib, Regorafenib, Copanlisib, Trametinib, Erlotinib, Ponatinib, Neratinib, Erdafitinib, Nintedanib, Capmatinib, More", "updated_at": 1767369485}, {"id": 242574, "ingredient1": "Vedolizumab", "ingredient2": "Bacillus calmette-guerin substrain tice live antigen", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence.", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy.  Vaccination should be deferred until after such therapy is discontinued for at least 3 months in most cases, and longer following treatment with agents that have a prolonged elimination half-life.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks.  Vedolizumab labeling recommends that patients be brought up-to-date with all immunizations according to current immunization guidelines prior to initiating treatment.  Live vaccines may be administered concurrently with vedolizumab only if the benefits outweigh the risks.", "mechanism_text": "Synergism", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275939/", "reference_text": "[1] \"Product Information. Meruvax II (rubella virus vaccine).\" Merck & Co., Inc  (2022):[2] \"Product Information. Attenuvax (measles virus vaccine).\" Merck & Co., Inc  (2022):[3] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD \"Harrison's Principles of Internal Medicine.\" New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Co., Inc  (2002):[7] \"Product Information. Entyvio (vedolizumab).\" Takeda Pharmaceuticals America  (2014):", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242575, "ingredient1": "Varicella Zoster Vaccine (Recombinant)", "ingredient2": "Vedolizumab", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual's risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, the U.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/275991/", "reference_text": "[1] \"Product Information. Fluzone (influenza virus vaccine, inactivated).\" Connaught Laboratories Inc[2] \"Product Information. Omnihib (haemophilus b conjugate vaccine (obsolete)).\" SmithKline Beecham[3] \"Product Information. Havrix (hepatitis A adult vaccine).\" SmithKline Beecham[4] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[5] \"Product Information. Imovax Rabies (rabies vaccine, human diploid cell).\" sanofi pasteur  (2022):[6] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc.  (2003):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline  (2022):[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations.  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf\"   (2019):[11] CDC Centers for Disease Control and Prevention \"Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html\"   (2022):", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242576, "ingredient1": "Glycerol phenylbutyrate", "ingredient2": "Enzalutamide", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 2C8 and/or 3A4 may decrease the plasma concentrations of enzalutamide, which is primarily metabolized by CYP450 2C8 to its pharmacologically active metabolite, N-desmethyl enzalutamide, and to a lesser extent by CYP450 3A4.", "source": "DDInter", "management_text": "Concomitant use of enzalutamide with potent CYP450 2C8 and/or 3A4 inducers such as carbamazepine, lumacaftor, mitotane, phenobarbital, phenytoin, primidone (partially metabolized to phenobarbital), rifamycins, and St. John's wort should generally be avoided.  Moderate inducers such as bosentan, efavirenz, etravirine, modafinil, nafcillin, and nevirapine should also be avoided if possible.  The extent to which other, less potent CYP450 3A4 inducers may interact with enzalutamide is unknown.  Caution is advised if they are used with enzalutamide.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of enzalutamide with potent CYP450 2C8 and/or 3A4 inducers such as carbamazepine, lumacaftor, mitotane, phenobarbital, phenytoin, primidone (partially metabolized to phenobarbital), rifamycins, and St.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276000/", "reference_text": "[1] \"Product Information. Xtandi (enzalutamide).\" Astellas Pharma US, Inc  (2012):", "alternatives_a": "Anastrozole, Aminoglutethimide, Letrozole, Toremifene, Fulvestrant, Abarelix, Flutamide, Bicalutamide, Degarelix, Nilutamide, Apalutamide, More", "alternatives_b": "Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Zinc acetate, Levocarnitine, Laronidase, Imiglucerase, More", "updated_at": 1767369485}, {"id": 242577, "ingredient1": "Enzalutamide", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 2C8 and/or 3A4 may decrease the plasma concentrations of enzalutamide, which is primarily metabolized by CYP450 2C8 to its pharmacologically active metabolite, N-desmethyl enzalutamide, and to a lesser extent by CYP450 3A4.", "source": "DDInter", "management_text": "Concomitant use of enzalutamide with potent CYP450 2C8 and/or 3A4 inducers such as carbamazepine, lumacaftor, mitotane, phenobarbital, phenytoin, primidone (partially metabolized to phenobarbital), rifamycins, and St. John's wort should generally be avoided.  Moderate inducers such as bosentan, efavirenz, etravirine, modafinil, nafcillin, and nevirapine should also be avoided if possible.  The extent to which other, less potent CYP450 3A4 inducers may interact with enzalutamide is unknown.  Caution is advised if they are used with enzalutamide.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of enzalutamide with potent CYP450 2C8 and/or 3A4 inducers such as carbamazepine, lumacaftor, mitotane, phenobarbital, phenytoin, primidone (partially metabolized to phenobarbital), rifamycins, and St.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276008/", "reference_text": "[1] \"Product Information. Xtandi (enzalutamide).\" Astellas Pharma US, Inc  (2012):", "alternatives_a": "Tamoxifen, Anastrozole, Aminoglutethimide, Letrozole, Fulvestrant, Abarelix, Flutamide, Bicalutamide, Degarelix, Nilutamide, Apalutamide, More", "alternatives_b": "Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Zinc acetate, Levocarnitine, Laronidase, Imiglucerase, More", "updated_at": 1767369485}, {"id": 242578, "ingredient1": "Enzalutamide", "ingredient2": "Perampanel", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations and pharmacologic effects of perampanel, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "According to the manufacturer, concomitant use of perampanel with strong CYP450 3A4 inducers should be avoided.", "mechanism_text": "Metabolism", "recommendation": "According to the manufacturer, concomitant use of perampanel with strong CYP450 3A4 inducers should be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276014/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):", "alternatives_a": "Darolutamide, Tamoxifen, Anastrozole, Letrozole, Toremifene, Fulvestrant, Abarelix, Flutamide, Relugolix, Bicalutamide, Degarelix, More", "alternatives_b": "Ethotoin, Gabapentin, Valproic acid, Topiramate, Paramethadione, Mephenytoin, Methsuximide, Fenfluramine, Phensuximide, Lamotrigine, Phenacemide, More", "updated_at": 1767369485}, {"id": 242579, "ingredient1": "Enzalutamide", "ingredient2": "Tivozanib", "severity": "Major", "effect": "Coadministration of tivozanib with strong CYP450 3A4 inducers may decrease the plasma concentrations and therapeutic effects of tivozanib, which has been shown to be a substrate of the isoenzyme.", "source": "DDInter", "management_text": "Due to the potential for reduced anti-tumor activity, concomitant use of tivozanib with a strong CYP450 3A4 inducer should generally be avoided.  If coadministration is necessary, some authorities advise caution, with clinical and laboratory monitoring to be considered whenever a strong CYP450 3A4 inducer is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Due to the potential for reduced anti-tumor activity, concomitant use of tivozanib with a strong CYP450 3A4 inducer should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276023/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Fotivda (tivozanib).\" Aveo Pharmaceuticals, Inc.  (2021):", "alternatives_a": "Darolutamide, Tamoxifen, Anastrozole, Letrozole, Toremifene, Fulvestrant, Abarelix, Flutamide, Relugolix, Bicalutamide, Degarelix, More", "alternatives_b": "Alectinib, Dacomitinib", "updated_at": 1767369485}, {"id": 242580, "ingredient1": "Epinephrine (ophthalmic)", "ingredient2": "Deserpidine", "severity": "Moderate", "effect": "Postganglionic adrenergic blocking agents may potentiate the pharmacologic effects of direct-acting sympathomimetic amines, while the hypotensive effect of the former may be diminished.  Postganglionic adrenergic blocking agents such as guanadrel, guanethidine, and rauwolfia alkaloids work by depleting catecholamine stores from adrenergic nerve endings, thus they may sensitize adrenergic receptors to direct-acting sympathomimetics.", "source": "DDInter", "management_text": "Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.  Conversely, alternatives to postganglionic adrenergic blocking agents should be considered in patients treated with sympathomimetic amines.  If the combination is used, blood pressure and heart rate should be closely monitored.", "mechanism_text": "Antagonism", "recommendation": "Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276026/", "reference_text": "[1] Spiers AS, Calne DB \"Action of dopamine on the human iris.\" Br Med J 4 (1969):  333-5[2] Muelheims GH, Entrup RW, Paiewonsky D, Mierzwiak DS \"Increased sensitivity of the heart to catecholamine-induced arrhythmias following guanethidine.\" Clin Pharmacol Ther 6 (1965):  757-62[3] Limbird LE eds., Gilman AG, Hardman JG \"Goodman and Gilman's the Pharmacological Basis of Therapeutics.\" New York, NY: McGraw-Hill  (1995):", "alternatives_a": "Prazosin, Clonidine, Hydralazine, Guanfacine, Clonidine, Methyldopa", "alternatives_b": "Tetracycline, Minocycline, Amphotericin B, Miconazole, Doxycycline, Metronidazole, Clotrimazole, Acetylsalicylic acid, Chlorhexidine, Neomycin, Formoterol, More", "updated_at": 1767369485}, {"id": 242581, "ingredient1": "Epinephrine (ophthalmic)", "ingredient2": "Ergometrine", "severity": "Major", "effect": "Additive or synergistic increases in blood pressure and/or ischemic response may occur when ergot alkaloids are combined with peripheral or central vasoconstrictors.  Ergot alkaloids produce arterial vasoconstriction by stimulating alpha-adrenergic and serotonin receptors and inhibiting endothelial-derived relaxation factor release.", "source": "DDInter", "management_text": "Ergot alkaloids should generally not be administered in combination with other vasoconstrictive agents.  If concomitant use is required, patients should be monitored for excessive vasoconstriction and have vital signs measured regularly.  Patients should also be advised to seek immediate medical attention if they experience potential symptoms of ischemia such as coldness, pallor, cyanosis, numbness, tingling, or pain in the extremities; muscle weakness; severe or worsening headache; visual disturbances; severe abdominal pain; chest pain; and shortness of breath.", "mechanism_text": "Synergism", "recommendation": "Ergot alkaloids should generally not be administered in combination with other vasoconstrictive agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276027/", "reference_text": "[1] Buchanan N, Cane RD, Miller M \"Symmetrical gangrene of the extremities associated with the use of dopamine subsequent to ergometrine administration.\" Intensive Care Med 3 (1977):  55-6[2] Barthel W, Glusa E, Koth W \"Interactions of dihydroergotamine with etilefrine in human leg veins in vitro and in situ.\" Int J Clin Pharmacol Ther Toxicol 25 (1987):  63-9[3] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation  (2002):[4] \"Product Information. Bellergal-S (ergotamine).\" Sandoz Pharmaceuticals Corporation  (2002):[5] \"Product Information. ProAmatine (midodrine).\" Roberts Pharmaceutical Corporation  (2001):[6] Chuang SS \"Finger ischemia secondary to the synergistic agonist effect of norepinephrine and ergonovine and in a burn patient.\" Burns 29 (2003):  92-4", "alternatives_a": "Amphotericin B, Hydrocortisone, Metronidazole, Prednisolone, Triamcinolone, Acetylsalicylic acid, Chlorhexidine, Neomycin, Formoterol, Cromoglicic acid, Ipratropium, More", "alternatives_b": "Misoprostol, Dinoprostone, Oxytocin", "updated_at": 1767369485}, {"id": 242582, "ingredient1": "Guanadrel", "ingredient2": "Epinephrine (ophthalmic)", "severity": "Moderate", "effect": "Postganglionic adrenergic blocking agents may potentiate the pharmacologic effects of direct-acting sympathomimetic amines, while the hypotensive effect of the former may be diminished.  Postganglionic adrenergic blocking agents such as guanadrel, guanethidine, and rauwolfia alkaloids work by depleting catecholamine stores from adrenergic nerve endings, thus they may sensitize adrenergic receptors to direct-acting sympathomimetics.", "source": "DDInter", "management_text": "Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.  Conversely, alternatives to postganglionic adrenergic blocking agents should be considered in patients treated with sympathomimetic amines.  If the combination is used, blood pressure and heart rate should be closely monitored.", "mechanism_text": "Antagonism", "recommendation": "Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276029/", "reference_text": "[1] Spiers AS, Calne DB \"Action of dopamine on the human iris.\" Br Med J 4 (1969):  333-5[2] Muelheims GH, Entrup RW, Paiewonsky D, Mierzwiak DS \"Increased sensitivity of the heart to catecholamine-induced arrhythmias following guanethidine.\" Clin Pharmacol Ther 6 (1965):  757-62[3] Limbird LE eds., Gilman AG, Hardman JG \"Goodman and Gilman's the Pharmacological Basis of Therapeutics.\" New York, NY: McGraw-Hill  (1995):", "alternatives_a": "Tetracycline, Minocycline, Amphotericin B, Miconazole, Doxycycline, Metronidazole, Clotrimazole, Acetylsalicylic acid, Chlorhexidine, Neomycin, Formoterol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242583, "ingredient1": "Guanethidine", "ingredient2": "Epinephrine (ophthalmic)", "severity": "Moderate", "effect": "Postganglionic adrenergic blocking agents may potentiate the pharmacologic effects of direct-acting sympathomimetic amines, while the hypotensive effect of the former may be diminished.  Postganglionic adrenergic blocking agents such as guanadrel, guanethidine, and rauwolfia alkaloids work by depleting catecholamine stores from adrenergic nerve endings, thus they may sensitize adrenergic receptors to direct-acting sympathomimetics.", "source": "DDInter", "management_text": "Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.  Conversely, alternatives to postganglionic adrenergic blocking agents should be considered in patients treated with sympathomimetic amines.  If the combination is used, blood pressure and heart rate should be closely monitored.", "mechanism_text": "Antagonism", "recommendation": "Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276030/", "reference_text": "[1] Spiers AS, Calne DB \"Action of dopamine on the human iris.\" Br Med J 4 (1969):  333-5[2] Muelheims GH, Entrup RW, Paiewonsky D, Mierzwiak DS \"Increased sensitivity of the heart to catecholamine-induced arrhythmias following guanethidine.\" Clin Pharmacol Ther 6 (1965):  757-62[3] Limbird LE eds., Gilman AG, Hardman JG \"Goodman and Gilman's the Pharmacological Basis of Therapeutics.\" New York, NY: McGraw-Hill  (1995):", "alternatives_a": "Tetracycline, Minocycline, Amphotericin B, Miconazole, Doxycycline, Metronidazole, Clotrimazole, Acetylsalicylic acid, Chlorhexidine, Neomycin, Formoterol, More", "alternatives_b": "Neostigmine, Brimonidine, Timolol, Levobunolol, Methazolamide, Pilocarpine, Physostigmine, Bimatoprost, Brinzolamide, Acetylcholine, Betaxolol, More", "updated_at": 1767369485}, {"id": 242584, "ingredient1": "Isoetharine", "ingredient2": "Epinephrine (ophthalmic)", "severity": "Moderate", "effect": "Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects.", "source": "DDInter", "management_text": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.  Blood pressure and heart rate should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276031/", "reference_text": "[1] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990):  1396-9[2] \"Product Information. Proventil (albuterol).\" Schering Corporation  (2002):[3] \"Product Information. Serevent (salmeterol).\" Glaxo Wellcome[4] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals  (2001):[5] \"Product Information. Xopenex (levalbuterol).\" Sepracor Inc  (2001):[6] \"Product Information. Foradil (formoterol).\" Novartis Pharmaceuticals  (2001):[7] \"Product Information. Brovana (arformoterol).\" Sepracor Inc  (2006):[8] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001):  45-51[9] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals  (2011):[10] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline  (2013):[11] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim  (2014):", "alternatives_a": "Tetracycline, Minocycline, Amphotericin B, Miconazole, Doxycycline, Metronidazole, Clotrimazole, Acetylsalicylic acid, Chlorhexidine, Neomycin, Mometasone furoate, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242585, "ingredient1": "Epinephrine (ophthalmic)", "ingredient2": "Ketamine", "severity": "Moderate", "effect": "Ketamine can cause hemodynamic instability such as arrhythmias and transient increases or decreases in blood pressure, heart rate, and cardiac index.  Coadministration of ketamine with direct or indirect acting sympathomimetics or vasopressin may enhance the sympathomimetic effects of ketamine leading to additive increases in blood pressure and heart rate.", "source": "DDInter", "management_text": "Close monitoring of vital signs, including blood pressure and heart rate is recommended whenever ketamine is used concomitantly with direct or indirect acting sympathomimetics or vasopressin.  Dosage adjustments should be considered according to the patient's clinical situation.  Some authorities suggest avoiding the use of ketamine in patients receiving drugs with a hypertensive effect such as ergometrine.", "mechanism_text": "Synergism", "recommendation": "Close monitoring of vital signs, including blood pressure and heart rate is recommended whenever ketamine is used concomitantly with direct or indirect acting sympathomimetics or vasopressin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276032/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Ketalar (ketamine).\" JHP Pharmaceuticals  (2009):", "alternatives_a": "Tetracycline, Minocycline, Miconazole, Doxycycline, Hydrocortisone, Metronidazole, Clotrimazole, Prednisolone, Triamcinolone, Acetylsalicylic acid, Chlorhexidine, More", "alternatives_b": "Halothane, Thiopental, Alfentanil, Remifentanil, Isoflurane, Sodium oxybate, Methohexital, Fentanyl, Desflurane, Nitrous oxide, Sufentanil, More", "updated_at": 1767369485}, {"id": 242586, "ingredient1": "Epinephrine (ophthalmic)", "ingredient2": "Ritodrine", "severity": "Moderate", "effect": "Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects.", "source": "DDInter", "management_text": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.  Blood pressure and heart rate should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276034/", "reference_text": "[1] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990):  1396-9[2] \"Product Information. Proventil (albuterol).\" Schering Corporation  (2002):[3] \"Product Information. Serevent (salmeterol).\" Glaxo Wellcome[4] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals  (2001):[5] \"Product Information. Xopenex (levalbuterol).\" Sepracor Inc  (2001):[6] \"Product Information. Foradil (formoterol).\" Novartis Pharmaceuticals  (2001):[7] \"Product Information. Brovana (arformoterol).\" Sepracor Inc  (2006):[8] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001):  45-51[9] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals  (2011):[10] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline  (2013):[11] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim  (2014):", "alternatives_a": "Tetracycline, Minocycline, Amphotericin B, Miconazole, Doxycycline, Metronidazole, Clotrimazole, Acetylsalicylic acid, Chlorhexidine, Neomycin, Mometasone furoate, More", "alternatives_b": "Bremelanotide, Flibanserin, Cabergoline, Black cohosh, Bromocriptine, Naproxen, Ibuprofen", "updated_at": 1767369485}, {"id": 242587, "ingredient1": "Heparin", "ingredient2": "Eplerenone", "severity": "Moderate", "effect": "Heparin and low molecular weight heparins (LMWHs) may cause hyperkalemia.  Concomitant use with potassium-sparing diuretics or aldosterone receptor antagonists may increase the risk and/or severity of hyperkalemia.", "source": "DDInter", "management_text": "Caution is advised when heparin or LMWHs are used with potassium-sparing diuretics or aldosterone receptor antagonists.  Serum potassium levels and renal function should be monitored regularly.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when heparin or LMWHs are used with potassium-sparing diuretics or aldosterone receptor antagonists.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276041/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Agencia Espala de Medicamentos y Productos Sanitarios Healthcare \"Centro de informaci online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Caplacizumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242588, "ingredient1": "Eplerenone", "ingredient2": "Osilodrostat", "severity": "Moderate", "effect": "Coadministration with osilodrostat may increase the plasma concentrations of drugs that are metabolized by CYP450 1A2, 2C19, 2D6, and/or 3A4.  Osilodrostat has been shown to be a moderate inhibitor of CYP450 1A2, a mild to borderline moderate inhibitor of CYP450 2C19, and a weak inhibitor of CYP450 2D6 and 3A4.", "source": "DDInter", "management_text": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever osilodrostat is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276048/", "reference_text": "[1] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Inc  (2020):[2] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Australia Pty Ltd  (2022):[3] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases UK Ltd  (2021):", "alternatives_a": "Amiloride, Triamterene, Spironolactone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242589, "ingredient1": "Eplerenone", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276052/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Amiloride, Triamterene, Spironolactone", "alternatives_b": "Entrectinib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Lapatinib, Selumetinib, Vandetanib, More", "updated_at": 1767369485}, {"id": 242590, "ingredient1": "Eplerenone", "ingredient2": "Rifapentine", "severity": "Minor", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of eplerenone, which is metabolized by the isoenzyme.  According to the product labeling, administration of a single 100 mg dose of eplerenone with the potent CYP450 3A4 inducer St John's wort resulted in an approximately 30% decrease in eplerenone systemic exposure (AUC).", "source": "DDInter", "management_text": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of eplerenone, which is metabolized by the isoenzyme.  According to the product labeling, administration of a single 100 mg dose of eplerenone with the potent CYP450 3A4 inducer St John's wort resulted in an approximately 30% decrease in eplerenone systemic exposure (AUC).  This is not considered clinically significant.", "mechanism_text": "Metabolism", "recommendation": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of eplerenone, which is metabolized by the isoenzyme.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276053/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] \"Product Information. Casodex (bicalutamide).\" Astra-Zeneca Pharmaceuticals  (2001):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Agencia Espala de Medicamentos y Productos Sanitarios Healthcare \"Centro de informaci online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):", "alternatives_a": "Amiloride, Triamterene, Spironolactone", "alternatives_b": "Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Streptomycin, Cycloserine, Rifabutin, Isoniazid, Ethambutol, Ethionamide, More", "updated_at": 1767369485}, {"id": 242591, "ingredient1": "Eplerenone", "ingredient2": "Tinzaparin", "severity": "Moderate", "effect": "Heparin and low molecular weight heparins (LMWHs) may cause hyperkalemia.  Concomitant use with potassium-sparing diuretics or aldosterone receptor antagonists may increase the risk and/or severity of hyperkalemia.", "source": "DDInter", "management_text": "Caution is advised when heparin or LMWHs are used with potassium-sparing diuretics or aldosterone receptor antagonists.  Serum potassium levels and renal function should be monitored regularly.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when heparin or LMWHs are used with potassium-sparing diuretics or aldosterone receptor antagonists.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276058/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Agencia Espala de Medicamentos y Productos Sanitarios Healthcare \"Centro de informaci online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Caplacizumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242592, "ingredient1": "Heparin (flush)", "ingredient2": "Epoprostenol", "severity": "Moderate", "effect": "Concomitant use of heparin flush and drugs that interfere with platelet function or coagulation or drugs that commonly cause thrombocytopenia may potentiate the risk of bleeding complications.  Although uncommon, inadvertent anticoagulation resulting in hemorrhagic events may occur with heparin flushes, particularly during repeated or excessive use or administration of higher concentration flush solutions.", "source": "DDInter", "management_text": "Caution and monitoring (e.g., platelet counts, hematocrits, tests for occult blood in stools) are advised when heparin flushes are given to patients receiving systemic anticoagulants, platelet inhibitors, antithrombotic agents, thrombolytics, or drugs with known risks of thrombocytopenia or bleeding.  An unexplained fall in hematocrit, fall in blood pressure, or any other unexplained symptom should lead to serious consideration of a hemorrhagic event.", "mechanism_text": "Synergism", "recommendation": "Caution and monitoring (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276066/", "reference_text": "[1] Passannante A, Macik BG \"The heparin flush syndrome: a cause of iatrogenic hemorrhage.\" Am J Med Sci 296 (1988):  71-3[2] \"Product Information. Heparin Sodium in Sodium Chloride (heparin flush).\" Baxter Healthcare Corporation  (2022):[3] \"Product Information. Canusal (heparin flush).\" Wockhardt UK Ltd  (2018):[4] \"Product Information. Heparinised Saline (Pfizer) (heparinised saline).\" Pfizer Australia Pty Ltd  (2022):", "alternatives_a": "Acenocoumarol, Selexipag", "alternatives_b": "Protein C, Acenocoumarol, Selexipag, Epoprostenol, Treprostinil, Ascorbic acid, Sirolimus, Vitamin A, Potassium Iodide, Acetylcysteine, Nandrolone", "updated_at": 1767369485}, {"id": 242593, "ingredient1": "Etonogestrel", "ingredient2": "Topiramate", "severity": "Major", "effect": "Coadministration with topiramate, particularly at dosages above 200 mg/day, may decrease the plasma concentrations and efficacy of contraceptive hormones.  The proposed mechanism is topiramate induction of CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of steroidal hormones.", "source": "DDInter", "management_text": "The potential for decreased contraceptive efficacy and increased breakthrough bleeding should be considered in patients using hormonal contraceptives (including oral, injectable, transdermal, and implantable forms) during treatment with topiramate, particularly at dosages above 200 mg/day.  Some clinicians and manufacturers recommend that patients on topiramate dosages at or above 200 mg/day who are taking oral contraceptives should receive a preparation containing no less than 30 or 35 mcg of estrogen, while others recommend at least 50 mcg.  Intrauterine systems are unlikely to be significantly affected because of their local action, thus they may be preferable to other routes of administration.  Patients should be advised to report any change in their bleeding patterns, although contraceptive efficacy can be decreased even in the absence of breakthrough bleeding.  Because use of topiramate can cause fetal harm, it is particularly important that patients not become pregnant during treatment.  Counseling should be provided regarding the use of alternative (non-hormonal) or additional (back-up) pregnancy prevention methods during and for at least 28 days after discontinuing topiramate.  Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.  Alternative, nonenzyme-inducing anticonvulsants that are not believed to interact significantly with hormonal contraceptives include clonazepam, ethosuximide, gabapentin, levetiracetam, pregabalin, tiagabine, valproic acid, vigabatrin, and zonisamide.", "mechanism_text": "Metabolism", "recommendation": "The potential for decreased contraceptive efficacy and increased breakthrough bleeding should be considered in patients using hormonal contraceptives (including oral, injectable, transdermal, and implantable forms) during treatment with topiramate, particularly at dosages above 200 mg/day.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276077/", "reference_text": "[1] \"Product Information. Depo-Provera (medroxyprogesterone).\" Pharmacia and Upjohn  (2001):[2] \"Product Information. Topamax (topiramate).\" Ortho McNeil Pharmaceutical  (2001):[3] Wilbur K, Ensom MHH \"Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants.\" Clin Pharmacokinet 38 (2000):  355-65[4] Rosenfeld WE, Doose DR, Walker SA, Nayak RK \"Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy.\" Epilepsia 38 (1997):  317-23[5] Patsalos PN, Froscher W, Pisani F, van Rijn CM \"The importance of drug interactions in epilepsy therapy.\" Epilepsia 43 (2002):  365-85[6] Doose DR, Wang SS, Padmanabhan M, Schwabe S, Jacobs D, Bialer M \"Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects.\" Epilepsia 44 (2003):  540-9[7] Nallani SC, Glauser TA, Hariparsad N, et al. \"Dose-dependent induction of cytochrome P450 (CYP) 3A4 and activation of pregnane X receptor by topiramate.\" Epilepsia 44 (2003):  1521-8[8] Bialer M, Doose DR, Murthy B, et al. \"Pharmacokinetic interactions of topiramate.\" Clin Pharmacokinet 43 (2004):  763-80[9] \"FFPRHC Guidance (April 2005). Drug interactions with hormonal contraception.\" J Fam Plann Reprod Health Care 31 (2005):  139-51[10] Perucca E \"Clinically relevant drug interactions with antiepileptic drugs.\" Br J Clin Pharmacol 61 (2006):  246-255[11] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[12] Harden CL, Leppik I \"Optimizing therapy of seizures in women who use oral contraceptives.\" Neurology 67(12 Suppl 4) (2006):  S56-8[13] Cerner Multum, Inc. \"Australian Product Information.\" O 0[14] \"Product Information. Qsymia (phentermine-topiramate).\" Vivus Inc  (2012):[15] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[16] \"Product Information. Nexplanon (etonogestrel).\" Organon Pharmaceuticals  (2017):[17] Sunaga T, Cicali B, Schmidt S, Brown J \"Comparison of contraceptive failures associated with CYP3A4-inducing drug-drug interactions by route of hormonal contraceptive in an adverse event reporting system.\" Contraception 103(Issue 4) (2021):  222-4[18] Doodipala SR \"Clinical pharmacokinetic interactions between antiepileptic drugs and hormonal contraceptives.\" Expert Rev Clin Pharmacol 3 (2010):  183-92", "alternatives_a": "Megestrol acetate, Estetrol", "alternatives_b": "Ezogabine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, Ganaxolone, Vigabatrin, Mephenytoin, More", "updated_at": 1767369485}, {"id": 242594, "ingredient1": "Felbamate", "ingredient2": "Topiramate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276079/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Methsuximide, Topiramate, Paramethadione, Phensuximide, Methylphenobarbital, Phenacemide, Trimethadione, Lacosamide", "alternatives_b": "Paramethadione, Phensuximide, Methylphenobarbital, Phenacemide, Felbamate, Lacosamide, Trimethadione", "updated_at": 1767369485}, {"id": 242595, "ingredient1": "Fenfluramine", "ingredient2": "Topiramate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276080/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Dexfenfluramine, Naltrexone, Ephedrine, Lorcaserin, Diethylpropion, Mazindol, Methsuximide, Topiramate, Paramethadione, Phensuximide, Methylphenobarbital, More", "alternatives_b": "Lacosamide, Fenfluramine", "updated_at": 1767369485}, {"id": 242596, "ingredient1": "Topiramate", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276083/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Cabergoline", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 242597, "ingredient1": "Topiramate", "ingredient2": "Melatonin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276084/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Thiopental, Ethchlorvynol, Methylphenobarbital, Dichloralphenazone", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 242598, "ingredient1": "Topiramate", "ingredient2": "Norgestrel", "severity": "Major", "effect": "Coadministration with topiramate, particularly at dosages above 200 mg/day, may decrease the plasma concentrations and efficacy of contraceptive hormones.  The proposed mechanism is topiramate induction of CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of steroidal hormones.", "source": "DDInter", "management_text": "The potential for decreased contraceptive efficacy and increased breakthrough bleeding should be considered in patients using hormonal contraceptives (including oral, injectable, transdermal, and implantable forms) during treatment with topiramate, particularly at dosages above 200 mg/day.  Some clinicians and manufacturers recommend that patients on topiramate dosages at or above 200 mg/day who are taking oral contraceptives should receive a preparation containing no less than 30 or 35 mcg of estrogen, while others recommend at least 50 mcg.  Intrauterine systems are unlikely to be significantly affected because of their local action, thus they may be preferable to other routes of administration.  Patients should be advised to report any change in their bleeding patterns, although contraceptive efficacy can be decreased even in the absence of breakthrough bleeding.  Because use of topiramate can cause fetal harm, it is particularly important that patients not become pregnant during treatment.  Counseling should be provided regarding the use of alternative (non-hormonal) or additional (back-up) pregnancy prevention methods during and for at least 28 days after discontinuing topiramate.  Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.  Alternative, nonenzyme-inducing anticonvulsants that are not believed to interact significantly with hormonal contraceptives include clonazepam, ethosuximide, gabapentin, levetiracetam, pregabalin, tiagabine, valproic acid, vigabatrin, and zonisamide.", "mechanism_text": "Metabolism", "recommendation": "The potential for decreased contraceptive efficacy and increased breakthrough bleeding should be considered in patients using hormonal contraceptives (including oral, injectable, transdermal, and implantable forms) during treatment with topiramate, particularly at dosages above 200 mg/day.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276085/", "reference_text": "[1] \"Product Information. Depo-Provera (medroxyprogesterone).\" Pharmacia and Upjohn  (2001):[2] \"Product Information. Topamax (topiramate).\" Ortho McNeil Pharmaceutical  (2001):[3] Wilbur K, Ensom MHH \"Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants.\" Clin Pharmacokinet 38 (2000):  355-65[4] Rosenfeld WE, Doose DR, Walker SA, Nayak RK \"Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy.\" Epilepsia 38 (1997):  317-23[5] Patsalos PN, Froscher W, Pisani F, van Rijn CM \"The importance of drug interactions in epilepsy therapy.\" Epilepsia 43 (2002):  365-85[6] Doose DR, Wang SS, Padmanabhan M, Schwabe S, Jacobs D, Bialer M \"Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects.\" Epilepsia 44 (2003):  540-9[7] Nallani SC, Glauser TA, Hariparsad N, et al. \"Dose-dependent induction of cytochrome P450 (CYP) 3A4 and activation of pregnane X receptor by topiramate.\" Epilepsia 44 (2003):  1521-8[8] Bialer M, Doose DR, Murthy B, et al. \"Pharmacokinetic interactions of topiramate.\" Clin Pharmacokinet 43 (2004):  763-80[9] \"FFPRHC Guidance (April 2005). Drug interactions with hormonal contraception.\" J Fam Plann Reprod Health Care 31 (2005):  139-51[10] Perucca E \"Clinically relevant drug interactions with antiepileptic drugs.\" Br J Clin Pharmacol 61 (2006):  246-255[11] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[12] Harden CL, Leppik I \"Optimizing therapy of seizures in women who use oral contraceptives.\" Neurology 67(12 Suppl 4) (2006):  S56-8[13] Cerner Multum, Inc. \"Australian Product Information.\" O 0[14] \"Product Information. Qsymia (phentermine-topiramate).\" Vivus Inc  (2012):[15] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[16] \"Product Information. Nexplanon (etonogestrel).\" Organon Pharmaceuticals  (2017):[17] Sunaga T, Cicali B, Schmidt S, Brown J \"Comparison of contraceptive failures associated with CYP3A4-inducing drug-drug interactions by route of hormonal contraceptive in an adverse event reporting system.\" Contraception 103(Issue 4) (2021):  222-4[18] Doodipala SR \"Clinical pharmacokinetic interactions between antiepileptic drugs and hormonal contraceptives.\" Expert Rev Clin Pharmacol 3 (2010):  183-92", "alternatives_a": "Megestrol acetate, Megestrol acetate, Estetrol", "alternatives_b": "Ezogabine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, Ganaxolone, Vigabatrin, Mephenytoin, More", "updated_at": 1767369485}, {"id": 242599, "ingredient1": "Heparin (flush)", "ingredient2": "Eptifibatide", "severity": "Moderate", "effect": "Concomitant use of heparin flush and drugs that interfere with platelet function or coagulation or drugs that commonly cause thrombocytopenia may potentiate the risk of bleeding complications.  Although uncommon, inadvertent anticoagulation resulting in hemorrhagic events may occur with heparin flushes, particularly during repeated or excessive use or administration of higher concentration flush solutions.", "source": "DDInter", "management_text": "Caution and monitoring (e.g., platelet counts, hematocrits, tests for occult blood in stools) are advised when heparin flushes are given to patients receiving systemic anticoagulants, platelet inhibitors, antithrombotic agents, thrombolytics, or drugs with known risks of thrombocytopenia or bleeding.  An unexplained fall in hematocrit, fall in blood pressure, or any other unexplained symptom should lead to serious consideration of a hemorrhagic event.", "mechanism_text": "Synergism", "recommendation": "Caution and monitoring (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276105/", "reference_text": "[1] Passannante A, Macik BG \"The heparin flush syndrome: a cause of iatrogenic hemorrhage.\" Am J Med Sci 296 (1988):  71-3[2] \"Product Information. Heparin Sodium in Sodium Chloride (heparin flush).\" Baxter Healthcare Corporation  (2022):[3] \"Product Information. Canusal (heparin flush).\" Wockhardt UK Ltd  (2018):[4] \"Product Information. Heparinised Saline (Pfizer) (heparinised saline).\" Pfizer Australia Pty Ltd  (2022):", "alternatives_a": "Acenocoumarol, Selexipag", "alternatives_b": "Eptifibatide, Antithrombin III human, Protein C, Acenocoumarol, Selexipag, Ascorbic acid, Cyclosporine, Sirolimus, Potassium Iodide, Vitamin A, Nandrolone", "updated_at": 1767369485}, {"id": 242600, "ingredient1": "Eravacycline", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276117/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Tetracycline, Minocycline, Oxytetracycline, Doxycycline, Omadacycline, Demeclocycline, Sarecycline, Tigecycline", "alternatives_b": "Entrectinib, Imatinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, More", "updated_at": 1767369485}, {"id": 242601, "ingredient1": "Ergotamine", "ingredient2": "Oxitriptan", "severity": "Major", "effect": "Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John's wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.", "source": "DDInter", "management_text": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.  Patients should be closely monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.  For example, some experts suggest a 5-week washout period following use of fluoxetine and 3 weeks following the use of vortioxetine before administering another serotonergic agent.  Individual product labeling for washout periods should be consulted for current recommendations.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.", "mechanism_text": "Synergism", "recommendation": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276118/", "reference_text": "[1] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[2] Achamallah NS \"Visual hallucinations after combining fluoxetine and dextromethorphan .\" Am J Psychiatry 149 (1992):  1406[3] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993):  84-8[4] Metz A \"Interaction between fluoxetine and buspirone.\" Can J Psychiatry 35 (1990):  722-3[5] Goldberg RJ, Huk M \"Serotonin syndrome from trazodone and buspirone.\" Psychosomatics 33 (1992):  235-6[6] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation  (2002):[7] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[8] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990):  213-7[9] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics.\" J Clin Psychopharmacol 10 (1990):  48-50[10] \"Product Information. Zoloft (sertraline).\" Roerig Division  (2001):[11] \"Product Information. Prozac (fluoxetine).\" Dista Products Company  (2001):[12] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[13] Insel TR, Roy BF, Cohen RM, Murphy DL \"Possible development of the serotonin syndrome in man.\" Am J Psychiatry 139 (1982):  954-5[14] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories  (2001):[15] Gilman AG, eds., Nies AS, Rall TW, Taylor P \"Goodman and Gilman's the Pharmacological Basis of Therapeutics.\" New York, NY: Pergamon Press Inc.  (1990):[16] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline  (2001):[17] \"Product Information. Flexeril (cyclobenzaprine).\" Merck & Co., Inc  (2001):[18] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[19] \"Product Information. Imitrex (sumatriptan).\" Glaxo Wellcome  (2001):[20] Ruiz F \"Fluoxetine and the serotonin syndrome.\" Ann Emerg Med 24 (1994):  983-5[21] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc  (2001):[22] Reeves RR, Bullen JA \"Serotonin syndrome produced by paroxetine and low-dose trazodone.\" Psychosomatics 36 (1995):  159-60[23] Harvey AT, Preskorn SH \"Interactions of serotonin reuptake inhibitors with tricyclic antidepressants.\" Arch Gen Psychiatry 52 (1995):  783-4[24] Baetz M, Malcolm D \"Serotonin syndrome from fluvoxamine and buspirone.\" Can J Psychiatry 40 (1995):  428-9[25] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995):  440-2[26] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995):  481-2[27] George TP, Godleski LS \"Possible serotonin syndrome with trazodone addition to fluoxetine.\" Biol Psychiatry 39 (1996):  384-5[28] Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM \"The serotonin syndrome associated wtih paroxetine, an over-the-counter cold remedy, and vascular disease.\" Am J Emerg Med 12 (1994):  642-4[29] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[30] John L, Perreault MM, Tao T, Blew PG \"Serotonin syndrome associated with nefazodone and paroxetine.\" Ann Emerg Med 29 (1997):  287-9[31] \"Product Information. Zomig (zolmitriptan).\" Astra-Zeneca Pharmaceuticals  (2001):[32] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[33] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[34] Bhatara VS, Magnus RD, Paul KL, Preskorn SH \"Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms.\" Ann Pharmacother 32 (1998):  432-6[35] \"Product Information. Maxalt (rizatriptan).\" Merck & Co., Inc  (2001):[36] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals  (2001):[37] Gardner DM, Lynd LD \"Sumatriptan contraindications and the serotonin syndrome.\" Ann Pharmacother 32 (1998):  33-8[38] Mathew NT, Tietjen GE, Lucker C \"Serotonin syndrome complicating migraine pharmacotherapy.\" Cephalalgia 16 (1996):  323-7[39] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[40] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[41] Weiner AL \"Meperidine as a potential cause of serotonin syndrome in the emergency department.\" Acad Emerg Med 6 (1999):  156-8[42] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[43] Gordon JB \"SSRI's and St. John's Wort: possible toxicity?\" Am Fam Physician 57 (1998):  950,953[44] Lantz MS, Buchalter E, Giambanco V \"St. John's wort and antidepressant drug interactions in the elderly.\" J Geriatr Psychiatr Neurol 12 (1999):  7-10[45] Fugh-Berman A \"Herb-drug interactions.\" Lancet 355 (2000):  134-8[46] \"Product Information. Zyvox (linezolid).\" Pharmacia and Upjohn  (2001):[47] Perry NK \"Venlafaxine-induced serotonin syndrome with relapse following amitriptyline.\" Postgrad Med J 76 (2000):  254-6[48] Manos GH \"Possible serotonin syndrome associated with buspirone added to fluoxetine.\" Ann Pharmacother 34 (2000):  871-4[49] Nijhawan PK, Katz G, Winter S \"Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission.\" Crit Care Med 24 (1996):  1086-9[50] Laird LK \"Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder.\" Psychopharmacol Bull 32 (1996):  569-78[51] Margolese HC, Chouinard G \"Serotonin syndrome from addition of low-dose trazodone to nefazodone.\" Am J Psychiatry 157 (2000):  1022[52] Mackay FJ, Dunn NR, Mann RD \"Antidepressants and the serotonin syndrome in general practice.\" Br J Gen Pract 49 (1999):  871-4[53] Smith DL, Wenegrat BG \"A case report of serotonin syndrome associated with combined nefazodone and fluoxetine.\" J Clin Psychiatry 61 (2000):  146[54] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[55] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001):  2163-75[56] Duggal HS, Fetchko J \"Serotonin syndrome and atypical antipsychotics.\" Am J Psychiatry 159 (2002):  672-3[57] Wigen CL, Goetz MB \"Serotonin syndrome and linezolid.\" Clin Infect Dis 34 (2002):  1651-2[58] Hammerness P, Parada H, Abrams A \"Linezolid: MAOI Activity and Potential Drug Interactions.\" Psychosomatics 43 (2002):  248-9[59] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[60] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[61] Turkel SB, Nadala JG, Wincor MZ \"Possible serotonin syndrome in association with 5-HT3 antagonist agents.\" Psychosomatics 42 (2001):  258-60[62] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[63] Lavery S, Ravi H, McDaniel WW, Pushkin YR \"Linezolid and serotonin syndrome.\" Psychosomatics 42 (2001):  432-4[64] Lane R, Baldwin D \"Selective serotonin reuptake inhibitor--induced serotonin syndrome: review.\" J Clin Psychopharmacol 17 (1997):  208-21[65] Bernard L, Stern R, Lew D, Hoffmeyer P \"Serotonin syndrome after concomitant treatment with linezolid and citalopram.\" Clin Infect Dis 36 (2003):  1197[66] Dannawi M \"Possible serotonin syndrome after combination of buspirone and St John's Wort.\" J Psychopharmacol 16 (2002):  401[67] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[68] Hachem RY, Hicks K, Huen A, Raad I \"Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients.\" Clin Infect Dis 37 (2003):  E8-E11[69] Gillman PK \"Linezolid and serotonin toxicity.\" Clin Infect Dis 37 (2003):  1274-5[70] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[71] Giese SY, Neborsky R \"Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl.\" Plast Reconstr Surg 107 (2001):  293-4[72] Jones SL, Athan E, O'Brien D \"Serotonin syndrome due to co-administration of linezolid and venlafaxine.\" J Antimicrob Chemother 54 (2004):  289-90[73] Tahir N \"Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram.\" J Am Med Dir Assoc 5 (2004):  111-3[74] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company  (2004):[75] Thomas CR, Rosenberg M, Blythe V, Meyer WJ 3rd \"Serotonin syndrome and linezolid.\" J Am Acad Child Adolesc Psychiatry 43 (2004):  790[76] Boyer EW, Shannon M \"The serotonin syndrome.\" N Engl J Med 352 (2005):  1112-20[77] Bergeron L, Boule M, Perreault S \"Serotonin toxicity associated with concomitant use of linezolid.\" Ann Pharmacother 39 (2005):  956-61[78] Morales N, Vermette H \"Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine.\" Psychosomatics 46 (2005):  274-5[79] Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M, Grau S \"Linezolid-associated serotonin syndrome: what we can learn from cases reported so far.\" J Antimicrob Chemother 56 (2005):  1176-8[80] DeBellis RJ, Schaefer OP, Liquori M, Volturo GA \"Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient.\" J Intensive Care Med 20 (2005):  351-3[81] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[82] Taylor JJ, Wilson JW, Estes LL \"Linezolid and serotonergic drug interactions: a retrospective survey.\" Clin Infect Dis 43 (2006):  180-7[83] Strouse TB, Kerrihard TN, Forscher CA, Zakowski P \"Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine.\" J Clin Psychopharmacol 26 (2006):  681-683[84] Keegan MT, Brown DR, Rabinstein AA \"Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs.\" Anesth Analg 103 (2006):  1466-8[85] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S \"Rare case of serotonin syndrome with therapeutic doses of paroxetine.\" Am J Ther 13 (2006):  550-552[86] Steinberg M, Morin AK \"Mild serotonin syndrome associated with concurrent linezolid and fluoxetine.\" Am J Health Syst Pharm 64 (2007):  59-62[87] Packer S, Berman SA \"Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid.\" Am J Psychiatry 164 (2007):  346-7[88] Shapiro RE, Tepper SJ \"The serotonin syndrome, triptans, and the potential for drug-drug interactions.\" Headache 47 (2007):  266-9[89] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[90] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories  (2008):[91] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[92] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals  (2009):[93] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals  (2009):[94] Lee J, Franz L, Goforth HW \"Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine.\" Psychosomatics 50 (2009):  638-9[95] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC  (2011):[96] Mugele J, Nanagas KA, Tormoehlen LM \"Serotonin Syndrome Associated With MDPV Use: A Case Report.\" Ann Emerg Med  (2012):[97] \"Product Information. Oleptro (trazodone).\" Labopharm Inc  (2012):[98] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals  (2013):[99] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America  (2013):", "alternatives_a": "Rimegepant, Eptinezumab, Ubrogepant, Galcanezumab, Atogepant, Clonidine, Erenumab, Fremanezumab", "alternatives_b": "Desipramine, Esketamine", "updated_at": 1767369485}, {"id": 242602, "ingredient1": "Imipramine", "ingredient2": "Ergotamine", "severity": "Major", "effect": "Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John's wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.", "source": "DDInter", "management_text": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.  Patients should be closely monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.  For example, some experts suggest a 5-week washout period following use of fluoxetine and 3 weeks following the use of vortioxetine before administering another serotonergic agent.  Individual product labeling for washout periods should be consulted for current recommendations.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.", "mechanism_text": "Synergism", "recommendation": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276122/", "reference_text": "[1] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[2] Achamallah NS \"Visual hallucinations after combining fluoxetine and dextromethorphan .\" Am J Psychiatry 149 (1992):  1406[3] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993):  84-8[4] Metz A \"Interaction between fluoxetine and buspirone.\" Can J Psychiatry 35 (1990):  722-3[5] Goldberg RJ, Huk M \"Serotonin syndrome from trazodone and buspirone.\" Psychosomatics 33 (1992):  235-6[6] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation  (2002):[7] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[8] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990):  213-7[9] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics.\" J Clin Psychopharmacol 10 (1990):  48-50[10] \"Product Information. Zoloft (sertraline).\" Roerig Division  (2001):[11] \"Product Information. Prozac (fluoxetine).\" Dista Products Company  (2001):[12] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[13] Insel TR, Roy BF, Cohen RM, Murphy DL \"Possible development of the serotonin syndrome in man.\" Am J Psychiatry 139 (1982):  954-5[14] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories  (2001):[15] Gilman AG, eds., Nies AS, Rall TW, Taylor P \"Goodman and Gilman's the Pharmacological Basis of Therapeutics.\" New York, NY: Pergamon Press Inc.  (1990):[16] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline  (2001):[17] \"Product Information. Flexeril (cyclobenzaprine).\" Merck & Co., Inc  (2001):[18] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[19] \"Product Information. Imitrex (sumatriptan).\" Glaxo Wellcome  (2001):[20] Ruiz F \"Fluoxetine and the serotonin syndrome.\" Ann Emerg Med 24 (1994):  983-5[21] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc  (2001):[22] Reeves RR, Bullen JA \"Serotonin syndrome produced by paroxetine and low-dose trazodone.\" Psychosomatics 36 (1995):  159-60[23] Harvey AT, Preskorn SH \"Interactions of serotonin reuptake inhibitors with tricyclic antidepressants.\" Arch Gen Psychiatry 52 (1995):  783-4[24] Baetz M, Malcolm D \"Serotonin syndrome from fluvoxamine and buspirone.\" Can J Psychiatry 40 (1995):  428-9[25] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995):  440-2[26] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995):  481-2[27] George TP, Godleski LS \"Possible serotonin syndrome with trazodone addition to fluoxetine.\" Biol Psychiatry 39 (1996):  384-5[28] Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM \"The serotonin syndrome associated wtih paroxetine, an over-the-counter cold remedy, and vascular disease.\" Am J Emerg Med 12 (1994):  642-4[29] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[30] John L, Perreault MM, Tao T, Blew PG \"Serotonin syndrome associated with nefazodone and paroxetine.\" Ann Emerg Med 29 (1997):  287-9[31] \"Product Information. Zomig (zolmitriptan).\" Astra-Zeneca Pharmaceuticals  (2001):[32] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[33] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[34] Bhatara VS, Magnus RD, Paul KL, Preskorn SH \"Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms.\" Ann Pharmacother 32 (1998):  432-6[35] \"Product Information. Maxalt (rizatriptan).\" Merck & Co., Inc  (2001):[36] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals  (2001):[37] Gardner DM, Lynd LD \"Sumatriptan contraindications and the serotonin syndrome.\" Ann Pharmacother 32 (1998):  33-8[38] Mathew NT, Tietjen GE, Lucker C \"Serotonin syndrome complicating migraine pharmacotherapy.\" Cephalalgia 16 (1996):  323-7[39] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[40] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[41] Weiner AL \"Meperidine as a potential cause of serotonin syndrome in the emergency department.\" Acad Emerg Med 6 (1999):  156-8[42] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[43] Gordon JB \"SSRI's and St. John's Wort: possible toxicity?\" Am Fam Physician 57 (1998):  950,953[44] Lantz MS, Buchalter E, Giambanco V \"St. John's wort and antidepressant drug interactions in the elderly.\" J Geriatr Psychiatr Neurol 12 (1999):  7-10[45] Fugh-Berman A \"Herb-drug interactions.\" Lancet 355 (2000):  134-8[46] \"Product Information. Zyvox (linezolid).\" Pharmacia and Upjohn  (2001):[47] Perry NK \"Venlafaxine-induced serotonin syndrome with relapse following amitriptyline.\" Postgrad Med J 76 (2000):  254-6[48] Manos GH \"Possible serotonin syndrome associated with buspirone added to fluoxetine.\" Ann Pharmacother 34 (2000):  871-4[49] Nijhawan PK, Katz G, Winter S \"Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission.\" Crit Care Med 24 (1996):  1086-9[50] Laird LK \"Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder.\" Psychopharmacol Bull 32 (1996):  569-78[51] Margolese HC, Chouinard G \"Serotonin syndrome from addition of low-dose trazodone to nefazodone.\" Am J Psychiatry 157 (2000):  1022[52] Mackay FJ, Dunn NR, Mann RD \"Antidepressants and the serotonin syndrome in general practice.\" Br J Gen Pract 49 (1999):  871-4[53] Smith DL, Wenegrat BG \"A case report of serotonin syndrome associated with combined nefazodone and fluoxetine.\" J Clin Psychiatry 61 (2000):  146[54] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[55] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001):  2163-75[56] Duggal HS, Fetchko J \"Serotonin syndrome and atypical antipsychotics.\" Am J Psychiatry 159 (2002):  672-3[57] Wigen CL, Goetz MB \"Serotonin syndrome and linezolid.\" Clin Infect Dis 34 (2002):  1651-2[58] Hammerness P, Parada H, Abrams A \"Linezolid: MAOI Activity and Potential Drug Interactions.\" Psychosomatics 43 (2002):  248-9[59] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[60] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[61] Turkel SB, Nadala JG, Wincor MZ \"Possible serotonin syndrome in association with 5-HT3 antagonist agents.\" Psychosomatics 42 (2001):  258-60[62] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[63] Lavery S, Ravi H, McDaniel WW, Pushkin YR \"Linezolid and serotonin syndrome.\" Psychosomatics 42 (2001):  432-4[64] Lane R, Baldwin D \"Selective serotonin reuptake inhibitor--induced serotonin syndrome: review.\" J Clin Psychopharmacol 17 (1997):  208-21[65] Bernard L, Stern R, Lew D, Hoffmeyer P \"Serotonin syndrome after concomitant treatment with linezolid and citalopram.\" Clin Infect Dis 36 (2003):  1197[66] Dannawi M \"Possible serotonin syndrome after combination of buspirone and St John's Wort.\" J Psychopharmacol 16 (2002):  401[67] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[68] Hachem RY, Hicks K, Huen A, Raad I \"Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients.\" Clin Infect Dis 37 (2003):  E8-E11[69] Gillman PK \"Linezolid and serotonin toxicity.\" Clin Infect Dis 37 (2003):  1274-5[70] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[71] Giese SY, Neborsky R \"Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl.\" Plast Reconstr Surg 107 (2001):  293-4[72] Jones SL, Athan E, O'Brien D \"Serotonin syndrome due to co-administration of linezolid and venlafaxine.\" J Antimicrob Chemother 54 (2004):  289-90[73] Tahir N \"Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram.\" J Am Med Dir Assoc 5 (2004):  111-3[74] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company  (2004):[75] Thomas CR, Rosenberg M, Blythe V, Meyer WJ 3rd \"Serotonin syndrome and linezolid.\" J Am Acad Child Adolesc Psychiatry 43 (2004):  790[76] Boyer EW, Shannon M \"The serotonin syndrome.\" N Engl J Med 352 (2005):  1112-20[77] Bergeron L, Boule M, Perreault S \"Serotonin toxicity associated with concomitant use of linezolid.\" Ann Pharmacother 39 (2005):  956-61[78] Morales N, Vermette H \"Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine.\" Psychosomatics 46 (2005):  274-5[79] Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M, Grau S \"Linezolid-associated serotonin syndrome: what we can learn from cases reported so far.\" J Antimicrob Chemother 56 (2005):  1176-8[80] DeBellis RJ, Schaefer OP, Liquori M, Volturo GA \"Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient.\" J Intensive Care Med 20 (2005):  351-3[81] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[82] Taylor JJ, Wilson JW, Estes LL \"Linezolid and serotonergic drug interactions: a retrospective survey.\" Clin Infect Dis 43 (2006):  180-7[83] Strouse TB, Kerrihard TN, Forscher CA, Zakowski P \"Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine.\" J Clin Psychopharmacol 26 (2006):  681-683[84] Keegan MT, Brown DR, Rabinstein AA \"Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs.\" Anesth Analg 103 (2006):  1466-8[85] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S \"Rare case of serotonin syndrome with therapeutic doses of paroxetine.\" Am J Ther 13 (2006):  550-552[86] Steinberg M, Morin AK \"Mild serotonin syndrome associated with concurrent linezolid and fluoxetine.\" Am J Health Syst Pharm 64 (2007):  59-62[87] Packer S, Berman SA \"Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid.\" Am J Psychiatry 164 (2007):  346-7[88] Shapiro RE, Tepper SJ \"The serotonin syndrome, triptans, and the potential for drug-drug interactions.\" Headache 47 (2007):  266-9[89] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[90] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories  (2008):[91] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[92] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals  (2009):[93] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals  (2009):[94] Lee J, Franz L, Goforth HW \"Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine.\" Psychosomatics 50 (2009):  638-9[95] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC  (2011):[96] Mugele J, Nanagas KA, Tormoehlen LM \"Serotonin Syndrome Associated With MDPV Use: A Case Report.\" Ann Emerg Med  (2012):[97] \"Product Information. Oleptro (trazodone).\" Labopharm Inc  (2012):[98] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals  (2013):[99] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America  (2013):", "alternatives_a": "Rimegepant, Eptinezumab, Ubrogepant, Galcanezumab, Atogepant, Methysergide, Erenumab, Fremanezumab", "alternatives_b": "Desipramine, Esketamine", "updated_at": 1767369485}, {"id": 242603, "ingredient1": "Ergotamine", "ingredient2": "Maprotiline", "severity": "Major", "effect": "Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John's wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.", "source": "DDInter", "management_text": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.  Patients should be closely monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.  For example, some experts suggest a 5-week washout period following use of fluoxetine and 3 weeks following the use of vortioxetine before administering another serotonergic agent.  Individual product labeling for washout periods should be consulted for current recommendations.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.", "mechanism_text": "Synergism", "recommendation": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276127/", "reference_text": "[1] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[2] Achamallah NS \"Visual hallucinations after combining fluoxetine and dextromethorphan .\" Am J Psychiatry 149 (1992):  1406[3] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993):  84-8[4] Metz A \"Interaction between fluoxetine and buspirone.\" Can J Psychiatry 35 (1990):  722-3[5] Goldberg RJ, Huk M \"Serotonin syndrome from trazodone and buspirone.\" Psychosomatics 33 (1992):  235-6[6] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation  (2002):[7] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[8] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990):  213-7[9] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics.\" J Clin Psychopharmacol 10 (1990):  48-50[10] \"Product Information. Zoloft (sertraline).\" Roerig Division  (2001):[11] \"Product Information. Prozac (fluoxetine).\" Dista Products Company  (2001):[12] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[13] Insel TR, Roy BF, Cohen RM, Murphy DL \"Possible development of the serotonin syndrome in man.\" Am J Psychiatry 139 (1982):  954-5[14] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories  (2001):[15] Gilman AG, eds., Nies AS, Rall TW, Taylor P \"Goodman and Gilman's the Pharmacological Basis of Therapeutics.\" New York, NY: Pergamon Press Inc.  (1990):[16] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline  (2001):[17] \"Product Information. Flexeril (cyclobenzaprine).\" Merck & Co., Inc  (2001):[18] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[19] \"Product Information. Imitrex (sumatriptan).\" Glaxo Wellcome  (2001):[20] Ruiz F \"Fluoxetine and the serotonin syndrome.\" Ann Emerg Med 24 (1994):  983-5[21] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc  (2001):[22] Reeves RR, Bullen JA \"Serotonin syndrome produced by paroxetine and low-dose trazodone.\" Psychosomatics 36 (1995):  159-60[23] Harvey AT, Preskorn SH \"Interactions of serotonin reuptake inhibitors with tricyclic antidepressants.\" Arch Gen Psychiatry 52 (1995):  783-4[24] Baetz M, Malcolm D \"Serotonin syndrome from fluvoxamine and buspirone.\" Can J Psychiatry 40 (1995):  428-9[25] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995):  440-2[26] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995):  481-2[27] George TP, Godleski LS \"Possible serotonin syndrome with trazodone addition to fluoxetine.\" Biol Psychiatry 39 (1996):  384-5[28] Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM \"The serotonin syndrome associated wtih paroxetine, an over-the-counter cold remedy, and vascular disease.\" Am J Emerg Med 12 (1994):  642-4[29] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[30] John L, Perreault MM, Tao T, Blew PG \"Serotonin syndrome associated with nefazodone and paroxetine.\" Ann Emerg Med 29 (1997):  287-9[31] \"Product Information. Zomig (zolmitriptan).\" Astra-Zeneca Pharmaceuticals  (2001):[32] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[33] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[34] Bhatara VS, Magnus RD, Paul KL, Preskorn SH \"Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms.\" Ann Pharmacother 32 (1998):  432-6[35] \"Product Information. Maxalt (rizatriptan).\" Merck & Co., Inc  (2001):[36] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals  (2001):[37] Gardner DM, Lynd LD \"Sumatriptan contraindications and the serotonin syndrome.\" Ann Pharmacother 32 (1998):  33-8[38] Mathew NT, Tietjen GE, Lucker C \"Serotonin syndrome complicating migraine pharmacotherapy.\" Cephalalgia 16 (1996):  323-7[39] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[40] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[41] Weiner AL \"Meperidine as a potential cause of serotonin syndrome in the emergency department.\" Acad Emerg Med 6 (1999):  156-8[42] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[43] Gordon JB \"SSRI's and St. John's Wort: possible toxicity?\" Am Fam Physician 57 (1998):  950,953[44] Lantz MS, Buchalter E, Giambanco V \"St. John's wort and antidepressant drug interactions in the elderly.\" J Geriatr Psychiatr Neurol 12 (1999):  7-10[45] Fugh-Berman A \"Herb-drug interactions.\" Lancet 355 (2000):  134-8[46] \"Product Information. Zyvox (linezolid).\" Pharmacia and Upjohn  (2001):[47] Perry NK \"Venlafaxine-induced serotonin syndrome with relapse following amitriptyline.\" Postgrad Med J 76 (2000):  254-6[48] Manos GH \"Possible serotonin syndrome associated with buspirone added to fluoxetine.\" Ann Pharmacother 34 (2000):  871-4[49] Nijhawan PK, Katz G, Winter S \"Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission.\" Crit Care Med 24 (1996):  1086-9[50] Laird LK \"Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder.\" Psychopharmacol Bull 32 (1996):  569-78[51] Margolese HC, Chouinard G \"Serotonin syndrome from addition of low-dose trazodone to nefazodone.\" Am J Psychiatry 157 (2000):  1022[52] Mackay FJ, Dunn NR, Mann RD \"Antidepressants and the serotonin syndrome in general practice.\" Br J Gen Pract 49 (1999):  871-4[53] Smith DL, Wenegrat BG \"A case report of serotonin syndrome associated with combined nefazodone and fluoxetine.\" J Clin Psychiatry 61 (2000):  146[54] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[55] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001):  2163-75[56] Duggal HS, Fetchko J \"Serotonin syndrome and atypical antipsychotics.\" Am J Psychiatry 159 (2002):  672-3[57] Wigen CL, Goetz MB \"Serotonin syndrome and linezolid.\" Clin Infect Dis 34 (2002):  1651-2[58] Hammerness P, Parada H, Abrams A \"Linezolid: MAOI Activity and Potential Drug Interactions.\" Psychosomatics 43 (2002):  248-9[59] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[60] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[61] Turkel SB, Nadala JG, Wincor MZ \"Possible serotonin syndrome in association with 5-HT3 antagonist agents.\" Psychosomatics 42 (2001):  258-60[62] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[63] Lavery S, Ravi H, McDaniel WW, Pushkin YR \"Linezolid and serotonin syndrome.\" Psychosomatics 42 (2001):  432-4[64] Lane R, Baldwin D \"Selective serotonin reuptake inhibitor--induced serotonin syndrome: review.\" J Clin Psychopharmacol 17 (1997):  208-21[65] Bernard L, Stern R, Lew D, Hoffmeyer P \"Serotonin syndrome after concomitant treatment with linezolid and citalopram.\" Clin Infect Dis 36 (2003):  1197[66] Dannawi M \"Possible serotonin syndrome after combination of buspirone and St John's Wort.\" J Psychopharmacol 16 (2002):  401[67] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[68] Hachem RY, Hicks K, Huen A, Raad I \"Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients.\" Clin Infect Dis 37 (2003):  E8-E11[69] Gillman PK \"Linezolid and serotonin toxicity.\" Clin Infect Dis 37 (2003):  1274-5[70] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[71] Giese SY, Neborsky R \"Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl.\" Plast Reconstr Surg 107 (2001):  293-4[72] Jones SL, Athan E, O'Brien D \"Serotonin syndrome due to co-administration of linezolid and venlafaxine.\" J Antimicrob Chemother 54 (2004):  289-90[73] Tahir N \"Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram.\" J Am Med Dir Assoc 5 (2004):  111-3[74] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company  (2004):[75] Thomas CR, Rosenberg M, Blythe V, Meyer WJ 3rd \"Serotonin syndrome and linezolid.\" J Am Acad Child Adolesc Psychiatry 43 (2004):  790[76] Boyer EW, Shannon M \"The serotonin syndrome.\" N Engl J Med 352 (2005):  1112-20[77] Bergeron L, Boule M, Perreault S \"Serotonin toxicity associated with concomitant use of linezolid.\" Ann Pharmacother 39 (2005):  956-61[78] Morales N, Vermette H \"Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine.\" Psychosomatics 46 (2005):  274-5[79] Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M, Grau S \"Linezolid-associated serotonin syndrome: what we can learn from cases reported so far.\" J Antimicrob Chemother 56 (2005):  1176-8[80] DeBellis RJ, Schaefer OP, Liquori M, Volturo GA \"Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient.\" J Intensive Care Med 20 (2005):  351-3[81] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[82] Taylor JJ, Wilson JW, Estes LL \"Linezolid and serotonergic drug interactions: a retrospective survey.\" Clin Infect Dis 43 (2006):  180-7[83] Strouse TB, Kerrihard TN, Forscher CA, Zakowski P \"Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine.\" J Clin Psychopharmacol 26 (2006):  681-683[84] Keegan MT, Brown DR, Rabinstein AA \"Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs.\" Anesth Analg 103 (2006):  1466-8[85] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S \"Rare case of serotonin syndrome with therapeutic doses of paroxetine.\" Am J Ther 13 (2006):  550-552[86] Steinberg M, Morin AK \"Mild serotonin syndrome associated with concurrent linezolid and fluoxetine.\" Am J Health Syst Pharm 64 (2007):  59-62[87] Packer S, Berman SA \"Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid.\" Am J Psychiatry 164 (2007):  346-7[88] Shapiro RE, Tepper SJ \"The serotonin syndrome, triptans, and the potential for drug-drug interactions.\" Headache 47 (2007):  266-9[89] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[90] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories  (2008):[91] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[92] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals  (2009):[93] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals  (2009):[94] Lee J, Franz L, Goforth HW \"Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine.\" Psychosomatics 50 (2009):  638-9[95] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC  (2011):[96] Mugele J, Nanagas KA, Tormoehlen LM \"Serotonin Syndrome Associated With MDPV Use: A Case Report.\" Ann Emerg Med  (2012):[97] \"Product Information. Oleptro (trazodone).\" Labopharm Inc  (2012):[98] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals  (2013):[99] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America  (2013):", "alternatives_a": "Rimegepant, Eptinezumab, Ubrogepant, Galcanezumab, Atogepant, Methysergide, Erenumab, Fremanezumab", "alternatives_b": "Desipramine, Esketamine", "updated_at": 1767369485}, {"id": 242604, "ingredient1": "Ergotamine", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276135/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Frovatriptan, Eptinezumab, Lasmiditan, Rizatriptan, Naratriptan, Galcanezumab, Zolmitriptan, Sumatriptan, Clonidine, Erenumab, Fremanezumab", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More", "updated_at": 1767369485}, {"id": 242605, "ingredient1": "Ergotamine", "ingredient2": "Remifentanil", "severity": "Major", "effect": "Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John's wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.", "source": "DDInter", "management_text": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.  Patients should be closely monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.  For example, some experts suggest a 5-week washout period following use of fluoxetine and 3 weeks following the use of vortioxetine before administering another serotonergic agent.  Individual product labeling for washout periods should be consulted for current recommendations.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.", "mechanism_text": "Synergism", "recommendation": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276137/", "reference_text": "[1] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[2] Achamallah NS \"Visual hallucinations after combining fluoxetine and dextromethorphan .\" Am J Psychiatry 149 (1992):  1406[3] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993):  84-8[4] Metz A \"Interaction between fluoxetine and buspirone.\" Can J Psychiatry 35 (1990):  722-3[5] Goldberg RJ, Huk M \"Serotonin syndrome from trazodone and buspirone.\" Psychosomatics 33 (1992):  235-6[6] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation  (2002):[7] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[8] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990):  213-7[9] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics.\" J Clin Psychopharmacol 10 (1990):  48-50[10] \"Product Information. Zoloft (sertraline).\" Roerig Division  (2001):[11] \"Product Information. Prozac (fluoxetine).\" Dista Products Company  (2001):[12] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[13] Insel TR, Roy BF, Cohen RM, Murphy DL \"Possible development of the serotonin syndrome in man.\" Am J Psychiatry 139 (1982):  954-5[14] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories  (2001):[15] Gilman AG, eds., Nies AS, Rall TW, Taylor P \"Goodman and Gilman's the Pharmacological Basis of Therapeutics.\" New York, NY: Pergamon Press Inc.  (1990):[16] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline  (2001):[17] \"Product Information. Flexeril (cyclobenzaprine).\" Merck & Co., Inc  (2001):[18] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[19] \"Product Information. Imitrex (sumatriptan).\" Glaxo Wellcome  (2001):[20] Ruiz F \"Fluoxetine and the serotonin syndrome.\" Ann Emerg Med 24 (1994):  983-5[21] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc  (2001):[22] Reeves RR, Bullen JA \"Serotonin syndrome produced by paroxetine and low-dose trazodone.\" Psychosomatics 36 (1995):  159-60[23] Harvey AT, Preskorn SH \"Interactions of serotonin reuptake inhibitors with tricyclic antidepressants.\" Arch Gen Psychiatry 52 (1995):  783-4[24] Baetz M, Malcolm D \"Serotonin syndrome from fluvoxamine and buspirone.\" Can J Psychiatry 40 (1995):  428-9[25] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995):  440-2[26] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995):  481-2[27] George TP, Godleski LS \"Possible serotonin syndrome with trazodone addition to fluoxetine.\" Biol Psychiatry 39 (1996):  384-5[28] Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM \"The serotonin syndrome associated wtih paroxetine, an over-the-counter cold remedy, and vascular disease.\" Am J Emerg Med 12 (1994):  642-4[29] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[30] John L, Perreault MM, Tao T, Blew PG \"Serotonin syndrome associated with nefazodone and paroxetine.\" Ann Emerg Med 29 (1997):  287-9[31] \"Product Information. Zomig (zolmitriptan).\" Astra-Zeneca Pharmaceuticals  (2001):[32] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[33] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[34] Bhatara VS, Magnus RD, Paul KL, Preskorn SH \"Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms.\" Ann Pharmacother 32 (1998):  432-6[35] \"Product Information. Maxalt (rizatriptan).\" Merck & Co., Inc  (2001):[36] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals  (2001):[37] Gardner DM, Lynd LD \"Sumatriptan contraindications and the serotonin syndrome.\" Ann Pharmacother 32 (1998):  33-8[38] Mathew NT, Tietjen GE, Lucker C \"Serotonin syndrome complicating migraine pharmacotherapy.\" Cephalalgia 16 (1996):  323-7[39] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[40] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[41] Weiner AL \"Meperidine as a potential cause of serotonin syndrome in the emergency department.\" Acad Emerg Med 6 (1999):  156-8[42] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[43] Gordon JB \"SSRI's and St. John's Wort: possible toxicity?\" Am Fam Physician 57 (1998):  950,953[44] Lantz MS, Buchalter E, Giambanco V \"St. John's wort and antidepressant drug interactions in the elderly.\" J Geriatr Psychiatr Neurol 12 (1999):  7-10[45] Fugh-Berman A \"Herb-drug interactions.\" Lancet 355 (2000):  134-8[46] \"Product Information. Zyvox (linezolid).\" Pharmacia and Upjohn  (2001):[47] Perry NK \"Venlafaxine-induced serotonin syndrome with relapse following amitriptyline.\" Postgrad Med J 76 (2000):  254-6[48] Manos GH \"Possible serotonin syndrome associated with buspirone added to fluoxetine.\" Ann Pharmacother 34 (2000):  871-4[49] Nijhawan PK, Katz G, Winter S \"Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission.\" Crit Care Med 24 (1996):  1086-9[50] Laird LK \"Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder.\" Psychopharmacol Bull 32 (1996):  569-78[51] Margolese HC, Chouinard G \"Serotonin syndrome from addition of low-dose trazodone to nefazodone.\" Am J Psychiatry 157 (2000):  1022[52] Mackay FJ, Dunn NR, Mann RD \"Antidepressants and the serotonin syndrome in general practice.\" Br J Gen Pract 49 (1999):  871-4[53] Smith DL, Wenegrat BG \"A case report of serotonin syndrome associated with combined nefazodone and fluoxetine.\" J Clin Psychiatry 61 (2000):  146[54] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[55] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001):  2163-75[56] Duggal HS, Fetchko J \"Serotonin syndrome and atypical antipsychotics.\" Am J Psychiatry 159 (2002):  672-3[57] Wigen CL, Goetz MB \"Serotonin syndrome and linezolid.\" Clin Infect Dis 34 (2002):  1651-2[58] Hammerness P, Parada H, Abrams A \"Linezolid: MAOI Activity and Potential Drug Interactions.\" Psychosomatics 43 (2002):  248-9[59] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[60] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[61] Turkel SB, Nadala JG, Wincor MZ \"Possible serotonin syndrome in association with 5-HT3 antagonist agents.\" Psychosomatics 42 (2001):  258-60[62] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[63] Lavery S, Ravi H, McDaniel WW, Pushkin YR \"Linezolid and serotonin syndrome.\" Psychosomatics 42 (2001):  432-4[64] Lane R, Baldwin D \"Selective serotonin reuptake inhibitor--induced serotonin syndrome: review.\" J Clin Psychopharmacol 17 (1997):  208-21[65] Bernard L, Stern R, Lew D, Hoffmeyer P \"Serotonin syndrome after concomitant treatment with linezolid and citalopram.\" Clin Infect Dis 36 (2003):  1197[66] Dannawi M \"Possible serotonin syndrome after combination of buspirone and St John's Wort.\" J Psychopharmacol 16 (2002):  401[67] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[68] Hachem RY, Hicks K, Huen A, Raad I \"Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients.\" Clin Infect Dis 37 (2003):  E8-E11[69] Gillman PK \"Linezolid and serotonin toxicity.\" Clin Infect Dis 37 (2003):  1274-5[70] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[71] Giese SY, Neborsky R \"Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl.\" Plast Reconstr Surg 107 (2001):  293-4[72] Jones SL, Athan E, O'Brien D \"Serotonin syndrome due to co-administration of linezolid and venlafaxine.\" J Antimicrob Chemother 54 (2004):  289-90[73] Tahir N \"Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram.\" J Am Med Dir Assoc 5 (2004):  111-3[74] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company  (2004):[75] Thomas CR, Rosenberg M, Blythe V, Meyer WJ 3rd \"Serotonin syndrome and linezolid.\" J Am Acad Child Adolesc Psychiatry 43 (2004):  790[76] Boyer EW, Shannon M \"The serotonin syndrome.\" N Engl J Med 352 (2005):  1112-20[77] Bergeron L, Boule M, Perreault S \"Serotonin toxicity associated with concomitant use of linezolid.\" Ann Pharmacother 39 (2005):  956-61[78] Morales N, Vermette H \"Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine.\" Psychosomatics 46 (2005):  274-5[79] Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M, Grau S \"Linezolid-associated serotonin syndrome: what we can learn from cases reported so far.\" J Antimicrob Chemother 56 (2005):  1176-8[80] DeBellis RJ, Schaefer OP, Liquori M, Volturo GA \"Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient.\" J Intensive Care Med 20 (2005):  351-3[81] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[82] Taylor JJ, Wilson JW, Estes LL \"Linezolid and serotonergic drug interactions: a retrospective survey.\" Clin Infect Dis 43 (2006):  180-7[83] Strouse TB, Kerrihard TN, Forscher CA, Zakowski P \"Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine.\" J Clin Psychopharmacol 26 (2006):  681-683[84] Keegan MT, Brown DR, Rabinstein AA \"Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs.\" Anesth Analg 103 (2006):  1466-8[85] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S \"Rare case of serotonin syndrome with therapeutic doses of paroxetine.\" Am J Ther 13 (2006):  550-552[86] Steinberg M, Morin AK \"Mild serotonin syndrome associated with concurrent linezolid and fluoxetine.\" Am J Health Syst Pharm 64 (2007):  59-62[87] Packer S, Berman SA \"Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid.\" Am J Psychiatry 164 (2007):  346-7[88] Shapiro RE, Tepper SJ \"The serotonin syndrome, triptans, and the potential for drug-drug interactions.\" Headache 47 (2007):  266-9[89] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[90] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories  (2008):[91] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[92] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals  (2009):[93] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals  (2009):[94] Lee J, Franz L, Goforth HW \"Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine.\" Psychosomatics 50 (2009):  638-9[95] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC  (2011):[96] Mugele J, Nanagas KA, Tormoehlen LM \"Serotonin Syndrome Associated With MDPV Use: A Case Report.\" Ann Emerg Med  (2012):[97] \"Product Information. Oleptro (trazodone).\" Labopharm Inc  (2012):[98] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals  (2013):[99] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America  (2013):", "alternatives_a": "Rimegepant, Eptinezumab, Ubrogepant, Galcanezumab, Atogepant, Methysergide, Erenumab, Fremanezumab", "alternatives_b": "Halothane, Thiopental, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, Sevoflurane, Etomidate", "updated_at": 1767369485}, {"id": 242606, "ingredient1": "Eribulin", "ingredient2": "Bacillus calmette-guerin substrain tice live antigen", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276141/", "reference_text": "[1] \"Product Information. Meruvax II (rubella virus vaccine).\" Merck & Co., Inc  (2022):[2] \"Product Information. Attenuvax (measles virus vaccine).\" Merck & Co., Inc  (2022):[3] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD \"Harrison's Principles of Internal Medicine.\" New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] \"Product Information. DENGVAXIA (dengue vaccine).\" sanofi pasteur  (2022):", "alternatives_a": "Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, Anagrelide, Ivosidenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242607, "ingredient1": "Eribulin", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276171/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Enasidenib, Porfimer sodium, Aflibercept, Trastuzumab, Hydroxyurea, More", "alternatives_b": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "updated_at": 1767369485}, {"id": 242608, "ingredient1": "Eribulin", "ingredient2": "Varicella Zoster Vaccine (Recombinant)", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual's risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, the U.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276199/", "reference_text": "[1] \"Product Information. Fluzone (influenza virus vaccine, inactivated).\" Connaught Laboratories Inc[2] \"Product Information. Omnihib (haemophilus b conjugate vaccine (obsolete)).\" SmithKline Beecham[3] \"Product Information. Havrix (hepatitis A adult vaccine).\" SmithKline Beecham[4] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[5] \"Product Information. Imovax Rabies (rabies vaccine, human diploid cell).\" sanofi pasteur  (2022):[6] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc.  (2003):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline  (2022):[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations.  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf\"   (2019):[11] CDC Centers for Disease Control and Prevention \"Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html\"   (2022):", "alternatives_a": "Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, Anagrelide, Ivosidenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242609, "ingredient1": "Pralsetinib", "ingredient2": "Pirfenidone", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276272/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Entrectinib, Dabrafenib, Acalabrutinib, Tepotinib, Avapritinib, Larotrectinib, Bosutinib, Lapatinib, Selumetinib, Ribociclib, Vandetanib, More", "updated_at": 1767369485}, {"id": 242610, "ingredient1": "Azatadine", "ingredient2": "Physostigmine (ophthalmic)", "severity": "Moderate", "effect": "Theoretically, anticholinergic agents and other agents with significant anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, class IA antiarrhythmics especially disopyramide) may antagonize the effects of topically administered cholinergic agents such as acetylcholine, carbachol, demecarium, echothiophate, isoflurophate, physostigmine, and pilocarpine.", "source": "DDInter", "management_text": "Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276274/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] \"Product Information. Pilopine-HS (pilocarpine ophthalmic).\" Alcon Laboratories Inc", "alternatives_a": "Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242611, "ingredient1": "Chlorcyclizine", "ingredient2": "Physostigmine (ophthalmic)", "severity": "Moderate", "effect": "Theoretically, anticholinergic agents and other agents with significant anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, class IA antiarrhythmics especially disopyramide) may antagonize the effects of topically administered cholinergic agents such as acetylcholine, carbachol, demecarium, echothiophate, isoflurophate, physostigmine, and pilocarpine.", "source": "DDInter", "management_text": "Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276275/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] \"Product Information. Pilopine-HS (pilocarpine ophthalmic).\" Alcon Laboratories Inc", "alternatives_a": "Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242612, "ingredient1": "Cyclizine", "ingredient2": "Physostigmine (ophthalmic)", "severity": "Moderate", "effect": "Theoretically, anticholinergic agents and other agents with significant anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, class IA antiarrhythmics especially disopyramide) may antagonize the effects of topically administered cholinergic agents such as acetylcholine, carbachol, demecarium, echothiophate, isoflurophate, physostigmine, and pilocarpine.", "source": "DDInter", "management_text": "Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276276/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] \"Product Information. Pilopine-HS (pilocarpine ophthalmic).\" Alcon Laboratories Inc", "alternatives_a": "Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242613, "ingredient1": "Physostigmine (ophthalmic)", "ingredient2": "Methdilazine", "severity": "Moderate", "effect": "Theoretically, anticholinergic agents and other agents with significant anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, class IA antiarrhythmics especially disopyramide) may antagonize the effects of topically administered cholinergic agents such as acetylcholine, carbachol, demecarium, echothiophate, isoflurophate, physostigmine, and pilocarpine.", "source": "DDInter", "management_text": "Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276277/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] \"Product Information. Pilopine-HS (pilocarpine ophthalmic).\" Alcon Laboratories Inc", "alternatives_a": "Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242614, "ingredient1": "Physostigmine (ophthalmic)", "ingredient2": "Methotrimeprazine", "severity": "Moderate", "effect": "Theoretically, anticholinergic agents and other agents with significant anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, class IA antiarrhythmics especially disopyramide) may antagonize the effects of topically administered cholinergic agents such as acetylcholine, carbachol, demecarium, echothiophate, isoflurophate, physostigmine, and pilocarpine.", "source": "DDInter", "management_text": "Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276278/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] \"Product Information. Pilopine-HS (pilocarpine ophthalmic).\" Alcon Laboratories Inc", "alternatives_a": "Asenapine, Pimavanserin, Iloperidone, Amisulpride, Droperidol, Cariprazine, Paliperidone, Lurasidone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242615, "ingredient1": "Physostigmine (ophthalmic)", "ingredient2": "Phenindamine", "severity": "Moderate", "effect": "Theoretically, anticholinergic agents and other agents with significant anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, class IA antiarrhythmics especially disopyramide) may antagonize the effects of topically administered cholinergic agents such as acetylcholine, carbachol, demecarium, echothiophate, isoflurophate, physostigmine, and pilocarpine.", "source": "DDInter", "management_text": "Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276279/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] \"Product Information. Pilopine-HS (pilocarpine ophthalmic).\" Alcon Laboratories Inc", "alternatives_a": "Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242616, "ingredient1": "Promazine", "ingredient2": "Physostigmine (ophthalmic)", "severity": "Moderate", "effect": "Theoretically, anticholinergic agents and other agents with significant anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, class IA antiarrhythmics especially disopyramide) may antagonize the effects of topically administered cholinergic agents such as acetylcholine, carbachol, demecarium, echothiophate, isoflurophate, physostigmine, and pilocarpine.", "source": "DDInter", "management_text": "Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276280/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] \"Product Information. Pilopine-HS (pilocarpine ophthalmic).\" Alcon Laboratories Inc", "alternatives_a": "Asenapine, Pimavanserin, Iloperidone, Amisulpride, Droperidol, Cariprazine, Paliperidone, Lurasidone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242617, "ingredient1": "Propiomazine", "ingredient2": "Physostigmine (ophthalmic)", "severity": "Moderate", "effect": "Theoretically, anticholinergic agents and other agents with significant anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, class IA antiarrhythmics especially disopyramide) may antagonize the effects of topically administered cholinergic agents such as acetylcholine, carbachol, demecarium, echothiophate, isoflurophate, physostigmine, and pilocarpine.", "source": "DDInter", "management_text": "Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276281/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] \"Product Information. Pilopine-HS (pilocarpine ophthalmic).\" Alcon Laboratories Inc", "alternatives_a": "Suvorexant, Triazolam, Flurazepam, Methohexital, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242618, "ingredient1": "Triflupromazine", "ingredient2": "Physostigmine (ophthalmic)", "severity": "Moderate", "effect": "Theoretically, anticholinergic agents and other agents with significant anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, class IA antiarrhythmics especially disopyramide) may antagonize the effects of topically administered cholinergic agents such as acetylcholine, carbachol, demecarium, echothiophate, isoflurophate, physostigmine, and pilocarpine.", "source": "DDInter", "management_text": "Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276282/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] \"Product Information. Pilopine-HS (pilocarpine ophthalmic).\" Alcon Laboratories Inc", "alternatives_a": "Asenapine, Pimavanserin, Iloperidone, Amisulpride, Droperidol, Cariprazine, Paliperidone, Lurasidone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242619, "ingredient1": "Alimemazine", "ingredient2": "Physostigmine (ophthalmic)", "severity": "Moderate", "effect": "Theoretically, anticholinergic agents and other agents with significant anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, class IA antiarrhythmics especially disopyramide) may antagonize the effects of topically administered cholinergic agents such as acetylcholine, carbachol, demecarium, echothiophate, isoflurophate, physostigmine, and pilocarpine.", "source": "DDInter", "management_text": "Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276283/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] \"Product Information. Pilopine-HS (pilocarpine ophthalmic).\" Alcon Laboratories Inc", "alternatives_a": "Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242620, "ingredient1": "Tripelennamine", "ingredient2": "Physostigmine (ophthalmic)", "severity": "Moderate", "effect": "Theoretically, anticholinergic agents and other agents with significant anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, class IA antiarrhythmics especially disopyramide) may antagonize the effects of topically administered cholinergic agents such as acetylcholine, carbachol, demecarium, echothiophate, isoflurophate, physostigmine, and pilocarpine.", "source": "DDInter", "management_text": "Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276284/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] \"Product Information. Pilopine-HS (pilocarpine ophthalmic).\" Alcon Laboratories Inc", "alternatives_a": "Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole, Lidocaine, Tetracaine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242621, "ingredient1": "Oxitriptan", "ingredient2": "Lithium carbonate", "severity": "Moderate", "effect": "Concomitant administration of lithium with serotonergic drugs (e.g., selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, tricyclic antidepressants, triptans (5-HT1 agonists), buspirone, fentanyl, St. John's wort, tramadol, tryptophan) or drugs that impair metabolism of serotonin (e.g., monoamine oxidase inhibitors) can precipitate serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.", "source": "DDInter", "management_text": "Close monitoring for potential serotonin toxicity and excessive CNS depression is advised when lithium is used with other serotonergic agents or monoamine oxidase inhibitors.  Particular caution is advised when increasing the dosages of these agents.  Patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for potential serotonin toxicity and excessive CNS depression is advised when lithium is used with other serotonergic agents or monoamine oxidase inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276285/", "reference_text": "[1] \"Product Information. Lithobid (lithium).\" Ciba-Geigy Pharmaceuticals  (2002):[2] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[3] Sobanski T, Bagli M, Laux G, Rao ML \"Serotonin syndrome after lithium add-on medication to paroxetine.\" Pharmacopsychiatry 30 (1997):  106-7[4] Gardner DM, Lynd LD \"Sumatriptan contraindications and the serotonin syndrome.\" Ann Pharmacother 32 (1998):  33-8[5] Mathew NT, Tietjen GE, Lucker C \"Serotonin syndrome complicating migraine pharmacotherapy.\" Cephalalgia 16 (1996):  323-7[6] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):", "alternatives_a": "Viloxazine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242622, "ingredient1": "Acrivastine", "ingredient2": "Lithium carbonate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276287/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Chlorcyclizine, Fexofenadine, Dexchlorpheniramine, Loratadine, Desloratadine, Azelastine, Pheniramine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242623, "ingredient1": "Frovatriptan", "ingredient2": "Lithium carbonate", "severity": "Moderate", "effect": "Concomitant administration of lithium with serotonergic drugs (e.g., selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, tricyclic antidepressants, triptans (5-HT1 agonists), buspirone, fentanyl, St. John's wort, tramadol, tryptophan) or drugs that impair metabolism of serotonin (e.g., monoamine oxidase inhibitors) can precipitate serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.", "source": "DDInter", "management_text": "Close monitoring for potential serotonin toxicity and excessive CNS depression is advised when lithium is used with other serotonergic agents or monoamine oxidase inhibitors.  Particular caution is advised when increasing the dosages of these agents.  Patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for potential serotonin toxicity and excessive CNS depression is advised when lithium is used with other serotonergic agents or monoamine oxidase inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276292/", "reference_text": "[1] \"Product Information. Lithobid (lithium).\" Ciba-Geigy Pharmaceuticals  (2002):[2] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[3] Sobanski T, Bagli M, Laux G, Rao ML \"Serotonin syndrome after lithium add-on medication to paroxetine.\" Pharmacopsychiatry 30 (1997):  106-7[4] Gardner DM, Lynd LD \"Sumatriptan contraindications and the serotonin syndrome.\" Ann Pharmacother 32 (1998):  33-8[5] Mathew NT, Tietjen GE, Lucker C \"Serotonin syndrome complicating migraine pharmacotherapy.\" Cephalalgia 16 (1996):  323-7[6] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):", "alternatives_a": "Rimegepant, Eptinezumab, Dihydroergotamine, Ubrogepant, Ergotamine, Galcanezumab, Atogepant, Methysergide, Erenumab, Fremanezumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242624, "ingredient1": "Glycerol phenylbutyrate", "ingredient2": "Lithium carbonate", "severity": "Moderate", "effect": "Coadministration of histone deacetylase (HDAC) inhibitors and phenylbutyrate may lead to excess inhibition of HDAC and additive adverse effects.  According to the prescribing information for sodium phenylbutyrate combined with taurursodiol (ursodoxicoltaurine), phenylbutyrate is a pan-HDAC inhibitor", "source": "DDInter", "management_text": "The prescribing information for sodium phenylbutyrate combined with taurursodiol recommends avoiding concomitant use of phenylbutyrate and other HDAC inhibitors.", "mechanism_text": "Synergism", "recommendation": "The prescribing information for sodium phenylbutyrate combined with taurursodiol recommends avoiding concomitant use of phenylbutyrate and other HDAC inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276296/", "reference_text": "[1] \"Product Information. Relyvrio (sodium phenylbutyrate-taurursodiol).\" Amylyx Pharmaceuticals  (2022):[2] \"Product Information. Albrioza (sodium phenylbutyrate-ursodoxicoltaurine).\" Innomar Strategies Inc.  (2022):", "alternatives_a": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Agalsidase beta, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242625, "ingredient1": "Lithium carbonate", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276300/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Amantadine, Cabergoline", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242626, "ingredient1": "Linezolid", "ingredient2": "Lithium carbonate", "severity": "Moderate", "effect": "Concomitant administration of lithium with drugs that can impair the metabolism of serotonin (e.g., monoamine oxidase inhibitors, or MAOIs) may precipitate serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.", "source": "DDInter", "management_text": "Close monitoring is advised when lithium is used with MAOIs or drugs that have MAOI activity.  Particular caution is advised when increasing the dosages of these agents.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.", "mechanism_text": "Synergism", "recommendation": "Close monitoring is advised when lithium is used with MAOIs or drugs that have MAOI activity.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276302/", "reference_text": "[1] \"Product Information. Lithobid (lithium).\" Ciba-Geigy Pharmaceuticals  (2002):[2] \"Product Information. Matulane (procarbazine).\" Roche Laboratories  (2001):[3] Gardner DM, Lynd LD \"Sumatriptan contraindications and the serotonin syndrome.\" Ann Pharmacother 32 (1998):  33-8[4] \"Product Information. Zyvox (linezolid).\" Pharmacia and Upjohn  (2001):[5] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[9] \"Product Information. Provayblue (methylene blue).\" American Regent Laboratories Inc  (2017):", "alternatives_a": "Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Methenamine, Spectinomycin, Nitrofurantoin, Fosfomycin, Tedizolid, Dalbavancin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242627, "ingredient1": "Melatonin", "ingredient2": "Lithium carbonate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276304/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam, Zopiclone, Thiopental", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242628, "ingredient1": "Methylene blue", "ingredient2": "Lithium carbonate", "severity": "Moderate", "effect": "Concomitant administration of lithium with drugs that can impair the metabolism of serotonin (e.g., monoamine oxidase inhibitors, or MAOIs) may precipitate serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.", "source": "DDInter", "management_text": "Close monitoring is advised when lithium is used with MAOIs or drugs that have MAOI activity.  Particular caution is advised when increasing the dosages of these agents.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.", "mechanism_text": "Synergism", "recommendation": "Close monitoring is advised when lithium is used with MAOIs or drugs that have MAOI activity.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276305/", "reference_text": "[1] \"Product Information. Lithobid (lithium).\" Ciba-Geigy Pharmaceuticals  (2002):[2] \"Product Information. Matulane (procarbazine).\" Roche Laboratories  (2001):[3] Gardner DM, Lynd LD \"Sumatriptan contraindications and the serotonin syndrome.\" Ann Pharmacother 32 (1998):  33-8[4] \"Product Information. Zyvox (linezolid).\" Pharmacia and Upjohn  (2001):[5] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[9] \"Product Information. Provayblue (methylene blue).\" American Regent Laboratories Inc  (2017):", "alternatives_a": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Cobicistat, Deferoxamine, Levoleucovorin, Arginine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242629, "ingredient1": "Pralsetinib", "ingredient2": "Lithium carbonate", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276310/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, Selumetinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242630, "ingredient1": "Procarbazine", "ingredient2": "Lithium carbonate", "severity": "Moderate", "effect": "Concomitant administration of lithium with drugs that can impair the metabolism of serotonin (e.g., monoamine oxidase inhibitors, or MAOIs) may precipitate serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.", "source": "DDInter", "management_text": "Close monitoring is advised when lithium is used with MAOIs or drugs that have MAOI activity.  Particular caution is advised when increasing the dosages of these agents.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.", "mechanism_text": "Synergism", "recommendation": "Close monitoring is advised when lithium is used with MAOIs or drugs that have MAOI activity.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276311/", "reference_text": "[1] \"Product Information. Lithobid (lithium).\" Ciba-Geigy Pharmaceuticals  (2002):[2] \"Product Information. Matulane (procarbazine).\" Roche Laboratories  (2001):[3] Gardner DM, Lynd LD \"Sumatriptan contraindications and the serotonin syndrome.\" Ann Pharmacother 32 (1998):  33-8[4] \"Product Information. Zyvox (linezolid).\" Pharmacia and Upjohn  (2001):[5] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[9] \"Product Information. Provayblue (methylene blue).\" American Regent Laboratories Inc  (2017):", "alternatives_a": "Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242631, "ingredient1": "Plantago seed", "ingredient2": "Lithium carbonate", "severity": "Minor", "effect": "A case has been reported in which a woman was admitted to a psychiatric unit due to \"behavioral changes\" probably due to low lithium levels caused by ingestion of psyllium.  Psyllium was believed to have inhibited the absorption of lithium from the gastrointestinal tract.", "source": "DDInter", "management_text": "Psyllium should be ingested at least 2 hours before or 2 hours after the lithium dose.", "mechanism_text": "Absorption", "recommendation": "Psyllium should be ingested at least 2 hours before or 2 hours after the lithium dose.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276312/", "reference_text": "[1] \"Product Information. Metamucil (psyllium).\" Procter and Gamble Pharmaceuticals  (2001):[2] Perlman BB \"Interaction between lithium salts and ispaghula husk [letter].\" Lancet 335 (1990):  416", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242632, "ingredient1": "Rizatriptan", "ingredient2": "Lithium carbonate", "severity": "Moderate", "effect": "Concomitant administration of lithium with serotonergic drugs (e.g., selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, tricyclic antidepressants, triptans (5-HT1 agonists), buspirone, fentanyl, St. John's wort, tramadol, tryptophan) or drugs that impair metabolism of serotonin (e.g., monoamine oxidase inhibitors) can precipitate serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.", "source": "DDInter", "management_text": "Close monitoring for potential serotonin toxicity and excessive CNS depression is advised when lithium is used with other serotonergic agents or monoamine oxidase inhibitors.  Particular caution is advised when increasing the dosages of these agents.  Patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for potential serotonin toxicity and excessive CNS depression is advised when lithium is used with other serotonergic agents or monoamine oxidase inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276314/", "reference_text": "[1] \"Product Information. Lithobid (lithium).\" Ciba-Geigy Pharmaceuticals  (2002):[2] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[3] Sobanski T, Bagli M, Laux G, Rao ML \"Serotonin syndrome after lithium add-on medication to paroxetine.\" Pharmacopsychiatry 30 (1997):  106-7[4] Gardner DM, Lynd LD \"Sumatriptan contraindications and the serotonin syndrome.\" Ann Pharmacother 32 (1998):  33-8[5] Mathew NT, Tietjen GE, Lucker C \"Serotonin syndrome complicating migraine pharmacotherapy.\" Cephalalgia 16 (1996):  323-7[6] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):", "alternatives_a": "Rimegepant, Eptinezumab, Dihydroergotamine, Ubrogepant, Ergotamine, Galcanezumab, Atogepant, Methysergide, Erenumab, Fremanezumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242633, "ingredient1": "Phenylbutyric acid", "ingredient2": "Lithium carbonate", "severity": "Moderate", "effect": "Coadministration of histone deacetylase (HDAC) inhibitors and phenylbutyrate may lead to excess inhibition of HDAC and additive adverse effects.  According to the prescribing information for sodium phenylbutyrate combined with taurursodiol (ursodoxicoltaurine), phenylbutyrate is a pan-HDAC inhibitor", "source": "DDInter", "management_text": "The prescribing information for sodium phenylbutyrate combined with taurursodiol recommends avoiding concomitant use of phenylbutyrate and other HDAC inhibitors.", "mechanism_text": "Synergism", "recommendation": "The prescribing information for sodium phenylbutyrate combined with taurursodiol recommends avoiding concomitant use of phenylbutyrate and other HDAC inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276315/", "reference_text": "[1] \"Product Information. Relyvrio (sodium phenylbutyrate-taurursodiol).\" Amylyx Pharmaceuticals  (2022):[2] \"Product Information. Albrioza (sodium phenylbutyrate-ursodoxicoltaurine).\" Innomar Strategies Inc.  (2022):", "alternatives_a": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Agalsidase beta, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242634, "ingredient1": "Esketamine", "ingredient2": "Diphenhydramine (topical)", "severity": "Major", "effect": "Concomitant use of esketamine with central nervous system (CNS) depressants may increase sedation and impairment of attention, judgment, thinking, reaction speed, and psychomotor skills.", "source": "DDInter", "management_text": "Caution is advised and patients should be closely monitored during concomitant use of esketamine with CNS depressants or other drugs that can cause sedation or dizziness.  Due to the risk of delayed or prolonged sedation and other adverse effects, patients should be monitored for at least 2 hours after esketamine administration, followed by an assessment to determine when the patient is considered clinically stable and ready to leave the healthcare setting.  Patients should be instructed not to engage in potentially hazardous activities that require complete mental alertness and motor coordination, such as driving a motor vehicle or operating machinery, until the next day after a restful sleep.", "mechanism_text": "Synergism", "recommendation": "Caution is advised and patients should be closely monitored during concomitant use of esketamine with CNS depressants or other drugs that can cause sedation or dizziness.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276326/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Spravato (esketamine).\" Janssen Pharmaceuticals  (2019):", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Citalopram, Sertraline, Maprotiline, St. John's Wort, Fluoxetine, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Isocarboxazid, More", "updated_at": 1767369485}, {"id": 242635, "ingredient1": "Esketamine", "ingredient2": "Enflurane", "severity": "Major", "effect": "Concomitant use of esketamine with central nervous system (CNS) depressants may increase sedation and impairment of attention, judgment, thinking, reaction speed, and psychomotor skills.", "source": "DDInter", "management_text": "Caution is advised and patients should be closely monitored during concomitant use of esketamine with CNS depressants or other drugs that can cause sedation or dizziness.  Due to the risk of delayed or prolonged sedation and other adverse effects, patients should be monitored for at least 2 hours after esketamine administration, followed by an assessment to determine when the patient is considered clinically stable and ready to leave the healthcare setting.  Patients should be instructed not to engage in potentially hazardous activities that require complete mental alertness and motor coordination, such as driving a motor vehicle or operating machinery, until the next day after a restful sleep.", "mechanism_text": "Synergism", "recommendation": "Caution is advised and patients should be closely monitored during concomitant use of esketamine with CNS depressants or other drugs that can cause sedation or dizziness.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276327/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Spravato (esketamine).\" Janssen Pharmaceuticals  (2019):", "alternatives_a": "Esketamine", "alternatives_b": "Citalopram, Sertraline, Maprotiline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Viloxazine, More", "updated_at": 1767369485}, {"id": 242636, "ingredient1": "Etomidate", "ingredient2": "Esketamine", "severity": "Major", "effect": "Concomitant use of esketamine with central nervous system (CNS) depressants may increase sedation and impairment of attention, judgment, thinking, reaction speed, and psychomotor skills.", "source": "DDInter", "management_text": "Caution is advised and patients should be closely monitored during concomitant use of esketamine with CNS depressants or other drugs that can cause sedation or dizziness.  Due to the risk of delayed or prolonged sedation and other adverse effects, patients should be monitored for at least 2 hours after esketamine administration, followed by an assessment to determine when the patient is considered clinically stable and ready to leave the healthcare setting.  Patients should be instructed not to engage in potentially hazardous activities that require complete mental alertness and motor coordination, such as driving a motor vehicle or operating machinery, until the next day after a restful sleep.", "mechanism_text": "Synergism", "recommendation": "Caution is advised and patients should be closely monitored during concomitant use of esketamine with CNS depressants or other drugs that can cause sedation or dizziness.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276328/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Spravato (esketamine).\" Janssen Pharmaceuticals  (2019):", "alternatives_a": "Sertraline, Maprotiline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Viloxazine, Amoxapine, More", "alternatives_b": "Esketamine", "updated_at": 1767369485}, {"id": 242637, "ingredient1": "Fospropofol", "ingredient2": "Esketamine", "severity": "Major", "effect": "Concomitant use of esketamine with central nervous system (CNS) depressants may increase sedation and impairment of attention, judgment, thinking, reaction speed, and psychomotor skills.", "source": "DDInter", "management_text": "Caution is advised and patients should be closely monitored during concomitant use of esketamine with CNS depressants or other drugs that can cause sedation or dizziness.  Due to the risk of delayed or prolonged sedation and other adverse effects, patients should be monitored for at least 2 hours after esketamine administration, followed by an assessment to determine when the patient is considered clinically stable and ready to leave the healthcare setting.  Patients should be instructed not to engage in potentially hazardous activities that require complete mental alertness and motor coordination, such as driving a motor vehicle or operating machinery, until the next day after a restful sleep.", "mechanism_text": "Synergism", "recommendation": "Caution is advised and patients should be closely monitored during concomitant use of esketamine with CNS depressants or other drugs that can cause sedation or dizziness.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276329/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Spravato (esketamine).\" Janssen Pharmaceuticals  (2019):", "alternatives_a": "Citalopram, Sertraline, Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Viloxazine, Fluvoxamine, Vilazodone, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242638, "ingredient1": "Guanfacine", "ingredient2": "Esketamine", "severity": "Major", "effect": "Concomitant use of esketamine with central nervous system (CNS) depressants may increase sedation and impairment of attention, judgment, thinking, reaction speed, and psychomotor skills.", "source": "DDInter", "management_text": "Caution is advised and patients should be closely monitored during concomitant use of esketamine with CNS depressants or other drugs that can cause sedation or dizziness.  Due to the risk of delayed or prolonged sedation and other adverse effects, patients should be monitored for at least 2 hours after esketamine administration, followed by an assessment to determine when the patient is considered clinically stable and ready to leave the healthcare setting.  Patients should be instructed not to engage in potentially hazardous activities that require complete mental alertness and motor coordination, such as driving a motor vehicle or operating machinery, until the next day after a restful sleep.", "mechanism_text": "Synergism", "recommendation": "Caution is advised and patients should be closely monitored during concomitant use of esketamine with CNS depressants or other drugs that can cause sedation or dizziness.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276332/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Spravato (esketamine).\" Janssen Pharmaceuticals  (2019):", "alternatives_a": "Duloxetine, Sertraline, Desvenlafaxine, Fluoxetine, Oxitriptan, Tryptophan, Milnacipran, Vortioxetine, Levomilnacipran, Vilazodone, Paroxetine, More", "alternatives_b": "Rauwolfia serpentina root, Reserpine, Methyldopa, Deserpidine", "updated_at": 1767369485}, {"id": 242639, "ingredient1": "Halothane", "ingredient2": "Esketamine", "severity": "Major", "effect": "Concomitant use of esketamine with central nervous system (CNS) depressants may increase sedation and impairment of attention, judgment, thinking, reaction speed, and psychomotor skills.", "source": "DDInter", "management_text": "Caution is advised and patients should be closely monitored during concomitant use of esketamine with CNS depressants or other drugs that can cause sedation or dizziness.  Due to the risk of delayed or prolonged sedation and other adverse effects, patients should be monitored for at least 2 hours after esketamine administration, followed by an assessment to determine when the patient is considered clinically stable and ready to leave the healthcare setting.  Patients should be instructed not to engage in potentially hazardous activities that require complete mental alertness and motor coordination, such as driving a motor vehicle or operating machinery, until the next day after a restful sleep.", "mechanism_text": "Synergism", "recommendation": "Caution is advised and patients should be closely monitored during concomitant use of esketamine with CNS depressants or other drugs that can cause sedation or dizziness.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276333/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Spravato (esketamine).\" Janssen Pharmaceuticals  (2019):", "alternatives_a": "Duloxetine, Vilazodone, Paroxetine, Desvenlafaxine, St. John's Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, More", "alternatives_b": "Esketamine", "updated_at": 1767369485}, {"id": 242640, "ingredient1": "Imipramine", "ingredient2": "Esketamine", "severity": "Major", "effect": "Concomitant use of esketamine with central nervous system (CNS) depressants may increase sedation and impairment of attention, judgment, thinking, reaction speed, and psychomotor skills.", "source": "DDInter", "management_text": "Caution is advised and patients should be closely monitored during concomitant use of esketamine with CNS depressants or other drugs that can cause sedation or dizziness.  Due to the risk of delayed or prolonged sedation and other adverse effects, patients should be monitored for at least 2 hours after esketamine administration, followed by an assessment to determine when the patient is considered clinically stable and ready to leave the healthcare setting.  Patients should be instructed not to engage in potentially hazardous activities that require complete mental alertness and motor coordination, such as driving a motor vehicle or operating machinery, until the next day after a restful sleep.", "mechanism_text": "Synergism", "recommendation": "Caution is advised and patients should be closely monitored during concomitant use of esketamine with CNS depressants or other drugs that can cause sedation or dizziness.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276334/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Spravato (esketamine).\" Janssen Pharmaceuticals  (2019):", "alternatives_a": "Imipramine, Desflurane, Enflurane, Etomidate, Nitrous oxide", "alternatives_b": "Citalopram, Sertraline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Viloxazine, Esketamine, Fluvoxamine, More", "updated_at": 1767369485}, {"id": 242641, "ingredient1": "Isoflurane", "ingredient2": "Esketamine", "severity": "Major", "effect": "Concomitant use of esketamine with central nervous system (CNS) depressants may increase sedation and impairment of attention, judgment, thinking, reaction speed, and psychomotor skills.", "source": "DDInter", "management_text": "Caution is advised and patients should be closely monitored during concomitant use of esketamine with CNS depressants or other drugs that can cause sedation or dizziness.  Due to the risk of delayed or prolonged sedation and other adverse effects, patients should be monitored for at least 2 hours after esketamine administration, followed by an assessment to determine when the patient is considered clinically stable and ready to leave the healthcare setting.  Patients should be instructed not to engage in potentially hazardous activities that require complete mental alertness and motor coordination, such as driving a motor vehicle or operating machinery, until the next day after a restful sleep.", "mechanism_text": "Synergism", "recommendation": "Caution is advised and patients should be closely monitored during concomitant use of esketamine with CNS depressants or other drugs that can cause sedation or dizziness.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276335/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Spravato (esketamine).\" Janssen Pharmaceuticals  (2019):", "alternatives_a": "Sertraline, Maprotiline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Viloxazine, Fluvoxamine, Oxitriptan, More", "alternatives_b": "Esketamine", "updated_at": 1767369485}, {"id": 242642, "ingredient1": "Esketamine", "ingredient2": "Kava", "severity": "Major", "effect": "Concomitant use of esketamine with central nervous system (CNS) depressants may increase sedation and impairment of attention, judgment, thinking, reaction speed, and psychomotor skills.", "source": "DDInter", "management_text": "Caution is advised and patients should be closely monitored during concomitant use of esketamine with CNS depressants or other drugs that can cause sedation or dizziness.  Due to the risk of delayed or prolonged sedation and other adverse effects, patients should be monitored for at least 2 hours after esketamine administration, followed by an assessment to determine when the patient is considered clinically stable and ready to leave the healthcare setting.  Patients should be instructed not to engage in potentially hazardous activities that require complete mental alertness and motor coordination, such as driving a motor vehicle or operating machinery, until the next day after a restful sleep.", "mechanism_text": "Synergism", "recommendation": "Caution is advised and patients should be closely monitored during concomitant use of esketamine with CNS depressants or other drugs that can cause sedation or dizziness.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276336/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Spravato (esketamine).\" Janssen Pharmaceuticals  (2019):", "alternatives_a": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion, Halothane, Sodium oxybate, Isoflurane, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242643, "ingredient1": "Esketamine", "ingredient2": "Methoxyflurane", "severity": "Major", "effect": "Concomitant use of esketamine with central nervous system (CNS) depressants may increase sedation and impairment of attention, judgment, thinking, reaction speed, and psychomotor skills.", "source": "DDInter", "management_text": "Caution is advised and patients should be closely monitored during concomitant use of esketamine with CNS depressants or other drugs that can cause sedation or dizziness.  Due to the risk of delayed or prolonged sedation and other adverse effects, patients should be monitored for at least 2 hours after esketamine administration, followed by an assessment to determine when the patient is considered clinically stable and ready to leave the healthcare setting.  Patients should be instructed not to engage in potentially hazardous activities that require complete mental alertness and motor coordination, such as driving a motor vehicle or operating machinery, until the next day after a restful sleep.", "mechanism_text": "Synergism", "recommendation": "Caution is advised and patients should be closely monitored during concomitant use of esketamine with CNS depressants or other drugs that can cause sedation or dizziness.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276337/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Spravato (esketamine).\" Janssen Pharmaceuticals  (2019):", "alternatives_a": "Citalopram, Sertraline, Maprotiline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Viloxazine, More", "alternatives_b": "Salicylic acid, Acetaminophen, Choline salicylate, Diflunisal, Salsalate, Acetylsalicylic acid", "updated_at": 1767369485}, {"id": 242644, "ingredient1": "Esketamine", "ingredient2": "Nitrous oxide", "severity": "Major", "effect": "Concomitant use of esketamine with central nervous system (CNS) depressants may increase sedation and impairment of attention, judgment, thinking, reaction speed, and psychomotor skills.", "source": "DDInter", "management_text": "Caution is advised and patients should be closely monitored during concomitant use of esketamine with CNS depressants or other drugs that can cause sedation or dizziness.  Due to the risk of delayed or prolonged sedation and other adverse effects, patients should be monitored for at least 2 hours after esketamine administration, followed by an assessment to determine when the patient is considered clinically stable and ready to leave the healthcare setting.  Patients should be instructed not to engage in potentially hazardous activities that require complete mental alertness and motor coordination, such as driving a motor vehicle or operating machinery, until the next day after a restful sleep.", "mechanism_text": "Synergism", "recommendation": "Caution is advised and patients should be closely monitored during concomitant use of esketamine with CNS depressants or other drugs that can cause sedation or dizziness.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276339/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Spravato (esketamine).\" Janssen Pharmaceuticals  (2019):", "alternatives_a": "Citalopram, Sertraline, Maprotiline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Viloxazine, More", "alternatives_b": "Esketamine", "updated_at": 1767369485}, {"id": 242645, "ingredient1": "Esketamine", "ingredient2": "Valbenazine", "severity": "Major", "effect": "Concomitant use of esketamine with central nervous system (CNS) depressants may increase sedation and impairment of attention, judgment, thinking, reaction speed, and psychomotor skills.", "source": "DDInter", "management_text": "Caution is advised and patients should be closely monitored during concomitant use of esketamine with CNS depressants or other drugs that can cause sedation or dizziness.  Due to the risk of delayed or prolonged sedation and other adverse effects, patients should be monitored for at least 2 hours after esketamine administration, followed by an assessment to determine when the patient is considered clinically stable and ready to leave the healthcare setting.  Patients should be instructed not to engage in potentially hazardous activities that require complete mental alertness and motor coordination, such as driving a motor vehicle or operating machinery, until the next day after a restful sleep.", "mechanism_text": "Synergism", "recommendation": "Caution is advised and patients should be closely monitored during concomitant use of esketamine with CNS depressants or other drugs that can cause sedation or dizziness.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276341/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Spravato (esketamine).\" Janssen Pharmaceuticals  (2019):", "alternatives_a": "Levomilnacipran, Oxitriptan, Vortioxetine, Milnacipran, Tryptophan, Vilazodone, Isoflurane, Nitrous oxide, Desflurane, Enflurane, Etomidate", "alternatives_b": "Dalfampridine, Riluzole, Inotersen, Pitolisant, Amifampridine, Tafamidis", "updated_at": 1767369485}, {"id": 242646, "ingredient1": "Esomeprazole", "ingredient2": "Pemigatinib", "severity": "Moderate", "effect": "Coadministration of pemigatinib with proton pump inhibitors may result in a reduction in the plasma concentrations of pemigatinib.  The mechanism for this interaction has not been delineated.", "source": "DDInter", "management_text": "Until more information is available, caution is recommended when pemigatinib is used concomitantly with proton pump inhibitors.  Patients should be monitored for potentially reduced efficacy.", "mechanism_text": "Others", "recommendation": "Until more information is available, caution is recommended when pemigatinib is used concomitantly with proton pump inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276353/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Tinidazole, Levofloxacin, Tetracycline, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Nizatidine, Ranitidine, Amoxicillin, More", "alternatives_b": "Entrectinib, Imatinib, Dabrafenib, Asciminib, Pacritinib, Tepotinib, Avapritinib, Vemurafenib, Ribociclib, Cobimetinib, Ibrutinib, More", "updated_at": 1767369485}, {"id": 242647, "ingredient1": "Esomeprazole", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276355/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Tetracycline, Sucralfate, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Nizatidine, Ranitidine, Amoxicillin, Fenoprofen, Meclofenamic acid, Ketorolac, More", "alternatives_b": "Entrectinib, Imatinib, Dabrafenib, Asciminib, Pacritinib, Tepotinib, Avapritinib, Vemurafenib, Ribociclib, Cobimetinib, Ibrutinib, More", "updated_at": 1767369485}, {"id": 242648, "ingredient1": "Esomeprazole", "ingredient2": "Selumetinib", "severity": "Moderate", "effect": "Coadministration with potent or moderate inhibitors of CYP450 2C19 may increase the plasma concentrations of selumetinib, which is primarily metabolized by CYP450 3A4 and to a lesser extent by CYP450 2C19, 1A2, 2C9, 2E1, and 3A5.  Selumetinib's active metabolite, N-desmethyl selumetinib, is generated by CYP450 2C19 and 1A2 with additional contribution by CYP450 2C9 and 2A6, and metabolized through the same routes as selumetinib.", "source": "DDInter", "management_text": "Caution is advised when selumetinib is used with potent or moderate CYP450 2C19 inhibitors.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when selumetinib is used with potent or moderate CYP450 2C19 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276357/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Koselugo (selumetinib).\" Astra-Zeneca Pharmaceuticals  (2020):", "alternatives_a": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, More", "alternatives_b": "Entrectinib, Imatinib, Dabrafenib, Asciminib, Pacritinib, Tepotinib, Avapritinib, Vemurafenib, Ribociclib, Cobimetinib, Ibrutinib, More", "updated_at": 1767369485}, {"id": 242649, "ingredient1": "Estazolam", "ingredient2": "Acrivastine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276362/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Methdilazine, Ketotifen, Chlorcyclizine, Fexofenadine, Thiethylperazine, Phenindamine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 242650, "ingredient1": "Estazolam", "ingredient2": "Chlormezanone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276365/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Butabarbital, Chloral hydrate, Nitrazepam, Paraldehyde, Butalbital, Propiomazine, Meprobamate, Methylphenobarbital, Zolpidem, Ethchlorvynol, Zopiclone, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242651, "ingredient1": "Ethchlorvynol", "ingredient2": "Estazolam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276367/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Butabarbital, Nitrazepam, Thiopental, Paraldehyde, Butalbital, Propiomazine, Meprobamate, Dexmedetomidine, Methylphenobarbital, Zolpidem, Ethchlorvynol, More", "alternatives_b": "Estazolam", "updated_at": 1767369485}, {"id": 242652, "ingredient1": "Fenfluramine", "ingredient2": "Estazolam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276368/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "Dexfenfluramine, Naltrexone, Ephedrine, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol, Lacosamide", "updated_at": 1767369485}, {"id": 242653, "ingredient1": "Halazepam", "ingredient2": "Estazolam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276372/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam, Chloral hydrate, Paraldehyde, Propiomazine, Zopiclone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242654, "ingredient1": "Estazolam", "ingredient2": "Methotrimeprazine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276375/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Temazepam, Chloral hydrate, Triazolam, Flurazepam, Quazepam, Paraldehyde, Nitrazepam, Propiomazine, Meprobamate, Eszopiclone, Ethchlorvynol, More", "alternatives_b": "Amisulpride, Pimavanserin", "updated_at": 1767369485}, {"id": 242655, "ingredient1": "Estazolam", "ingredient2": "Paraldehyde", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276379/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Chloral hydrate, Nitrazepam, Thiopental, Paraldehyde, Propiomazine, Ethchlorvynol, Zolpidem, Zopiclone, Pentobarbital, Zaleplon", "alternatives_b": "Estazolam", "updated_at": 1767369485}, {"id": 242656, "ingredient1": "Estazolam", "ingredient2": "Pentobarbital", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276380/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam, Paraldehyde, Ethchlorvynol, Zopiclone, Pentobarbital, Zaleplon", "alternatives_b": "Estazolam", "updated_at": 1767369485}, {"id": 242657, "ingredient1": "Estazolam", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276382/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Methohexital, Methylphenobarbital, Pentobarbital, Dichloralphenazone, Valerian, Temazepam, Butabarbital, Secobarbital, Chloral hydrate, Paraldehyde, Ethchlorvynol, More", "alternatives_b": "Entrectinib, Asciminib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Ribociclib, More", "updated_at": 1767369485}, {"id": 242658, "ingredient1": "Esterified estrogens", "ingredient2": "Osilodrostat", "severity": "Moderate", "effect": "Coadministration with osilodrostat may increase the plasma concentrations of drugs that are metabolized by CYP450 1A2, 2C19, 2D6, and/or 3A4.  Osilodrostat has been shown to be a moderate inhibitor of CYP450 1A2, a mild to borderline moderate inhibitor of CYP450 2C19, and a weak inhibitor of CYP450 2D6 and 3A4.", "source": "DDInter", "management_text": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever osilodrostat is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276391/", "reference_text": "[1] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Inc  (2020):[2] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Australia Pty Ltd  (2022):[3] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases UK Ltd  (2021):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242659, "ingredient1": "Estradiol (topical)", "ingredient2": "Lefamulin", "severity": "Moderate", "effect": "When administered orally, lefamulin may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme.  Based on interaction with midazolam, a sensitive CYP450 3A4 substrate, lefamulin may be a moderate CYP450 3A4 inhibitor.", "source": "DDInter", "management_text": "Caution is advised when oral lefamulin is used concomitantly with drugs that are substrates of CYP450 3A4, particularly sensitive substrates or those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever oral lefamulin is added to or withdrawn from therapy.  Patients should be monitored for the development of adverse effects.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration of a moderate CYP450 3A4 inhibitor like lefamulin and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when oral lefamulin is used concomitantly with drugs that are substrates of CYP450 3A4, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276396/", "reference_text": "[1] \"Product Information. Xenleta (lefamulin).\" Nabriva Therapeutics US, Inc.  (2019):", "alternatives_a": "Dienogest, Etynodiol, Diethylstilbestrol, Bazedoxifene, Prasterone, Methyltestosterone, Dienogest, Estetrol, Etynodiol, Ganirelix, Cetrorelix, More", "alternatives_b": "Tinidazole, Linezolid, Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Metronidazole, Telavancin, Methenamine, Spectinomycin, More", "updated_at": 1767369485}, {"id": 242660, "ingredient1": "Estradiol (topical)", "ingredient2": "Osilodrostat", "severity": "Moderate", "effect": "Coadministration with osilodrostat may increase the plasma concentrations of drugs that are metabolized by CYP450 1A2, 2C19, 2D6, and/or 3A4.  Osilodrostat has been shown to be a moderate inhibitor of CYP450 1A2, a mild to borderline moderate inhibitor of CYP450 2C19, and a weak inhibitor of CYP450 2D6 and 3A4.", "source": "DDInter", "management_text": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever osilodrostat is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276403/", "reference_text": "[1] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Inc  (2020):[2] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Australia Pty Ltd  (2022):[3] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases UK Ltd  (2021):", "alternatives_a": "Dienogest, Etynodiol, Diethylstilbestrol, Bazedoxifene, Prasterone, Methyltestosterone, Dienogest, Estetrol, Etynodiol, Nafarelin, Octreotide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242661, "ingredient1": "Estradiol (topical)", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276405/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Megestrol acetate, Chlorotrianisene, Diethylstilbestrol, Bazedoxifene, Prasterone, Methyltestosterone, Megestrol acetate, Estetrol, Nafarelin, Elagolix, Cetrorelix, More", "alternatives_b": "Entrectinib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Bosutinib, Lapatinib, Selumetinib, Ribociclib, Vandetanib, More", "updated_at": 1767369485}, {"id": 242662, "ingredient1": "Estrone sulfate", "ingredient2": "Osilodrostat", "severity": "Moderate", "effect": "Coadministration with osilodrostat may increase the plasma concentrations of drugs that are metabolized by CYP450 1A2, 2C19, 2D6, and/or 3A4.  Osilodrostat has been shown to be a moderate inhibitor of CYP450 1A2, a mild to borderline moderate inhibitor of CYP450 2C19, and a weak inhibitor of CYP450 2D6 and 3A4.", "source": "DDInter", "management_text": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever osilodrostat is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276416/", "reference_text": "[1] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Inc  (2020):[2] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Australia Pty Ltd  (2022):[3] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases UK Ltd  (2021):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242663, "ingredient1": "Estrone sulfate", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276418/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Entrectinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Ribociclib, Vandetanib, Cobimetinib, Capmatinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242664, "ingredient1": "Eszopiclone", "ingredient2": "Acrivastine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276422/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Chlorcyclizine, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 242665, "ingredient1": "Fenfluramine", "ingredient2": "Eszopiclone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276424/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "Dexfenfluramine, Naltrexone, Ephedrine, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol, Lacosamide", "updated_at": 1767369485}, {"id": 242666, "ingredient1": "Eszopiclone", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276429/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "Amantadine, Cabergoline", "updated_at": 1767369485}, {"id": 242667, "ingredient1": "Eszopiclone", "ingredient2": "Melatonin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276432/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Melatonin, Nitrazepam, Zopiclone", "alternatives_b": "Eszopiclone, Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 242668, "ingredient1": "Eszopiclone", "ingredient2": "Osilodrostat", "severity": "Moderate", "effect": "Coadministration with osilodrostat may increase the plasma concentrations of drugs that are metabolized by CYP450 1A2, 2C19, 2D6, and/or 3A4.  Osilodrostat has been shown to be a moderate inhibitor of CYP450 1A2, a mild to borderline moderate inhibitor of CYP450 2C19, and a weak inhibitor of CYP450 2D6 and 3A4.", "source": "DDInter", "management_text": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever osilodrostat is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276437/", "reference_text": "[1] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Inc  (2020):[2] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Australia Pty Ltd  (2022):[3] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases UK Ltd  (2021):", "alternatives_a": "Temazepam, Remimazolam, Chloral hydrate, Nitrazepam, Thiopental, Paraldehyde, Propiomazine, Meprobamate, Scopolamine, Dexmedetomidine, Methohexital, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242669, "ingredient1": "Eszopiclone", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276439/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Methohexital, Methylphenobarbital, Pentobarbital, Dichloralphenazone, Valerian, Temazepam, Butabarbital, Secobarbital, Chloral hydrate, Paraldehyde, Ethchlorvynol, More", "alternatives_b": "Entrectinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, More", "updated_at": 1767369485}, {"id": 242670, "ingredient1": "Ethchlorvynol", "ingredient2": "Acrivastine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276445/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Chlorcyclizine, Triprolidine, Tripelennamine, Azelastine, Promethazine, Fexofenadine, Meclizine, Azatadine, Alimemazine, Loratadine, More", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 242671, "ingredient1": "Ethchlorvynol", "ingredient2": "Bepridil", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276446/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Suvorexant, Chloral hydrate, Nitrazepam, Thiopental, Paraldehyde, Propiomazine, Ramelteon, Scopolamine, Eszopiclone, Methohexital, Lemborexant, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242672, "ingredient1": "Ethchlorvynol", "ingredient2": "Carteolol", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276448/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Latanoprost, Methazolamide, Neostigmine, Pilocarpine, Physostigmine, Acetylcholine, Diclofenamide, Bimatoprost, Travoprost, Acetazolamide, Brinzolamide, More", "alternatives_b": "Suvorexant, Methohexital, Methylphenobarbital, Pentobarbital, Valerian, Butabarbital, Secobarbital, Chloral hydrate, Paraldehyde, Ramelteon, Lemborexant, More", "updated_at": 1767369485}, {"id": 242673, "ingredient1": "Ethchlorvynol", "ingredient2": "Chloral hydrate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276449/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Butabarbital, Nitrazepam, Thiopental, Paraldehyde, Butalbital, Propiomazine, Meprobamate, Dexmedetomidine, Methylphenobarbital, Zolpidem, Ethchlorvynol, More", "alternatives_b": "Nitrazepam, Chloral hydrate, Paraldehyde, Propiomazine, Zopiclone", "updated_at": 1767369485}, {"id": 242674, "ingredient1": "Ethchlorvynol", "ingredient2": "Cyclizine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276450/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Chlorcyclizine, Triprolidine, Tripelennamine, Azelastine, Promethazine, Fexofenadine, Meclizine, Azatadine, Alimemazine, Loratadine, More", "alternatives_b": "Butabarbital, Chloral hydrate, Nitrazepam, Paraldehyde, Butalbital, Propiomazine, Meprobamate, Methylphenobarbital, Zopiclone, Dichloralphenazone", "updated_at": 1767369485}, {"id": 242675, "ingredient1": "Ethchlorvynol", "ingredient2": "Deserpidine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276451/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Prazosin, Guanethidine, Hydralazine, Methyldopa", "alternatives_b": "Suvorexant, Methylphenobarbital, Pentobarbital, Valerian, Butabarbital, Secobarbital, Chloral hydrate, Paraldehyde, Ramelteon, Lemborexant, Zopiclone, More", "updated_at": 1767369485}, {"id": 242676, "ingredient1": "Ethchlorvynol", "ingredient2": "Dezocine", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276452/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "alternatives_b": "Nitrazepam, Chloral hydrate, Paraldehyde, Propiomazine, Zopiclone", "updated_at": 1767369485}, {"id": 242677, "ingredient1": "Ethchlorvynol", "ingredient2": "Dicoumarol", "severity": "Minor", "effect": "Ethchlorvynol and paraldehyde may inhibit the hypoprothrombinemic response to warfarin due to hepatic enzyme induction.", "source": "DDInter", "management_text": "Monitor patient for altered anticoagulant effect if these drugs are added to or removed from a patient's regimen.", "mechanism_text": "Metabolism", "recommendation": "Monitor patient for altered anticoagulant effect if these drugs are added to or removed from a patient's regimen.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276453/", "reference_text": "[1] \"Product Information. Coumadin (warfarin).\" DuPont Pharmaceuticals  (2001):", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Clopidogrel, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, More", "alternatives_b": "Suvorexant, Triazolam, Flurazepam, Zolpidem, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Chloral hydrate, Quazepam, Paraldehyde, More", "updated_at": 1767369485}, {"id": 242678, "ingredient1": "Fenfluramine", "ingredient2": "Ethchlorvynol", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276454/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "Dexfenfluramine, Naltrexone, Ephedrine, Phentermine, Orlistat, Lorcaserin, Sibutramine, Diethylpropion, Mazindol, Tiagabine, Ethotoin, More", "updated_at": 1767369485}, {"id": 242679, "ingredient1": "Fospropofol", "ingredient2": "Ethchlorvynol", "severity": "Moderate", "effect": "Additive central nervous system and cardiorespiratory depressant effects may occur when fospropofol or propofol is administered with other depressants such as sedative-hypnotic agents and narcotic analgesics.", "source": "DDInter", "management_text": "Patients should be monitored closely for excessive sedation and cardiorespiratory depression, and the medication dosage(s) adjusted accordingly.  Supportive therapy should be provided if needed.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for excessive sedation and cardiorespiratory depression, and the medication dosage(s) adjusted accordingly.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276455/", "reference_text": "[1] McClune S, McKay AC, Wright PM, et al. \"Synergistic interaction between midazolam and propofol.\" Br J Anaesth 69 (1992):  240-5[2] Gill SS, Wright EM, Reilly CS \"Pharmacokinetic interaction of propofol and fentanyl: single bolus injection study.\" Br J Anaesth 65 (1990):  760-5[3] \"Product Information. Diprivan (propofol).\" Astra-Zeneca Pharmaceuticals  (2001):[4] Pavlin DJ, Coda B, Shen DD, et al. \"Effects of combining propofol and alfentanil on ventilation, analgesia, sedation, and emesis in human volunteers.\" Anesthesiology 84 (1996):  23-37[5] Hamaoka N, Oda Y, Hase I, Mizutani K, Nakamoto T, Ishizaki T, Asada A \"Propofol decreases the clearance of midazolam by inhibiting CYP3A4: An in vivo and in vitro study.\" Clin Pharmacol Ther 66 (1999):  110-7[6] \"Product Information. Lusedra (fospropofol).\" Eisai Inc  (2008):", "alternatives_a": "Nitrazepam, Butalbital, Scopolamine, Zopiclone, Melatonin, Primidone, Valerian", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242680, "ingredient1": "Gabapentin", "ingredient2": "Ethchlorvynol", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276456/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam", "alternatives_b": "Tiagabine, Ethotoin, Topiramate, Paramethadione, Mephenytoin, Methsuximide, Phensuximide, Lamotrigine, Fosphenytoin, Methylphenobarbital, Phenacemide, More", "updated_at": 1767369485}, {"id": 242681, "ingredient1": "Guanadrel", "ingredient2": "Ethchlorvynol", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276459/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Suvorexant, Methohexital, Methylphenobarbital, Pentobarbital, Valerian, Butabarbital, Secobarbital, Ramelteon, Lemborexant, Zopiclone, Amobarbital, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242682, "ingredient1": "Halazepam", "ingredient2": "Ethchlorvynol", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276460/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam, Chloral hydrate, Paraldehyde, Propiomazine, Zopiclone", "alternatives_b": "Meprobamate, Hydroxyzine", "updated_at": 1767369485}, {"id": 242683, "ingredient1": "Ethchlorvynol", "ingredient2": "Diamorphine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276461/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine", "alternatives_b": "Nitrazepam, Chloral hydrate, Paraldehyde, Propiomazine, Zopiclone", "updated_at": 1767369485}, {"id": 242684, "ingredient1": "Isocarboxazid", "ingredient2": "Ethchlorvynol", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276462/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "Sertraline, Maprotiline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Viloxazine, Amoxapine, Imipramine, Fluvoxamine, More", "updated_at": 1767369485}, {"id": 242685, "ingredient1": "Ethchlorvynol", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276463/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "Ropinirole, Cabergoline, Tolcapone, Entacapone, Pramipexole, Amantadine", "updated_at": 1767369485}, {"id": 242686, "ingredient1": "Ethchlorvynol", "ingredient2": "Levacetylmethadol", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276464/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Nitrazepam, Chloral hydrate, Paraldehyde, Propiomazine, Zopiclone", "alternatives_b": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine", "updated_at": 1767369485}, {"id": 242687, "ingredient1": "Ethchlorvynol", "ingredient2": "Melatonin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276465/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Melatonin, Nitrazepam, Zopiclone", "alternatives_b": "Butabarbital, Nitrazepam, Thiopental, Paraldehyde, Butalbital, Propiomazine, Meprobamate, Dexmedetomidine, Methylphenobarbital, Zolpidem, Ethchlorvynol, More", "updated_at": 1767369485}, {"id": 242688, "ingredient1": "Ethchlorvynol", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276467/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam, Zopiclone, Midazolam", "alternatives_b": "Butabarbital, Nitrazepam, Thiopental, Paraldehyde, Butalbital, Propiomazine, Meprobamate, Dexmedetomidine, Methylphenobarbital, Zolpidem, Ethchlorvynol, More", "updated_at": 1767369485}, {"id": 242689, "ingredient1": "Ethchlorvynol", "ingredient2": "Penbutolol", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276468/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Suvorexant, Nitrazepam, Thiopental, Eszopiclone, Ramelteon, Lemborexant, Methohexital, Estazolam, Zopiclone, Melatonin, Valerian", "alternatives_b": "Timolol", "updated_at": 1767369485}, {"id": 242690, "ingredient1": "Ethchlorvynol", "ingredient2": "Triazolam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276470/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Triazolam", "alternatives_b": "Butabarbital, Nitrazepam, Thiopental, Paraldehyde, Butalbital, Propiomazine, Meprobamate, Dexmedetomidine, Methylphenobarbital, Zolpidem, Ethchlorvynol, More", "updated_at": 1767369485}, {"id": 242691, "ingredient1": "Ethchlorvynol", "ingredient2": "Trichlormethiazide", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276471/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Suvorexant, Methohexital, Methylphenobarbital, Pentobarbital, Valerian, Butabarbital, Secobarbital, Chloral hydrate, Paraldehyde, Ramelteon, Lemborexant, More", "alternatives_b": "Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, More", "updated_at": 1767369485}, {"id": 242692, "ingredient1": "Ethosuximide", "ingredient2": "Acrivastine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276476/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 242693, "ingredient1": "Ethosuximide", "ingredient2": "Chlorcyclizine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276478/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "Oxcarbazepine, Ethotoin, Methsuximide, Paramethadione, Carbamazepine, Phensuximide, Fosphenytoin, Methylphenobarbital, Phenacemide, Phenytoin, Felbamate, More", "updated_at": 1767369485}, {"id": 242694, "ingredient1": "Ethosuximide", "ingredient2": "Cyclizine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276479/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "Methsuximide, Paramethadione, Phensuximide, Methylphenobarbital, Phenacemide, Trimethadione, Lacosamide", "updated_at": 1767369485}, {"id": 242695, "ingredient1": "Felbamate", "ingredient2": "Ethosuximide", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276481/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Paramethadione, Phensuximide, Methylphenobarbital, Phenacemide, Felbamate, Lacosamide, Trimethadione", "alternatives_b": "Tiagabine, Methsuximide, Paramethadione, Phensuximide, Methylphenobarbital, Phenacemide, Trimethadione, Ethosuximide, Lacosamide", "updated_at": 1767369485}, {"id": 242696, "ingredient1": "Fenfluramine", "ingredient2": "Ethosuximide", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276482/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Lacosamide, Fenfluramine", "alternatives_b": "Dexfenfluramine, Naltrexone, Ephedrine, Bupropion, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol, Tiagabine, Methsuximide, More", "updated_at": 1767369485}, {"id": 242697, "ingredient1": "Gabapentin", "ingredient2": "Ethosuximide", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276484/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Gabapentin, Lacosamide", "alternatives_b": "Tiagabine, Methsuximide, Paramethadione, Phensuximide, Methylphenobarbital, Phenacemide, Trimethadione, Ethosuximide, Lacosamide", "updated_at": 1767369485}, {"id": 242698, "ingredient1": "Ethosuximide", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276488/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Lacosamide", "alternatives_b": "Amantadine, Cabergoline", "updated_at": 1767369485}, {"id": 242699, "ingredient1": "Ethosuximide", "ingredient2": "Melatonin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276490/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Lacosamide", "alternatives_b": "Nitrazepam, Thiopental, Ethchlorvynol, Methylphenobarbital, Zopiclone", "updated_at": 1767369485}, {"id": 242700, "ingredient1": "Ethosuximide", "ingredient2": "Methotrimeprazine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276491/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Tiagabine, Ethotoin, Methsuximide, Paramethadione, Mephenytoin, Phensuximide, Lamotrigine, Phenacemide, Trimethadione, Lacosamide, Levetiracetam", "alternatives_b": "Amisulpride, Pimavanserin", "updated_at": 1767369485}, {"id": 242701, "ingredient1": "Ethosuximide", "ingredient2": "Osilodrostat", "severity": "Moderate", "effect": "Coadministration with osilodrostat may increase the plasma concentrations of drugs that are metabolized by CYP450 1A2, 2C19, 2D6, and/or 3A4.  Osilodrostat has been shown to be a moderate inhibitor of CYP450 1A2, a mild to borderline moderate inhibitor of CYP450 2C19, and a weak inhibitor of CYP450 2D6 and 3A4.", "source": "DDInter", "management_text": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever osilodrostat is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276496/", "reference_text": "[1] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Inc  (2020):[2] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Australia Pty Ltd  (2022):[3] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases UK Ltd  (2021):", "alternatives_a": "Ethotoin, Brivaracetam, Gabapentin, Valproic acid, Topiramate, Paramethadione, Methsuximide, Perampanel, Phensuximide, Lamotrigine, Phenacemide, More", "alternatives_b": "Ketoconazole", "updated_at": 1767369485}, {"id": 242702, "ingredient1": "Ethosuximide", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276498/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Brivaracetam, Topiramate, Lamotrigine, Methylphenobarbital, Levetiracetam, Oxcarbazepine, Ethotoin, Rufinamide, Paramethadione, Perampanel, Vigabatrin, More", "alternatives_b": "Entrectinib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, More", "updated_at": 1767369485}, {"id": 242703, "ingredient1": "Ethosuximide", "ingredient2": "Ziprasidone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276502/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Lacosamide", "alternatives_b": "Amisulpride, Pimavanserin", "updated_at": 1767369485}, {"id": 242704, "ingredient1": "Ginkgo biloba", "ingredient2": "Etodolac", "severity": "Moderate", "effect": "Ginkgo may potentiate the risk of bleeding associated with anticoagulants, platelet inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), and thrombolytic agents.  Ginkgolide B, a component of ginkgo, inhibits platelet-activating factor by displacing it from its receptor-binding site, resulting in reduced platelet aggregation.", "source": "DDInter", "management_text": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.  In general, consumption of ginkgo should be avoided during use of coagulation-modifying agents and at least two weeks prior to surgery.  In patients who have used this herb extensively prior to receiving anticoagulation, antiplatelet, NSAID or thrombolytic therapy, the potential for an interaction should be considered.  Close clinical and laboratory observation for hematologic complications is recommended.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276503/", "reference_text": "[1] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[2] Rosenblatt M, Mindel J \"Spontaneous hyphema associated with ingestion of Ginkgo biloba extract.\" N Engl J Med 336 (1997):  1108[3] Rowin J, Lewis SL \"Spontaneous bilateral subdural hematomas associated with chronic Gingko biloba ingestion.\" Neurology 46 (1996):  1775-6[4] Chung KF, McCusker M, Page CP, Dent G, Guinot P, Barnes PJ \"Effect of ginkgolide mixture (BN 52063) in antagonising skin and platelet responses to platelet acitivating factor in man.\" Lancet 1 (1987):  248-51[5] Fugh-Berman A \"Herb-drug interactions.\" Lancet 355 (2000):  134-8[6] Heck AM, DeWitt BA, Lukes AL \"Potential interactions between alternative therapies and warfarin.\" Am J Health Syst Pharm 57 (2000):  1221-7; quiz 1228-30[7] Vaes LP, Chyka PA \"Interactions of warfarin with garlic, ginger, or ginseng: nature of evidence.\" Ann Pharmacother 34 (2000):  1478-82[8] Fessenden JM, Wittenborn W, Clarke L \"Gingko biloba: A case report of herbal medicine and bleeding postoperatively from a laparoscopic cholecystectomy.\" Am Surg 67 (2001):  33-5[9] Benjamin J, Muir T, Briggs K, Pentland B \"A case of cerebral haemorrhage - can Ginkgo biloba be implicated?.\" Postgrad Med J 77 (2001):  112-3[10] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001):  2163-75[11] Evans V \"Herbs and the brain: friend or foe? The effects of ginkgo and garlic on warfarin use.\" J Neurosci Nurs 32 (2000):  229-32[12] Cupp MJ \"Herbal remedies: adverse effects and drug interactions.\" Am Fam Physician 59 (1999):  1239-45[13] Matthews MK Jr \"Association of Ginko biloba with intracerebral hemorrhage.\" Neurology 50 (1998):  1933-4[14] Engelsen J, Nielsen JD, Winther K \"Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in stable, long-term warfarin treated outpatients. A randomised, double blind, placebo-crossover trial.\" Thromb Haemost 87 (2002):  1075-6[15] Fong KC, Kinnear PE \"Retrobulbar haemorrhage associated with chronic Gingko biloba ingestion.\" Postgrad Med J 79 (2003):  531-2[16] Sierpina VS, Wollschlaeger B, Blumenthal M \"Ginkgo biloba.\" Am Fam Physician 68 (2003):  923-6[17] Jiang X, Williams KM, Liauw WS, et al. \"Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.\" Br J Clin Pharmacol 59 (2005):  425-32[18] Jayasekera N, Moghal A, Kashif F, Karalliedde L \"Herbal medicines and postoperative haemorrhage.\" Anaesthesia 60 (2005):  725-6[19] Wolf HR \"Does Ginkgo biloba special extract EGb 761 provide additional effects on coagulation and bleeding when added to acetylsalicylic acid 500 mg daily?\" Drugs R D 7 (2006):  163-72", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "alternatives_b": "Rivastigmine, Galantamine, Tacrine, Aducanumab", "updated_at": 1767369485}, {"id": 242705, "ingredient1": "Heparin (flush)", "ingredient2": "Etodolac", "severity": "Moderate", "effect": "Concomitant use of heparin flush and drugs that interfere with platelet function or coagulation or drugs that commonly cause thrombocytopenia may potentiate the risk of bleeding complications.  Although uncommon, inadvertent anticoagulation resulting in hemorrhagic events may occur with heparin flushes, particularly during repeated or excessive use or administration of higher concentration flush solutions.", "source": "DDInter", "management_text": "Caution and monitoring (e.g., platelet counts, hematocrits, tests for occult blood in stools) are advised when heparin flushes are given to patients receiving systemic anticoagulants, platelet inhibitors, antithrombotic agents, thrombolytics, or drugs with known risks of thrombocytopenia or bleeding.  An unexplained fall in hematocrit, fall in blood pressure, or any other unexplained symptom should lead to serious consideration of a hemorrhagic event.", "mechanism_text": "Synergism", "recommendation": "Caution and monitoring (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276504/", "reference_text": "[1] Passannante A, Macik BG \"The heparin flush syndrome: a cause of iatrogenic hemorrhage.\" Am J Med Sci 296 (1988):  71-3[2] \"Product Information. Heparin Sodium in Sodium Chloride (heparin flush).\" Baxter Healthcare Corporation  (2022):[3] \"Product Information. Canusal (heparin flush).\" Wockhardt UK Ltd  (2018):[4] \"Product Information. Heparinised Saline (Pfizer) (heparinised saline).\" Pfizer Australia Pty Ltd  (2022):", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "alternatives_b": "Protein C, Acenocoumarol, Selexipag, Pentosan polysulfate, Vitamin A, Ascorbic acid, Nandrolone, Acetylcysteine", "updated_at": 1767369485}, {"id": 242706, "ingredient1": "Etonogestrel", "ingredient2": "Osilodrostat", "severity": "Moderate", "effect": "Coadministration with osilodrostat may increase the plasma concentrations of drugs that are metabolized by CYP450 1A2, 2C19, 2D6, and/or 3A4.  Osilodrostat has been shown to be a moderate inhibitor of CYP450 1A2, a mild to borderline moderate inhibitor of CYP450 2C19, and a weak inhibitor of CYP450 2D6 and 3A4.", "source": "DDInter", "management_text": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever osilodrostat is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276526/", "reference_text": "[1] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Inc  (2020):[2] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Australia Pty Ltd  (2022):[3] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases UK Ltd  (2021):", "alternatives_a": "Dienogest, Estetrol, Etynodiol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242707, "ingredient1": "Etonogestrel", "ingredient2": "Selumetinib", "severity": "Moderate", "effect": "Coadministration with selumetinib may reduce the effectiveness of hormonal contraceptives.", "source": "DDInter", "management_text": "Until further data are available, females of reproductive potential using hormonal contraceptives should be advised to add a barrier method during treatment with selumetinib and for 1 week after the final dose.  In addition, men with female partners of reproductive potential should also use effective contraception during treatment with selumetinib and for 1 week after the last dose.", "mechanism_text": "Antagonism", "recommendation": "Until further data are available, females of reproductive potential using hormonal contraceptives should be advised to add a barrier method during treatment with selumetinib and for 1 week after the final dose.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276528/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Megestrol acetate, Ulipristal, Estradiol", "alternatives_b": "Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Ribociclib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, More", "updated_at": 1767369485}, {"id": 242708, "ingredient1": "Etonogestrel", "ingredient2": "Tivozanib", "severity": "Moderate", "effect": "Coadministration with tivozanib may decrease the efficacy of contraceptive hormones.", "source": "DDInter", "management_text": "Until more information is known, caution is advised when tivozanib is prescribed concomitantly with hormonal contraceptives.  Some authorities recommend that female patients of childbearing potential use an additional method of contraception.  An acceptable barrier method (e.g., diaphragm with spermicide, cervical cap with spermicide, contraceptive sponge, male condom, female condom) in addition to the hormonal contraceptive of choice may be advisable during the duration of tivozanib therapy and for at least one month after completing therapy.", "mechanism_text": "Antagonism", "recommendation": "Until more information is known, caution is advised when tivozanib is prescribed concomitantly with hormonal contraceptives.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276531/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Fotivda (tivozanib).\" Aveo Pharmaceuticals, Inc.  (2021):", "alternatives_a": "Megestrol acetate, Estetrol, Ulipristal, Estradiol", "alternatives_b": "Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Ribociclib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, More", "updated_at": 1767369485}, {"id": 242709, "ingredient1": "Flutamide", "ingredient2": "Etidocaine", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276556/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Meloxicam", "alternatives_b": "Darolutamide, Tamoxifen, Anastrozole, Aminoglutethimide, Letrozole, Toremifene, Fulvestrant, Abarelix, Enzalutamide, Relugolix, Bicalutamide, More", "updated_at": 1767369485}, {"id": 242710, "ingredient1": "Flutamide", "ingredient2": "Levobupivacaine", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276560/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Darolutamide, Tamoxifen, Anastrozole, Letrozole, Toremifene, Fulvestrant, Abarelix, Relugolix, Degarelix, Nilutamide, Abiraterone, Exemestane", "alternatives_b": "Meloxicam", "updated_at": 1767369485}, {"id": 242711, "ingredient1": "Flutamide", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276566/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Anastrozole, Aminoglutethimide, Fulvestrant", "alternatives_b": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, Ibrutinib, More", "updated_at": 1767369485}, {"id": 242712, "ingredient1": "Flutamide", "ingredient2": "Procaine", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276567/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Darolutamide, Tamoxifen, Anastrozole, Aminoglutethimide, Letrozole, Toremifene, Fulvestrant, Abarelix, Enzalutamide, Relugolix, Bicalutamide, More", "alternatives_b": "Meloxicam, Zinc sulfate, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Isosorbide dinitrate, Zinc chloride, Prednisolone, Betamethasone, Fluorometholone, More", "updated_at": 1767369485}, {"id": 242713, "ingredient1": "Flutamide", "ingredient2": "Silver nitrate (topical)", "severity": "Moderate", "effect": "Topical nitrate and silver (e.g., cerium nitrate, silver nitrate, silver sulfadiazine) preparations can be systemically absorbed and have been associated with rare reports of methemoglobinemia, primarily in burn patients.  In addition, bacterial conversion of nitrate to nitrite can contribute to methemoglobinemia.  Coadministration with other oxidizing agents that can also induce methemoglobinemia such as ester and amide local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), systemic nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Depending on the circumstances, caution may be advisable when topical nitrate and silver preparations are used concomitantly with other methemoglobin-inducing agents.  Clinicians should be aware of the potential for methemoglobinemia, particularly when treating burn patients.  Signs and symptoms of methemoglobinemia may be delayed some hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Depending on the circumstances, caution may be advisable when topical nitrate and silver preparations are used concomitantly with other methemoglobin-inducing agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276569/", "reference_text": "[1] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[2] Geffner ME, Powars DR, Choctaw WT \"Acquired methemoglobinemia.\" West J Med 134 (1981):  7-10[3] Poredos P, Gradisek P, Testen C, Derganc M \"Severe methemoglobinaemia due to benzocaine-containing 'burn cream': two case reports in an adult and in a child.\" Burns 37 (2011):  e63-6[4] Gala HC, Madave A \"An unusual case of neonatal methemoglobinemia.\" Indian Pediatr 54 (2017):  163[5] Reese AD, Keyloun JW, Garg G, et.a \"Compounded cerium nitrate-silver sulfadiazine cream is safe and effective for the treatment of burn wounds: a burn center's four-year experience.\" J Burn Care Res 20 (2021):  Epub ahead of print[6] Cartotto R \"Topical antimicrobial agents for pediatric burns.\" Burns Trauma 5 (2017):  33", "alternatives_a": "Darolutamide, Tamoxifen, Anastrozole, Aminoglutethimide, Letrozole, Toremifene, Fulvestrant, Abarelix, Enzalutamide, Relugolix, Bicalutamide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242714, "ingredient1": "Flutamide", "ingredient2": "Silver sulfadiazine (topical)", "severity": "Moderate", "effect": "Topical nitrate and silver (e.g., cerium nitrate, silver nitrate, silver sulfadiazine) preparations can be systemically absorbed and have been associated with rare reports of methemoglobinemia, primarily in burn patients.  In addition, bacterial conversion of nitrate to nitrite can contribute to methemoglobinemia.  Coadministration with other oxidizing agents that can also induce methemoglobinemia such as ester and amide local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), systemic nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Depending on the circumstances, caution may be advisable when topical nitrate and silver preparations are used concomitantly with other methemoglobin-inducing agents.  Clinicians should be aware of the potential for methemoglobinemia, particularly when treating burn patients.  Signs and symptoms of methemoglobinemia may be delayed some hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Depending on the circumstances, caution may be advisable when topical nitrate and silver preparations are used concomitantly with other methemoglobin-inducing agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276570/", "reference_text": "[1] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[2] Geffner ME, Powars DR, Choctaw WT \"Acquired methemoglobinemia.\" West J Med 134 (1981):  7-10[3] Poredos P, Gradisek P, Testen C, Derganc M \"Severe methemoglobinaemia due to benzocaine-containing 'burn cream': two case reports in an adult and in a child.\" Burns 37 (2011):  e63-6[4] Gala HC, Madave A \"An unusual case of neonatal methemoglobinemia.\" Indian Pediatr 54 (2017):  163[5] Reese AD, Keyloun JW, Garg G, et.a \"Compounded cerium nitrate-silver sulfadiazine cream is safe and effective for the treatment of burn wounds: a burn center's four-year experience.\" J Burn Care Res 20 (2021):  Epub ahead of print[6] Cartotto R \"Topical antimicrobial agents for pediatric burns.\" Burns Trauma 5 (2017):  33", "alternatives_a": "Darolutamide, Tamoxifen, Anastrozole, Aminoglutethimide, Letrozole, Toremifene, Fulvestrant, Abarelix, Enzalutamide, Relugolix, Bicalutamide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242715, "ingredient1": "Pralsetinib", "ingredient2": "Magnesium hydroxide", "severity": "Moderate", "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.  The recommended dosage and duration of use should not be exceeded.  Patients treated with lactulose for more than six months should be monitored periodically for electrolyte imbalance.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276598/", "reference_text": "[1] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998):  517-8[2] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993):  138-45[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Schaefer DC, Cheskin LJ \"Constipation in the elderly.\" Am Fam Physician 58 (1998):  907-14", "alternatives_a": "Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Phenyl salicylate, Ammonium chloride, More", "alternatives_b": "Imatinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, More", "updated_at": 1767369485}, {"id": 242716, "ingredient1": "Rivastigmine", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276613/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "alternatives_b": "Memantine, Ginkgo biloba, Aducanumab", "updated_at": 1767369485}, {"id": 242717, "ingredient1": "Ezogabine", "ingredient2": "Acrivastine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276815/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Azelastine, Fexofenadine, Thiethylperazine, Loratadine, Desloratadine, Methdilazine", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 242718, "ingredient1": "Ezogabine", "ingredient2": "Chlorcyclizine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276818/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Azelastine, Fexofenadine, Thiethylperazine, Loratadine, Desloratadine, Methdilazine", "alternatives_b": "Oxcarbazepine, Ethotoin, Methsuximide, Paramethadione, Carbamazepine, Phensuximide, Fosphenytoin, Methylphenobarbital, Phenacemide, Phenytoin, Felbamate, More", "updated_at": 1767369485}, {"id": 242719, "ingredient1": "Fenfluramine", "ingredient2": "Ezogabine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276820/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Lacosamide, Fenfluramine", "alternatives_b": "Dexfenfluramine, Naltrexone, Ephedrine, Bupropion, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol, Lacosamide, Ezogabine", "updated_at": 1767369485}, {"id": 242720, "ingredient1": "Ezogabine", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276824/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Lacosamide", "alternatives_b": "Amantadine, Cabergoline", "updated_at": 1767369485}, {"id": 242721, "ingredient1": "Ezogabine", "ingredient2": "Melatonin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276826/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Lacosamide", "alternatives_b": "Propiomazine, Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 242722, "ingredient1": "Ezogabine", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276829/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Brivaracetam, Topiramate, Lamotrigine, Methylphenobarbital, Levetiracetam, Oxcarbazepine, Ethotoin, Rufinamide, Paramethadione, Perampanel, Vigabatrin, More", "alternatives_b": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, Selumetinib, More", "updated_at": 1767369485}, {"id": 242723, "ingredient1": "Gemifloxacin", "ingredient2": "Axicabtagene ciloleucel", "severity": "Minor", "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics.  The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.", "source": "DDInter", "management_text": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics.  The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.  In six patients with newly diagnosed hematologic malignancy, treatment with various antineoplastic agents (cyclophosphamide, cytarabine, daunorubicin, doxorubicin, mitoxantrone, prednisolone, vincristine) decreased the mean peak serum concentration (Cmax) and area under the concentration-time curve (AUC 0 to 4 hours) of ciprofloxacin by approximately 46% each.  Data are not available for other quinolone antibiotics.", "mechanism_text": "Absorption", "recommendation": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276833/", "reference_text": "[1] Johnson EJ, MacGowan AP, Potter MN, et al. \"Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy.\" J Antimicrob Chemother 25 (1990):  837-42", "alternatives_a": "Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Omacetaxine mepesuccinate, Tazemetostat, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, Enasidenib, More", "alternatives_b": "Enoxacin, Lomefloxacin, Grepafloxacin", "updated_at": 1767369485}, {"id": 242724, "ingredient1": "Gemifloxacin", "ingredient2": "Melphalan flufenamide", "severity": "Minor", "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics.  The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.", "source": "DDInter", "management_text": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics.  The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.  In six patients with newly diagnosed hematologic malignancy, treatment with various antineoplastic agents (cyclophosphamide, cytarabine, daunorubicin, doxorubicin, mitoxantrone, prednisolone, vincristine) decreased the mean peak serum concentration (Cmax) and area under the concentration-time curve (AUC 0 to 4 hours) of ciprofloxacin by approximately 46% each.  Data are not available for other quinolone antibiotics.", "mechanism_text": "Absorption", "recommendation": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276850/", "reference_text": "[1] Johnson EJ, MacGowan AP, Potter MN, et al. \"Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy.\" J Antimicrob Chemother 25 (1990):  837-42", "alternatives_a": "Bendamustine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242725, "ingredient1": "Gemifloxacin", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276859/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Enoxacin, Trovafloxacin, Nalidixic acid, Cinoxacin", "alternatives_b": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "updated_at": 1767369485}, {"id": 242726, "ingredient1": "Iloperidone", "ingredient2": "Fenfluramine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276870/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Dexfenfluramine, Naltrexone, Ephedrine, Phentermine, Orlistat, Diethylpropion, Mazindol, Lacosamide", "alternatives_b": "Amisulpride, Pimavanserin", "updated_at": 1767369485}, {"id": 242727, "ingredient1": "Iloperidone", "ingredient2": "Melatonin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276878/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Amisulpride, Pimavanserin", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 242728, "ingredient1": "Iloperidone", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276883/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Amisulpride, Loxapine, Molindone, Thiothixene", "alternatives_b": "Imatinib, Acalabrutinib, Pexidartinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More", "updated_at": 1767369485}, {"id": 242729, "ingredient1": "Toremifene", "ingredient2": "Palbociclib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of toremifene, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Clinical and laboratory monitoring for altered efficacy and safety of toremifene may be appropriate whenever a CYP450 3A inhibitor is added to or withdrawn from therapy.  Complete blood counts, electrolyte levels (calcium, magnesium, potassium), and liver function tests should be obtained periodically.  Patients should be advised to contact their physician if they experience vaginal bleeding or potential signs of blood clots such as chest pain, shortness of breath, sudden loss of vision, and pain, redness or swelling in an extremity.  Patients should seek immediate medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, or syncope.", "mechanism_text": "Metabolism", "recommendation": "Clinical and laboratory monitoring for altered efficacy and safety of toremifene may be appropriate whenever a CYP450 3A inhibitor is added to or withdrawn from therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276899/", "reference_text": "[1] \"Product Information. Fareston (toremifene).\" Schering Corporation  (2001):", "alternatives_a": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, Zanubrutinib, More", "alternatives_b": "Tamoxifen, Anastrozole, Letrozole, Fulvestrant, Abarelix, Flutamide, Relugolix, Bicalutamide, Degarelix, Nilutamide, Abiraterone, Exemestane", "updated_at": 1767369485}, {"id": 242730, "ingredient1": "Toremifene", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276902/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, Zanubrutinib, More", "alternatives_b": "Anastrozole, Aminoglutethimide, Fulvestrant", "updated_at": 1767369485}, {"id": 242731, "ingredient1": "Bacillus calmette-guerin substrain tice live antigen", "ingredient2": "Panobinostat", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276908/", "reference_text": "[1] \"Product Information. Meruvax II (rubella virus vaccine).\" Merck & Co., Inc  (2022):[2] \"Product Information. Attenuvax (measles virus vaccine).\" Merck & Co., Inc  (2022):[3] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD \"Harrison's Principles of Internal Medicine.\" New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] \"Product Information. DENGVAXIA (dengue vaccine).\" sanofi pasteur  (2022):", "alternatives_a": "Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, Anagrelide, Ivosidenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242732, "ingredient1": "Glycerol phenylbutyrate", "ingredient2": "Panobinostat", "severity": "Moderate", "effect": "Coadministration of histone deacetylase (HDAC) inhibitors and phenylbutyrate may lead to excess inhibition of HDAC and additive adverse effects.  According to the prescribing information for sodium phenylbutyrate combined with taurursodiol (ursodoxicoltaurine), phenylbutyrate is a pan-HDAC inhibitor", "source": "DDInter", "management_text": "The prescribing information for sodium phenylbutyrate combined with taurursodiol recommends avoiding concomitant use of phenylbutyrate and other HDAC inhibitors.", "mechanism_text": "Synergism", "recommendation": "The prescribing information for sodium phenylbutyrate combined with taurursodiol recommends avoiding concomitant use of phenylbutyrate and other HDAC inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276912/", "reference_text": "[1] \"Product Information. Relyvrio (sodium phenylbutyrate-taurursodiol).\" Amylyx Pharmaceuticals  (2022):[2] \"Product Information. Albrioza (sodium phenylbutyrate-ursodoxicoltaurine).\" Innomar Strategies Inc.  (2022):", "alternatives_a": "Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Zinc acetate, Nitisinone, Levocarnitine, Laronidase, More", "alternatives_b": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "updated_at": 1767369485}, {"id": 242733, "ingredient1": "Heparin (flush)", "ingredient2": "Panobinostat", "severity": "Moderate", "effect": "Concomitant use of heparin flush and drugs that interfere with platelet function or coagulation or drugs that commonly cause thrombocytopenia may potentiate the risk of bleeding complications.  Although uncommon, inadvertent anticoagulation resulting in hemorrhagic events may occur with heparin flushes, particularly during repeated or excessive use or administration of higher concentration flush solutions.", "source": "DDInter", "management_text": "Caution and monitoring (e.g., platelet counts, hematocrits, tests for occult blood in stools) are advised when heparin flushes are given to patients receiving systemic anticoagulants, platelet inhibitors, antithrombotic agents, thrombolytics, or drugs with known risks of thrombocytopenia or bleeding.  An unexplained fall in hematocrit, fall in blood pressure, or any other unexplained symptom should lead to serious consideration of a hemorrhagic event.", "mechanism_text": "Synergism", "recommendation": "Caution and monitoring (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276916/", "reference_text": "[1] Passannante A, Macik BG \"The heparin flush syndrome: a cause of iatrogenic hemorrhage.\" Am J Med Sci 296 (1988):  71-3[2] \"Product Information. Heparin Sodium in Sodium Chloride (heparin flush).\" Baxter Healthcare Corporation  (2022):[3] \"Product Information. Canusal (heparin flush).\" Wockhardt UK Ltd  (2018):[4] \"Product Information. Heparinised Saline (Pfizer) (heparinised saline).\" Pfizer Australia Pty Ltd  (2022):", "alternatives_a": "Protein C, Dicoumarol, Acenocoumarol, Selexipag, Ascorbic acid, Sirolimus, Vitamin A, Potassium Iodide, Acetylcysteine, Nandrolone", "alternatives_b": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, Ixazomib, More", "updated_at": 1767369485}, {"id": 242734, "ingredient1": "Pralsetinib", "ingredient2": "Panobinostat", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276942/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Enasidenib, Porfimer sodium, Aflibercept, Trastuzumab, Hydroxyurea, More", "alternatives_b": "Dacomitinib, Tepotinib, Selumetinib, Cobimetinib, Capmatinib, Afatinib, Tivozanib, Brigatinib, Axitinib, Ripretinib, Alpelisib, More", "updated_at": 1767369485}, {"id": 242735, "ingredient1": "Phenylbutyric acid", "ingredient2": "Panobinostat", "severity": "Moderate", "effect": "Coadministration of histone deacetylase (HDAC) inhibitors and phenylbutyrate may lead to excess inhibition of HDAC and additive adverse effects.  According to the prescribing information for sodium phenylbutyrate combined with taurursodiol (ursodoxicoltaurine), phenylbutyrate is a pan-HDAC inhibitor", "source": "DDInter", "management_text": "The prescribing information for sodium phenylbutyrate combined with taurursodiol recommends avoiding concomitant use of phenylbutyrate and other HDAC inhibitors.", "mechanism_text": "Synergism", "recommendation": "The prescribing information for sodium phenylbutyrate combined with taurursodiol recommends avoiding concomitant use of phenylbutyrate and other HDAC inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276962/", "reference_text": "[1] \"Product Information. Relyvrio (sodium phenylbutyrate-taurursodiol).\" Amylyx Pharmaceuticals  (2022):[2] \"Product Information. Albrioza (sodium phenylbutyrate-ursodoxicoltaurine).\" Innomar Strategies Inc.  (2022):", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, More", "alternatives_b": "Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Zinc acetate, Nitisinone, Levocarnitine, Laronidase, More", "updated_at": 1767369485}, {"id": 242736, "ingredient1": "Varicella Zoster Vaccine (Recombinant)", "ingredient2": "Panobinostat", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual's risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, the U.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276972/", "reference_text": "[1] \"Product Information. Fluzone (influenza virus vaccine, inactivated).\" Connaught Laboratories Inc[2] \"Product Information. Omnihib (haemophilus b conjugate vaccine (obsolete)).\" SmithKline Beecham[3] \"Product Information. Havrix (hepatitis A adult vaccine).\" SmithKline Beecham[4] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[5] \"Product Information. Imovax Rabies (rabies vaccine, human diploid cell).\" sanofi pasteur  (2022):[6] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc.  (2003):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline  (2022):[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations.  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf\"   (2019):[11] CDC Centers for Disease Control and Prevention \"Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html\"   (2022):", "alternatives_a": "Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, Anagrelide, Ivosidenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242737, "ingredient1": "Felbamate", "ingredient2": "Fedratinib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 2C19 may increase the plasma concentrations of fedratinib, which is primarily metabolized by CYP450 3A4 and to a lesser extent by CYP450 2C19 and flavin-containing monooxygenase 3 (FMO3).", "source": "DDInter", "management_text": "Caution is advised when fedratinib is used with CYP450 2C19 inhibitors, particularly those that may also inhibit CYP450 3A4 (e.g., amiodarone, cimetidine, fexinidazole, isoniazid, osilodrostat, rucaparib) or if combined with other drugs that can inhibit CYP450 3A4.  Patients should be monitored for adverse reactions such as nausea, vomiting, diarrhea, anemia, thrombocytopenia, neutropenia, encephalopathy (including Wernicke's), liver (ALT, AST) and pancreatic (amylase, lipase) enzyme elevations, increased blood creatinine, and secondary malignancies.  Dosage adjustment or treatment interruption may be required based on patient tolerance and response in accordance with the prescribing information.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when fedratinib is used with CYP450 2C19 inhibitors, particularly those that may also inhibit CYP450 3A4 (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276975/", "reference_text": "[1] \"Product Information. Inrebic (fedratinib).\" Bristol-Myers Squibb  (2022):[2] \"Product Information. Inrebic (fedratinib).\" Bristol-Myers Squibb Pharmaceuticals Ltd  (2021):", "alternatives_a": "Futibatinib, Regorafenib, Lenvatinib, Erdafitinib, Pralsetinib, Dabrafenib, Asciminib, Vandetanib, Neratinib, Afatinib, Trametinib, More", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Methylphenobarbital, Lacosamide, Levetiracetam, Oxcarbazepine, Ethotoin, Rufinamide, Paramethadione, More", "updated_at": 1767369485}, {"id": 242738, "ingredient1": "Fostamatinib", "ingredient2": "Fedratinib", "severity": "Moderate", "effect": "Coadministration of fostamatinib with inhibitors of CYP450 3A4 may increase exposure to the active metabolite known as R406, the predominant moiety in the systemic circulation following fostamatinib administration.  Fostamatinib is metabolized in the gut by alkaline phosphatase to R406, which then undergoes oxidation via CYP450 3A4 and glucuronidation via UGT1A9.  In vitro, R406 is also a substrate of the P-glycoprotein (P-gp) efflux transporter.", "source": "DDInter", "management_text": "Patients should be monitored for toxicities of fostamatinib during concomitant use of potent or moderate CYP450 3A4 inhibitors or dual CYP450 3A4/P-gp inhibitors, and the fostamatinib dosage adjusted as necessary in accordance with the product labeling.", "mechanism_text": "Metabolism", "recommendation": "Patients should be monitored for toxicities of fostamatinib during concomitant use of potent or moderate CYP450 3A4 inhibitors or dual CYP450 3A4/P-gp inhibitors, and the fostamatinib dosage adjusted as necessary in accordance with the product labeling.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276978/", "reference_text": "[1] \"Product Information. Tavalisse (fostamatinib).\" Rigel Pharmaceuticals  (2018):", "alternatives_a": "Pralsetinib, Asciminib, Acalabrutinib, Dacomitinib, Pacritinib, Avapritinib, Selumetinib, Capmatinib, Ibrutinib, Duvelisib, Tivozanib, More", "alternatives_b": "Eltrombopag, Romiplostim, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, More", "updated_at": 1767369485}, {"id": 242739, "ingredient1": "Givosiran", "ingredient2": "Fedratinib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 2C19 may increase the plasma concentrations of fedratinib, which is primarily metabolized by CYP450 3A4 and to a lesser extent by CYP450 2C19 and flavin-containing monooxygenase 3 (FMO3).", "source": "DDInter", "management_text": "Caution is advised when fedratinib is used with CYP450 2C19 inhibitors, particularly those that may also inhibit CYP450 3A4 (e.g., amiodarone, cimetidine, fexinidazole, isoniazid, osilodrostat, rucaparib) or if combined with other drugs that can inhibit CYP450 3A4.  Patients should be monitored for adverse reactions such as nausea, vomiting, diarrhea, anemia, thrombocytopenia, neutropenia, encephalopathy (including Wernicke's), liver (ALT, AST) and pancreatic (amylase, lipase) enzyme elevations, increased blood creatinine, and secondary malignancies.  Dosage adjustment or treatment interruption may be required based on patient tolerance and response in accordance with the prescribing information.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when fedratinib is used with CYP450 2C19 inhibitors, particularly those that may also inhibit CYP450 3A4 (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276980/", "reference_text": "[1] \"Product Information. Inrebic (fedratinib).\" Bristol-Myers Squibb  (2022):[2] \"Product Information. Inrebic (fedratinib).\" Bristol-Myers Squibb Pharmaceuticals Ltd  (2021):", "alternatives_a": "Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Avapritinib, Larotrectinib, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 242740, "ingredient1": "Grepafloxacin", "ingredient2": "Fedratinib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of fedratinib, which is primarily metabolized by CYP450 3A4 and to a lesser extent by CYP450 2C19 and flavin-containing monooxygenase 3 (FMO3).", "source": "DDInter", "management_text": "Caution is advised when fedratinib is used with CYP450 3A4 inhibitors, particularly those that may also inhibit CYP450 2C19 (e.g., amiodarone, cimetidine, fexinidazole, isoniazid, osilodrostat, rucaparib) or if combined with other drugs that can inhibit CYP450 2C19 (e.g., esomeprazole, fenofibrate, fluoxetine, lansoprazole, letrozole, moclobemide, omeprazole, parecoxib, ticlopidine).  Patients should be monitored for adverse reactions such as nausea, vomiting, diarrhea, anemia, thrombocytopenia, neutropenia, encephalopathy (including Wernicke's), liver (ALT, AST) and pancreatic (amylase, lipase) enzyme elevations, increased blood creatinine, and secondary malignancies.  Dosage adjustment or treatment interruption may be required based on patient tolerance and response in accordance with the prescribing information.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when fedratinib is used with CYP450 3A4 inhibitors, particularly those that may also inhibit CYP450 2C19 (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276981/", "reference_text": "[1] Wu F, Krishna G, Surapaneni S \"Physiologically based pharmacokinetic modeling to assess metabolic drug-drug interaction risks and inform the drug label for fedratinib.\" Cancer Chemother Pharmacol 86 (2020):  461-73[2] \"Product Information. Inrebic (fedratinib).\" Bristol-Myers Squibb  (2022):[3] \"Product Information. Inrebic (fedratinib).\" Bristol-Myers Squibb Pharmaceuticals Ltd  (2021):", "alternatives_a": "Dabrafenib, Dacomitinib, Pexidartinib, Capmatinib, Afatinib, Tivozanib, Regorafenib, Alpelisib, Erdafitinib, Ponatinib, Neratinib, More", "alternatives_b": "Enoxacin, Gatifloxacin, Norfloxacin, Levofloxacin, Nalidixic acid, Gemifloxacin, Lomefloxacin, Moxifloxacin, Cinoxacin, Trovafloxacin, Delafloxacin, More", "updated_at": 1767369485}, {"id": 242741, "ingredient1": "Heparin (flush)", "ingredient2": "Fedratinib", "severity": "Moderate", "effect": "Concomitant use of heparin flush and drugs that interfere with platelet function or coagulation or drugs that commonly cause thrombocytopenia may potentiate the risk of bleeding complications.  Although uncommon, inadvertent anticoagulation resulting in hemorrhagic events may occur with heparin flushes, particularly during repeated or excessive use or administration of higher concentration flush solutions.", "source": "DDInter", "management_text": "Caution and monitoring (e.g., platelet counts, hematocrits, tests for occult blood in stools) are advised when heparin flushes are given to patients receiving systemic anticoagulants, platelet inhibitors, antithrombotic agents, thrombolytics, or drugs with known risks of thrombocytopenia or bleeding.  An unexplained fall in hematocrit, fall in blood pressure, or any other unexplained symptom should lead to serious consideration of a hemorrhagic event.", "mechanism_text": "Synergism", "recommendation": "Caution and monitoring (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276982/", "reference_text": "[1] Passannante A, Macik BG \"The heparin flush syndrome: a cause of iatrogenic hemorrhage.\" Am J Med Sci 296 (1988):  71-3[2] \"Product Information. Heparin Sodium in Sodium Chloride (heparin flush).\" Baxter Healthcare Corporation  (2022):[3] \"Product Information. Canusal (heparin flush).\" Wockhardt UK Ltd  (2018):[4] \"Product Information. Heparinised Saline (Pfizer) (heparinised saline).\" Pfizer Australia Pty Ltd  (2022):", "alternatives_a": "Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Larotrectinib, Bosutinib, More", "alternatives_b": "Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Warfarin, Streptokinase, Eptifibatide, Selexipag, Abciximab, Dicoumarol, Tenecteplase, More", "updated_at": 1767369485}, {"id": 242742, "ingredient1": "Fedratinib", "ingredient2": "Mephenytoin", "severity": "Moderate", "effect": "Coadministration with fedratinib may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4, 2C19, and/or 2D6 isoenzymes.", "source": "DDInter", "management_text": "Caution is recommended when fedratinib is used concomitantly with substrates of CYP450 3A4, 2C19, and/or 2D6.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever fedratinib is added to or withdrawn from therapy, particularly those with a narrow therapeutic index.", "mechanism_text": "Metabolism", "recommendation": "Caution is recommended when fedratinib is used concomitantly with substrates of CYP450 3A4, 2C19, and/or 2D6.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276988/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Inrebic (fedratinib).\" Celgene Corporation  (2019):", "alternatives_a": "Entrectinib, Imatinib, Asciminib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Avapritinib, Larotrectinib, Bosutinib, Vemurafenib, More", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Methylphenobarbital, Lacosamide, Levetiracetam, Oxcarbazepine, Ethotoin, Rufinamide, Paramethadione, More", "updated_at": 1767369485}, {"id": 242743, "ingredient1": "Fedratinib", "ingredient2": "Methylnaltrexone", "severity": "Moderate", "effect": "Coadministration with fedratinib may decrease the renal clearance of drugs that are excreted via organic cation transporter (OCT) 2 and multidrug and toxin extrusion (MATE) 1/2-K.", "source": "DDInter", "management_text": "Caution is advised when fedratinib is used with drugs that are renally excreted via OCT2, MATE1, and MATE2-K.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever fedratinib is added to or withdrawn from therapy, particularly those with a narrow therapeutic index.", "mechanism_text": "Excretion", "recommendation": "Caution is advised when fedratinib is used with drugs that are renally excreted via OCT2, MATE1, and MATE2-K.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276989/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Inrebic (fedratinib).\" Celgene Corporation  (2019):", "alternatives_a": "Entrectinib, Imatinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Larotrectinib, Bosutinib, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Bisacodyl, Lactulose, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 242744, "ingredient1": "Fedratinib", "ingredient2": "Pimavanserin", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of pimavanserin, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised when pimavanserin is used with CYP450 3A4 inhibitors.  Patients should be monitored for adverse effects such as peripheral edema and QT prolongation, and the pimavanserin dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when pimavanserin is used with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276993/", "reference_text": "[1] \"Product Information. Nuplazid (pimavanserin).\" Accelis Pharma  (2016):", "alternatives_a": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, Zanubrutinib, More", "alternatives_b": "Asenapine, Promazine, Prochlorperazine, Thiothixene, Olanzapine, Trifluoperazine, Amisulpride, Triflupromazine, Loxapine, Molindone, Droperidol, Paliperidone", "updated_at": 1767369485}, {"id": 242745, "ingredient1": "Fedratinib", "ingredient2": "Procainamide", "severity": "Moderate", "effect": "Coadministration with fedratinib may decrease the renal clearance of drugs that are excreted via organic cation transporter (OCT) 2 and multidrug and toxin extrusion (MATE) 1/2-K.", "source": "DDInter", "management_text": "Caution is advised when fedratinib is used with drugs that are renally excreted via OCT2, MATE1, and MATE2-K.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever fedratinib is added to or withdrawn from therapy, particularly those with a narrow therapeutic index.", "mechanism_text": "Excretion", "recommendation": "Caution is advised when fedratinib is used with drugs that are renally excreted via OCT2, MATE1, and MATE2-K.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/276995/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Inrebic (fedratinib).\" Celgene Corporation  (2019):", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, Capmatinib, More", "alternatives_b": "Lidocaine, Tocainide, Bretylium, Moricizine, Ibutilide", "updated_at": 1767369485}, {"id": 242746, "ingredient1": "Felbamate", "ingredient2": "Acrivastine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277003/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Methdilazine, Ketotifen, Chlorcyclizine, Fexofenadine, Thiethylperazine, Dexchlorpheniramine, Loratadine, Phenindamine, Astemizole, Desloratadine, Azelastine, More", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 242747, "ingredient1": "Felbamate", "ingredient2": "Cyclizine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277006/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Methdilazine, Ketotifen, Chlorcyclizine, Fexofenadine, Thiethylperazine, Dexchlorpheniramine, Loratadine, Phenindamine, Astemizole, Desloratadine, Azelastine, More", "alternatives_b": "Methsuximide, Paramethadione, Phensuximide, Methylphenobarbital, Phenacemide, Trimethadione, Lacosamide", "updated_at": 1767369485}, {"id": 242748, "ingredient1": "Felbamate", "ingredient2": "Fenfluramine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277008/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Lacosamide, Fenfluramine", "alternatives_b": "Dexfenfluramine, Ephedrine, Bupropion, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol, Paramethadione, Phensuximide, Methylphenobarbital, More", "updated_at": 1767369485}, {"id": 242749, "ingredient1": "Felbamate", "ingredient2": "Lamotrigine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277014/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ethotoin, Methsuximide, Paramethadione, Phensuximide, Lamotrigine, Methylphenobarbital, Phenacemide, Trimethadione, Mephenytoin", "alternatives_b": "Paramethadione, Phensuximide, Methylphenobarbital, Phenacemide, Felbamate, Lacosamide, Trimethadione", "updated_at": 1767369485}, {"id": 242750, "ingredient1": "Felbamate", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277016/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Lacosamide", "alternatives_b": "Amantadine, Cabergoline", "updated_at": 1767369485}, {"id": 242751, "ingredient1": "Felbamate", "ingredient2": "Melatonin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277019/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Lacosamide", "alternatives_b": "Nitrazepam, Ethchlorvynol, Methylphenobarbital, Zopiclone, Dichloralphenazone", "updated_at": 1767369485}, {"id": 242752, "ingredient1": "Felbamate", "ingredient2": "Methotrimeprazine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277020/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Tiagabine, Ethotoin, Methsuximide, Paramethadione, Mephenytoin, Phensuximide, Lamotrigine, Phenacemide, Trimethadione, Lacosamide, Levetiracetam", "alternatives_b": "Amisulpride", "updated_at": 1767369485}, {"id": 242753, "ingredient1": "Felbamate", "ingredient2": "Procyclidine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277024/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Lacosamide, Paramethadione, Phenacemide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242754, "ingredient1": "Felbamate", "ingredient2": "Tiagabine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277027/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Tiagabine, Methsuximide, Paramethadione, Methylphenobarbital, Phenacemide, Trimethadione, Ethosuximide, Lacosamide", "alternatives_b": "Paramethadione, Phensuximide, Methylphenobarbital, Phenacemide, Felbamate, Lacosamide, Trimethadione", "updated_at": 1767369485}, {"id": 242755, "ingredient1": "Felodipine", "ingredient2": "Osilodrostat", "severity": "Moderate", "effect": "Coadministration with osilodrostat may increase the plasma concentrations of drugs that are metabolized by CYP450 1A2, 2C19, 2D6, and/or 3A4.  Osilodrostat has been shown to be a moderate inhibitor of CYP450 1A2, a mild to borderline moderate inhibitor of CYP450 2C19, and a weak inhibitor of CYP450 2D6 and 3A4.", "source": "DDInter", "management_text": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever osilodrostat is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277043/", "reference_text": "[1] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Inc  (2020):[2] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Australia Pty Ltd  (2022):[3] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases UK Ltd  (2021):", "alternatives_a": "Metoprolol, Nebivolol, Bisoprolol, Acetylsalicylic acid, Atenolol, Clevidipine, Celecoxib, Enalapril, Moexipril, Ramipril, Hydrochlorothiazide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242756, "ingredient1": "Felodipine", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277046/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Propranolol, Metoprolol, Nebivolol, Bisoprolol, Acetylsalicylic acid, Atenolol, Clevidipine, Levamlodipine, Enalapril, Moexipril, Ramipril, More", "alternatives_b": "Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, Capmatinib, Ibrutinib, More", "updated_at": 1767369485}, {"id": 242757, "ingredient1": "Felodipine", "ingredient2": "Pyrophosphoric acid", "severity": "Moderate", "effect": "Medicinal products including sodium heparin, prazosin, methyldopa, hydralazine, quinidine, beta blockers, calcium channel blockers, digitalis glycosides, nitrates, anthracyclines, and iodinated contrast agents may interfere with the blood pool images taken using Technetium Tc 99m pyrophosphate.  This is characterized by a reduction in the amount of injected radioactivity remaining in the blood pool.", "source": "DDInter", "management_text": "Clinicians should be aware of the possibility of a diagnostic interference.  When use of iodinated contrast media is anticipated, it is recommended to perform the scintigraphy with (99mTc)-labeled red blood cells prior to administration of the iodinated contrast media to avoid adversely affecting the red blood cell labeling.", "mechanism_text": "Distribution", "recommendation": "Clinicians should be aware of the possibility of a diagnostic interference.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277047/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Pyrophosphate (pyrophosphate).\" Pharmalucence Inc  (2012):", "alternatives_a": "Acetylsalicylic acid, Ivabradine, Mibefradil, Celecoxib, Enalapril, Moexipril, Ramipril, Hydrochlorothiazide, Lisinopril, Perindopril, Benazepril, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242758, "ingredient1": "Osilodrostat", "ingredient2": "Letrozole", "severity": "Moderate", "effect": "Coadministration with osilodrostat may increase the plasma concentrations of drugs that are metabolized by CYP450 1A2, 2C19, 2D6, and/or 3A4.  Osilodrostat has been shown to be a moderate inhibitor of CYP450 1A2, a mild to borderline moderate inhibitor of CYP450 2C19, and a weak inhibitor of CYP450 2D6 and 3A4.", "source": "DDInter", "management_text": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever osilodrostat is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277062/", "reference_text": "[1] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Inc  (2020):[2] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Australia Pty Ltd  (2022):[3] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases UK Ltd  (2021):", "alternatives_a": "Anastrozole, Exemestane, Fulvestrant", "alternatives_b": "Ketoconazole", "updated_at": 1767369485}, {"id": 242759, "ingredient1": "Pralsetinib", "ingredient2": "Letrozole", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277064/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Anastrozole, Aminoglutethimide, Fulvestrant", "alternatives_b": "Entrectinib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Vandetanib, Cobimetinib, More", "updated_at": 1767369485}, {"id": 242760, "ingredient1": "Selumetinib", "ingredient2": "Letrozole", "severity": "Moderate", "effect": "Coadministration with potent or moderate inhibitors of CYP450 2C19 may increase the plasma concentrations of selumetinib, which is primarily metabolized by CYP450 3A4 and to a lesser extent by CYP450 2C19, 1A2, 2C9, 2E1, and 3A5.  Selumetinib's active metabolite, N-desmethyl selumetinib, is generated by CYP450 2C19 and 1A2 with additional contribution by CYP450 2C9 and 2A6, and metabolized through the same routes as selumetinib.", "source": "DDInter", "management_text": "Caution is advised when selumetinib is used with potent or moderate CYP450 2C19 inhibitors.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when selumetinib is used with potent or moderate CYP450 2C19 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277065/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Koselugo (selumetinib).\" Astra-Zeneca Pharmaceuticals  (2020):", "alternatives_a": "Darolutamide, Tamoxifen, Anastrozole, Fulvestrant, Toremifene, Abarelix, Flutamide, Relugolix, Degarelix, Nilutamide, Abiraterone, Exemestane", "alternatives_b": "Entrectinib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Vandetanib, Cobimetinib, More", "updated_at": 1767369485}, {"id": 242761, "ingredient1": "Fenfluramine", "ingredient2": "Acrivastine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277068/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Dexfenfluramine, Naltrexone, Ephedrine, Bupropion, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol, Lacosamide", "updated_at": 1767369485}, {"id": 242762, "ingredient1": "Fenfluramine", "ingredient2": "Azatadine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277069/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Dexfenfluramine, Naltrexone, Ephedrine, Bupropion, Phentermine, Orlistat, Lorcaserin, Sibutramine, Diethylpropion, Mazindol, Tiagabine, More", "updated_at": 1767369485}, {"id": 242763, "ingredient1": "Fenfluramine", "ingredient2": "Butalbital", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277071/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "Dexfenfluramine, Naltrexone, Ephedrine, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol, Lacosamide, Methylphenobarbital", "updated_at": 1767369485}, {"id": 242764, "ingredient1": "Fenfluramine", "ingredient2": "Pentoxyverine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277073/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Dexfenfluramine, Naltrexone, Ephedrine, Bupropion, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol, Lacosamide", "alternatives_b": "Benzonatate", "updated_at": 1767369485}, {"id": 242765, "ingredient1": "Fenfluramine", "ingredient2": "Chloral hydrate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277074/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "Dexfenfluramine, Naltrexone, Ephedrine, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol, Lacosamide, Paramethadione, Phensuximide, Phenacemide", "updated_at": 1767369485}, {"id": 242766, "ingredient1": "Fenfluramine", "ingredient2": "Chlorcyclizine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277075/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Dexfenfluramine, Naltrexone, Ephedrine, Bupropion, Phentermine, Orlistat, Lorcaserin, Sibutramine, Diethylpropion, Mazindol, Oxcarbazepine, More", "updated_at": 1767369485}, {"id": 242767, "ingredient1": "Fenfluramine", "ingredient2": "Chlormezanone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277076/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Tizanidine", "alternatives_b": "Dexfenfluramine, Naltrexone, Ephedrine, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol, Paramethadione, Phensuximide, Methylphenobarbital, More", "updated_at": 1767369485}, {"id": 242768, "ingredient1": "Fenfluramine", "ingredient2": "Chlorphenesin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277077/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Fluconazole, Selenium Sulfide, Thiabendazole, Miconazole, Nystatin, Ciclopirox, Griseofulvin, Ketoconazole, Econazole, Flucytosine, Tioconazole, Clotrimazole", "alternatives_b": "Dexfenfluramine, Naltrexone, Ephedrine, Bupropion, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol, Lacosamide, Paramethadione, More", "updated_at": 1767369485}, {"id": 242769, "ingredient1": "Fenfluramine", "ingredient2": "Cyclizine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277078/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Dexfenfluramine, Naltrexone, Ephedrine, Bupropion, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol, Methsuximide, Paramethadione, More", "updated_at": 1767369485}, {"id": 242770, "ingredient1": "Fenfluramine", "ingredient2": "Ethotoin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277079/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Lacosamide, Fenfluramine", "alternatives_b": "Dexfenfluramine, Ephedrine, Bupropion, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol, Ethotoin, Paramethadione, Mephenytoin, More", "updated_at": 1767369485}, {"id": 242771, "ingredient1": "Flavoxate", "ingredient2": "Fenfluramine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277081/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Dexfenfluramine, Naltrexone, Ephedrine, Bupropion, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol, Lacosamide", "alternatives_b": "Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Trospium, Alprostadil, Acetohydroxamic acid, Yohimbine, Avanafil, Papaverine, More", "updated_at": 1767369485}, {"id": 242772, "ingredient1": "Gabapentin", "ingredient2": "Fenfluramine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277083/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Dexfenfluramine, Naltrexone, Ephedrine, Lorcaserin, Diethylpropion, Mazindol, Gabapentin, Lacosamide", "alternatives_b": "Lacosamide, Fenfluramine", "updated_at": 1767369485}, {"id": 242773, "ingredient1": "Guanfacine", "ingredient2": "Fenfluramine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277086/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Dexfenfluramine, Naltrexone, Ephedrine, Phentermine, Orlistat, Lorcaserin, Sibutramine, Diethylpropion, Mazindol, Topiramate, Ezogabine, More", "alternatives_b": "Rauwolfia serpentina root, Reserpine, Deserpidine", "updated_at": 1767369485}, {"id": 242774, "ingredient1": "Halazepam", "ingredient2": "Fenfluramine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277087/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Dexfenfluramine, Naltrexone, Ephedrine, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol, Lacosamide, Paramethadione, Phensuximide, Phenacemide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242775, "ingredient1": "Fenfluramine", "ingredient2": "Diamorphine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277088/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine", "alternatives_b": "Dexfenfluramine, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol, Lacosamide, Paramethadione, Phensuximide, Phenacemide", "updated_at": 1767369485}, {"id": 242776, "ingredient1": "Fenfluramine", "ingredient2": "Kava", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277090/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Dexfenfluramine, Ephedrine, Bupropion, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol, Lacosamide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242777, "ingredient1": "Fenfluramine", "ingredient2": "Lamotrigine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277091/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Dexfenfluramine, Ephedrine, Lorcaserin, Sibutramine, Diethylpropion, Mazindol, Ethotoin, Methsuximide, Paramethadione, Phensuximide, Lamotrigine, More", "alternatives_b": "Lacosamide, Fenfluramine", "updated_at": 1767369485}, {"id": 242778, "ingredient1": "Fenfluramine", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277092/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Dexfenfluramine, Naltrexone, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol, Lacosamide", "alternatives_b": "Apomorphine, Amantadine, Cabergoline", "updated_at": 1767369485}, {"id": 242779, "ingredient1": "Fenfluramine", "ingredient2": "Lofexidine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277093/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Dexfenfluramine, Ephedrine, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol, Lacosamide", "alternatives_b": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine", "updated_at": 1767369485}, {"id": 242780, "ingredient1": "Fenfluramine", "ingredient2": "Lurasidone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277094/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Dexfenfluramine, Naltrexone, Ephedrine, Phentermine, Orlistat, Diethylpropion, Mazindol, Lacosamide", "alternatives_b": "Amisulpride, Pimavanserin", "updated_at": 1767369485}, {"id": 242781, "ingredient1": "Fenfluramine", "ingredient2": "Melatonin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277096/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Dexfenfluramine, Naltrexone, Ephedrine, Bupropion, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol, Lacosamide", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 242782, "ingredient1": "Fenfluramine", "ingredient2": "Mephenytoin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277097/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Dexfenfluramine, Ephedrine, Bupropion, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol, Ethotoin, Paramethadione, Mephenytoin, More", "alternatives_b": "Lacosamide, Fenfluramine", "updated_at": 1767369485}, {"id": 242783, "ingredient1": "Fenfluramine", "ingredient2": "Methylphenobarbital", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277098/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Dexfenfluramine, Naltrexone, Ephedrine, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol, Tiagabine, Ethotoin, Topiramate, More", "alternatives_b": "Lacosamide, Fenfluramine, Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 242784, "ingredient1": "Fenfluramine", "ingredient2": "Meprobamate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277099/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Dexfenfluramine, Naltrexone, Ephedrine, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol, Lacosamide, Methylphenobarbital", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 242785, "ingredient1": "Fenfluramine", "ingredient2": "Metaxalone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277100/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Dexfenfluramine, Ephedrine, Bupropion, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol, Fosphenytoin, Lacosamide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242786, "ingredient1": "Fenfluramine", "ingredient2": "Methdilazine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277101/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Dexfenfluramine, Orlistat, Naltrexone, Mazindol, Tiagabine, Ethotoin, Ezogabine, Paramethadione, Mephenytoin, Phensuximide, Lamotrigine, More", "alternatives_b": "Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "updated_at": 1767369485}, {"id": 242787, "ingredient1": "Fenfluramine", "ingredient2": "Methocarbamol", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277102/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Dexfenfluramine, Naltrexone, Ephedrine, Phentermine, Lorcaserin, Diethylpropion, Mazindol, Lacosamide", "alternatives_b": "Tizanidine", "updated_at": 1767369485}, {"id": 242788, "ingredient1": "Fenfluramine", "ingredient2": "Methotrimeprazine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277103/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Dexfenfluramine, Orlistat, Naltrexone, Mazindol, Tiagabine, Ethotoin, Methsuximide, Paramethadione, Mephenytoin, Phensuximide, Lamotrigine, More", "alternatives_b": "Amisulpride, Pimavanserin", "updated_at": 1767369485}, {"id": 242789, "ingredient1": "Fenfluramine", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277106/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Dexfenfluramine, Naltrexone, Ephedrine, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol, Lacosamide", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 242790, "ingredient1": "Fenfluramine", "ingredient2": "Molindone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277107/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Dexfenfluramine, Naltrexone, Ephedrine, Phentermine, Orlistat, Diethylpropion, Mazindol, Lacosamide", "alternatives_b": "Amisulpride, Pimavanserin", "updated_at": 1767369485}, {"id": 242791, "ingredient1": "Fenfluramine", "ingredient2": "Opicapone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277108/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Dexfenfluramine, Naltrexone, Ephedrine, Bupropion, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol, Lacosamide", "alternatives_b": "Apomorphine, Amantadine, Cabergoline", "updated_at": 1767369485}, {"id": 242792, "ingredient1": "Fenfluramine", "ingredient2": "Opium", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277109/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Dexfenfluramine, Ephedrine, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol, Lacosamide", "alternatives_b": "Loperamide, Eluxadoline, Dextropropoxyphene, Acetaminophen, Naltrexone", "updated_at": 1767369485}, {"id": 242793, "ingredient1": "Fenfluramine", "ingredient2": "Osilodrostat", "severity": "Moderate", "effect": "Coadministration with osilodrostat may increase the plasma concentrations of drugs that are metabolized by CYP450 1A2, 2C19, 2D6, and/or 3A4.  Osilodrostat has been shown to be a moderate inhibitor of CYP450 1A2, a mild to borderline moderate inhibitor of CYP450 2C19, and a weak inhibitor of CYP450 2D6 and 3A4.", "source": "DDInter", "management_text": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever osilodrostat is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277110/", "reference_text": "[1] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Inc  (2020):[2] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Australia Pty Ltd  (2022):[3] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases UK Ltd  (2021):", "alternatives_a": "Dexfenfluramine, Naltrexone, Ephedrine, Bupropion, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol, Ethotoin, Brivaracetam, More", "alternatives_b": "Ketoconazole", "updated_at": 1767369485}, {"id": 242794, "ingredient1": "Fenfluramine", "ingredient2": "Paliperidone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277111/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Dexfenfluramine, Naltrexone, Ephedrine, Phentermine, Orlistat, Diethylpropion, Mazindol, Lacosamide", "alternatives_b": "Amisulpride, Pimavanserin", "updated_at": 1767369485}, {"id": 242795, "ingredient1": "Fenfluramine", "ingredient2": "Paraldehyde", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277112/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Dexfenfluramine, Naltrexone, Ephedrine, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol, Lacosamide, Paramethadione, Phensuximide, Phenacemide", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 242796, "ingredient1": "Fenfluramine", "ingredient2": "Paramethadione", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277113/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Dexfenfluramine, Naltrexone, Ephedrine, Bupropion, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol, Tiagabine, Ethotoin, More", "alternatives_b": "Lacosamide, Fenfluramine", "updated_at": 1767369485}, {"id": 242797, "ingredient1": "Fenfluramine", "ingredient2": "Pentobarbital", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277114/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Dexfenfluramine, Naltrexone, Ephedrine, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol, Lacosamide", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 242798, "ingredient1": "Fenfluramine", "ingredient2": "Perampanel", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277115/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Dexfenfluramine, Naltrexone, Ephedrine, Bupropion, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol, Lacosamide, Perampanel", "alternatives_b": "Lacosamide, Fenfluramine", "updated_at": 1767369485}, {"id": 242799, "ingredient1": "Fenfluramine", "ingredient2": "Pergolide", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277116/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Dexfenfluramine, Naltrexone, Ephedrine, Phentermine, Orlistat, Diethylpropion, Mazindol, Lacosamide", "alternatives_b": "Apomorphine, Amantadine, Cabergoline", "updated_at": 1767369485}, {"id": 242800, "ingredient1": "Fenfluramine", "ingredient2": "Phenacemide", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277117/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Dexfenfluramine, Naltrexone, Ephedrine, Bupropion, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol, Tiagabine, Ethotoin, More", "alternatives_b": "Lacosamide, Fenfluramine", "updated_at": 1767369485}, {"id": 242801, "ingredient1": "Fenfluramine", "ingredient2": "Phenindamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277118/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Dexfenfluramine, Naltrexone, Ephedrine, Bupropion, Phentermine, Orlistat, Lorcaserin, Sibutramine, Diethylpropion, Mazindol, Tiagabine, More", "alternatives_b": "Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "updated_at": 1767369485}, {"id": 242802, "ingredient1": "Fenfluramine", "ingredient2": "Phensuximide", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277119/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Dexfenfluramine, Naltrexone, Ephedrine, Bupropion, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol, Clonazepam, Topiramate, More", "alternatives_b": "Lacosamide, Fenfluramine", "updated_at": 1767369485}, {"id": 242803, "ingredient1": "Fenfluramine", "ingredient2": "Pimozide", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277120/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Dexfenfluramine, Naltrexone, Ephedrine, Phentermine, Orlistat, Diethylpropion, Mazindol, Lacosamide", "alternatives_b": "Amisulpride, Pimavanserin", "updated_at": 1767369485}, {"id": 242804, "ingredient1": "Fenfluramine", "ingredient2": "Pramipexole", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277121/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Dexfenfluramine, Ephedrine, Phentermine, Lorcaserin, Sibutramine, Diethylpropion, Mazindol, Fosphenytoin, Lacosamide", "alternatives_b": "Apomorphine, Amantadine, Cabergoline", "updated_at": 1767369485}, {"id": 242805, "ingredient1": "Fenfluramine", "ingredient2": "Pregabalin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277122/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Dexfenfluramine, Ephedrine, Lorcaserin, Diethylpropion, Mazindol, Lacosamide, Pregabalin", "alternatives_b": "Lacosamide, Fenfluramine", "updated_at": 1767369485}, {"id": 242806, "ingredient1": "Fenfluramine", "ingredient2": "Primidone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277123/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Dexfenfluramine, Naltrexone, Ephedrine, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol, Lacosamide, Primidone", "alternatives_b": "Nitrazepam, Zopiclone, Lacosamide, Fenfluramine", "updated_at": 1767369485}, {"id": 242807, "ingredient1": "Fenfluramine", "ingredient2": "Procyclidine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277124/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Dexfenfluramine, Naltrexone, Ephedrine, Bupropion, Phentermine, Orlistat, Lorcaserin, Sibutramine, Diethylpropion, Mazindol, Lacosamide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242808, "ingredient1": "Fenfluramine", "ingredient2": "Promazine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277125/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Dexfenfluramine, Orlistat, Naltrexone, Mazindol, Lacosamide, Paramethadione, Phensuximide, Phenacemide", "alternatives_b": "Amisulpride, Pimavanserin", "updated_at": 1767369485}, {"id": 242809, "ingredient1": "Fenfluramine", "ingredient2": "Propiomazine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277126/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Dexfenfluramine, Orlistat, Naltrexone, Mazindol, Ezogabine, Paramethadione, Phensuximide, Phenacemide, Lacosamide", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 242810, "ingredient1": "Fenfluramine", "ingredient2": "Mepyramine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277127/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Dexfenfluramine, Naltrexone, Ephedrine, Bupropion, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol, Lacosamide", "alternatives_b": "Lidocaine, Tetracaine, Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "updated_at": 1767369485}, {"id": 242811, "ingredient1": "Fenfluramine", "ingredient2": "Ramelteon", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277128/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Dexfenfluramine, Naltrexone, Ephedrine, Bupropion, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol, Lacosamide", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 242812, "ingredient1": "Fenfluramine", "ingredient2": "Rifampicin", "severity": "Moderate", "effect": "Coadministration with rifampin or potent inducers of CYP450 1A2 and 2B6 may decrease the plasma concentrations of fenfluramine, which is primarily metabolized by CYP450 1A2, 2B6, and 2D6 in vitro.  The mechanism involves induction of CYP450 1A2- and/or 2B6-mediated metabolism of fenfluramine.", "source": "DDInter", "management_text": "Patients should be monitored for diminished therapeutic effects of fenfluramine therapy.  An increased dose of fenfluramine may be required.", "mechanism_text": "Metabolism", "recommendation": "Patients should be monitored for diminished therapeutic effects of fenfluramine therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277129/", "reference_text": "[1] \"Product Information. Fintepla (fenfluramine).\" Zogenix, Inc  (2020):", "alternatives_a": "Dexfenfluramine, Ephedrine, Phentermine, Orlistat, Lorcaserin, Sibutramine, Diethylpropion, Mazindol, Rufinamide, Topiramate, Ezogabine, More", "alternatives_b": "Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Rifapentine, Streptomycin, Trimethoprim, Cycloserine, Rifabutin, Isoniazid, More", "updated_at": 1767369485}, {"id": 242813, "ingredient1": "Fenfluramine", "ingredient2": "Ropinirole", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277130/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Dexfenfluramine, Naltrexone, Ephedrine, Lorcaserin, Sibutramine, Diethylpropion, Mazindol, Fosphenytoin, Lacosamide", "alternatives_b": "Apomorphine, Amantadine, Cabergoline", "updated_at": 1767369485}, {"id": 242814, "ingredient1": "Fenfluramine", "ingredient2": "Rotigotine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277131/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Dexfenfluramine, Naltrexone, Ephedrine, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol, Lacosamide", "alternatives_b": "Apomorphine, Amantadine, Cabergoline", "updated_at": 1767369485}, {"id": 242815, "ingredient1": "Fenfluramine", "ingredient2": "Tasimelteon", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277135/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Dexfenfluramine, Naltrexone, Ephedrine, Bupropion, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol, Lacosamide", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 242816, "ingredient1": "Fenfluramine", "ingredient2": "Thiopental", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277136/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Dexfenfluramine, Naltrexone, Ephedrine, Bupropion, Phentermine, Orlistat, Lorcaserin, Sibutramine, Diethylpropion, Mazindol, Tiagabine, More", "alternatives_b": "Halothane, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate, Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 242817, "ingredient1": "Fenfluramine", "ingredient2": "Tiagabine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277137/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Dexfenfluramine, Naltrexone, Ephedrine, Phentermine, Orlistat, Lorcaserin, Sibutramine, Diethylpropion, Mazindol, Tiagabine, Methsuximide, More", "alternatives_b": "Lacosamide, Fenfluramine", "updated_at": 1767369485}, {"id": 242818, "ingredient1": "Fenfluramine", "ingredient2": "Triazolam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277139/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Dexfenfluramine, Naltrexone, Ephedrine, Phentermine, Lorcaserin, Diethylpropion, Mazindol, Lacosamide", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 242819, "ingredient1": "Fenfluramine", "ingredient2": "Triflupromazine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277140/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Dexfenfluramine, Orlistat, Naltrexone, Mazindol, Lacosamide, Paramethadione, Phensuximide, Phenacemide", "alternatives_b": "Amisulpride, Pimavanserin", "updated_at": 1767369485}, {"id": 242820, "ingredient1": "Fenfluramine", "ingredient2": "Alimemazine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277141/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Dexfenfluramine, Orlistat, Naltrexone, Mazindol, Lacosamide, Paramethadione, Phensuximide, Phenacemide", "updated_at": 1767369485}, {"id": 242821, "ingredient1": "Fenfluramine", "ingredient2": "Tripelennamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277142/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Dexfenfluramine, Naltrexone, Ephedrine, Bupropion, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol, Lacosamide, Paramethadione, More", "alternatives_b": "Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole, Lidocaine, Tetracaine", "updated_at": 1767369485}, {"id": 242822, "ingredient1": "Fenfluramine", "ingredient2": "Triprolidine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277143/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Dexfenfluramine, Naltrexone, Ephedrine, Bupropion, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol, Lacosamide", "alternatives_b": "Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "updated_at": 1767369485}, {"id": 242823, "ingredient1": "Fenfluramine", "ingredient2": "Valbenazine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277144/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Dexfenfluramine, Naltrexone, Ephedrine, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol, Lacosamide", "alternatives_b": "Dalfampridine, Tafamidis, Riluzole", "updated_at": 1767369485}, {"id": 242824, "ingredient1": "Fenfluramine", "ingredient2": "Valerian", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277145/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Dexfenfluramine, Naltrexone, Ephedrine, Bupropion, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol, Lacosamide", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 242825, "ingredient1": "Fenfluramine", "ingredient2": "Vigabatrin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277146/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Dexfenfluramine, Naltrexone, Ephedrine, Bupropion, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol, Lacosamide, Vigabatrin", "alternatives_b": "Lacosamide, Fenfluramine", "updated_at": 1767369485}, {"id": 242826, "ingredient1": "Fenfluramine", "ingredient2": "Ziprasidone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277147/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Dexfenfluramine, Naltrexone, Ephedrine, Diethylpropion, Mazindol, Lacosamide", "alternatives_b": "Amisulpride, Pimavanserin", "updated_at": 1767369485}, {"id": 242827, "ingredient1": "Fenofibric acid", "ingredient2": "Macitentan", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 or moderate dual or combined inhibitors of CYP450 3A4 and CYP450 2C9 may increase the plasma concentrations of macitentan.  Macitentan is primarily metabolized by CYP450 3A4 and to a minor extent by CYP450 2C8, CYP450 2C9 and CYP450 2C19.", "source": "DDInter", "management_text": "Caution is advisable if macitentan is used with inhibitors of CYP450 3A4.  The product labeling recommends avoiding concomitant use with potent inhibitors (e.g., protease inhibitors, clarithromycin, cobicistat, conivaptan, delavirdine, itraconazole, ketoconazole, nefazodone, posaconazole, voriconazole).  The manufacturer of macitentan also recommends avoiding concomitant use with moderate dual inhibitors of CYP450 3A4 and 2C9 (e.g., fluconazole, amiodarone) or in combination with both a moderate CYP450 3A4 inhibitor and a moderate CYP450 2C9 inhibitor.", "mechanism_text": "Metabolism", "recommendation": "Caution is advisable if macitentan is used with inhibitors of CYP450 3A4.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277149/", "reference_text": "[1] \"Product Information. Opsumit (macitentan).\" Actelion Pharmaceuticals US Inc  (2013):", "alternatives_a": "Cholestyramine, Rosuvastatin, Evinacumab, Dextrothyroxine, Simvastatin, Probucol, Cerivastatin, Niacin, Ezetimibe, Atorvastatin, Colesevelam, More", "alternatives_b": "Riociguat, Metyrosine, Tadalafil, Bosentan, Ambrisentan", "updated_at": 1767369485}, {"id": 242828, "ingredient1": "Ginkgo biloba", "ingredient2": "Fenoprofen", "severity": "Moderate", "effect": "Ginkgo may potentiate the risk of bleeding associated with anticoagulants, platelet inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), and thrombolytic agents.  Ginkgolide B, a component of ginkgo, inhibits platelet-activating factor by displacing it from its receptor-binding site, resulting in reduced platelet aggregation.", "source": "DDInter", "management_text": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.  In general, consumption of ginkgo should be avoided during use of coagulation-modifying agents and at least two weeks prior to surgery.  In patients who have used this herb extensively prior to receiving anticoagulation, antiplatelet, NSAID or thrombolytic therapy, the potential for an interaction should be considered.  Close clinical and laboratory observation for hematologic complications is recommended.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277151/", "reference_text": "[1] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[2] Rosenblatt M, Mindel J \"Spontaneous hyphema associated with ingestion of Ginkgo biloba extract.\" N Engl J Med 336 (1997):  1108[3] Rowin J, Lewis SL \"Spontaneous bilateral subdural hematomas associated with chronic Gingko biloba ingestion.\" Neurology 46 (1996):  1775-6[4] Chung KF, McCusker M, Page CP, Dent G, Guinot P, Barnes PJ \"Effect of ginkgolide mixture (BN 52063) in antagonising skin and platelet responses to platelet acitivating factor in man.\" Lancet 1 (1987):  248-51[5] Fugh-Berman A \"Herb-drug interactions.\" Lancet 355 (2000):  134-8[6] Heck AM, DeWitt BA, Lukes AL \"Potential interactions between alternative therapies and warfarin.\" Am J Health Syst Pharm 57 (2000):  1221-7; quiz 1228-30[7] Vaes LP, Chyka PA \"Interactions of warfarin with garlic, ginger, or ginseng: nature of evidence.\" Ann Pharmacother 34 (2000):  1478-82[8] Fessenden JM, Wittenborn W, Clarke L \"Gingko biloba: A case report of herbal medicine and bleeding postoperatively from a laparoscopic cholecystectomy.\" Am Surg 67 (2001):  33-5[9] Benjamin J, Muir T, Briggs K, Pentland B \"A case of cerebral haemorrhage - can Ginkgo biloba be implicated?.\" Postgrad Med J 77 (2001):  112-3[10] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001):  2163-75[11] Evans V \"Herbs and the brain: friend or foe? The effects of ginkgo and garlic on warfarin use.\" J Neurosci Nurs 32 (2000):  229-32[12] Cupp MJ \"Herbal remedies: adverse effects and drug interactions.\" Am Fam Physician 59 (1999):  1239-45[13] Matthews MK Jr \"Association of Ginko biloba with intracerebral hemorrhage.\" Neurology 50 (1998):  1933-4[14] Engelsen J, Nielsen JD, Winther K \"Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in stable, long-term warfarin treated outpatients. A randomised, double blind, placebo-crossover trial.\" Thromb Haemost 87 (2002):  1075-6[15] Fong KC, Kinnear PE \"Retrobulbar haemorrhage associated with chronic Gingko biloba ingestion.\" Postgrad Med J 79 (2003):  531-2[16] Sierpina VS, Wollschlaeger B, Blumenthal M \"Ginkgo biloba.\" Am Fam Physician 68 (2003):  923-6[17] Jiang X, Williams KM, Liauw WS, et al. \"Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.\" Br J Clin Pharmacol 59 (2005):  425-32[18] Jayasekera N, Moghal A, Kashif F, Karalliedde L \"Herbal medicines and postoperative haemorrhage.\" Anaesthesia 60 (2005):  725-6[19] Wolf HR \"Does Ginkgo biloba special extract EGb 761 provide additional effects on coagulation and bleeding when added to acetylsalicylic acid 500 mg daily?\" Drugs R D 7 (2006):  163-72", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "alternatives_b": "Rivastigmine, Galantamine, Aducanumab, Memantine, Tacrine", "updated_at": 1767369485}, {"id": 242829, "ingredient1": "Heparin (flush)", "ingredient2": "Fenoprofen", "severity": "Moderate", "effect": "Concomitant use of heparin flush and drugs that interfere with platelet function or coagulation or drugs that commonly cause thrombocytopenia may potentiate the risk of bleeding complications.  Although uncommon, inadvertent anticoagulation resulting in hemorrhagic events may occur with heparin flushes, particularly during repeated or excessive use or administration of higher concentration flush solutions.", "source": "DDInter", "management_text": "Caution and monitoring (e.g., platelet counts, hematocrits, tests for occult blood in stools) are advised when heparin flushes are given to patients receiving systemic anticoagulants, platelet inhibitors, antithrombotic agents, thrombolytics, or drugs with known risks of thrombocytopenia or bleeding.  An unexplained fall in hematocrit, fall in blood pressure, or any other unexplained symptom should lead to serious consideration of a hemorrhagic event.", "mechanism_text": "Synergism", "recommendation": "Caution and monitoring (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277152/", "reference_text": "[1] Passannante A, Macik BG \"The heparin flush syndrome: a cause of iatrogenic hemorrhage.\" Am J Med Sci 296 (1988):  71-3[2] \"Product Information. Heparin Sodium in Sodium Chloride (heparin flush).\" Baxter Healthcare Corporation  (2022):[3] \"Product Information. Canusal (heparin flush).\" Wockhardt UK Ltd  (2018):[4] \"Product Information. Heparinised Saline (Pfizer) (heparinised saline).\" Pfizer Australia Pty Ltd  (2022):", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "alternatives_b": "Protein C, Acenocoumarol, Selexipag, Pentosan polysulfate, Vitamin A, Ascorbic acid, Nandrolone, Acetylcysteine", "updated_at": 1767369485}, {"id": 242830, "ingredient1": "Isocarboxazid", "ingredient2": "Fesoterodine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277180/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Mirabegron, Acetohydroxamic acid, Phenyl salicylate, Magnesium hydroxide, Ammonium chloride, Dimethyl sulfoxide", "alternatives_b": "Desvenlafaxine, Oxitriptan, Mirtazapine, Trazodone, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone, Esketamine, Venlafaxine", "updated_at": 1767369485}, {"id": 242831, "ingredient1": "Fesoterodine", "ingredient2": "Botulinum toxin type A", "severity": "Moderate", "effect": "Use of anticholinergic drugs after administration of botulinum toxin may potentiate systemic anticholinergic effects such as dry mouth, blurred vision, and urinary disorders.  Botulinum toxin inhibits the release of acetylcholine from peripheral cholinergic nerve endings, thus additive or synergistic anticholinergic effects may occur when these agents are used together.", "source": "DDInter", "management_text": "Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) are used after administration of botulinum toxin.", "mechanism_text": "Synergism", "recommendation": "Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277186/", "reference_text": "[1] \"Product Information. Myobloc (rimabotulinumtoxinB).\" Elan Pharmaceuticals[2] \"Product Information. Dysport (abobotulinumtoxinA).\" Tercica Inc[3] \"Product Information. Botox (onabotulinumtoxinA).\" Allergan Inc[4] \"Product Information. Xeomin (incobotulinumtoxinA).\" Merz Pharmaceuticals  (2022):[5] \"Product Information. Jeuveau (prabotulinumtoxinA).\" Evolus, Inc.  (2022):[6] \"Product Information. Daxxify (daxibotulinumtoxinA).\" Revance Therapeutics, Inc.  (2022):", "alternatives_a": "Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Avanafil, Papaverine, More", "alternatives_b": "Atracurium, Doxacurium, Succinylcholine, Rocuronium, Vecuronium, Tubocurarine, Mivacurium, Pancuronium, Pipecuronium, Cisatracurium", "updated_at": 1767369485}, {"id": 242832, "ingredient1": "Fesoterodine", "ingredient2": "Palbociclib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of fesoterodine's active metabolite, 5-hydroxymethyl tolterodine, which is partially metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring is advised whenever a CYP450 3A4 inhibitor is added to or withdrawn from fesoterodine therapy, and the dosage adjusted if necessary.  Patients should be advised to notify their physician if they experience potential adverse effects of fesoterodine such as irregular heartbeat, blurry vision, difficulty urinating, dry mouth, headache, drowsiness, dizziness, gastrointestinal upset, or constipation.", "mechanism_text": "Metabolism", "recommendation": "Close clinical and laboratory monitoring is advised whenever a CYP450 3A4 inhibitor is added to or withdrawn from fesoterodine therapy, and the dosage adjusted if necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277187/", "reference_text": "[1] \"Product Information. Toviaz (fesoterodine).\" Pfizer U.S. Pharmaceuticals Group  (2008):", "alternatives_a": "Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Avanafil, Papaverine, More", "alternatives_b": "Pralsetinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, More", "updated_at": 1767369485}, {"id": 242833, "ingredient1": "Fesoterodine", "ingredient2": "Phenelzine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277188/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Mirabegron, Acetohydroxamic acid, Phenyl salicylate, Magnesium hydroxide, Ammonium chloride, Dimethyl sulfoxide", "alternatives_b": "Desvenlafaxine, Oxitriptan, Mirtazapine, Trazodone, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone, Esketamine, Venlafaxine", "updated_at": 1767369485}, {"id": 242834, "ingredient1": "Fesoterodine", "ingredient2": "Botulinum toxin type B", "severity": "Moderate", "effect": "Use of anticholinergic drugs after administration of botulinum toxin may potentiate systemic anticholinergic effects such as dry mouth, blurred vision, and urinary disorders.  Botulinum toxin inhibits the release of acetylcholine from peripheral cholinergic nerve endings, thus additive or synergistic anticholinergic effects may occur when these agents are used together.", "source": "DDInter", "management_text": "Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) are used after administration of botulinum toxin.", "mechanism_text": "Synergism", "recommendation": "Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277192/", "reference_text": "[1] \"Product Information. Myobloc (rimabotulinumtoxinB).\" Elan Pharmaceuticals[2] \"Product Information. Dysport (abobotulinumtoxinA).\" Tercica Inc[3] \"Product Information. Botox (onabotulinumtoxinA).\" Allergan Inc[4] \"Product Information. Xeomin (incobotulinumtoxinA).\" Merz Pharmaceuticals  (2022):[5] \"Product Information. Jeuveau (prabotulinumtoxinA).\" Evolus, Inc.  (2022):[6] \"Product Information. Daxxify (daxibotulinumtoxinA).\" Revance Therapeutics, Inc.  (2022):", "alternatives_a": "Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Avanafil, Papaverine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242835, "ingredient1": "Filgrastim", "ingredient2": "Melphalan flufenamide", "severity": "Moderate", "effect": "The safety and efficacy of hematopoietic growth factors such as colony-stimulating factors (G-CSF and GM-CSF) and stem cell factors (SCF) given simultaneously with cancer chemotherapy have not been established.  Theoretical concerns exist regarding their concomitant administration because hematopoietic growth factors stimulate myeloid cell proliferation while antineoplastic agents primarily target rapidly dividing cells.", "source": "DDInter", "management_text": "Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, hematopoietic growth factors should not be used within 24 hours before or 24 hours after administration of antineoplastic agents.", "mechanism_text": "Others", "recommendation": "Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, hematopoietic growth factors should not be used within 24 hours before or 24 hours after administration of antineoplastic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277497/", "reference_text": "[1] \"Product Information. Neupogen (filgrastim).\" Amgen  (2002):[2] \"Product Information. Leukine (sargramostim).\" Immunex Corporation  (2001):[3] \"Product Information. Stemgen (ancestim).\" Amgen  (2001):[4] \"Product Information. Granix (tbo-filgrastim).\" Teva Pharmaceuticals USA  (2013):", "alternatives_a": "Interferon alfa-n1, Oprelvekin, Elapegademase, Interferon beta-1b, Peginterferon alfa-2a, Peginterferon beta-1a, Interferon alfacon-1, Interferon beta-1a, Histamine, Pegademase, Peginterferon alfa-2b, Glatiramer", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242836, "ingredient1": "Fingolimod", "ingredient2": "Bacillus calmette-guerin substrain tice live antigen", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during fingolimod therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence.  Fingolimod causes reversible sequestration of lymphocytes in lymphoid tissues.", "source": "DDInter", "management_text": "The use of live attenuated vaccines should be avoided during and for two months after treatment with fingolimod.  In patients who have recently been vaccinated, fingolimod therapy should be postponed for one month to allow the full effect of vaccination to occur.", "mechanism_text": "Synergism", "recommendation": "The use of live attenuated vaccines should be avoided during and for two months after treatment with fingolimod.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277848/", "reference_text": "[1] \"Product Information. Meruvax II (rubella virus vaccine).\" Merck & Co., Inc  (2022):[2] \"Product Information. Attenuvax (measles virus vaccine).\" Merck & Co., Inc  (2022):[3] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD \"Harrison's Principles of Internal Medicine.\" New York, NY: McGraw-Hill Health Professionals Division  (1998):[4] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[5] \"Product Information. Gilenya (fingolimod).\" Novartis Pharmaceuticals  (2010):", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242837, "ingredient1": "Fingolimod", "ingredient2": "Lorlatinib", "severity": "Moderate", "effect": "The risk of bradycardia and atrioventricular (AV) block may be increased during initiation of fingolimod treatment in patients receiving beta-blockers, calcium channel blockers, digitalis, or other drugs that can slow the heart rate or AV conduction such as alectinib, atazanavir, flecainide, ivabradine, lacosamide, lithium, mefloquine, moricizine, propafenone, succinylcholine, thalidomide, H2-receptor antagonists, tricyclic antidepressants, and anticholinesterase or cholinergic agents.", "source": "DDInter", "management_text": "Fingolimod has not been adequately studied in patients receiving other drugs that can slow the heart rate or AV conduction.  Close monitoring is recommended during initiation of fingolimod treatment in these patients.  The first dose should always be administered in a setting where resources to appropriately manage symptomatic bradycardia are available.  Patients should be observed for a period of six hours after the first dose for signs and symptoms of bradycardia with hourly pulse and blood pressure measurement.  An electrocardiogram should be obtained prior to dosing and at the end of the observation period.  Additional observation is recommended if the heart rate 6 hours postdose is less than 45 bpm or is at the lowest value postdose, or if the ECG 6 hours postdose shows new onset second-degree or higher AV block.  Should postdose symptomatic bradycardia occur, initiate appropriate management, begin continuous ECG monitoring, and continue observation until the symptoms have resolved.  Should a patient require pharmacologic intervention for symptomatic bradycardia, continuous overnight ECG monitoring in a medical facility should be instituted, and the first-dose monitoring strategy should be repeated after the second dose of fingolimod.  The same precautions are applicable if, after the first month of treatment, fingolimod is discontinued for more than two weeks and then restarted, since the effects on heart rate and AV conduction may recur on reintroduction of fingolimod.  Within the first 2 weeks of treatment, first-dose procedures are also recommended after interruption of one day or more; during week 3 and 4 of treatment, first-dose procedures are recommended after treatment interruption of more than 7 days.", "mechanism_text": "Synergism", "recommendation": "Fingolimod has not been adequately studied in patients receiving other drugs that can slow the heart rate or AV conduction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277864/", "reference_text": "[1] \"Product Information. Gilenya (fingolimod).\" Novartis Pharmaceuticals  (2010):[2] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Revised recommendations for cardiovascular monitoring and use of multiple sclerosis drug Gilenya (fingolimod).  http://www.fda.gov/Drugs/DrugSafety/ucm303192.htm#data\"   (2012):", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Methotrexate, Abatacept, More", "alternatives_b": "Dabrafenib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Larotrectinib, Selumetinib, Capmatinib, Afatinib, Tivozanib, Axitinib, More", "updated_at": 1767369485}, {"id": 242838, "ingredient1": "Fingolimod", "ingredient2": "Melphalan flufenamide", "severity": "Major", "effect": "The safety and efficacy of fingolimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated.", "source": "DDInter", "management_text": "The safety and efficacy of fingolimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated.  Caution is advised during coadministration.  A complete blood count is recommended prior to starting fingolimod if a recent one (i.e., within last 6 months) is not available.  Treatment suspension should be considered in patients who develop a serious infection, and the benefits and risks reassessed prior to restarting treatment.  Because fingolimod remains in the blood for up to two months after the last dose, continued monitoring is recommended throughout this period, and initiating other drugs during this period warrants the same considerations needed for concomitant administration.  Likewise, caution should be applied when switching patients from long-acting therapies with immune effects such as natalizumab or mitoxantrone.", "mechanism_text": "Others", "recommendation": "The safety and efficacy of fingolimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277866/", "reference_text": "[1] \"Product Information. Gilenya (fingolimod).\" Novartis Pharmaceuticals  (2010):", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242839, "ingredient1": "Fingolimod", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277881/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Dabrafenib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Larotrectinib, Selumetinib, Capmatinib, Afatinib, Tivozanib, Axitinib, More", "updated_at": 1767369485}, {"id": 242840, "ingredient1": "Fingolimod", "ingredient2": "Siponimod", "severity": "Major", "effect": "Coadministration of fingolimod with antineoplastic, immunosuppressive, or other immune-modulating therapies may increase the risk of infections.  Fingolimod causes reversible sequestration of lymphocytes in lymphoid tissues.", "source": "DDInter", "management_text": "Fingolimod has not been studied in patients receiving drugs that can prolong the QT interval.  Because bradycardia and AV block are recognized risk factors for QT prolongation and torsade de pointes arrhythmia, close monitoring is recommended during initiation of fingolimod treatment in patients receiving concomitant drugs that can prolong the QT interval, patients with significant QT prolongation (QTc >470 msec in females or >450 msec in males), or patients with relevant risk factors for QT prolongation (e.g., hypokalemia, hypomagnesemia, congenital QT prolongation).  Overnight continuous ECG monitoring after the first dose is recommended in accordance with the product labeling.  Fingolimod should not be given if baseline QTc interval is 500 msec or greater.  The same precautions are applicable if, after the first month of treatment, fingolimod is discontinued for more than two weeks and then restarted, since the effects on heart rate and AV conduction may recur on reintroduction of fingolimod.  Within the first 2 weeks of treatment, first-dose procedures are also recommended after interruption of one day or more; during week 3 and 4 of treatment, first-dose procedures are recommended after treatment interruption of more than 7 days.", "mechanism_text": "Synergism", "recommendation": "Fingolimod has not been studied in patients receiving drugs that can prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277900/", "reference_text": "[1] \"Product Information. Gilenya (fingolimod).\" Novartis Pharmaceuticals  (2010):[2] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Revised recommendations for cardiovascular monitoring and use of multiple sclerosis drug Gilenya (fingolimod).  http://www.fda.gov/Drugs/DrugSafety/ucm303192.htm#data\"   (2012):", "alternatives_a": "Siponimod, Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "Pegcetacoplan, Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Fingolimod, Eculizumab, Sutimlimab", "updated_at": 1767369485}, {"id": 242841, "ingredient1": "Fingolimod", "ingredient2": "Varicella Zoster Vaccine (Recombinant)", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines during fingolimod therapy is generally safe but may be associated with a diminished or suboptimal immunologic response.  Vaccination may be less effective during and for up to two months after discontinuation of fingolimod therapy.", "source": "DDInter", "management_text": "Immune response to vaccines may be reduced during and for up to two months after discontinuation of fingolimod therapy.  In patients who have recently been vaccinated, fingolimod therapy should preferably be postponed for one month to allow the full effect of vaccination to occur.", "mechanism_text": "Antagonism", "recommendation": "Immune response to vaccines may be reduced during and for up to two months after discontinuation of fingolimod therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277910/", "reference_text": "[1] \"Product Information. Gilenya (fingolimod).\" Novartis Pharmaceuticals  (2010):", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242842, "ingredient1": "Pemigatinib", "ingredient2": "Lansoprazole", "severity": "Moderate", "effect": "Coadministration of pemigatinib with proton pump inhibitors may result in a reduction in the plasma concentrations of pemigatinib.  The mechanism for this interaction has not been delineated.", "source": "DDInter", "management_text": "Until more information is available, caution is recommended when pemigatinib is used concomitantly with proton pump inhibitors.  Patients should be monitored for potentially reduced efficacy.", "mechanism_text": "Others", "recommendation": "Until more information is available, caution is recommended when pemigatinib is used concomitantly with proton pump inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277921/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Tinidazole, Levofloxacin, Tetracycline, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Nizatidine, Ranitidine, Amoxicillin", "alternatives_b": "Entrectinib, Dabrafenib, Asciminib, Pacritinib, Tepotinib, Avapritinib, Larotrectinib, Vemurafenib, Ribociclib, Cobimetinib, Ibrutinib, More", "updated_at": 1767369485}, {"id": 242843, "ingredient1": "Pralsetinib", "ingredient2": "Lansoprazole", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277923/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Tetracycline, Sucralfate, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Nizatidine, Ranitidine, Amoxicillin", "alternatives_b": "Entrectinib, Dabrafenib, Asciminib, Pacritinib, Tepotinib, Avapritinib, Larotrectinib, Vemurafenib, Ribociclib, Cobimetinib, Ibrutinib, More", "updated_at": 1767369485}, {"id": 242844, "ingredient1": "Selumetinib", "ingredient2": "Lansoprazole", "severity": "Moderate", "effect": "Coadministration with potent or moderate inhibitors of CYP450 2C19 may increase the plasma concentrations of selumetinib, which is primarily metabolized by CYP450 3A4 and to a lesser extent by CYP450 2C19, 1A2, 2C9, 2E1, and 3A5.  Selumetinib's active metabolite, N-desmethyl selumetinib, is generated by CYP450 2C19 and 1A2 with additional contribution by CYP450 2C9 and 2A6, and metabolized through the same routes as selumetinib.", "source": "DDInter", "management_text": "Caution is advised when selumetinib is used with potent or moderate CYP450 2C19 inhibitors.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when selumetinib is used with potent or moderate CYP450 2C19 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277925/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Koselugo (selumetinib).\" Astra-Zeneca Pharmaceuticals  (2020):", "alternatives_a": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, More", "alternatives_b": "Entrectinib, Dabrafenib, Asciminib, Pacritinib, Tepotinib, Avapritinib, Larotrectinib, Vemurafenib, Ribociclib, Cobimetinib, Ibrutinib, More", "updated_at": 1767369485}, {"id": 242845, "ingredient1": "Pemigatinib", "ingredient2": "Omeprazole", "severity": "Moderate", "effect": "Coadministration of pemigatinib with proton pump inhibitors may result in a reduction in the plasma concentrations of pemigatinib.  The mechanism for this interaction has not been delineated.", "source": "DDInter", "management_text": "Until more information is available, caution is recommended when pemigatinib is used concomitantly with proton pump inhibitors.  Patients should be monitored for potentially reduced efficacy.", "mechanism_text": "Others", "recommendation": "Until more information is available, caution is recommended when pemigatinib is used concomitantly with proton pump inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277938/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Tinidazole, Levofloxacin, Tetracycline, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Nizatidine, Ranitidine, Amoxicillin", "alternatives_b": "Entrectinib, Dabrafenib, Asciminib, Pacritinib, Tepotinib, Avapritinib, Vemurafenib, Ribociclib, Cobimetinib, Ibrutinib, Afatinib, More", "updated_at": 1767369485}, {"id": 242846, "ingredient1": "Pralsetinib", "ingredient2": "Omeprazole", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277940/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Tetracycline, Sucralfate, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Nizatidine, Ranitidine, Amoxicillin", "alternatives_b": "Entrectinib, Dabrafenib, Asciminib, Pacritinib, Tepotinib, Avapritinib, Vemurafenib, Ribociclib, Cobimetinib, Ibrutinib, Afatinib, More", "updated_at": 1767369485}, {"id": 242847, "ingredient1": "Selumetinib", "ingredient2": "Omeprazole", "severity": "Moderate", "effect": "Coadministration with potent or moderate inhibitors of CYP450 2C19 may increase the plasma concentrations of selumetinib, which is primarily metabolized by CYP450 3A4 and to a lesser extent by CYP450 2C19, 1A2, 2C9, 2E1, and 3A5.  Selumetinib's active metabolite, N-desmethyl selumetinib, is generated by CYP450 2C19 and 1A2 with additional contribution by CYP450 2C9 and 2A6, and metabolized through the same routes as selumetinib.", "source": "DDInter", "management_text": "Caution is advised when selumetinib is used with potent or moderate CYP450 2C19 inhibitors.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when selumetinib is used with potent or moderate CYP450 2C19 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277942/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Koselugo (selumetinib).\" Astra-Zeneca Pharmaceuticals  (2020):", "alternatives_a": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, More", "alternatives_b": "Entrectinib, Dabrafenib, Asciminib, Pacritinib, Tepotinib, Avapritinib, Vemurafenib, Ribociclib, Cobimetinib, Ibrutinib, Afatinib, More", "updated_at": 1767369485}, {"id": 242848, "ingredient1": "Cefamandole", "ingredient2": "Vancomycin", "severity": "Moderate", "effect": "The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277945/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Imipenem, Loracarbef, Cefadroxil, Cefonicid, Ceftizoxime, Ceftibuten, Cefaclor, Cefditoren, Cefiderocol, Meropenem, Cefapirin, More", "alternatives_b": "Tinidazole, Linezolid, Oritavancin, Daptomycin, Telavancin, Metronidazole, Methenamine, Spectinomycin, Lefamulin, Nitrofurantoin, Fosfomycin, More", "updated_at": 1767369485}, {"id": 242849, "ingredient1": "Cefotetan", "ingredient2": "Vancomycin", "severity": "Moderate", "effect": "The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277946/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Imipenem, Loracarbef, Cefadroxil, Cefonicid, Ceftizoxime, Ceftibuten, Cefaclor, Cefditoren, Cefiderocol, Meropenem, Cefapirin, More", "alternatives_b": "Tinidazole, Linezolid, Polymyxin B, Oritavancin, Daptomycin, Telavancin, Metronidazole, Methenamine, Spectinomycin, Lefamulin, Nitrofurantoin, More", "updated_at": 1767369485}, {"id": 242850, "ingredient1": "Cefradine", "ingredient2": "Vancomycin", "severity": "Moderate", "effect": "The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277947/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Imipenem, Loracarbef, Cefadroxil, Cefonicid, Ceftizoxime, Ceftibuten, Cefaclor, Cefditoren, Cefiderocol, Meropenem, Cefapirin, More", "alternatives_b": "Tinidazole, Linezolid, Polymyxin B, Oritavancin, Daptomycin, Telavancin, Metronidazole, Methenamine, Spectinomycin, Lefamulin, Nitrofurantoin, More", "updated_at": 1767369485}, {"id": 242851, "ingredient1": "Vancomycin", "ingredient2": "Nalidixic acid", "severity": "Moderate", "effect": "The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277955/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Enoxacin, Levofloxacin, Gemifloxacin, Lomefloxacin, Grepafloxacin, Cinoxacin, Trovafloxacin, Delafloxacin, Sparfloxacin", "alternatives_b": "Tinidazole, Linezolid, Oritavancin, Daptomycin, Metronidazole, Methenamine, Spectinomycin, Lefamulin, Nitrofurantoin, Fosfomycin, Tedizolid, More", "updated_at": 1767369485}, {"id": 242852, "ingredient1": "Vancomycin", "ingredient2": "Nimodipine", "severity": "Moderate", "effect": "The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277956/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Nisoldipine, Isradipine, Clevidipine, Levamlodipine, Mibefradil", "alternatives_b": "Tinidazole, Oritavancin, Daptomycin, Metronidazole, Methenamine, Spectinomycin, Nitrofurantoin, Fosfomycin, Tedizolid, Dalbavancin, Rifamycin, More", "updated_at": 1767369485}, {"id": 242853, "ingredient1": "Vancomycin", "ingredient2": "Pentamidine", "severity": "Moderate", "effect": "The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277957/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Miltefosine, Fexinidazole, Nifurtimox, Benznidazole", "alternatives_b": "Tinidazole, Linezolid, Oritavancin, Daptomycin, Methenamine, Spectinomycin, Nitrofurantoin, Fosfomycin, Tedizolid, Dalbavancin, Rifamycin, More", "updated_at": 1767369485}, {"id": 242854, "ingredient1": "Vancomycin", "ingredient2": "Sulfamethoxazole", "severity": "Moderate", "effect": "The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277959/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Rifamycin, Bedaquiline, Rifapentine, Cycloserine, Rifabutin, Pyridoxine, Ethionamide, Pretomanid, Aminosalicylic acid, Sulfadiazine, Sulfamethizole, More", "alternatives_b": "Tinidazole, Linezolid, Oritavancin, Daptomycin, Spectinomycin, Nitrofurantoin, Fosfomycin, Tedizolid, Dalbavancin, Rifamycin, Kanamycin, More", "updated_at": 1767369485}, {"id": 242855, "ingredient1": "Vancomycin", "ingredient2": "Uracil mustard", "severity": "Moderate", "effect": "The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277962/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Lomustine, Mechlorethamine, Bendamustine, Melphalan flufenamide, Streptozocin", "alternatives_b": "Tinidazole, Linezolid, Oritavancin, Daptomycin, Metronidazole, Methenamine, Spectinomycin, Lefamulin, Nitrofurantoin, Fosfomycin, Tedizolid, More", "updated_at": 1767369485}, {"id": 242856, "ingredient1": "Pralsetinib", "ingredient2": "Metronidazole", "severity": "Moderate", "effect": "QT prolongation has been reported with metronidazole, particularly when administered with drugs that have the potential for prolonging the QT interval.  This may increase the risk of ventricular arrhythmias associated with QT prolongation including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is recommended when metronidazole is used concomitantly with agents known to cause QT prolongation.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended when metronidazole is used concomitantly with agents known to cause QT prolongation.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277970/", "reference_text": "[1] \"Product Information. Flagyl (metronidazole).\" Searle  (2001):[2] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005):  472-3[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Pylera (bismuth subcitrate potassium/metronidazo/TCN).\" Aptalis Pharma  (2022):", "alternatives_a": "Tetracycline, Sucralfate, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Nizatidine, Ranitidine, Amoxicillin, Quinacrine, Secnidazole, Atovaquone, More", "alternatives_b": "Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, Capmatinib, More", "updated_at": 1767369485}, {"id": 242857, "ingredient1": "Flavoxate", "ingredient2": "Melatonin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277980/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "alternatives_b": "Ethchlorvynol, Zopiclone, Thiopental, Nitrazepam", "updated_at": 1767369485}, {"id": 242858, "ingredient1": "Flavoxate", "ingredient2": "Botulinum toxin type A", "severity": "Moderate", "effect": "Use of anticholinergic drugs after administration of botulinum toxin may potentiate systemic anticholinergic effects such as dry mouth, blurred vision, and urinary disorders.  Botulinum toxin inhibits the release of acetylcholine from peripheral cholinergic nerve endings, thus additive or synergistic anticholinergic effects may occur when these agents are used together.", "source": "DDInter", "management_text": "Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) are used after administration of botulinum toxin.", "mechanism_text": "Synergism", "recommendation": "Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277981/", "reference_text": "[1] \"Product Information. Myobloc (rimabotulinumtoxinB).\" Elan Pharmaceuticals[2] \"Product Information. Dysport (abobotulinumtoxinA).\" Tercica Inc[3] \"Product Information. Botox (onabotulinumtoxinA).\" Allergan Inc[4] \"Product Information. Xeomin (incobotulinumtoxinA).\" Merz Pharmaceuticals  (2022):[5] \"Product Information. Jeuveau (prabotulinumtoxinA).\" Evolus, Inc.  (2022):[6] \"Product Information. Daxxify (daxibotulinumtoxinA).\" Revance Therapeutics, Inc.  (2022):", "alternatives_a": "Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Avanafil, Papaverine, More", "alternatives_b": "Atracurium, Doxacurium, Succinylcholine, Rocuronium, Vecuronium, Tubocurarine, Mivacurium, Pancuronium, Pipecuronium, Cisatracurium", "updated_at": 1767369485}, {"id": 242859, "ingredient1": "Flavoxate", "ingredient2": "Botulinum toxin type B", "severity": "Moderate", "effect": "Use of anticholinergic drugs after administration of botulinum toxin may potentiate systemic anticholinergic effects such as dry mouth, blurred vision, and urinary disorders.  Botulinum toxin inhibits the release of acetylcholine from peripheral cholinergic nerve endings, thus additive or synergistic anticholinergic effects may occur when these agents are used together.", "source": "DDInter", "management_text": "Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) are used after administration of botulinum toxin.", "mechanism_text": "Synergism", "recommendation": "Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277982/", "reference_text": "[1] \"Product Information. Myobloc (rimabotulinumtoxinB).\" Elan Pharmaceuticals[2] \"Product Information. Dysport (abobotulinumtoxinA).\" Tercica Inc[3] \"Product Information. Botox (onabotulinumtoxinA).\" Allergan Inc[4] \"Product Information. Xeomin (incobotulinumtoxinA).\" Merz Pharmaceuticals  (2022):[5] \"Product Information. Jeuveau (prabotulinumtoxinA).\" Evolus, Inc.  (2022):[6] \"Product Information. Daxxify (daxibotulinumtoxinA).\" Revance Therapeutics, Inc.  (2022):", "alternatives_a": "Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Avanafil, Papaverine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242860, "ingredient1": "Flecainide", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/277988/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Moricizine, Tocainide, Bretylium, Mexiletine", "alternatives_b": "Dabrafenib, Acalabrutinib, Pexidartinib, Tepotinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More", "updated_at": 1767369485}, {"id": 242861, "ingredient1": "Simvastatin", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278003/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, More", "alternatives_b": "Lixisenatide, Albiglutide, Guar gum, Acarbose, Pramlintide, Canagliflozin, Alogliptin, Liraglutide, Troglitazone, Ertugliflozin, Semaglutide, More", "updated_at": 1767369485}, {"id": 242862, "ingredient1": "Tamsulosin", "ingredient2": "Osilodrostat", "severity": "Moderate", "effect": "Coadministration with osilodrostat may increase the plasma concentrations of drugs that are metabolized by CYP450 1A2, 2C19, 2D6, and/or 3A4.  Osilodrostat has been shown to be a moderate inhibitor of CYP450 1A2, a mild to borderline moderate inhibitor of CYP450 2C19, and a weak inhibitor of CYP450 2D6 and 3A4.", "source": "DDInter", "management_text": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever osilodrostat is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278020/", "reference_text": "[1] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Inc  (2020):[2] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Australia Pty Ltd  (2022):[3] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases UK Ltd  (2021):", "alternatives_a": "Terazosin, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, Clindamycin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242863, "ingredient1": "Tamsulosin", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278023/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Entrectinib, Acalabrutinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Lapatinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, More", "alternatives_b": "Terazosin, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, Clindamycin, Trichlormethiazide, Ciclopirox, More", "updated_at": 1767369485}, {"id": 242864, "ingredient1": "Fludrocortisone", "ingredient2": "Axicabtagene ciloleucel", "severity": "Major", "effect": "Prophylactic use of systemic corticosteroids prior to CD19- or BCMA-directed genetically modified autologous T cell immunotherapy may interfere with the therapeutic effects of such drugs as axicabtagene ciloleucel, brexucabtagene autoleucel, idecabtagene vicleucel, ciltacabtagene autoleucel and lisocabtagene maraleucel.  The mechanism for this interaction has not been delineated.  Administration of systemic corticosteroids in an effort to manage the toxicities associated with these drugs does not affect the expansion and persistence of CAR T cells.", "source": "DDInter", "management_text": "The prophylactic use of systemic corticosteroids prior to CD19- or BCMA-directed genetically modified autologous T cell immunotherapy with drugs such as axicabtagene ciloleucel, brexucabtagene autoleucel, idecabtagene vicleucel, ciltacabtagene autoleucel and lisocabtagene maraleucel is not recommended.  However, systemic corticosteroids may be used for the management of adverse effects associated with these drugs, such as cytokine release syndrome and neurological-related toxicities, without affecting the expansion and persistence of CAR T cells.", "mechanism_text": "Others", "recommendation": "The prophylactic use of systemic corticosteroids prior to CD19- or BCMA-directed genetically modified autologous T cell immunotherapy with drugs such as axicabtagene ciloleucel, brexucabtagene autoleucel, idecabtagene vicleucel, ciltacabtagene autoleucel and lisocabtagene maraleucel is not recommended.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278032/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Yescarta (axicabtagene ciloleucel).\" Kite Pharma, Inc.  (2017):[3] \"Product Information. Tecartus (brexucabtagene autoleucel).\" Kite Pharma, Inc.  (2020):[4] \"Product Information. Breyanzi (lisocabtagene maraleucel).\" Bristol-Myers Squibb  (2021):[5] \"Product Information. Abecma (idecabtagene vicleucel).\" Celgene Corporation  (2021):", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Enasidenib, More", "alternatives_b": "Fluocinolone acetonide, Fluorometholone, Indomethacin, Fluocinolone acetonide, Diclofenac", "updated_at": 1767369485}, {"id": 242865, "ingredient1": "Fludrocortisone", "ingredient2": "Bacillus calmette-guerin substrain tice live antigen", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278033/", "reference_text": "[1] \"Product Information. Meruvax II (rubella virus vaccine).\" Merck & Co., Inc  (2022):[2] \"Product Information. Attenuvax (measles virus vaccine).\" Merck & Co., Inc  (2022):[3] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD \"Harrison's Principles of Internal Medicine.\" New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] \"Product Information. DENGVAXIA (dengue vaccine).\" sanofi pasteur  (2022):", "alternatives_a": "Fluocinolone acetonide, Fluorometholone, Indomethacin, Fluocinolone acetonide, Diclofenac", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242866, "ingredient1": "Fludrocortisone", "ingredient2": "Osilodrostat", "severity": "Moderate", "effect": "Coadministration with osilodrostat may increase the plasma concentrations of drugs that are metabolized by CYP450 1A2, 2C19, 2D6, and/or 3A4.  Osilodrostat has been shown to be a moderate inhibitor of CYP450 1A2, a mild to borderline moderate inhibitor of CYP450 2C19, and a weak inhibitor of CYP450 2D6 and 3A4.", "source": "DDInter", "management_text": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever osilodrostat is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278057/", "reference_text": "[1] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Inc  (2020):[2] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Australia Pty Ltd  (2022):[3] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases UK Ltd  (2021):", "alternatives_a": "Fluocinolone acetonide, Fluorometholone, Indomethacin, Fluocinolone acetonide, Diclofenac", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242867, "ingredient1": "Fludrocortisone", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278067/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Fluocinolone acetonide, Fluocinolone acetonide, Fluorometholone", "alternatives_b": "Entrectinib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, More", "updated_at": 1767369485}, {"id": 242868, "ingredient1": "Fludrocortisone", "ingredient2": "Varicella Zoster Vaccine (Recombinant)", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual's risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, the U.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278098/", "reference_text": "[1] \"Product Information. Fluzone (influenza virus vaccine, inactivated).\" Connaught Laboratories Inc[2] \"Product Information. Omnihib (haemophilus b conjugate vaccine (obsolete)).\" SmithKline Beecham[3] \"Product Information. Havrix (hepatitis A adult vaccine).\" SmithKline Beecham[4] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[5] \"Product Information. Imovax Rabies (rabies vaccine, human diploid cell).\" sanofi pasteur  (2022):[6] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc.  (2003):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline  (2022):[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations.  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf\"   (2019):[11] CDC Centers for Disease Control and Prevention \"Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html\"   (2022):", "alternatives_a": "Fluocinolone acetonide, Fluorometholone, Indomethacin, Fluocinolone acetonide, Diclofenac", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242869, "ingredient1": "Axicabtagene ciloleucel", "ingredient2": "Ofloxacin", "severity": "Minor", "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics.  The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.", "source": "DDInter", "management_text": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics.  The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.  In six patients with newly diagnosed hematologic malignancy, treatment with various antineoplastic agents (cyclophosphamide, cytarabine, daunorubicin, doxorubicin, mitoxantrone, prednisolone, vincristine) decreased the mean peak serum concentration (Cmax) and area under the concentration-time curve (AUC 0 to 4 hours) of ciprofloxacin by approximately 46% each.  Data are not available for other quinolone antibiotics.", "mechanism_text": "Absorption", "recommendation": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278100/", "reference_text": "[1] Johnson EJ, MacGowan AP, Potter MN, et al. \"Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy.\" J Antimicrob Chemother 25 (1990):  837-42", "alternatives_a": "Pertuzumab, Olaparib, Tisagenlecleucel, Omacetaxine mepesuccinate, Tazemetostat, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, Enasidenib, Belzutifan, More", "alternatives_b": "Enoxacin, Lomefloxacin, Grepafloxacin, Tinidazole, Tetracycline, Cefepime, Fluconazole, Metronidazole, Cefuroxime, Secnidazole, Cefixime, More", "updated_at": 1767369485}, {"id": 242870, "ingredient1": "Ofloxacin", "ingredient2": "Melphalan flufenamide", "severity": "Minor", "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics.  The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.", "source": "DDInter", "management_text": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics.  The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.  In six patients with newly diagnosed hematologic malignancy, treatment with various antineoplastic agents (cyclophosphamide, cytarabine, daunorubicin, doxorubicin, mitoxantrone, prednisolone, vincristine) decreased the mean peak serum concentration (Cmax) and area under the concentration-time curve (AUC 0 to 4 hours) of ciprofloxacin by approximately 46% each.  Data are not available for other quinolone antibiotics.", "mechanism_text": "Absorption", "recommendation": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278116/", "reference_text": "[1] Johnson EJ, MacGowan AP, Potter MN, et al. \"Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy.\" J Antimicrob Chemother 25 (1990):  837-42", "alternatives_a": "Bendamustine", "alternatives_b": "Tinidazole, Tetracycline, Cefepime, Fluconazole, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, More", "updated_at": 1767369485}, {"id": 242871, "ingredient1": "Pralsetinib", "ingredient2": "Ofloxacin", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278125/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Enoxacin, Trovafloxacin, Nalidixic acid, Cinoxacin, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, More", "alternatives_b": "Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, Capmatinib, More", "updated_at": 1767369485}, {"id": 242872, "ingredient1": "Floxuridine", "ingredient2": "Bacillus calmette-guerin substrain tice live antigen", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278131/", "reference_text": "[1] \"Product Information. Meruvax II (rubella virus vaccine).\" Merck & Co., Inc  (2022):[2] \"Product Information. Attenuvax (measles virus vaccine).\" Merck & Co., Inc  (2022):[3] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD \"Harrison's Principles of Internal Medicine.\" New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] \"Product Information. DENGVAXIA (dengue vaccine).\" sanofi pasteur  (2022):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242873, "ingredient1": "Ibritumomab tiuxetan", "ingredient2": "Floxuridine", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.  Dosing adjustments may be necessary.  The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278137/", "reference_text": "[1] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb  (2001):[2] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb  (2001):[3] \"Product Information. Fluorouracil (fluorouracil).\" Roche Laboratories  (2022):[4] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn  (2001):[5] \"Product Information. Ellence (epirubicin).\" Pharmacia and Upjohn  (2001):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] Agencia Espala de Medicamentos y Productos Sanitarios Healthcare \"Centro de informaci online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):", "alternatives_a": "Azacitidine, Pralatrexate, Trifluridine", "alternatives_b": "Tositumomab, Iodide I-131", "updated_at": 1767369485}, {"id": 242874, "ingredient1": "Floxuridine", "ingredient2": "Melphalan flufenamide", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.  Dosing adjustments may be necessary.  The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278146/", "reference_text": "[1] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb  (2001):[2] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb  (2001):[3] \"Product Information. Fluorouracil (fluorouracil).\" Roche Laboratories  (2022):[4] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn  (2001):[5] \"Product Information. Ellence (epirubicin).\" Pharmacia and Upjohn  (2001):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] Agencia Espala de Medicamentos y Productos Sanitarios Healthcare \"Centro de informaci online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):", "alternatives_a": "Azacitidine, Pralatrexate, Trifluridine", "alternatives_b": "Uracil mustard", "updated_at": 1767369485}, {"id": 242875, "ingredient1": "Floxuridine", "ingredient2": "Varicella Zoster Vaccine (Recombinant)", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual's risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, the U.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278182/", "reference_text": "[1] \"Product Information. Fluzone (influenza virus vaccine, inactivated).\" Connaught Laboratories Inc[2] \"Product Information. Omnihib (haemophilus b conjugate vaccine (obsolete)).\" SmithKline Beecham[3] \"Product Information. Havrix (hepatitis A adult vaccine).\" SmithKline Beecham[4] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[5] \"Product Information. Imovax Rabies (rabies vaccine, human diploid cell).\" sanofi pasteur  (2022):[6] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc.  (2003):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline  (2022):[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations.  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf\"   (2019):[11] CDC Centers for Disease Control and Prevention \"Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html\"   (2022):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242876, "ingredient1": "Fludarabine", "ingredient2": "Bacillus calmette-guerin substrain tice live antigen", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278183/", "reference_text": "[1] \"Product Information. Meruvax II (rubella virus vaccine).\" Merck & Co., Inc  (2022):[2] \"Product Information. Attenuvax (measles virus vaccine).\" Merck & Co., Inc  (2022):[3] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD \"Harrison's Principles of Internal Medicine.\" New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] \"Product Information. DENGVAXIA (dengue vaccine).\" sanofi pasteur  (2022):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242877, "ingredient1": "Ibritumomab tiuxetan", "ingredient2": "Fludarabine", "severity": "Moderate", "effect": "Administration of radiolabeled ibritumomab tiuxetan (after pretreatment with rituximab) results in severe and prolonged cytopenia that is generally reversible, and the risk may be increased after prior therapy with fludarabine-containing regimens.", "source": "DDInter", "management_text": "Clinicians should be aware that there may be an increased risk of hematologic toxicity when radiolabeled ibritumomab tiuxetan is administered shortly (within 4 months) after fludarabine-containing regimens.  Complete blood cell and platelet counts should be monitored closely in accordance with product labeling recommendations.", "mechanism_text": "Synergism", "recommendation": "Clinicians should be aware that there may be an increased risk of hematologic toxicity when radiolabeled ibritumomab tiuxetan is administered shortly (within 4 months) after fludarabine-containing regimens.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278189/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Azacitidine, Pralatrexate, Trifluridine", "alternatives_b": "Tositumomab, Iodide I-131", "updated_at": 1767369485}, {"id": 242878, "ingredient1": "Fludarabine", "ingredient2": "Melphalan flufenamide", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.  Dosing adjustments may be necessary.  The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278198/", "reference_text": "[1] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb  (2001):[2] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb  (2001):[3] \"Product Information. Fluorouracil (fluorouracil).\" Roche Laboratories  (2022):[4] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn  (2001):[5] \"Product Information. Ellence (epirubicin).\" Pharmacia and Upjohn  (2001):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] Agencia Espala de Medicamentos y Productos Sanitarios Healthcare \"Centro de informaci online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):", "alternatives_a": "Azacitidine, Pralatrexate, Trifluridine", "alternatives_b": "Uracil mustard, Mechlorethamine, Temozolomide", "updated_at": 1767369485}, {"id": 242879, "ingredient1": "Fludarabine", "ingredient2": "Varicella Zoster Vaccine (Recombinant)", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual's risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, the U.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278236/", "reference_text": "[1] \"Product Information. Fluzone (influenza virus vaccine, inactivated).\" Connaught Laboratories Inc[2] \"Product Information. Omnihib (haemophilus b conjugate vaccine (obsolete)).\" SmithKline Beecham[3] \"Product Information. Havrix (hepatitis A adult vaccine).\" SmithKline Beecham[4] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[5] \"Product Information. Imovax Rabies (rabies vaccine, human diploid cell).\" sanofi pasteur  (2022):[6] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc.  (2003):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline  (2022):[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations.  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf\"   (2019):[11] CDC Centers for Disease Control and Prevention \"Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html\"   (2022):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242880, "ingredient1": "Flunisolide", "ingredient2": "Axicabtagene ciloleucel", "severity": "Major", "effect": "Prophylactic use of systemic corticosteroids prior to CD19- or BCMA-directed genetically modified autologous T cell immunotherapy may interfere with the therapeutic effects of such drugs as axicabtagene ciloleucel, brexucabtagene autoleucel, idecabtagene vicleucel, ciltacabtagene autoleucel and lisocabtagene maraleucel.  The mechanism for this interaction has not been delineated.  Administration of systemic corticosteroids in an effort to manage the toxicities associated with these drugs does not affect the expansion and persistence of CAR T cells.", "source": "DDInter", "management_text": "The prophylactic use of systemic corticosteroids prior to CD19- or BCMA-directed genetically modified autologous T cell immunotherapy with drugs such as axicabtagene ciloleucel, brexucabtagene autoleucel, idecabtagene vicleucel, ciltacabtagene autoleucel and lisocabtagene maraleucel is not recommended.  However, systemic corticosteroids may be used for the management of adverse effects associated with these drugs, such as cytokine release syndrome and neurological-related toxicities, without affecting the expansion and persistence of CAR T cells.", "mechanism_text": "Others", "recommendation": "The prophylactic use of systemic corticosteroids prior to CD19- or BCMA-directed genetically modified autologous T cell immunotherapy with drugs such as axicabtagene ciloleucel, brexucabtagene autoleucel, idecabtagene vicleucel, ciltacabtagene autoleucel and lisocabtagene maraleucel is not recommended.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278242/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Yescarta (axicabtagene ciloleucel).\" Kite Pharma, Inc.  (2017):[3] \"Product Information. Tecartus (brexucabtagene autoleucel).\" Kite Pharma, Inc.  (2020):[4] \"Product Information. Breyanzi (lisocabtagene maraleucel).\" Bristol-Myers Squibb  (2021):[5] \"Product Information. Abecma (idecabtagene vicleucel).\" Celgene Corporation  (2021):", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, More", "alternatives_b": "Mupirocin, Mometasone furoate, Epinephrine, Vitamin A, Ephedrine, Olopatadine, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, Phenylephrine, More", "updated_at": 1767369485}, {"id": 242881, "ingredient1": "Fluoxetine", "ingredient2": "Acrivastine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278246/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Chlorcyclizine, Dexchlorpheniramine, Azelastine, Pheniramine", "alternatives_b": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "updated_at": 1767369485}, {"id": 242882, "ingredient1": "Fluoxetine", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278254/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242883, "ingredient1": "Fluoxetine", "ingredient2": "Melatonin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278257/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Vilazodone, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Bupropion, Esketamine", "alternatives_b": "Ethchlorvynol, Nitrazepam", "updated_at": 1767369485}, {"id": 242884, "ingredient1": "Fluoxetine", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278262/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Phenelzine, Duloxetine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Bupropion, More", "alternatives_b": "Dabrafenib, Pexidartinib, Tepotinib, Larotrectinib, Bosutinib, Cobimetinib, Capmatinib, Afatinib, Duvelisib, Tivozanib, Brigatinib, More", "updated_at": 1767369485}, {"id": 242885, "ingredient1": "Fluoxetine", "ingredient2": "Selumetinib", "severity": "Moderate", "effect": "Coadministration with potent or moderate inhibitors of CYP450 2C19 may increase the plasma concentrations of selumetinib, which is primarily metabolized by CYP450 3A4 and to a lesser extent by CYP450 2C19, 1A2, 2C9, 2E1, and 3A5.  Selumetinib's active metabolite, N-desmethyl selumetinib, is generated by CYP450 2C19 and 1A2 with additional contribution by CYP450 2C9 and 2A6, and metabolized through the same routes as selumetinib.", "source": "DDInter", "management_text": "Caution is advised when selumetinib is used with potent or moderate CYP450 2C19 inhibitors.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when selumetinib is used with potent or moderate CYP450 2C19 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278263/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Koselugo (selumetinib).\" Astra-Zeneca Pharmaceuticals  (2020):", "alternatives_a": "Amitriptyline, Citalopram, Sertraline, Maprotiline, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Isocarboxazid, Amoxapine, More", "alternatives_b": "Dabrafenib, Pexidartinib, Tepotinib, Larotrectinib, Bosutinib, Cobimetinib, Capmatinib, Afatinib, Duvelisib, Tivozanib, Brigatinib, More", "updated_at": 1767369485}, {"id": 242886, "ingredient1": "Fluphenazine", "ingredient2": "Melatonin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278282/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Amisulpride, Pimavanserin", "alternatives_b": "Ethchlorvynol, Zopiclone, Nitrazepam", "updated_at": 1767369485}, {"id": 242887, "ingredient1": "Fluphenazine", "ingredient2": "Botulinum toxin type A", "severity": "Moderate", "effect": "Use of anticholinergic drugs after administration of botulinum toxin may potentiate systemic anticholinergic effects such as dry mouth, blurred vision, and urinary disorders.  Botulinum toxin inhibits the release of acetylcholine from peripheral cholinergic nerve endings, thus additive or synergistic anticholinergic effects may occur when these agents are used together.", "source": "DDInter", "management_text": "Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) are used after administration of botulinum toxin.", "mechanism_text": "Synergism", "recommendation": "Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278285/", "reference_text": "[1] \"Product Information. Myobloc (rimabotulinumtoxinB).\" Elan Pharmaceuticals[2] \"Product Information. Dysport (abobotulinumtoxinA).\" Tercica Inc[3] \"Product Information. Botox (onabotulinumtoxinA).\" Allergan Inc[4] \"Product Information. Xeomin (incobotulinumtoxinA).\" Merz Pharmaceuticals  (2022):[5] \"Product Information. Jeuveau (prabotulinumtoxinA).\" Evolus, Inc.  (2022):[6] \"Product Information. Daxxify (daxibotulinumtoxinA).\" Revance Therapeutics, Inc.  (2022):", "alternatives_a": "Quetiapine, Asenapine, Pimavanserin, Ziprasidone, Lumateperone, Iloperidone, Risperidone, Amisulpride, Aripiprazole, Droperidol, Cariprazine, More", "alternatives_b": "Atracurium, Doxacurium, Succinylcholine, Rocuronium, Vecuronium, Tubocurarine, Mivacurium, Pancuronium, Pipecuronium, Cisatracurium", "updated_at": 1767369485}, {"id": 242888, "ingredient1": "Fluphenazine", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278287/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Amisulpride, Loxapine, Molindone, Thiothixene", "alternatives_b": "Dabrafenib, Acalabrutinib, Pexidartinib, Tepotinib, Avapritinib, Larotrectinib, Bosutinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, More", "updated_at": 1767369485}, {"id": 242889, "ingredient1": "Fluphenazine", "ingredient2": "Botulinum toxin type B", "severity": "Moderate", "effect": "Use of anticholinergic drugs after administration of botulinum toxin may potentiate systemic anticholinergic effects such as dry mouth, blurred vision, and urinary disorders.  Botulinum toxin inhibits the release of acetylcholine from peripheral cholinergic nerve endings, thus additive or synergistic anticholinergic effects may occur when these agents are used together.", "source": "DDInter", "management_text": "Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) are used after administration of botulinum toxin.", "mechanism_text": "Synergism", "recommendation": "Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278289/", "reference_text": "[1] \"Product Information. Myobloc (rimabotulinumtoxinB).\" Elan Pharmaceuticals[2] \"Product Information. Dysport (abobotulinumtoxinA).\" Tercica Inc[3] \"Product Information. Botox (onabotulinumtoxinA).\" Allergan Inc[4] \"Product Information. Xeomin (incobotulinumtoxinA).\" Merz Pharmaceuticals  (2022):[5] \"Product Information. Jeuveau (prabotulinumtoxinA).\" Evolus, Inc.  (2022):[6] \"Product Information. Daxxify (daxibotulinumtoxinA).\" Revance Therapeutics, Inc.  (2022):", "alternatives_a": "Quetiapine, Asenapine, Pimavanserin, Ziprasidone, Lumateperone, Iloperidone, Risperidone, Amisulpride, Aripiprazole, Droperidol, Cariprazine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242890, "ingredient1": "Fluvastatin", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278303/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Gemfibrozil, Fenofibric acid, Evinacumab, Evolocumab, Bempedoic acid, Dextrothyroxine, Cholestyramine, Clofibrate, Colestipol, Pravastatin, Niacin, More", "alternatives_b": "Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Bosutinib, Lapatinib, Selumetinib, Ribociclib, Vandetanib, More", "updated_at": 1767369485}, {"id": 242891, "ingredient1": "Fluvoxamine", "ingredient2": "Acrivastine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278306/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Methdilazine, Ketotifen, Meclizine, Chlorcyclizine, Thiethylperazine, Dexchlorpheniramine, Phenindamine, Desloratadine, Azelastine, Pheniramine", "alternatives_b": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "updated_at": 1767369485}, {"id": 242892, "ingredient1": "Fluvoxamine", "ingredient2": "Cyclizine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278309/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Methdilazine, Ketotifen, Meclizine, Chlorcyclizine, Thiethylperazine, Dexchlorpheniramine, Phenindamine, Desloratadine, Azelastine, Pheniramine", "alternatives_b": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "updated_at": 1767369485}, {"id": 242893, "ingredient1": "Fluvoxamine", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278317/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "alternatives_b": "Apomorphine", "updated_at": 1767369485}, {"id": 242894, "ingredient1": "Bacillus calmette-guerin substrain tice live antigen", "ingredient2": "Pralatrexate", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278326/", "reference_text": "[1] \"Product Information. Meruvax II (rubella virus vaccine).\" Merck & Co., Inc  (2022):[2] \"Product Information. Attenuvax (measles virus vaccine).\" Merck & Co., Inc  (2022):[3] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD \"Harrison's Principles of Internal Medicine.\" New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] \"Product Information. DENGVAXIA (dengue vaccine).\" sanofi pasteur  (2022):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242895, "ingredient1": "Varicella Zoster Vaccine (Recombinant)", "ingredient2": "Pralatrexate", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual's risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, the U.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278377/", "reference_text": "[1] \"Product Information. Fluzone (influenza virus vaccine, inactivated).\" Connaught Laboratories Inc[2] \"Product Information. Omnihib (haemophilus b conjugate vaccine (obsolete)).\" SmithKline Beecham[3] \"Product Information. Havrix (hepatitis A adult vaccine).\" SmithKline Beecham[4] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[5] \"Product Information. Imovax Rabies (rabies vaccine, human diploid cell).\" sanofi pasteur  (2022):[6] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc.  (2003):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline  (2022):[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations.  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf\"   (2019):[11] CDC Centers for Disease Control and Prevention \"Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html\"   (2022):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242896, "ingredient1": "Insulin human", "ingredient2": "Formoterol", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, sirolimus, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents.  These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.  Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.  Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.  Likewise, patients should be observed for hypoglycemia when these drugs are withdrawn from their therapeutic regimen.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278380/", "reference_text": "[1] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987):  761-4[2] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989):  868-73[3] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981):  1508-12[4] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991):  968-70[5] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988):  427-9[6] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969):  556-60[7] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978):  1887-8[8] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969):  1372-9[9] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968):  798-801[10] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972):  1592-3[11] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970):  13-6[12] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972):  1741-2[13] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967):  209-10[14] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989):  462-3[15] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980):  135-8[16] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982):  1293-5[17] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969):  19-28[18] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966):  623-4[19] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977):  15-8[20] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham  (2002):[21] \"Product Information. Diabinese (chlorpropamide).\" Pfizer U.S. Pharmaceuticals  (2002):[22] \"Product Information. Glucotrol (glipizide).\" Pfizer U.S. Pharmaceuticals  (2002):[23] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[24] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical  (2002):[25] \"Product Information. Carafate (sucralfate).\" Hoechst Marion Roussel  (2001):[26] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974):  679-83[27] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972):  339-42[28] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968):  443-56[29] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973):  438-41[30] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993):  99-103,[31] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993):  860[32] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985):  25-6[33] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and  their effects on some metabolic parameters.\" Contraception 39 (1989):  619-32[34] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term  users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986):  291-6[35] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993):  557-9[36] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969):  172-8[37] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989):  1315-6[38] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989):  71-4[39] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993):  84-7[40] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968):  188[41] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974):  85-90[42] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986):  631-6[43] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981):  154-63[44] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983):  79-83[45] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980):  611-8[46] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986):  151-5[47] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb  (2001):[48] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995):  853-9[49] \"Product Information. Precose (acarbose).\" Bayer  (2001):[50] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical  (2001):[51] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion Roussel  (2001):[52] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993):  809-10[53] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990):  474-5[54] \"Product Information. Crixivan (indinavir).\" Merck & Co., Inc  (2001):[55] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996):  861-4[56] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc  (2001):[57] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997):  713-4[58] \"Product Information. Oncaspar (pegaspargase).\" Rhone Poulenc Rorer  (2001):[59] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc  (2001):[60] \"Product Information. Elspar (asparaginase).\" Merck & Co., Inc  (2001):[61] \"Product Information. Hyperstat (diazoxide).\" Apothecon Inc  (2022):[62] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb  (2001):[63] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998):  837-8[64] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome  (2001):[65] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999):  162-3[66] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999):  114-7[67] \"Product Information. Tolinase (tolazamide).\" Pharmacia and Upjohn  (2001):[68] \"Product Information. Orinase (tolbutamide).\" Pharmacia and Upjohn  (2001):[69] \"Product Information. Dymelor (acetohexamide).\" Lilly, Eli and Company  (2001):[70] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000):  844-7[71] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000):  2050-6[72] \"Product Information. Fortovase (saquinavir).\" Roche Laboratories  (2001):[73] \"Product Information. Starlix (nateglinide).\" Novartis Pharmaceuticals  (2001):[74] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001):  343-51[75] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984):  455-61[76] \"Product Information. NovoLOG Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc  (2022):[77] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb  (2003):[78] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline  (2003):[79] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[80] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc  (2006):[81] \"Product Information. Zolinza (vorinostat).\" Merck & Co., Inc  (2006):[82] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories  (2007):[83] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):[84] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics  (2019):[85] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals  (2019):", "alternatives_a": "Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Fluticasone, Cromoglicic acid, Ipratropium, Pirbuterol, Bitolterol, Olodaterol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242897, "ingredient1": "Formoterol", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278384/", "reference_text": "[1] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987):  65-71[2] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977):  861-9[3] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978):  767-9[4] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981):  500-1[5] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986):  619-20[6] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990):  1396-9[7] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980):  1225-6[8] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990):  575-9[9] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981):  723-5[10] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982):  726-32[11] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988):  763-6[12] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977):  174-9[13] \"Product Information. Proventil (albuterol).\" Schering Corporation  (2002):[14] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990):  259-61[15] \"Product Information. Serevent (salmeterol).\" Glaxo Wellcome[16] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals  (2001):[17] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994):  729-33[18] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994):  1654-9[19] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997):  1867-75[20] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998):  145-7[21] \"Product Information. Xopenex (levalbuterol).\" Sepracor Inc  (2001):[22] \"Product Information. Foradil (formoterol).\" Novartis Pharmaceuticals  (2001):[23] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003):  1817-24[24] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006):  582-90[25] \"Product Information. Brovana (arformoterol).\" Sepracor Inc  (2006):[26] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001):  45-51[27] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998):  1400-5[28] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals  (2011):[29] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline  (2013):[30] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim  (2014):", "alternatives_a": "Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Epinephrine, Cromoglicic acid, Ipratropium, Tiotropium, Beclomethasone dipropionate, Ephedrine", "alternatives_b": "Imatinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, More", "updated_at": 1767369485}, {"id": 242898, "ingredient1": "Foscarnet", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278416/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Lamivudine, Cabotegravir, Zanamivir, Valaciclovir, Dolutegravir, Oseltamivir, Acyclovir, Stavudine, Remdesivir, Elbasvir, Famciclovir, More", "alternatives_b": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Ribociclib, More", "updated_at": 1767369485}, {"id": 242899, "ingredient1": "Fospropofol", "ingredient2": "Chloral hydrate", "severity": "Moderate", "effect": "Additive central nervous system and cardiorespiratory depressant effects may occur when fospropofol or propofol is administered with other depressants such as sedative-hypnotic agents and narcotic analgesics.", "source": "DDInter", "management_text": "Patients should be monitored closely for excessive sedation and cardiorespiratory depression, and the medication dosage(s) adjusted accordingly.  Supportive therapy should be provided if needed.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for excessive sedation and cardiorespiratory depression, and the medication dosage(s) adjusted accordingly.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278444/", "reference_text": "[1] McClune S, McKay AC, Wright PM, et al. \"Synergistic interaction between midazolam and propofol.\" Br J Anaesth 69 (1992):  240-5[2] Gill SS, Wright EM, Reilly CS \"Pharmacokinetic interaction of propofol and fentanyl: single bolus injection study.\" Br J Anaesth 65 (1990):  760-5[3] \"Product Information. Diprivan (propofol).\" Astra-Zeneca Pharmaceuticals  (2001):[4] Pavlin DJ, Coda B, Shen DD, et al. \"Effects of combining propofol and alfentanil on ventilation, analgesia, sedation, and emesis in human volunteers.\" Anesthesiology 84 (1996):  23-37[5] Hamaoka N, Oda Y, Hase I, Mizutani K, Nakamoto T, Ishizaki T, Asada A \"Propofol decreases the clearance of midazolam by inhibiting CYP3A4: An in vivo and in vitro study.\" Clin Pharmacol Ther 66 (1999):  110-7[6] \"Product Information. Lusedra (fospropofol).\" Eisai Inc  (2008):", "alternatives_a": "Nitrazepam, Butalbital, Scopolamine, Zopiclone, Melatonin, Primidone, Valerian", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242900, "ingredient1": "Fospropofol", "ingredient2": "Chlormezanone", "severity": "Moderate", "effect": "Additive central nervous system and cardiorespiratory depressant effects may occur when fospropofol or propofol is administered with other depressants such as sedative-hypnotic agents and narcotic analgesics.", "source": "DDInter", "management_text": "Patients should be monitored closely for excessive sedation and cardiorespiratory depression, and the medication dosage(s) adjusted accordingly.  Supportive therapy should be provided if needed.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for excessive sedation and cardiorespiratory depression, and the medication dosage(s) adjusted accordingly.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278445/", "reference_text": "[1] McClune S, McKay AC, Wright PM, et al. \"Synergistic interaction between midazolam and propofol.\" Br J Anaesth 69 (1992):  240-5[2] Gill SS, Wright EM, Reilly CS \"Pharmacokinetic interaction of propofol and fentanyl: single bolus injection study.\" Br J Anaesth 65 (1990):  760-5[3] \"Product Information. Diprivan (propofol).\" Astra-Zeneca Pharmaceuticals  (2001):[4] Pavlin DJ, Coda B, Shen DD, et al. \"Effects of combining propofol and alfentanil on ventilation, analgesia, sedation, and emesis in human volunteers.\" Anesthesiology 84 (1996):  23-37[5] Hamaoka N, Oda Y, Hase I, Mizutani K, Nakamoto T, Ishizaki T, Asada A \"Propofol decreases the clearance of midazolam by inhibiting CYP3A4: An in vivo and in vitro study.\" Clin Pharmacol Ther 66 (1999):  110-7[6] \"Product Information. Lusedra (fospropofol).\" Eisai Inc  (2008):", "alternatives_a": "Carisoprodol, Orphenadrine, Chlorzoxazone, Tizanidine, Cyclobenzaprine, Methocarbamol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242901, "ingredient1": "Fospropofol", "ingredient2": "Dezocine", "severity": "Moderate", "effect": "Additive central nervous system and cardiorespiratory depressant effects may occur when fospropofol or propofol is administered with other depressants such as sedative-hypnotic agents and narcotic analgesics.", "source": "DDInter", "management_text": "Patients should be monitored closely for excessive sedation and cardiorespiratory depression, and the medication dosage(s) adjusted accordingly.  Supportive therapy should be provided if needed.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for excessive sedation and cardiorespiratory depression, and the medication dosage(s) adjusted accordingly.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278446/", "reference_text": "[1] McClune S, McKay AC, Wright PM, et al. \"Synergistic interaction between midazolam and propofol.\" Br J Anaesth 69 (1992):  240-5[2] Gill SS, Wright EM, Reilly CS \"Pharmacokinetic interaction of propofol and fentanyl: single bolus injection study.\" Br J Anaesth 65 (1990):  760-5[3] \"Product Information. Diprivan (propofol).\" Astra-Zeneca Pharmaceuticals  (2001):[4] Pavlin DJ, Coda B, Shen DD, et al. \"Effects of combining propofol and alfentanil on ventilation, analgesia, sedation, and emesis in human volunteers.\" Anesthesiology 84 (1996):  23-37[5] Hamaoka N, Oda Y, Hase I, Mizutani K, Nakamoto T, Ishizaki T, Asada A \"Propofol decreases the clearance of midazolam by inhibiting CYP3A4: An in vivo and in vitro study.\" Clin Pharmacol Ther 66 (1999):  110-7[6] \"Product Information. Lusedra (fospropofol).\" Eisai Inc  (2008):", "alternatives_a": "Naltrexone, Tapentadol, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242902, "ingredient1": "Halazepam", "ingredient2": "Fospropofol", "severity": "Moderate", "effect": "Additive central nervous system and cardiorespiratory depressant effects may occur when fospropofol or propofol is administered with other depressants such as sedative-hypnotic agents and narcotic analgesics.", "source": "DDInter", "management_text": "Patients should be monitored closely for excessive sedation and cardiorespiratory depression, and the medication dosage(s) adjusted accordingly.  Supportive therapy should be provided if needed.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for excessive sedation and cardiorespiratory depression, and the medication dosage(s) adjusted accordingly.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278447/", "reference_text": "[1] McClune S, McKay AC, Wright PM, et al. \"Synergistic interaction between midazolam and propofol.\" Br J Anaesth 69 (1992):  240-5[2] Gill SS, Wright EM, Reilly CS \"Pharmacokinetic interaction of propofol and fentanyl: single bolus injection study.\" Br J Anaesth 65 (1990):  760-5[3] \"Product Information. Diprivan (propofol).\" Astra-Zeneca Pharmaceuticals  (2001):[4] Pavlin DJ, Coda B, Shen DD, et al. \"Effects of combining propofol and alfentanil on ventilation, analgesia, sedation, and emesis in human volunteers.\" Anesthesiology 84 (1996):  23-37[5] Hamaoka N, Oda Y, Hase I, Mizutani K, Nakamoto T, Ishizaki T, Asada A \"Propofol decreases the clearance of midazolam by inhibiting CYP3A4: An in vivo and in vitro study.\" Clin Pharmacol Ther 66 (1999):  110-7[6] \"Product Information. Lusedra (fospropofol).\" Eisai Inc  (2008):", "alternatives_a": "Hydroxyzine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242903, "ingredient1": "Fospropofol", "ingredient2": "Diamorphine", "severity": "Moderate", "effect": "Additive central nervous system and cardiorespiratory depressant effects may occur when fospropofol or propofol is administered with other depressants such as sedative-hypnotic agents and narcotic analgesics.", "source": "DDInter", "management_text": "Patients should be monitored closely for excessive sedation and cardiorespiratory depression, and the medication dosage(s) adjusted accordingly.  Supportive therapy should be provided if needed.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for excessive sedation and cardiorespiratory depression, and the medication dosage(s) adjusted accordingly.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278448/", "reference_text": "[1] McClune S, McKay AC, Wright PM, et al. \"Synergistic interaction between midazolam and propofol.\" Br J Anaesth 69 (1992):  240-5[2] Gill SS, Wright EM, Reilly CS \"Pharmacokinetic interaction of propofol and fentanyl: single bolus injection study.\" Br J Anaesth 65 (1990):  760-5[3] \"Product Information. Diprivan (propofol).\" Astra-Zeneca Pharmaceuticals  (2001):[4] Pavlin DJ, Coda B, Shen DD, et al. \"Effects of combining propofol and alfentanil on ventilation, analgesia, sedation, and emesis in human volunteers.\" Anesthesiology 84 (1996):  23-37[5] Hamaoka N, Oda Y, Hase I, Mizutani K, Nakamoto T, Ishizaki T, Asada A \"Propofol decreases the clearance of midazolam by inhibiting CYP3A4: An in vivo and in vitro study.\" Clin Pharmacol Ther 66 (1999):  110-7[6] \"Product Information. Lusedra (fospropofol).\" Eisai Inc  (2008):", "alternatives_a": "Acamprosate, Lofexidine, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242904, "ingredient1": "Fospropofol", "ingredient2": "Levacetylmethadol", "severity": "Moderate", "effect": "Additive central nervous system and cardiorespiratory depressant effects may occur when fospropofol or propofol is administered with other depressants such as sedative-hypnotic agents and narcotic analgesics.", "source": "DDInter", "management_text": "Patients should be monitored closely for excessive sedation and cardiorespiratory depression, and the medication dosage(s) adjusted accordingly.  Supportive therapy should be provided if needed.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for excessive sedation and cardiorespiratory depression, and the medication dosage(s) adjusted accordingly.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278449/", "reference_text": "[1] McClune S, McKay AC, Wright PM, et al. \"Synergistic interaction between midazolam and propofol.\" Br J Anaesth 69 (1992):  240-5[2] Gill SS, Wright EM, Reilly CS \"Pharmacokinetic interaction of propofol and fentanyl: single bolus injection study.\" Br J Anaesth 65 (1990):  760-5[3] \"Product Information. Diprivan (propofol).\" Astra-Zeneca Pharmaceuticals  (2001):[4] Pavlin DJ, Coda B, Shen DD, et al. \"Effects of combining propofol and alfentanil on ventilation, analgesia, sedation, and emesis in human volunteers.\" Anesthesiology 84 (1996):  23-37[5] Hamaoka N, Oda Y, Hase I, Mizutani K, Nakamoto T, Ishizaki T, Asada A \"Propofol decreases the clearance of midazolam by inhibiting CYP3A4: An in vivo and in vitro study.\" Clin Pharmacol Ther 66 (1999):  110-7[6] \"Product Information. Lusedra (fospropofol).\" Eisai Inc  (2008):", "alternatives_a": "Acamprosate, Lofexidine, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242905, "ingredient1": "Fospropofol", "ingredient2": "Methoxyflurane", "severity": "Moderate", "effect": "Additive central nervous system and cardiorespiratory depressant effects may occur when fospropofol or propofol is administered with other depressants such as sedative-hypnotic agents and narcotic analgesics.", "source": "DDInter", "management_text": "Patients should be monitored closely for excessive sedation and cardiorespiratory depression, and the medication dosage(s) adjusted accordingly.  Supportive therapy should be provided if needed.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for excessive sedation and cardiorespiratory depression, and the medication dosage(s) adjusted accordingly.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278450/", "reference_text": "[1] McClune S, McKay AC, Wright PM, et al. \"Synergistic interaction between midazolam and propofol.\" Br J Anaesth 69 (1992):  240-5[2] Gill SS, Wright EM, Reilly CS \"Pharmacokinetic interaction of propofol and fentanyl: single bolus injection study.\" Br J Anaesth 65 (1990):  760-5[3] \"Product Information. Diprivan (propofol).\" Astra-Zeneca Pharmaceuticals  (2001):[4] Pavlin DJ, Coda B, Shen DD, et al. \"Effects of combining propofol and alfentanil on ventilation, analgesia, sedation, and emesis in human volunteers.\" Anesthesiology 84 (1996):  23-37[5] Hamaoka N, Oda Y, Hase I, Mizutani K, Nakamoto T, Ishizaki T, Asada A \"Propofol decreases the clearance of midazolam by inhibiting CYP3A4: An in vivo and in vitro study.\" Clin Pharmacol Ther 66 (1999):  110-7[6] \"Product Information. Lusedra (fospropofol).\" Eisai Inc  (2008):", "alternatives_a": "Salicylic acid, Acetaminophen, Choline salicylate, Ziconotide, Diflunisal, Salsalate, Acetylsalicylic acid", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242906, "ingredient1": "Fospropofol", "ingredient2": "Paraldehyde", "severity": "Moderate", "effect": "Additive central nervous system and cardiorespiratory depressant effects may occur when fospropofol or propofol is administered with other depressants such as sedative-hypnotic agents and narcotic analgesics.", "source": "DDInter", "management_text": "Patients should be monitored closely for excessive sedation and cardiorespiratory depression, and the medication dosage(s) adjusted accordingly.  Supportive therapy should be provided if needed.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for excessive sedation and cardiorespiratory depression, and the medication dosage(s) adjusted accordingly.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278451/", "reference_text": "[1] McClune S, McKay AC, Wright PM, et al. \"Synergistic interaction between midazolam and propofol.\" Br J Anaesth 69 (1992):  240-5[2] Gill SS, Wright EM, Reilly CS \"Pharmacokinetic interaction of propofol and fentanyl: single bolus injection study.\" Br J Anaesth 65 (1990):  760-5[3] \"Product Information. Diprivan (propofol).\" Astra-Zeneca Pharmaceuticals  (2001):[4] Pavlin DJ, Coda B, Shen DD, et al. \"Effects of combining propofol and alfentanil on ventilation, analgesia, sedation, and emesis in human volunteers.\" Anesthesiology 84 (1996):  23-37[5] Hamaoka N, Oda Y, Hase I, Mizutani K, Nakamoto T, Ishizaki T, Asada A \"Propofol decreases the clearance of midazolam by inhibiting CYP3A4: An in vivo and in vitro study.\" Clin Pharmacol Ther 66 (1999):  110-7[6] \"Product Information. Lusedra (fospropofol).\" Eisai Inc  (2008):", "alternatives_a": "Nitrazepam, Butalbital, Scopolamine, Zopiclone, Melatonin, Primidone, Valerian", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242907, "ingredient1": "Fospropofol", "ingredient2": "Propiomazine", "severity": "Moderate", "effect": "Additive central nervous system and cardiorespiratory depressant effects may occur when fospropofol or propofol is administered with other depressants such as sedative-hypnotic agents and narcotic analgesics.", "source": "DDInter", "management_text": "Patients should be monitored closely for excessive sedation and cardiorespiratory depression, and the medication dosage(s) adjusted accordingly.  Supportive therapy should be provided if needed.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for excessive sedation and cardiorespiratory depression, and the medication dosage(s) adjusted accordingly.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278452/", "reference_text": "[1] McClune S, McKay AC, Wright PM, et al. \"Synergistic interaction between midazolam and propofol.\" Br J Anaesth 69 (1992):  240-5[2] Gill SS, Wright EM, Reilly CS \"Pharmacokinetic interaction of propofol and fentanyl: single bolus injection study.\" Br J Anaesth 65 (1990):  760-5[3] \"Product Information. Diprivan (propofol).\" Astra-Zeneca Pharmaceuticals  (2001):[4] Pavlin DJ, Coda B, Shen DD, et al. \"Effects of combining propofol and alfentanil on ventilation, analgesia, sedation, and emesis in human volunteers.\" Anesthesiology 84 (1996):  23-37[5] Hamaoka N, Oda Y, Hase I, Mizutani K, Nakamoto T, Ishizaki T, Asada A \"Propofol decreases the clearance of midazolam by inhibiting CYP3A4: An in vivo and in vitro study.\" Clin Pharmacol Ther 66 (1999):  110-7[6] \"Product Information. Lusedra (fospropofol).\" Eisai Inc  (2008):", "alternatives_a": "Nitrazepam, Butalbital, Scopolamine, Zopiclone, Melatonin, Primidone, Valerian", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242908, "ingredient1": "Fospropofol", "ingredient2": "Thiopental", "severity": "Moderate", "effect": "Additive central nervous system and cardiorespiratory depressant effects may occur when fospropofol or propofol is administered with other depressants such as sedative-hypnotic agents and narcotic analgesics.", "source": "DDInter", "management_text": "Patients should be monitored closely for excessive sedation and cardiorespiratory depression, and the medication dosage(s) adjusted accordingly.  Supportive therapy should be provided if needed.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for excessive sedation and cardiorespiratory depression, and the medication dosage(s) adjusted accordingly.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278453/", "reference_text": "[1] McClune S, McKay AC, Wright PM, et al. \"Synergistic interaction between midazolam and propofol.\" Br J Anaesth 69 (1992):  240-5[2] Gill SS, Wright EM, Reilly CS \"Pharmacokinetic interaction of propofol and fentanyl: single bolus injection study.\" Br J Anaesth 65 (1990):  760-5[3] \"Product Information. Diprivan (propofol).\" Astra-Zeneca Pharmaceuticals  (2001):[4] Pavlin DJ, Coda B, Shen DD, et al. \"Effects of combining propofol and alfentanil on ventilation, analgesia, sedation, and emesis in human volunteers.\" Anesthesiology 84 (1996):  23-37[5] Hamaoka N, Oda Y, Hase I, Mizutani K, Nakamoto T, Ishizaki T, Asada A \"Propofol decreases the clearance of midazolam by inhibiting CYP3A4: An in vivo and in vitro study.\" Clin Pharmacol Ther 66 (1999):  110-7[6] \"Product Information. Lusedra (fospropofol).\" Eisai Inc  (2008):", "alternatives_a": "Propofol, Nitrazepam, Butalbital, Scopolamine, Zopiclone, Melatonin, Primidone, Valerian", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242909, "ingredient1": "Fostamatinib", "ingredient2": "Osilodrostat", "severity": "Moderate", "effect": "Coadministration of fostamatinib with inhibitors of CYP450 3A4 may increase exposure to the active metabolite known as R406, the predominant moiety in the systemic circulation following fostamatinib administration.  Fostamatinib is metabolized in the gut by alkaline phosphatase to R406, which then undergoes oxidation via CYP450 3A4 and glucuronidation via UGT1A9.  In vitro, R406 is also a substrate of the P-glycoprotein (P-gp) efflux transporter.", "source": "DDInter", "management_text": "Patients should be monitored for toxicities of fostamatinib during concomitant use of potent or moderate CYP450 3A4 inhibitors or dual CYP450 3A4/P-gp inhibitors, and the fostamatinib dosage adjusted as necessary in accordance with the product labeling.", "mechanism_text": "Metabolism", "recommendation": "Patients should be monitored for toxicities of fostamatinib during concomitant use of potent or moderate CYP450 3A4 inhibitors or dual CYP450 3A4/P-gp inhibitors, and the fostamatinib dosage adjusted as necessary in accordance with the product labeling.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278466/", "reference_text": "[1] \"Product Information. Tavalisse (fostamatinib).\" Rigel Pharmaceuticals  (2018):", "alternatives_a": "Eltrombopag, Romiplostim, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Epinephrine, Coagulation Factor IX Human", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242910, "ingredient1": "Fostemsavir", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278476/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Lamivudine, Cabotegravir, Zanamivir, Valaciclovir, Dolutegravir, Oseltamivir, Acyclovir, Stavudine, Remdesivir, Elbasvir, Famciclovir, More", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Fedratinib, Larotrectinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Duvelisib, More", "updated_at": 1767369485}, {"id": 242911, "ingredient1": "Ethinylestradiol", "ingredient2": "Tivozanib", "severity": "Moderate", "effect": "Coadministration with tivozanib may decrease the efficacy of contraceptive hormones.", "source": "DDInter", "management_text": "Until more information is known, caution is advised when tivozanib is prescribed concomitantly with hormonal contraceptives.  Some authorities recommend that female patients of childbearing potential use an additional method of contraception.  An acceptable barrier method (e.g., diaphragm with spermicide, cervical cap with spermicide, contraceptive sponge, male condom, female condom) in addition to the hormonal contraceptive of choice may be advisable during the duration of tivozanib therapy and for at least one month after completing therapy.", "mechanism_text": "Antagonism", "recommendation": "Until more information is known, caution is advised when tivozanib is prescribed concomitantly with hormonal contraceptives.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278483/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Fotivda (tivozanib).\" Aveo Pharmaceuticals, Inc.  (2021):", "alternatives_a": "Megestrol acetate, Estetrol, Ulipristal, Estradiol, Diethylstilbestrol, Histrelin, Megestrol acetate, Leuprolide, Bicalutamide, Triptorelin, Goserelin, More", "alternatives_b": "Acalabrutinib, Dacomitinib, Avapritinib, Bosutinib, Ribociclib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Zanubrutinib, More", "updated_at": 1767369485}, {"id": 242912, "ingredient1": "Imatinib", "ingredient2": "Tivozanib", "severity": "Moderate", "effect": "Coadministration with tivozanib may increase the plasma concentrations and therapeutic effects of drugs that are substrates of the breast cancer resistance protein (BCRP) transporter.  The proposed mechanism, based on in vitro data, is decreased clearance due to inhibition of BCRP-mediated intestinal efflux by tivozanib.", "source": "DDInter", "management_text": "Caution and clinical monitoring are advised if tivozanib is prescribed with orally administered drugs that are sensitive substrates for BCRP, such as rosuvastatin.  If coadministration is necessary, the manufacturer suggests separating the administration times by 2 or more hours.", "mechanism_text": "Absorption", "recommendation": "Caution and clinical monitoring are advised if tivozanib is prescribed with orally administered drugs that are sensitive substrates for BCRP, such as rosuvastatin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278484/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Fotivda (tivozanib).\" Aveo Pharmaceuticals, Inc.  (2021):", "alternatives_a": "Entrectinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Bosutinib, Selumetinib, More", "alternatives_b": "Sunitinib, Regorafenib, Imatinib, Lenvatinib, Erlotinib, Trametinib, Nintedanib, Vandetanib, Afatinib, Alectinib, Dacomitinib, More", "updated_at": 1767369485}, {"id": 242913, "ingredient1": "Tivozanib", "ingredient2": "Lapatinib", "severity": "Moderate", "effect": "Coadministration with tivozanib may increase the plasma concentrations and therapeutic effects of drugs that are substrates of the breast cancer resistance protein (BCRP) transporter.  The proposed mechanism, based on in vitro data, is decreased clearance due to inhibition of BCRP-mediated intestinal efflux by tivozanib.", "source": "DDInter", "management_text": "Caution and clinical monitoring are advised if tivozanib is prescribed with orally administered drugs that are sensitive substrates for BCRP, such as rosuvastatin.  If coadministration is necessary, the manufacturer suggests separating the administration times by 2 or more hours.", "mechanism_text": "Absorption", "recommendation": "Caution and clinical monitoring are advised if tivozanib is prescribed with orally administered drugs that are sensitive substrates for BCRP, such as rosuvastatin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278485/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Fotivda (tivozanib).\" Aveo Pharmaceuticals, Inc.  (2021):", "alternatives_a": "Entrectinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Bosutinib, Selumetinib, More", "alternatives_b": "Regorafenib, Bosutinib, Lapatinib, Trametinib, Dacomitinib, Alectinib", "updated_at": 1767369485}, {"id": 242914, "ingredient1": "Tivozanib", "ingredient2": "Larotrectinib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4, P-glycoprotein (P-gp), and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of larotrectinib.", "source": "DDInter", "management_text": "Caution is advised when larotrectinib is used with CYP450 3A4, P-gp, and/or BCRP inhibitors.  Patients should be monitored more frequently for adverse effects such as neurotoxicity (delirium, dysarthria, dizziness, gait disturbance, paraesthesia, encephalopathy, memory impairment, tremor) and hepatotoxicity (elevations in liver transaminases), and the larotrectinib dosage adjusted based on severity of emergent adverse reactions in accordance with the product labeling.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when larotrectinib is used with CYP450 3A4, P-gp, and/or BCRP inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278486/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Vitrakvi (larotrectinib).\" Bayer Pharmaceutical Inc  (2022):", "alternatives_a": "Entrectinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Bosutinib, Selumetinib, More", "alternatives_b": "Larotrectinib, Lenvatinib, Erdafitinib, Neratinib, Trametinib, Afatinib, Dacomitinib, Alectinib, Binimetinib", "updated_at": 1767369485}, {"id": 242915, "ingredient1": "Tivozanib", "ingredient2": "Lusutrombopag", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of lusutrombopag, which is a substrate of both efflux transporter proteins.", "source": "DDInter", "management_text": "Caution is advised if lusutrombopag is prescribed in combination with P-gp and/or BCRP inhibitors.  Pharmacologic response to lusutrombopag should be monitored more closely following initiation, discontinuation, or change of dosage of the concomitant P-gp or BCRP inhibitor.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if lusutrombopag is prescribed in combination with P-gp and/or BCRP inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278488/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\"   (2013):", "alternatives_a": "Eltrombopag, Romiplostim, Fostamatinib, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, More", "alternatives_b": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, Selumetinib, Cobimetinib, More", "updated_at": 1767369485}, {"id": 242916, "ingredient1": "Tivozanib", "ingredient2": "Mitotane", "severity": "Major", "effect": "Coadministration of tivozanib with strong CYP450 3A4 inducers may decrease the plasma concentrations and therapeutic effects of tivozanib, which has been shown to be a substrate of the isoenzyme.", "source": "DDInter", "management_text": "Due to the potential for reduced anti-tumor activity, concomitant use of tivozanib with a strong CYP450 3A4 inducer should generally be avoided.  If coadministration is necessary, some authorities advise caution, with clinical and laboratory monitoring to be considered whenever a strong CYP450 3A4 inducer is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Due to the potential for reduced anti-tumor activity, concomitant use of tivozanib with a strong CYP450 3A4 inducer should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278489/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Fotivda (tivozanib).\" Aveo Pharmaceuticals, Inc.  (2021):", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, More", "alternatives_b": "Futibatinib, Lenvatinib, Trametinib, Ribociclib, Afatinib, Dacomitinib, Alectinib, Binimetinib", "updated_at": 1767369485}, {"id": 242917, "ingredient1": "Tivozanib", "ingredient2": "Norgestrel", "severity": "Moderate", "effect": "Coadministration with tivozanib may decrease the efficacy of contraceptive hormones.", "source": "DDInter", "management_text": "Until more information is known, caution is advised when tivozanib is prescribed concomitantly with hormonal contraceptives.  Some authorities recommend that female patients of childbearing potential use an additional method of contraception.  An acceptable barrier method (e.g., diaphragm with spermicide, cervical cap with spermicide, contraceptive sponge, male condom, female condom) in addition to the hormonal contraceptive of choice may be advisable during the duration of tivozanib therapy and for at least one month after completing therapy.", "mechanism_text": "Antagonism", "recommendation": "Until more information is known, caution is advised when tivozanib is prescribed concomitantly with hormonal contraceptives.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278490/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Fotivda (tivozanib).\" Aveo Pharmaceuticals, Inc.  (2021):", "alternatives_a": "Megestrol acetate, Progesterone, Estradiol, Megestrol acetate, Estetrol, Ulipristal, Estradiol", "alternatives_b": "Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Ribociclib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, More", "updated_at": 1767369485}, {"id": 242918, "ingredient1": "Tivozanib", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278493/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Entrectinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Bosutinib, Selumetinib, More", "alternatives_b": "Copanlisib, Abemaciclib, Erdafitinib, Neratinib, Erlotinib, Pralsetinib, Dacomitinib, Alectinib, Binimetinib", "updated_at": 1767369485}, {"id": 242919, "ingredient1": "Tivozanib", "ingredient2": "Primidone", "severity": "Major", "effect": "Coadministration of tivozanib with strong CYP450 3A4 inducers may decrease the plasma concentrations and therapeutic effects of tivozanib, which has been shown to be a substrate of the isoenzyme.", "source": "DDInter", "management_text": "Due to the potential for reduced anti-tumor activity, concomitant use of tivozanib with a strong CYP450 3A4 inducer should generally be avoided.  If coadministration is necessary, some authorities advise caution, with clinical and laboratory monitoring to be considered whenever a strong CYP450 3A4 inducer is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Due to the potential for reduced anti-tumor activity, concomitant use of tivozanib with a strong CYP450 3A4 inducer should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278494/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Fotivda (tivozanib).\" Aveo Pharmaceuticals, Inc.  (2021):", "alternatives_a": "Suvorexant, Triazolam, Flurazepam, Methohexital, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, More", "alternatives_b": "Futibatinib, Lenvatinib, Trametinib, Dacomitinib, Alectinib", "updated_at": 1767369485}, {"id": 242920, "ingredient1": "Tivozanib", "ingredient2": "Rifabutin", "severity": "Major", "effect": "Coadministration of tivozanib with strong CYP450 3A4 inducers may decrease the plasma concentrations and therapeutic effects of tivozanib, which has been shown to be a substrate of the isoenzyme.", "source": "DDInter", "management_text": "Due to the potential for reduced anti-tumor activity, concomitant use of tivozanib with a strong CYP450 3A4 inducer should generally be avoided.  If coadministration is necessary, some authorities advise caution, with clinical and laboratory monitoring to be considered whenever a strong CYP450 3A4 inducer is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Due to the potential for reduced anti-tumor activity, concomitant use of tivozanib with a strong CYP450 3A4 inducer should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278495/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Fotivda (tivozanib).\" Aveo Pharmaceuticals, Inc.  (2021):", "alternatives_a": "Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Streptomycin, Trimethoprim, Cycloserine, Isoniazid, Ethambutol, Pyridoxine, More", "alternatives_b": "Futibatinib, Lenvatinib, Trametinib, Nintedanib, Dacomitinib, Alectinib, Binimetinib", "updated_at": 1767369485}, {"id": 242921, "ingredient1": "Tivozanib", "ingredient2": "Rifampicin", "severity": "Major", "effect": "Coadministration of tivozanib with strong CYP450 3A4 inducers may decrease the plasma concentrations and therapeutic effects of tivozanib, which has been shown to be a substrate of the isoenzyme.", "source": "DDInter", "management_text": "Due to the potential for reduced anti-tumor activity, concomitant use of tivozanib with a strong CYP450 3A4 inducer should generally be avoided.  If coadministration is necessary, some authorities advise caution, with clinical and laboratory monitoring to be considered whenever a strong CYP450 3A4 inducer is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Due to the potential for reduced anti-tumor activity, concomitant use of tivozanib with a strong CYP450 3A4 inducer should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278496/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Fotivda (tivozanib).\" Aveo Pharmaceuticals, Inc.  (2021):", "alternatives_a": "Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Streptomycin, Trimethoprim, Cycloserine, Isoniazid, Ethambutol, Pyridoxine, More", "alternatives_b": "Alectinib, Trametinib, Dacomitinib", "updated_at": 1767369485}, {"id": 242922, "ingredient1": "Tivozanib", "ingredient2": "Rifapentine", "severity": "Major", "effect": "Coadministration of tivozanib with strong CYP450 3A4 inducers may decrease the plasma concentrations and therapeutic effects of tivozanib, which has been shown to be a substrate of the isoenzyme.", "source": "DDInter", "management_text": "Due to the potential for reduced anti-tumor activity, concomitant use of tivozanib with a strong CYP450 3A4 inducer should generally be avoided.  If coadministration is necessary, some authorities advise caution, with clinical and laboratory monitoring to be considered whenever a strong CYP450 3A4 inducer is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Due to the potential for reduced anti-tumor activity, concomitant use of tivozanib with a strong CYP450 3A4 inducer should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278497/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Fotivda (tivozanib).\" Aveo Pharmaceuticals, Inc.  (2021):", "alternatives_a": "Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Streptomycin, Trimethoprim, Cycloserine, Isoniazid, Ethambutol, Pyridoxine, More", "alternatives_b": "Alectinib, Lenvatinib, Trametinib, Dacomitinib", "updated_at": 1767369485}, {"id": 242923, "ingredient1": "Tivozanib", "ingredient2": "Rimegepant", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may significantly increase the plasma concentrations of rimegepant.  The proposed mechanism is decreased clearance due to inhibition of P-gp- and/or BCRP-mediated metabolism of rimegepant.", "source": "DDInter", "management_text": "Coadministration of rimegepant with P-gp and/or BCRP inhibitors should be avoided.", "mechanism_text": "Metabolism", "recommendation": "Coadministration of rimegepant with P-gp and/or BCRP inhibitors should be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278498/", "reference_text": "[1] \"Product Information. Nurtec ODT (rimegepant).\" Biohaven Pharmaceuticals  (2020):", "alternatives_a": "Frovatriptan, Dihydroergotamine, Eptinezumab, Lasmiditan, Atogepant, Eletriptan, Rizatriptan, Ergotamine, Clonidine, Naratriptan, Galcanezumab, More", "alternatives_b": "Acalabrutinib, Dacomitinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Zanubrutinib, Brigatinib, Axitinib, Sunitinib, Ripretinib, More", "updated_at": 1767369485}, {"id": 242924, "ingredient1": "Tivozanib", "ingredient2": "Rucaparib", "severity": "Moderate", "effect": "Coadministration with tivozanib may increase the plasma concentrations and therapeutic effects of drugs that are substrates of the breast cancer resistance protein (BCRP) transporter.  The proposed mechanism, based on in vitro data, is decreased clearance due to inhibition of BCRP-mediated intestinal efflux by tivozanib.", "source": "DDInter", "management_text": "Caution and clinical monitoring are advised if tivozanib is prescribed with orally administered drugs that are sensitive substrates for BCRP, such as rosuvastatin.  If coadministration is necessary, the manufacturer suggests separating the administration times by 2 or more hours.", "mechanism_text": "Absorption", "recommendation": "Caution and clinical monitoring are advised if tivozanib is prescribed with orally administered drugs that are sensitive substrates for BCRP, such as rosuvastatin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278499/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Fotivda (tivozanib).\" Aveo Pharmaceuticals, Inc.  (2021):", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, More", "alternatives_b": "Regorafenib, Copanlisib, Abemaciclib, Erlotinib, Dabrafenib, Trametinib, Nintedanib, Dacomitinib, Alectinib", "updated_at": 1767369485}, {"id": 242925, "ingredient1": "Topotecan", "ingredient2": "Tivozanib", "severity": "Moderate", "effect": "Coadministration with tivozanib may increase the plasma concentrations and therapeutic effects of drugs that are substrates of the breast cancer resistance protein (BCRP) transporter.  The proposed mechanism, based on in vitro data, is decreased clearance due to inhibition of BCRP-mediated intestinal efflux by tivozanib.", "source": "DDInter", "management_text": "Caution and clinical monitoring are advised if tivozanib is prescribed with orally administered drugs that are sensitive substrates for BCRP, such as rosuvastatin.  If coadministration is necessary, the manufacturer suggests separating the administration times by 2 or more hours.", "mechanism_text": "Absorption", "recommendation": "Caution and clinical monitoring are advised if tivozanib is prescribed with orally administered drugs that are sensitive substrates for BCRP, such as rosuvastatin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278501/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Fotivda (tivozanib).\" Aveo Pharmaceuticals, Inc.  (2021):", "alternatives_a": "Dabrafenib, Dacomitinib, Pexidartinib, Larotrectinib, Fedratinib, Lapatinib, Selumetinib, Vandetanib, Afatinib, Lorlatinib, Axitinib, More", "alternatives_b": "Trabectedin, Cabazitaxel, Vinblastine, Paclitaxel, Vincristine, Teniposide, Irinotecan, Vinorelbine, Etoposide, Docetaxel", "updated_at": 1767369485}, {"id": 242926, "ingredient1": "Ubrogepant", "ingredient2": "Tivozanib", "severity": "Moderate", "effect": "Coadministration with breast cancer resistance protein (BCRP) and/or P-glycoprotein (P-gp) only inhibitors may increase the exposure of ubrogepant, which is a substrate of these transporters.", "source": "DDInter", "management_text": "The manufacturer recommends an initial ubrogepant dose of 50 mg when coadministered with BCRP and/or P-gp only inhibitors.  If needed, a second 50 mg dose of ubrogepant may be administered at least 2 hours after the initial dose.", "mechanism_text": "Metabolism", "recommendation": "The manufacturer recommends an initial ubrogepant dose of 50 mg when coadministered with BCRP and/or P-gp only inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278502/", "reference_text": "[1] \"Product Information. Ubrelvy (ubrogepant).\" Allergan Inc  (2019):", "alternatives_a": "Acalabrutinib, Dacomitinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Zanubrutinib, Axitinib, Sunitinib, Ripretinib, More", "alternatives_b": "Frovatriptan, Dihydroergotamine, Eptinezumab, Lasmiditan, Atogepant, Eletriptan, Rizatriptan, Ergotamine, Clonidine, Naratriptan, Galcanezumab, More", "updated_at": 1767369485}, {"id": 242927, "ingredient1": "Vemurafenib", "ingredient2": "Tivozanib", "severity": "Moderate", "effect": "Coadministration with tivozanib may increase the plasma concentrations and therapeutic effects of drugs that are substrates of the breast cancer resistance protein (BCRP) transporter.  The proposed mechanism, based on in vitro data, is decreased clearance due to inhibition of BCRP-mediated intestinal efflux by tivozanib.", "source": "DDInter", "management_text": "Caution and clinical monitoring are advised if tivozanib is prescribed with orally administered drugs that are sensitive substrates for BCRP, such as rosuvastatin.  If coadministration is necessary, the manufacturer suggests separating the administration times by 2 or more hours.", "mechanism_text": "Absorption", "recommendation": "Caution and clinical monitoring are advised if tivozanib is prescribed with orally administered drugs that are sensitive substrates for BCRP, such as rosuvastatin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278503/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Fotivda (tivozanib).\" Aveo Pharmaceuticals, Inc.  (2021):", "alternatives_a": "Futibatinib, Fedratinib, Regorafenib, Vemurafenib, Trametinib, Nintedanib, Cobimetinib, Dacomitinib, Alectinib", "alternatives_b": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, More", "updated_at": 1767369485}, {"id": 242928, "ingredient1": "Venetoclax", "ingredient2": "Tivozanib", "severity": "Moderate", "effect": "Coadministration with tivozanib may increase the plasma concentrations and therapeutic effects of drugs that are substrates of the breast cancer resistance protein (BCRP) transporter.  The proposed mechanism, based on in vitro data, is decreased clearance due to inhibition of BCRP-mediated intestinal efflux by tivozanib.", "source": "DDInter", "management_text": "Caution and clinical monitoring are advised if tivozanib is prescribed with orally administered drugs that are sensitive substrates for BCRP, such as rosuvastatin.  If coadministration is necessary, the manufacturer suggests separating the administration times by 2 or more hours.", "mechanism_text": "Absorption", "recommendation": "Caution and clinical monitoring are advised if tivozanib is prescribed with orally administered drugs that are sensitive substrates for BCRP, such as rosuvastatin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278504/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Fotivda (tivozanib).\" Aveo Pharmaceuticals, Inc.  (2021):", "alternatives_a": "Acalabrutinib, Dacomitinib, Avapritinib, Selumetinib, Cobimetinib, Zanubrutinib, Axitinib, Sunitinib, Ruxolitinib, Lenvatinib, Erlotinib, More", "alternatives_b": "Pertuzumab, Olaparib, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, More", "updated_at": 1767369485}, {"id": 242929, "ingredient1": "Imipramine", "ingredient2": "Frovatriptan", "severity": "Major", "effect": "Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John's wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.", "source": "DDInter", "management_text": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.  Patients should be closely monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.  For example, some experts suggest a 5-week washout period following use of fluoxetine and 3 weeks following the use of vortioxetine before administering another serotonergic agent.  Individual product labeling for washout periods should be consulted for current recommendations.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.", "mechanism_text": "Synergism", "recommendation": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278507/", "reference_text": "[1] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[2] Achamallah NS \"Visual hallucinations after combining fluoxetine and dextromethorphan .\" Am J Psychiatry 149 (1992):  1406[3] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993):  84-8[4] Metz A \"Interaction between fluoxetine and buspirone.\" Can J Psychiatry 35 (1990):  722-3[5] Goldberg RJ, Huk M \"Serotonin syndrome from trazodone and buspirone.\" Psychosomatics 33 (1992):  235-6[6] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation  (2002):[7] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[8] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990):  213-7[9] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics.\" J Clin Psychopharmacol 10 (1990):  48-50[10] \"Product Information. Zoloft (sertraline).\" Roerig Division  (2001):[11] \"Product Information. Prozac (fluoxetine).\" Dista Products Company  (2001):[12] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[13] Insel TR, Roy BF, Cohen RM, Murphy DL \"Possible development of the serotonin syndrome in man.\" Am J Psychiatry 139 (1982):  954-5[14] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories  (2001):[15] Gilman AG, eds., Nies AS, Rall TW, Taylor P \"Goodman and Gilman's the Pharmacological Basis of Therapeutics.\" New York, NY: Pergamon Press Inc.  (1990):[16] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline  (2001):[17] \"Product Information. Flexeril (cyclobenzaprine).\" Merck & Co., Inc  (2001):[18] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[19] \"Product Information. Imitrex (sumatriptan).\" Glaxo Wellcome  (2001):[20] Ruiz F \"Fluoxetine and the serotonin syndrome.\" Ann Emerg Med 24 (1994):  983-5[21] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc  (2001):[22] Reeves RR, Bullen JA \"Serotonin syndrome produced by paroxetine and low-dose trazodone.\" Psychosomatics 36 (1995):  159-60[23] Harvey AT, Preskorn SH \"Interactions of serotonin reuptake inhibitors with tricyclic antidepressants.\" Arch Gen Psychiatry 52 (1995):  783-4[24] Baetz M, Malcolm D \"Serotonin syndrome from fluvoxamine and buspirone.\" Can J Psychiatry 40 (1995):  428-9[25] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995):  440-2[26] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995):  481-2[27] George TP, Godleski LS \"Possible serotonin syndrome with trazodone addition to fluoxetine.\" Biol Psychiatry 39 (1996):  384-5[28] Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM \"The serotonin syndrome associated wtih paroxetine, an over-the-counter cold remedy, and vascular disease.\" Am J Emerg Med 12 (1994):  642-4[29] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[30] John L, Perreault MM, Tao T, Blew PG \"Serotonin syndrome associated with nefazodone and paroxetine.\" Ann Emerg Med 29 (1997):  287-9[31] \"Product Information. Zomig (zolmitriptan).\" Astra-Zeneca Pharmaceuticals  (2001):[32] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[33] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[34] Bhatara VS, Magnus RD, Paul KL, Preskorn SH \"Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms.\" Ann Pharmacother 32 (1998):  432-6[35] \"Product Information. Maxalt (rizatriptan).\" Merck & Co., Inc  (2001):[36] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals  (2001):[37] Gardner DM, Lynd LD \"Sumatriptan contraindications and the serotonin syndrome.\" Ann Pharmacother 32 (1998):  33-8[38] Mathew NT, Tietjen GE, Lucker C \"Serotonin syndrome complicating migraine pharmacotherapy.\" Cephalalgia 16 (1996):  323-7[39] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[40] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[41] Weiner AL \"Meperidine as a potential cause of serotonin syndrome in the emergency department.\" Acad Emerg Med 6 (1999):  156-8[42] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[43] Gordon JB \"SSRI's and St. John's Wort: possible toxicity?\" Am Fam Physician 57 (1998):  950,953[44] Lantz MS, Buchalter E, Giambanco V \"St. John's wort and antidepressant drug interactions in the elderly.\" J Geriatr Psychiatr Neurol 12 (1999):  7-10[45] Fugh-Berman A \"Herb-drug interactions.\" Lancet 355 (2000):  134-8[46] \"Product Information. Zyvox (linezolid).\" Pharmacia and Upjohn  (2001):[47] Perry NK \"Venlafaxine-induced serotonin syndrome with relapse following amitriptyline.\" Postgrad Med J 76 (2000):  254-6[48] Manos GH \"Possible serotonin syndrome associated with buspirone added to fluoxetine.\" Ann Pharmacother 34 (2000):  871-4[49] Nijhawan PK, Katz G, Winter S \"Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission.\" Crit Care Med 24 (1996):  1086-9[50] Laird LK \"Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder.\" Psychopharmacol Bull 32 (1996):  569-78[51] Margolese HC, Chouinard G \"Serotonin syndrome from addition of low-dose trazodone to nefazodone.\" Am J Psychiatry 157 (2000):  1022[52] Mackay FJ, Dunn NR, Mann RD \"Antidepressants and the serotonin syndrome in general practice.\" Br J Gen Pract 49 (1999):  871-4[53] Smith DL, Wenegrat BG \"A case report of serotonin syndrome associated with combined nefazodone and fluoxetine.\" J Clin Psychiatry 61 (2000):  146[54] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[55] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001):  2163-75[56] Duggal HS, Fetchko J \"Serotonin syndrome and atypical antipsychotics.\" Am J Psychiatry 159 (2002):  672-3[57] Wigen CL, Goetz MB \"Serotonin syndrome and linezolid.\" Clin Infect Dis 34 (2002):  1651-2[58] Hammerness P, Parada H, Abrams A \"Linezolid: MAOI Activity and Potential Drug Interactions.\" Psychosomatics 43 (2002):  248-9[59] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[60] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[61] Turkel SB, Nadala JG, Wincor MZ \"Possible serotonin syndrome in association with 5-HT3 antagonist agents.\" Psychosomatics 42 (2001):  258-60[62] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[63] Lavery S, Ravi H, McDaniel WW, Pushkin YR \"Linezolid and serotonin syndrome.\" Psychosomatics 42 (2001):  432-4[64] Lane R, Baldwin D \"Selective serotonin reuptake inhibitor--induced serotonin syndrome: review.\" J Clin Psychopharmacol 17 (1997):  208-21[65] Bernard L, Stern R, Lew D, Hoffmeyer P \"Serotonin syndrome after concomitant treatment with linezolid and citalopram.\" Clin Infect Dis 36 (2003):  1197[66] Dannawi M \"Possible serotonin syndrome after combination of buspirone and St John's Wort.\" J Psychopharmacol 16 (2002):  401[67] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[68] Hachem RY, Hicks K, Huen A, Raad I \"Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients.\" Clin Infect Dis 37 (2003):  E8-E11[69] Gillman PK \"Linezolid and serotonin toxicity.\" Clin Infect Dis 37 (2003):  1274-5[70] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[71] Giese SY, Neborsky R \"Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl.\" Plast Reconstr Surg 107 (2001):  293-4[72] Jones SL, Athan E, O'Brien D \"Serotonin syndrome due to co-administration of linezolid and venlafaxine.\" J Antimicrob Chemother 54 (2004):  289-90[73] Tahir N \"Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram.\" J Am Med Dir Assoc 5 (2004):  111-3[74] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company  (2004):[75] Thomas CR, Rosenberg M, Blythe V, Meyer WJ 3rd \"Serotonin syndrome and linezolid.\" J Am Acad Child Adolesc Psychiatry 43 (2004):  790[76] Boyer EW, Shannon M \"The serotonin syndrome.\" N Engl J Med 352 (2005):  1112-20[77] Bergeron L, Boule M, Perreault S \"Serotonin toxicity associated with concomitant use of linezolid.\" Ann Pharmacother 39 (2005):  956-61[78] Morales N, Vermette H \"Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine.\" Psychosomatics 46 (2005):  274-5[79] Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M, Grau S \"Linezolid-associated serotonin syndrome: what we can learn from cases reported so far.\" J Antimicrob Chemother 56 (2005):  1176-8[80] DeBellis RJ, Schaefer OP, Liquori M, Volturo GA \"Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient.\" J Intensive Care Med 20 (2005):  351-3[81] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[82] Taylor JJ, Wilson JW, Estes LL \"Linezolid and serotonergic drug interactions: a retrospective survey.\" Clin Infect Dis 43 (2006):  180-7[83] Strouse TB, Kerrihard TN, Forscher CA, Zakowski P \"Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine.\" J Clin Psychopharmacol 26 (2006):  681-683[84] Keegan MT, Brown DR, Rabinstein AA \"Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs.\" Anesth Analg 103 (2006):  1466-8[85] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S \"Rare case of serotonin syndrome with therapeutic doses of paroxetine.\" Am J Ther 13 (2006):  550-552[86] Steinberg M, Morin AK \"Mild serotonin syndrome associated with concurrent linezolid and fluoxetine.\" Am J Health Syst Pharm 64 (2007):  59-62[87] Packer S, Berman SA \"Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid.\" Am J Psychiatry 164 (2007):  346-7[88] Shapiro RE, Tepper SJ \"The serotonin syndrome, triptans, and the potential for drug-drug interactions.\" Headache 47 (2007):  266-9[89] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[90] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories  (2008):[91] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[92] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals  (2009):[93] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals  (2009):[94] Lee J, Franz L, Goforth HW \"Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine.\" Psychosomatics 50 (2009):  638-9[95] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC  (2011):[96] Mugele J, Nanagas KA, Tormoehlen LM \"Serotonin Syndrome Associated With MDPV Use: A Case Report.\" Ann Emerg Med  (2012):[97] \"Product Information. Oleptro (trazodone).\" Labopharm Inc  (2012):[98] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals  (2013):[99] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America  (2013):", "alternatives_a": "Rimegepant, Eptinezumab, Ubrogepant, Galcanezumab, Atogepant, Methysergide, Erenumab, Fremanezumab", "alternatives_b": "Bupropion, Viloxazine, Esketamine", "updated_at": 1767369485}, {"id": 242930, "ingredient1": "Frovatriptan", "ingredient2": "Maprotiline", "severity": "Major", "effect": "Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John's wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.", "source": "DDInter", "management_text": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.  Patients should be closely monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.  For example, some experts suggest a 5-week washout period following use of fluoxetine and 3 weeks following the use of vortioxetine before administering another serotonergic agent.  Individual product labeling for washout periods should be consulted for current recommendations.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.", "mechanism_text": "Synergism", "recommendation": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278508/", "reference_text": "[1] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[2] Achamallah NS \"Visual hallucinations after combining fluoxetine and dextromethorphan .\" Am J Psychiatry 149 (1992):  1406[3] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993):  84-8[4] Metz A \"Interaction between fluoxetine and buspirone.\" Can J Psychiatry 35 (1990):  722-3[5] Goldberg RJ, Huk M \"Serotonin syndrome from trazodone and buspirone.\" Psychosomatics 33 (1992):  235-6[6] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation  (2002):[7] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[8] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990):  213-7[9] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics.\" J Clin Psychopharmacol 10 (1990):  48-50[10] \"Product Information. Zoloft (sertraline).\" Roerig Division  (2001):[11] \"Product Information. Prozac (fluoxetine).\" Dista Products Company  (2001):[12] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[13] Insel TR, Roy BF, Cohen RM, Murphy DL \"Possible development of the serotonin syndrome in man.\" Am J Psychiatry 139 (1982):  954-5[14] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories  (2001):[15] Gilman AG, eds., Nies AS, Rall TW, Taylor P \"Goodman and Gilman's the Pharmacological Basis of Therapeutics.\" New York, NY: Pergamon Press Inc.  (1990):[16] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline  (2001):[17] \"Product Information. Flexeril (cyclobenzaprine).\" Merck & Co., Inc  (2001):[18] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[19] \"Product Information. Imitrex (sumatriptan).\" Glaxo Wellcome  (2001):[20] Ruiz F \"Fluoxetine and the serotonin syndrome.\" Ann Emerg Med 24 (1994):  983-5[21] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc  (2001):[22] Reeves RR, Bullen JA \"Serotonin syndrome produced by paroxetine and low-dose trazodone.\" Psychosomatics 36 (1995):  159-60[23] Harvey AT, Preskorn SH \"Interactions of serotonin reuptake inhibitors with tricyclic antidepressants.\" Arch Gen Psychiatry 52 (1995):  783-4[24] Baetz M, Malcolm D \"Serotonin syndrome from fluvoxamine and buspirone.\" Can J Psychiatry 40 (1995):  428-9[25] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995):  440-2[26] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995):  481-2[27] George TP, Godleski LS \"Possible serotonin syndrome with trazodone addition to fluoxetine.\" Biol Psychiatry 39 (1996):  384-5[28] Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM \"The serotonin syndrome associated wtih paroxetine, an over-the-counter cold remedy, and vascular disease.\" Am J Emerg Med 12 (1994):  642-4[29] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[30] John L, Perreault MM, Tao T, Blew PG \"Serotonin syndrome associated with nefazodone and paroxetine.\" Ann Emerg Med 29 (1997):  287-9[31] \"Product Information. Zomig (zolmitriptan).\" Astra-Zeneca Pharmaceuticals  (2001):[32] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[33] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[34] Bhatara VS, Magnus RD, Paul KL, Preskorn SH \"Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms.\" Ann Pharmacother 32 (1998):  432-6[35] \"Product Information. Maxalt (rizatriptan).\" Merck & Co., Inc  (2001):[36] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals  (2001):[37] Gardner DM, Lynd LD \"Sumatriptan contraindications and the serotonin syndrome.\" Ann Pharmacother 32 (1998):  33-8[38] Mathew NT, Tietjen GE, Lucker C \"Serotonin syndrome complicating migraine pharmacotherapy.\" Cephalalgia 16 (1996):  323-7[39] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[40] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[41] Weiner AL \"Meperidine as a potential cause of serotonin syndrome in the emergency department.\" Acad Emerg Med 6 (1999):  156-8[42] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[43] Gordon JB \"SSRI's and St. John's Wort: possible toxicity?\" Am Fam Physician 57 (1998):  950,953[44] Lantz MS, Buchalter E, Giambanco V \"St. John's wort and antidepressant drug interactions in the elderly.\" J Geriatr Psychiatr Neurol 12 (1999):  7-10[45] Fugh-Berman A \"Herb-drug interactions.\" Lancet 355 (2000):  134-8[46] \"Product Information. Zyvox (linezolid).\" Pharmacia and Upjohn  (2001):[47] Perry NK \"Venlafaxine-induced serotonin syndrome with relapse following amitriptyline.\" Postgrad Med J 76 (2000):  254-6[48] Manos GH \"Possible serotonin syndrome associated with buspirone added to fluoxetine.\" Ann Pharmacother 34 (2000):  871-4[49] Nijhawan PK, Katz G, Winter S \"Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission.\" Crit Care Med 24 (1996):  1086-9[50] Laird LK \"Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder.\" Psychopharmacol Bull 32 (1996):  569-78[51] Margolese HC, Chouinard G \"Serotonin syndrome from addition of low-dose trazodone to nefazodone.\" Am J Psychiatry 157 (2000):  1022[52] Mackay FJ, Dunn NR, Mann RD \"Antidepressants and the serotonin syndrome in general practice.\" Br J Gen Pract 49 (1999):  871-4[53] Smith DL, Wenegrat BG \"A case report of serotonin syndrome associated with combined nefazodone and fluoxetine.\" J Clin Psychiatry 61 (2000):  146[54] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[55] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001):  2163-75[56] Duggal HS, Fetchko J \"Serotonin syndrome and atypical antipsychotics.\" Am J Psychiatry 159 (2002):  672-3[57] Wigen CL, Goetz MB \"Serotonin syndrome and linezolid.\" Clin Infect Dis 34 (2002):  1651-2[58] Hammerness P, Parada H, Abrams A \"Linezolid: MAOI Activity and Potential Drug Interactions.\" Psychosomatics 43 (2002):  248-9[59] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[60] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[61] Turkel SB, Nadala JG, Wincor MZ \"Possible serotonin syndrome in association with 5-HT3 antagonist agents.\" Psychosomatics 42 (2001):  258-60[62] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[63] Lavery S, Ravi H, McDaniel WW, Pushkin YR \"Linezolid and serotonin syndrome.\" Psychosomatics 42 (2001):  432-4[64] Lane R, Baldwin D \"Selective serotonin reuptake inhibitor--induced serotonin syndrome: review.\" J Clin Psychopharmacol 17 (1997):  208-21[65] Bernard L, Stern R, Lew D, Hoffmeyer P \"Serotonin syndrome after concomitant treatment with linezolid and citalopram.\" Clin Infect Dis 36 (2003):  1197[66] Dannawi M \"Possible serotonin syndrome after combination of buspirone and St John's Wort.\" J Psychopharmacol 16 (2002):  401[67] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[68] Hachem RY, Hicks K, Huen A, Raad I \"Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients.\" Clin Infect Dis 37 (2003):  E8-E11[69] Gillman PK \"Linezolid and serotonin toxicity.\" Clin Infect Dis 37 (2003):  1274-5[70] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[71] Giese SY, Neborsky R \"Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl.\" Plast Reconstr Surg 107 (2001):  293-4[72] Jones SL, Athan E, O'Brien D \"Serotonin syndrome due to co-administration of linezolid and venlafaxine.\" J Antimicrob Chemother 54 (2004):  289-90[73] Tahir N \"Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram.\" J Am Med Dir Assoc 5 (2004):  111-3[74] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company  (2004):[75] Thomas CR, Rosenberg M, Blythe V, Meyer WJ 3rd \"Serotonin syndrome and linezolid.\" J Am Acad Child Adolesc Psychiatry 43 (2004):  790[76] Boyer EW, Shannon M \"The serotonin syndrome.\" N Engl J Med 352 (2005):  1112-20[77] Bergeron L, Boule M, Perreault S \"Serotonin toxicity associated with concomitant use of linezolid.\" Ann Pharmacother 39 (2005):  956-61[78] Morales N, Vermette H \"Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine.\" Psychosomatics 46 (2005):  274-5[79] Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M, Grau S \"Linezolid-associated serotonin syndrome: what we can learn from cases reported so far.\" J Antimicrob Chemother 56 (2005):  1176-8[80] DeBellis RJ, Schaefer OP, Liquori M, Volturo GA \"Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient.\" J Intensive Care Med 20 (2005):  351-3[81] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[82] Taylor JJ, Wilson JW, Estes LL \"Linezolid and serotonergic drug interactions: a retrospective survey.\" Clin Infect Dis 43 (2006):  180-7[83] Strouse TB, Kerrihard TN, Forscher CA, Zakowski P \"Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine.\" J Clin Psychopharmacol 26 (2006):  681-683[84] Keegan MT, Brown DR, Rabinstein AA \"Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs.\" Anesth Analg 103 (2006):  1466-8[85] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S \"Rare case of serotonin syndrome with therapeutic doses of paroxetine.\" Am J Ther 13 (2006):  550-552[86] Steinberg M, Morin AK \"Mild serotonin syndrome associated with concurrent linezolid and fluoxetine.\" Am J Health Syst Pharm 64 (2007):  59-62[87] Packer S, Berman SA \"Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid.\" Am J Psychiatry 164 (2007):  346-7[88] Shapiro RE, Tepper SJ \"The serotonin syndrome, triptans, and the potential for drug-drug interactions.\" Headache 47 (2007):  266-9[89] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[90] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories  (2008):[91] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[92] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals  (2009):[93] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals  (2009):[94] Lee J, Franz L, Goforth HW \"Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine.\" Psychosomatics 50 (2009):  638-9[95] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC  (2011):[96] Mugele J, Nanagas KA, Tormoehlen LM \"Serotonin Syndrome Associated With MDPV Use: A Case Report.\" Ann Emerg Med  (2012):[97] \"Product Information. Oleptro (trazodone).\" Labopharm Inc  (2012):[98] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals  (2013):[99] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America  (2013):", "alternatives_a": "Rimegepant, Eptinezumab, Ubrogepant, Galcanezumab, Atogepant, Methysergide, Erenumab, Fremanezumab", "alternatives_b": "Bupropion, Viloxazine, Esketamine", "updated_at": 1767369485}, {"id": 242931, "ingredient1": "Frovatriptan", "ingredient2": "Remifentanil", "severity": "Major", "effect": "Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John's wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.", "source": "DDInter", "management_text": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.  Patients should be closely monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.  For example, some experts suggest a 5-week washout period following use of fluoxetine and 3 weeks following the use of vortioxetine before administering another serotonergic agent.  Individual product labeling for washout periods should be consulted for current recommendations.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.", "mechanism_text": "Synergism", "recommendation": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278509/", "reference_text": "[1] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[2] Achamallah NS \"Visual hallucinations after combining fluoxetine and dextromethorphan .\" Am J Psychiatry 149 (1992):  1406[3] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993):  84-8[4] Metz A \"Interaction between fluoxetine and buspirone.\" Can J Psychiatry 35 (1990):  722-3[5] Goldberg RJ, Huk M \"Serotonin syndrome from trazodone and buspirone.\" Psychosomatics 33 (1992):  235-6[6] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation  (2002):[7] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[8] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990):  213-7[9] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics.\" J Clin Psychopharmacol 10 (1990):  48-50[10] \"Product Information. Zoloft (sertraline).\" Roerig Division  (2001):[11] \"Product Information. Prozac (fluoxetine).\" Dista Products Company  (2001):[12] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[13] Insel TR, Roy BF, Cohen RM, Murphy DL \"Possible development of the serotonin syndrome in man.\" Am J Psychiatry 139 (1982):  954-5[14] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories  (2001):[15] Gilman AG, eds., Nies AS, Rall TW, Taylor P \"Goodman and Gilman's the Pharmacological Basis of Therapeutics.\" New York, NY: Pergamon Press Inc.  (1990):[16] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline  (2001):[17] \"Product Information. Flexeril (cyclobenzaprine).\" Merck & Co., Inc  (2001):[18] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[19] \"Product Information. Imitrex (sumatriptan).\" Glaxo Wellcome  (2001):[20] Ruiz F \"Fluoxetine and the serotonin syndrome.\" Ann Emerg Med 24 (1994):  983-5[21] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc  (2001):[22] Reeves RR, Bullen JA \"Serotonin syndrome produced by paroxetine and low-dose trazodone.\" Psychosomatics 36 (1995):  159-60[23] Harvey AT, Preskorn SH \"Interactions of serotonin reuptake inhibitors with tricyclic antidepressants.\" Arch Gen Psychiatry 52 (1995):  783-4[24] Baetz M, Malcolm D \"Serotonin syndrome from fluvoxamine and buspirone.\" Can J Psychiatry 40 (1995):  428-9[25] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995):  440-2[26] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995):  481-2[27] George TP, Godleski LS \"Possible serotonin syndrome with trazodone addition to fluoxetine.\" Biol Psychiatry 39 (1996):  384-5[28] Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM \"The serotonin syndrome associated wtih paroxetine, an over-the-counter cold remedy, and vascular disease.\" Am J Emerg Med 12 (1994):  642-4[29] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[30] John L, Perreault MM, Tao T, Blew PG \"Serotonin syndrome associated with nefazodone and paroxetine.\" Ann Emerg Med 29 (1997):  287-9[31] \"Product Information. Zomig (zolmitriptan).\" Astra-Zeneca Pharmaceuticals  (2001):[32] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[33] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[34] Bhatara VS, Magnus RD, Paul KL, Preskorn SH \"Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms.\" Ann Pharmacother 32 (1998):  432-6[35] \"Product Information. Maxalt (rizatriptan).\" Merck & Co., Inc  (2001):[36] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals  (2001):[37] Gardner DM, Lynd LD \"Sumatriptan contraindications and the serotonin syndrome.\" Ann Pharmacother 32 (1998):  33-8[38] Mathew NT, Tietjen GE, Lucker C \"Serotonin syndrome complicating migraine pharmacotherapy.\" Cephalalgia 16 (1996):  323-7[39] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[40] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[41] Weiner AL \"Meperidine as a potential cause of serotonin syndrome in the emergency department.\" Acad Emerg Med 6 (1999):  156-8[42] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[43] Gordon JB \"SSRI's and St. John's Wort: possible toxicity?\" Am Fam Physician 57 (1998):  950,953[44] Lantz MS, Buchalter E, Giambanco V \"St. John's wort and antidepressant drug interactions in the elderly.\" J Geriatr Psychiatr Neurol 12 (1999):  7-10[45] Fugh-Berman A \"Herb-drug interactions.\" Lancet 355 (2000):  134-8[46] \"Product Information. Zyvox (linezolid).\" Pharmacia and Upjohn  (2001):[47] Perry NK \"Venlafaxine-induced serotonin syndrome with relapse following amitriptyline.\" Postgrad Med J 76 (2000):  254-6[48] Manos GH \"Possible serotonin syndrome associated with buspirone added to fluoxetine.\" Ann Pharmacother 34 (2000):  871-4[49] Nijhawan PK, Katz G, Winter S \"Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission.\" Crit Care Med 24 (1996):  1086-9[50] Laird LK \"Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder.\" Psychopharmacol Bull 32 (1996):  569-78[51] Margolese HC, Chouinard G \"Serotonin syndrome from addition of low-dose trazodone to nefazodone.\" Am J Psychiatry 157 (2000):  1022[52] Mackay FJ, Dunn NR, Mann RD \"Antidepressants and the serotonin syndrome in general practice.\" Br J Gen Pract 49 (1999):  871-4[53] Smith DL, Wenegrat BG \"A case report of serotonin syndrome associated with combined nefazodone and fluoxetine.\" J Clin Psychiatry 61 (2000):  146[54] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[55] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001):  2163-75[56] Duggal HS, Fetchko J \"Serotonin syndrome and atypical antipsychotics.\" Am J Psychiatry 159 (2002):  672-3[57] Wigen CL, Goetz MB \"Serotonin syndrome and linezolid.\" Clin Infect Dis 34 (2002):  1651-2[58] Hammerness P, Parada H, Abrams A \"Linezolid: MAOI Activity and Potential Drug Interactions.\" Psychosomatics 43 (2002):  248-9[59] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[60] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[61] Turkel SB, Nadala JG, Wincor MZ \"Possible serotonin syndrome in association with 5-HT3 antagonist agents.\" Psychosomatics 42 (2001):  258-60[62] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[63] Lavery S, Ravi H, McDaniel WW, Pushkin YR \"Linezolid and serotonin syndrome.\" Psychosomatics 42 (2001):  432-4[64] Lane R, Baldwin D \"Selective serotonin reuptake inhibitor--induced serotonin syndrome: review.\" J Clin Psychopharmacol 17 (1997):  208-21[65] Bernard L, Stern R, Lew D, Hoffmeyer P \"Serotonin syndrome after concomitant treatment with linezolid and citalopram.\" Clin Infect Dis 36 (2003):  1197[66] Dannawi M \"Possible serotonin syndrome after combination of buspirone and St John's Wort.\" J Psychopharmacol 16 (2002):  401[67] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[68] Hachem RY, Hicks K, Huen A, Raad I \"Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients.\" Clin Infect Dis 37 (2003):  E8-E11[69] Gillman PK \"Linezolid and serotonin toxicity.\" Clin Infect Dis 37 (2003):  1274-5[70] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[71] Giese SY, Neborsky R \"Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl.\" Plast Reconstr Surg 107 (2001):  293-4[72] Jones SL, Athan E, O'Brien D \"Serotonin syndrome due to co-administration of linezolid and venlafaxine.\" J Antimicrob Chemother 54 (2004):  289-90[73] Tahir N \"Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram.\" J Am Med Dir Assoc 5 (2004):  111-3[74] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company  (2004):[75] Thomas CR, Rosenberg M, Blythe V, Meyer WJ 3rd \"Serotonin syndrome and linezolid.\" J Am Acad Child Adolesc Psychiatry 43 (2004):  790[76] Boyer EW, Shannon M \"The serotonin syndrome.\" N Engl J Med 352 (2005):  1112-20[77] Bergeron L, Boule M, Perreault S \"Serotonin toxicity associated with concomitant use of linezolid.\" Ann Pharmacother 39 (2005):  956-61[78] Morales N, Vermette H \"Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine.\" Psychosomatics 46 (2005):  274-5[79] Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M, Grau S \"Linezolid-associated serotonin syndrome: what we can learn from cases reported so far.\" J Antimicrob Chemother 56 (2005):  1176-8[80] DeBellis RJ, Schaefer OP, Liquori M, Volturo GA \"Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient.\" J Intensive Care Med 20 (2005):  351-3[81] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[82] Taylor JJ, Wilson JW, Estes LL \"Linezolid and serotonergic drug interactions: a retrospective survey.\" Clin Infect Dis 43 (2006):  180-7[83] Strouse TB, Kerrihard TN, Forscher CA, Zakowski P \"Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine.\" J Clin Psychopharmacol 26 (2006):  681-683[84] Keegan MT, Brown DR, Rabinstein AA \"Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs.\" Anesth Analg 103 (2006):  1466-8[85] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S \"Rare case of serotonin syndrome with therapeutic doses of paroxetine.\" Am J Ther 13 (2006):  550-552[86] Steinberg M, Morin AK \"Mild serotonin syndrome associated with concurrent linezolid and fluoxetine.\" Am J Health Syst Pharm 64 (2007):  59-62[87] Packer S, Berman SA \"Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid.\" Am J Psychiatry 164 (2007):  346-7[88] Shapiro RE, Tepper SJ \"The serotonin syndrome, triptans, and the potential for drug-drug interactions.\" Headache 47 (2007):  266-9[89] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[90] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories  (2008):[91] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[92] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals  (2009):[93] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals  (2009):[94] Lee J, Franz L, Goforth HW \"Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine.\" Psychosomatics 50 (2009):  638-9[95] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC  (2011):[96] Mugele J, Nanagas KA, Tormoehlen LM \"Serotonin Syndrome Associated With MDPV Use: A Case Report.\" Ann Emerg Med  (2012):[97] \"Product Information. Oleptro (trazodone).\" Labopharm Inc  (2012):[98] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals  (2013):[99] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America  (2013):", "alternatives_a": "Rimegepant, Eptinezumab, Ubrogepant, Galcanezumab, Atogepant, Methysergide, Erenumab, Fremanezumab", "alternatives_b": "Halothane, Thiopental, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, Sevoflurane, More", "updated_at": 1767369485}, {"id": 242932, "ingredient1": "Pegfilgrastim", "ingredient2": "Melphalan flufenamide", "severity": "Moderate", "effect": "The safety and efficacy of hematopoietic growth factors such as colony-stimulating factors (G-CSF and GM-CSF) and stem cell factors (SCF) given simultaneously with cancer chemotherapy have not been established.  Theoretical concerns exist regarding their concomitant administration because hematopoietic growth factors stimulate myeloid cell proliferation while antineoplastic agents primarily target rapidly dividing cells.", "source": "DDInter", "management_text": "Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, the prescribing information recommends that pegfilgrastim and eflapegrastim not be given from 14 days before until 24 hours after administration of antineoplastic agents.", "mechanism_text": "Others", "recommendation": "Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, the prescribing information recommends that pegfilgrastim and eflapegrastim not be given from 14 days before until 24 hours after administration of antineoplastic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278511/", "reference_text": "[1] \"Product Information. Neulasta (pegfilgrastim).\" Amgen  (2002):[2] \"Product Information. Rolvedon (eflapegrastim).\" Spectrum Pharmaceuticals Inc  (2022):", "alternatives_a": "Interferon alfa-n1, Oprelvekin, Elapegademase, Interferon beta-1b, Peginterferon alfa-2a, Peginterferon beta-1a, Interferon alfacon-1, Interferon beta-1a, Histamine, Pegademase, Peginterferon alfa-2b, Glatiramer", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242933, "ingredient1": "Venetoclax", "ingredient2": "Pegfilgrastim", "severity": "Moderate", "effect": "The safety and efficacy of hematopoietic growth factors such as colony-stimulating factors (G-CSF and GM-CSF) and stem cell factors (SCF) given simultaneously with cancer chemotherapy have not been established.  Theoretical concerns exist regarding their concomitant administration because hematopoietic growth factors stimulate myeloid cell proliferation while antineoplastic agents primarily target rapidly dividing cells.", "source": "DDInter", "management_text": "Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, the prescribing information recommends that pegfilgrastim and eflapegrastim not be given from 14 days before until 24 hours after administration of antineoplastic agents.", "mechanism_text": "Others", "recommendation": "Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, the prescribing information recommends that pegfilgrastim and eflapegrastim not be given from 14 days before until 24 hours after administration of antineoplastic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278515/", "reference_text": "[1] \"Product Information. Neulasta (pegfilgrastim).\" Amgen  (2002):[2] \"Product Information. Rolvedon (eflapegrastim).\" Spectrum Pharmaceuticals Inc  (2022):", "alternatives_a": "Interferon alfa-n1, Oprelvekin, Elapegademase, Interferon beta-1b, Peginterferon alfa-2a, Peginterferon beta-1a, Interferon alfacon-1, Interferon beta-1a, Histamine, Aldesleukin, Pegademase, More", "alternatives_b": "Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, Aflibercept, Anagrelide, More", "updated_at": 1767369485}, {"id": 242934, "ingredient1": "Etidocaine", "ingredient2": "Nitrofurantoin", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278528/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Tinidazole, Linezolid, Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Metronidazole, Telavancin, Methenamine, Spectinomycin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242935, "ingredient1": "Nitrofurantoin", "ingredient2": "Levobupivacaine", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278533/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Tinidazole, Linezolid, Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Metronidazole, Telavancin, Methenamine, Spectinomycin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242936, "ingredient1": "Procaine", "ingredient2": "Nitrofurantoin", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278536/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Tinidazole, Linezolid, Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Metronidazole, Telavancin, Methenamine, Spectinomycin, More", "alternatives_b": "Zinc sulfate, Zinc acetate, Fluocinolone acetonide, Isosorbide dinitrate, Zinc chloride, Betamethasone, Fluorometholone, Zinc gluconate", "updated_at": 1767369485}, {"id": 242937, "ingredient1": "Ropivacaine", "ingredient2": "Nitrofurantoin", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278539/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Tinidazole, Linezolid, Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Metronidazole, Telavancin, Methenamine, Spectinomycin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242938, "ingredient1": "Silver nitrate (topical)", "ingredient2": "Nitrofurantoin", "severity": "Moderate", "effect": "Topical nitrate and silver (e.g., cerium nitrate, silver nitrate, silver sulfadiazine) preparations can be systemically absorbed and have been associated with rare reports of methemoglobinemia, primarily in burn patients.  In addition, bacterial conversion of nitrate to nitrite can contribute to methemoglobinemia.  Coadministration with other oxidizing agents that can also induce methemoglobinemia such as ester and amide local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), systemic nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Depending on the circumstances, caution may be advisable when topical nitrate and silver preparations are used concomitantly with other methemoglobin-inducing agents.  Clinicians should be aware of the potential for methemoglobinemia, particularly when treating burn patients.  Signs and symptoms of methemoglobinemia may be delayed some hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Depending on the circumstances, caution may be advisable when topical nitrate and silver preparations are used concomitantly with other methemoglobin-inducing agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278540/", "reference_text": "[1] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[2] Geffner ME, Powars DR, Choctaw WT \"Acquired methemoglobinemia.\" West J Med 134 (1981):  7-10[3] Poredos P, Gradisek P, Testen C, Derganc M \"Severe methemoglobinaemia due to benzocaine-containing 'burn cream': two case reports in an adult and in a child.\" Burns 37 (2011):  e63-6[4] Gala HC, Madave A \"An unusual case of neonatal methemoglobinemia.\" Indian Pediatr 54 (2017):  163[5] Reese AD, Keyloun JW, Garg G, et.a \"Compounded cerium nitrate-silver sulfadiazine cream is safe and effective for the treatment of burn wounds: a burn center's four-year experience.\" J Burn Care Res 20 (2021):  Epub ahead of print[6] Cartotto R \"Topical antimicrobial agents for pediatric burns.\" Burns Trauma 5 (2017):  33", "alternatives_a": "Tinidazole, Linezolid, Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Metronidazole, Telavancin, Methenamine, Spectinomycin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242939, "ingredient1": "Silver sulfadiazine (topical)", "ingredient2": "Nitrofurantoin", "severity": "Moderate", "effect": "Topical nitrate and silver (e.g., cerium nitrate, silver nitrate, silver sulfadiazine) preparations can be systemically absorbed and have been associated with rare reports of methemoglobinemia, primarily in burn patients.  In addition, bacterial conversion of nitrate to nitrite can contribute to methemoglobinemia.  Coadministration with other oxidizing agents that can also induce methemoglobinemia such as ester and amide local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), systemic nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Depending on the circumstances, caution may be advisable when topical nitrate and silver preparations are used concomitantly with other methemoglobin-inducing agents.  Clinicians should be aware of the potential for methemoglobinemia, particularly when treating burn patients.  Signs and symptoms of methemoglobinemia may be delayed some hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Depending on the circumstances, caution may be advisable when topical nitrate and silver preparations are used concomitantly with other methemoglobin-inducing agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278541/", "reference_text": "[1] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[2] Geffner ME, Powars DR, Choctaw WT \"Acquired methemoglobinemia.\" West J Med 134 (1981):  7-10[3] Poredos P, Gradisek P, Testen C, Derganc M \"Severe methemoglobinaemia due to benzocaine-containing 'burn cream': two case reports in an adult and in a child.\" Burns 37 (2011):  e63-6[4] Gala HC, Madave A \"An unusual case of neonatal methemoglobinemia.\" Indian Pediatr 54 (2017):  163[5] Reese AD, Keyloun JW, Garg G, et.a \"Compounded cerium nitrate-silver sulfadiazine cream is safe and effective for the treatment of burn wounds: a burn center's four-year experience.\" J Burn Care Res 20 (2021):  Epub ahead of print[6] Cartotto R \"Topical antimicrobial agents for pediatric burns.\" Burns Trauma 5 (2017):  33", "alternatives_a": "Tinidazole, Linezolid, Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Metronidazole, Telavancin, Methenamine, Spectinomycin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242940, "ingredient1": "Furosemide", "ingredient2": "Polymyxin B", "severity": "Moderate", "effect": "Increased adverse effects are possible when glycopeptide, polypeptide, or polymyxin antibiotics are administered concomitantly with other potentially nephrotoxic and neurotoxic drugs.", "source": "DDInter", "management_text": "If these drugs must be used together, renal function, auditory and vestibular function, and serum drug concentrations should be monitored.", "mechanism_text": "Synergism", "recommendation": "If these drugs must be used together, renal function, auditory and vestibular function, and serum drug concentrations should be monitored.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278684/", "reference_text": "[1] \"Product Information. Vancocin (vancomycin).\" Lilly, Eli and Company  (2001):[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015):  1903-7", "alternatives_a": "Bendroflumethiazide, Trichlormethiazide, Bumetanide, Chlorthalidone, Metolazone, Hydrochlorothiazide, Torasemide, Bumetanide, Tamsulosin, Tinidazole, Ascorbic acid, More", "alternatives_b": "Rifamycin, Tinidazole, Oritavancin, Daptomycin, Methenamine, Spectinomycin, Lefamulin, Fosfomycin, Tedizolid, Dalbavancin, Paromomycin, More", "updated_at": 1767369485}, {"id": 242941, "ingredient1": "Furosemide", "ingredient2": "Selumetinib", "severity": "Moderate", "effect": "Coadministration with selumetinib may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of organic anion transporter 3 (OAT3).  The proposed mechanism, based on in vivo data, is decreased clearance due to selumetinib-mediated inhibition of OAT3 transporter.", "source": "DDInter", "management_text": "Caution is advised if selumetinib is used concomitantly with drugs that are substrates of OAT3, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring of the OAT3 substrate should be considered whenever selumetinib is added to or withdrawn from therapy.  Patients should be monitored for the development of adverse effects.", "mechanism_text": "Excretion", "recommendation": "Caution is advised if selumetinib is used concomitantly with drugs that are substrates of OAT3, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278685/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Aubagio (teriflunomide).\" Genzyme Corporation  (2012):", "alternatives_a": "Bendroflumethiazide, Trichlormethiazide, Bumetanide, Chlorthalidone, Metolazone, Hydrochlorothiazide, Torasemide, Etacrynic acid, Bumetanide, Tamsulosin, Tinidazole, More", "alternatives_b": "Entrectinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, More", "updated_at": 1767369485}, {"id": 242942, "ingredient1": "Furosemide", "ingredient2": "Telavancin", "severity": "Moderate", "effect": "Increased adverse effects are possible when glycopeptide, polypeptide, or polymyxin antibiotics are administered concomitantly with other potentially nephrotoxic and neurotoxic drugs.", "source": "DDInter", "management_text": "If these drugs must be used together, renal function, auditory and vestibular function, and serum drug concentrations should be monitored.", "mechanism_text": "Synergism", "recommendation": "If these drugs must be used together, renal function, auditory and vestibular function, and serum drug concentrations should be monitored.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278688/", "reference_text": "[1] \"Product Information. Vancocin (vancomycin).\" Lilly, Eli and Company  (2001):[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015):  1903-7", "alternatives_a": "Bendroflumethiazide, Trichlormethiazide, Bumetanide, Chlorthalidone, Metolazone, Hydrochlorothiazide, Torasemide, Bumetanide, Tamsulosin, Tinidazole, Ascorbic acid, More", "alternatives_b": "Tinidazole, Oritavancin, Daptomycin, Methenamine, Spectinomycin, Lefamulin, Fosfomycin, Tedizolid, Dalbavancin", "updated_at": 1767369485}, {"id": 242943, "ingredient1": "Gabapentin", "ingredient2": "Acrivastine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278693/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Terfenadine, Astemizole", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 242944, "ingredient1": "Gabapentin", "ingredient2": "Chlorcyclizine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278695/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Terfenadine, Astemizole", "alternatives_b": "Oxcarbazepine, Ethotoin, Methsuximide, Paramethadione, Carbamazepine, Phensuximide, Fosphenytoin, Methylphenobarbital, Phenacemide, Phenytoin, Felbamate, More", "updated_at": 1767369485}, {"id": 242945, "ingredient1": "Gabapentin", "ingredient2": "Cyclizine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278696/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Terfenadine, Astemizole", "alternatives_b": "Methsuximide, Paramethadione, Phensuximide, Methylphenobarbital, Phenacemide, Trimethadione, Lacosamide", "updated_at": 1767369485}, {"id": 242946, "ingredient1": "Gabapentin", "ingredient2": "Ethotoin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278698/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Gabapentin, Lacosamide", "alternatives_b": "Ethotoin, Paramethadione, Mephenytoin, Zonisamide, Lamotrigine, Fosphenytoin, Methylphenobarbital, Phenacemide, Phenytoin, Trimethadione, Lacosamide, Levetiracetam", "updated_at": 1767369485}, {"id": 242947, "ingredient1": "Guanfacine", "ingredient2": "Gabapentin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278701/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Paramethadione, Perampanel, Vigabatrin, More", "alternatives_b": "Rauwolfia serpentina root, Reserpine, Deserpidine", "updated_at": 1767369485}, {"id": 242948, "ingredient1": "Gabapentin", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278702/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Lacosamide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242949, "ingredient1": "Gabapentin", "ingredient2": "Melatonin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278703/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Lacosamide", "alternatives_b": "Nitrazepam", "updated_at": 1767369485}, {"id": 242950, "ingredient1": "Gabapentin", "ingredient2": "Mephenytoin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278704/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ethotoin, Paramethadione, Mephenytoin, Zonisamide, Lamotrigine, Fosphenytoin, Methylphenobarbital, Phenacemide, Phenytoin, Trimethadione, Lacosamide, Levetiracetam", "alternatives_b": "Gabapentin, Lacosamide", "updated_at": 1767369485}, {"id": 242951, "ingredient1": "Gabapentin", "ingredient2": "Methylphenobarbital", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278705/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Tiagabine, Ethotoin, Topiramate, Paramethadione, Mephenytoin, Methsuximide, Phensuximide, Lamotrigine, Methylphenobarbital, Felbamate, Ethosuximide, More", "alternatives_b": "Gabapentin, Lacosamide, Nitrazepam", "updated_at": 1767369485}, {"id": 242952, "ingredient1": "Gabapentin", "ingredient2": "Methdilazine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278706/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Tiagabine, Ethotoin, Ezogabine, Paramethadione, Mephenytoin, Phensuximide, Lamotrigine, Phenacemide, Felbamate, Lacosamide, Levetiracetam, Trimethadione", "alternatives_b": "Ketotifen, Terfenadine, Astemizole", "updated_at": 1767369485}, {"id": 242953, "ingredient1": "Gabapentin", "ingredient2": "Methotrimeprazine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278707/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Tiagabine, Ethotoin, Methsuximide, Paramethadione, Mephenytoin, Phensuximide, Lamotrigine, Phenacemide, Trimethadione, Lacosamide, Levetiracetam", "alternatives_b": "Amisulpride, Pimavanserin", "updated_at": 1767369485}, {"id": 242954, "ingredient1": "Gabapentin", "ingredient2": "Paramethadione", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278708/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Tiagabine, Ethotoin, Clonazepam, Topiramate, Paramethadione, Mephenytoin, Methsuximide, Phensuximide, Lamotrigine, Fosphenytoin, Methylphenobarbital, More", "alternatives_b": "Gabapentin, Lacosamide", "updated_at": 1767369485}, {"id": 242955, "ingredient1": "Gabapentin", "ingredient2": "Phenacemide", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278709/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Tiagabine, Ethotoin, Clonazepam, Topiramate, Paramethadione, Mephenytoin, Methsuximide, Zonisamide, Phensuximide, Lamotrigine, Fosphenytoin, More", "alternatives_b": "Gabapentin, Lacosamide", "updated_at": 1767369485}, {"id": 242956, "ingredient1": "Gabapentin", "ingredient2": "Phenindamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278710/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Tiagabine, Ethotoin, Paramethadione, Mephenytoin, Phensuximide, Lamotrigine, Fosphenytoin, Methylphenobarbital, Phenacemide, Felbamate, Lacosamide, More", "alternatives_b": "Ketotifen, Terfenadine, Astemizole", "updated_at": 1767369485}, {"id": 242957, "ingredient1": "Gabapentin", "ingredient2": "Phensuximide", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278711/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Clonazepam, Topiramate, Paramethadione, Methsuximide, Zonisamide, Phensuximide, Lamotrigine, Methylphenobarbital, Phenacemide, Felbamate, Ethosuximide, More", "alternatives_b": "Gabapentin, Lacosamide", "updated_at": 1767369485}, {"id": 242958, "ingredient1": "Gabapentin", "ingredient2": "Thiopental", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278712/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Tiagabine, Topiramate, Methsuximide, Lamotrigine, Fosphenytoin, Phenytoin, Ethosuximide, Lacosamide, Levetiracetam, Stiripentol", "alternatives_b": "Nitrous oxide, Desflurane, Enflurane, Halothane, Etomidate, Nitrazepam", "updated_at": 1767369485}, {"id": 242959, "ingredient1": "Acrivastine", "ingredient2": "Tiagabine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278870/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Methdilazine, Azatadine, Ketotifen, Meclizine, Thiethylperazine, Dexchlorpheniramine, Phenindamine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 242960, "ingredient1": "Chlorcyclizine", "ingredient2": "Tiagabine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278872/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Methdilazine, Azatadine, Ketotifen, Meclizine, Thiethylperazine, Dexchlorpheniramine, Phenindamine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "Oxcarbazepine, Ethotoin, Methsuximide, Paramethadione, Carbamazepine, Phensuximide, Fosphenytoin, Methylphenobarbital, Phenacemide, Phenytoin, Felbamate, More", "updated_at": 1767369485}, {"id": 242961, "ingredient1": "Ibritumomab tiuxetan", "ingredient2": "Tiagabine", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.  Dosing adjustments may be necessary.  The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278875/", "reference_text": "[1] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb  (2001):[2] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb  (2001):[3] \"Product Information. Fluorouracil (fluorouracil).\" Roche Laboratories  (2022):[4] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn  (2001):[5] \"Product Information. Ellence (epirubicin).\" Pharmacia and Upjohn  (2001):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] Agencia Espala de Medicamentos y Productos Sanitarios Healthcare \"Centro de informaci online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):", "alternatives_a": "Tositumomab, Iodide I-131", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Phenytoin, Ethosuximide, Lacosamide, Levetiracetam, Oxcarbazepine, More", "updated_at": 1767369485}, {"id": 242962, "ingredient1": "Tiagabine", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278877/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Amantadine, Entacapone, Cabergoline", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 242963, "ingredient1": "Tiagabine", "ingredient2": "Melatonin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278880/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam, Thiopental, Ethchlorvynol, Methylphenobarbital, Dichloralphenazone", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 242964, "ingredient1": "Tiagabine", "ingredient2": "Melphalan flufenamide", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.  Dosing adjustments may be necessary.  The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278881/", "reference_text": "[1] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb  (2001):[2] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb  (2001):[3] \"Product Information. Fluorouracil (fluorouracil).\" Roche Laboratories  (2022):[4] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn  (2001):[5] \"Product Information. Ellence (epirubicin).\" Pharmacia and Upjohn  (2001):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] Agencia Espala de Medicamentos y Productos Sanitarios Healthcare \"Centro de informaci online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):", "alternatives_a": "Temozolomide, Thiotepa, Carmustine, Cyclophosphamide, Busulfan, Chlorambucil, Lomustine, Dacarbazine, Mechlorethamine, Bendamustine, Melphalan, More", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Phenytoin, Ethosuximide, Lacosamide, Levetiracetam, Oxcarbazepine, More", "updated_at": 1767369485}, {"id": 242965, "ingredient1": "Tiagabine", "ingredient2": "Osilodrostat", "severity": "Moderate", "effect": "Coadministration with osilodrostat may increase the plasma concentrations of drugs that are metabolized by CYP450 1A2, 2C19, 2D6, and/or 3A4.  Osilodrostat has been shown to be a moderate inhibitor of CYP450 1A2, a mild to borderline moderate inhibitor of CYP450 2C19, and a weak inhibitor of CYP450 2D6 and 3A4.", "source": "DDInter", "management_text": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever osilodrostat is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278884/", "reference_text": "[1] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Inc  (2020):[2] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Australia Pty Ltd  (2022):[3] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases UK Ltd  (2021):", "alternatives_a": "Ketoconazole", "alternatives_b": "Ethotoin, Brivaracetam, Gabapentin, Valproic acid, Topiramate, Paramethadione, Methsuximide, Perampanel, Phensuximide, Lamotrigine, Phenacemide, More", "updated_at": 1767369485}, {"id": 242966, "ingredient1": "Tiagabine", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278886/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Entrectinib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, Cobimetinib, More", "alternatives_b": "Brivaracetam, Topiramate, Lamotrigine, Methylphenobarbital, Levetiracetam, Oxcarbazepine, Ethotoin, Rufinamide, Paramethadione, Perampanel, Vigabatrin, More", "updated_at": 1767369485}, {"id": 242967, "ingredient1": "Gadoxetic acid", "ingredient2": "Bepridil", "severity": "Moderate", "effect": "Coadministration of calcium channel blockers may increase the cardiovascular effects of ionic X-ray contrast media.  The mechanism is unknown.", "source": "DDInter", "management_text": "Patients taking calcium channel blockers should be closely monitored for increased cardiovascular effects of ionic X-ray contrast media, such as hypotension.  Use of a nonionic contrast agent, such as iopamidol, may be considered instead of ionic contrast where clinically appropriate.", "mechanism_text": "Others", "recommendation": "Patients taking calcium channel blockers should be closely monitored for increased cardiovascular effects of ionic X-ray contrast media, such as hypotension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278888/", "reference_text": "[1] Morris DL, Wisneski JA, Gertz EW, et al. \"Potentiation by nifedipine and diltiazem of the hypotensive response after contrast angiography.\" J Am Coll Cardiol 6 (1985):  785-91[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Gadoversetamide, Gadobutrol, Gadofosveset trisodium, Gadoteric acid, Gadodiamide, Gadobenic acid, Gadoteridol, Ferumoxsil", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242968, "ingredient1": "Gadoxetic acid", "ingredient2": "Carteolol", "severity": "Moderate", "effect": "Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral contrast media.  In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat.  The mechanism is unknown.  Theoretically, beta-blocker ophthalmic solutions may also interact, as they are systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.", "source": "DDInter", "management_text": "Patients who have received beta-blockers should be closely monitored for adverse reactions to contrast media.  If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine.  Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm.  Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.", "mechanism_text": "Synergism", "recommendation": "Patients who have received beta-blockers should be closely monitored for adverse reactions to contrast media.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278889/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Latanoprost, Apraclonidine, Methazolamide, Neostigmine, Pilocarpine, Clonidine, Physostigmine, Acetylcholine, Diclofenamide, Bimatoprost, Travoprost, More", "alternatives_b": "Gadoversetamide, Gadoteric acid, Gadodiamide, Gadoteridol, Ferumoxsil", "updated_at": 1767369485}, {"id": 242969, "ingredient1": "Iopanoic acid", "ingredient2": "Gadoxetic acid", "severity": "Moderate", "effect": "Renal toxicity has been reported in a few patients with liver dysfunction who were given an oral cholecystographic agent followed by intravenous contrast agents.", "source": "DDInter", "management_text": "Administration of any intravascular contrast agent should be deferred for 48 hours in patients with hepatic or biliary disorders who have recently received an oral cholecystographic contrast agent.", "mechanism_text": "Synergism", "recommendation": "Administration of any intravascular contrast agent should be deferred for 48 hours in patients with hepatic or biliary disorders who have recently received an oral cholecystographic contrast agent.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278890/", "reference_text": "[1] \"Product Information. Ultravist (iopromide).\" Berlex Laboratories  (2001):[2] \"Product Information. Visipaque (iodixanol).\" Nycomed Inc  (2001):[3] \"Product Information. Omniscan (gadodiamide).\" Novation  (2004):", "alternatives_a": "Gadoversetamide, Gadoteric acid, Gadodiamide, Gadoteridol, Ferumoxsil", "alternatives_b": "Ioxilan, Iomeprol, Iodipamide, Ioversol, Iohexol, Iodamide, Iodixanol, Ethiodized oil, Iothalamic acid, Ioxaglic acid, Iopromide, More", "updated_at": 1767369485}, {"id": 242970, "ingredient1": "Iopodic acid", "ingredient2": "Gadoxetic acid", "severity": "Moderate", "effect": "Renal toxicity has been reported in a few patients with liver dysfunction who were given an oral cholecystographic agent followed by intravenous contrast agents.", "source": "DDInter", "management_text": "Administration of any intravascular contrast agent should be deferred for 48 hours in patients with hepatic or biliary disorders who have recently received an oral cholecystographic contrast agent.", "mechanism_text": "Synergism", "recommendation": "Administration of any intravascular contrast agent should be deferred for 48 hours in patients with hepatic or biliary disorders who have recently received an oral cholecystographic contrast agent.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278891/", "reference_text": "[1] \"Product Information. Ultravist (iopromide).\" Berlex Laboratories  (2001):[2] \"Product Information. Visipaque (iodixanol).\" Nycomed Inc  (2001):[3] \"Product Information. Omniscan (gadodiamide).\" Novation  (2004):", "alternatives_a": "Gadoversetamide, Gadoteric acid, Gadodiamide, Gadoteridol, Ferumoxsil", "alternatives_b": "Ioxilan, Iomeprol, Iodipamide, Ioversol, Iohexol, Iodamide, Iodixanol, Ethiodized oil, Iothalamic acid, Ioxaglic acid, Iopromide, More", "updated_at": 1767369485}, {"id": 242971, "ingredient1": "Gadoxetic acid", "ingredient2": "Levobetaxolol (ophthalmic)", "severity": "Moderate", "effect": "Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral contrast media.  In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat.  The mechanism is unknown.  Theoretically, beta-blocker ophthalmic solutions may also interact, as they are systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.", "source": "DDInter", "management_text": "Patients who have received beta-blockers should be closely monitored for adverse reactions to contrast media.  If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine.  Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm.  Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.", "mechanism_text": "Synergism", "recommendation": "Patients who have received beta-blockers should be closely monitored for adverse reactions to contrast media.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278892/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Gadoversetamide, Gadoteric acid, Gadodiamide, Gadoteridol, Ferumoxsil", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242972, "ingredient1": "Gadoxetic acid", "ingredient2": "Penbutolol", "severity": "Moderate", "effect": "Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral contrast media.  In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat.  The mechanism is unknown.  Theoretically, beta-blocker ophthalmic solutions may also interact, as they are systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.", "source": "DDInter", "management_text": "Patients who have received beta-blockers should be closely monitored for adverse reactions to contrast media.  If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine.  Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm.  Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.", "mechanism_text": "Synergism", "recommendation": "Patients who have received beta-blockers should be closely monitored for adverse reactions to contrast media.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278894/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Ferumoxsil", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242973, "ingredient1": "Gadoxetic acid", "ingredient2": "Tyropanoic acid", "severity": "Moderate", "effect": "Renal toxicity has been reported in a few patients with liver dysfunction who were given an oral cholecystographic agent followed by intravenous contrast agents.", "source": "DDInter", "management_text": "Administration of any intravascular contrast agent should be deferred for 48 hours in patients with hepatic or biliary disorders who have recently received an oral cholecystographic contrast agent.", "mechanism_text": "Synergism", "recommendation": "Administration of any intravascular contrast agent should be deferred for 48 hours in patients with hepatic or biliary disorders who have recently received an oral cholecystographic contrast agent.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278895/", "reference_text": "[1] \"Product Information. Ultravist (iopromide).\" Berlex Laboratories  (2001):[2] \"Product Information. Visipaque (iodixanol).\" Nycomed Inc  (2001):[3] \"Product Information. Omniscan (gadodiamide).\" Novation  (2004):", "alternatives_a": "Gadoversetamide, Gadoteric acid, Gadodiamide, Gadoteridol, Ferumoxsil", "alternatives_b": "Ioxilan, Iomeprol, Iodipamide, Ioversol, Iohexol, Iodamide, Iodixanol, Ethiodized oil, Iothalamic acid, Ioxaglic acid, Iopromide, More", "updated_at": 1767369485}, {"id": 242974, "ingredient1": "Galantamine", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278905/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Memantine, Ginkgo biloba, Aducanumab", "alternatives_b": "Dabrafenib, Acalabrutinib, Pexidartinib, Tepotinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More", "updated_at": 1767369485}, {"id": 242975, "ingredient1": "Zinc acetate", "ingredient2": "Axicabtagene ciloleucel", "severity": "Minor", "effect": "Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat's claw, and zinc may antagonize the pharmacologic effects of immunosuppressants.  However, clinical cases of drug interactions have not been reported.", "source": "DDInter", "management_text": "The effect of this interaction is not well established, and the possibility of an interaction should be considered if an adverse event occurs when combining Cat's Claw with an immune-related drug.", "mechanism_text": "Others", "recommendation": "The effect of this interaction is not well established, and the possibility of an interaction should be considered if an adverse event occurs when combining Cat's Claw with an immune-related drug.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278908/", "reference_text": "[1] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[2] Pepping J \"Echinacea.\" Am J Health Syst Pharm 56 (1999):  121-2[3] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001):  2163-75[4] Therapeutic Research Faculty \"Natural Medicines Comprehensive Database.  http://www.naturaldatabase.com\"   (2008):", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, More", "alternatives_b": "Lidocaine, Diltiazem, Tetracaine, Fluocinolone acetonide, Fluocinonide, Isosorbide dinitrate, Zinc chloride, Procaine, Fluorometholone, Nitroglycerin, Teduglutide, More", "updated_at": 1767369485}, {"id": 242976, "ingredient1": "Ceftibuten", "ingredient2": "Zinc acetate", "severity": "Moderate", "effect": "Oral products containing zinc such as mineral supplements and multivitamins may interfere with the gastrointestinal absorption of cephalexin, ceftibuten or cephradine.", "source": "DDInter", "management_text": "Oral medications or mineral supplements that contain zinc are recommended to be administered at least 3 hours after the cephalexin, ceftibuten or cephradine dose.", "mechanism_text": "Absorption", "recommendation": "Oral medications or mineral supplements that contain zinc are recommended to be administered at least 3 hours after the cephalexin, ceftibuten or cephradine dose.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278909/", "reference_text": "[1] Ding Y, Jia Y, Li F, et al. \"The Effect of Staggered Administration of Zinc Sulfate on the Pharmacokinetics of Oral Cephalexin*\" Br J Clin Pharmacol 73 (2011):  422-7[2] World Health Organization \"WHO Public Assessment Reports (WHOPARs)  https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars\"   (2020):[3] Okamura M, Terada t, KatsuraT, Saito H, Inui K \"Inhibitory effect of zinc on PEPT1-mediated transport of glycylsarcosine and beta-lactam antibiotics in human intestinal cell line Caco-2\" Pharm Res 20 (2003):  1389-93", "alternatives_a": "Cefepime, Imipenem, Aztreonam, Ceftazidime, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefuroxime, Cefoperazone, More", "alternatives_b": "Lidocaine, Diltiazem, Tetracaine, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Isosorbide dinitrate, Zinc chloride, Procaine, Prednisolone, Betamethasone, More", "updated_at": 1767369485}, {"id": 242977, "ingredient1": "Cephalexin", "ingredient2": "Zinc acetate", "severity": "Moderate", "effect": "Oral products containing zinc such as mineral supplements and multivitamins may interfere with the gastrointestinal absorption of cephalexin, ceftibuten or cephradine.", "source": "DDInter", "management_text": "Oral medications or mineral supplements that contain zinc are recommended to be administered at least 3 hours after the cephalexin, ceftibuten or cephradine dose.", "mechanism_text": "Absorption", "recommendation": "Oral medications or mineral supplements that contain zinc are recommended to be administered at least 3 hours after the cephalexin, ceftibuten or cephradine dose.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278910/", "reference_text": "[1] Ding Y, Jia Y, Li F, et al. \"The Effect of Staggered Administration of Zinc Sulfate on the Pharmacokinetics of Oral Cephalexin*\" Br J Clin Pharmacol 73 (2011):  422-7[2] World Health Organization \"WHO Public Assessment Reports (WHOPARs)  https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars\"   (2020):[3] Okamura M, Terada t, KatsuraT, Saito H, Inui K \"Inhibitory effect of zinc on PEPT1-mediated transport of glycylsarcosine and beta-lactam antibiotics in human intestinal cell line Caco-2\" Pharm Res 20 (2003):  1389-93", "alternatives_a": "Cefepime, Imipenem, Aztreonam, Ceftazidime, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefuroxime, Cefoperazone, More", "alternatives_b": "Tetracaine, Fluocinolone acetonide, Zinc chloride, Procaine, Betamethasone, Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, More", "updated_at": 1767369485}, {"id": 242978, "ingredient1": "Cefradine", "ingredient2": "Zinc acetate", "severity": "Moderate", "effect": "Oral products containing zinc such as mineral supplements and multivitamins may interfere with the gastrointestinal absorption of cephalexin, ceftibuten or cephradine.", "source": "DDInter", "management_text": "Oral medications or mineral supplements that contain zinc are recommended to be administered at least 3 hours after the cephalexin, ceftibuten or cephradine dose.", "mechanism_text": "Absorption", "recommendation": "Oral medications or mineral supplements that contain zinc are recommended to be administered at least 3 hours after the cephalexin, ceftibuten or cephradine dose.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278911/", "reference_text": "[1] Ding Y, Jia Y, Li F, et al. \"The Effect of Staggered Administration of Zinc Sulfate on the Pharmacokinetics of Oral Cephalexin*\" Br J Clin Pharmacol 73 (2011):  422-7[2] World Health Organization \"WHO Public Assessment Reports (WHOPARs)  https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars\"   (2020):[3] Okamura M, Terada t, KatsuraT, Saito H, Inui K \"Inhibitory effect of zinc on PEPT1-mediated transport of glycylsarcosine and beta-lactam antibiotics in human intestinal cell line Caco-2\" Pharm Res 20 (2003):  1389-93", "alternatives_a": "Cefepime, Imipenem, Aztreonam, Ceftazidime, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefuroxime, Cefoperazone, More", "alternatives_b": "Lidocaine, Diltiazem, Tetracaine, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Isosorbide dinitrate, Zinc chloride, Procaine, Prednisolone, Betamethasone, More", "updated_at": 1767369485}, {"id": 242979, "ingredient1": "Zinc acetate", "ingredient2": "Melphalan flufenamide", "severity": "Minor", "effect": "Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat's claw, and zinc may antagonize the pharmacologic effects of immunosuppressants.  However, clinical cases of drug interactions have not been reported.", "source": "DDInter", "management_text": "The effect of this interaction is not well established, and the possibility of an interaction should be considered if an adverse event occurs when combining Cat's Claw with an immune-related drug.", "mechanism_text": "Others", "recommendation": "The effect of this interaction is not well established, and the possibility of an interaction should be considered if an adverse event occurs when combining Cat's Claw with an immune-related drug.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278914/", "reference_text": "[1] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[2] Pepping J \"Echinacea.\" Am J Health Syst Pharm 56 (1999):  121-2[3] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001):  2163-75[4] Therapeutic Research Faculty \"Natural Medicines Comprehensive Database.  http://www.naturaldatabase.com\"   (2008):", "alternatives_a": "Temozolomide, Thiotepa, Carmustine, Cyclophosphamide, Busulfan, Chlorambucil, Lomustine, Dacarbazine, Mechlorethamine, Bendamustine, Ifosfamide, More", "alternatives_b": "Lidocaine, Diltiazem, Tetracaine, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Isosorbide dinitrate, Procaine, Prednisolone, Betamethasone, Fluorometholone, More", "updated_at": 1767369485}, {"id": 242980, "ingredient1": "Human immunoglobulin G (intravenous and subcutaneous)", "ingredient2": "Bacillus calmette-guerin substrain tice live antigen", "severity": "Moderate", "effect": "The passive transfer of antibodies present in immune globulin preparations may interfere with the immune response to live vaccines.", "source": "DDInter", "management_text": "Varicella virus vaccine should not be given for at least 5 months, and other live vaccines should not be given for at least 3 months, after administration of immune globulin.  If such vaccinations are given shortly before or after immune globulin therapy, a revaccination may be necessary.  Some experts have recommended that administration of measles virus vaccine be deferred for at least 8 months following human intravenous immune globulin therapy for immunodeficiency disease; 8 to 10 months following treatment for immune thrombocytopenic purpura (ITP); and at least 11 months following treatment for Kawasaki syndrome.  In the event that immune globulin and measles virus vaccine must be administered concurrently, it is advisable to separate the injection sites by as much as possible and to administer an additional dose of vaccine at the appropriate specified interval.  An additional dose of live measles, mumps, or rubella vaccine is usually not needed if the vaccine was administered at least two weeks prior to immune globulin administration.  Hepatitis B immune globulin has been reported to not interfere with measles vaccination, although data are limited.", "mechanism_text": "Antagonism", "recommendation": "Varicella virus vaccine should not be given for at least 5 months, and other live vaccines should not be given for at least 3 months, after administration of immune globulin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278919/", "reference_text": "[1] \"Interference of immune globulin with measles and rubella immunization.\" Eur J Pediatr 152 (1993):  536[2] \"Product Information. Sandoglobulin (immune globulin intravenous).\" Sandoz Pharmaceuticals Corporation[3] \"Product Information. Bayrab (rabies immune globulin, human).\" Bayer  (2001):[4] \"Product Information. Varivax (varicella virus vaccine).\" Merck & Co., Inc  (2022):[5] \"Product Information. Attenuvax (measles virus vaccine).\" Merck & Co., Inc  (2022):[6] \"Product Information. Baygam (immunglobulin, intramuskult).\" Bayer[7] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[8] \"Product Information. Thymoglobulin (immune globulin intravenous).\" SangStat Medical Corporation, Menlo Park, CA.[9] \"Product Information. H-BIG (hepatitis B immune globulin).\" Allscrips Pharmaceutical Company[10] \"Product Information. Cytogam (cytomegalovirus immune globulin).\" CSL Behring LLC  (2002):[11] \"Product Information. Varicella Zoster Immune Globulin (varicella zoster immune globulin).\" American Red Cross Blood Services  (2002):[12] \"Product Information. Baytet (tetanus immune globulin).\" Bayer  (2002):[13] \"Product Information. WinRho SDF (RHo (D) immune globulin).\" Apothecon Inc  (2022):[14] \"Product Information. BayRHo-D (RHo (D) immune globulin).\" Bayer[15] \"Product Information. Bayhep B (hepatitis B immune globulin).\" Bayer Pharmaceutical Inc  (2022):[16] \"Product Information. Nabi-HB (hepatitis B immune globulin).\" Biotest Pharmaceuticals Corporation  (2022):[17] \"Product Information. Rhophylac (RHo (D) immune globulin).\" Apothecon Inc  (2022):[18] \"Product Information. HyperRHO S/D Full Dose (RHo (D) immune globulin).\" Talecris Biotherapeutics  (2022):[19] \"Product Information. Vivaglobin (immune globulin subcutaneous).\" *ZLB Bioplasma Inc  (2006):[20] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[21] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[22] \"Product Information. BabyBIG (botulism immune globulin).\" FFF Enterprises  (2008):[23] \"Product Information. Hyperhep B (hepatitis B immune globulin).\" Apothecon Inc  (2022):[24] \"Product Information. Imogam Rabies-HT (rabies immune globulin, human).\" sanofi pasteur  (2010):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242981, "ingredient1": "Human immunoglobulin G (intravenous and subcutaneous)", "ingredient2": "Moxetumomab Pasudotox", "severity": "Major", "effect": "Coadministration of intravenous immune globulin preparations with nephrotoxic agents may potentiate the risk of renal impairment.", "source": "DDInter", "management_text": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.g., e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents).  The manufacturers recommend administering immune globulin infusions at the minimum concentration available and at the minimum rate of infusion feasible in such patients.  Clinicians should ensure that patients are not volume depleted prior to the initiation of immune globulin therapy.  Monitoring of urine output and renal function tests, including the measurement of blood urea nitrogen (BUN) and serum creatinine, is recommended prior to the initial infusion and at appropriate intervals thereafter.  If renal function deteriorates, discontinuation of the product should be considered.  Patients should be advised to seek medical attention if they experience symptoms that may indicate nephrotoxicity such as decreased urine output, sudden weight gain, fluid retention, edema, or shortness of breath.", "mechanism_text": "Synergism", "recommendation": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/278923/", "reference_text": "[1] \"Product Information. Cytogam (cytomegalovirus immune globulin).\" CSL Behring LLC  (2002):[2] \"Product Information. Respigam (respiratory syncytial virus immune globulin).\" Medimmune Inc  (2005):[3] \"Product Information. BabyBIG (botulism immune globulin).\" FFF Enterprises  (2008):[4] \"Product Information. Bivigam (immune globulin intravenous).\" Biotest Pharmaceuticals Corporation  (2013):[5] MMWR Morb Mortal Wkly Rep \"Renal insufficiency and failure associated with immune globulin intravenous therapy -- United States, 1985-1998.  http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4824a3.htm\"   (2013):[6] Pusey EY, Levy JB \"Nephrotoxicity of intravenous immunoglobulin.  http://qjmed.oxfordjournals.org/content/93/11/751.full.pdf+html\"   (2013):[7] KDIGO. Kidney Disease Improving Global Outcomes \"KDIGO clinical practice guideline for acute kidney injury.  http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-AKI-Suppl-Appendices-A-F_March2012.pdf\"   (2013):[8] Guo X, Nzerue C \"How to prevent, recognize, and treat drug-induced nephrotoxicity.  http://www.ccjm.org/content/69/4/289.full.pdf\"   (2013):[9] Perazella MA \"Renal vulnerability to drug toxicity.  http://www.ccjm.org/content/69/4/289.full.pdf\"   (2013):[10] Naughton CA \"Drug-induced nephrotoxicity.  http://www.aafp.org/afp/2008/0915/p743.html\"   (2013):[11] Moses S \"Nephrotoxic drugs, drug-induced nephrotoxicity.  http://www.fpnotebook.com/Renal/Pharm/NphrtxcDrgs.htm\"   (2013):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242982, "ingredient1": "Anisindione", "ingredient2": "Sulfisoxazole", "severity": "Major", "effect": "Coadministration with a sulfonamide may increase the plasma concentrations and hypoprothrombinemic effects of coumarin anticoagulants.  The proposed mechanism is sulfonamide inhibition of coumarin metabolism via CYP450 2C9 and possibly also displacement of coumarin derivatives from plasma protein binding sites.", "source": "DDInter", "management_text": "Patients receiving coumarin anticoagulants should be closely monitored during concomitant therapy with sulfonamides.  The INR should be checked frequently and coumarin dosage adjusted accordingly, particularly following initiation or discontinuation of sulfonamide therapy in patients who are stabilized on their anticoagulant regimen.  The same precaution may be applicable during therapy with other oral anticoagulants (e.g., indandiones), although clinical data are lacking.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Metabolism, Distribution", "recommendation": "Patients receiving coumarin anticoagulants should be closely monitored during concomitant therapy with sulfonamides.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279082/", "reference_text": "[1] O'Reilly RA \"Stereoselective interaction of trimethoprim-sulfamethaxazole with the separated enantiomorphs of racemic warfarin in man.\" N Engl J Med 302 (1980):  33-5[2] Kelly JG, O'Malley K \"Clinical pharmacokinetics of oral anticoagulants.\" Clin Pharmacokinet 4 (1979):  1-15[3] Sioris LJ, Weibert RT, Pentel PR \"Potentiation of warfarin anaticoagulation by sulfisoxazole.\" Arch Intern Med 140 (1980):  546-7[4] O'Donnell D \"Antibiotic-induced potentiation of oral anticoagulant agents.\" Med J Aust 150 (1989):  163-4[5] Lumholtz B, Siersbaek-Nielsen K, Skovsted L, Kampmann J, Hansen JM \"Sulfamethizole-induced inhibition of diphenylhydantoin, tolbutamide, and warfarin metabolism.\" Clin Pharmacol Ther 17 (1975):  731-4[6] O'Reilly RA, Motley CH \"Racemic warfarin and trimethoprim-sulfamethoxazole interaction in humans.\" Ann Intern Med 91 (1979):  34-6[7] Self TH, Evans W, Ferguson T \"Interaction of sulfisoxizole and warfarin.\" Circulation 52 (1975):  528[8] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994):  676-83[9] Serlin MJ, Breckenridge AM \"Drug interactions with warfarin.\" Drugs 25 (1983):  610-20[10] Cook DE, Ponte CD \"Suspected trimethoprim sulfamethoxazole induced hypoprothrombinemia.\" J Fam Pract 39 (1994):  589-91[11] Hermans JJ, Thijssen HH \"Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics.\" Br J Pharmacol 110 (1993):  482-90[12] Miners JO, Birkett DJ \"Cytochrome P4502C9: an enzyme of major importance in human drug metabolism.\" Br J Clin Pharmacol 45 (1998):  525-38[13] Venkatakrishnan K, vonMoltke LL, Greenblatt DJ \"Effects of the antifungal agents on oxidative drug metabolism - Clinical relevance.\" Clin Pharmacokinet 38 (2000):  111-80[14] Thijssen HH, Flinois JP, Beaune PH \"Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes.\" Drug Metab Disposition 28 (2000):  1284-90[15] Penning-van Beest FJ, van Meegen E, Rosendaal FR, Stricker BH \"Drug interactions as a cause of overanticoagulation on phenprocoumon or acenocoumarol predominantly concern antibacterial drugs.\" Clin Pharmacol Ther 69 (2001):  451-7[16] Hermida J, Zarza J, Alberca I, et al. \"Differential effects of 2C9*3 and 2C9*2 variants of cytochrome P-450 CYP2C9 on sensitivity to acenocoumarol.\" Blood 99 (2002):  4237-9[17] Visser LE, Penning-Van Bees FJ, Harrie Kasbergen AA, et al. \"Overanticoagulation associated with combined use of antibacterial drugs and acenocoumarol or phenprocoumon anticoagulants.\" Thromb Haemost 88 (2002):  705-10[18] Takahashi H, Wilkinson GR, Caraco Y, et al. \"Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients.\" Clin Pharmacol Ther 73 (2003):  253-63[19] Penning-van Beest F, Erkens J, Petersen KU, Koelz HR, Herings R \"Main comedications associated with major bleeding during anticoagulant therapy with coumarins.\" Eur J Clin Pharmacol 61 (2005):  439-44[20] Glasheen JJ, Fugit RV, Prochazka AV \"The risk of overanticoagulation with antibiotic use in outpatients on stable warfarin regimens.\" J Gen Intern Med 20 (2005):  653-6[21] Fischer HD, Juurlink DN, Mamdani MM, Kopp A, Laupacis A \"Hemorrhage during warfarin therapy associated with cotrimoxazole and other urinary tract anti-infective agents: a population-based study.\" Arch Intern Med 170 (2010):  617-21", "alternatives_a": "Sulfamethizole, Tamsulosin, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, Trichlormethiazide, Ciclopirox, Vemurafenib, Probenecid, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242983, "ingredient1": "Bifidobacterium longum infantis", "ingredient2": "Sulfisoxazole", "severity": "Moderate", "effect": "Coadministration of oral probiotic preparations with oral antibiotics may reduce the efficacy of the probiotic.  It has been theorized that concomitant antibiotics may kill the live organisms found in lactobacillus-, bacillus coagulans-, and bifidobacteria-containing oral probiotic preparations.", "source": "DDInter", "management_text": "Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.", "mechanism_text": "Antagonism", "recommendation": "Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279083/", "reference_text": "[1] Clarion Brands, Inc. \"Florajen Probiotics.  https://www.florajen.com/products/florajen-women\"   (2020):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Rosuvastatin, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242984, "ingredient1": "Dicoumarol", "ingredient2": "Sulfisoxazole", "severity": "Major", "effect": "Coadministration with a sulfonamide may increase the plasma concentrations and hypoprothrombinemic effects of coumarin anticoagulants.  The proposed mechanism is sulfonamide inhibition of coumarin metabolism via CYP450 2C9 and possibly also displacement of coumarin derivatives from plasma protein binding sites.", "source": "DDInter", "management_text": "Patients receiving coumarin anticoagulants should be closely monitored during concomitant therapy with sulfonamides.  The INR should be checked frequently and coumarin dosage adjusted accordingly, particularly following initiation or discontinuation of sulfonamide therapy in patients who are stabilized on their anticoagulant regimen.  The same precaution may be applicable during therapy with other oral anticoagulants (e.g., indandiones), although clinical data are lacking.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Metabolism, Distribution", "recommendation": "Patients receiving coumarin anticoagulants should be closely monitored during concomitant therapy with sulfonamides.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279085/", "reference_text": "[1] O'Reilly RA \"Stereoselective interaction of trimethoprim-sulfamethaxazole with the separated enantiomorphs of racemic warfarin in man.\" N Engl J Med 302 (1980):  33-5[2] Kelly JG, O'Malley K \"Clinical pharmacokinetics of oral anticoagulants.\" Clin Pharmacokinet 4 (1979):  1-15[3] Sioris LJ, Weibert RT, Pentel PR \"Potentiation of warfarin anaticoagulation by sulfisoxazole.\" Arch Intern Med 140 (1980):  546-7[4] O'Donnell D \"Antibiotic-induced potentiation of oral anticoagulant agents.\" Med J Aust 150 (1989):  163-4[5] Lumholtz B, Siersbaek-Nielsen K, Skovsted L, Kampmann J, Hansen JM \"Sulfamethizole-induced inhibition of diphenylhydantoin, tolbutamide, and warfarin metabolism.\" Clin Pharmacol Ther 17 (1975):  731-4[6] O'Reilly RA, Motley CH \"Racemic warfarin and trimethoprim-sulfamethoxazole interaction in humans.\" Ann Intern Med 91 (1979):  34-6[7] Self TH, Evans W, Ferguson T \"Interaction of sulfisoxizole and warfarin.\" Circulation 52 (1975):  528[8] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994):  676-83[9] Serlin MJ, Breckenridge AM \"Drug interactions with warfarin.\" Drugs 25 (1983):  610-20[10] Cook DE, Ponte CD \"Suspected trimethoprim sulfamethoxazole induced hypoprothrombinemia.\" J Fam Pract 39 (1994):  589-91[11] Hermans JJ, Thijssen HH \"Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics.\" Br J Pharmacol 110 (1993):  482-90[12] Miners JO, Birkett DJ \"Cytochrome P4502C9: an enzyme of major importance in human drug metabolism.\" Br J Clin Pharmacol 45 (1998):  525-38[13] Venkatakrishnan K, vonMoltke LL, Greenblatt DJ \"Effects of the antifungal agents on oxidative drug metabolism - Clinical relevance.\" Clin Pharmacokinet 38 (2000):  111-80[14] Thijssen HH, Flinois JP, Beaune PH \"Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes.\" Drug Metab Disposition 28 (2000):  1284-90[15] Penning-van Beest FJ, van Meegen E, Rosendaal FR, Stricker BH \"Drug interactions as a cause of overanticoagulation on phenprocoumon or acenocoumarol predominantly concern antibacterial drugs.\" Clin Pharmacol Ther 69 (2001):  451-7[16] Hermida J, Zarza J, Alberca I, et al. \"Differential effects of 2C9*3 and 2C9*2 variants of cytochrome P-450 CYP2C9 on sensitivity to acenocoumarol.\" Blood 99 (2002):  4237-9[17] Visser LE, Penning-Van Bees FJ, Harrie Kasbergen AA, et al. \"Overanticoagulation associated with combined use of antibacterial drugs and acenocoumarol or phenprocoumon anticoagulants.\" Thromb Haemost 88 (2002):  705-10[18] Takahashi H, Wilkinson GR, Caraco Y, et al. \"Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients.\" Clin Pharmacol Ther 73 (2003):  253-63[19] Penning-van Beest F, Erkens J, Petersen KU, Koelz HR, Herings R \"Main comedications associated with major bleeding during anticoagulant therapy with coumarins.\" Eur J Clin Pharmacol 61 (2005):  439-44[20] Glasheen JJ, Fugit RV, Prochazka AV \"The risk of overanticoagulation with antibiotic use in outpatients on stable warfarin regimens.\" J Gen Intern Med 20 (2005):  653-6[21] Fischer HD, Juurlink DN, Mamdani MM, Kopp A, Laupacis A \"Hemorrhage during warfarin therapy associated with cotrimoxazole and other urinary tract anti-infective agents: a population-based study.\" Arch Intern Med 170 (2010):  617-21", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Clopidogrel, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, More", "alternatives_b": "Sulfamethizole, Tamsulosin, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, Trichlormethiazide, Ciclopirox, Vemurafenib, Probenecid, More", "updated_at": 1767369485}, {"id": 242985, "ingredient1": "Etidocaine", "ingredient2": "Sulfisoxazole", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279086/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Meloxicam", "alternatives_b": "Sulfamethizole, Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Lactic acid, Mitapivat, More", "updated_at": 1767369485}, {"id": 242986, "ingredient1": "Sulfisoxazole", "ingredient2": "Levobupivacaine", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279090/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Meloxicam", "alternatives_b": "Sulfamethizole, Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Lactic acid, Methazolamide, More", "updated_at": 1767369485}, {"id": 242987, "ingredient1": "Sulfisoxazole", "ingredient2": "Procaine", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279092/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Meloxicam, Zinc sulfate, Diltiazem, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Isosorbide dinitrate, Zinc chloride, Prednisolone, Betamethasone, More", "alternatives_b": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Lactic acid, Mitapivat, Methazolamide, More", "updated_at": 1767369485}, {"id": 242988, "ingredient1": "Sulfisoxazole", "ingredient2": "Ropivacaine", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279094/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Meloxicam", "alternatives_b": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Lactic acid, Mitapivat, Methazolamide, More", "updated_at": 1767369485}, {"id": 242989, "ingredient1": "Sulfisoxazole", "ingredient2": "Silver nitrate (topical)", "severity": "Moderate", "effect": "Topical nitrate and silver (e.g., cerium nitrate, silver nitrate, silver sulfadiazine) preparations can be systemically absorbed and have been associated with rare reports of methemoglobinemia, primarily in burn patients.  In addition, bacterial conversion of nitrate to nitrite can contribute to methemoglobinemia.  Coadministration with other oxidizing agents that can also induce methemoglobinemia such as ester and amide local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), systemic nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Depending on the circumstances, caution may be advisable when topical nitrate and silver preparations are used concomitantly with other methemoglobin-inducing agents.  Clinicians should be aware of the potential for methemoglobinemia, particularly when treating burn patients.  Signs and symptoms of methemoglobinemia may be delayed some hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Depending on the circumstances, caution may be advisable when topical nitrate and silver preparations are used concomitantly with other methemoglobin-inducing agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279095/", "reference_text": "[1] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[2] Geffner ME, Powars DR, Choctaw WT \"Acquired methemoglobinemia.\" West J Med 134 (1981):  7-10[3] Poredos P, Gradisek P, Testen C, Derganc M \"Severe methemoglobinaemia due to benzocaine-containing 'burn cream': two case reports in an adult and in a child.\" Burns 37 (2011):  e63-6[4] Gala HC, Madave A \"An unusual case of neonatal methemoglobinemia.\" Indian Pediatr 54 (2017):  163[5] Reese AD, Keyloun JW, Garg G, et.a \"Compounded cerium nitrate-silver sulfadiazine cream is safe and effective for the treatment of burn wounds: a burn center's four-year experience.\" J Burn Care Res 20 (2021):  Epub ahead of print[6] Cartotto R \"Topical antimicrobial agents for pediatric burns.\" Burns Trauma 5 (2017):  33", "alternatives_a": "Sulfadiazine, Sulfamethoxazole, Sulfamethizole, Trimethoprim, Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242990, "ingredient1": "Sulfisoxazole", "ingredient2": "Silver sulfadiazine (topical)", "severity": "Moderate", "effect": "Topical nitrate and silver (e.g., cerium nitrate, silver nitrate, silver sulfadiazine) preparations can be systemically absorbed and have been associated with rare reports of methemoglobinemia, primarily in burn patients.  In addition, bacterial conversion of nitrate to nitrite can contribute to methemoglobinemia.  Coadministration with other oxidizing agents that can also induce methemoglobinemia such as ester and amide local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), systemic nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Depending on the circumstances, caution may be advisable when topical nitrate and silver preparations are used concomitantly with other methemoglobin-inducing agents.  Clinicians should be aware of the potential for methemoglobinemia, particularly when treating burn patients.  Signs and symptoms of methemoglobinemia may be delayed some hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Depending on the circumstances, caution may be advisable when topical nitrate and silver preparations are used concomitantly with other methemoglobin-inducing agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279096/", "reference_text": "[1] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[2] Geffner ME, Powars DR, Choctaw WT \"Acquired methemoglobinemia.\" West J Med 134 (1981):  7-10[3] Poredos P, Gradisek P, Testen C, Derganc M \"Severe methemoglobinaemia due to benzocaine-containing 'burn cream': two case reports in an adult and in a child.\" Burns 37 (2011):  e63-6[4] Gala HC, Madave A \"An unusual case of neonatal methemoglobinemia.\" Indian Pediatr 54 (2017):  163[5] Reese AD, Keyloun JW, Garg G, et.a \"Compounded cerium nitrate-silver sulfadiazine cream is safe and effective for the treatment of burn wounds: a burn center's four-year experience.\" J Burn Care Res 20 (2021):  Epub ahead of print[6] Cartotto R \"Topical antimicrobial agents for pediatric burns.\" Burns Trauma 5 (2017):  33", "alternatives_a": "Sulfadiazine, Sulfamethoxazole, Sulfamethizole, Trimethoprim, Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242991, "ingredient1": "Gentamicin (topical)", "ingredient2": "Gentamicin", "severity": "Moderate", "effect": "Topically applied aminoglycosides may be systemically absorbed and have potentially additive effects with systemically administered aminoglycosides.", "source": "DDInter", "management_text": "Topical preparations containing an aminoglycoside should not be used with other aminoglycosides in circumstances where significant systemic absorption could occur (e.g., application to burnt or broken skin; use of large quantities or on large areas for prolonged periods).  The normally recommended dosages of these products should not be exceeded.", "mechanism_text": "Synergism", "recommendation": "Topical preparations containing an aminoglycoside should not be used with other aminoglycosides in circumstances where significant systemic absorption could occur (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279097/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Gatifloxacin, Rifamycin, Lomefloxacin, Ampicillin, Azithromycin, Ofloxacin, Acyclovir, Polymyxin B, Ciprofloxacin, Famciclovir, Cefuroxime, More", "alternatives_b": "Tetracycline, Gatifloxacin, Ganciclovir, Rifamycin, Oxytetracycline, Norfloxacin, Lomefloxacin, Sulfamethizole, Trifluridine, Moxifloxacin, Sulfisoxazole, More", "updated_at": 1767369485}, {"id": 242992, "ingredient1": "Gentamicin", "ingredient2": "Botulinum toxin type A", "severity": "Major", "effect": "The effects of botulinum toxin may be potentiated by neuromuscular blockers, aminoglycoside antibiotics, and other drugs that can interfere with neuromuscular transmission.  Botulinum toxin inhibits the release of acetylcholine from peripheral cholinergic nerve endings, thus additive neuromuscular blocking effects may occur when these agents are used together.", "source": "DDInter", "management_text": "Caution is advised when botulinum toxin is used in combination with neuromuscular blockers, aminoglycoside antibiotics, or other drugs that can interfere with neuromuscular transmission.  These drugs should be avoided in patients suspected of having botulinum toxin overdose or poisoning.  Because the effects of botulinum toxin products may spread from the area of injection, patients should be monitored closely for adverse effects such as asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties, which can occur hours to weeks after injection.  Swallowing and breathing difficulties may be life-threatening or fatal.  Patients with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis, or neuromuscular junctional disorders such as myasthenia gravis or Lambert-Eaton syndrome may be particularly susceptible.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when botulinum toxin is used in combination with neuromuscular blockers, aminoglycoside antibiotics, or other drugs that can interfere with neuromuscular transmission.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279102/", "reference_text": "[1] \"Product Information. Myobloc (rimabotulinumtoxinB).\" Elan Pharmaceuticals[2] \"Product Information. Dysport (abobotulinumtoxinA).\" Tercica Inc[3] \"Product Information. Botox (onabotulinumtoxinA).\" Allergan Inc[4] \"Product Information. Xeomin (incobotulinumtoxinA).\" Merz Pharmaceuticals  (2022):[5] \"Product Information. Jeuveau (prabotulinumtoxinA).\" Evolus, Inc.  (2022):[6] \"Product Information. Daxxify (daxibotulinumtoxinA).\" Revance Therapeutics, Inc.  (2022):", "alternatives_a": "Gatifloxacin, Rifamycin, Lomefloxacin, Ampicillin, Azithromycin, Ofloxacin, Acyclovir, Ciprofloxacin, Famciclovir, Cefuroxime, Trifluridine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242993, "ingredient1": "Gentamicin", "ingredient2": "Botulinum toxin type B", "severity": "Major", "effect": "The effects of botulinum toxin may be potentiated by neuromuscular blockers, aminoglycoside antibiotics, and other drugs that can interfere with neuromuscular transmission.  Botulinum toxin inhibits the release of acetylcholine from peripheral cholinergic nerve endings, thus additive neuromuscular blocking effects may occur when these agents are used together.", "source": "DDInter", "management_text": "Caution is advised when botulinum toxin is used in combination with neuromuscular blockers, aminoglycoside antibiotics, or other drugs that can interfere with neuromuscular transmission.  These drugs should be avoided in patients suspected of having botulinum toxin overdose or poisoning.  Because the effects of botulinum toxin products may spread from the area of injection, patients should be monitored closely for adverse effects such as asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties, which can occur hours to weeks after injection.  Swallowing and breathing difficulties may be life-threatening or fatal.  Patients with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis, or neuromuscular junctional disorders such as myasthenia gravis or Lambert-Eaton syndrome may be particularly susceptible.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when botulinum toxin is used in combination with neuromuscular blockers, aminoglycoside antibiotics, or other drugs that can interfere with neuromuscular transmission.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279104/", "reference_text": "[1] \"Product Information. Myobloc (rimabotulinumtoxinB).\" Elan Pharmaceuticals[2] \"Product Information. Dysport (abobotulinumtoxinA).\" Tercica Inc[3] \"Product Information. Botox (onabotulinumtoxinA).\" Allergan Inc[4] \"Product Information. Xeomin (incobotulinumtoxinA).\" Merz Pharmaceuticals  (2022):[5] \"Product Information. Jeuveau (prabotulinumtoxinA).\" Evolus, Inc.  (2022):[6] \"Product Information. Daxxify (daxibotulinumtoxinA).\" Revance Therapeutics, Inc.  (2022):", "alternatives_a": "Gatifloxacin, Rifamycin, Lomefloxacin, Ampicillin, Azithromycin, Ofloxacin, Acyclovir, Ciprofloxacin, Famciclovir, Cefuroxime, Trifluridine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 242994, "ingredient1": "Gentamicin", "ingredient2": "Telavancin", "severity": "Moderate", "effect": "The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279107/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Tetracycline, Ganciclovir, Rifamycin, Oxytetracycline, Famciclovir, Vancomycin, Trifluridine, Sulfamethizole, Benzylpenicillin, Ampicillin, Chloramphenicol, More", "alternatives_b": "Tinidazole, Oritavancin, Daptomycin, Methenamine, Spectinomycin, Lefamulin, Nitrofurantoin, Fosfomycin, Tedizolid, Dalbavancin", "updated_at": 1767369485}, {"id": 242995, "ingredient1": "Abarelix", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279114/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Anastrozole, Aminoglutethimide, Fulvestrant", "alternatives_b": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Ribociclib, More", "updated_at": 1767369485}, {"id": 242996, "ingredient1": "Acetohexamide", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279115/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Lixisenatide, Albiglutide, Guar gum, Acarbose, Pramlintide, Canagliflozin, Alogliptin, Liraglutide, Troglitazone, Ertugliflozin, Semaglutide, More", "alternatives_b": "Entrectinib, Imatinib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, More", "updated_at": 1767369485}, {"id": 242997, "ingredient1": "Alvimopan", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may increase the plasma concentrations of drugs that are P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), organic anion transporting polypeptide 1B1 (OATP1B1), OATP1B3, organic anion transporter 1 (OAT1), multidrug and toxin extrusion 1 (MATE1), and/or MATE2-K substrates.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of P-gp, BCRP, OATP1B1, OATP1B3, OAT1, MATE1, and/or MATE2-K, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with substrates of these transporters for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism, Excretion", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of P-gp, BCRP, OATP1B1, OATP1B3, OAT1, MATE1, and/or MATE2-K, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279116/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Sorbitol, Magnesium sulfate, Tegaserod, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Magnesium oxide, Linaclotide, Naloxone, Magnesium carbonate", "alternatives_b": "Entrectinib, Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, More", "updated_at": 1767369485}, {"id": 242998, "ingredient1": "Pralsetinib", "ingredient2": "Astemizole", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279117/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, More", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, Zanubrutinib, More", "updated_at": 1767369485}, {"id": 242999, "ingredient1": "Pralsetinib", "ingredient2": "Axitinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279118/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Copanlisib, Abemaciclib, Erdafitinib, Neratinib, Erlotinib, Pralsetinib, Dacomitinib, Alectinib, Binimetinib", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More", "updated_at": 1767369485}, {"id": 243000, "ingredient1": "Bepridil", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279119/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Selumetinib, Capmatinib, Ibrutinib, Duvelisib, Tivozanib, Zanubrutinib, More", "alternatives_b": "", "updated_at": 1767369485}]